<SEC-DOCUMENT>0000950170-24-022073.txt : 20240228
<SEC-HEADER>0000950170-24-022073.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228161044
ACCESSION NUMBER:		0000950170-24-022073
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RxSight, Inc.
		CENTRAL INDEX KEY:			0001111485
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				943268801
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40690
		FILM NUMBER:		24695436

	BUSINESS ADDRESS:	
		STREET 1:		100 COLUMBIA STREET
		STREET 2:		SUITE 120
		CITY:			ALISO VIEJO
		STATE:			CA
		ZIP:			92656
		BUSINESS PHONE:		949-521-7822

	MAIL ADDRESS:	
		STREET 1:		100 COLUMBIA STREET
		STREET 2:		SUITE 120
		CITY:			ALISO VIEJO
		STATE:			CA
		ZIP:			92656

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALHOUN VISION INC
		DATE OF NAME CHANGE:	20000410
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rxst-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:rxst="http://rxsight.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5dd7fb70-dd6f-4dc3-a6d8-55878776b401" name="dei:CurrentFiscalYearEndDate" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f">--12-31</ix:nonNumeric><ix:nonNumeric id="F_490b6b1d-3bf1-4eeb-b099-513a5c99a6e9" name="dei:AmendmentFlag" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_e99068eb-24aa-45a4-aac9-7f3e912cf5c2" name="dei:EntityCentralIndexKey" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f">0001111485</ix:nonNumeric><ix:nonNumeric id="F_4efa97b4-2f73-48e3-b9a0-8446f86a165b" name="dei:DocumentFiscalPeriodFocus" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f">FY</ix:nonNumeric><ix:nonFraction id="F_89532d2d-44fa-416d-9656-337fd8e5f25d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2ed9af09-c8c9-47b5-bea3-2da165653b77" name="us-gaap:CommitmentsAndContingencies" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_1a6bb245-6eba-41dd-bf62-8d7ed791fd8f">P3Y</ix:nonNumeric><ix:nonNumeric id="F_ad232f5c-7ce0-4d92-95b3-b3019e7d245b" name="us-gaap:InvestmentTypeExtensibleEnumeration" contextRef="C_d19decf9-3310-45a2-abd2-b456a757f5d2">http://fasb.org/us-gaap/2023#USGovernmentAgenciesShorttermDebtSecuritiesMember</ix:nonNumeric><ix:nonNumeric id="F_1f005e07-66a8-4957-933b-b4aede44a4d8" name="us-gaap:InvestmentTypeExtensibleEnumeration" contextRef="C_bc1f24f5-960c-4f14-a149-a28449446cd0">http://fasb.org/us-gaap/2023#USGovernmentAgenciesShorttermDebtSecuritiesMember</ix:nonNumeric><ix:nonNumeric id="F_98a9eb22-5875-4665-9fe4-7da6a3667f55" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric id="F_4215fd74-502e-4548-a8dd-7b80b1cd43f0" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric id="F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_c8f26f61-f9dd-4949-8795-ad61341c192b" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_b14603c8-a5d6-41d8-b49d-2b04b4c22671" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_cfa28257-8c04-4096-a2b8-5d3340f0d040" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_1c8ef374-722f-4dc2-918b-df585e24ce25" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rxst-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b64f86a3-1985-43c1-be28-347c081c8c0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_300d62ab-2d34-4a7f-a559-6b38f6978705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd90b2d8-aec9-4102-be22-34321f15f5b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c0d5359-a0dc-4cfd-ae75-3d2013478591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c4862f1-51c5-4005-ad1c-acfd1c889569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b57291d-8c21-44bb-84bc-64c21d397bcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25a0e726-e847-4009-b9ba-5e81ccb68e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-30</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b42dce2-cf09-4fb9-9b81-1ed4c14f7dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_366621b7-b9f6-4be8-a093-a9b4299ad983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:RightOfUseEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec5af07-2372-4042-a3f4-8511845cf529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7350b8e-419b-4564-9523-4be12bc48b7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_436ef63d-fc6d-4417-9b9b-5376ba16f03f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:StockOptionsIssuedAndOutstandingUnderPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fc400ca-bc44-4785-8a4c-ad2af354ffac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbfab71f-6665-4527-940a-db6f796b7bbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_080706bb-030b-4069-b6d7-d7d31567a27c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f7038cd-03eb-4dd6-8464-7a639831af3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-08</xbrli:startDate><xbrli:endDate>2022-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cad5a80-a737-4f91-a14b-3bb394a8f508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4dc177f-a41b-4a6c-9a51-c41f851cea5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cd00306-7aef-4100-8205-c4511dea8fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b5f35bb-1962-4ed8-958d-db0a4a14c1cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfff9d89-3c68-4d8a-aaf1-ae180ad5659f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b82dab6-564a-4b17-993f-52bc89ea5908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_619af7c1-a3fb-4ce4-9615-d637396286e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a53c973f-68a7-4092-8c03-15c10d086cf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:RightOfUseEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47ec21cb-9507-465f-9a93-95dbd904a764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e670d03-0073-40c0-81aa-a64691a64651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bd8958d-ac74-435f-a9b1-65f5c5df5463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c024e436-4a63-48c9-b8e3-a71a5ce33e50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:ServiceWarrantyServiceContractsAndAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e15cdba7-7d58-4afa-a398-ee69435f47e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ee404e1-09d9-4e49-8567-7e3e99def558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f255c0ae-0062-4072-976a-b8a141cbb369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7039d17-9ee2-4e22-b624-e5756e318526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49f1aec2-a4e1-4190-a936-3eb5ce2b4155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b31877-61d1-447b-9f36-a10b15a4cba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_115b5518-d11e-4805-8e6b-f554aae35196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec480dfc-096a-4260-9524-3d1d45f8ffe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d24bcbd2-389a-48da-b2a7-d4fe20dbb56e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-28</xbrli:startDate><xbrli:endDate>2021-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e2c5118-f472-4fd8-bd76-d3936f7e7ba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab197fb1-568a-479c-8dca-51ebd28598ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f69db501-f7ea-4cc8-80d2-81597ec37696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b78bc7b3-79c3-4faf-8705-31df15a4698c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d126cea-f298-4eca-b4ae-c0648a9c58e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b77127b8-810a-4edb-a388-e4c235f9b291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a6bb245-6eba-41dd-bf62-8d7ed791fd8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0769e4e2-f071-4d16-811c-15ab6db50acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_055117f2-9811-4160-9a40-b17c1f912611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a21676c-9a43-4d66-b8cc-6cd51899920b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c2cf702-64b7-49e4-996a-cc8a823efe97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18f22b78-7783-4b48-a916-de31acc7d1e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa175e83-4ae0-4e56-8332-28c4e9813a04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04d3ef87-f8dc-4a39-8e22-74626d458f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38073016-ce8b-4023-8081-103f403ab2bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fed1b82c-fcdc-47fb-8e4c-b26548a6ea85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb92c51b-50ce-4557-91aa-51fc17ad1a81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec88e75c-ff75-4185-a750-95225b1dcd49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88cb89e8-ba4b-4206-a251-8f43f4a4a237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4f444db-5996-4c90-8623-059c3f481ab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e78c7069-b653-4177-963e-9d1bbcfd973f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f291850-e62c-4bcf-9ff7-f62a97675a66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26a351db-d159-4b04-884c-9e54b986cc5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bc13ab9-a18c-40ae-9c04-bd63e0ed3ba8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70360018-fdc1-4362-ac4e-ba7f96b09f5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f491cf28-fab6-4049-bce7-7c1f825422fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37cd287f-b1fe-417b-bb04-4b5f0d4c6f3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-28</xbrli:startDate><xbrli:endDate>2021-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa88a57b-a838-484b-b8a6-d0306d09b381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1e80520-b096-4bb3-86ce-8009a5315cb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:StockOptionsIssuedAndOutstandingUnderPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d1a568f-d394-4720-a1b6-9a88ef02d12b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d19decf9-3310-45a2-abd2-b456a757f5d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e4f8477-6783-483b-8846-75d4dd7609bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c3e38f4-8300-4d9a-93f9-acfee4e73ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:SharesAvailableForFutureSaleUnderTheAtmOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28619841-2fee-441e-b364-8cc0d0d59ea3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fa4f2fd-ca66-4db8-b0ed-9ab91076fb17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffa1d143-149d-4487-a305-e878c9ce191c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:LDDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84f4cc9e-e25e-43fa-81e5-13a42f6b8d68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfeaa0f9-8a0e-4a4c-af2e-cbfcae368f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rxst:AugustFourTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f267633b-a252-4c4b-a433-0ca95b359c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3ce3f5e-c938-4989-9d48-abb64a18b225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d583f1d4-bd83-4639-a274-fe28298e7a88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee2d4d90-23fb-46e2-9141-296d7b75f054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a7af93b-ffbb-4eba-bf5d-00c6faec0f6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:ServiceWarrantyServiceContractsAndAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_245fe6f8-26ec-4721-8201-1bc9132d6013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:SharesAvailableForFutureSaleUnderTheAtmOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88b18fd6-1484-4233-9ccd-4639da1f1dde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-28</xbrli:startDate><xbrli:endDate>2021-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2eee38f7-b0f6-4df6-b5d8-aa6c3374c148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rxst:NoCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e12529e-af41-4c48-9b3a-2cd9a1e05936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e59788db-8615-4e43-8e9d-3d404e52eb66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28c73d3b-1f4e-47eb-8983-ab2974f6fec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49a84f59-2893-49df-9918-73f7863dfea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f203818c-89e0-4e29-82a7-a9e012aac75d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_062bed15-9f98-4171-bfad-0df8a119278e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:NewLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b74aaf6-1816-4ba8-b25b-06f474253518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:NewLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e853287-f8f2-492f-b2ee-7e9d752ea4ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bc5a935-0234-4618-aba4-1ab485aa91f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8faa684a-3959-4ad4-91fa-5f5f141cb065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3836ee42-99e1-4b4c-b3f6-d7a829aa62e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0abec27c-e9d5-42ec-8f2f-cd858ce7ee0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_613e254a-d190-4764-a1ac-1d0b1edcfaae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_023ec558-5797-47a9-a985-808a5dc77077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f2eeece-26e5-4b45-bad6-a36623117435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:RxlalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22015c87-a9d7-40c9-bba3-3d510e3d5d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:LDDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_271a9f64-d7fb-4c83-8f60-0616504ca74e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41c727ce-a38b-4fac-af15-b2f7c97ca3f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:RxlalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34ca7f16-9126-43a4-886f-fec2f9b38b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4100cff0-e3c8-4a4e-a04b-cac826120706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rxst:NoCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bafa0c3-726b-4976-a24a-5029c3f3ff37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bda624d3-25b5-47d8-97a1-87d5fd21b451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4eedea1-0f5b-4dfb-bc30-d9f477763ebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06262739-6be2-40d0-a27d-2ee73ccd9a32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_829b96d2-f2b7-4707-8dc5-c513602f5c40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2848131a-3718-4555-b34d-a2e75cc52c9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-04</xbrli:startDate><xbrli:endDate>2023-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_935e5c68-4a2f-4fe7-830e-c64554a43bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-08</xbrli:startDate><xbrli:endDate>2022-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_668f69a7-acb0-43b4-a348-1ac42e4921ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d466df4-3d33-403f-8a77-220f9e7e5b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea603303-001a-4544-b085-bb841cb42c83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3910fa9f-eae3-48ac-b145-d6273c7505d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e81e1959-5dc9-462d-a83b-fe7fb4c2dc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc1f24f5-960c-4f14-a149-a28449446cd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35054392-155d-4fc2-92bb-5c95eec04e48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2256ad1c-8fe9-4d3b-ad3f-3872402cb7c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e03f7a2-cd01-43e0-96bd-e479c8471a97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13836f48-52b4-4300-9d56-4f50c234e19e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87f27813-04b4-43a9-89cf-60f99646eed6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4cbdee-0ada-4ebf-982e-0a37a5748260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c73432c-1e8b-41d2-a8a2-ad9cf9e153b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001111485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Subsidiary"><xbrli:measure>rxst:Subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>rxst:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Item"><xbrli:measure>rxst:Item</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed" fromRefs="F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c F_34d697a0-dc87-4fab-baef-c88c9f27381b"></ix:relationship></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71880674-2bd2-4945-afb1-3f72c4851f95" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_26a782d5-6f81-462e-a366-f1723b670ab3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09aec78e-44ef-482d-867c-043b58679319" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0036a8b2-8e50-4df9-bad9-36712f7d6772" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a4f5405e-e24e-45f1-a7f6-f541fb81a83b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from                      to</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22b2c70d-4775-48c6-b0d6-83afeec0f6db" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-40690</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6fef7bb-7ed2-4b4d-ad67-6baa05785f7c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">RxSight, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37eb7a5c-3f2b-4005-bee7-0e91865cb96c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_50e7f6e7-1498-474a-ac58-0109d2d9869c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94-3268801</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_db17e565-d4f3-4097-b5d5-0b0781a5354a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">100 Columbia</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_55e6aeff-d596-4980-9b64-85b1828844c1" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aliso Viejo</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_dd5a7f0f-f02c-4359-a369-b29cc1f2a713" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3aec0577-0f1c-45a5-ba8a-f028893e22b2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92656</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1182c5dd-2961-442a-be8f-82416ceb515d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(949)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f81b72bc-2108-4615-be96-1302ee9d1a11" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">521-7830</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a6471bf0-4921-448e-99a4-1bd195327b84" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_1785f41f-89d6-4b8c-b634-1fcafe0324a3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RXST</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_985b1dc6-30f3-43df-bb5b-1d3156fe365a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d7b405b-6fc0-4730-95cd-81af458bde47" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_533200a4-6133-445c-8b89-672106cc39db" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a97cfd2e-a354-4c01-92d0-a08fef9e9bde" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d119eb5-2ed1-416a-8a22-ba75c6affa2b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_521454c4-24af-4fc9-80b1-26418b2179cb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_8af0ef4a-87b9-41d9-a1a8-cb97f8301e03" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_bf199b2d-3253-4291-880d-9ad80a82a4d4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f033c78-4eb6-4197-9e0a-8bc959c5499e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbcdfe00-ee39-4616-bf4b-77063c775892" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d725045-37f3-49d8-9216-de69a459d4b4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_089af205-4e95-4d30-ba8d-59c30358eb10" contextRef="C_b64f86a3-1985-43c1-be28-347c081c8c0f" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> million based upon the closing price of $28.80 on the Nasdaq Global Market on such date.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of registrant&#8217;s Common Stock outstanding as of February 15, 2024 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_985981e1-5019-4442-835c-57c389afc035" contextRef="C_ec480dfc-096a-4260-9524-3d1d45f8ffe9" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,987,556</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_ce713a58-a626-4177-a386-76c52f3680ea" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2023. Except with respect to information specifically incorporated by reference, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:82%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_market"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following discussion and analysis should be read together with our consolidated financial statements and the notes to those statements included elsewhere in this report. This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. In this report, &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to RxSight, Inc., a Delaware corporation, and its consolidated subsidiaries.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements are contained principally in the section entitled &#8220;Risk Factors&#8221; in Part I, Item 1A of this report and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this report. Forward-looking statements include, but are not limited to, statements concerning the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements, including our expectation that we do not anticipate the need to raise additional capital or incur additional debt in order to reach profit from operations, as disclosed in the Company&#8217;s future Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;);</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to conduct further clinical trials and any expectations related to the timing or outcomes of such trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans and expected timeline related to our products, or developing new products, to address additional indications or otherwise;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected acceptance and use of our products by doctors;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain, maintain and expand regulatory clearances for our products and any new products we create;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected growth of our business and our organization;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intentions regarding investment in our business as we pursue growth;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expected uses of our existing resources;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding government and third-party payer coverage and reimbursement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain an adequate supply of materials and components for our products from our third-party suppliers, including single- and sole-source suppliers;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manufacture sufficient quantities of our products with appropriate quality;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain, maintain and enforce intellectual property protection for our products and protect our intellectual property rights;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to expand our business into new geographic markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to comply with applicable SEC rules and Nasdaq continued listing requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to comply with existing and future government laws, rules and regulations both in the United States and internationally;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding allocation of resources toward expenses associated with being a public company;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the volatility of the trading price of our common stock;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify and develop new and planned products and/or acquire new products;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development and projections relating to our competitors or our industry, including anticipated growth rates for the conventional and premium intraocular lens (&#8220;IOL&#8221;) markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of local, regional, national or political conditions and events; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of worldwide political and economic conditions and unknown future events on our business, financial condition and results of operations.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward-looking statements include statements that are not historical facts and can be identified by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; or the negative of such terms and other same terminology.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part I, Item 1A, &#8220;Risk Factors,&#8221; elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements made in this report relate only to events as of the date on which the statements are made. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDUSTRY, BUSINESS AND MARKET DATA</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This report also contains estimates, projections and other information concerning our industry, our business, and market opportunity, including data regarding the estimated size of the market. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This report contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of it by, any other companies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Business</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Light Adjustable Lens system (&#8220;RxSight system&#8221;) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;LAL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), RxSight Light Delivery Device (&#8220;LDD&#153;&#8221;) and accessories. Our LAL is a premium intraocular lens (&#8220;IOL&#8221;) made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet (&#8220;UV&#8221;) light generated by our LDD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We designed our RxSight system to address the shortcomings of competitive premium IOL technologies and provide a solution that doctors can trust to improve visual outcomes and achieve high levels of patient satisfaction. Competitive premium IOLs require patients to specify their visual priorities before surgery and be willing to accept various optical trade-offs associated with those choices. Once a patient has selected a competitive premium IOL, the surgeon must rely on a series of preoperative diagnostic tests and predictive formulae to choose the appropriate lens power. If the doctor&#8217;s prediction is suboptimal, then the patient may experience suboptimal results that could necessitate a subsequent corneal refractive procedure or certain other compromises in order to reach vision targets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In contrast, with the RxSight system, the surgeon implants the LAL as they would in any other cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient&#8217;s desired vision outcomes. We believe our RxSight system provides doctors and patients increased confidence and peace of mind by eliminating the high-stakes preoperative guesswork common to competitive premium IOLs and allowing patients to iterate their final vision characteristics with customized post-surgical adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A cataract is the loss of transparency in the eye&#8217;s natural lens, which causes blurry or hazy vision and can eventually lead to blindness. Approximately 50% of all individuals develop some form of cataracts by age 60, usually in both eyes, and prevalence increases with age. Among the world&#8217;s most commonly performed procedures, cataract surgery involves removing the cloudy natural lens and replacing it with a clear IOL. Prior to surgery, patients can opt for either a spherical monofocal IOL, which usually results in improved vision but requires glasses for best vision, or a premium IOL, which also corrects for astigmatism and/or presbyopia, thereby reducing spectacle dependence. In the United States, Medicare and private insurers typically cover the full cost of spherical IOL procedures, while premium IOL procedures require patients to pay an incremental out-of-pocket fee, typically ranging from $1,000 to $4,000 per eye depending on the specific premium IOL used. In the United States, the world&#8217;s largest premium IOL market, 2023 premium procedures represented about 21% of all cataract procedures and generated approximately $780 million in revenue, a figure that is projected to grow at a 9.5% compound annual growth rate (&#8220;CAGR&#8221;) by 2028, according to the Market Scope 2023 Premium Cataract Surgery Market Report.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the premium cataract surgery market remains underpenetrated due to both doctors&#8217; reluctance to recommend competitive premium IOLs to the full universe of eligible patients and patients&#8217; confusion in assessing the associated trade-offs and side effects with competitive premium IOLs. We believe competitive premium IOLs often fail to deliver on patients&#8217; expectations for quality vision across a range of distances without glasses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our RxSight system offers doctors and patients a significantly more reliable approach that can consistently deliver optimal, fully customized visual outcomes with few compromises, ultimately driving broad adoption and establishing it as the standard of care for premium cataract procedures. The key benefits of our solution include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allowing full customization and optimization of patient vision after surgery.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LAL uses a proprietary silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. Our LDD uses proprietary software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction in 0.25 diopter increments, similar to the adjustment increments used to refract patients for glasses or contact lenses, as well as in other refractive procedures like LASIK. All other premium IOLs are fixed-power lenses that cannot be adjusted following surgery;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delivering superior visual outcomes with low risk of side effects. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In our Food and Drug Administration (&#8220;FDA&#8221;) clinical trial, 70% of LAL patients achieved 20/20 or better uncorrected visual acuity without glasses, while in similar trials of other premium IOLs, only about 40% of patients achieved this performance level. Additionally, LAL patients do not experience increased incidence of glare or halos that are common with other premium IOLs;  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Providing accuracy and precision to optimize vision with both eyes.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most LAL patients choose minor differences in the refractive correction of each eye, resulting in glasses-free vision across a full range of distances. In our most recent Phase IV commercial study data over 90% of patients were able to achieve 20/20 or better at distance without glasses, which is approximately twice the rate of any of the alternative IOLs. In addition, over 90% of patients were also able to read 5-point font at near vision, which is typically the size of footnotes on a page;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enabling patients to preview and compare possible vision outcomes.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LAL patients are the only premium IOL patients able to test-drive their vision after surgery but before selecting a final refractive outcome. With up to three possible UV light treatments to adjust the LAL, patients direct their optimal visual acuity through an interactive and iterative process; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Empowering doctors to grow their practices with a premium IOL they can trust and confidently recommend.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our RxSight system has been shown to deliver excellent visual outcomes across a broad range of patient types and preferences. In our 2022 RxSight customer survey, 89% of respondents said they thought our RxSight system delivered the highest quality vision, 98% said they would recommend the LAL to others and 75% said they would select it for their own eyes. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial efforts began in 2019 and have been primarily focused in the United States, where we are building a &#8220;razor and razor blade&#8221; business model to drive new customer adoption and ongoing LAL volume growth. Our U.S. commercial organization includes a direct sales team of LDD sales personnel and LAL account managers, as well as clinical specialists, field service engineers and marketing personnel. Our sales efforts are concentrated on the roughly 4,000 U.S. cataract surgeons that perform 70%-80% of all premium IOL procedures. As of December 31, 2023, we had established an installed base of 666 LDDs in ophthalmology practices and, since our inception though December 31, 2023, surgeons have implanted over 96,000 LALs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to grow our business primarily by expanding the size of our LDD installed base and driving increased utilization of our LAL through heightened awareness of the superior clinical outcomes our RxSight system provides patients. To continue to strengthen our competitive position in the premium IOL market, our research and development activities are focused primarily on programs that improve clinical outcomes, improve customer experience, expand our indications for use, reduce manufacturing costs and lifecycle management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our market and industry</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cataracts and other common vision conditions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common vision conditions can be roughly divided by two defining factors: 1) the typical age of onset and 2) whether the condition is more closely linked to the cornea, the front surface of the eye that controls about two-thirds of its focusing ability, or the natural lens, which sits behind the iris and is responsible for the eye&#8217;s remaining focusing power.  From childhood through the fourth decade of life, refractive conditions related primarily to the cornea &#8211; myopia, hyperopia and astigmatism &#8211; typically have the greatest impact on visual acuity and are usually addressed with glasses and contact lenses. In adults with these conditions, corneal procedures like LASIK can reduce dependence on glasses and contact lenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By age 50, most people also experience presbyopia, which manifests itself as increased difficulty seeing at near and intermediate distances without glasses or contact lenses. Presbyopia occurs because the natural lens is losing its elasticity and, therefore, its ability to focus light rays on near objects. By age 60, approximately half of all individuals also develop some form of cataracts, in which the normally clear lens loses its transparency and increasingly obstructs or otherwise interferes with the passage of light to the retina. The result is blurry or hazy vision and increased sensitivity to light, particularly at night, that cannot be treated with glasses or contact lenses. Cataracts are irreversible, progressive and usually affect both eyes. Cataracts can significantly interfere with daily activities, affect quality of life and eventually cause</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">blindness. According to the National Eye Institute, despite the availability of effective surgical treatment, cataracts are the leading cause of blindness worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><img src="img50815396_0.jpg" alt="img50815396_0.jpg" style="width:621px;height:130px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cataract surgery</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cataract surgery is among the most common surgical procedures performed in the world and involves replacement of the patient&#8217;s natural cloudy lens with a clear artificial IOL. In the United States, the procedure is commonly performed in an outpatient setting, such as an Ambulatory Surgery Center (&#8220;ASC&#8221;), by an ophthalmologist specializing in cataract surgery and often requires only 5 to 15 minutes to complete. In most cases, surgery begins with removal of the cataractous lens through a process known as phacoemulsification. During phacoemulsification, the ophthalmic surgeon makes a small surgical incision in the cornea and inserts an ultrasonic probe that breaks up, or emulsifies, the lens while a hollow needle removes the pieces of the lens (see image 1 below). After the cataract is removed, the surgeon inserts the replacement IOL through the same surgical incision (see image 2 below). Following implantation, the IOL sits firmly in place just behind the iris (see image 3 below).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img50815396_1.jpg" alt="img50815396_1.jpg" style="width:563px;height:138px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conventional vs. premium cataract surgery</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cataract surgery is often bifurcated into two categories based on IOL type, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conventional:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patient receives a monofocal IOL, which is designed to provide vision at one pre-defined distance without correction for other visual problems that often affect cataract surgery patients such as corneal astigmatism and presbyopia. Nearly all patients undergoing conventional cataract surgery will need to rely on glasses following cataract surgery to achieve the best distance, intermediate and near vision. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Premium:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The patient receives a premium IOL, which is designed to address the shortcomings of conventional monofocal lenses by also correcting for the additional visual problems of astigmatism and/or presbyopia. Premium IOLs reduce the need for glasses relative to conventional IOLs but may impose trade-offs related to their ability to provide glasses-free near, intermediate and distance vision, as well as the potential for increased incidence of halos, glare and other side effects related to monofocal IOLs.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare payors typically cover the full cost of conventional cataract procedures. In the United States, a healthcare payor (primarily Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)) typically provides reimbursement for a conventional cataract procedure of approximately $500 for a surgeon fee and approximately $1,000 for a facility fee, which includes the cost of a conventional monofocal IOL. Accounting for reductions in CMS reimbursement and for inflation, reimbursement rates have decreased by two thirds since 1991. The surgeon fee covers all pre-operative cataract testing, the cataract operation and follow-up care for three months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. premium cataract procedures, the healthcare payor (primarily CMS) reimburses the same surgeon and facility fees, but the patient pays the surgeon an additional fee between $1,000-$2,000 for implantation of a toric IOL and an average between $2,000-$4,000 for implantation of other premium lenses, which includes the cost of the premium IOL. Consequently, premium cataract procedures are between 10 and 15 times more profitable for the doctors and ophthalmology practices than conventional cataract procedures and are less impacted by changes in reimbursement rates. At the same time, because premium cataract patients pay an additional out-of-pocket fee, they tend to have high expectations that the surgeon will satisfy their desire for quality, glasses-free vision.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our market opportunity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Market Scope 2023 Premium Cataract Surgery Market Report and 2023 Market Scope IOL Report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately 31 million cataract surgeries were performed globally in 2023, including 4.7 million in the United States. The number of procedures worldwide is projected to grow at a CAGR of 3.9% to over 37 million by 2028. In the United States, procedures are expected to grow at a CAGR of 4.5% to 5.9 million by 2028;  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States is the world&#8217;s largest premium IOL market. In 2023, premium IOL procedures represented approximately 21% and 11% of cataract surgeries in the United States and worldwide, respectively;  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, premium IOL revenue was approximately $2.4 billion globally and $780 million in the United States, and is expected to grow at a CAGR of 11.0% and 9.5%, respectively, through 2028. Key growth drivers include the increasing number of patients who prefer to be glasses-free, technological innovations, increased access to healthcare and rising disposable income; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there are approximately 8,000 ophthalmic surgeons that perform cataract surgery, including approximately 4,000 that perform roughly 70%-80% of premium IOL cataract procedures.  </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe there is an opportunity to gain market share in the premium IOL market segment and also increase the penetration of premium IOLs in the broader market by converting doctors and patients currently electing for conventional cataract surgery. We believe that the premium cataract surgery market remains underpenetrated due to both doctors&#8217; reluctance to recommend premium IOL offerings to the full universe of eligible patients and patients&#8217; confusion in assessing the trade-offs associated with the wide range of commercially available premium IOL offerings. Furthermore, we believe current non-adjustable premium IOL offerings often cannot deliver on patient expectations regarding their desire to see at near, intermediate and far distances without reliance on glasses and to avoid troubling side effects such as glare, halos and loss of contrast sensitivity.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently focused on driving awareness and penetration of our RxSight system in the premium cataract market, and primarily concentrating our near-term commercial efforts on the United States. We believe the United States is the most compelling market given the large population of individuals over the age of 60 that are covered by health insurance, the concentrated base of cataract surgeons experienced with premium IOL offerings, the high gross domestic product per capita and the favorable U.S. healthcare reimbursement system, which has a well-established history of covering a portion of the cost for cataract surgery.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-adjustable premium IOLs and their limitations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the commercial availability of our RxSight system, doctors and patients chose from two primary types of premium IOLs, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Multifocal Lenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Multifocal lenses have two or more corrective zones, which allow the patient to receive focused light from different distances. Although multifocal lenses provide patients with a wider range of vision compared to the standard monofocal IOLs, multifocal lenses split light across the multiple corrective zones on the lens, sometimes impacting visual quality. For example, approximately two to three times as many patients who choose a multifocal lens over a monofocal lens experience side effects such as glare and halos, as well as reduced contrast vision, which are especially problematic in low light situations such as driving at night. For some patients these become more pronounced and can lead to explantation (removal of the IOL and replacement with another type of IOL). Extended-depth-of-focus (&#8220;EDOF&#8221;) lenses are similar to multifocals, except they have only one corrective zone. They create an elongated focal point that allows for a broader range of vision, although patients will still often require glasses for distance and near vision. EDOF lenses will still typically result in glare and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">halos, as well as reduced contrast vision, although generally less severe than those experienced with multifocal lenses; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Astigmatism-Correcting or Toric Lenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Toric lenses correct for astigmatism, a condition in which the cornea is not uniformly curved leading to distortion of near and distance vision. According to the 2023 Market Scope IOL Report, approximately 70% of the population has clinically significant astigmatism of 0.5 diopters or more. Corrective toric lenses can provide additional distance, intermediate or near vision correction depending on the power of the lens selected and if their optical design incorporates either multifocal or EDOF features. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When preparing patients for premium cataract surgery, surgeons must have a comprehensive understanding of available premium IOL options and how to best match a patient to the technology that fits their priorities. Patient decisions are based on several factors and tend to be heavily influenced by surgeon recommendations, as well as the patient&#8217;s motivation for independence from glasses and willingness to tolerate side effects. During an initial consultation, surgeons often ask patients to fill out a survey regarding their vision experiences and expectations to determine if the patient is a good premium IOL candidate. If so, the surgeon helps select the appropriate premium IOL based on the patient&#8217;s lifestyle and the type of vision they most value (i.e., near, intermediate or distance). Significant time is often required to educate patients on the various trade-offs with respect to the visual outcomes associated with each type of premium IOL. Following this consultation, surgery is usually scheduled within several weeks or months.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to surgery, the patient&#8217;s eyes are measured using one or more diagnostic devices to help the surgeon predict the lens focusing power best suited to achieve the optimal postoperative outcome. Focusing power, expressed in diopters (D), refers to how a lens focuses light to a point (spherical power) or a line (cylindrical or astigmatic power). Accurately predicting lens power is critical to reducing postoperative residual refractive error and delivering the best possible visual outcomes. Because the lens power of competitive premium IOLs cannot be changed after implantation, doctors rely on a series of preoperative diagnostic tests and predictive formulae to determine the lens power. Typically, the patient returns a day after surgery to have their eye evaluated and ensure healing is underway. After approximately one month, premium cataract patients that are dissatisfied with their results may be fitted for glasses or elect to undergo a secondary, remedial procedure to meet desired vision targets. A separate LASIK procedure is the most common surgical procedure to correct any residual visual errors following the cataract procedure.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key limitation of these competitive premium IOLs is that they cannot be adjusted after the surgery and, as such, require the patient to commit to a desired visual outcome prior to the procedure. However, in discussing vision optimization options with patients ahead of the procedure, it can be difficult to effectively demonstrate different visual outcomes. Once a premium IOL is selected, another key limitation is the ability of the surgeon to precisely predict the correct lens power and then implant the IOL with the level of accuracy required to deliver the patient&#8217;s expected outcome. Additionally, the incision made to remove the cloudy lens and insert the IOL along with the resultant healing process often creates additional levels of astigmatism, which cannot be predicted with precision before cataract surgery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the need to commit to a visual outcome before surgery combined with the limited ability to make adjustments following the procedure are key factors contributing to the low levels of premium IOL penetration. When expectations regarding postoperative visual acuity and independence from glasses are not met, patients are often disappointed. As a result, even though 60% of cataract patients rate &#8220;being glasses free after cataract surgery&#8221; as extremely important, surgeons are often hesitant to recommend existing premium IOLs to their patients.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our solution</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We designed our RxSight system to address the shortcomings of existing premium IOL technologies and provide a solution that doctors can trust to improve visual outcomes and achieve high levels of patient satisfaction. We began commercializing our solution in the United States in 2019 and are focused on establishing the RxSight system as the standard of care for premium IOL procedures.  As of December 31, 2023, we had an installed base of 666 LDDs in ophthalmology practices, and since our inception over 96,000 surgeries have been performed with our RxSight system.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of the RxSight system</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RxSight system is the first and only FDA-approved IOL technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. With the RxSight system, the doctor performs a standard cataract procedure to implant the LAL, determines refractive error with patient input after healing is complete, then uses the LDD to reshape the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LAL to achieve the patients&#8217; desired vision outcomes. Our RxSight system is comprised of two key components, along with other intraoperative and postoperative accessories:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSight Light Adjustable Lens: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LAL is our proprietary IOL that can be adjusted postoperatively to improve uncorrected visual acuity. Our IOL is made of special photosensitive material that changes shape and power when a specific pattern of UV light is delivered from the LDD. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSight Light Delivery Device: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LDD is our proprietary office-based light treatment device that delivers UV light in a precisely programmed pattern to induce a predictable change in the shape and refractive properties of the LAL, enabling surgeons to precisely modify the LAL based on the visual correction needed to achieve the patient&#8217;s desired vision after cataract surgery.  </span></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img50815396_2.jpg" alt="img50815396_2.jpg" style="width:283px;height:189px;"/><img src="img50815396_3.jpg" alt="img50815396_3.jpg" style="width:150px;height:225px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our foundational technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed our RxSight system over the last 20 years, incorporating expertise and proprietary technologies across multiple disciplines, including optics, material science, chemistry, software and hardware engineering. The proprietary RxSight technology that enables post-operative adjustability is based on the principles of photochemistry. The LAL is made of a photosensitive material that changes shape and power when a specific pattern of UV light is delivered to the LAL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LAL, which we manufacture using our proprietary silicone formulation, leverages the unique material properties of silicone. Silicone consists of an inorganic silicon-oxygen backbone, which is a chain of alternating silicon and oxygen atoms with an attached side group, which is a pair of organic molecules bonded to each silicon atom in the chain. Combined with organic side functionality including reactive groups, silicones can be cross-linked at multiple points resulting in three-dimensional structures. By varying chain length, attached side group and cross-linking design, silicone polymers can be tailored to have unique properties, leading to their broad use across a wide array of applications. We have developed a novel application of silicone to optimize the mechanical and optical properties of IOLs in order to improve vision in patients following cataract surgery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To create the LAL, we use a composition of silicone polymers including low molecular weight functionalized polymer, we call them &#8220;macromers&#8221;, mixed with photo-active molecules and other compounds. The initial composition of our lens material is a viscous liquid that is thermally cured in a lens mold. Thermal curing and photopolymerization use temperature and ultraviolet light, respectively, to initiate and propagate a polymerization reaction. To avoid polymerizing the macromers in the composition, the thermal curing is performed at a low temperature. The partial polymerization of the LAL results in a solid but soft silicone lens, leaving the photosensitive macromers unpolymerized and distributed throughout the lens. While the resulting lens is optically clear, the macromers and photo-active molecules remain free to continuously move within the lens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After packaging and sterilization, the LAL is ready to be implanted as part of a standard cataract surgical procedure to replace the patient&#8217;s natural lens. Once wound healing is complete, a short exposure of UV light is applied to the LAL to adjust the refractive properties of the lens. When the UV light is directed to a specific portion of the lens, the exposed macromers in that portion of the lens are polymerized and become stationary. This creates an excess concentration of free macromers in the unexposed portion of the lens and sets up a diffusion gradient over which the unpolymerized macromers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">move from the concentrated area to the less concentrated area. Over the next one to two days, the unpolymerized macromers redistribute across the lens to achieve a uniform distribution. The redistribution of the macromers causes the exposed portion of the lens to swell relative to the unexposed portion of the lens, enabling refractive power change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The movement of the macromers causes a highly predictable change in the curvature of the lens. If the central portion of the lens is exposed to UV light, unpolymerized macromers in the periphery of the lens move into the central portion. As a result, the central portion of the lens swells, creating a lens shape for correction of hyperopia. Conversely, if the periphery of the lens is exposed to UV light, unpolymerized macromers in the central portion of the lens migrate into the periphery. As a result, the periphery of the lens swells, creating a lens shape for correction of myopia. In addition to spherical correction for myopia or hyperopia, customized cylinder adjustments along any axis of the lens can be targeted to correct for astigmatism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To achieve the desired refractive change in the LAL, our LDD uses proprietary software and algorithms to deliver a short UV exposure treatment that polymerizes specific portions of the lens according to a predefined pattern of light, called a nomogram. Nomograms allow for adjustment of spherical and cylindrical refraction in 0.25 diopter increments, like the adjustment increments used to refract patients for glasses or contact lenses, as well as in other refractive procedures like LASIK, which has similar refractive accuracy. Designed for placement in the doctor&#8217;s office, the LDD is a combination of a standard slit lamp and a digital light projector. The slit lamp portion allows the doctor to see inside the patient&#8217;s eye and align the light beam with the LAL. The digital light projector portion projects an image onto the LAL using DLP technology that has approximately 250,000 micro mirrors that are electronically activated to represent an image stored in memory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each UV light treatment consumes only a portion of the macromers in the lens, allowing the LAL to be adjusted multiple times. This process can be repeated up to three times over a period of several weeks, until the patient and doctor are satisfied. The entire lens is then polymerized to provide a stable correction. After adjustment light treatments are completed, one or two lock-in light treatments are applied to consume all remaining macromers and photo-active compounds. After the final lock-in treatment, the lens power can no longer be adjusted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the RxSight system, the surgeon performs a standard IOL implant procedure, replacing the patients&#8217; natural lens with the LAL. Two to three weeks following surgery, the patient visits the doctor&#8217;s office for a standard postoperative refraction, which is similar to the eye test used to create a prescription for eye glasses. Using a traditional phoropter and vision chart, a clinician determines the refractive error and prescription required and inputs the information into the LDD&#8217;s graphical user interface. The patient&#8217;s eye is dilated and a contact lens is applied to the eye as the patient is seated in front of the LDD for a light treatment. Based on the prescription input, the LDD generates a programmed, predetermined exposure of UV light. For approximately 100 seconds, the light painlessly and non-invasively reshapes the implanted LAL to correct the measured refractive error. The entire treatment takes less than five minutes. The patient returns approximately three to five days later for additional light treatments to further adjust their vision, if desired, or to lock-in the lens. While patients can receive up to three adjustments, the average number of adjustments in our FDA clinical trial was 1.6.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RxSight system enables a fully interactive and iterative process to optimize visual acuity with patients able to test drive their vision, comparing possible outcomes before selecting a final prescription for their LAL. In clinical practice since our FDA approval, roughly 60% of patients undergoing multiple adjustments have requested a change from their original spherical target, underscoring the value of adjustability and customization. From the time of surgery until 24 hours after the LAL is locked in, the patient wears UV light protective glasses as unprotected exposure to light can cause uncontrolled changes in the LAL. Since late 2021, we have included ActivShield technology on all LALs, which provides an extra layer of UV protection on the lens surface and reduces dependence on patient compliance with protective glasses.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Key benefits of RxSight system for patients</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Superior vision outcomes. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the pivotal study that formed the basis for our FDA approval, the observed rate of eyes with 20/20 or better uncorrected distance visual acuity for our LAL was 70.1%. This compares favorably to the results of pivotal studies with similar study designs and patient populations that supported FDA approval of Alcon&#8217;s Acrysof Toric (38.4%) and J&amp;J&#8217;s Tecnis Toric (43.6%). Most LAL patients choose minor differences in the refractive correction of each eye, resulting in glasses-free vision across a full range of distances. In our most recent Phase IV commercial study data over 90% of LAL patients who chose to optimize vision with both eyes, achieved 20/20 distance vision and were also able to read 5-point font without glasses;   </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Postoperative customization.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RxSight system enables patients to preview and compare possible vision outcomes after surgery based on their unique preferences and lifestyle requirements before they select a final prescription for their LAL. With up to three possible adjusting light treatments, patients can dial-in their optimal visual acuity through an interactive and iterative process; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No increase in glare and halo.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LALs do not induce higher rates of glare and halos compared to monofocal IOLs. In contrast, multifocal IOLs, generally relied upon to improve near vision, are associated with a higher incidence of unwanted side effects including reduced contrast sensitivity and increased glare and halos around bright lights. These problems can lead to explants, in which patients undergo another procedure to remove the multifocal IOL and replace it with another type of IOL. In FDA studies for the Alcon Panoptix, J&amp;J Symfony and Alcon Vivity lenses, 48.8%, 59.2% and 17.0% of subjects, respectively, reported being bothered by halos postoperatively; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corrects residual refractive error</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The RxSight system can reduce the potential for secondary surgical procedures by correcting residual refractive error after surgery using our office based LDD to shape the LAL. With other premium IOLs, a separate LASIK procedure is generally the only way to correct for residual visual errors following the primary cataract procedure. </span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Key benefits of RxSight system for doctors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clear value proposition for patients, helping doctors to build their premium cataract practices. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rather than explaining the complicated trade-offs with respect to visual outcomes and predicting refraction before surgery, the surgeon may simply tell patients that their vision will be corrected postoperatively via a painless, in-office process similar to being prescribed glasses. The doctor can also share the LAL&#8217;s clinical results with the patient to provide reassurance that the procedure will deliver desired results; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increased confidence. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical benefit of &#8220;dialing-in&#8221; to achieve superior visual outcomes postoperatively increases doctors&#8217; confidence that the LAL can meet patients&#8217; expectations. The doctor does not need to decide prior to surgery whether the patient will be particularly sensitive to suboptimal visual outcomes or side effects (such as glare, halo and loss of contrast). The patient is also unlikely to need a postoperative adjustment such as LASIK to improve their outcome; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fewer intraoperative measurements.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With other premium IOLs, the lens power is fixed and cannot be changed after surgery, requiring doctors to spend considerable time on preoperative and intraoperative measurements to estimate the most suitable lens power to implant and lens position. With our RxSight system, surgeons are not as dependent on preoperative and intraoperative equipment for measurements. Instead, they can focus on the surgical procedure, knowing refractive error will be corrected postoperatively with the LDD, and with the patient&#8217;s active involvement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Broad application across different patients&#8217; needs.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We offer a single IOL that can address a broad range of patient types and needs, while providing a solution that doctors can trust to improve visual outcomes, eliminating the need for extensive preoperative discussions with patients about which IOL may best fit their lifestyle and visual preferences. Moreover, the superior outcomes and patient-centered approach of the RxSight system helps drive patient referrals and grow premium cataract volumes, which generally produce higher practice revenue and profit margin than conventional procedures; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Economic benefits that drive practice growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   A recent economic impact survey by Haffey &amp; Company of almost 50 practices using the RxSight system revealed that LAL procedures were sourced from all other categories of other IOLs. For example, respondents indicated that approximately 40% of their LAL patients would have otherwise selected a conventional monofocal IOL, which is far less profitable for a practice than a LAL procedure. In addition, based on an average of 9 LALs implanted per month at these practices, doctors observed a payback period of approximately nine months for the LDD, based on the current list purchase price. Following this payback period, practices continue to reap the financial benefit of converting patients to the RxSight system.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our growth strategies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are leveraging the tangible and compelling benefits of our RxSight solution to achieve broad adoption of our technology and establish it as the standard of care for premium cataract surgery. Our growth strategies include:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establishing new customers and growing our installed base of LDDs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our technology offers a differentiated value proposition to doctors and patients, providing us an opportunity to grow our share in the premium IOL market and increase the penetration of premium IOLs in the broader cataract surgery market. To grow our installed base, we are focused primarily on converting high-volume premium cataract surgeons to the RxSight system by highlighting its clinical, economic and workflow benefits compared to competing premium IOL technologies. Secondarily, we are focused on the broader pool of cataract surgeons who may implant premium IOLs sparingly or not at all due to suboptimal visual outcomes, persistent side effects and uneven patient satisfaction sometimes associated with non-adjustable premium IOL offerings. Because our RxSight system is designed to overcome these shortcomings, we believe many of these doctors have the potential to be successful RxSight customers. We are also investing in professional education, additional clinical studies and registries that expand our evidence base, facilitating peer-to-peer dialogue and forums and communicating the benefits of our technology through marketing initiatives, tradeshows and podium presentations;  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increasing the utilization of our LALs by empowering doctors to grow their practices. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We work closely with every new customer to conduct a thorough training and onboarding process, providing a high level of service to help the practice succeed with the RxSight system.  This support helps the practice confidently recommend the LAL to an increasing number of patients and, in turn, grow their practice. In a recent RxSight customer survey, 89% of doctors said they thought our RxSight system delivered the highest quality vision, 98% said they would recommend the LAL to others and 75% said they would select it for their own eyes. In addition to personnel support, we also provide practices with marketing materials, such as patient brochures, literature and digital content for website and social media promotions. We also provide ongoing training related to new technology features and developments, as well as education on the patient benefits of our solution;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategically expanding our commercial organization and marketing activities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since launching the RxSight system commercially in 2019, we have substantially increased the size and scope of our U.S. commercial organization. While we believe our current commercial organization is well built to reach our focused target of high-volume premium cataract surgeons, we will add highly qualified personnel for time to time, with a strategic mix of sales personnel and clinical specialists, to drive higher levels of awareness and penetration in certain regions. We also expect to accelerate marketing initiatives and professional education, including training on best practices and techniques;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing in RxSight system enhancements and expanding indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  We continue to enhance our RxSight system to improve the patient and doctor experience, meet evolving customer needs and address the widest possible patient population. Since our initial FDA approval in November 2017 through December 31, 2023, we have received approximately 30 supplemental approvals. Recent enhancements include increasing the range of available LAL powers, modifying the LAL to improve image quality, reducing the margin of residual refractive error, allowing an optional third refractive adjustment, developing new UV glasses with improved aesthetics and usability, and adding a photosensitive anterior layer (ActivShield&#153;) to the LAL to help protect the lens from unwanted UV exposure. We believe these technological advancements help to drive increased adoption of our RxSight system;  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scaling our business to achieve cost and production efficiencies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to realize operating leverage through increased scale efficiencies as our commercial operations grow. We have executed a number of design and manufacturing process improvements to streamline both LAL and LDD production, and have developed a more compact LDD, which was approved by the FDA in January 2023 and began shipping in the third quarter of 2023. We are also concurrently executing on our strategy to optimize our diverse supply chain and to develop second sources from less expensive suppliers. We anticipate that the combination of these strategies will drive margin improvement in the future when introduced into production and offered for sale; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Growing our commercial operations in international markets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> While our current commercial focus is on the large opportunity within the United States, we believe the RxSight system offers compelling benefits for cataract doctors and patients in select international markets. According to the Market Scope 2023 Premium Report, over 75% of the premium IOL procedures in 2023 were outside the United States. Our RxSight system has approval in Mexico and Canada for improving uncorrected visual acuity by adjusting the LAL power to correct residual </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">postoperative refractive error. We may selectively pursue commercial expansion outside the United States that accept these approvals in the future, with a priority on markets where we see significant potential growth opportunities. New approvals may also be sought in large cataract markets with more complex regulatory environments such as Asia.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA clinical studies</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, we completed our FDA Phase 3 pivotal randomized clinical study of 600 subjects, designed to evaluate the safety and effectiveness of performing light treatments to correct postoperative spherical and cylindrical refractive error. In this study, 391 subjects had the LAL implanted in one eye and the results were compared at the six-month postoperative visit against 193 subjects with a monofocal control IOL implanted in one eye. The LAL met all primary effectiveness endpoints and was approved by the FDA on November 22, 2017 as the first commercially available adjustable IOL. In the study, 70.1% of LAL subjects achieved monocular uncorrected distance visual acuity of 20/20 or better compared to 36.3% of the eyes implanted with the monofocal control IOL. In addition to being statistically significantly better than the control IOL, the observed rate of eyes with 20/20 or better uncorrected distance visual acuity was the highest reported for any approved intraocular lens and approximately twice what was observed by the two most popular astigmatism-correcting IOLs (38.4% by Alcon&#8217;s Acrysof Toric, and 43.6% by J&amp;J&#8217;s Tecnis Toric) in similar patient populations in the pivotal studies that led to their approvals by the FDA. Additionally, LAL patients reported a low rate of glare or halo, visual side effects that are frequently reported with premium IOLs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a 500-eye prospective, randomized, controlled multicenter Post Approval Study, which was a requirement of our Premarket Approval (&#8220;PMA&#8221;) approval. Subjects are randomized in a 2:1 ratio to receive either the LAL or a monofocal IOL. Study subjects will be followed for six months. The results will compare effectiveness and safety of the LAL and monofocal IOL. We anticipate completing enrollment in 2024.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We commenced commercial launch of our RxSight system in the United States in 2019 and are initially focused on the estimated 4,000 surgeons that perform 70%-80% of premium cataract surgery procedures. These surgeons are usually part of larger ophthalmology practices with multiple cataract surgeons. They typically have refractive surgery practices offering LASIK and are skilled at selling premium procedures based on delivery of better visual outcomes. Our U.S. commercial organization includes a direct sales team comprised of LDD sales personnel and LAL account managers, as well as clinical specialists and field service engineers and marketing personnel. While we believe we can effectively cover our concentrated target market with our focused commercial organization, we will add highly qualified personnel from time to time, with a strategic mix of sales personnel and clinical specialists, to drive further awareness and penetration among cataract surgeons.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial efforts are designed to create a &#8220;razor and razor blade&#8221; business model by building a sizable LDD installed base to drive ongoing growth in LAL procedure volumes. LDD sales personnel are responsible for establishing relationships with doctors and securing new customers. New customer contracts typically include sale of the LDD between approximately $110,000 - $145,000, sale of LALs for approximately $1,000 each and an LAL consignment agreement. Once the LDD is installed, our clinical specialists work closely with the practice&#8217;s doctors, technicians and staff members to ensure that they are fully trained, proficient LAL providers. Our LAL account managers oversee this process and engage with practices on an ongoing basis to assist with patient awareness and education programs, development of efficient patient flow processes and other initiatives. To achieve broad awareness of the RxSight system among cataract surgeons, we also conduct various marketing programs, including promotions at industry and society conferences, podium presentations, social media, and educational webinars focused on the differentiated benefits of our RxSight system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RxSight system has received regulatory approval in Mexico and Canada. We sell our products in Canada through a distribution partner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities are focused on programs that improve clinical outcomes, improve customer experience, expand our indications for use, reduce manufacturing costs and lifecycle management. Since our initial FDA approval in November 2017 through December 31, 2023, we have received approximately 30 supplemental approvals that advance these objectives.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the FDA approved our PMA supplement to our compact LDD for various modifications. This LDD will also require a submission for approval in countries outside the United States.  Research and development expenses were $29.1 million and $26.0 million for the years ended December 31, 2023 and 2022, respectively.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and supply</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently manufacture, assemble, test, and ship our LAL and LDD in Aliso Viejo, California at our campus of four facilities which consist of an aggregate of approximately 121,000 total square feet. We have intentionally pursued a vertically integrated manufacturing strategy offering critical advantages, including control over our product quality and rapid product iteration using strong R&amp;D and quality groups. We believe our current manufacturing capacity is sufficient to meet our current expected demand for at least the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are registered with the FDA as a medical device manufacturer and are licensed by the State of California to manufacture and distribute our medical devices. We are required to manufacture our products in compliance with the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) (21 CFR 820). The FDA enforces the QSR through periodic inspections and may also inspect the facilities of our suppliers. All of our current Aliso Viejo, California facilities have been registered with the FDA, the State of California, and the European Notified Body (British Standards Institution) for the manufacture and distribution of medical devices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received International Organization for Standardization (&#8220;ISO&#8221;) 13485:2016 certification for our quality management system. ISO certification generally includes recertification audits every third year, scheduled annual surveillance audits and periodic unannounced audits. We have also received quality system certification to the Medical Device Single Audit Program (&#8220;MDSAP&#8221;) to cover the jurisdictions of United States, Canada, Brazil, Japan, and Australia from the British Standards Institution. The MDSAP certification follows the ISO 13485:2016 certification schedule. The most recent recertification and surveillance audit was conducted in July 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LAL is a silicone intraocular lens made from a proprietary blend of custom chemical components. Chemical component vendors produce the raw materials, which we inspect, blend, further purify, and process, and formulate into uncured silicone blend. Using this uncured silicone, we mold the lens in one of our two Class 7 clean rooms. After curing, the molded lens is inspected and packaged and then sent to a third-party ethylene oxide sterilization vendor. After sterilization, the lens is returned to us for final inspection, packaging, and shipment to customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LDD is a UV projector medical device, which consists of an anterior segment biomicroscope, computer controllers for performing light treatments, and a biometrically designed patient interface and table. The optics are bonded into their mounts using epoxies, which are then oven cured, assembled into the main optical housing and optimized on a proprietary precision alignment station. The completed optical head is integrated into the table, along with a computer, power supplies and other electro-mechanical parts. We outsource the cables and circuit boards used in the LDD to certified specialty contract manufacturers. The fully assembled LDD is put through an electrical safety and final acceptance test process, and then reviewed by quality control, packaged and shipped directly to our customers for installation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a combination of internally manufactured and externally sourced components to produce the LAL and LDD.  We rely on third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of our products that include off-the-shelf chemical, materials, microchips integrated into printed circuit boards and cables, sub-assemblies, and custom parts that are provided by qualified and approved suppliers. We also employ a third-party sterilization vendor.  We do not have long-term supply agreements with, or guaranteed commitments from our suppliers, including single and sole source suppliers. We utilize purchase orders or blanket orders covering the medium term of 18&#8211;24 months for the majority of our supplier base. While we depend on our suppliers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements, vendors will miss delivery dates, extend delivery dates or in some circumstances cancel purchase orders because these suppliers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. The expansion of global lead times has resulted in the lack of availability of raw materials, including semiconductors, computers, monitors electronic parts, metals, packaging, adhesives, chemicals, resins and subcontract painted components. Certain suppliers have passed on higher prices, surcharges and expedited shipping fees to defray the higher commodity prices they are paying due to short supply and pushed out delivery dates. Additionally, due to these supply chain constraints we will identify and qualify new vendors or substitute components which requires testing, validations and documentation adding to internal costs and diverting engineering resources from other projects.  While we have taken measures to mitigate business continuity risk, including increasing standard lead times, payment of expedite fees, issuance of a limited number of non-cancelable purchase orders, advance delivery of critical components ahead of normal delivery dates and second sourcing, our suppliers may cease producing the components we purchase from them or otherwise decide to cease doing business with us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our suppliers are evaluated, qualified, and approved as part of our supplier quality program, which includes verification and monitoring procedures to ensure that our suppliers comply with FDA and ISO standards, as well as our own</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specifications and requirements. We inspect and verify externally sourced components under strict processes supported by internal policies and procedures. We maintain a rigorous change control policy to assure that no product or process changes are implemented without our prior review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party reimbursement and patient billing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dual aspect payment model</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the CMS has determined that the additional refractive correction provided by astigmatism correcting and presbyopia correcting (premium) IOLs is not a covered benefit. As described in two CMS rulings (CMS 05-01 and CMS 1536-R), premium IOLs have both a covered and non-covered aspect, providing the framework for the &#8220;dual-aspect payment model.&#8221; In effect since 2005, this model means that CMS does not reimburse the physician or the facility for the additional costs associated with a premium IOL, while still covering the cost of the conventional IOL procedure. Instead, the patient selecting a premium IOL is responsible for the additional charges from the physician and from the facility that exceed the regular charges for insertion of a conventional IOL that are submitted to CMS by each of these providers. As of 2017, CMS has recognized the LAL as an astigmatism correcting (premium) IOL, making it eligible for the dual aspect payment model. Most commercial payers mirror the Medicare rulings, but this can vary by payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Procedure coding and payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we primarily sell our LAL products to ambulatory surgical centers (&#8220;ASCs&#8221;) and occasionally to hospitals. These customers in turn bill various third-party payors, such as commercial payors and state and government payors, as well as patients and doctors directly for the services provided to each patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors require physicians and hospitals to identify the service for which they are seeking reimbursement by using Current Procedural Terminology, or CPT, codes, which are created and maintained by the American Medical Association, or AMA. For cataract surgery, the most common specific CPT codes are 66984 (Cataract surgery with IOL, on stage) and 66982 (Cataract surgery, complex). The facility fees associated with these codes include payment for a conventional IOL of up to $150. A specific HCPCS code is listed on the CMS claim by the facility to indicate use of premium IOL for tracking purposes only (V2787 or V2788 for astigmatism-correcting or presbyopia-correction function of IOL, respectively). Similarly, the physician includes HCPCS code A9270 (non-covered item or service) on their claim to Medicare (or another third party) to indicate charges for extended care related to the correction of refractive error.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While an Advanced Beneficiary Notice (&#8220;ABN&#8221;) or Notice of Exclusion from Medicare Benefits (&#8220;NEMB&#8221;) is not required, most providers issue an ABN or NEMB to alert patients that CMS (or non-Medicare payers) do not cover the additional charges associated with a premium IOL and to get the patient&#8217;s agreement to pay these charges. Patients are then billed directly by the physician and the ASC for these charges. In some cases, the physician bills the patient exclusively and then reimburses the ASC for the additional cost of the premium IOL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial payor and government program coverage</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the dual aspect payment model has been in use for over 15 years, the extent to which this model will be used by non-government third-party payors, such as commercial insurance, and managed healthcare organizations may vary. One third-party payor&#8217;s decision does not ensure that other payors will also follow this model. As a result, the coverage determination process can require manufacturers to provide additional support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that the dual aspect model will be applied consistently.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reimbursement outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems also vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In many countries, analogous determinations to the dual aspect CMS ruling have been made, allowing for partial coverage of the cataract procedure by national health systems, with patients paying out of pocket for refractive services associated with the premium IOL. In other countries, such dual billing is not allowed, forcing patients to pay for the entire cost of the cataract surgery and IOL when a premium IOL is used. In such markets, it may be possible for doctors to charge separately for the cost of light treatments, which are not part of the cataract procedure. This method would require a different billing methodology by us than is currently used in the United States, where light treatments are included with the purchase of the LAL. There is no assurance that these methodologies will be allowed or that an adequate level of payment will be established, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part on our ability to obtain, maintain, protect, and enforce our intellectual property rights, including our patent rights, preserve the confidentiality of our trade secrets, operate without infringing, misappropriating or otherwise violating the intellectual property rights of others and prevent others from infringing, misappropriating or otherwise violating our intellectual property rights. We rely on a combination of patent, trademark, trade secret, copyright and other intellectual property rights and measures to protect the products and technology that we consider important to our business. We also rely on know-how and continuing technological innovation to develop and maintain our competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our technology, inventions, improvements and products that are important to the development and implementation of our business. Our patent portfolio covers various aspects of our LDD, LAL and related devices and methods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. Generally, in the United States, issued patents are granted a term of 20 years from the earliest claimed non-provisional or Patent Cooperation Treaty (&#8220;PCT&#8221;) filing date. In certain instances, a patent term can be adjusted to recapture a portion of delay by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), in examining the patent application (patent term adjustment, or PTA) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension, or PTE), or both. Additionally, a patent term may be shortened if a patent is terminally disclaimed over an earlier filed patent. However, the life of the patent, and the protection it affords, is limited. In addition, we cannot provide any assurance that any patents will be issued from our pending or future applications or that any issued patents will adequately protect our current and future products. We also cannot predict the breadth of claims that may be allowed or enforced in our owned or in-licensed patents or whether such claims, if issued, will cover our products, provide sufficient protection from competitors or otherwise provide any competitive advantage. Any issued patents that we may own or in-license in the future may be challenged, invalidated, narrowed, held unenforceable, infringed or circumvented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our patent estate is directed to various aspects of our programs and technology, including our LAL and our LDD as well as lens adjustment procedure and other technology. Any U.S. or foreign patents issued or pending would be scheduled to expire on various dates from 2025 and 2043, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity, and other governmental fees. Further details on certain segments of our patent portfolio, including our owned and exclusively in-licensed issued patents and patent applications, are included below.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current LAL: Some of the patents directed to our current LAL include, for example, U.S. Pat. No. 9,119,710, which is expected to expire in 2026, U.S. Pat. No. 10,470,874, which is expected to expire in 2026, and U.S. Pat. No. 10,874,505, which is expected to expire in 2033. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LDD: Some of the patents directed to our LDD include, for example, U.S. Pat. No. 10,864,075, which is expected to expire in 2038, and U.S. Pat. No. 10,932,864, which is expected to expire in 2039. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lens adjustment procedure: Some of the patents directed to our lens adjustment procedure include, for example, U.S. Pat. No. 10,010,406, which is expected to expire in 2032, and U.S. Pat. No. 10,166,731, which is expected to expire in 2036. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RxSight system accessories: Some of the patents directed to our RxSight system accessories include, for example, U.S. Pat. No. 11,083,568, which is expected to expire in 2037. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the agreement with QAD, Inc. (&#8220;QAD&#8221;) dated October 29, 2015 (the &#8220;QAD Agreement&#8221;), we received a nonexclusive, non-transferable, perpetual license to use certain QAD software at the physical location where we install the software. Under the agreement, we purchase such QAD software through individual orders (&#8220;Purchase Orders&#8221;), and each Purchase Order has a respective payment fee and maintenance fee. We use the software licensed under the QAD agreement for inventory, shipping, receiving, sales order, work order, planning and financial transactions for the business. Maintenance for the software is offered by QAD and available for purchase by us on an annual basis, and such purchase was compulsory for the first year of the agreement. After the first year, maintenance purchased under the agreement automatically renews for successive one-year periods unless terminated by us or QAD 60 days prior to the effective date of any renewal term. Further, we grant QAD audit rights to verify our usage of QAD software, and if following such audit our use of the QAD software is in excess of our license, we are obligated to pay to QAD the amounts necessary to become compliant. QAD provides limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warranties to the software and retains all intellectual property ownership rights in the QAD software including any modifications made by us, however we receive a license to use any modifications made by us. Unless earlier terminated, the term of the QAD agreement is perpetual. Both parties have the right to terminate the agreement for convenience by giving the other party 90 days prior written notice and such termination does not affect the license granted. Either party to the agreement may terminate the agreement with notice, if the other materially breaches the agreement, and the breach is not cured within specified time periods. In addition, either party may terminate if the other party is adjudicated bankrupt or an official is appointed to manage its financial affairs. Upon termination for cause, we must immediately discontinue all use of the software.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that we have certain know-how and trade secrets relating to our technology and current and future products. We rely on trade secrets to protect certain aspects of our technology related to our current and future products. However, trade secrets and know-how can be difficult to protect. We seek to protect our trade secrets and know-how, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors but these agreements may not provide meaningful protection, and we cannot guarantee that we have executed such agreements with all applicable counterparties. These agreements may also be breached, and we may not have an adequate remedy for any such breach. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we take steps to protect our trade secrets and know-how, third parties may independently develop or otherwise gain access to our trade secrets and know-how.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For more information regarding risks related to our intellectual property, please see &#8220;Risk Factors-Risks related to Intellectual Property&#8221; in Part I, Item 1A of this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition in the surgical ophthalmology market is intense and is primarily driven by technological innovation and the regulatory approval required to commercialize products in the key markets around the world. The development of new or improved products may make existing products less attractive, reduce them to commodity status or even make them obsolete. We believe the principal competitive factors in our markets include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the quality of patient outcomes, oftentimes measured by visual acuity, and adverse event rates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient experience, including patient recovery time and level of discomfort; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance by treating doctors and referral sources; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">doctor learning curves and willingness to adopt new technologies; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ease-of-use and reliability; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic benefits and cost savings; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">strength of clinical evidence; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective distribution and marketing to surgeons and potential patients; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product price and qualification for coverage and reimbursement. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From a commercial perspective, we believe our primary competitors in the cataract IOL market are alternative premium IOL providers, including Alcon, Johnson &amp; Johnson and Bausch + Lomb. According to Market Scope, the global cataract IOL market is highly concentrated, with these top three players accounting for approximately 77% of the total U.S. premium cataract surgery market and approximately 61% of the global manufacturer market revenue.  Our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. We believe our ability to compete effectively will be dependent on our ability to build the commercial infrastructure necessary to effectively and cost-efficiently drive awareness of the unique value of our RxSight system.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, patients who receive an LAL will be required to wear UV protective glasses until final lock-in which is approximately 4-5 weeks after surgery. They will also be required to return for an additional two to three clinic visits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compared to traditional cataract surgery. The additional clinic visits are non-surgical but do require the patient&#8217;s eyes to be dilated. Due to these additional requirements, market acceptance of the LAL may be impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The most popular premium IOLs families approved for cataract treatment are toric and multifocal Acrysof and Tecnis IOL models. According to the Market Scope 2023 Premium Report Alcon, Johnson &amp; Johnson, Bausch + Lomb are three of the top IOL manufacturers, with an estimated 2022 revenue share of the world-wide premium IOL market of approximately 51%, 24%, and 2% respectively. The Acrysof and Tecnis families of IOLs are available in a monofocal Toric, multifocal Toric and EDOF Toric versions. The PC and Toric versions of these lenses represented over half of all premium multifocal IOLs sold in 2023. The rest of the market is shared between several smaller companies each with under 5% market share. From a technology perspective, we believe the LAL competes with nearly all of the existing IOLs, including conventional, premium astigmatism correcting and premium presbyopia correcting lenses.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our products and operations are subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, (the &#8220;FDCA&#8221;) and its implementing regulations, as well as other federal, state and local regulatory authorities in the United States, as well as foreign regulatory authorities. The FDA regulates, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, record keeping and reporting, clearance or approval, marketing, distribution, promotion, import and export, and post-marketing surveillance in the United States to assure the safety and effectiveness of medical products for their intended use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA regulation of medical devices</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees, unless an exemption is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA classifies medical devices into one of three classes &#8211; Class I, Class II or Class III &#8211; depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class I devices are those for which safety and effectiveness can be reasonably assured by adherence to the FDA&#8217;s general controls for medical devices, which include compliance with the applicable portions of FDA&#8217;s current good manufacturing practices for devices, as reflected in of the Quality System Regulation, or QSR, establishment registration and device listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices, also called Class I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class II devices are those that are subject to the FDA&#8217;s general controls and any other special controls deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, product-specific FDA guidance documents, special labeling requirements and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA through the 510(k) premarket notification process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. Due to the level of risk associated with Class III devices, the FDA&#8217;s general controls and special controls alone are insufficient to assure their safety and effectiveness. Devices placed in Class III generally require the submission of a PMA application, demonstrating the safety and effectiveness of the device which must be approved by the FDA prior to marketing, or the receipt of a 510(k) de novo classification, which provides for the reclassification of the device into Class I or II. The PMA approval process is generally more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several years, and generally requires significant scientific and clinical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investigational device process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed, and IRB approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and effectiveness, even if the trial meets its intended success criteria.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s good clinical practice regulations for institutional review board approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of clinical testing may be unfavorable, or, even if the intended safety and effectiveness success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients do not enroll in clinical trials at the rate expected;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients do not comply with trial protocols;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient follow-up is not at the rate expected; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients experience adverse events; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients die during a clinical trial, even though their death may not be related to the products that are part of the trial; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Device malfunctions occur with unexpected frequency or potential adverse consequences;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Side effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Institutional review boards and third-party clinical investigators may delay or reject the trial protocol;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party investigators are disqualified by the FDA;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records, and reports of sponsors of clinical investigations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or we or investigators fail to disclose such interests;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in government regulations or administrative actions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The 510(k) clearance process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or Class I, or a device that was previously found substantially equivalent through the 510(k) process. A device is considered to be substantially equivalent if, with respect to the predicate device, it has the same intended use, and has either (i) the same technological characteristics; or (ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes, but not always, required to support substantial equivalence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before the FDA will accept a 510(k) premarket notification for substantive review, the FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If the FDA determines that the 510(k) submission lacks necessary information for substantive review, the FDA will issue a &#8220;Refuse to Accept&#8221; letter which generally outlines the information the FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information before the FDA will proceed with additional review of the submission. If a 510(k) submission is accepted for substantive review, the Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can be delayed if FDA raises questions or requests additional information during the review process. As a practical matter, clearance often takes longer, and clearance is never assured. Thus, as a practical matter, clearance often takes longer than 90 days. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturer can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical devices can only be marketed for the indications for which they are cleared or approved. After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application or de novo classification. The determination as to whether or not a modification constitutes such a change is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until new 510(k) clearance or PMA approval is obtained. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The PMA approval process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the substantive review. The FDA, by statute and by regulation, has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The device may not be shown safe or effective to the FDA&#8217;s satisfaction;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing process or facilities may not meet applicable requirements; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in FDA approval policies or adoption of new regulations may require additional data. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting or life-sustaining devices used outside a device user facility. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use. Significant modifications to the manufacturing process, labeling and design for a device which has received approval through the PMA process may require submission of a new PMA application or PMA supplement prior to marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing regulation by the FDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even after the FDA permits a device to be marketed, numerous regulatory requirements apply, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment registration and device listing; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the QSR, or Quality Management System Regulation (&#8220;QMSR&#8221;), which goes into effect in February 2026, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation, and other quality assurance procedures during the manufacturing process; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">labeling regulations, advertising and promotion requirements, restrictions on sale distribution or use of a device, each including the FDA general prohibition against the promotion of products for any uses other than those authorized by the FDA, which are commonly known as &#8220;off label&#8221; uses;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Medical Device Reporting (&#8220;MDR&#8221;) regulation, which requires that manufactures report to the FDA if their device may have caused or contributed to a death or serious injury or if their device malfunctioned and the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">medical device corrections and removal reporting regulations, which require that manufactures report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FDCA Act that may present a risk to health; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an order of repair, replacement or refund; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">device tracking requirements; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post market study and surveillance requirements. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) or possibly a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or possibly a PMA. The FDA could also require us to cease marketing and distribution and/or recall the modified device until 510(k) clearance or a PMA is obtained. Also, in these circumstances, we may be subject to significant regulatory fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some changes to an approved PMA device, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new PMA application or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA often require the submission of the same type of information required for an original PMA application, except that the supplement is generally limited to that information needed to support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewing PMA supplements as it does in reviewing original PMA applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA regulations require us to register as a medical device manufacturer with the FDA. Additionally, some states also require medical device manufacturers and/or distributors doing business within the state to register with the state or apply for a state license, which could subject our facility to state inspection as well as FDA inspection on a routine basis for compliance with the QSR and any applicable state requirements. The FDA issued a final rule in February 2024 replacing the QSR with QMSR, which incorporates by reference the quality management system requirements of ISO 13485:2016. The FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the existing QSR. The FDA will begin to enforce the QMSR requirements upon the effective date, February 2, 2026. These regulations require that we manufacture our products and maintain related documentation in a prescribed manner with respect to manufacturing, testing and control activities. Further, the FDA requires us to comply with various FDA regulations regarding labeling. Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or state authorities, which may include any of the following sanctions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning or untitled letters, fines, injunctions, consent decrees and civil penalties; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customer notifications, voluntary or mandatory recall or seizure of our products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions, partial suspension or total shutdown of production; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay in processing, clearing or approving submissions or applications for new products or modifications to existing products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of FDA approvals or clearances that have already been granted; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">criminal prosecution. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory clearance or approval of our products under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the applicable United States medical device regulatory requirements could result in, among other things, warning letters, untitled letters, fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds, recalls or seizures of products, operating restrictions, total or partial suspension of production, the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries, the FDA&#8217;s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product clearances or approvals and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When the FDA conducts an inspection, the inspectors will identify any deficiencies they believe exist in the form of a notice of inspectional observations, or Form FDA 483. If we receive a notice of inspectional observations or deficiencies from the FDA following an inspection, we would be required to respond in writing, and would be required to undertake corrective and/or preventive or other actions in order to address the FDA&#8217;s or other regulators&#8217; concerns. Failure to address the FDA&#8217;s concerns may result in the issuance of a warning letter or other enforcement or administrative actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">International medical device premarket authorization process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Union has adopted numerous directives and standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Our products are regulated in the European Union as medical devices per European Union Directive 93/42/EEC, also known as the Medical Device Directive (&#8220;MDD&#8221;). The MDD sets out the basic regulatory framework for medical devices in the European Union. The system of regulating medical devices operates by way of a certification for each medical device. Each certified device is marked with the CE mark which shows that the device has a Certificat de Conformit&#233;. There are national bodies known as Competent Authorities in each member state which oversee the implementation of the MDD within their jurisdiction. The means for achieving the requirements for the CE mark vary according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the conformity assessment required before the CE mark can be placed on a product. Conformity assessments for our products are carried out as required by the MDD. Each member state</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">can appoint Notified Bodies within its jurisdiction. If a Notified Body of a one-member state has issued a Certificat de Conformit&#233;, the device can be sold throughout the European Union without further conformance tests being required in other member states. The CE mark is contingent upon continued compliance with the applicable regulations and the quality system requirements of the ISO 13485 standard.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new European Union Medical Devices Regulation 2017/745, or EU MDR, which was published in May 2017 with a transition period of three years, replaces the MDD and will expand and modify the pre-market and post-market obligations of the MDD. The date of application of the EU MDR has been postponed to May 26, 2024 with implementation dates based off of risk classification of the medical device. Recently, the European Commission proposed legislative amendments, including amendments to extend the transition period to the new rules from May 26, 2024 to December 31, 2027 for higher risk devices and until December 31, 2028 for medium and lower risk devices.  The EU MDR will impose additional requirements on clinical evaluation process, safety, classification and performance of medical device products. The EU MDR will have no impact on our current and future products as registrations to the EU MDR are in process and are scheduled for completion prior to the implementation dates. The company has passed the MDR upgrade assessment with no observations and a recommendation for certification by the European Notified Body in December 2021. In addition to inspections by the FDA and other regulatory entities, we are also subject to periodic inspections by applicable European Notified Body with respect to regulatory requirements that apply to medical devices designed and manufactured by us and clinical trials sponsored by us. We are also certified to the Medical Device Single Audit Program (&#8220;MDSAP&#8221;) for the jurisdictions of the United States, Canada, Japan, Brazil, and Australia which allows for one single audit performed by Notified Body to cover those jurisdictions with respect to quality systems. All registrations and certifications due to Great Britain leaving the European Union (Brexit) and Switzerland ending a joint agreement with the European Union (Swexit) have been done to the timelines as required for these countries and will continue to be performed to the updated timelines as published during these processes.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other U.S. regulatory matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical device companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Manufacturing, sales, promotion and other activities following product clearance or approval are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the CMS, other divisions of the Department of Health and Human Services, the Department of Justice, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state and local governments. For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse, anti-kickback false claims, transparency, government price reporting, anti-corruption, and health information privacy and security laws and regulations. Internationally, other governments also impose regulations in connection with their healthcare reimbursement programs and the delivery of healthcare items and services. These laws include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. federal healthcare fraud and abuse laws generally apply to our activities because our products are covered under federal healthcare programs such as Medicare and Medicaid. The Anti-Kickback Statute is particularly relevant because of its broad applicability. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription medical device manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular medical device, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Almost any financial arrangement with a healthcare provider, patient or customer could implicate the Anti-Kickback Statute. Statutory exceptions and regulatory safe harbors protect certain arrangements if specific requirements are met. The government can exercise enforcement discretion in taking action against arrangements that do not fit within a safe harbor. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Penalties for violations of the Anti- Kickback Statute include, but are not limited to, criminal, civil and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from Medicare, Medicaid and other federal healthcare programs. Our exclusion would mean that procedures using our products would no longer be eligible for reimbursement under federal healthcare programs; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Another development affecting the healthcare industry is the increased use of the federal Civil False Claims Act and, in particular, actions brought pursuant to the False Claims Act&#8217;s &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions. In </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recent years, the number of suits brought against healthcare companies by private individuals has increased dramatically. The federal civil and criminal false claims acts, including the civil FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. No specific intent to defraud is required under the civil FCA. The criminal FCA provides for criminal penalties for submitting false claims, including imprisonment and criminal fines;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Civil Monetary Penalty Act of 1981 and implementing regulations impose penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDCA, which prohibits, among other things, the adulteration or misbranding of medical devices; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, there has been a recent trend of increased federal and state regulation of payments made to doctors. The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, medical devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti-kickback, anti-referral, and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require certain biotechnology, pharmaceutical, and medical device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require applicable manufacturers to disclose or report certain information related to payments and other transfers of value to doctors and entities or sales, marketing, pricing, clinical trials, marketing expenditures and activities, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to doctors that have entered into consulting agreements with us, could be subject to challenge under one or more of such laws. The growth of our business and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to various interpretations. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Also, we may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant civil, criminal and administrative penalties, including damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States health care reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage for the procedures associated with the use of our products or result in lower reimbursement for those procedures. The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the sale of our products. Changes in healthcare policy, including changes in the implementation or the repeal of the ACA in the United States, could increase our costs, decrease our revenue and impact sales of and reimbursement and coverage for our current and future products. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. In particular, on December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and held oral arguments in November 2020. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. It is unclear how this Supreme Court decision, future litigation, and healthcare measures of the Biden administration will impact the ACA and our business. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2032 absent additional congressional action, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional action is taken by Congress.  Moreover, there recently has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the rates we will be able to charge for our current and future products or the amounts of reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">available for our current and future products from governmental agencies or third-party payors. Current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data privacy and security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical device companies may be subject to foreign and U.S. federal and state health information privacy, data protection, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective &#8220;business associates,&#8221; individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the United States Department of Health and Human Services (&#8220;HHS&#8221;), affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, or PHI, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even when HIPAA does not apply, failing to take appropriate steps to keep personal information secure may constitute a violation of laws or unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of personal information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Personally identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Any actual or perceived failure to comply with these laws can result in private claims, demands and litigation, regulatory investigations and other proceedings, and the imposition of significant civil and/or criminal penalties and other relief. For example, California enacted the California Consumer Privacy Act, (&#8220;CCPA&#8221;), which went into effect January 1, 2020. The CCPA, among other things, created new data privacy obligations for covered companies and provided new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, in November 2020, California voters passed the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;). The CPRA, which became effective January 1, 2023 created additional obligations with respect to certain data relating to consumers, significantly expands the CCPA, including by introducing additional obligations such as data minimization and storage limitations, granting additional rights to consumers, such as correction of personal information and additional opt-out rights, and creates a new entity, the California Privacy Protection Agency, to implement and enforce the law. The CCPA and CPRA may increase our compliance costs and potential liability. In addition to the CCPA, numerous other states&#8217; legislatures have passed or are considering similar laws that will require ongoing compliance efforts and investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU also has laws and regulations dealing with the collection, use and processing of personal data obtained from individuals in the EU, including the EU General Data Protection Regulation, or GDPR. These laws and regulations are often more restrictive than those in the United States and restrict transfers of personal data to the United States unless certain requirements are met. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Further, the United Kingdom has adopted the UK General Data Protection Regulation and UK Data Protection Act of 2018, which retains the GDPR in the United Kingdom&#8217;s national law and provides for a penalty structure similar to the GDPR. Because the interpretation and application of laws, regulations, standards and other obligations relating to privacy, data protection and security are still uncertain, it is possible that these laws, regulations, standards and other obligations may be interpreted and applied in a manner that is inconsistent with our data processing practices and policies. If our practices are not consistent, or are viewed as not consistent, with changes in laws, regulations and standards or the interpretations or applications of existing laws, regulations and standards,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may also become subject to fines, audits, inquiries, whistleblower complaints, adverse media coverage, investigations, lawsuits, loss of export privileges, severe criminal or civil sanction or other penalties.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and human capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 374 full-time employees. All of our employees are full-time and none of our employees are represented by a labor union or covered under a collective bargaining agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are in Aliso Viejo, California where we lease four facilities housing our headquarters, manufacturing, research and development and administrative offices. The facility leases are for approximately 121,000 square feet in the aggregate. The leases terminate on (a) September 30, 2024, with one option to extend for five years; (b) January 31, 2026, with three options to extend for five years each; (c) March 31, 2025, with two options to extend for five years each; and (d) August 31, 2024, with one option to extend for five years.  We believe that our existing facilities are adequate for our near-term needs but expect to need additional space as we grow. We believe that suitable additional or alternative space would be available in the future as required on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in California on March 5, 1997 as Calhoun Vision, Inc. and changed our name to RxSight, Inc. in October 2016. We reincorporated in Delaware on July 6, 2021.We maintain a website at www.rxsight.com. Information contained on our website is not incorporated by reference into this Annual Report on Form 10-K or any other filings we make with the SEC. <br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We operate in a rapidly changing environment that involves numerous uncertainties and risks. In addition to the other information included in this report, the following risks and uncertainties may have a material and adverse effect on our business, financial condition, results of operations, or stock price. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this report. The risks and uncertainties described below may not be the only ones we face. If any of the risks or uncertainties we face were to occur, the trading price of our securities could decline, and you may lose all or part of your investment. This report also contains forward-looking statements that involve risks and uncertainties. See the section titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; appearing elsewhere in this report.  Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary Risk Factors</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our following risks and uncertainties are among the most significant we face, however, the risks and uncertainties identified in this subsection are not the only ones we face and are qualified in their entirety by reference to all of the risk factors described herein:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our business and products:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history, and if we fail to effectively train our sales force, increase our sales and marketing capabilities, or develop broad brand awareness in a cost-effective manner, our growth will be impeded, and our business will suffer. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a history of net operating losses, and we expect to continue to incur losses in the future. If we ever achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our RxSight system. If we are unable to successfully market and sell our RxSight system, our business prospects will be significantly harmed, and we may be unable to achieve revenue growth.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic, political and market conditions, including downgrades of the U.S. credit rating, may adversely affect our business, results of operations and financial condition, including our revenue growth and profitability.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently maintain all of our cash, cash equivalents and short-term investments in one financial institution and, therefore, our cash, cash equivalents and short-term investments could be adversely affected if the financial institution in which we hold our cash, cash equivalents and short-term investments fails.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to intellectual property:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to government regulation:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations may be harmed.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to reliance on third parties:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend upon third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of the RxSight system, making us vulnerable to supply disruptions and price fluctuations.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our common stock:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether an active, liquid and orderly trading market will exist for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General risk factors:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must recruit, retain, manage and motivate qualified executives as we build out the management team, and we are highly dependent on our management team.</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future litigation proceedings could adversely affect our business.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our business and products</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history and if we fail to effectively train our sales force, increase our sales and marketing capabilities or develop broad brand awareness in a cost-effective manner, our growth will be impeded, and our business will suffer.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in March 1997 and began commercializing our products in the second half of 2019, when we initiated a full launch of our LAL and LDD. Accordingly, our limited commercialization experience and limited number of approved or cleared products make it difficult to evaluate our current business and assess our prospects. We also currently have limited sales and marketing experience. If we are unable to establish or scale effective sales and marketing capabilities, or if we are unable to commercialize any of our products, we may not be able to generate sufficient product revenue, sustain revenue growth and compete effectively. In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure to increase our customer base and grow our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and recruiting qualified sales and marketing personnel and training them on our products, applicable federal and state laws and regulations, and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, or in the event we are unable to reduce costs in the face of an unexpected decline in demand for our products. Any failure to hire, develop and retain talented sales and marketing personnel, to achieve desired productivity levels in a reasonable timeframe or timely leverage our fixed costs could have a material adverse effect on our business, financial condition and results of operations. Moreover, the members of our direct sales force are at-will employees. The loss of these personnel to competitors or otherwise could materially harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill technical expertise in replacement personnel, our revenue and results of operations could be materially harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to increase our customer base and achieve broader market acceptance of our products will also depend to a significant extent on our ability to expand our marketing efforts. Our business may be harmed if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our brand in a cost-effective manner is critical to achieving broad acceptance of our products and penetrating new customer accounts. Brand promotion activities may not generate patient or doctor awareness or increased revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the doctor acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors also make it difficult for us to forecast our financial performance and growth, and such forecasts are subject to a number of uncertainties, including our ability to successfully develop additional products that add functionality, reduce the cost of products sold, and broaden our commercial portfolio offerings and our ability to obtain the required regulatory approvals and clearances under applicable law both domestically and internationally, including FDA 510(k)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clearance or pre-market approval, or PMA, for, and successfully commercialize, market and sell, our planned or future products in the United States or in international markets. If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur losses in the future. If we ever achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses from operations since our inception and expect to continue to incur losses from operations in the future. We reported losses from operations of $50.1 million and $63.3 million for the years ended December 31, 2023 and 2022, respectively.  As a result of these losses, as of December 31, 2023, we had an accumulated deficit of $594.6 million. We expect to continue to incur significant sales and marketing, research and development, regulatory and other expenses as we expand our marketing efforts to increase adoption of our products, expand existing relationships with our customers, obtain regulatory clearances or approvals for our planned or future products, conduct clinical trials on our existing and planned or future products and develop new products or add new features to our existing products. In addition, we expect our general and administrative expenses to increase due to the costs associated with being a public company.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net losses that we incur may fluctuate from period to period. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In order to support our continued operations and the growth of our business, we may seek to raise additional capital, which may not be available to us on acceptable terms, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect capital expenditures and operating expenses to increase over the next several years as we continue to operate our business and expand our infrastructure, commercial operations and research and development activities. Our primary uses of capital are, and we expect will continue to be, investment in our commercial organization and related expenses, clinical research and development services, laboratory and related supplies, legal and other regulatory expenses, general administrative costs and working capital. In addition, we may in the future seek to acquire or invest in additional businesses, products, services or technologies that we believe could complement or expand our product portfolio, enhance our technical capabilities or otherwise offer growth opportunities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of these and other factors, we expect to continue to incur net losses and negative cash flows from operations in the future. Our future liquidity and capital funding requirements will depend on numerous factors, including:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our sales growth;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our research and development efforts;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our sales and marketing activities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success in leveraging future strategic partnerships;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">working capital investments, primarily in inventories and accounts receivable;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to borrow or raise additional funds through future debt or equity offerings to finance our operations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, costs and timing of any clinical trial results for our current or future products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the emergence and effect of competing or complementary products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability and amount of reimbursement for procedures using our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain, expand, enforce and defend our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain our current employees and the need and ability to hire additional management, sales, research and development, scientific and customer support personnel; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating and finance lease payments for our facilities; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products or technologies.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we determine that we need to raise additional funds, we may do so through equity or debt financings, which may not be available to us when needed or on terms that we deem to be favorable. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected, including potentially requiring us to delay, limit, reduce or terminate certain of our product discovery and development activities or future commercialization efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to products or technologies we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the conflicts in Eastern Europe, the Middle East and otherwise.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $127.2 million in cash, cash equivalents and short-term investments. While we believe that our existing cash, cash equivalents and short-term investments and anticipated cash generated from sales of our products will be sufficient to meet our anticipated cash needs for at least 12 months following the date of this report, we cannot assure you that we will be able to generate sufficient liquidity as and when needed. Further, although we do not anticipate the need to raise additional capital or incur additional debt in order to reach profit from operations, as such metric may be disclosed in the Company&#8217;s future Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q filed with the SEC, we have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.  We cannot assure you that we will be able to generate sufficient liquidity as and when needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Global economic, political and market conditions, including downgrades of the U.S. credit rating, may adversely affect our business, results of operations and financial condition, including our revenue growth and profitability.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current worldwide economic and financial environment, as well as various social and political tensions in the U.S. and around the world, may contribute to increased market volatility, may have long-term effects on the U.S. and worldwide financial markets and may cause economic uncertainties or deterioration in the U.S. and worldwide. The impact of downgrades by rating agencies to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness as well as potential government shutdowns could adversely affect the U.S. and global financial markets and economic conditions. U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the U.S. In addition, disagreement over the federal budget has caused the U.S. federal government to shut down for periods of time. Continued adverse political and economic conditions could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deterioration in the economic conditions globally resulting in instability in global financial markets, including the following, may pose a risk to our business: inflation and rising interest rates, large sovereign debts and fiscal deficits of several countries in Europe and in emerging markets&#8217; jurisdictions, levels of non-performing loans on the balance sheets of European banks, the effect of the United Kingdom leaving the European Union, and instability in the capital markets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide and have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently maintain all of our cash, cash equivalents and short-term investments in one financial institution and, therefore, our cash, cash equivalents and short-term investments could be adversely affected if the financial institution in which we hold our cash, cash equivalents and short-term investments fails.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently maintain all of our cash, cash equivalents and short-term investments with one financial institution.  At the current time, our cash, cash equivalents and short-term investment balances with such financial institution are held primarily in U.S. treasury bills with a duration of less than 12 months. A portion of our operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The failure of the financial institution in which our cash, cash equivalents and short-term-investments are held, the resulting inability for us to obtain the return of our funds from that financial institution, or any other adverse condition suffered by the financial institution, could impact access to our operating cash and a temporary inability to access our short-term investments in U.S. treasury bills which could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends in large part on our RxSight system. If we are unable to successfully market and sell our RxSight system, our business prospects will be significantly harmed, and we may be unable to achieve revenue growth.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial success will depend substantially on our ability to effectively and profitably market and sell our RxSight system to ophthalmic practices. The commercial success of our RxSight system and any of our planned or future products will depend on a number of factors, including the following:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the actual and perceived effectiveness and reliability of our RxSight system, especially relative to alternative products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any adverse patient events involving our RxSight system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical studies and trials relating to our RxSight system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to sustain meaningful clinical benefits for our patients;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain regulatory approval to market our planned or future products for use in the United States or internationally;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability, relative cost and perceived advantages and disadvantages of alternative technologies or treatment methods for conditions treated by our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree of patient willingness to pay for the additional costs associated with our premium intraocular lens out of pocket;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree to which doctors adopt our RxSight system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fact that governmental and private health care providers and payors around the world are increasingly utilizing managed care for the delivery of health care services, centralizing purchasing, limiting the number of vendors that may participate in purchasing programs, forming group purchasing organizations and integrated health delivery networks and pursuing consolidation to improve their purchasing leverage and using competitive bid processes to procure health care products and services;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain, maintain, protect and enforce our intellectual property rights in and to our RxSight system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree to which patients value the customized vision delivered by the RxSight system and are satisfied with their results;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving and maintaining compliance with regulatory requirements applicable to our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we are successful in educating doctors about IOLs in general, and the benefits of our RxSight system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation among doctors;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of our marketing and commercial organization;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our marketing and sales efforts in the United States, including our efforts to build out our sales team;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to expand the commercialization of our products into international markets;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to continue to develop, validate and maintain a commercially viable manufacturing process that is compliant with the Quality Systems Regulations (&#8220;QSR&#8221;), or QSMR when it goes into effect in February 2026,  and other applicable foreign, federal and state regulatory requirements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our ongoing or future clinical trials; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are required by the FDA or comparable non-U.S. regulatory authorities to conduct additional clinical trials for current or future indications.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to successfully market and sell our products, we will not be able to grow our revenue or achieve profitability, which will have a material adverse effect on our business, financial condition and results of operations. Our ability to grow our revenue in future periods will depend on our ability to successfully penetrate our target markets and increase sales of our RxSight system and any new product or product indications that we introduce, which will, in turn, depend in part on our success in growing our user base and driving increased use of our products. New products or product indications will also need to be approved or cleared by the FDA and comparable non-U.S. regulatory agencies in any international markets we target in order to commercialize them. If we cannot achieve revenue growth or achieve or sustain profitability, it could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adoption of our products depends upon appropriate training for doctors, and inadequate training may lead to negative patient outcomes, affect adoption of our products and adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our products depends in part on our customers&#8217; adherence to appropriate patient selection and proper techniques provided in training sessions conducted by our training faculty. For example, we train our customers to ensure correct use of our RxSight system. However, doctors rely on their previous medical training and experience, and we cannot guarantee that all such doctors will have the necessary skills or training to effectively utilize our products. We do not control which doctors use our products or how much training they receive, and doctors who have not completed our training sessions may nonetheless attempt to use our products. In addition, doctors may use our products in a manner that is not consistent with their labeled indications for which no training is available. If doctors use our products in a manner that is inconsistent with their labeled indications, with components that are not compatible with our products or otherwise without adhering to or completing our training sessions, their patient outcomes may not be consistent with the outcomes achieved by other doctors or in our clinical trials. This result may negatively impact the perception of patient benefit and safety and limit adoption of our products, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently require limited training in the use of our products because we market primarily to doctors who are experienced in the specific techniques required to use our devices. If demand for our products continues to grow, less experienced doctors will likely use our products, potentially leading to more injury and an increased risk of product liability claims. The use or misuse of our products may in the future result in complications and potentially lead to product liability claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The commercial success of our RxSight system will depend upon attaining significant market acceptance of these products among patients and doctors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success will depend, in part, on the acceptance of our RxSight system as safe, effective and, with respect to doctors, cost-effective. We cannot predict how quickly, if at all, patients, doctors, or payors will accept our RxSight system or, if accepted, how frequently it will be used. Our RxSight system and planned or future products we may develop or market may never gain broad market acceptance for some or all of our targeted indications. Patients and doctors must believe that our products offer benefits over alternative treatment methods. To date, a substantial majority of our product sales and revenue have been derived from a limited number of customers who have adopted our RxSight system. Our future growth and profitability largely depend on our ability to increase doctors&#8217; awareness of our RxSight system and our products and on the willingness of patients and doctors to adopt them. These parties may not adopt our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products are safe, effective and, with respect to providers, cost-effective, on a stand-alone basis and relative to competitors&#8217; products. Patients and doctors must believe that our products offer benefits over alternative treatment methods. Even if we are able to raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awareness, doctors tend to be slow in changing their medical treatment practices and may be hesitant to select our products for recommendation to their patients for a variety of reasons, including:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">long-standing relationships with competing companies and distributors that sell other products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitive response and negative selling efforts from providers of alternative products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of experience with our products and concerns that we are relatively new to market;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack or perceived lack of sufficient clinical evidence, including long-term data, supporting safety or clinical benefits;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">time commitment and skill development that may be required to gain familiarity and proficiency with our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient confusion regarding the wide range of commercially available premium IOL offerings and their ability to deliver promised results at near, middle and far distances without reliance on glasses;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient reticence to select a premium IOL due to nonperformance and adverse side effects associated with competing products in the market;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient non-compliance with the RxSight system requirement to wear protective glasses following surgery until the LAL is locked to avoid UV exposure and an unintended change to the LAL, resulting in patient dissatisfaction with the results and possible need to remove the LAL; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to generate patient referral due to dissatisfaction with results obtained through treatment with our products, the out-of-pocket cost of treatments using our products or otherwise.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order for doctors to use our RxSight system, they must make a significant up-front investment to purchase the LDD. This can result in a lengthy sales cycle and require extensive negotiations and management time. If we are unsuccessful in placing LDDs with providers, our sales may decrease, and our operating results may be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Doctors play a significant role in determining the course of a patient&#8217;s treatment, and, as a result, the type of treatment that will be utilized and provided to a patient. We focus our sales, marketing and education efforts primarily on doctors, and aim to educate referring doctors on the patient population that would benefit from our products. However, we cannot assure you that we will achieve broad market acceptance among doctors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, some doctors may choose to utilize our RxSight system on only a subset of their total patient population or may not adopt our RxSight system at all. If we are not able to effectively demonstrate that the use of our RxSight system is beneficial in a broad range of patients, adoption of our product will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of operations. We cannot assure you that our products will achieve broad market acceptance among doctors. Additionally, even if our products achieve market acceptance, they may not maintain that market acceptance over time if competing products, procedures or technologies are considered safer or more cost-effective or otherwise superior. Any failure of our products to generate sufficient demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reputation among our current or potential customers, as well as among doctors, could also be negatively affected by safety or customer satisfaction issues involving us or our products, including product recalls. Future product recalls or other safety or customer satisfaction issues relating to our reputation could negatively affect our ability to establish or maintain broad adoption of our products, which would harm our future prospects and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RxSight system involves surgical risks and is contraindicated in certain patients, which may limit adoption.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks of using our products include those associated with cataract surgery and IOL implantation. There are also possible, but rare, complications due to the use of UV light from the LDD, including a temporary or long-lasting change to vision. We are aware of certain characteristics and features of our RxSight system that may prevent widespread market adoption, including the fact that doctors would need to adopt a new procedure, and training for doctors will be required to enable them to effectively operate our products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. We compete with manufacturers and distributors of premium and conventional IOLs. Our most significant competitors in the IOL field include Alcon, Johnson &amp; Johnson Vision and Bausch + Lomb. Many of our competitors are large, well-capitalized companies with significantly greater market share and resources than we have. Therefore, they can spend more on product development, marketing, sales and other product initiatives than we can. We also compete with smaller medical device companies that have a single product or a limited range of products. In addition, patients who receive an LAL will be required to wear UV protective glasses until final lock-in which is approximately four to five weeks after surgery. They will also be required to return for an additional two to three clinic visits compared to traditional monofocal cataract surgery. The additional clinic visits are non-surgical but do require the patient&#8217;s eyes to be dilated. Due to these additional requirements, market acceptance of the LAL may be impacted. We believe the principal competitive factors in our markets include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quality of patient outcomes, oftentimes measured by visual acuity, and adverse event rates;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient experience, including patient recovery time and level of discomfort;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acceptance by treating doctors and referral sources;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Doctor learning curves and willingness to adopt new technologies;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ease-of-use and reliability;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Economic benefits and cost savings;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strength of clinical evidence;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective distribution and marketing to surgeons and potential patients; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product price and qualification for coverage and reimbursement.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We compete primarily on the basis that our products are designed to enable more doctors to treat more patients more efficiently and effectively. Our continued success depends on our ability to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to develop innovative, proprietary products that address significant clinical needs in a manner that is safe and effective for patients and easy-to-use for doctors;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain and maintain regulatory clearances or approvals;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstrate safety and effectiveness in our sponsored and third-party clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our sales force across key markets to increase doctors&#8217; awareness;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain and maintain coverage and adequate reimbursement for procedures using our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract and retain skilled research, development, sales and clinical personnel;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effectively manufacture, market and sell our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide doctors with a sufficient return on investment as compared to alternative premium IOL procedures that justifies the upfront cost of our LDD; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain, maintain, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We can provide no assurance that we will be successful in developing new products or commercializing them in ways that achieve market acceptance. If we develop new products, sales of those products may reduce revenue generated from our existing products. Moreover, any significant delays in our product launches may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate from these products. We may experience</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in any phase of a product development, including during research and development, clinical trials, regulatory review, manufacturing and marketing. Delays in product introductions could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many medical device companies are consolidating to create new companies with greater market power. As the medical device industry consolidates, competition to provide goods and services to industry participants will become more intense. These industry participants may try to use their market power to negotiate price concessions or reductions for our products. If we reduce our prices because of consolidation in the healthcare industry, our revenue may decrease, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our facilities become damaged or inoperable, or if we are required to vacate a facility, we may be unable to manufacture our products or we may experience delays in production or an increase in costs, which could adversely affect our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently maintain our research and development, manufacturing and administrative operations in Aliso Viejo, California, and we do not have redundant facilities. We operate in four separate facilities, designated as a single manufacturing facility, and should any one of these facilities be significantly damaged or destroyed by natural or man-made disasters, such as earthquakes, fires (both of which are prevalent in California) or other events, it could take months to relocate or rebuild, during which time our employees may seek other positions, our research, development and manufacturing would cease or be delayed and our products may be unavailable. A major interruption in the manufacturing operations at this facility would materially impact our ability to operate. Because of the time required to authorize manufacturing in a new facility under federal, state and non-U.S. regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity. While we maintain property and business interruption insurance, such insurance has limits and would not cover all damages, including losses caused by earthquakes or losses we may suffer due to our products being replaced by competitors&#8217; products. The inability to perform our research, development and manufacturing activities if our facilities become inoperable, combined with our limited inventory of materials and components and manufactured products, may cause doctors to discontinue using our products or harm our reputation, and we may be unable to re-establish relationships with such doctors in the future. Consequently, a catastrophic event at our current facility or any future facilities could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the current leases on our four facilities expire, respectively, on (i) September 30, 2024, with one option to extend for five years; (ii) January 31, 2026, with three options to extend for five years each; (iii) March 31, 2025 with two options to extend for five years each, and (iv) August 31, 2024, with one option to extend for five years. We may be unable to renew our leases or find a new facility on commercially reasonable terms, or at all. If we were unable or unwilling to renew at the proposed rates, relocating our manufacturing facility would involve significant expense in connection with the movement and installation of key manufacturing equipment and any necessary recertification with regulatory bodies, and we cannot assure you that such a move would not delay or otherwise adversely affect our manufacturing activities or operating results. If our manufacturing capabilities were impaired by any such move, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Technological change may adversely affect sales of our products and may cause our products to become obsolete.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The medical device market is characterized by extensive research and development and rapid technological change. There can be no assurance that other companies, including current competitors or new entrants, will not succeed in developing or marketing products that are more effective than our products or that would render our products obsolete or noncompetitive. Additionally, new surgical procedures, medications and other therapies could be developed that replace or reduce the importance of our products. If we are unable to innovate successfully, our products could become obsolete and our revenue would decline as our customers purchase our competitors&#8217; products. Our failure to develop new products, applications or features could result from insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills, a lack of other research and development resources or other constraints. Our failure or inability to devote adequate research and development resources or compete effectively with the research and development programs of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our current or future competitors could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited data and experience regarding the safety and efficacy of our RxSight system. Results of earlier studies may not be predictive of future clinical trial results, and planned studies may not establish an adequate safety or efficacy profile for our RxSight system and other planned or future products, which would affect market acceptance of our RxSight system.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our RxSight system technology is a relatively new treatment to optimize vision after cataract surgery, we have performed clinical trials only with limited patient populations. The long-term effects of using our products in a large number of patients have not been studied and the results of short-term clinical use of such products do not necessarily predict long-term clinical benefits or reveal long-term adverse effects. The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials in other patient populations. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials and subsequently failed to obtain marketing approval. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our clinical trials are unsuccessful or significantly delayed, or if we do not complete our clinical trials, our business may be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is a long, expensive and uncertain process and is subject to delays and the risk that products may ultimately prove unsafe or ineffective in treating the indications for which they are designed. We are currently engaged in post-market clinical trials of our RxSight system. Completion of clinical trials may take several years or more. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a trial, in reaching an agreement on acceptable clinical trial terms with prospective sites, in obtaining institutional review board approval at each site, in recruiting patients to participate in a trial or in obtaining sufficient supplies of clinical trial materials. We cannot provide any assurance that we will successfully, or in a timely manner, enroll our clinical trials, that our clinical trials will meet their primary endpoints or that such trials or their results will be accepted by the FDA or foreign regulatory authorities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience numerous unforeseen events during, or because of, the clinical trial process that could delay or prevent us from receiving regulatory clearance or approval for new products, modifications of existing products, or new indications for existing products, including:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful and timely completion of nonclinical studies or clinical development of our products, as well as the associated costs, including any unforeseen costs we may incur as a result of clinical trial delays;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enrollment in our clinical trials may be slower than we anticipate, or we may experience high screen failure rates in our clinical trials, resulting in significant delays;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing which may be expensive and time-consuming;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trial results may not meet the level of statistical significance required by the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or similar foreign regulatory authorities may find that one or more of our products is not sufficiently safe for investigational use in humans;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or similar foreign regulatory authorities may interpret data from preclinical testing and clinical trials in different ways than we do;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be delays or failure in obtaining approval of our clinical trial protocols from the FDA or other regulatory authorities;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be delays in obtaining institutional review board approvals or governmental approvals to conduct clinical trials at prospective sites;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or similar foreign regulatory authorities may find our or our suppliers&#8217; manufacturing processes or facilities unsatisfactory;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or similar foreign regulatory authorities may change their review policies or adopt new regulations that may negatively affect or delay our ability to bring a product to market or receive approvals or clearances to treat new indications;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may have trouble in managing multiple clinical sites;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may have trouble finding patients to enroll in our trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in agreeing on acceptable terms with third-party research organizations and trial sites that may help us conduct the clinical trials; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or regulators, may suspend or terminate our clinical trials because the participating patients are being exposed to unacceptable health risks.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failures or perceived failures in our clinical trials will delay and may prevent our product development and regulatory approval process, damage our business prospects and negatively affect our reputation and competitive position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unauthorized third parties may seek to access our devices or other products and services, or related devices, products, and services, and modify or use them in a way inconsistent with our FDA clearances and approvals, which may create risks to users.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical devices are increasingly connected to the internet, hospital networks, and other medical devices to provide features that improve healthcare and increase the ability of healthcare providers to treat patients and patients to manage their conditions. While currently bidirectional connectivity and interoperability of our RxSight system with other devices, local networks and the internet is not enabled, this may change in the future. Enablement of such features may increase cybersecurity risks and the risks of unauthorized access and use by third parties. For example, unauthorized third parties may seek to access our devices or other products and services, or related devices, products, and services, and modify or use them in a way inconsistent with our FDA clearances and approvals, which may create risks to users and potential exposure to the company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may experience a significant disruption in our information technology systems or breaches of data security.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon the capacity, reliability and security of our information technology infrastructure and our ability to expand and continually update this infrastructure in response to our business needs. In some cases, we rely upon third-party hosting and support services to meet these needs. The internet has experienced increasingly sophisticated and damaging threats in the form of phishing emails, malware, malicious websites, ransomware, exploitation of application vulnerabilities, and nation-state attacks. It is also becoming more common for these attacks to leverage previously unknown vulnerabilities. The growing and evolving cyber-risk environment means that individuals, companies, and organizations of all sizes, including ourselves, our customers, suppliers and our hosting and support partners, are increasingly vulnerable to attacks and disruptions on their networks and systems by a wide range of actors on an ongoing and regular basis.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain information security tools and technologies, staff, policies and procedures for managing risk to our networks and information systems, and conduct employee training on cybersecurity designed to mitigate persistent and continuously evolving cybersecurity threats. Our network security controls are comprised of administrative, physical and technical controls, which include, but are not limited to, the implementation of firewalls, anti-virus protection, patches, log monitors, routine backups, off-site storage, network audits and other routine updates and modifications. We also routinely monitor and develop our internal information technology systems to address risks to our information systems. Any system failure, accident or security breach could result in disruptions to our business processes, network degradation, and system down time, along with the potential that a third-party will gain unauthorized access to, or acquire intellectual property, proprietary business information, and data related to our employees, customers, suppliers, and business partners, including personal data. To the extent that any disruption, degradation, downtime or other security event results in a loss or damage to our data or systems, or in inappropriate disclosure of confidential or personal data, it could adversely impact us and our customers, potentially resulting in, among other things, financial losses, loss of customers or business, our inability to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transact business, adverse impact on our reputation, violations of applicable privacy, data protection, security and other laws, regulatory fines, penalties, litigation, reputational damage, reimbursement, or additional compliance and regulatory costs. We may also incur additional costs related to cybersecurity risk management and remediation. There can be no assurance that we or our service providers, if applicable, will not suffer losses relating to cyber-attacks or security breaches or incidents in the future or that our insurance coverage will be adequate to cover all the costs resulting from such events. No assurances can be given that our efforts to reduce the risk of such attacks or to detect attacks that occur will be successful and our failure to do so could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product or indication and fail to capitalize on products or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on specific products and indications. As a result, we may forgo or delay pursuit of other opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications or enhancements may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular potential product, we may relinquish valuable rights to that potential product through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such potential product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to develop, license or acquire new products, enhance the capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our ability to develop, license or acquire and commercialize additional products and to develop new applications for our technologies in existing and new markets, while improving the performance and cost-effectiveness of our existing products, in each case in ways that address current and anticipated customer requirements. We intend to develop and commercialize additional products through our research and development program and by licensing or acquiring additional products and technologies from third parties. Our success is dependent upon several factors, including functionality, competitive pricing, ease of use, the safety and efficacy of our products and our ability to identify, select and acquire the rights to products and technologies on terms that are acceptable to us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The medical device industry is characterized by rapid technological change and innovation. New technologies, techniques or products could emerge that might offer better combinations of price and performance or better address customer requirements as compared to our current or future products. Competitors, who may have greater financial, marketing and sales resources than we do, may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. Any new product we identify for internal development, licensing or acquisition may require additional development efforts prior to commercial sale, including extensive clinical testing and approval or clearance by the FDA and applicable foreign regulatory authorities. Due to the significant lead time and complexity involved in bringing a new product to market, we are required to make a number of assumptions and estimates regarding the commercial feasibility of a new product. These assumptions and estimates may prove incorrect, resulting in our introduction of a product that is not competitive at the time of launch. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the market with new technologies. Our ability to mitigate downward pressure on our selling prices will be dependent upon our ability to maintain or increase the value we offer to doctors as well as payors. All new products are prone to the risks of failure inherent in medical device product development, including the possibility that the product will not be shown to be sufficiently safe and effective for approval or clearance by regulatory authorities. In addition, we cannot assure you that any such products that are approved or cleared will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace. The expenses or losses associated with unsuccessful product development or launch activities, or a lack of market acceptance of our new products, could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to attract new customer accounts depends in large part on our ability to enhance and improve our existing products and to introduce compelling new products. The success of any enhancement to our products depends on several factors, including adoption and continued use by doctors, competitive pricing and overall market acceptance. Any new product that we develop may not be introduced in a timely or cost-effective manner, may contain defects or may not achieve the market acceptance necessary to generate significant revenue. If we are unable to successfully develop, license or acquire</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">new products, enhance our existing products to meet customer requirements or otherwise gain market acceptance, our business, financial condition and results of operations would be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The typical development cycle of new medical device products can be lengthy and complicated and may require complex technology and engineering. Such developments may involve external suppliers and service providers, making the management of development projects complex and subject to risks and uncertainties regarding timing, timely delivery of required components or services and satisfactory technical performance of such components or assembled products. If we do not achieve the required technical specifications or successfully manage new product development processes, or if development work is not performed according to schedule, then such new technologies or products may be adversely impacted, and our business and operating results may be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to identify, acquire and develop other products, we may be unable to grow our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a significant part of our growth strategy, we intend to develop and commercialize additional products through our research and development program or by licensing or acquiring additional products and technologies from third parties. The success of this strategy depends upon our ability to identify, select and acquire the right to products and technologies on terms that are acceptable to us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product we identify, license or acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval or clearance by the FDA and applicable foreign regulatory authorities. All products are prone to the risks of failure inherent in medical device product development, including the possibility that the product will not be shown to be sufficiently safe and effective for approval or clearance by regulatory authorities. In addition, we cannot assure you that any such products that are approved or cleared will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proposing, negotiating and implementing an economically viable product or technology acquisition or license is a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for the acquisition or license of approved or cleared products. We may not be able to acquire or license the rights to additional approved or cleared products on terms that we find acceptable, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to develop suitable potential products through internal research programs or by obtaining rights from third parties, it could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may acquire other companies or technologies, which could fail to result in a commercial product or increased revenue, divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we currently have no agreements or commitments to complete any such transactions, we may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities. However, we cannot assure you that we would be able to successfully complete any acquisition we choose to pursue, or that we would be able to successfully integrate any acquired business, product or technology in a cost-effective and non-disruptive manner. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies. We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial condition may suffer.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement and/or the ability of patients to pay for the difference between the price charged by practices and the reimbursement amount may not be available for our products in sufficient markets, which could diminish our sales or affect our ability to sell our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both U.S. and non-U.S. markets, our ability to successfully commercialize and achieve market acceptance of our products depends, in significant part, on the availability of adequate financial remuneration to doctor practices and surgical centers. This remuneration can come from a combination of sources, including third-party payors, such as Medicare and Medicaid programs in the United States, managed care organizations and private health insurers. Third-party payors decide which treatments they will cover and establish reimbursement rates for those treatments. They also can preclude patients from paying extra to receive additional services, such as those associated with placement of premium IOLs. Our products are purchased by doctors who will then seek reimbursement from third-party payors and patients for the procedures performed using our products. Reimbursement systems and patient billing rules in international markets vary significantly by country and by region within some countries, and reimbursement and/or non-reimbursement approvals must be obtained on a country-by-country basis. In certain international markets, a product must be approved for reimbursement before it can be approved for sale in that country. Furthermore, many international markets have government-managed healthcare systems that control reimbursement for new devices and procedures, as well as the ability to charge patients directly for non-reimbursed devices and procedures. In most markets there are private insurance systems as well as government-managed systems.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While third-party payors currently cover and provide reimbursement for a portion of the cost of the procedures performed using our currently cleared or approved products, we can give no assurance that these third-party payors will continue to provide coverage and adequate reimbursement or permit patient payment for the non-reimbursed portion sufficient to permit doctors to offer procedures using our products to patients requiring treatment. If sufficient coverage and reimbursement or flexibility to enable patient payment is not available for the procedures performed using our products, in either the United States or any international markets we enter, the demand for our products and our revenue will be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the overall amount of reimbursement available for products and procedures intended to treat cataract and refractive conditions of the eye could remain at current levels or decrease in the future. Failure by doctors to obtain and maintain coverage and adequate reimbursement as well as patient charges for the procedures performed using our products would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors are also increasingly examining the cost effectiveness of products, in addition to their safety and efficacy, when making coverage and payment decisions. Third-party payors have also instituted initiatives to limit the growth of healthcare costs using, for example, price regulation or controls and competitive pricing programs. Some third-party payors also require demonstrated superiority, on the basis of randomized clinical trials, or pre-approval of coverage, for new or innovative devices or procedures before they will reimburse healthcare providers who use such devices or procedures. Additionally, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. It is uncertain whether our current products or any planned or future products will be viewed (or continue to be viewed) as sufficiently cost effective to warrant coverage and adequate reimbursement levels for procedures using such products in any given jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the marketing and sale of our products. For example, we may be sued if our products cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, we rely on doctors in connection with the use of our products on patients. If these doctors are not properly trained or are negligent, the capabilities of our products may be diminished, or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt commercialization of our products. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exhaustion of any available insurance and our capital resources; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to market and sell our products.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of products we develop. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our customers and prospective customers may also have difficulty in procuring or maintaining liability insurance to cover their operations and use of our products. Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our products and potential customers may opt against purchasing our products due to the cost or inability to procure insurance coverage.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We intend to expand sales of our products internationally in the future, but we may experience difficulties in obtaining regulatory clearance or approval or in successfully marketing our products internationally even if approved. A variety of risks associated with marketing our products internationally could materially adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of our products outside of the United States would be subject to foreign regulatory requirements governing clinical trials and marketing approval. We will incur substantial expenses in connection with our international expansion. Additional risks related to operating in foreign countries include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries, including changes to regulatory requirements and implementation of new regulations in foreign countries;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in compliance with non-U.S. laws and regulations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or non-U.S. governments;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the FCPA or comparable foreign regulations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations in international markets, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, where applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade.  For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#8217; ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers, our business, liquidity, financial condition, and/or results of operations would be materially and adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there can be no guarantee that we will receive approval to sell our products in the international markets we target, nor can there be any guarantee that any sales would result even if such approval is received. Even if the FDA grants marketing approval for a product, comparable regulatory authorities of foreign countries must also approve the manufacturing or marketing of the product in those countries. Approval in the United States, or in any other jurisdiction, does not ensure approval in other jurisdictions. Obtaining foreign approvals could result in significant delays, difficulties and costs for us and require additional trials and additional expenses. Regulatory requirements can vary widely from country to country and could delay the introduction of our products in those countries. Clinical trials conducted in one country may not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accepted by other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. If we fail to comply with these regulatory requirements or to obtain and maintain required approvals, our target market will be reduced and our ability to generate revenue will be diminished. Our inability to successfully enter all our desired international markets and manage business on a global scale could negatively affect our business, financial results and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to achieve or maintain satisfactory pricing and margins for our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the levels we have historically achieved. Any decline in the amount that payors reimburse doctors performing cataract procedures, or any reduction in the flexibility to charge patients for non-reimbursed procedures could make it difficult for us to convince our customers to make the up-front investment in our LDD and could create additional pricing pressure with respect to the patient&#8217;s decision to pay the additional cost associated with our LALs and potentially a reduction in the number of procedures performed using the RxSight system and corresponding sales of LDDs, LALs, accessories and services. If we are forced to lower the price we charge for our products, our revenue and gross margins will decrease, which will adversely affect our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode. We will continue to be subject to significant pricing pressure, which could harm our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our estimates of the annual total addressable markets for our current products and products under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients who have undergone cataract surgery, and the assumed prices at which we can sell our RxSight system. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. In addition, our estimates of the sizes of the cataract surgery patient population include patients who might never be likely candidates for treatment with our products. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell future products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To the extent changes to state regulations and interpretation of the practice of optometry, changes to insurance coverage and government reimbursement rates for our products and related procedures and/or changes in medical or professional malpractice insurance coverage for doctors who perform procedures using our products are implemented, such changes could affect the adoption of our products and our future revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">States regulate the practice of optometry, including the types of procedures optometrists are authorized to perform in each state.  To the extent states change the scope of optometry with respect to those who are qualified to perform LDD procedures involving our RxSight system, such state regulation or policy can have a material impact on our business.  Additionally, payor restrictions on the coverage and/or reimbursement levels for procedures using our RxSight system can negatively impact our business. Changes to medical or professional malpractice insurance coverage policies for doctors who perform procedures using our products, can also impact the adoption of our products and our business operations. We can provide no assurance on the impact of current and future federal and state legislative, executive, and administrative actions, including measures implemented by state boards of examiners in optometry, as well as policies of malpractice insurance carriers and payors on us, our business operations, and the business of our customers. The implementation of cost containment measures or other policy and regulatory changes may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal government is considering ways to change, and has changed, the manner in which healthcare services are paid for in the United States. Individual states may also enact legislation that impacts Medicaid payments to doctors. In addition, CMS establishes Medicare payment levels for doctors on an annual basis, which can increase or decrease payment to such entities. Internationally, medical reimbursement systems vary significantly from country to country, with some countries limiting medical centers&#8217; spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement. In addition, the ability to charge patients directly for premium IOLs and associated services also varies widely across different countries and could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">become more restricted. Even if we succeed in bringing our products to market internationally, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our quarterly and annual results of operations, including our revenue, profitability and cash flow, may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. Fluctuations in quarterly and annual results may decrease the value of our common stock. Because our quarterly results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have expanded, and expect to continue to expand, our organization, including expanding our sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have and expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and marketing and finance and accounting. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert or stretch our management and business development resources in a way that we may not anticipate. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain of our operating results and financial metrics may be difficult to predict as a result of seasonality.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is not uncommon in our industry to experience seasonally weaker revenue during the summer months and end-of-year holiday season. We may be affected by other seasonal trends in the future, including severe weather (which can impact the number of elective procedures performed), particularly as our business matures. Additionally, this seasonality may be reflected to a much lesser extent, and sometimes may not be immediately apparent, in our revenue. To the extent we experience this seasonality, it may cause fluctuations in our operating results and financial metrics and make forecasting our future operating results and financial metrics more difficult.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $311.2 million, which will begin to expire in various years ranging from 2024 to 2037. Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Under the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;), as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act, as modified by the CARES Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in our ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in our stock ownership. Our ability to utilize those NOLs could be limited by an &#8220;ownership change&#8221; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to intellectual property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain, maintain, protect and enforce patent and other intellectual property protection in the United States and other countries with respect to our products and technology we develop. If we fail to obtain, maintain, protect and enforce our intellectual property, third parties may be able to compete more effectively against us, we may lose our technological or competitive advantage, or we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to protect our position by in-licensing intellectual property relating to our products and filing patent applications in the United States and abroad related to our technologies and products that are important to our business. We also rely on a combination of contractual provisions, confidentiality procedures and copyright, trademark, trade secret and other intellectual property rights to protect the proprietary aspects of our brands, products, technologies and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success will depend, in part, on obtaining and maintaining patents, copyrights, trademarks, trade secrets, data and know-how and other intellectual property rights.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to obtain and maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. For example, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, contractors, clients and other vendors who have access to such information, and could otherwise become known or be independently discovered by third parties. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our intellectual property at all. Despite our efforts to protect our intellectual property, unauthorized parties may be able to obtain and use information that we regard as proprietary.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and our owned and in-licensed issued patents may be challenged in courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO, challenging the validity of one or more claims of our owned or in-licensed issued patents. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our owned or in-licensed pending patent applications.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, contractors, collaborators, vendors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. We may not be able to obtain or maintain patent applications and issued patents due to the subject matter claimed in such patent applications and issued patents being in disclosures in the public domain, and we may not be able to prevent any third party from using any of our technology that is in the public domain to compete with our technologies. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or in-licensed issued patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or in-licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of medical device companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and in-licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the claims of any</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents will provide sufficient protection from competitors. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed or invalidated by third parties. Additionally, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Third parties may also have blocking patents that could prevent us from marketing our own products and practicing our own technology. Alternatively, third parties may seek approval to market their own products similar to or otherwise compete with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed, in which case, our competitors and other third parties may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given that patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our products. Competitors may also contest our patents, if issued, by showing the USPTO, or the applicable other foreign patent agency that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our owned and in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other intellectual property, including our trademarks, could also be challenged, invalidated, infringed and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks, in which case we could be forced to re-brand our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future also be subject to claims by our former employees, consultants or contractors asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants, contractors and any other partners or collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to obtain and maintain patents, trademarks and other intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, this could arise if the research resulting in certain of our owned or in-licensed patent rights and technology was funded in part by the United States government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to United States industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Recently, the government released a draft framework that may be used by an agency when deciding to exercise its march-in rights for public comments, and as such, the framework for deciding when march-in rights are exercised may change.  Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, a portion of our intellectual property has been acquired from one or more third parties. While we have conducted diligence with respect to such acquisitions, because we did not participate in the development or prosecution of much of the acquired intellectual property, we cannot guarantee that our diligence efforts identified and/or remedied all issues related to such intellectual property, including potential ownership errors, potential errors during prosecution of such intellectual property, and potential encumbrances that could limit our ability to enforce such intellectual property rights.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on technology for an adequate amount of time.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest claimed U.S. non-provisional or Patent Cooperation Treaty application filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent life has expired for a product, we may be open to competition. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours for a meaningful amount of time, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and patent applications are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of such issued patents and patent applications. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. We are dependent on our licensors to take the necessary action to comply with these requirements with respect to certain of our in-licensed intellectual property, and if we or any of our current or future licensors fail to maintain the patents and patent applications covering our RxSight system or any future products, our competitors may be able to enter the market, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current and future products in any jurisdiction.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we expect to rely on a third party to manufacture our RxSight system, and any future products, and we expect to collaborate with third parties on the continuing development of our RxSight system, and any future products, we must, at times, share trade secrets with them. We also expect to conduct R&amp;D programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations with our advisors, employees, contractors, CMOs, CROs, other service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors, CMOs, CROs, other service providers and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors. Litigation may be necessary to defend against these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. In addition, we may lose personnel as a result of such claims. Any such litigation, or the threat thereof, may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which would have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we or our licensors may in the future be subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or in-licensed issued patents or patent applications. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology. Such</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges may also result in our inability to develop, manufacture or commercialize our technology without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or in-licensed issued patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications, copyrights, or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets. Additionally, our products include components that we purchase from vendors, and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, copyrights, trademarks and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents, copyrights, or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names. Because patent applications can take years to issue and are often afforded confidentiality for some period of time, there may currently be pending applications, unknown to us, that later result in issued patents that could cover one or more of our products. Moreover, in recent years, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. We may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our owned or in-licensed patent portfolio may therefore have no deterrent effect. We may in the future become party to adversarial proceedings or litigation where our competitors or other third parties may assert claims against us, alleging that our products or services infringe, misappropriate or otherwise violate their intellectual property rights, including patents and trade secrets. The defense of these matters can be time consuming, be costly, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third party&#8217;s patent or trademark or of misappropriating a third party&#8217;s trade secret, or any indemnification granted by such vendors may not be sufficient to address any liability and costs we incur as a result of such claims. Additionally, we may be obligated to indemnify our customers or business partners in connection with litigation and to obtain licenses or refund subscription fees, which could further exhaust our resources.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we believe a third party&#8217;s intellectual property claims are without merit, there is no assurance that a court would find in our favor, including on questions of infringement, validity, enforceability or priority of patents. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any products or technology we may develop, and any other products or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if patents, trademarks, copyrights, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from developing, manufacturing, marketing or selling our products, or result in obligations to pay license fees, damages, attorney fees and court costs, which could be significant. In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although patent, copyright, trademark, trade secret and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. In addition, if any license we obtain is non-exclusive, we may not be able to prevent our competitors and other third parties from using the intellectual property or technology covered by such license to compete with us. If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement. Any of these events could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, interference or derivation proceedings provoked by third parties or brought by the USPTO, may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications. We may also become involved in other proceedings, such as reexamination, inter partes review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would have a significant adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. Competitors may infringe our issued patents or other intellectual property, which we may not always be able to detect. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or alleging that our intellectual property is invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise challenges to the validity of certain of our owned or in-licensed patent claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). In any such</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lawsuit or other proceedings, a court or other administrative body may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products or products that we may develop. If our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Any of these events could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developed intellectual property portfolios. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. Uncertainties resulting from the initiation and continuation of patent and other intellectual property litigation or other proceedings could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing, misappropriating or otherwise violating our owned or in-licensed patents, any patents that may be issued as a result of our future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our products are subject, in part, to the terms and conditions of licenses granted to us by others.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not currently rely upon any material licenses to any patent rights, proprietary technology, or other intellectual property from any third parties for the development of our products and technology, we may in the future rely, in part, upon licenses to certain patent rights, proprietary technology and other intellectual property from third parties that are important or necessary to the development of our products and technology, including future products and technology. Further development and commercialization of our current products, and development of any future products, may require us to enter into license or collaboration agreements. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, and as such, in the future we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. Additionally, patents that may be licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. If our potential licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our potential licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. This could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement. In spite of our best efforts, our licensors might also conclude that we have materially breached our license agreements and terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be unable to successfully develop and commercialize the affected products. Any of these events could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the future, we may enter agreements involving licenses or collaborations that provide for access or sharing of intellectual property. If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently, and in the future may continue to, license from third parties certain intellectual property relating to our current and future products. In the event we do so, we may have certain obligations to such licensors. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our products, and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to transfer or assign the license; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by any of our future licensors and us and our partners.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected products, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, we or our future licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our future licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even where we have the right to control patent prosecution of patents and patent applications under future license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our technology acquired or licensed in the future from various third parties may be subject to retained rights. Our predecessors or licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or future licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are limited in our ability to utilize acquired or future licensed technologies, or if we lose our rights to critical future in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies, and possibly in the future licensed technology, into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining necessary rights to any products we may develop through acquisitions and in-licenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need to obtain additional licenses from our existing licensors or otherwise acquire or in-license any intellectual property rights from third parties that we identify as necessary for our products. It is possible that we may be unable to obtain any additional licenses or acquire such intellectual property rights at a reasonable cost or on reasonable terms, if at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. In that event, we may be required to expend significant time and resources to redesign our technology, products, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected products, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our current and future products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former consultants, contractors or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our products. Furthermore, individuals executing invention assignment agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Any such events could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. In addition, the laws of many foreign countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">could reduce the differentiation of our products and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against such parties or those to whom they communicate such trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in United States patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States has enacted and implemented wide-ranging patent reform legislation. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. We cannot predict how decisions or actions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, and defending patents covering our RxSight system, and any of our future products throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are less extensive than those in the United States. In some cases, we or our licensors may not be able to obtain patent protection for certain technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the United States, even in jurisdictions where we or our licensors do pursue patent protection, or from selling or importing products made using our or our licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may have or obtain patent protection, but where patent enforcement is not as strong as that in the United States. These unauthorized products may compete with our products in such jurisdictions and take away our market share where we do not have any issued or in-licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in enforcing and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since June 1, 2023, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). This is a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make a product that is similar to our current products and future products we intend to commercialize and that is not covered by the patents that we own or exclusively in-license and have the right to enforce;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we and any of our current or future licensors or collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own, license or may own or license in the future;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or any of our current or future licensors or collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our current or future owned or in-licensed patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or in-license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges, including as a result of legal challenges by our competitors;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future use of &#8220;open source&#8221; software could subject our proprietary software to general release, adversely affect our ability to sell our products and subject us to possible litigation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to incorporate open source software in future products or technologies licensed, developed and/or distributed by us. Open source software is generally licensed by its authors or other third parties under open source licenses. Some open source licenses contain requirements that we disclose source code for modifications we make to the open source software and that we license such modifications to third parties at no cost. In some circumstances, distribution of our software in connection with open source software could require that we disclose and license some or all of our proprietary source code in that software, as well as distribute our products that use particular open source software at no cost to the user. We intend to monitor our use of open source software in an effort to avoid uses in a manner that would require us to disclose or grant licenses under our proprietary source code; however, there can be no assurance that such efforts will be successful. Open source license terms are often ambiguous and such use could inadvertently occur. There is little legal precedent governing the interpretation of many of the terms of these licenses, and the potential impact of these terms on our business may result in unanticipated obligations regarding our products and technologies. Companies that incorporate open source software into their products have, in the past, faced claims seeking enforcement of open source license provisions and claims asserting ownership of open source software incorporated into their product. If an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of an open source license, we could incur significant legal costs defending ourselves against such allegations. In the event such claims were successful, we could be subject to significant damages or be enjoined from the distribution of our products. In addition, if we combine our proprietary software with open source software in certain ways, under some open source licenses, we could be required to release the source code of our proprietary software, which could substantially help our competitors develop products that are similar to or better than ours and otherwise adversely affect our business. These risks could be difficult to eliminate or manage, and, if not addressed, could harm our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks, service marks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors and have registered or applied to register these trademarks. We cannot assure you that our trademark and service mark applications will be approved. During trademark and service mark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark and service mark applications and to seek to cancel registered trademarks and service marks. Opposition or cancellation proceedings may be filed against our trademarks and service marks, and our trademarks and service marks may not survive such proceedings. In the event that our trademarks and service marks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands. At times, competitors may adopt trade names, trademarks or service marks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. As a means to enforce our trademark and service mark rights and prevent infringement and other violations, we may be required to file claims against third parties or initiate opposition proceedings. This can be expensive and time-consuming. In addition, there could be potential trademark or service mark infringement claims brought by owners of other registered trademarks, service marks, or trademarks or service marks that incorporate variations of our registered or unregistered trademarks or service marks. Certain of our current or future trademarks or service marks may become so well known by the public that their use becomes generic and they lose trademark or service mark protection. Over the long term, if we are unable to establish name recognition based on our trademarks, service marks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to government regulation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our products are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we may choose to do business. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product design, development and manufacture;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record keeping;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product safety and effective;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product changes;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product marketing, promotion and advertising, sales and distribution; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">post marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before a new medical device, or a new intended use for an existing product, can be marketed in the United States, a company must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the FDCA, or approval of a premarket approval, or PMA, application from the FDA, unless an exemption applies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In many cases, the process of obtaining PMA approval is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based on extensive data, including technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk. Modifications to products that are approved through a PMA application generally need prior FDA approval of a PMA supplement. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k), or such modification may put the device into class III and require PMA approval. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months but may last longer. The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the disagreement of the FDA or the applicable foreign regulatory body with the design, conduct or implementation of our clinical trials or the analyses or interpretation of data from pre-clinical studies or clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the applicable regulatory authority may identify significant deficiencies in our manufacturing processes, facilities or analytical methods or those of our third-party contract manufacturers;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or foreign regulatory authorities may audit our clinical trial data and conclude that the data is not sufficiently reliable to support approval or clearance.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, regulators may determine that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Moreover, the FDA and European Union regulatory authorities strictly regulate the labeling, promotion and advertising of medical devices, including comparative and superiority claims vis a vis competitors&#8217; products, that may be made about products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. Failure to conduct the post-approval study in compliance with applicable regulations or to timely complete required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are required to timely file various reports with the FDA, including Medical Device Reporting (&#8220;MDR&#8221;), that requires that we report to the regulatory authorities if our products may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these reports are not filed in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we initiate a correction or removal action for our products to reduce a significant risk to health posed by our products, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our products. Furthermore, the submission of these reports could be used by competitors against us and cause doctors to delay or cancel procedures, which could harm our reputation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising, promotion and labeling of our products to ensure that the claims we make are consistent with our regulatory clearances and approvals, that there is adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including adverse publicity and warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions, partial suspension or total shutdown of production;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">denial of our requests for 510(k) clearance or PMA of new products, new intended uses or modifications to existing products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of 510(k) clearance or PMAs that have already been granted; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">criminal prosecution.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these events were to occur, our business and financial condition could be harmed. In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our products and operations are subject to extensive government regulation and oversight in the United States.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical devices regulated by the FDA are subject to &#8220;general controls&#8221; which include: registration with the FDA; listing commercially distributed products with the FDA; complying with all applicable requirements under the QSR, or QSMR when its goes into effect in February 2026; filing reports with the FDA of and keeping records relative to certain types of adverse events associated with devices under the medical device reporting regulation; assuring that device labeling complies with device labeling requirements; reporting certain device field removals and corrections to the FDA; and obtaining pre-market notification 510(k) clearance for devices prior to marketing. Some devices known as &#8220;510(k)-exempt&#8221; devices can be marketed without prior marketing-clearance or approval from the FDA. In addition to the &#8220;general controls,&#8221; some Class II medical devices are also subject to &#8220;special controls,&#8221; including adherence to a particular guidance document and compliance with the performance standard. Instead of obtaining 510(k) clearance, most Class III devices are subject to PMA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although our products have received regulatory approval or clearance from FDA in the United States for a particular patient population, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, effectiveness and other post-market information, including both federal and state requirements in the United States and requirements of comparable non-U.S. regulatory authorities in any international markets we choose to enter.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory clearances or approvals that we have received for our products will be subject to limitations on the cleared or approved indicated uses for which the product may be marketed and promoted, will be subject to the conditions of approval, or will contain requirements for potentially costly post-marketing testing. We are required to report certain adverse events and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing product safety issues could result in increased costs to assure compliance. The FDA and other agencies, including the DOJ, closely regulate and monitor the post-clearance or approval marketing and promotion of products to ensure that they are marketed and distributed only for the cleared or approved indications and in accordance with the provisions of the cleared or approved labeling. We have to comply with requirements concerning advertising and promotion for our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Promotional communications with respect to devices are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the products&#8217; cleared or approved labeling. As such, we may not promote our products for indications or uses for which they do not have clearance or approval. We received a PMA for the LAL and LDD, which is indicated for the reduction of residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag, in adult patients with pre-existing corneal astigmatism of &gt; 0.75 diopters and without pre-existing macular disease. We also received a 510(k) clearance for our contact lens, which is indicated for visualization and treatment in the anterior segment of the eye. We train</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our marketing and sales force against promoting our products for uses outside of the cleared or approved indications for use, known as &#8220;off-label uses.&#8221; However, doctors may use our products for off-label purposes and are allowed to do so when in the doctor&#8217;s independent professional medical judgment he or she deems it appropriate. If the FDA determines that our promotional materials or training constitute promotion of an off-label or other improper use, or that our internal policies and procedures are inadequate to prevent such off-label uses, it could subject us to regulatory or enforcement actions as discussed below.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we cannot make comparative claims regarding the use of our products against any alternative treatments without conducting head-to-head comparative clinical studies, which would be expensive and time-consuming. If the FDA determines that our promotional, reimbursement or training materials for sales representatives or doctors constitute promotion of an off-label use, the FDA could request that we modify our training, promotional or reimbursement materials and/or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, disgorgement of profits, significant penalties, including civil fines and criminal penalties. Other federal, state or foreign governmental authorities also might take action if they consider our promotion, reimbursement or training materials to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Although we train our sales force not to promote our products for off-label uses, and our instructions for use in all markets specify that our products are not intended for use outside of those indications cleared or approved for use, the FDA or another regulatory agency could conclude that we have engaged in off-label promotion. For example, the government may take the position that off-label promotion resulted in inappropriate reimbursement for an off-label use in violation of the federal civil False Claims Act for which it might impose significant civil fines and even pursue criminal action. In those possible events, our reputation could be damaged, and adoption of the products would be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with our facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject our facility to an adverse inspectional finding or Form 483, or other compliance or enforcement notice, communication or correspondence;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning or untitled letters that would result in adverse publicity or may require corrective advertising;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose civil or criminal penalties;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory clearances or approvals;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to clear or approve pending applications or supplements to approved applications submitted by us;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our operations, including closing our sub-assembly suppliers&#8217; facilities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products; or</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require a product recall.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, violations of the FDCA relating to the promotion of approved products may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory clearance or approval is withdrawn, it would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the policies of the FDA and of comparable foreign regulatory authorities may change and additional laws, regulations and government actions may be enacted that could prevent, limit, or delay regulatory approval of our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, if the Supreme Court reverses or curtails the Chevron doctrine, which gives deference to regulatory agencies in litigation against FDA and other agencies, more companies may bring lawsuits against FDA to challenge longstanding decisions and policies of FDA, which could undermine FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt FDA&#8217;s normal operations, which could delay FDA&#8217;s review of our marketing applications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material modifications to our products may require new 510(k) clearances or pre-market approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Modifications that could significantly affect the safety and effectiveness of our approved or cleared products, such as changes to the intended use or technological characteristics of our products, will require new 510(k) clearances or PMAs or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Based on FDA published guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplemental approval or clearance; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA-cleared device that could significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a PMA. We may not be able to obtain the required 510(k) clearances or PMAs, or PMA supplements, or similar marketing authorization in applicable foreign jurisdictions, for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our products in the past and expect to make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA or a comparable foreign regulatory authority disagrees and requires new clearances or approvals for these modifications, we may be required to recall and to stop selling or marketing such products as modified, which could harm our operating results and require us to redesign such products. In these circumstances, we may be subject to significant enforcement actions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our current and future products in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our current and future products in other jurisdictions. The FDA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approvals or clearances of our current and future products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval or clearance of a current or future product, comparable regulatory authorities in foreign jurisdictions must also approve or clear the manufacturing, marketing and promotion and reimbursement of a current or future product in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RxSight system is approved for improving uncorrected visual acuity by adjusting the LAL power to correct residual postoperative refractive error, including for -2.0 to + 2.0 diopters of sphere and -3.0 to -0.50 diopters of cylinder and by changing lens curvature to introduce controlled amounts of spherical aberration (+/- 1 micron) and center near add (up to 2.0 diopters) which is also registered with the MHRA in the United Kingdom, in Canada and in Mexico. Obtaining additional foreign regulatory approvals and establishing and ensuring compliance with foreign regulatory requirements in jurisdictions where we conduct business currently or in the future, could be time-consuming and expensive, and could delay the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals or clearances, our target market will be reduced and our ability to realize the full market potential of our current and future products will be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have conducted clinical trials in Mexico and may choose to conduct further international clinical trials. The acceptance of study data by the FDA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials are performed by clinical investigators of recognized competence and pursuant to current good clinical practices regulations; and (3) audits by regulatory authorities of the clinical data do not identify significant data integrity issues. Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our products not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our products may be subject to recalls after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation and adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and similar foreign governmental authorities have the authority to require the recall of our products because of any failure to comply with applicable laws and regulations, or defects in design or manufacture. A government mandated or voluntary product recall by us could occur because of, for example, component failures, device malfunctions or other adverse events, such as serious injuries or deaths, or quality-related issues, such as manufacturing errors or design or labeling defects. Any future recalls of our products could divert managerial and financial resources, harm our reputation and adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we initiate a correction or removal for one of our devices to reduce a risk to health posed by the device, we would be required to submit a publicly available Correction and Removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our devices. Furthermore, the submission of these reports has been and could be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders and would harm our reputation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are subject to medical device reporting regulations that require us to report to the FDA or similar foreign governmental authorities if one of our products may have caused or contributed to a death or serious injury or if we become aware that it has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction recurred. Failures to properly identify reportable events or to file timely reports, as well as failure to address each of the observations to the FDA&#8217;s satisfaction, can subject us to sanctions and penalties, including warning letters and recalls.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Doctors may make similar reports to regulatory authorities. Any such reports may trigger an investigation by the FDA or similar foreign regulatory bodies, which could divert managerial and financial resources, harm our reputation and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we, or our suppliers, fail to comply with the FDA&#8217;s QSR or QSMR when it goes into effect in February 2026, or other applicable foreign regulations, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our manufacturing and design processes and those of our third-party component suppliers are required to comply with the FDA&#8217;s QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products in the United States. We are also subject to similar state requirements and licenses, and to ongoing ISO 13485 compliance in our operations, including design, manufacturing, and service, to maintain our CE Mark in Europe. In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities, EU Notified Bodies, and comparable agencies in other countries. Further, the FDA issued a final rule in February 2024 replacing the QSR with Quality Management System Regulation (&#8220;QMSR&#8221;), which incorporates by reference the quality management system requirements of ISO 13485:2016. The FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the existing QSR. The FDA will begin to enforce the QMSR requirements upon the effective date, February 2, 2026. If we or any of our suppliers or contractors fail to meet the regulatory requirements or a regulatory inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take timely and adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenue to decline.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Public Health (&#8220;CDPH&#8221;), and our Notified Body to determine our compliance with the QSR and other regulations at both our design and manufacturing facilities, and these inspections may include the manufacturing facilities of our suppliers.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We can provide no assurance that we will continue to remain in material compliance with the QSR, or QSMR when it goes into effect in February 2026. If the FDA, CDPH, or any applicable notified body in the European Union or United Kingdom inspects any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility, we may be unable to produce our products, which would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare reform initiatives and other administrative and legislative proposals may adversely affect our business, financial condition, results of operations and cash flows in our key markets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been and continue to be proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. Certain of these proposals could limit the prices we are able to charge for our products or the coverage and reimbursement available for our products and could limit the acceptance and availability of our products. The adoption of proposals to control costs could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in the United States, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, together, the Affordable Care Act (&#8220;ACA&#8221;), was enacted. The ACA is a sweeping measure intended to expand healthcare coverage within the United States, primarily through the imposition of health insurance mandates on employers and individuals, the provision of subsidies to eligible individuals enrolled in plans offered on the health insurance exchanges and the expansion of the Medicaid program. The ACA has impacted existing government healthcare programs and has resulted in the development of new programs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain provisions of the ACA have been subject to judicial and Congressional challenges. For example, various portions of the ACA have been the subject of legal and constitutional challenges, including legal proceedings in the Fifth Circuit Court of Appeals. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. It is unclear how this Supreme Court decision, future litigation, and healthcare measures promulgated by the Biden administration will impact the ACA, our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, includes reductions to Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2032, with the exception of a temporary suspension implemented under various COVID-19 relief legislation.  In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and accordingly, our financial operations. We cannot assure you that the ACA, as currently enacted or as amended in the future, will not harm our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several United States Congressional inquiries and proposed and enacted federal legislation designed to bring transparency to product pricing and reduce the cost of products and services under government healthcare programs. While some of these measures may require additional authorization to become effective, Congress and the federal administration have each indicated that it will continue to seek new legislative and/or administrative measures to control healthcare costs. Additionally, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what products to purchase and which suppliers will be included in their healthcare programs. Adoption of price controls and other cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures may prevent or limit our ability to generate revenue and attain profitability. Various new healthcare reform proposals are emerging at the federal and state level. Any new federal and state healthcare initiatives that may be adopted could limit the amounts that federal and state governments will pay for healthcare products and services and could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with United States federal and state fraud and abuse and other healthcare laws and regulations, we could face substantial penalties and our business operations and financial condition could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and third-party payors play a primary role in the distribution, recommendation, ordering and purchasing of any medical device for which we have or obtain marketing clearance or approval. Through our arrangements with principal investigators, healthcare professionals, third-party payors and customers, we are exposed to broadly applicable anti-fraud and abuse, anti-kickback, false claims and other healthcare laws and regulations that may constrain our business, our arrangements and relationships with customers, and how we market, sell and distribute our marketed medical devices. We have a compliance program, a Code of Conduct and associated policies and procedures, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent noncompliance may not be effective in protecting us from governmental investigations for failure to comply with applicable fraud and abuse or other healthcare laws and regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we are subject to various state and federal anti-fraud and abuse laws, including, without limitation, the federal healthcare Anti-Kickback Statute and federal civil False Claims Act. There are similar laws in other countries. Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market, and distribute any products for which we obtain marketing approval. Healthcare fraud and abuse laws and related regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. The laws that may affect our ability to operate include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug or medical device manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, or order of, items or services for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal False Claims Act, including its civil provisions that can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties prohibiting individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, and/or impose exclusions from federal health care programs and/or penalties for parties who engage in such prohibited conduct;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations also impose obligations on covered entities such as health insurance plans, healthcare clearinghouses, and certain health care providers and their respective business associates and their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act, also referred to as the CMS Open Payments, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding certain payments and other transfers of value to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require medical device manufacturers to report information related to payments and other transfers of value to doctors or marketing expenditures and require the registration of their sales representatives; state laws that require medical device companies to report information on the pricing of certain medical device products; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and federal regulatory and enforcement agencies continue to actively investigate violations of healthcare laws and regulations, and the U.S. Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018 (&#8220;BBA&#8221;), increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the Anti-Kickback Statute. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government agencies recently have increased regulatory scrutiny and enforcement activity with respect to manufacturer reimbursement support activities and patient support programs, including bringing criminal charges or civil enforcement actions under the Anti-Kickback Statute, federal civil False Claims Act and HIPAA&#8217;s healthcare fraud and privacy provisions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to doctors that have entered into consulting agreements with us, could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. We may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment of individuals, exclusion from participation in government programs, such as Medicare and Medicaid, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Achieving and sustaining compliance with applicable federal and state anti-fraud and abuse laws may prove costly. If we or our employees are found to have violated any of the above laws we may be subjected to substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any action or investigation against us for the violation of these healthcare fraud and abuse laws, even if successfully defended, could result in significant legal expenses and could divert our management&#8217;s attention from the operation of our business. Companies settling federal civil False Claims Act, Anti-Kickback Statute or civil monetary penalties law cases also may be required to enter into a Corporate Integrity Agreement with the OIG in order to avoid exclusion from participation (i.e., loss of coverage for their products) in federal healthcare programs such as Medicare and Medicaid. Corporate Integrity Agreements typically impose substantial costs on companies to ensure compliance. Defending against any such actions can be costly, time-consuming and may require significant personnel resources, and may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in the CMS fee schedules may harm our revenue and operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government payers, such as CMS as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services. From time to time, the United States Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation. Reductions of reimbursement by Medicare or Medicaid for procedures that use our products or changes in policy regarding coverage of these procedures, such as adding requirements for payment, or prior authorizations, may be implemented from time to time. Reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur as well. Similar changes in the past have resulted in reduced payments for procedures that use medical device products as well as added costs and have added more complex regulatory and administrative requirements. Further changes in federal, state, local and third-party payer regulations or policies may have a material adverse impact on the demand for our products and on our business. Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of our planned or future products and to manufacture, market and distribute our products after clearance or approval is obtained.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future products could make it more difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing products. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with the EU Medical Device Regulation, applicable regulations in the United Kingdom, and other applicable foreign regulations, as well as any changes to existing regulations, may be costly and disruptive to our business, and expose us to increased liability.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2017, the European Union (&#8220;EU&#8221;) published the new EU Medical Device Regulation (&#8220;EU MDR&#8221;) (2017/745), the application of which was postponed until May 26, 2021 for class I devices (lowest risk) and May 26, 2024 for all other class devices (higher risk devices). In February 2023, EU Parliament voted to extend the EU MDR transition timelines, which postpones application until December 2027 for higher-risk Class III and implantable IIb devices and until December 2028 for lower-risk Class I and IIa devices. The new regulations replace predecessor directives and emphasize a global convergence of regulations. With the transition from the Medical Devices Directive (&#8220;MDD&#8221;), to the EU MDR, notified bodies are required to seek designation to operate as conformity assessment authorities under the new law. While we are currently in compliance with the EU MDR and in process of transferring certification from MDD to EU MDR, compliance with any new or changing regulations in the EU or other jurisdictions where we currently commercialize our products or intend to commercialize in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future is a time consuming process that may require comprehensive quality system audits and new conformity assessment certifications for our products. Major changes include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reclassification of some products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater emphasis on clinical data;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">data transparency, including publication of clinical trial data and safety summaries;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defined content and structure for technical files to support registration;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unique device identification system;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater burden on post-market surveillance and clinical follow-up;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduction of adverse event reporting time from 30 to 15 days after the event; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delayed review times; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">more power to notified bodies.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implementation of the Medical Device Regulations introduces substantial changes to the obligations with which medical device manufacturers must comply in the EU. High risk medical devices will be subject to additional scrutiny during the conformity assessment procedure. For any products that we may develop in the future, complying with these new regulations may result in Europe being less attractive as a &#8220;first market&#8221; destination. Marketing authorization timelines will become more protracted and the costs of operating in Europe will increase. A significantly more costly path to regulatory compliance is anticipated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be required to conduct clinical studies that demonstrate competent and reliable evidence that our products are safe and effective before we can commercialize our products. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our products for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our products. Even if regulatory approval is secured for any of our products, the terms of such approval may limit the scope and use of our products, which may also limit their commercial potential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Defects or failures associated with our products could lead to recalls, safety alerts or litigation, as well as significant costs and negative publicity.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to significant risks associated with manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects. In addition, component failures, design defects, off-label uses, or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and result in significant costs, negative publicity and adverse competitive pressure. The circumstances giving rise to recalls are unpredictable, and any recalls of existing or future products could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We provide a limited warranty that our products are free of material defects and conform to specifications and offer to repair the LDD in the event of a defect and replace or refund the purchase price of a defective LAL. As a result, we bear the risk of potential warranty claims on our products. In the event that we attempt to recover some or all of the expenses associated with a warranty claim against us from our suppliers or vendors, we may not be successful in claiming such recovery, or any recovery from such vendor or supplier may be inadequate or unavailable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The medical device industry has historically been subject to extensive litigation over product liability claims. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to doctor error. In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, doctors or others purchasing or using our products, even if our products were not the actual cause of such injury or death. We may choose to settle any claims to avoid a determination of fault, even if we believe fault was not due to failure of our products. An adverse outcome involving one of our products could result in reduced market acceptance and demand for such products or any or all of our other products and could harm our brand and reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations. Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#8217;s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to file adverse event reports under MDR regulations with the FDA that are publicly available on the FDA&#8217;s website. We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur. Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales. If we fail to report events required to be reported to the FDA within the required timeframes, or at all, the FDA could take enforcement action and impose sanctions against us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require our time and capital, distract management from operating our business and may harm our reputation and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the laws of the FDA and other similar foreign regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulators; (ii) manufacturing standards; (iii) healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or (iv) laws that require the true, complete and accurate reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">monetary fines, disgorgement, individual imprisonment, additional integrity reporting and oversight obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Environmental health and safety laws may result in liabilities, expenses and restrictions on our operations. Failure to comply with environmental laws and regulations could subject us to significant liability.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal, state, local and foreign laws regarding environmental protection, hazardous substances and human health and safety may adversely affect our business. Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal and remediation of, as well as human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. These operations are permitted by regulatory authorities, and the resultant waste materials are disposed of in material compliance with environmental laws and regulations. Using hazardous substances in our operations exposes us to the risk of accidental injury, contamination or other liability from the use, storage, importation, handling or disposal of hazardous materials. If our or our suppliers&#8217; operations result in the contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and fines, and any liability could significantly exceed our insurance coverage and have a material adverse effect on our on our business, financial condition and results of operations. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive, and non-compliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face risks related to our collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data and security protection practices.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business processes personal data, including some data related to health. When conducting clinical trials, we face risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and regulations, such as the Common Rule (&#8220;GCP&#8221;) guidelines, or FDA human subject protection regulations. We also face risks inherent in handling large volumes of data and in protecting the security of such data. We could be subject to attacks on our systems by outside parties or fraudulent or inappropriate behavior by our service providers or employees. Third parties may also gain access to users&#8217; accounts using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks or other means, and may use such access to obtain users&#8217; personal data or prevent use of their accounts. Data breaches or other incidents could result in a violation of applicable United States and international privacy, data protection, security and other laws, and subject us to individual or consumer class action litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This risk is enhanced in certain jurisdictions and, as we expand our operations domestically and internationally, we may be subject to additional laws in other jurisdictions. Any failure, or perceived failure, by us to comply with privacy, data protection or security laws, rules and regulations could result in proceedings or actions against us by governmental entities or others. These proceedings or actions may subject us to significant penalties and negative publicity, require us to change our business practices, increase our costs and severely disrupt our business. In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection Bureau and the Federal Trade Commission, have adopted, or are considering adopting, laws, regulations or rules concerning personal information and data security and have prioritized privacy and security violations for enforcement actions. Additionally, in the United States, California adopted the CCPA in January 2020, which requires certain companies that process information of California consumers to, among other things, provide new disclosures to California consumers and afford such consumers new abilities to exercise certain rights with respect to their personal information and opt out of certain sales of personal information, in addition to severely limiting our ability to use their information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the unauthorized access and exfiltration, theft, or disclosure of personal information. Furthermore, in November 2020, California voters passed the CPRA, which became effective January 1, 2023. The CPRA imposes additional obligations on covered companies and significantly modifies the CCPA, including by expanding California residents&#8217; rights with respect to certain sensitive personal information. Other states have proposed or enacted privacy laws that are similar to the CCPA and CPRA, further complicating the legal landscape. Further, other states have enacted laws that cover certain aspects of the collection, use, disclosure, and/or other processing of health information, such as Washington&#8217;s My Health, My Data Act, which, among other things, provides for a private right of action. It remains unclear how various provisions of the CCPA and these other new and evolving state laws will be interpreted and enforced. In addition, laws in all 50 states require businesses to provide notice to consumers whose personal information has been accessed or acquired as a result of a data breach (and, in some cases, to regulators). The effects of the CCPA, CPRA and other such privacy laws are potentially significant, and may require us to modify our practices and policies and to incur substantial costs and expenses in an effort to comply.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are subject to international laws, regulations and standards in many jurisdictions, which apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example, the GDPR, which was adopted by the EU and became effective in May 2018, applies extraterritorially and imposes several stringent requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of personal data and pseudonymized (i.e., key-coded) data and additional obligations when we contract third-party processors in connection with the processing of the personal data.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR provides that EU member states may make their own laws and regulations limiting the (i) processing of personal data, including special categories of data (e.g., racial or ethnic origin, political opinions, religious or philosophical beliefs) and (ii) profiling and automated individual decision-making of individuals, which could limit our ability to use and share personal data or other data and could cause our costs to increase, harming our business and financial condition. Non-compliance with GDPR is subject to significant penalties, including fines of up to &#8364;20 million or 4% of total worldwide revenue, whichever is greater. Interpretations of the GDPR by local data protection authorities in EU member states, along with the complexity of the regime itself, create uncertainty regarding the interpretation and enforcement of the law, with potential inconsistencies across EU member states. Other jurisdictions outside the EU are similarly introducing or enhancing laws and regulations relating to privacy, data protection or security, which enhances risks relating to compliance with such laws. Further, the United Kingdom has adopted the UK General Data Protection Regulation and UK Data Protection Act, which retain the GDPR in the United Kingdom&#8217;s national law and provide for a penalty structure similar to the GDPR. These recent developments have required us to review and modify the legal means by which we process personal data and may require us to make other modifications. The implementation and enforcement of the GDPR and other evolving legislation may subject us to enforcement risk and requirements to change certain of our data collection, processing and other policies and practices. We could incur significant costs investigating and defending such claims and, if we are found liable, significant damages. If any of these events were to occur, our business and financial results could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are subject to laws and regulations regarding cross-border transfers of personal data, including laws relating to transfer of personal data outside of the European Economic Area (&#8220;EEA&#8221;), Switzerland, and the United Kingdom. We rely on transfer mechanisms permitted under these laws, including EU Standard Contractual Clauses (&#8220;SCCs&#8221;). Such mechanisms have received heightened regulatory and judicial scrutiny in recent years.  The Court of Justice of the European Union (&#8220;CJEU&#8221;) issued a decision in 2020 invalidating a transfer of personal data from the EEA and Switzerland to the U.S. and imposing additional obligations on companies using the SCCs. The European Commission has adopted new SCCs that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are required to be implemented, and the United Kingdom has adopted new standard contractual clauses that also are required to be implemented.  In June 2021, the European Commission issued an adequacy decision in respect of the United Kingdom&#8217;s data protection framework, enabling data transfers from EU member states to the United Kingdom to continue without requiring contractual or other additional measures. While it is intended to last for at least four years, the European Commission may revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. These developments and other regulatory guidance or developments may impose additional obligations with respect to the transfer of personal data from the EEA, Switzerland, and the United Kingdom, all of which could restrict our activities in those jurisdictions, limit our ability to provide our products and services in those jurisdictions, require us to modify our policies and practices, and to engage in additional contractual negotiations, or increase our costs and obligations and impose limitations upon our ability to efficiently transfer personal data from the EEA, Switzerland, and the United Kingdom to the U.S. This could adversely affect the manner in which we provide our services and thus materially affect our operations and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the interpretation and application of laws, regulations, standards and other obligations relating to privacy, data protection and security are still uncertain, it is possible that these laws, regulations, standards and other obligations may be interpreted and applied in a manner that is inconsistent with our practices and policies. Any noncompliance, or perceived noncompliance, with laws, regulations, standards and other obligations or changes in interpretations or applications of existing laws, regulations, standards and other obligations, may subject us to fines, audits, inquiries, whistleblower complaints, adverse media coverage, investigations, lawsuits, loss of export privileges, severe criminal or civil sanction or other penalties. Additionally, although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policies and other statements that provide notices and representations about privacy, data protection or security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any concerns about our privacy, data protection or security practices, even if unfounded, could damage the reputation of our businesses and discourage potential users from our products and services. Any of the foregoing could have an adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies, including delays, travel restrictions, and staffing shortages, may also slow the time necessary for new medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies such as the FDA had to furlough critical employees and stop critical activities. In March 2020, in response to the COVID-19 pandemic, foreign and domestic inspections of facilities were largely placed on hold, the FDA worked to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. During 2020 and 2021 a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications.  While the FDA has largely caught up with domestic preapproval inspections, it continues to work through its backlog of foreign inspections. However, the FDA may not be able to continue its current inspection pace or may be unable to complete required inspections during the review period, which can delay clinical development and result in a complete response letter. On May 11, 2023, the federal government ended the COVID-19 public health emergency, which ended a number of temporary changes made to federally funded programs while some continue to be in effect. The full impact of such policy changes and the wind-down of the public health emergency on the FDA and other regulatory policies and operations is unclear.  Disruptions at the FDA could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our global operations can expose us to numerous and sometimes conflicting legal and regulatory requirements, including to anti-bribery and anti-corruption laws, such as the FCPA and the U.K. Bribery Act, and violation of these requirements could result in substantial penalties and prosecution and harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have commercialized the RxSight system outside of the United States and each component is registered with the MHRA in the United Kingdom. We are subject to numerous, and sometimes conflicting, legal regimes in the countries in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which we operate, including on matters as diverse as health and safety standards, marketing and promotional activities, anticorruption, import/export controls, content requirements, trade restrictions, tariffs, taxation, sanctions, immigration, internal and disclosure control obligations, securities regulation, anti-competition, data protection privacy, security and labor relations. This includes in emerging markets where legal systems may be less familiar to us. We strive to abide by and maintain compliance with these laws and regulations. Compliance with diverse legal requirements is costly, time-consuming and requires significant resources. Violations of one or more of these regulations in the conduct of our business could result in significant fines, criminal sanctions against us or our officers, prohibitions on doing business and damage to our reputation. Violations of these regulations in connection with the performance of our obligations to our customers also could result in liability for significant monetary damages, fines and/or criminal prosecution, unfavorable publicity and other reputational damage, restrictions on our ability to process information and allegations by our customers or distributors that we have not performed our contractual obligations. Due to the varying degrees of development of the legal systems of the countries in which we operate, local laws might be insufficient to protect our rights.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations outside of the United States are subject to various heavily enforced anti-bribery and anti-corruption laws, such as the FCPA, U.K. Bribery Act and similar laws around the world. These laws generally prohibit U.S. companies and their employees and intermediaries from offering, promising, authorizing or making improper payments to foreign government officials for the purpose of obtaining or retaining business or gaining any advantage. We face significant risks if we, which includes our third-party business partners and intermediaries, fail to comply with the FCPA or other anti-corruption and anti-bribery laws. Responding to any enforcement action or related investigation may result in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees. Any violation of the FCPA or other applicable anti-bribery, anti-corruption or anti-money laundering laws could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, severe criminal or civil sanctions and, in the case of the FCPA, suspension or debarment from U.S. government contracts, which could have a material and adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our international operations could be affected by changes in laws, trade regulations, labor and employment regulations, and procedures and actions affecting approval, products and solutions, pricing, reimbursement and marketing of our products and solutions, as well as by inter-governmental disputes. Any of these changes could adversely affect our business. The imposition of new laws or regulations, including potential trade barriers, may increase our operating costs, impose restrictions on our operations or require us to spend additional funds to gain compliance with the new rules, if possible, which could have an adverse impact on our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to reliance on third parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">From time to time, we engage outside parties to perform services related to certain of our clinical studies and trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we engage consultants to help design, monitor and analyze the results of certain of our clinical studies and trials. The consultants we engage interact with clinical investigators to enroll patients in our clinical trials. We depend on these consultants and clinical investigators to conduct clinical studies and trials and monitor and analyze data from these studies and trials under the investigational plan and protocol for the study or trial and in compliance with applicable regulations and standards, such as GCP guidelines, the Common Rule, and FDA human subject protection regulations. We may face delays in our regulatory approval process if these parties do not perform their obligations in a timely, compliant or competent manner. If these third parties do not successfully carry out their duties or meet expected deadlines, or if the quality, completeness or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical trial protocols or for other reasons, our clinical studies or trials may be extended, delayed or terminated or may otherwise prove to be unsuccessful, and we may have to conduct additional studies, which would significantly increase our costs, in order to obtain the regulatory clearances or approvals that we need to commercialize our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our component suppliers may not meet regulatory quality standards applicable to our manufacturing processes, which could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a medical device manufacturer, we must register with the FDA and non-U.S. regulatory agencies in jurisdictions where we commercialize our products, and we are subject to periodic inspection by the FDA and foreign regulatory agencies, for compliance with certain good manufacturing practices, including design controls, product validation and verification, in process testing, quality control and documentation procedures. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA and foreign regulatory agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our manufacturer, component, and sub-component suppliers are also required to meet certain standards applicable to their manufacturing processes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that we or our component suppliers comply or can continue to comply with all regulatory requirements. The failure by us or one of our component suppliers to achieve or maintain compliance with these requirements or quality standards may disrupt our ability to supply products sufficient to meet demand until compliance is achieved or, with a component supplier, until a new supplier has been identified and evaluated. Our or any of our component supplier&#8217;s failure to comply with applicable regulations could cause sanctions to be imposed on us, including warning letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals or clearances, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, which could harm our business. We cannot assure you that if we need to engage new suppliers to satisfy our business requirements, we can locate new suppliers in compliance with regulatory requirements at a reasonable cost and in an acceptable timeframe. Our failure to do so could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For products that we currently distribute or market in the EU and the United Kingdom, as well as future products for which we obtain the applicable marketing authorization, we must maintain certain International Organization for Standardization (&#8220;ISO&#8221;), certifications to sell our products and must undergo periodic inspections by notified bodies, such as BSI, to obtain and maintain these certifications. If we fail these inspections or fail to meet these regulatory standards, it could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend upon third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of the RxSight system making us vulnerable to supply disruptions and price fluctuations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of our products. We do not have long-term supply agreements with, or guaranteed commitments from our suppliers, including single and sole source suppliers. We utilize purchase orders or blanket orders covering the medium term of 18&#8211;24 months for the majority of our supplier base. While we depend on our suppliers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements, vendors will miss delivery dates, extend delivery dates or in some circumstances cancel purchase orders because these suppliers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. The expansion of global lead times has resulted in the lack of availability of raw materials, including semiconductors, computers, monitors electronic parts, metals, packaging, adhesives, chemicals, resins and subcontract painted components. Certain suppliers have passed on higher prices, surcharges and expedited shipping fees to defray the higher commodity prices they are paying due to short supply and pushed out delivery dates. Additionally, due to these supply chain constraints we will identify and qualify new vendors or substitute components which requires testing, validations and documentation adding to internal costs and diverting engineering resources from other projects.  While we have taken measures to mitigate business continuity risk, including increasing standard lead times, payment of expedite fees, issuance of a limited number of non-cancelable purchase orders, advance delivery of critical components ahead of normal delivery dates and second sourcing, our suppliers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Any supply interruption from our suppliers or failure to obtain additional suppliers for any of the components or subcomponents used in our products would limit our ability to manufacture our current and new products and could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on suppliers, vendors, outsourcing partners, consultants, and other third parties to research, develop, manufacture and commercialize our products. Using these third parties poses a number of risks, such as: (i) they may not perform to our standards or legal requirements; (ii) they may not produce reliable results; (iii) they may not perform in a timely manner; (iv) they may not maintain confidentiality of our proprietary information; (v) disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi) disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration. Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy, data protection and security risk given current legal and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory environments. Failure of third parties to meet their contractual, regulatory and other obligations may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our common stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which we cannot control. From the date of our initial public offering through February 1, 2024, our common stock has traded at a low of $8.80 and a high of $50.20 on the Nasdaq Global Market.  The stock market in general has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Part I, Item 1A, &#8220;Risk Factors,&#8221; and elsewhere in this report, these factors include:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement of our results of operations and updates regarding our business;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of preclinical studies and clinical trials of our current and future products or those of our competitors;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our products or our competitors&#8217; products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the medical device sector;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions, including global and national events, such as the conflicts in Eastern Europe, and general economic downturns.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this Part I, Item1A, &#8220;Risk Factors,&#8221; could have a dramatic and adverse impact on the market price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will rely in part on the research and reports that equity research analysts publish about us and our business. We will not have any control of the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not know whether an active, liquid and orderly trading market will exist for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is currently traded on Nasdaq Global Market, but we can provide no assurance that we will be able to maintain an active trading market on Nasdaq Global Market or any other exchange in the future. If an active trading market does not develop, or is not maintained, or if we fail to satisfy the continued listing standards of the Nasdaq Global Market or applicable SEC rules for any reason and our securities are delisted, you may have difficulty selling any of our shares of common stock that you buy. The lack of an active trading market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active trading market may also reduce the fair market value of your shares. Furthermore, an inactive trading market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 36,139,513 shares of common stock issued and outstanding.  All of these shares are available for sale in the public market, subject to limitations under Rule 144 with respect to affiliates of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have filed registration statements on Form S-8 under the Securities Act registering the offer and sale of up to an aggregate of 9,216,217 shares of common stock pursuant to our Equity Incentive Plans and an aggregate of 757,694 shares of common stock pursuant to our 2021 ESPP. Our 2021 Plan and 2021 ESPP each contain an evergreen provision that may increase The number of shares available for issuance pursuant to such plans on the first day of each fiscal year. See Note 9 &#8211; Stock-Based Compensation Expense in the Notes to the consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, we filed a $200.0 million shelf registration statement which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits us to sell, from time to time, up to $200.0 million in aggregate value of our common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide us with flexibility to access additional capital when market conditions are appropriate.  At the time of filing of the shelf registration statement, we also filed a prospectus supplement to sell up to an aggregate value of $50.0 million dollars of our common stock through an &#8220;at-the-market&#8221; (the &#8220;ATM&#8221;) offering.  The shares were offered through BofA Securities, Inc. as sales agent. As of December 31, 2023, the full $50 million authorized under the ATM offering was sold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, immediately following the filing of this Form 10-K, we will file on Form S-8 under the Securities Act to register the issuance of 1,445,580 shares of common stock subject to options or other equity awards reserved for future issuance under the 2021 Plan.  The number of shares to be registered represents the annual evergreen increase calculated as 4% of the outstanding shares of our common stock on the last day of fiscal year 2023 under our 2021 Plan.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, and employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 our executive officers, directors, holders of 5% or more of our common stock and their respective affiliates beneficially owned approximately 20% of our voting common stock. As a result, this group of stockholders will have the ability to control us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred increased costs as a result of operating as a public company, and our management devotes substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company we are incurring significant legal, accounting and other expenses and these expenses may increase even more as we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel will need to devote a substantial amount of time and effort to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified employees and persons to serve on our Board of Directors, our board committees or as executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, because we no longer qualify as an &#8220;emerging growth company&#8221; we will incur additional expenses and management&#8217;s time may be diverted in an effort to comply with compliance-related activities as we implement additional corporate governance practices to comply with the increased documentation and reporting requirements under Section 404(b) of the Sarbanes-Oxley Act of 2002.  The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly.  Beginning with fiscal year ended December 31, 2023, our independent registered public accounting firm will have to attest to the effectiveness of our internal control over financial reporting under Section 404(b).  We have implemented improved processes for documenting and evaluating our system of internal controls required under Section 404(b) however, the rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant judgment, documentation, testing and possible remediation to meet the detailed standards. During the course of documenting, evaluating and testing our internal control over financial reporting, our management may identify significant deficiencies or material weaknesses which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to comply with the requirements of Section 404(b) of the Sarbanes-Oxley Act effectively and if management identifies one or more significant deficiencies or material weaknesses, or if our independent registered public accounting firm is unable to attest that our management&#8217;s report is fairly stated or if they are unable to express an opinion on the effectiveness of our internal controls or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements any of which could result in a loss of investor confidence or negative investor perceptions.  If any of the above were to happen, the market price of our stock could decline significantly and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our certificate of incorporation, bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified Board of Directors so that not all members of our board are elected at one time;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permit only the Board of Directors to establish the number of directors and fill vacancies on the board;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a poison pill);</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit cumulative voting;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our Board of Directors to amend the bylaws;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require a super-majority vote of stockholders to amend some provisions described above.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware, (&#8220;DGCL&#8221;), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our bylaws provide that, unless the company consents in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim of breach of fiduciary duty;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our bylaws; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Delaware forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that the stockholder finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. If a court were to find this Delaware forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with litigating such disputes in multiple and/or other jurisdictions, which could seriously harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended against any person in connection with any offering of the Company&#8217;s securities, including but not limited to any auditor, underwriter, expert, control person, or other defendant. This federal forum provision may limit a stockholder&#8217;s ability to bring a Securities Act claim in a judicial forum that the stockholder finds favorable, which may discourage lawsuits against us and our directors, officers and other employees. Any person purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. While the Delaware Supreme Court has held such provisions to be facially valid as a matter of Delaware law and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions. If a court were to find this federal forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Delaware forum provision does not apply to actions arising under the Securities Exchange Act of 1934 because the federal courts have exclusive jurisdiction over such claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added or similar taxes, and we could be subject to liability with respect to past or future sales, which could adversely affect our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third party software for state and local tax rates, updated whenever tax rates change. We also rely on state exemptions, when applicable, for medical devices and services, which are determined by management&#8217;s review of each state&#8217;s sales tax laws and regulations concerning prescribed medical treatments. However, as laws and regulations change from time to time, these exemptions may or may not continue to apply to our products in the various taxing jurisdictions. Certain jurisdictions in which we do not collect such taxes on sales of our products may later assert that such taxes are applicable, which could result in tax assessments, penalties and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties and interest or future requirements may adversely affect the results of our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Board of Directors are authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation authorizes our Board of Directors, without the approval of our stockholders, to issue shares of our preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our amended and restated certificate of incorporation, as shares of preferred stock in series, to establish from time to time the number of shares to be included in each such series and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The powers, preferences and rights of these additional series of preferred stock may be senior to or on parity with our common stock, which may reduce its value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tax Act enacted many significant changes to the U.S. tax laws, the consequences of which have not yet been fully determined. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of foreign earnings and the deductibility of expenses contained in the Tax Act or other tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years and could increase our future U.S. tax expense. As an example, beginning in 2022, the Tax Act eliminates the option to immediately deduct research and development expenditures currently and requires taxpayers to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">capitalize and amortize them over five or fifteen years pursuant to Section 174 of the Code, which may impact our effective tax rate and our cash tax liability in 2022 or in future years. Regulatory or legislative developments may arise from the proposed U.S. tax reform under the Biden Administration, which has proposed several changes to the corporate income tax regime, which, if adopted, could result in increased taxation of our business operations. There is uncertainty regarding what changes, if any, will be enacted and the effect on our business and financial results. The foregoing items, as well as any future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition or results of operations.   We will also continue to monitor and assess the impact of international tax reform, including but not limited to the 15% global minimal tax proposed by the Organisation for Economic Co-operation and Development.  Finally, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), was effective beginning in fiscal year 2023. We do not currently expect that the IRA will have a material impact on our income tax liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General risk factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To succeed, we must recruit, retain, manage and motivate qualified executives as we build out the management team, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and need to add executives with operational and commercialization experience as we plan for commercialization of our current and future products and build out a leadership team that can manage our operations as a public company. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the medical device and ophthalmology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the other medical device and biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our current and future products will be limited and the potential for successfully growing our business will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of system failures or security breaches or incidents.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our computer systems, as well as those of our contractors and consultants, are vulnerable to damage from computer viruses, ransomware and other malicious code, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of the commercialization of our RxSight system and our future products. For example, the loss, corruption, or unavailability of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any disruption or security breach or incident resulting in, or believed or perceived to have reported in, the loss or unavailability of or damage to our data or applications, or inappropriate disclosure or other processing of personal, confidential or proprietary information, could cause us to incur liability and cause the commercialization of our RxSight system and the further development of our current and future products to be delayed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due to technical vulnerabilities, employee error, malfeasance or other disruptions. Although, to our knowledge, we have not experienced such material security breach to date , any security  breach or security incident could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, stolen, or otherwise processed without authorization. Any such actual or perceived access, disclosure or other security breach or incident, loss, or unauthorized processing of information (whether affecting us or one of our third-party service providers) could result in legal claims and proceedings, regulatory investigations, and other proceedings and liability under laws that protect the privacy of personal information, significant regulatory penalties or other fines or remedies, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to commercialize our products and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct clinical trials, which could adversely affect our reputation and delay the commercialization of our RxSight system and clinical development of our current and future products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The techniques and sophistication used to conduct cyber-attacks and security breaches or other incidents, including of information technology systems, as well as the sources and targets of these attacks, may take many forms (including phishing, social engineering, denial or degradation of service attacks, ransomware, malware or other malicious code), change frequently and are often not recognized until such attacks are launched or have been in place for a period of time. In addition, our employees, contractors, or third parties with whom we do business or to whom we outsource business operations may attempt to circumvent our security measures in order to misappropriate regulated, protected, or personally identifiable information, and may purposefully or inadvertently cause a breach or incident involving or compromise of such information. Third parties may have the technology or know-how to breach the security of the information collected, stored, or transmitted by us, and our respective security measures, as well as those of our third-party service providers, may not effectively prohibit others from obtaining improper access to this information. Advances in computer and software capabilities and encryption technology, new tools, and other developments may increase the risk of such a breach, incident, or compromise. There is no assurance that any security procedures or controls that we or our third-party providers have implemented will be sufficient to prevent data-security related incidents from occurring.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be required to expend significant capital and other resources to protect against, respond to, and recover from any potential, attempted or existing security breaches, incidents, or failures and their consequences. As data security-related threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. We could be forced to expend significant financial and operational resources in responding to a security breach or incident, including investigating and remediating any information security vulnerabilities, defending against and resolving legal and regulatory claims and complying with notification obligations, all of which could divert resources and the attention of our management and key personnel away from our business operations and adversely affect our business, financial condition and results of operations. In addition, our remediation efforts may not be successful, and we could be unable to implement, maintain and upgrade adequate safeguards.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Economic conditions may adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic, political and market conditions, armed conflict, including in Eastern Europe and the Middle East, and general economic downturns, may negatively impact our business. Challenging or uncertain economic conditions including those related to global epidemics, pandemics, or contagious diseases, geopolitical turmoil, and macroeconomic conditions, inflation, fluctuations in foreign exchange rates, instability in the global banking system, disruptions in supply chains and interest rates, could make it difficult for our customers and potential customers to accurately forecast and plan future business activities and may cause our customers and potential customers to slow or reduce spending, or vary order frequency, on our products. Furthermore, during challenging or uncertain economic times, our customers may face difficulties gaining timely access to sufficient credit and experience decreasing cash flow, which could impact their willingness to make purchases and their ability to make timely payments to us. Global economic conditions could have an adverse effect on demand for our products, including on our ability to predict future operating results and on our financial condition and operating results. If global economic conditions remain uncertain or deteriorate, it may materially impact our business, operating results and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we and other key international economies are currently operating in a period of economic uncertainty and the United States has recently experienced historically high levels of inflation and rising interest rates, which has led to increased costs of labor, capital, employee compensation and other similar effects. If unfavorable conditions in the national and global economy persist, or worsen, our current and potential customers&#8217; operating costs will likely increase, which could result in reduced operating budgets. Our revenue may be disproportionately affected by delays or reductions in spending.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present conditions and state of the U.S. and global economies make it difficult to predict whether, when and to what extent a recession has occurred or will occur in the near future. We cannot predict the timing, strength or duration of any economic slowdown, instability or recovery, generally or within any particular industry. If the economic conditions of the general economy or markets in which we operate do not improve, or worsen from present levels, our business, results of operations, and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, adverse worldwide economic conditions may also adversely impact our suppliers&#8217; ability to provide us with materials and components, cause them to limit or place burdensome conditions upon future transactions with us, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">affect their ability to fulfill their respective contractual obligations to us, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation and other legal proceedings may adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, severe weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our products. Our ability to obtain clinical supplies of our products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Aliso Viejo, California, near major earthquake faults and fire zones, and the ultimate impact on us for being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but due to the expansion of global lead times, particularly in Europe and Asia, has resulted in the lack of availability of raw materials, including semiconductors, computers, monitors electronic parts, metals, packaging, adhesives, chemicals, resins and subcontract painted components, limiting our ability to maintain as much inventory of components, sub-assemblies, materials and finished products on hand as would be ideal under normal circumstances. To ensure adequate inventory supply and manage our operations with our third-party manufacturers and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions. Our ability to accurately forecast demand for our products could be negatively affected by many factors, including our limited historical commercial experience, rapid growth, failure to accurately manage our expansion strategy, the expansion of global lead times, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory levels in excess of customer demand, including as a result of our introduction of product enhancements, may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs, which could have a material adverse effect on our business, financial condition and results of operations. Conversely, if we underestimate customer demand for our products or our own requirements for components, subassemblies and materials, our third-party manufacturers and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business. In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or materials may not be available when required on terms that are acceptable to us, or at all, and our third-party manufacturers and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our business, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecur</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the Audit Committee pursuant to its charter. Our Audit Committee is primarily responsible for monitoring and assessing strategic risk exposure and receives periodic updates from management at Audit Committee meetings regarding cybersecurity threat risks and management&#8217;s strategies to manage the same, and our management is responsible for the day-to-day management of the material risks we face.  Our Audit Committee reports to the board of directors regarding its activities, including with respect to cybersecurity risk oversight as appropriate, on a quarterly basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risks from cybersecurity threats and have processes for monitoring and assessing strategic risk exposures and reporting to the Audit Committee and board of directors. We regularly assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing within our IT infrastructure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct periodic risk assessments to identify cybersecurity threats that may affect information systems that may be vulnerable to cybersecurity threats.  These risk assessments include identification of reasonably foreseeable internal and external risks and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following these risk assessments, if necessary, we implement and maintain reasonable safeguards to minimize identified risks and regularly monitor the effectiveness of our safeguards. We devote significant resources, including engaging experienced consultants and designate senior-level information technology management (&#8220;IT management&#8221;) to manage the risk assessment and mitigation process. Personnel tasked with managing cybersecurity risks periodically report to senior management and the Audit Committee. We use automated tools and trained personnel to maintain real-time threat monitoring and 24x7 alerting of all of our IT infrastructure and endpoints. We leverage various software tools, internal personnel and consultants to identify, triage, escalate and remediate threats. In the event of a security incident, we follow communication protocols to alert senior-level management as to the nature and severity of the threat while leveraging consultants and forensic tools to contain, document and mitigate the threat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our overall risk management system, IT management monitors and tests our safeguards and trains our employees on these safeguards. Personnel at all levels and departments are made aware of our cybersecurity policies and risks through communication and trainings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have engaged, and expect to continue to engage, consultants, or other third parties in connection with our risk assessment processes. These providers assist us in designing and implementing our cybersecurity policies and procedures, as well as monitoring and testing the design of our processes. To oversee and identify risks from cybersecurity threats associated with our use of third-party service providers we expect them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information regarding whether any risks from cybersecurity threats have materially affected or are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this report, including the risk factor entitled</span><span style="color:#211d1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;We may experience a significant disruption in our information technology systems or breaches of data security&#8221; and &#8220;Unauthorized third parties may seek to access our devices or other products and services, or related devices, products, and services, and modify or use them in a way inconsistent with our FDA clearances and approvals, which may create risks to users.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Roboto',sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#211d1e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this report, we do not believe that we have experienced a material cybersecurity incident.</span><span style="color:#211d1e;white-space:pre-wrap;font-size:12pt;font-family:'Roboto',sans-serif;min-width:fit-content;">   </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Properties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently lease four facilities which includes our headquarters, manufacturing, research and development and administrative offices in Aliso Viejo, California. The facility leases are for approximately 121,000 square feet in the aggregate. The leases terminate, respectively, on (i) September 30, 2024, with one option to extend for five years; (ii) January 31, 2026, with three options to extend for five years each; (iii) March 31, 2025 with two options to extend for five years each; and (iv) August 31, 2024, with one option to extend for five years. We believe that our facilities are adequate to meet our current needs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. Except as indicated above, we are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market information and holders</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock has been publicly traded on the Nasdaq Global Market under the symbol &#8220;RXST&#8221; since July 30, 2021.  Prior to that time, there was no public market for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2024, there were approximately 150 registered stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend policy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our Board of Directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of then-existing debt instruments, if any, and other factors our Board of Directors deems relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unregistered sales of equity securities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuer purchases of equity securities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reserved]</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this report. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#8220;Risk Factors&#8221; in Part I, Item 1A and elsewhere in this report. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a commercial-stage medical technology company dedicated to providing high quality customized vision to patients following cataract surgery. Our proprietary RxSight</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Light Adjustable Lens system (&#8220;RxSight system&#8221;) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;LAL&#8221;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), RxSight Light Delivery Device (&#8220;LDD&#8221;&#153;) and accessories. Our LAL is a premium intraocular lens (&#8220;IOL&#8221;) made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet (&#8220;UV&#8221;) light generated by our LDD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We designed our RxSight system to address the shortcomings of competitive premium IOL technologies and provide a solution that doctors can trust to improve visual outcomes and achieve high levels of patient satisfaction. Competitive premium IOLs require patients to specify their visual priorities before surgery and be willing to accept various optical trade-offs associated with those choices. Once a patient has selected a competitive premium IOL, the surgeon must rely on a series of preoperative diagnostic tests and predictive formulae to choose the appropriate lens power. If the doctor&#8217;s prediction isn&#8217;t exact, the patient may experience suboptimal results that could necessitate a subsequent corneal refractive procedure or certain other compromises in order to reach vision targets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient&#8217;s desired vision outcomes. We believe our RxSight system provides doctors and patients increased confidence and peace of mind by eliminating the high-stakes preoperative guesswork common to competitive premium IOLs and allowing patients to iterate their final vision characteristics with customized post-surgical adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We compete primarily in the IOL market in the U.S. The LAL is a premium IOL which is partially reimbursable under Medicare, and in some cases by private payors. Premium IOLs are sold at a higher price point than conventional IOLs, as they provide refractive correction of vision unlike a conventional IOL that only replaces the natural lens with a clear lens (which is the standard for Medicare reimbursement).  Our RxSight system is approved in Mexico and Canada for improving uncorrected visual acuity by adjusting the LAL power to correct residual postoperative refractive error. We may selectively pursue commercial expansion in these or other geographies that accept these approvals in the future, with a priority on markets where we see significant potential future opportunities. New approvals may also be sought in large foreign cataract markets with more complex regulatory processes such as Asia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a Delaware corporation headquartered in Aliso Viejo, California with one wholly owned subsidiary located in Amsterdam, Netherlands.  The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial efforts began in 2019 and have been primarily focused in the United States, where we are building a &#8220;razor and razor blade&#8221; business model to drive new customer adoption and ongoing LAL volume growth. Our United States commercial organization includes a direct sales team of LDD sales personnel and LAL account managers, as well as clinical specialists, field service engineers and marketing personnel. Our sales efforts are concentrated on the roughly 4,000 U.S. cataract surgeons that perform 70%-80% of all premium IOL procedures. As of December 31, 2023, we had established an installed base of 666 LDDs in ophthalmology practices and, since our inception though December 31, 2023, surgeons have implanted over 96,000 LALs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe this business model provides an attractive and concentrated market opportunity addressable with a focused sales force. We intend to continue to make significant investments in our sales and marketing organization. We believe selectively increasing the number of sales representatives, practice development personnel and clinical trainers will help facilitate further adoption of our products among existing customer accounts as well as broaden awareness of our products to new accounts. We plan to grow our business primarily by expanding the size of our LDD installed base and driving increased</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilization of our LAL through heightened awareness of the superior clinical outcomes that our RxSight system provides patients. To continue to strengthen our competitive position in the premium IOL market, our research and development activities are focused primarily on programs that improve clinical outcomes, improve customer experience, expand our indications for use, reduce manufacturing costs and lifecycle management.  Our near-term research and development activities are focused on enhancements to the RxSight system to improve the patient and doctor experience, expand the range of patients that can be treated, as well as expand the RxSight system indications and drive adoption. We believe that over time, our adjustable lens solution can be used to address a broad range of cataract surgery patients, including those that would otherwise elect for a conventional cataract procedure today. Additional development and clinical studies that are designed to provide clinical evidence of the safety and effectiveness of our existing and future generations of products are also anticipated. Finally, we may in the future seek to acquire or invest in additional businesses, products or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to continue to make investments in our sales and marketing organization, primarily sales representatives, clinical applications specialists and technical service personnel to support new customers and upgrades and LAL account managers to facilitate adoption of use of our LALs among existing accounts. We will expand our marketing efforts with additional print and digital, social media and other customer tools to expand their local advertising. We will also continue to make significant investments in research and development and clinical expenses to make enhancements in our current products. Additionally, as a public company, we have incurred and expect to continue to incur increased costs for employee-related expenses, director and officer insurance premiums, audit fees, (including costs for compliance with Section 404(b) of the Sarbanes-Oxley Act), legal fees, investor relations fees and fees to members of our Board and expenses for compliance with public-company reporting requirements. Because of these and other factors, we expect to continue to incur net losses and negative cash flows from operations in the near future.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key business metrics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly review several operating and financial metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate our business plan and make strategic decisions. We believe the number of LDDs installed and, LALs implanted are indicators of our ability to drive adoption and generate revenue. We believe these are important metrics for our business.  We may not yet be able to accurately assess seasonality and other trends, and we will continue to evaluate our business in the future using these and other financial metrics as we observe trends in our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the number of LDDs sold in each quarter and our LDD installed base at the end of each period are important metrics as they represent an installed base into which we can sell our LALs. Our fourth quarter of 2023 was consistent with the typical seasonality patterns for cataract surgery volumes, which tend to be stronger in the fourth quarter.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.26%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.28%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.28%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.28%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.4%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.28%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.28%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.18%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q1</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q2</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q3</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q4</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q1</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q2</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q3</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q4</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDDs Sold</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Installed Base at End of Period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">666</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*     </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Reduced by one LDD taken out of installed base in Q2 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the number of LALs sold (reported as implanted in a patient) in each quarter is an important metric indicative of adoption and utilization of our RxSight system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.265%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.481%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q1</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q2</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q3</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q4</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q1</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q2</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q3</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Q4</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LALs Sold</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,523</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,622</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,657</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,071</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, we had increased LDD sales of 71 and increased LAL sales of 29,589 when compared to 2022 from strong adoption of our RxSight technology by practices and doctors combined with an increased LDD installed base.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our sales consist of the sale of LALs used in cataract surgeries, the LDDs for delivering light to the LALs to adjust the lens post-surgery, as needed, and service and accessories. Revenue is derived from sales of products primarily in the United States. Customers are primarily comprised of ophthalmic practices (LDD sales) and ambulatory surgery centers (LAL sales). We expect revenue to increase in absolute dollars as we expand our sales organization and sales territories, add customers,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand the base of doctors that are trained to use our products, and expand awareness of our products with new and existing customers and as doctors perform more procedures using our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LALs are held at customer sites on consignment. Revenue is recognized for LALs upon customer notification that the LALs have been implanted in a patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LDD contracts contain multiple performance obligations bundled into one transaction price, with all obligations generally satisfied within one year. The LDD capital asset and related components revenue is recognized upon installation and customer acceptance, training revenue is recognized upon completion of training by at least one doctor and the initial warranty and service agreement are recognized ratably over the service period. After the first year, service contracts can be purchased separately on a standalone basis.  Revenue for such service agreements will be recognized over the term of each contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 and 2022, revenue from contracts with customers consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.039%;"/>
    <td style="width:1.821%;"/>
    <td style="width:1%;"/>
    <td style="width:24.369999999999997%;"/>
    <td style="width:1%;"/>
    <td style="width:1.821%;"/>
    <td style="width:1%;"/>
    <td style="width:18.127%;"/>
    <td style="width:1%;"/>
    <td style="width:1.821%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDD (including training)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,091</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,515</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LAL</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,092</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,965</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service warranty, service contracts, and accessories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,525</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,077</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,005</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 and 2022 we had no customers who individually accounted for more than 10% of revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales consist of materials, labor and manufacturing overhead internally to produce our products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management and stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty and license fee expense. Shipping costs billed to customers are included in sales. We expect cost of sales to increase in absolute dollars as our revenue grows and more of our products are sold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We calculate gross margin as gross profit/(loss) divided by sales. Our gross margin has been and will continue to be affected by a variety of factors, including average selling prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, headcount and cost-reduction strategies. Our gross margin could fluctuate from quarter to quarter as we introduce new products, and as we adopt new manufacturing processes and technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our LDD, as is typical of many medical device capital equipment products, has a low gross margin, as the material cost of the LDD is significant, representing greater than 50% of the total cost to manufacture. In addition, we do not mark up our LDD substantially, as LDDs, as sold, generate LAL procedures. Our LAL gross margin is higher, with low material cost but high fixed overhead costs. As our manufacturing volume of the LAL increases, we expect the gross margin may improve significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, general and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative (&#8220;SG&amp;A&#8221;), expenses consist primarily of personnel-related expenses, including wages, incentive bonuses, stock-based compensation and benefits related to administrative, selling and marketing functions, education programs for doctors, commercial operations and analytics, finance, information technology and human resource functions. Other SG&amp;A expenses include sales commissions, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, training for doctors, professional services fees such as legal, patent registration costs, accounting, audit fees, (including costs for compliance with Section 404(b) of the Sarbanes-Oxley Act), tax fees, board of directors&#8217; expenses, insurance costs, general corporate expenses and facilities-related expenses. We expect SG&amp;A expenses to continue to increase in absolute dollars as we expand our sales and marketing organization and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infrastructure to both drive and support the anticipated growth in revenue and due to additional legal, accounting audit and tax fees, insurance and other expenses associated with being a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of expenses incurred in performing research and development and engineering activities for new products and technology, clinical studies and regulatory submissions and compliance. The expenses include personnel-related expenses, including wages, incentive bonuses, stock-based compensation and benefits, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs, including those related to various laboratory and research equipment and supplies, expense of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the development of manufacturing processes in excess of capitalizable value, fees paid to consultants and contract clinical organizations and direct FDA related costs and costs related to FDA premarket approval submission preparation. Research and development expenses are expensed as incurred. We expect research and development expenses as a percentage of revenue to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trials and registries and other related activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest expense</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense consist primarily of interest incurred on indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with indebtedness and interest on leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest and other income, net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and other income, net consist primarily of interest income earned on our short-term investments and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on extinguishment of term loan</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss on extinguishment of term loan consist of the loss from extinguishment of term loan due to repayment of the Oxford debt.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments and foreign currency translation adjustments.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the years ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022, together with the dollar increase or decrease and percentage change in those items:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.72%;"/>
    <td style="width:1%;"/>
    <td style="width:11.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:11.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:11.22%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.700000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(%)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,077</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,005</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,072</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,312</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,677</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,635</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,765</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,328</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,437</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152.1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,799</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,665</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,134</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,051</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,070</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,850</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,646</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,204</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.7</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(50,085</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(63,318</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,233</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20.9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,308</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,946</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,638</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33.1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,574</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,517</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,057</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of term loan</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,769</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,769</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net:</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,497</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,926</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(143.7</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48,588</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66,747</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,159</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27.2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48,608</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66,756</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,148</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27.2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on short-term investments</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(226.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation gain (loss)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(176.5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive income (loss)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(75</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(220.2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48,518</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66,831</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,313</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales increased by $40.1 million, or 81.8%, to $89.1 million for the year ended December 31, 2023 from $49.0 million for the year ended December 31, 2022. The increase was due to incremental sales of 29,589 LALs primarily due to an increased LDD installed base of 266 and incremental sales of 71 LDDs from strong adoption of our RxSight technology by practices and doctors.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales increased by $7.6 million, or 27.6%, to $35.3 million for the year ended December 31, 2023 from $27.7 million for the year ended December 31, 2022, primarily due to the increase in the number of LALs and LDDs sold during the period.  Gross margin increased to 60.4% in the year ended December 31, 2023 from 43.5% in 2022 primarily due to improved operating leverage, favorable product mix from a greater percentage of revenue from LAL sales and increased margins on our LDD due to lower material costs from the introduction of our compact LDD during the third quarter of 2023.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, general and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses increased by $16.1 million, or 27.5%, to $74.8 million for the year ended December 31, 2023, from $58.7 million for the year ended December 31, 2022. This increase was primarily attributable to an increase in selling and marketing personnel costs of $12.5 million due mainly to additional headcount of 29, increased sales commissions, incentive bonuses and employee benefits of $7.5 million, $2.0 million of increased stock-based compensation expense, $0.9 million in additional post market study costs, and new customer acquisition costs, in each case when compared to the year ended December 31, 2022.  General and administrative expenses increased by $3.7 million primarily due to an additional $2.5 million from increased personnel costs and increased stock-based compensation as well as $1.7 million of increased legal, audit and audit related costs related to operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $3.1 million to $29.1 million for the year ended December 31, 2023 from $26.0 million for the year ended December 31, 2022, an increase of 11.4%. This increase was primarily attributable to $2.9 million in increased personnel costs which includes stock-based compensation and $0.4 million in increased clinical study costs.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense), net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net decreased by $4.9 million to income of $1.5 million for the year ended December 31, 2023 from expense of $3.4 million for the year ended December 31, 2022.  This change was primarily due to increased interest income of $5.1 million from higher interest rates earned on higher short-term investment balances and decreased interest expense of $1.6 million on the Oxford term loan, which were offset by an increase of $1.8 million loss from extinguishment of term loan due to the repayment of the Oxford debt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $9.7 million, short-term investments of $117.5 million, and accumulated deficit of $594.6 million. For the years ended December 31, 2023 and 2022, our net losses from operations were $50.1 and $63.3 million, respectively. We generated sales of $89.1 million and had a net loss of $48.6 million for the year ended December 31, 2023, compared to sales of $49.0 million and net loss of $66.8 million for the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, we filed a $200.0 million shelf registration statement which became effective on August 12, 2022. The shelf registration is effective for three years and permits us to sell, from time to time, up to $200.0 million in aggregate value of our common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement was intended to provide us with flexibility to access additional capital when market conditions are appropriate.  At the time of filing the shelf registration statement, we also filed a prospectus supplement to sell up to an aggregate value of $50.0 million dollars of our common stock through an ATM offering, through BofA Securities, Inc. as sales agent (the &#8220;ATM Facility&#8221;).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this report, a total of 2,617,964 shares of our common stock, for total gross proceeds of $50.0 million (net proceeds of $47.5 million), representing the full authorized amount under the ATM Facility, have been issued and sold. On February 7, 2023, we entered into an underwriting agreement with BofA Securities, Inc., pursuant to which we agreed to issue and sell 4,000,000 shares of our common stock in a public offering, pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $12.50 per share. Under the terms of the underwriting agreement, we also granted the underwriters an option exercisable for 30 days from the date of the underwriting agreement to purchase up to an additional 600,000 shares of common stock on the same terms and conditions. The public offering closed on February 10, 2023. The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023. We received net proceeds of approximately $53.6 million from the public offering, after deducting underwriters' discounts and commissions of $3.5 million and offering expenses of $0.5 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Refinancing and Payoff of Oxford Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 29, 2020, we and Oxford Finance LLC (&#8220;Oxford&#8221;), as collateral agent, and certain lenders (&#8220;Lenders&#8221;) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the &#8220;May 2022 LSA&#8221;), pursuant to which the Lenders provided to us certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the &#8220;May 2022 Term Loan&#8221;). The May 2022 LSA increased the loan and security agreement to $60.0 million, of which $40.0 million was fully drawn upon as of May 3, 2022 from the original term loan. On June 30, 2023, we entered into a new Loan and Security Agreement (the &#8220;June 2023 LSA&#8221;) with Oxford as collateral agent and the lenders party thereto, pursuant to which we borrowed $20.0 million in aggregate Term A Loans (the &#8220;Term A Loans&#8221;).  On that same date, we prepaid the May 2022 Term Loan in full which included approximately $1.2 million in final payment and other fees using a combination of cash, primarily comprised of $19.4 million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $20.0 million in Term A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loans and $1.7 million in cash reserves. On August 4, 2023, we prepaid the Term A Loans in full, including accrued interest and fees, using $11.9 million of cash, net, raised under the ATM Facility and $9.3 million in cash reserves. The paydown in full of our debt is expected to reduce anticipated interest expense in 2024 by approximately $2.3 million.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future liquidity and capital funding requirements will depend on numerous factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our sales growth;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our research and development efforts; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our sales and marketing activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success in leveraging future strategic partnerships;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">working capital investments, primarily in inventories and accounts receivable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to borrow or raise additional funds through future debt or equity offerings to finance our operations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, costs and timing of any clinical trial results for our current or future products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the emergence and effect of competing or complementary products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain, expand, enforce and defend our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain our current employees and the need and ability to hire additional management, sales, research and development, scientific and customer support personnel; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of any collaborative, licensing or other arrangements that we have or may establish; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating and finance lease payments for our facilities; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products or technologies.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we determine that we need to raise additional funds, we may do so through equity or debt financings, which may not be available to us when needed or on terms that we deem to be favorable. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected, including potentially requiring us to delay, limit, reduce or terminate certain of our product discovery and development activities or future commercialization efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to products or technologies we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the conflicts in Eastern Europe, the Middle East and otherwise.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $9.7 million, short-term investments of $117.5 million, and an accumulated deficit of $594.6 million. We believe that our current cash, cash equivalents and short-term investments through the date of filing of this report will be sufficient to fund our operations for at least the next 12 months.  Although, based on our current planned operations, we do not anticipate the need to raise additional capital or incur additional debt in order to reach profit from operations, as the same may be disclosed in the Company&#8217;s future Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q filed with the SEC, we may be required to raise additional capital through public or private equity offerings or debt financings, credit or loan facilities or by entering into partnerships or a combination of one or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">more of these funding sources in order to meet our liquidity requirements.  If we raise additional funds by issuing equity securities, our stockholders may experience dilution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Part I, Item 1A (Risk Factors) of this report for additional risks associated with our substantial capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary statement of cash flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for each of the periods presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,593</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(58,850</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,129</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,950</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,524</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,332</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of foreign exchange rate on cash, cash equivalents<br/>&#160;&#160;&#160;and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,192</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,577</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023 was $41.6 million consisting primarily of a net loss of $48.6 million, a change in operating assets and liabilities of $9.1 million, partially offset by non-cash stock-based compensation of $15.7 million, and depreciation and amortization of $4.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022 was $58.8 million, consisting primarily of a net loss of $66.8 million, a change in operating assets and liabilities of $7.4 million, partially offset by non-cash stock-based compensation of $11.4 million, and depreciation and amortization of $3.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash (used in) provided by investing activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2023 was $22.1 million, consisting of net purchases of short-term investments of $17.3 million and purchases of property and equipment of $4.8 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2022 was $40.0 million, consisting of net maturity of short-term investments of $42.3 million which was partially offset by purchases of property and equipment of $2.4 million.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023 was $61.5 million, consisting primarily of proceeds from issuances of common stock from our public offering of $54.1 million, proceeds from issuance of common stock for at-the-market offerings of $42.4 million and proceeds from issuance of common stock of $9.5 million partially offset by a net paydown of the June 2023 LSA of $40.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022 was $6.3 million, consisting primarily of net proceeds from our at-the-market offering of $6.0 million and proceeds from stock options exercised and issuance of common stock under the employee stock purchase plan of $1.8 million which were partially offset by payments of employee taxes of $0.6 million and payments for offering costs of $0.6 million in connection with the filing of our shelf registration statement.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual obligations and commitments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Standby letter of credit</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have a standby letter of credit, expiring September 30, 2024, issued by a financial institution as a required security for one operating lease. The aggregate amount of the letter of credit was $0.2 million and $0.3 million as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical accounting policies, significant judgments and use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, which may affect our future financial statement presentation, financial condition, results of operations and cash flows.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in more detail in the &#8220;Summary of Accounting Polices&#8221; in Note 2 in the Notes to Consolidated Financial Statements included in Part II - Item 8 in this report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue recognition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery. Revenue is recognized from sales of products in the U.S. Canada and Europe to ambulatory surgery centers, hospitals, and physician private practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize LDD revenue primarily at the point in time at installation and customer acceptance of the LDD is satisfied.  LALs are held at customer sites on consignment. Revenue is recognized for LALs upon customer notification that the LALs have been implanted in a patient.  The timing of revenue recognition for LDD transactions and LAL transactions requires management judgment. Revenue recognition is reasonably likely to have a material impact on our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement, misappropriation or other violation claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these arrangements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is minimal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Accounting Policies&#8212;Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in Note 2 to our Consolidated Financial Statements included in Part II - Item 8 in this Annual Report on Form 10-K for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss of &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; status</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the last business day of the second quarter of 2023, the aggregate market value of the shares of our common stock held by non-affiliate stockholders exceeded $700 million. As a result, as of December 31, 2023, we are considered a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act, and have ceased to be an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also previously qualified as a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 under the Exchange Act, and have been permitted to rely, and have relied, on the reduced disclosure requirements available to smaller reporting companies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we lost our status as an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; as of December 31, 2023, we have elected to comply with the scaled disclosure requirements applicable to smaller reporting companies for this report, as permitted by available transitional relief under SEC rules, because we were a smaller reporting company in 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supply chain constraints and inflation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of our products. We do not have long-term supply agreements with, or guaranteed commitments from our suppliers, including single and sole source suppliers. We utilize purchase orders or blanket orders covering the medium term of 18&#8211;24 months for the majority of our supplier base. While we depend on our suppliers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements, vendors will miss delivery dates, extend delivery dates or in some circumstances cancel purchase orders because these suppliers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. The expansion of global lead times has resulted in the lack of availability of raw materials, including semiconductors, computers, monitors electronic parts, metals, packaging, adhesives, chemicals, resins and subcontract painted components. Certain suppliers have passed on higher prices, surcharges and expedited shipping fees to defray the higher commodity prices they are paying due to short supply and pushed out delivery dates. Additionally, due to these supply chain constraints we will identify and qualify new vendors or substitute components which requires testing, validations and documentation adding to internal costs and diverting engineering resources from other projects.  While we have taken measures to mitigate business continuity risk, including increasing standard lead times, payment of expedite fees, issuance of a limited number of non-cancelable purchase orders, advance delivery of critical components ahead of normal delivery dates and second sourcing, our suppliers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Any supply interruption from our suppliers or failure to obtain additional suppliers for any of the components or subcomponents used in our products would limit our ability to manufacture our current and new products and could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertain macroeconomic conditions including recent inflationary pressures and the rise in interest rates have created significant uncertainty in the U.S. economy and capital markets, which is expected to continue through 2024 and beyond and could negatively impact our financial results and liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_market"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. Market risk is the potential loss arising from the adverse changes in market rates and prices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest Fluctuation Rate Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had cash and cash equivalents and short-term investments of $127.2 million as of December 31, 2023, which consisted of $117.5 million in highly liquid money market and U.S. Treasury securities with maturities of twelve months or less. The primary goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes. We believe that we do not have any material exposure to changes in the fair value of these assets as a result of changes in interest rates due to the short-term nature of our cash and cash equivalents and short-term investments. Declines in interest rates, however, would reduce future investment income. We considered the historical volatility of short-term interest rates and determined that it was reasonably possible that an adverse change of 100 basis points could be experienced in the near term. A hypothetical 1.00% (100 basis points) increase in interest rates would not have materially impacted the fair value of our marketable securities as of December 31, 2023 and December 31, 2022. If overall interest rates had increased or decreased by 1.00% (100 basis points), our interest income would not have been materially affected during the years ended December 31, 2023 or December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Exchange Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have de minimis amounts of revenue and expenses that are denominated in currencies other than U.S. dollars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_accounting"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">(PCAOB ID: </span><span><ix:nonNumeric id="F_6e011409-d850-46b9-858d-328dc86d68d7" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balancesheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statment_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_equity_consolidated"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_flows_consolidated"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="report_independent_registered_accounting"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of RxSight, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of RxSight, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"><br/>We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23%;"/>
    <td style="width:3%;"/>
    <td style="width:74%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Revenue Recognition for LDD Capital Asset Sales</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Description of</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">the Matter</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">As discussed in Note 2 of the consolidated financial statements, the Company derives revenue from the sale of Light Delivery Devices (LDD) and Light Adjustable Lenses. Customers are primarily comprised of ambulatory surgery centers, hospitals and physician private practices. The Company recognizes LDD revenue as performance obligations are satisfied primarily at the point in time when the installation and customer acceptance of the LDD occurs. Additional audit effort was required to evaluate the timing of revenue recognition for LDD transactions and whether the performance obligation related to the installation and customer acceptance of the LDD was satisfied.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test the timing of revenue recognized from the sale of LDD assets during the year, our audit procedures, among others, included inspecting contracts, as well as documentation for a sample of transactions to evidence LDD installation and customer acceptance.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ee1ec76-67b1-4ea4-9360-1aaa29e905f2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2015.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e49b727-e06f-4875-aaf4-c38291df2379" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Irvine, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">February 28, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balancesheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC.<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.82%;"/>
    <td style="width:1%;"/>
    <td style="width:14.86%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:14.74%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4fae2a0-1e83-4aba-8e51-22aa80070a37" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e90a865e-93b3-40fa-8281-a31c2c9cd2e5" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f1d6993-5f64-4bfa-a385-9eecc59194f5" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d1a6f8f-5395-42dc-aef3-e21deb20e973" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f50b246-d39e-4977-a213-da6ca5eb1ea1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c335f773-df6a-438b-bcff-bec81ce2c1c7" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7e46b9-5433-4642-bae8-1df7e4dfea56" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4103480e-2930-4fc8-89a1-0be5e255c3e6" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other current assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dad4e26-8baf-4e28-a5ec-0f2e13ba8fdb" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d44d5d4-7687-4fd2-9998-400879a45902" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,962</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4f15582-2134-40b3-8ca8-ff3793dd3a69" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,407</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b52413e-2c8f-45d0-91a0-c4a9105dada5" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4038770-c5d0-441c-9dcd-a697ae5d82d1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ebbf07f-9deb-4a12-962e-09ac9d31e800" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases right-of-use assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03904796-a1a7-415a-a1f7-4c62bb393041" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cbcdad3-ec08-4e6d-841b-5e185dbf1488" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,943</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6996f6b5-7deb-4b4c-b58e-a6ab39b2df14" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">711</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55cf1b68-0b07-42f9-840b-8d37178ef302" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b011a31-e74a-452a-b882-950e6721fd80" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e16d4c9b-cd7d-4688-8ce8-e486c3753256" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad5aeeb8-3e18-4048-9efb-8c22e6cf49bb" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,550</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3755f3b5-31e6-4cea-ae3b-1d7cd70b5cce" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b057676-ba46-4f7e-8e4b-35003b16f16b" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_691215f5-dff8-4d7b-a1d2-cbae02f756fd" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48345122-0517-4d61-bfb0-044a41a78343" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f6f01ef-fb4f-4419-a520-6a0ce98d8ba3" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d9c526e-4527-4a5f-8107-cd6c1a2da5eb" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:LeaseLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2c58354-f7c1-45f0-99cd-e6ba75e3a85e" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:LeaseLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aabe28d8-9027-40dd-b342-596ff481f811" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1918539-5c31-4190-9b6f-6fdfc28c1b7d" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,237</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed0025f-bb53-4e6b-b380-df30da40dd81" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:LeaseLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37b148e4-a3a3-4757-8ca3-e38c22d7a314" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:LeaseLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan, net</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c9dd094-4ac8-4c56-a0eb-07bb46157e7b" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d062a59a-9fc3-4bc8-a1ca-f057ec6960d4" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98477ac1-8640-4772-a928-9fd4a7dbd27b" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_556fa291-f45e-4fbe-acc6-04d95713fd8a" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb78345c-306c-42ca-bfe7-084a11f18899" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0d8b6ca-23f3-40e3-8201-075360ca1565" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_89532d2d-44fa-416d-9656-337fd8e5f25d;"><span style="-sec-ix-hidden:F_2ed9af09-c8c9-47b5-bea3-2da165653b77;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Common stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28f8336-53b0-43e5-8c0f-9057055b6b93" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_69577cd8-c2b2-46fc-b628-24279d55dd15" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value, </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18038717-8e0a-4dae-a23a-bb985f1a4d40" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d0b2c3e7-d986-4127-9602-733872bd72e4" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">900,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1242c0f-fd52-4970-b231-3860e288fc47" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d2332ec8-8347-4c63-98fd-f6d1906bd595" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,139,513</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares<br/>&#160;&#160;issued and outstanding as of December 31, 2023 and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51f6a607-bc56-46ca-9310-da7a26cd9303" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bdeff3ed-0394-4cee-a543-b515ba683eb5" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,268,389</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares <br/>&#160;&#160;issued and outstanding as of December 31, 2022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_704b664d-963b-429c-be4c-6c529a56d137" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31d6af6c-2302-4f31-8608-8964be1b5cc4" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f0bf33d-5841-4bec-b89a-4c297dae2a4e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4c48ad80-bb78-4603-b646-be94e202b628" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value, </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d617cb93-0329-42e5-af2e-a8a0b4c0bd98" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_78fa0bed-eb2b-41db-bfe9-009bf6a86989" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e1ccb6c-e59c-4238-b963-de8be6b1daa0" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_346244c2-85ca-4019-9389-c7f8f407f8d8" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_454c987d-ded8-42e1-b847-d7c23af95644" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_9533f045-4c60-4171-af0b-08f100791914" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued<br/>&#160;&#160;and outstanding</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d286e360-fbed-4943-b040-b25b097c67f9" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea1ec8d-0c16-4e80-884c-21430af43bc6" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a369ad3-cdd3-430b-86fa-31c76cf3e810" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754,971</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7117168f-e07e-47cb-ae0a-fcb16e418510" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">636,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd6bfbdb-1051-47a3-b3fe-512e5703e579" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec122c86-5e3a-4266-9582-378a2a63542e" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66a107af-001f-414c-afd2-9efb0ecdd8c3" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">594,640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c8a7eb8-6560-46fe-8841-2e86d2df42e3" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">546,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88d1c02a-8d64-4c76-8be5-05451a565bf6" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52ac70f2-284c-45cd-b63a-3f9c8f052bf7" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,902</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3f9122f-5bff-4421-a2cd-986e4848229f" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,550</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_085faa89-a8b0-49f7-9f49-e7a421c34c03" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statment_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC. <br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.511%;"/>
    <td style="width:1%;"/>
    <td style="width:20.264%;"/>
    <td style="width:1%;"/>
    <td style="width:1.96%;"/>
    <td style="width:1%;"/>
    <td style="width:20.264%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e62979f-e79d-4c10-934c-5f38afeaf303" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,077</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ba0c292-d96a-4884-92d5-43c3011fce64" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35bc45bc-264c-433f-94b1-a9048f12fbdb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53aa72ed-2f4b-4870-800d-c73610213f1c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14749023-aaae-40e8-bf24-f22471e3b092" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06271496-51d8-40d9-bde4-b79f22013692" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,328</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f58b69-828f-4587-abf4-7594c4298600" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b87bd24-9ab6-4b81-a837-1efb9176cc1a" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac2c6d13-c87a-4d12-af8c-57bde87d63e3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,051</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f8c8763-5cbe-4148-89a1-47b07e2a61d9" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,981</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04af8894-47f9-46ab-a981-8c8d0d69a226" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,850</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91cec819-f277-4cf3-9043-6303e2b9f6c0" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,646</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f1b7e1-7203-40a4-9a14-ed2d5cd36707" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5170ea48-3426-44d0-84cb-68013774d112" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5f4b267-88ad-4fe1-a366-9f7949101d84" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0127fb46-5573-4718-8faa-a1331505456c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e02d6e81-2e1b-4179-afc9-c46b87712953" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,574</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23621363-8e82-42e7-ab15-0c7a720d5bb0" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of term loan</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14cbbab-d27d-4598-8d94-7c3cf44a3320" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_791cea26-8d74-4506-8770-2199d1f3a379" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b668d942-1e86-49ec-a216-756700b57bee" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7965e41b-6800-47f9-9fbf-04997b4df6d5" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,747</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a591a7a-9d66-4c09-9dab-11b6818db996" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f095ea-f648-4813-8995-42b50b0aa88d" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63080e55-a41c-4ba5-b78f-ea05d9ca2280" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,608</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b839b0ef-4ee8-4dea-a926-a06cb7ad8584" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,756</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on short-term investments</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26fc4928-2407-415f-b293-36d498f22030" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5578357-eccb-4213-b289-a419a982e33e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation gain (loss)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab0102fb-c191-4688-bb82-5c1566160b1b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0853117d-ed41-4084-9948-3d7904b19c95" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive income (loss)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dba38e9f-bc45-45d5-8b57-b6037d08186d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d22b930-aafa-42f1-9823-4df9f385374c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6066b52-6556-4e0a-a9cc-6681447edef0" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6815d5dc-02c0-4c21-bbd2-ef35bbb892bb" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic &amp; diluted</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d273af1b-e775-477f-8741-c5f577941215" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_10d1b4ff-ed2f-4202-8429-ff130f9f63cb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a29b18e9-ca2c-4063-97de-75f07c200afc" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f058dd0c-9718-4965-8336-24ab10f3c281" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.41</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Attributable to common stock, basic &amp; diluted</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_674888e9-2207-4746-9cf8-977c226ccf7b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_adb3ac2b-27ed-4035-9585-c24369a8b99f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,455,111</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_526c80fd-dcae-4d3a-a2d9-64c66ed9271c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cafa4137-be1e-43b5-9e65-790822ab14f2" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,661,982</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity_consolidated"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:1.5pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except number of shares)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.429%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.016%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.757%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:9.456%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:10.236%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:10.236%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:8.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional paid-in</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated other</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total stockholders'</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">comprehensive loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dd3ef6c-71f7-44be-a5d5-4310e8b3f5fe" contextRef="C_8cad5a80-a737-4f91-a14b-3bb394a8f508" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,366,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_345b46d9-cdb6-4b88-adfd-0335a50e036a" contextRef="C_8cad5a80-a737-4f91-a14b-3bb394a8f508" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_603833a4-290b-4840-8445-2bddd7ae671b" contextRef="C_8faa684a-3959-4ad4-91fa-5f5f141cb065" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">617,511</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a3b7afe-a595-4b6f-a34d-bc286f672bfc" contextRef="C_d583f1d4-bd83-4639-a274-fe28298e7a88" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5785d78-dc32-4d6f-963c-38038d03d70c" contextRef="C_f69db501-f7ea-4cc8-80d2-81597ec37696" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">479,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f47eb0-5920-4ff3-9e9a-60f6a31a7a31" contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,242</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issued for the exercise of stock options<br/>&#160;and vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41200469-0694-4f86-82ad-962b75aa90f6" contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">382,506</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaac4d48-a4aa-4a5b-92eb-54be5a8eb008" contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce193bf4-c08e-4d78-a4a1-3ba5e72ef032" contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_574c4463-a3ca-4206-934d-00cb46dd2447" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares redeemed for employee tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99c0423f-5536-41d2-85a4-327c0ee36d85" contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3" name="rxst:SharesRedeemedForEmployeeTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">49,456</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c95ac422-fba4-409f-8a9f-b0ac3f9a29dd" contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa" name="rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c05da786-6ff5-49fa-a48a-c007542c2ed1" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f23ed0-fcbf-401d-be93-ed94a8008a8a" contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951dd948-f948-47ac-b486-c1f157c62f36" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issued for the employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b9b16e9-8747-4a05-97a4-bb3da6e82926" contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">92,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c24e7b-91d7-4d29-baae-b8e613541738" contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa" name="rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f504fafb-d2b9-485b-a3f7-a1bebe4a64f9" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for at-the-market offerings, <br/>net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef83addf-183b-47ef-a76f-fa38894454a4" contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3" name="rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">475,875</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79badad7-afc6-43f8-90e7-81635a85dd3b" contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,959</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_158afc5c-d3d0-42fe-8243-6e30dd2f016b" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,959</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a4c0cd1-42ba-4332-998f-38cc447be39a" contextRef="C_26a351db-d159-4b04-884c-9e54b986cc5c" name="rxst:OtherComprehensiveLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00b607fc-4d86-46ff-899c-f3ebe70544af" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:OtherComprehensiveLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_add9a189-abea-4c92-b9be-b5fc05b5ed67" contextRef="C_a3ce3f5e-c938-4989-9d48-abb64a18b225" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,756</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f3f0697-ecb2-4e24-8f6f-0ad2e2f1140b" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,756</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03b05f0d-04b6-4a14-bac3-3769655027af" contextRef="C_e78c7069-b653-4177-963e-9d1bbcfd973f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,268,389</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22132119-21ce-475b-8ada-7669d71297d7" contextRef="C_e78c7069-b653-4177-963e-9d1bbcfd973f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d52e6e60-8744-4590-8292-a66684661d58" contextRef="C_619af7c1-a3fb-4ce4-9615-d637396286e3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">636,001</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c5587c2-5c9a-4022-b56b-cc05f72a9a83" contextRef="C_26a351db-d159-4b04-884c-9e54b986cc5c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea7bd5e8-63cb-4f8c-ad9d-6c2ff6348b41" contextRef="C_fa175e83-4ae0-4e56-8332-28c4e9813a04" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">546,032</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34bf62bf-70ed-43dc-8ab3-66caa6900b8f" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,902</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issued for the exercise of stock options<br/>&#160;and vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d01da811-65a7-4ae6-a684-41de68ba9629" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,103,974</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a9e09c9-461c-4165-8b6f-9728453ad09d" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9eeea97-8e25-42b5-9f0a-9d6a35782e8b" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,351</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c513fa1-cae3-4d51-bec6-aabac939a92b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares redeemed for employee tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa1fb4af-61fb-407e-ba50-8833f713f0a6" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:SharesRedeemedForEmployeeTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,068</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_248eb63d-0be1-4d80-8751-a8b1ef37e882" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27184c8f-1d0d-43ef-b165-474e6d7ba042" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_406444d7-dc21-4271-b718-9fb3f8940e18" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e1846d1-8bcd-4ffa-bfe6-a754822b4f81" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issued for the employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c91dae0-9db0-4611-94ca-b8e2a2db7627" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">87,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6778b5d-fbbc-4846-b43e-f8fcf23c9b3e" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_608669e0-c2b2-4acc-850e-228019a091fa" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for the public offering,<br/>net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09b4f598-9d51-41d7-ab6e-3f425b075177" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,600,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c4ba2e-039d-4e59-9b36-a9bff4101a2b" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55be754d-086b-4a4a-a570-e2d2b0f12411" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f8de83b-b57b-4308-a795-88d0c3c31270" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for at-the-market offerings, <br/>net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d91cebe-72e9-4b4b-84ea-44d7f1c401e5" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,142,089</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0ee4db6-be59-496d-ba76-fbd47a6585c5" contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79e8802f-33a6-47a1-b3e6-b58137ef2737" contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea5dbf86-754c-4267-97d1-2388ff79fab7" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,582</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_609df9d7-2c1e-40be-97be-36aca3b98c12" contextRef="C_ab197fb1-568a-479c-8dca-51ebd28598ff" name="rxst:OtherComprehensiveLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e755c15c-3e13-47f5-aa6d-23ff8f179327" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:OtherComprehensiveLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cef1079-6815-4c27-80cd-fefc3eb1ad58" contextRef="C_ea603303-001a-4544-b085-bb841cb42c83" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,608</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7551c737-fc57-47b9-a068-512e835cb89f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,608</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8529229-a5d4-4316-9897-edbeb24b5f43" contextRef="C_1bc5a935-0234-4618-aba4-1ab485aa91f4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,139,513</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b769c43-2791-4974-ad3e-11d0c3fc5447" contextRef="C_1bc5a935-0234-4618-aba4-1ab485aa91f4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05749270-b4ca-482e-803e-7b083640d7db" contextRef="C_055117f2-9811-4160-9a40-b17c1f912611" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">754,971</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a71893ed-03d0-41f4-a7c0-8c7bc4848a3c" contextRef="C_ab197fb1-568a-479c-8dca-51ebd28598ff" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da408fc8-1959-4170-87b4-ff7dfd6b4688" contextRef="C_2e670d03-0073-40c0-81aa-a64691a64651" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">594,640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5fe6672-e6be-4606-946f-7af4fb95f0e2" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_flows_consolidated"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> STATEMENTS OF CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:1.5pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.42%;"/>
    <td style="width:1%;"/>
    <td style="width:13.083%;"/>
    <td style="width:1%;"/>
    <td style="width:1.42%;"/>
    <td style="width:1%;"/>
    <td style="width:13.083%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8179f6f8-ccf7-4f96-be11-7c4af3c96d32" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,608</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42c47a72-6060-4613-947a-e5bf5bfb14a5" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,756</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a02ee5f-b900-4cba-8b4c-36a2978b7dfe" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d3e39c4-c90e-465c-a665-446ac06a5faa" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,884</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of right-of-use lease assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a563014-d328-421a-a044-d3d1e8806bf4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_414cf562-1b86-4bf4-8f6f-64fe3433782c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs and premium</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d745de6-a60b-4821-ba38-5c319beb1b01" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c14610cc-88cc-42e8-9368-80e379e55cf5" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f697672f-19ba-4895-9b35-34a4859a8a39" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bd2506c-fb56-42ab-8a2a-1313022d8214" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of discount on short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef40cd1e-a192-4e63-970e-706d763690b3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62caf35c-5024-42d2-bae4-d8573e8f33c0" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,405</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e90ff2e-d19d-4db7-bbea-fca021706d8c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec08ed3d-f593-4808-bf72-0d6d573cc72b" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for excess and obsolete inventory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b6081d3-9e3e-421c-85e7-dc4ed7d166bc" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1debe4d6-f8df-4a38-8620-c37858f5fb21" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35cff366-22b3-4af7-b10e-b14e8ebfc6f0" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a745f78b-91de-407c-b52b-ea787e08a620" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,094</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf4616b-8545-4511-986d-f20001fb5e38" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9042850-9074-4c38-9997-ef5a80084c58" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af7c0c3a-310e-4688-a366-28938d7c42e2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae12045-c802-4370-aa5d-a944d7fe58a8" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c712bf09-c972-443b-9b0e-70efe5a4408e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5480c5c-fe86-4afb-bec7-7edd0dae4404" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15d80818-16e5-4f4c-8825-dbd007e835be" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f574e15-1f65-4e93-8701-9a28169295e1" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f19abd42-710c-4daa-b348-ebd32b3d22fe" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,593</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cf4d37d-112e-4053-9b10-21b480bd2676" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,850</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d82b50c-f3ed-45b2-8f6c-cb60bb130db8" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,814</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef12c31c-82de-4829-af5f-09de34eba5ae" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,393</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturity of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_806de204-df9e-4f80-aca6-558f7ee1dddb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eeaca8d0-03e6-405f-8eb7-ac672ab9a5dc" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a05242c-d13a-46c3-a875-d2e0882edd26" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94c538c2-44fb-46da-9f96-8caf7165ea0d" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212,657</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb4c5fd5-0f92-4f10-ab5a-291e142e72af" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4adfdfb-8de8-48f6-9644-fbc6e7d9f105" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,950</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_484d8cdf-e2ea-4ccb-b1c2-351034bf5295" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProceedsFromNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13caca8a-a699-4dca-aa66-dd7e0522d421" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProceedsFromNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15beb827-b44d-430f-98f9-a9add83bc88f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:RepaymentOfTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e19174-46b9-4927-857c-d50f0fb8b4b7" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:RepaymentOfTermLoan" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock from public offering</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dbb727d-812d-418e-97db-c11466d560ce" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d66a4ba5-6835-4a0d-aed1-1adeb8b540cd" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock for at-the-market offerings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8a14af5-74f6-403a-8baa-61fb51c8a0a1" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91057fd6-b835-4bf3-9e44-653c1d9107b2" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0556f4f3-7a7b-43ae-b8ab-f8aee9ed9b86" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,473</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01865601-4534-4b54-9fb1-11ac6d16a6c1" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,778</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments for employee taxes related to stock compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd5a48d6-a54c-482e-89c5-cea628bc6706" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf83f3d4-f122-4092-91b5-456c3855e39c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal payments on finance lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4910d61d-464f-44d6-b32d-6cc30b793db4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab3b93cd-5d60-4f7d-8a96-334a033ab4ff" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments of deferred offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bed03b35-45db-475d-a82e-c31c80a76eb1" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">622</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9be900a7-5676-4909-91f3-1f107e536405" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments of debt issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cd6e6d5-d987-4058-9a79-b2ade86783cb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_786800ac-8b48-4c51-b299-18d048a6194f" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb9675e4-b5c6-4ba7-8985-170f95f57c2f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,524</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b483a01-fe19-4536-be06-4ead042845e5" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,332</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effect of foreign exchange rate on cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ad8389f-615c-4629-bcfe-fbef7045791a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7759d8c6-f17d-44ed-b084-f4c1caa3c86e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3425fb0d-12fe-4a11-bfd9-e7308d650308" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58c50327-0767-41d9-a524-f5937d33c93f" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,577</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash, cash equivalents and restricted cash - beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e65b8a0e-9db9-4855-981f-d0f93a389c42" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2dddcee-9fc6-45bd-be4b-a3984bb4f187" contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash, cash equivalents and restricted cash - end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd3cc35d-4449-4caf-80b7-cf3ea69b4916" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a0144e-2300-440f-878e-51c109614f0b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93de472b-27a5-4f89-b97a-3a9fa70b7df8" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_260f8531-7f61-469a-8806-8e735cff6d7c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,187</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c5d03a4-4d55-4971-9854-c4d3f1e9a79f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_406cf420-fe68-4d70-99f3-128fc4c76e1c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest on financing leases</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c267266f-bf3d-4d4d-9756-cc4d4af159ea" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:InterestPaidOnFinancingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28e8ea48-df69-4419-a52f-e9311d0409bf" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:InterestPaidOnFinancingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest on term loan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdc6eab7-3810-411f-8b4f-564cfe74bf36" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:InterestPaidOnTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a51af69-1bfa-4198-bf88-972d6a9d2083" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:InterestPaidOnTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_948becd7-63e6-44ae-acb4-578e74d2a8f5" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3b73b44-7890-4109-99f7-b427eb291ff0" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e0c690-e0e2-4b97-8440-7b4c9e1cb3fd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3c979c1-834d-42ce-bfe8-8feeea960e99" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease obligations recorded for right-of-use assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435172b9-9d15-4dde-933b-8956748e3eee" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:OperatingLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d75f472-4bb4-492e-aa32-030103a52c65" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:OperatingLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a97520f-2af5-4363-b484-0e3de0a03eef" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:FinanceLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b503262-0ff9-4a77-a3f1-ec420bc5d506" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:FinanceLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition of property and equipment included in accounts payable and accrued expenses <br/>&#160;&#160;and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a1e3905-3546-4244-b0f2-2fba10ad7939" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9654c72f-5cf4-4ff8-930c-929c68c2edb9" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred offering costs included in accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a92924d-5032-4c6b-b728-144584144bd4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:DeferredOfferingCostsIncludedInAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27d7baac-2f1e-40f5-854d-1875e4d96c63" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:DeferredOfferingCostsIncludedInAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of deferred financing costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb51021e-b649-48c8-9ddc-e16228ab0260" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:ReclassificationOfDeferredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,390</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7535e52-f5a3-4a23-a84e-06b9e2df5956" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:ReclassificationOfDeferredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da78ea31-6f4c-4ae4-99ed-0d61029c9bd6" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 &#8211; Organization and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSight</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc. (the &#8220;Company&#8221;) is a Delaware corporation headquartered in Aliso Viejo, California with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d49e288-44e7-472b-a83c-40d245e6bfd3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:NumberOfWhollyOwnedSubsidiaries" unitRef="U_Subsidiary" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> wholly owned subsidiary located in Amsterdam, Netherlands (&#8220;RxSight, B.V.&#8221;).  The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany (&#8220;RxSight GmbH&#8221;).  The Company is engaged in the research and development, manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products, which include the light adjustable lens (&#8220;LAL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and a specially designed machine for delivering light to the eye, the Light Delivery Device (&#8220;LDD</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), are approved by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) primarily for sale in the U.S. and have regulatory approval in the U.S., Europe, Canada and Mexico. The Company began marketing its products in 2019. The LAL is a premium intraocular lens (&#8220;IOL&#8221;) which is partially reimbursable under Medicare. The Company competes with other IOLs in the premium market.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ce2c82f-fba1-4bac-bd9e-3f515cdcc50d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of RxSight, Inc. and its wholly-owned subsidiaries, RxSight, B.V., and RxSight GmbH. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All significant inter-company balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company&#8217;s chief operating decision-maker (&#8220;CODM&#8221;), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.  The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_801c0b37-9d38-4360-92e6-b015a53babdc" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca4f1a31-79e9-4796-aa3e-1c4fcf65d79e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:LiquidityAndFinancialPositionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, the Company filed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c977391-e038-4dac-8db3-e58019eae4f5" contextRef="C_935e5c68-4a2f-4fe7-830e-c64554a43bf9" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement on Form S-3 (&#8220;shelf registration statement&#8221;) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de5549af-18e9-4663-9423-48e8d0156a7a" contextRef="C_115b5518-d11e-4805-8e6b-f554aae35196" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital.  At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0064dd20-9a96-4253-840b-88e6934a3a8a" contextRef="C_8cd00306-7aef-4100-8205-c4511dea8fb8" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million dollars of common stock through an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, through the ATM offering, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3c53975-d893-4799-a0de-d0d57a11a06a" contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,617,964</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7e071e-0857-4af0-8423-1a8450193f37" contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, have been issued and sold, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed50d3c4-cf8c-4e67-90d3-ad1218a88dec" contextRef="C_5e4f8477-6783-483b-8846-75d4dd7609bf" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,142,089</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b943798e-0e5e-4fc3-aed1-ab8169fcc610" contextRef="C_5e4f8477-6783-483b-8846-75d4dd7609bf" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were sold during the twelve months ended December 31, 2023.  As of December 31, 2023, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6f875b5-f8e1-455f-8dc9-3a8ac537d7c7" contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million authorized under the ATM offering was sold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50eb3c51-2cdd-4eca-8b8f-72306e8ddf35" contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 7, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90d500bd-8621-46e0-852b-517263715487" contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock in a public offering (&#8220;Public Offering&#8221;), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02ccf930-04ff-4b0a-837f-a82fc9b8ae85" contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">days from the date of the underwriting agreement to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf5d58e-a117-4ad7-8a11-9dbd1e36ddb5" contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb" name="rxst:AdditionalNumberOfCommonSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock on the same terms and conditions.  The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023.  The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb8eac6e-4894-42ff-8cab-21078eac4389" contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Public Offering, after deducting underwriters' discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8db41f8c-fe38-4715-b04b-0cbeb1326acc" contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369" name="rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9ce8018-ec1c-4d8c-8ff4-f063f6aba3f0" contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369" name="rxst:CommonStockOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022 the Company has cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd26a721-4077-4117-832d-e0d9b63b4743" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">127.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1302e4d-49c7-4fa5-aaea-9d2c6a89b0a4" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company&#8217;s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the years ended December 31, 2023 and 2022, the Company incurred losses from operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dbe7ccd-ae66-44f4-acfa-a8db68921c32" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:OperatingIncomeLoss1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a95171ba-c762-4474-9e01-dc818d1e2341" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:OperatingIncomeLoss1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.  Based on the Company&#8217;s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company&#8217;s products and achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements.  The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and meet its future capital funding needs, as needed, through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_09e20fc8-794f-4ece-be67-8f4ab1cbf45a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Summary of Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7d7fb8b-666c-4413-a4b4-8c1ee5aa9808" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict.  Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_14f0cdf2-8eb6-48b5-9cba-ab59565c3efd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_14f0cdf2-8eb6-48b5-9cba-ab59565c3efd_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span></ix:nonNumeric></span></p><div><ix:continuation id="F_14f0cdf2-8eb6-48b5-9cba-ab59565c3efd_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents. Cash equivalents are recorded at face value or cost, which approximates fair market value.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1ba8560-8bc3-4c15-9b19-940191396930" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:ShortTermInvestmentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company&#8217;s short-term investments, which are government securities, are classified as available-for-sale and are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company&#8217;s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders&#8217; Equity on the consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the investment has been in a continuous loss position for over 12 months; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration to maturity of investments; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the credit rating, financial condition and near-term prospects of the issuer and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type of investments made.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had an unrealized gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc153b3c-1588-40d7-b395-64519f9ee759" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93ec9c3b-e2c9-4c44-934f-7f16a7879737" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrealized losses related to short-term investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023  and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15429682-f746-4ca3-8f5e-d6a0002a690e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d563d21a-75aa-403f-987f-42688b800c25" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an allowance for credit losses for these investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.   For additional information see Note 3 &#8211; Short-Term Investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f292c4b5-8d36-4ea3-a3fe-ab9648546a00" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of cash held as collateral for a letter of credit as security for future facility lease payments and corporate credit cards at the Company&#8217;s bank. Restricted cash decreased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dac12bdb-4a7f-49ae-84d5-4ea12e5fecbd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:IncreasedDecreasedInRestrictedCash" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71df588c-0d3d-4000-9a55-ec61af9093a1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:RestrictedCash" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">711,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as required for these operating activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4c4999d-a313-4e71-b0e4-79b4281f84ab" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.92%;"/>
          <td style="width:1.86%;"/>
          <td style="width:1%;"/>
          <td style="width:24.86%;"/>
          <td style="width:1%;"/>
          <td style="width:1.86%;"/>
          <td style="width:1%;"/>
          <td style="width:18.5%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60228ba1-bd78-4312-8acd-9b83408e137d" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,692</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b318fba-79f5-46fe-aa80-1dc5887a50ad" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,834</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c4718f4-6f11-418c-aa4c-341d6f1023ec" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">711</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cf0e20b-e065-475c-bd2d-d7aaad4cb992" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f6b41b2-05ad-4696-bc81-bacbb2a68c5e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,403</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_596c37ac-e32b-41ee-84c9-17d64af971d3" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,595</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7eef8e1-f291-4c28-a28a-a45783d4d9e4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company&#8217;s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company&#8217;s business and may impact business in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d557dcf-e0bb-41c3-b3b9-087b4abf6af9" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are presented net of allowances for credit losses. Accounts receivable are typically due between 30 and 90 days after invoicing.  The Company does not have a high concentration of business with any individual customer as of December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company did not have any customer who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af9d609-8fc2-48a4-9d05-da6de940e302" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:AccountsReceivablePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c3bb6f66-f84b-42b4-95ea-61a5dc691e7e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:AccountsReceivablePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. The allowance for credit losses is calculated quarterly and is developed using an aging of receivables where receivables are segregated into various categories based upon due date, and a historical loss percentage is applied to each category that is adjusted for current receivable composition, counterparty and specific risk and prevailing economic condition and supportable forecasted economic conditions. If a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the allowance for credit losses. The Company closely monitors the credit quality of its customers and has yet to experience a write-off of a receivable or uncollected receivable. After evaluation of the collectability of accounts receivable, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a5ba23c-63e3-480e-9428-022c900c0821" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_06f8eb57-35ff-4570-b847-b73c7d2ab798" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any significant allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company does not generally require collateral or other security on receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df56aab8-9cd9-49cf-ac0d-cf45586a0af3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.  Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable and operating lease liabilities. Cash, cash equivalents, accounts receivable and accounts payable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company&#8217;s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and amended term loan at December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of that date.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac94c43f-0779-4a83-b792-c9d1655a3af6" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_493d4d3d-84cc-452f-bd4b-02a81c40b169" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment and leasehold improvements are recorded at cost, net of accumulated depreciation and amortization. Property and equipment are depreciated over the estimated useful lives of the related assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d91e2c-b3a0-43eb-ab11-b91dbe431329" contextRef="C_d19decf9-3310-45a2-abd2-b456a757f5d2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, using a straight-line method. Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or their estimated economic lives. Repairs and maintenance costs are charged directly to operations as incurred, while renewals and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All long-lived assets are reviewed for impairment whenever circumstances such as events or changes in the business indicate that an asset or asset group&#8217;s carrying value may not be recoverable based on undiscounted future operating cash flows to be derived from their use. Factors that are considered important that could trigger an impairment review include a current period operating or cash flow loss or a history of operating or cash flow losses and a projection or forecast that demonstrates continuing losses or insufficient income associated with the use of a long-lived asset or asset group. Other factors include a significant change in the manner of the use of the asset or a significant negative industry or economic trend. This evaluation is performed based on estimated undiscounted future cash flows from operating activities compared with the carrying value of the related assets. If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized, measured by the difference between the carrying value and the estimated fair value of the assets. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ddd976f-1ddb-4a07-8700-22e5b34ab29d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (&#8220;Commencement Date&#8221;) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9cb291b-50df-4ef9-91c6-6c4584de4066" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e22d2d64-65c7-4c2a-bb24-69de25cce447" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.332%;"/>
          <td style="width:1%;"/>
          <td style="width:17.684%;"/>
          <td style="width:1%;"/>
          <td style="width:1.48%;"/>
          <td style="width:1%;"/>
          <td style="width:18.504%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75f3b7da-d457-4f95-95d5-4fa480faeb8f" contextRef="C_b1e80520-b096-4bb3-86ce-8009a5315cb9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,860,328</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f3284c4-e271-491d-8e85-fea8523b39df" contextRef="C_436ef63d-fc6d-4417-9b9b-5376ba16f03f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,926,226</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4393910-4051-4779-92dd-47661c05c396" contextRef="C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">685,029</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1264d3da-30de-436a-8ed2-a672a79fd08f" contextRef="C_84f4cc9e-e25e-43fa-81e5-13a42f6b8d68" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">543,538</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock issuable in offering period under the 2021 Employee Stock Purchase Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06dae184-0cd7-4597-961f-7ff90ee08357" contextRef="C_e81e1959-5dc9-462d-a83b-fe7fb4c2dc14" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,189</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd8e8156-8515-4c40-a154-a09da9d250e6" contextRef="C_5bafa0c3-726b-4976-a24a-5029c3f3ff37" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,594</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_24c83ba6-24cc-49bc-af69-c7e1d795a816" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_24c83ba6-24cc-49bc-af69-c7e1d795a816_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_24c83ba6-24cc-49bc-af69-c7e1d795a816_1" continuedAt="F_24c83ba6-24cc-49bc-af69-c7e1d795a816_2"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. Canada and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company&#8217;s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer.  Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer&#8217;s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer&#8217;s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation.  Revenue for training is also recorded at a point in time, generally 60 days after installation.  Revenue for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales are recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the years ended December 31, 2023 and 2022, credits related to returns and rebates on list prices were not significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company&#8217;s contracts. Revenue for service agreements is recognized ratably over the term of each contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14bede62-17db-47d5-a459-e5dc89778b55" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from contracts with customers consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"/>
          <td style="width:1.821%;"/>
          <td style="width:1%;"/>
          <td style="width:24.369999999999997%;"/>
          <td style="width:1%;"/>
          <td style="width:1.821%;"/>
          <td style="width:1%;"/>
          <td style="width:18.127%;"/>
          <td style="width:1%;"/>
          <td style="width:1.821%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDD (including training)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e096a88-f08b-4c84-a512-6bf3111e1a10" contextRef="C_22015c87-a9d7-40c9-bba3-3d510e3d5d06" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,091</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d79634-e7dc-402e-a545-e7a0b04eda0f" contextRef="C_ffa1d143-149d-4487-a305-e878c9ce191c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,515</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LAL</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2635d735-0f66-4d5c-a84b-6807295636ef" contextRef="C_41c727ce-a38b-4fac-af15-b2f7c97ca3f0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,092</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20c48965-1fc2-45a3-84b6-6b7adac295e1" contextRef="C_3f2eeece-26e5-4b45-bad6-a36623117435" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,965</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service warranty, service contracts, and accessories</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213e0b92-5302-4579-b27c-c80e1a5dd0b5" contextRef="C_4a7af93b-ffbb-4eba-bf5d-00c6faec0f6e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,894</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ef98758-53c7-4b8f-bcbd-f09b200f2ee4" contextRef="C_c024e436-4a63-48c9-b8e3-a71a5ce33e50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,525</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7361696b-474c-4181-b8fe-71dce6b7e4d6" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,077</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f33e872d-8c52-46b4-b539-0fbae4aee89a" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,005</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. the Company did not have any customers who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e580e24a-2ba3-4b20-8305-a75f81080664" contextRef="C_4100cff0-e3c8-4a4e-a04b-cac826120706" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1077e9d2-012b-4c13-aa0b-3a165d98b843" contextRef="C_2eee38f7-b0f6-4df6-b5d8-aa6c3374c148" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee378c0c-984c-4797-9e55-4b8b284d189c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" escape="true" continuedAt="F_ee378c0c-984c-4797-9e55-4b8b284d189c_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"/>
          <td style="width:1.821%;"/>
          <td style="width:1%;"/>
          <td style="width:24.369999999999997%;"/>
          <td style="width:1%;"/>
          <td style="width:1.821%;"/>
          <td style="width:1%;"/>
          <td style="width:18.127%;"/>
          <td style="width:1%;"/>
          <td style="width:1.821%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:40pt;vertical-align:bottom;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8272a89-2c52-40e7-b2c1-7b624d7055f8" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredRevenue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_871ced67-af00-48b3-b3b4-d2d35f91cc47" contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075" name="rxst:DeferredRevenue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions during the period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17745e99-809b-4661-97ac-28d5e241f7b4" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredRevenueAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_477a6fb3-1122-4a87-91c7-ea9402a5d2bb" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredRevenueAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,052</ix:nonFraction></span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a92b204-5cb3-4a71-96a8-ef378dc5abca" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,721</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f955e3a1-f06f-4b66-9c16-9fc26ade687e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,405</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ed04ae2-df44-4979-bd6f-a8b96eaade2e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:DeferredRevenue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,888</ix:nonFraction></span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cf3d9d5-440d-4969-80e6-169687deda8a" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredRevenue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><ix:continuation id="F_ee378c0c-984c-4797-9e55-4b8b284d189c_1"><span><ix:continuation id="F_24c83ba6-24cc-49bc-af69-c7e1d795a816_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></ix:continuation></span></ix:continuation></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf36b9dc-70e6-490c-8f16-122760deed3c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true" continuedAt="F_cf36b9dc-70e6-490c-8f16-122760deed3c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Sales </span></ix:nonNumeric></span><span style=""></span></p><div><ix:continuation id="F_cf36b9dc-70e6-490c-8f16-122760deed3c_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales consists of materials, labor and manufacturing overhead incurred to produce the Company&#8217;s products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as royalty and license fee expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf3c7f63-1d92-4d9e-89c7-b3667c2eb604" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses are expensed as incurred. Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities for new products and technology. The expenses include personnel-related costs, including compensation and benefits and stock-based compensation, consultants hired to perform research projects, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs related to FDA premarket approval submission preparation, various laboratory and research supplies, write-off of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of manufacturing processes in excess of capitalizable value, fees paid to contract research organizations and direct FDA related costs. The Company also accrued the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_664e43af-598d-4dff-8211-945c451f8613" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for equity-based awards on the date of grant to employees, board of directors and consultants based on the estimated grant date fair value of the award Equity-based payments include stock options, restricted stock units and employee stock plan purchases. The fair value of the option awards are estimated using the Black-Scholes option-pricing model and recognized in expense in the consolidated statements of operations and comprehensive loss over the requisite service period, which is generally four years. The Company amortizes the stock-based compensation for equity awards with service conditions on a straight-line basis over the vesting period of the awards. Compensation cost for stock options with performance conditions is recognized based upon the probability of that performance condition being met. Forfeitures of unvested stock option awards are recognized as reductions of expense as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company&#8217;s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;), and its shares being traded on the Nasdaq Global Market, the fair value of the Company&#8217;s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company&#8217;s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company&#8217;s common stock. For all grants subsequent to the Company's shares being traded on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#8217;s expected term; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the lack of historical exercise history, the expected term for options granted is calculated using the &#8220;simplified method&#8221; and represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is derived from the historical volatilities of a select group of comparable peer companies, for a look-back period commensurate with the expected term of the stock options, as the Company has limited trading history of common stock. </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3f70995-aee1-4df2-b674-6048ecb08be6" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in tax rates is recognized in the Consolidated Statements of Operations and Comprehensive Loss in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history and reliability of forecasting. The Company recognized a valuation allowance on deferred tax assets as of December 31, 2023 and 2022 after evaluating that it is more likely than not that deferred tax assets will not be realized as of those dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the accounting for uncertainty in income tax recognized in the consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax positions where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031b37a0-e654-4dbb-be70-42c90e329e32" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:LiabilityOnUncertainTaxPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2ddf4dc4-391e-4edc-b2c6-99423b2c294a" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:LiabilityOnUncertainTaxPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States, United Kingdom, Germany and Netherlands. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect on such jurisdictions, which could impact the amount of tax paid. An amount is accrued for the estimate of additional tax liabilities, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The accrual for uncertain tax positions is updated when more definitive information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_836add38-f207-4958-9ce8-c1ccdebea645" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfcb2cef-709c-42c0-9d26-80e5c98d4b1a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of accounting standards updates (&#8220;ASU&#8221;). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that are of significance or potential significance to the Company.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd9148cb-d7f7-4247-9ec7-1e3f7fae91f5" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3 &#8211; Short-Term Investments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d6f208a-4327-4634-a12b-f61e8d240d2c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.94%;"/>
        <td style="width:2.24%;"/>
        <td style="width:1%;"/>
        <td style="width:16.459999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.24%;"/>
        <td style="width:1%;"/>
        <td style="width:22.259999999999998%;"/>
        <td style="width:1%;"/>
        <td style="width:2.24%;"/>
        <td style="width:1%;"/>
        <td style="width:22.619999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aed0d33-6ba6-45ab-a300-a1d46c43a437" contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0014623f-e875-4ef2-868a-052aa1eb7d6b" contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77d373aa-185a-4f7e-9a6f-16ed2b49fd60" contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.471%;"/>
        <td style="width:2.181%;"/>
        <td style="width:1%;"/>
        <td style="width:16.066%;"/>
        <td style="width:1%;"/>
        <td style="width:2.181%;"/>
        <td style="width:1%;"/>
        <td style="width:22.089%;"/>
        <td style="width:1%;"/>
        <td style="width:2.181%;"/>
        <td style="width:1%;"/>
        <td style="width:22.828999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a39e2bb1-d844-42c8-a1cd-93451222c522" contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,043</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb0a9c0c-6fbe-4c1d-b356-f8b806880981" contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a69f738d-7cba-4f9a-a292-cd4d7b782cb5" contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All available-for-sale securities held as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> had a maturity of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ad232f5c-7ce0-4d92-95b3-b3019e7d245b;"><span style="-sec-ix-hidden:F_1f005e07-66a8-4957-933b-b4aede44a4d8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company&#8217;s ability and intent to use any and all of those marketable securities to satisfy the Company&#8217;s liquidity requirements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company&#8217;s intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer&#8217;s industry, and any significant deterioration in economic conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest expense in the consolidated statements of operations through an allowance for credit losses. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Unrealized losses on available-for-sale debt securities as of December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Further, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf432402-4d10-4728-8495-194dfe6ec712" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f5160b0a-889e-4892-9e10-b3fdf34be24b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an allowance for credit losses with these investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b08db59b-0816-43da-8702-8f309bde012f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:InventoryDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30904506-60e0-41c1-a2f3-738725936f1f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.74%;"/>
        <td style="width:1.76%;"/>
        <td style="width:1%;"/>
        <td style="width:14.200000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:5.16%;"/>
        <td style="width:1%;"/>
        <td style="width:14.200000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.94%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e39171ba-d37e-48d6-9187-382ffc6cc0d5" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,092</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bde2be0-9f84-4a94-88c6-b892fb2fb812" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,408</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63ff8beb-9447-4544-af2d-5060156ed508" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,680</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1152a7f-2b49-4843-9254-0f4b113e25b2" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dbcd99b-da02-468c-a426-f9481ccb2881" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,145</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a0b191-50f2-4f58-b728-8a7512dc548c" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,567</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cca4090-fe20-4580-99a8-bfa5548bf273" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,917</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c739c76-f96e-419a-a20a-f3f2b383f75b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: reserve for excess and obsolete inventory</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f0e3a1d-e031-4d05-8867-3de44ecd7476" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_420aaf17-d3f8-4653-9fc6-158d14f808b9" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">634</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7f8ef70-c943-4ffd-9fed-3fe6c846263d" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,421</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9eb2362-2e12-49f5-a131-6a8e1e129351" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,835</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023 and 2022, finished goods included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc21228d-1f13-4fb3-93a0-677e9a530f10" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_064e22f7-0ae4-40a6-8163-a43d0174165c" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of inventory held on consignment at customer sites, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6156133-343a-4050-b5e5-064d2e95c615" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5 &#8211; Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1219e2e-724b-4e1f-83c3-e3267d333391" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_828b8127-5bce-40c0-b5eb-a7ab459a44b0" contextRef="C_668f69a7-acb0-43b4-a348-1ac42e4921ca" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,638</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70511ca9-6ec0-41dd-b484-2ed4a6cead4b" contextRef="C_04d3ef87-f8dc-4a39-8e22-74626d458f80" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30dc1b71-dbe2-4fe3-9003-a86a60dc8a88" contextRef="C_0c0d5359-a0dc-4cfd-ae75-3d2013478591" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,553</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f355fdf5-c1a1-4211-93f0-ecbe60aa0c07" contextRef="C_7e03f7a2-cd01-43e0-96bd-e479c8471a97" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98249842-250d-4431-867c-ac045ad1631f" contextRef="C_8d126cea-f298-4eca-b4ae-c0648a9c58e4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8140d17c-b264-4200-a5db-e9672f0efd45" contextRef="C_f7039d17-9ee2-4e22-b624-e5756e318526" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,331</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ed13e0-3f32-4503-ba80-edb54c2e8d16" contextRef="C_47ec21cb-9507-465f-9a93-95dbd904a764" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e8d32fd-d0fe-4b92-b2c4-1777a5b71486" contextRef="C_c4dc177f-a41b-4a6c-9a51-c41f851cea5f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,693</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Production molds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96357c09-2019-4374-b07d-28d08ecdfdc1" contextRef="C_28c73d3b-1f4e-47eb-8983-ab2974f6fec1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,005</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_702105c2-e5e2-49f6-a7c4-027c348775f1" contextRef="C_fd90b2d8-aec9-4102-be22-34321f15f5b4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,873</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7ddab0-e5b9-49b4-a1e1-46f9e09879c7" contextRef="C_0b42dce2-cf09-4fb9-9b81-1ed4c14f7dca" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1039099c-6bbd-46c4-bb82-fa361793f04b" contextRef="C_9e2c5118-f472-4fd8-bd76-d3936f7e7ba0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bd847c9-839b-4950-88ca-5f9d85346959" contextRef="C_366621b7-b9f6-4be8-a093-a9b4299ad983" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_065ea6d6-a9e7-492a-b58b-d89124eb4b73" contextRef="C_a53c973f-68a7-4092-8c03-15c10d086cf9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef110426-2dc1-436d-9852-799bfc3afe9e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,539</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7362d410-ba2b-42a4-9bd7-7f51c83d551a" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8113e69e-7d1f-4b16-aac0-3e33df36c1cb" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1067a064-66f0-4e89-8927-c0f806d523a0" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,898</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a8dc2ef-bded-4e83-bef2-17a6b3e4c062" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,841</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8beda4d-f5cf-46f1-9ac2-e08049ae72ee" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06b294c1-347e-4a90-a137-7972bf2dab4e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb2b6e51-bcc3-4981-ad4a-f21908fde4b1" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in depreciation and amortization expense for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e3d642b-8dec-407d-8fcb-8e5c3af523ac" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6 &#8211; Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below (in thousands) present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value. The Company did not have any assets or liabilities measured at fair value on a recurring basis within Level 3 fair value measurements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. U.S. Treasury are measured at fair value using Level 2 inputs. The Company reviews trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c610718-0f48-45a4-9736-4545e6e0d06c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d440456d-e3a6-457b-adf7-900b80874b16" contextRef="C_87f27813-04b4-43a9-89cf-60f99646eed6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50ada839-bcbd-4117-8788-4c2744664d2b" contextRef="C_8d466df4-3d33-403f-8a77-220f9e7e5b8e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_477c6a9b-af54-48a1-a781-9795e806808d" contextRef="C_e59788db-8615-4e43-8e9d-3d404e52eb66" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18ab1630-42dc-45d5-b06c-a507002493b8" contextRef="C_829b96d2-f2b7-4707-8dc5-c513602f5c40" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8a48e6b-cb27-4208-86fc-a9fa48e2f157" contextRef="C_6bd8958d-ac74-435f-a9b1-65f5c5df5463" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29a9b9b0-6fa6-4305-8bf0-bb4632903d7c" contextRef="C_fed1b82c-fcdc-47fb-8e4c-b26548a6ea85" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6818a93-56be-4325-9c7d-d7826d4a9d17" contextRef="C_8c73432c-1e8b-41d2-a8a2-ad9cf9e153b2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48cd46e7-0b0b-49d5-b624-d69b3abe0a52" contextRef="C_0769e4e2-f071-4d16-811c-15ab6db50acd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8b88708-416f-49a0-8452-66af86d2f87c" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.438%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddd0f34a-3258-4547-ba6d-cc5a0ca614d0" contextRef="C_7e12529e-af41-4c48-9b3a-2cd9a1e05936" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd8d9d4a-f83d-4b30-9ca4-e7af6bac66d5" contextRef="C_aa88a57b-a838-484b-b8a6-d0306d09b381" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b3e415-55c1-4716-b6d7-a511012ad481" contextRef="C_b78bc7b3-79c3-4faf-8705-31df15a4698c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce5bd1e-78c4-4c47-989e-6e687941af3e" contextRef="C_28619841-2fee-441e-b364-8cc0d0d59ea3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bc2b05b-c351-4ab0-8e96-2462e59da09e" contextRef="C_88cb89e8-ba4b-4206-a251-8f43f4a4a237" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_800608ab-2a33-4dc9-967c-c4285738f3b3" contextRef="C_bfff9d89-3c68-4d8a-aaf1-ae180ad5659f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75092cc1-c534-4667-8266-e3592571bfa5" contextRef="C_13836f48-52b4-4300-9d56-4f50c234e19e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdc2e7c9-96b4-495a-9224-a850b3da8c46" contextRef="C_f203818c-89e0-4e29-82a7-a9e012aac75d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,968</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_324de39a-a702-4e19-85bb-fc8a4e510422" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4cf6ee8-d077-4d33-97b5-90ad51469a0d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7 &#8211; Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_8bbf4836-2d85-4062-a1dc-bbe50cf397b3" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.9%;"/>
        <td style="width:27.04%;"/>
        <td style="width:1%;"/>
        <td style="width:15.700000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:13.360000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c241574-76ef-48b7-90ee-c6a1d7476d98" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,637</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee532dda-0f40-4972-9b9c-06154c9e760b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,537</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6503e48-4a0d-446e-bfc9-d3e3f0c06c23" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f99efe07-7752-48d7-8990-b031d08ff1e0" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98e1259b-2ec9-40d1-9485-51c2196b9889" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:AccruedInterestCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf7fe860-3fd0-43cf-901f-6e1db0204819" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:AccruedInterestCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">455</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c2634e2-6750-4c1a-b004-32b9937727b3" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea56b239-1cd7-4e23-ad79-1faef212d0b3" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9957bdfe-fa64-4d77-8f01-ec06a320cfe1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e92595-877f-4dc0-a90a-a1d5916daa20" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17c4538d-eeb4-4f57-90c1-6b9b3b148d52" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8 &#8211; Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Refinancing and Payoff of Oxford Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 29, 2020, the Company and Oxford Finance LLC (&#8220;Oxford&#8221;), as collateral agent, and certain lenders (&#8220;Lenders&#8221;) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the &#8220;May 2022 LSA&#8221;), pursuant to which the Lenders provided to the Company certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the &#8220;May 2022 Term Loan&#8221;).  The May 2022 LSA increased the loan and security agreement to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b9894db-4565-40ad-8d3f-723b2bf1ffeb" contextRef="C_ec88e75c-ff75-4185-a750-95225b1dcd49" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09ab27f1-2997-4120-884b-93e963bd4921" contextRef="C_8e853287-f8f2-492f-b2ee-7e9d752ea4ca" name="us-gaap:ProceedsFromLoanOriginations1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was fully drawn upon as of May 3, 2022 from the original term loan.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2023, the Company entered into a new Loan and Security Agreement (the &#8220;June 2023 LSA&#8221;) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24171641-2832-4576-9e63-fb3c875f8366" contextRef="C_062bed15-9f98-4171-bfad-0df8a119278e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate Term A Loans (the &#8220;Term A Loans&#8221;). On that same date, the Company prepaid the May 2022 Term Loan in full which included approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27558ce4-72e5-4dae-9f51-0ac2edaac283" contextRef="C_ca4cbdee-0ada-4ebf-982e-0a37a5748260" name="us-gaap:PaymentsForFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in final payment and other fees using a combination of cash, primarily comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b87c239-c7a9-4b91-aa9f-0faf64126493" contextRef="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75757591-b651-48a3-9173-6aecab89a36e" contextRef="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4" name="us-gaap:ProceedsFromLoanOriginations1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Term A Loans and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_883bc6e5-5329-4319-9d5f-103b7237e04d" contextRef="C_70360018-fdc1-4362-ac4e-ba7f96b09f5a" name="rxst:DebtFromCashReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash reserves.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023, the Company repaid its outstanding June 2023 LSA of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98281379-7d2a-4e8c-b9e4-6bc3105d5233" contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million early which included outstanding accrued interest of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_684301ca-44e0-432a-b808-8bbb51621e13" contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3b373de-d595-4a8a-8ec8-9f27ab342f8b" contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518" name="us-gaap:PaymentsForFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in final payment and other fees using $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e33ed535-3d40-498c-b838-04713f2be000" contextRef="C_4a21676c-9a43-4d66-b8cc-6cd51899920b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, net, raised under the ATM Facility and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8641eea-b949-4e1f-ab3a-294d44f6ec8f" contextRef="C_cfeaa0f9-8a0e-4a4c-af2e-cbfcae368f77" name="rxst:DebtFromCashReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash reserves.</span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_598fc128-dea7-4a8d-ab3c-31171b677eb2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9 &#8211; Stock-Based Compensation Expense</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has three equity incentive compensation plans: the 2006 Stock Plan (the &#8220;2006 Plan&#8221;), the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) and the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;).</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2006 Plan was originally adopted by the Board and approved by the Company&#8217;s stockholders in 2006. The 2006 Plan was terminated in 2015 in connection with the adoption of the 2015 Plan and as a result no new awards may be issued under the 2006 Plan. However, the 2006 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2015 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2015 Plan was originally adopted by the Board and approved by the Company&#8217;s stockholders in 2015. The 2015 Plan was most recently amended in March 2021. In July 2021, upon completion of the IPO, the 2015 Plan terminated immediately prior to effectiveness of the 2021 Plan with respect to the grant of future awards. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2015 Plan.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2021, the 2021 Plan was adopted and approved by the Board and stockholders prior to the IPO and became effective on the business day immediately prior to the effective date of the Company&#8217;s IPO registration statement.  The 2021 Plan provides for the grant of incentive stock options to employees and any subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;), and performance awards to employees, directors, and consultants and subsidiary corporations&#8217; employees and consultants.  The number of shares of the Company&#8217;s common stock originally available for issuance under the 2021 Plan was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2966b61b-e69f-46e6-8eb6-fde766070e7d" contextRef="C_c9b31877-61d1-447b-9f36-a10b15a4cba2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,420,135</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock plus any shares subject to awards granted under the 2015 Plan and the 2006 Plan that, after the effectiveness of the 2021 Plan, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by the Company for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest, with the maximum number of shares to be added to the 2021 Plan from the 2015 Plan and 2006 Plan equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb9616f-d2db-4002-8b83-9d417f7ffc0f" contextRef="C_a4f444db-5996-4c90-8623-059c3f481ab2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,569,530</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evergreen provision</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common shares reserved for issuance under the 2021 Plan will be increased automatically on the first day of each fiscal year beginning with the 2022 fiscal year and ending on the ten year anniversary of the date the Board approved the 2021 Plan, by a number equal to the least of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a99a7dce-293b-4433-91f6-0baf5f995048" contextRef="C_c9b31877-61d1-447b-9f36-a10b15a4cba2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,260,406</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c44aad2-bbf9-43fe-a57e-89881d9770a1" contextRef="C_d24bcbd2-389a-48da-b2a7-d4fe20dbb56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such lesser number of shares of our common stock as the administrator may determine. The 2021 Plan is administered by the Board.  On January 1, 2023 and 2022, the number of shares available under the 2021 Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a3bd39-6615-4016-9b2e-efd6f2d0e283" contextRef="C_e15cdba7-7d58-4afa-a398-ee69435f47e1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,130,735</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbf3f3e4-78ba-4d29-961f-45ae7d8c2144" contextRef="C_6fa4f2fd-ca66-4db8-b0ed-9ab91076fb17" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,094,670</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively pursuant to this feature.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 ESPP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2021, the Board and stockholders adopted and approved the 2021 ESPP. The number of shares of the Company&#8217;s common stock originally available for issuance under the 2021 ESPP was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f72df2d6-0125-458e-892f-a41a22ea0ca2" contextRef="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">664,976</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and the initial purchase period began on November 1, 2021.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 ESPP provides eligible employees of the Company and its subsidiaries with the opportunity to purchase shares of the Company&#8217;s Common Stock at a purchase price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7234591f-6f5e-4375-be1b-f838b7ad5a6d" contextRef="C_37cd287f-b1fe-417b-bb04-4b5f0d4c6f3f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the common stock&#8217;s fair market value on the first trading day or last trading day of each purchase period, whichever is lower. The 2021 ESPP provides for two six-month purchase periods every twelve months: May 1 through October 31 and November 1 through April 30. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the number of shares of the Company&#8217;s common stock available for future issuance under the 2021 ESPP was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c2f7123-f2ed-4128-a3c5-169b312f8cf8" contextRef="C_7f7038cd-03eb-4dd6-8464-7a639831af3e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">577,847</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evergreen provision</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common shares reserved for issuance under the 2021 ESPP plan will be increased automatically on the first day of each fiscal year beginning with our 2022 fiscal year, by a number equal to the least of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5dea144-c888-411c-86ab-d33320dd54d4" contextRef="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,452,081</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a807deb-6355-47a2-8006-9d78ef843419" contextRef="C_88b18fd6-1484-4233-9ccd-4639da1f1dde" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such other amount as the administrator may determine. The 2021 ESPP is administered by the Board. The Board determined that no additional shares would be reserved for issuance on January 1, 2023 pursuant to this feature. On January 1, 2022, the number of shares available under the 2021 ESPP increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a275e84-70d2-48d5-ad75-f725d145b024" contextRef="C_9b5f35bb-1962-4ed8-958d-db0a4a14c1cf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">273,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to this feature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purpose of the 2021 Plan and 2021 ESPP is to provide a means by which eligible recipients of stock awards may be given an opportunity to benefit from increases in the value of the common stock in order to retain or procure the services of the employees, members of the Board and consultants and provide them with an incentive to promote the Company&#8217;s success and accomplish corporate goals.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56ce79fa-d40d-4ab6-a352-1fc525d8708c" contextRef="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d60f3931-87de-4322-9fc5-e65f25c67ade" contextRef="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows, subject to the optionee&#8217;s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.</span></ix:nonNumeric></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2028879b-0ef5-419a-a68f-ddd39915e098" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_2028879b-0ef5-419a-a68f-ddd39915e098_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activities related to the Plans, as of and for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.549%;"/>
        <td style="width:1.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.342%;"/>
        <td style="width:1%;"/>
        <td style="width:2.04%;"/>
        <td style="width:1%;"/>
        <td style="width:6.941%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.922%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.102%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Avg<br/>Remaining<br/>Contractual Life<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9e7cc80-e7bb-4ba0-9cb6-94aa54125634" contextRef="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,339,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2b28ffc-9c56-499b-9890-cf0a6e5ac4ed" contextRef="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.88</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3fc6ca6d-4c9d-47d3-a45f-542080e24763" contextRef="C_5bc13ab9-a18c-40ae-9c04-bd63e0ed3ba8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0d24e7f-b993-47f6-9e1f-000f7e4a2cc6" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,465,466</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ff65197-4b31-47f0-b20e-92822261170d" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f1facf0-2872-49c1-8e91-dd481db926ed" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fd14b50-d2e9-4b80-a6f2-ef083548a82b" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">841,896</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a42dc8d-cf27-405e-b2e8-c1aba8ff8ea7" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be887812-cc21-42db-b1a7-38e8e9882fd7" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a41cc1d-8c7f-4bea-8cc3-86a6cd117d8b" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">120,711</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c684d5d8-fe45-4559-bb5b-41fa3a7e239e" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c69623dc-bb1e-4b25-9e06-e377aae12b1b" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c313241-74f6-498f-8a25-60dba862eb60" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,013</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea29434e-f743-45c7-8486-aa32ce3f66d5" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebd5a7af-6036-4a29-8b95-f8545c643c29" contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,777,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6830d5d-50df-4db6-84fb-a2e215095b4d" contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.02</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e5e87dff-f3fe-4e77-be41-05d448597d3e" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.51</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17610f3b-0df8-4b95-ae6b-cd3e8928f872" contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,237,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63300eea-a396-4198-a39f-9eeee0fe1132" contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bd0bcced-66cd-4a27-9526-eca97cb0005e" contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.30</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><ix:continuation id="F_2028879b-0ef5-419a-a68f-ddd39915e098_1"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:continuation></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4254f09e-96d9-404c-890d-1d706f4d7af0" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_4254f09e-96d9-404c-890d-1d706f4d7af0_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of restricted stock unit activities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span></ix:nonNumeric></span></p><div style="font-size:10.5pt;font-family:Times New Roman;"><ix:continuation id="F_4254f09e-96d9-404c-890d-1d706f4d7af0_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.472%;"/>
        <td style="width:1.7%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:15.163%;"/>
        <td style="width:1%;"/>
        <td style="width:2.661%;"/>
        <td style="width:1%;"/>
        <td style="width:14.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce21a6fc-da01-4555-ac84-7c23a28ef6a0" contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">492,862</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bfca334-af15-4223-8633-1556aff1f53a" contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.08</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a71d9f24-6d50-45df-9d48-7378f6e0d177" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">430,926</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8533593d-ad08-43e8-afac-a4fb0309851b" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ec1024a-f163-4a2e-a292-2a296b8d19cf" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">262,078</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28edc59e-f0a4-43a9-b74b-315b19a02cec" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84911e00-d800-44f7-847f-f75e9469046e" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,353</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3381288-adda-4d5a-90d1-4ad178bc5656" contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24b6a36b-1ae8-4cd9-ad03-905a215d19b7" contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">650,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b22b4d0e-751c-4a5a-a03b-fdaf0078261e" contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the intrinsic value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0782d30-b530-4379-a327-0859ae717678" contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">121.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_700c814c-6298-4ed3-a3da-f1b83af6ad3a" contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and of all options outstanding was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_540220ba-d1f6-464f-bfbc-981e77c88e78" contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">185.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70255ed5-3aa4-46b3-b3da-a098be37eedb" contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. During the year ended  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the total cash received from the exercise of stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a856812-dd4b-49c6-8e1a-7f460ce6a1af" contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77b3b0fd-3797-4e0c-ae43-074b0a25f7e8" contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The total fair value less strike price of these options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0776930f-5c3c-4f07-99e3-bf88a4791345" contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e94f4c0e-8a81-483e-b88c-20a7d7c0b7d7" contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05767cbc-3591-4ef7-97a0-582cb5593225" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the accompanying consolidated statements of operations and comprehensive income (loss) as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.031%;"/>
        <td style="width:2.12%;"/>
        <td style="width:1%;"/>
        <td style="width:17.503%;"/>
        <td style="width:1%;"/>
        <td style="width:2.12%;"/>
        <td style="width:1%;"/>
        <td style="width:18.224%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31cf9281-ccd8-4184-81e8-5d2cb8497ab6" contextRef="C_0c2cf702-64b7-49e4-996a-cc8a823efe97" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,963</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a62c572f-2523-419c-9e93-d7c0f0673278" contextRef="C_1d1a568f-d394-4720-a1b6-9a88ef02d12b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,064</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed42c5e5-3194-4f54-b74b-e612bce98be8" contextRef="C_9fc400ca-bc44-4785-8a4c-ad2af354ffac" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00d73044-6fa5-4d13-9f2c-d3bd866259ea" contextRef="C_cb92c51b-50ce-4557-91aa-51fc17ad1a81" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ac1d6c2-49a0-47ee-8d9b-a0430720138b" contextRef="C_2256ad1c-8fe9-4d3b-ad3f-3872402cb7c7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd4e6426-5e82-433d-830c-a3977cc1c455" contextRef="C_1c4862f1-51c5-4005-ad1c-acfd1c889569" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">934</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4631a03a-8266-46d1-bc74-b92bbb6e268a" contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,746</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_661357fc-74c8-4a4c-997f-5abf081f3dc0" contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_648c8515-7e30-4b5e-b3f8-d268ffa59754" contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,539,445</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cadc36da-1127-4a02-abf2-b5da9e7c7091" contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,447,687</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unvested options, respectively. Total unrecognized expense related to unvested stock options was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_639b188a-e005-4265-aa09-f956b143b8d7" contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eab1a06-e60f-4775-bb6d-2db0b7850559" contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amounts are expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63281e4a-6b1d-466c-ad4e-c362bda521db" contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9eea829-99e2-4ca1-83c9-55f6c2d75322" contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized expense related to unvested restricted stock units was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73589d31-b91d-4d39-a440-7eb5a774c207" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39b1fdba-7896-4c48-8665-303be7a74083" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amounts are expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8579c4bb-a935-4fd7-ac69-c24b86ed2916" contextRef="C_34ca7f16-9126-43a4-886f-fec2f9b38b8b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f171370-a4c2-4d7d-836c-e03fb02cef6f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.81%;"/>
        <td style="width:1.581%;"/>
        <td style="width:17.467%;"/>
        <td style="width:1.581%;"/>
        <td style="width:17.467%;"/>
        <td style="width:1.581%;"/>
        <td style="width:17.467%;"/>
        <td style="width:1.581%;"/>
        <td style="width:17.467%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91fff7aa-e20a-4081-ba9c-4a04f3fba15e" contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">64.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aebcf64-80c8-40d1-a647-7b573f893241" contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87279b86-c118-467d-9889-19267918aefd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">64.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faa55623-0d15-487c-9d96-408b5e48061c" contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">62.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ced1821b-57fc-433a-91c9-54a15faa509b" contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">64.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40168d1d-d786-4408-8b07-552e0fb66520" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">63.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951552dc-be05-47b8-a21c-5c1dffaea3f7" contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_751a44a2-4447-4cc9-8649-4b04e875ab90" contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73ba641f-1e18-4620-a2f4-43e5ec50f256" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99f2bf8a-2382-4df2-a97a-fb39022ed6c0" contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d35fc53b-c743-4077-a3ba-b64a52006f3e" contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c70487-faf0-421b-83ec-4d97e8def5d6" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2da0a8f3-92c0-4f6d-9e1e-deace2b41ef2" contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_95e16254-3460-4b38-a0ba-16d5bb278bd3" contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dd3feb9d-e277-4510-871e-54f55992ae21" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c43811e8-8b8d-4422-9e65-c6969c664331" contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_9732db76-927b-4ae2-bde8-5a0242581169" contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_21ed4eb8-9da7-4046-8a6f-bcd0aad154c7" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a01a493-61fd-4946-924f-8f4803f42ba2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b7755f-5290-41db-ba93-4a23ed21b940" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6cc8f89-f281-4d42-ae3d-4a437773da31" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d136439d-1474-4a21-b248-8a5a3854fb5a" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant date fair value</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e046b0c9-1a04-439d-a413-428e49239b0e" contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_833ba533-9e5c-4de5-b6c2-5ec1e4c001b4" contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">39.71</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e89708b5-ab30-4e98-9773-b8c401f36af5" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.60</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7d3fdea-1311-4b21-95ea-10d8d21f5e16" contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03ca2d5-f2d4-4ea7-896e-d94393d62932" contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.52</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f19f7c-1eb0-40d1-a05a-1640bae81b70" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.73</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb89adff-0758-4d07-8f29-9ea685a11b73" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10 &#8211; Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, the Company filed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6ae82c1-12b7-489b-b714-bb4472274473" contextRef="C_18f22b78-7783-4b48-a916-de31acc7d1e6" name="rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement which became effective on August 12, 2022. The shelf registration statement is effective for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_611e695f-732b-45be-981b-bcd49b74bc8d" contextRef="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a" name="us-gaap:RegistrationPaymentArrangementTerm"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and permits the Company to sell, from time to time, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09f08f3b-8e2e-47e5-9083-a6b721062a51" contextRef="C_0abec27c-e9d5-42ec-8f2f-cd858ce7ee0c" name="rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate value of our common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.  Included in the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c573d6f5-05ae-4ab1-8d73-9e03c010d694" contextRef="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a" name="us-gaap:RegistrationPaymentArrangementGainsAndLosses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afc30172-e63e-47ef-aabb-ff01689476d3" contextRef="C_b7350b8e-419b-4564-9523-4be12bc48b7b" name="rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million dollars of our common stock through an ATM offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Offering</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2f5c0a82-ebc1-48e4-8e08-a70a07991a98" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">475,875</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef58ab0d-a646-4ba1-8484-3cf7dcb78705" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and other offering expenses.  As of December 31, 2023, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b6b5fd5-c5f5-49d6-8b7e-ec79bb49eaf0" contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,617,964</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for total gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5174926-43d7-4ad5-96e9-54830a265535" contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713cb167-b858-47bd-a5cd-de137c056939" contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million), have been issued and sold pursuant to the ATM offering, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_732814d4-4f0b-49f8-aecf-325ee11fa573" contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,142,089</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c5d41c6-b368-4ad9-b188-c79f1edd2c49" contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were sold during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which was the remaining authorized value of the common stock under the ATM offering.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed178054-dd8a-47f3-9bff-ce909cf02e82" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_790daa40-ef18-46ba-bb3f-2188633a2212" contextRef="C_b4eedea1-0f5b-4dfb-bc30-d9f477763ebe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,777,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5aa26584-b3b0-4883-a416-286c92d8b4a9" contextRef="C_5ee404e1-09d9-4e49-8567-7e3e99def558" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,339,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4919383e-85f5-4509-8396-4d22b2c250fd" contextRef="C_bbfab71f-6665-4527-940a-db6f796b7bbd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">358,610</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e463d07e-b6b4-46bd-9660-45574d08b204" contextRef="C_080706bb-030b-4069-b6d7-d7d31567a27c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">865,122</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70469496-0629-4f6c-8e00-1ab8f8658734" contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">650,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_274c29cb-2092-4b43-aa68-31e322f0ecdb" contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">492,862</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under 2021 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_718633b6-b768-4a29-9026-a1773f8faeb2" contextRef="C_023ec558-5797-47a9-a985-808a5dc77077" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">577,847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c13c788-d12a-4aea-b690-b0c73d1b9125" contextRef="C_49f1aec2-a4e1-4190-a936-3eb5ce2b4155" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">664,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future sale under the ATM offering </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34d697a0-dc87-4fab-baef-c88c9f27381b" contextRef="C_6c3e38f4-8300-4d9a-93f9-acfee4e73ff2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c" contextRef="C_245fe6f8-26ec-4721-8201-1bc9132d6013" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,454,064</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19cb7ab3-b6ab-4466-8cd3-4e812c2e4d1a" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,364,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b80bba3-8795-4b7c-ad12-84eedc31148e" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,816,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed" xml:lang="en-US"><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The ATM offering was completed in July 2023.</span></p><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d13fe3ae-ad65-4729-9fb7-b05a797f7c34" contextRef="C_25a0e726-e847-4009-b9ba-5e81ccb68e86" name="rxst:ClosingStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as reported on the Nasdaq Global Market on December 30, 2022.</span></p></ix:footnote></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a0c85f2-fd03-459a-8256-fed6d14ba37b" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d3506ee-5b58-4621-bcf9-299eba51bc6d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before income taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"/>
        <td style="width:6.661%;"/>
        <td style="width:1%;"/>
        <td style="width:14.483%;"/>
        <td style="width:1%;"/>
        <td style="width:3.341%;"/>
        <td style="width:1%;"/>
        <td style="width:15.543000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. loss before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_863f427a-30de-45d1-a9c0-b3ad0c0a1011" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_878b89de-43dc-414b-bee1-ccd1f9f28477" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,750</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_659f58e6-3c5e-4314-895c-15dbf36bdf54" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eca05a8-3d0c-496a-93db-8c5d9fb77817" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a6f005c-2317-40ed-9b64-066a2ed700ac" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,588</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61b9ba37-9e06-4de3-b6bf-93a338f7b221" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,747</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76ea7fbd-b6df-497e-882f-aba7e60efefc" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"/>
        <td style="width:6.661%;"/>
        <td style="width:1%;"/>
        <td style="width:14.483%;"/>
        <td style="width:1%;"/>
        <td style="width:3.341%;"/>
        <td style="width:1%;"/>
        <td style="width:15.543000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9005f8c-7739-4df2-b4d8-eb778efe9755" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc78428a-5324-4f5a-b88c-72ae69850ff7" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56b455ae-ac76-4dc9-ac21-fad10bda0b85" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45d8752e-23c4-4f65-ae0a-fd6c21c106c4" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34976fe2-0195-4021-831d-7b694f559b7a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_709e41b2-9528-4921-9894-40a6d63a27c5" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fd558c7-25a9-4e0f-8a0c-67df717c4565" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9f131d9-88ad-467c-b100-927c4fa91c7d" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a2312ec-07d0-443d-8723-04b5561d85f9" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f338eb05-8b5f-4a6a-be4b-89ca6c31a824" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_418928ff-4dd1-438a-9655-677c818d4126" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,266</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_190990d0-5221-47ea-9de2-feab77fa7f1c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6927f463-04cb-4e40-a04d-16e814d24416" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c38a11c4-b317-43bb-b7ab-92189750bd80" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff7c02a0-1ca0-4e7d-b060-14dc680dddd6" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa984898-ba1e-4caf-9f13-8c502408db17" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d76fb5-5056-4a30-99d2-24ea1f0c6fec" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6576f0b6-32fc-4330-8bf9-0fb58badf198" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00719e86-fad2-4d13-b62d-388f8e5046c7" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da38fe89-5cc2-438e-852d-caf8272950c6" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45af50bc-dfba-4142-afad-a7c873be0fcd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components that comprised the Company&#8217;s net deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"/>
        <td style="width:6.661%;"/>
        <td style="width:1%;"/>
        <td style="width:14.483%;"/>
        <td style="width:1%;"/>
        <td style="width:3.341%;"/>
        <td style="width:1%;"/>
        <td style="width:15.543000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0300e7ad-39d9-4e2e-bd96-6f74c3489294" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c679bad-aa76-4f34-a61e-b7fc2f996f1e" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04648cad-e299-4786-b96c-e27a8c761015" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:DeferredTaxAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00fb097d-8fed-4d91-a760-3dd2cca101aa" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredTaxAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D expenditures capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92cc554e-43c4-4945-b391-4031f8642c95" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aa96169-49ad-40c8-8569-94aa962abcd1" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_817d62c9-93f4-4cf4-9733-7da98d7811fc" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,292</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee73bcec-a0b0-4001-a385-2cd61c3200ed" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_325cd315-f454-4e5b-84bf-5204b9280f7e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec257443-9b64-4506-adaf-756339080966" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75875517-ec4b-49f3-87b6-0a0c3791ac98" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:DeferredTaxAssetRightOfUseOfLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72caa325-8e30-498e-a91f-856b18fe7aea" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredTaxAssetRightOfUseOfLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4bd9657-55cd-498b-99d4-e2ee7334cbec" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:DeferredTaxAssetDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a6ceda-c8ed-4d1b-be31-f2f61fd4aeb6" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredTaxAssetDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_384f70af-a26f-42bb-a695-0065e54c9d19" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,934</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_081dc949-bc03-410d-b1f2-9e997b856181" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04b6eb07-074b-451f-b4c5-301ab34234a3" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332ef87f-8cf3-43b3-845b-40bfaed44024" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3badbc2-10db-4781-b07c-14c190e6e29c" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,242</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a27aa86f-c855-4163-95b0-59cd2cf3ba6d" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,471</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccd4a461-c568-4b32-83b9-a1a6b925d189" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92b294ea-0d1d-4905-97e0-dda491920ee2" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b4dbbea-34da-407a-a49f-482f5df65a12" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:DeferredTaxAssetRightOfUseOfAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb814320-6570-4ae9-963b-7b633c9b84de" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:DeferredTaxAssetRightOfUseOfAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4840fb2-ca0d-4ec7-9c2a-8c6c31bb28aa" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99f8298e-a196-4f80-930b-6c634a5dd034" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e5fe148-6441-4695-aa23-c06df779df63" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d5b1cb-f704-4fb3-9cae-a76ce5cbb19b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1603d2da-dd58-44b5-9699-3486eb7732b0" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes with the expected income tax computed by applying the federal statutory income tax rate to loss before provision for income taxes was calculated as follows (amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.98%;"/>
        <td style="width:4.54%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:2.5%;"/>
        <td style="width:1%;"/>
        <td style="width:11.16%;"/>
        <td style="width:1%;"/>
        <td style="width:3.6%;"/>
        <td style="width:1%;"/>
        <td style="width:9.26%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.120000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision at the federal statutory tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd7fec7e-c8da-48cf-afa1-49dda6d02a90" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72757851-faa0-46eb-803d-739d5475a86d" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34ed2eae-07ca-4ec6-be7f-bdbf33684b86" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bf146f2-0be0-42fc-8db9-4f52eaff07f3" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8131b3c3-097c-44c0-8fa9-af07c1e79939" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e75a5e29-2fe9-4f54-a420-59a2d38dc0dd" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,992</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1020c382-7898-4e32-bdc7-f6ea01692dcb" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3326a427-38dc-4fd6-a612-748d5079e626" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,358</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a15856-9cc7-4687-a0ce-d8cf60f14d3e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_967b1edc-e8de-4156-84d0-6daef9811ad9" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,805</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c8940ab-b8d9-4f0c-8ec7-e1e1f94da44c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_516c6d05-4163-45ca-aaf2-65bae71dac1e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,269</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e9a17bb-027d-4faa-b327-c7ebe8a5a3e8" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3545991-0861-4cef-8580-5a8a14e47b0f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d1496d3-c616-4c76-bcc7-66bea0126346" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1bf9f3b-d0ab-4fef-a4a8-dd43c27c7e1c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd88d1bc-b7d1-4ac6-8676-d9517730b55e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fbe5d53-da9c-4b64-a19d-74f5b421e8c5" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11042ef4-ecfa-47f9-99b0-bb4233d3d08b" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599990ab-7307-4ac2-9556-c20ac266ab55" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired tax attributes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf96c24-ce51-41e4-965d-dcaf3e3b6508" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c665f077-361f-4435-92ce-8d1a4791d55c" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8922e4-bd46-4022-aeda-8d8ae65ba07c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5298276-5dc5-4b86-94ea-402740669246" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_627798c3-58a8-44b3-9c90-98270128bbfb" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61cb183e-60e8-4b96-9199-71d4f2a07ca2" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:IncomeTaxReconciliationTaxCreditOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_428d17e1-d946-4b1a-8ad2-4eb209c48d13" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cad47e15-52a9-4998-b958-182577e1fc16" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:IncomeTaxReconciliationTaxCreditOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9657d3cd-f11e-4a75-896b-8fba332fda07" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40b11ed9-4044-476b-8c56-c6eacc3d55f8" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b003eb9b-4fe0-4eac-99d4-312992945ced" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">22.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8e7c61c-b556-4129-b97e-e8b163dea385" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e48fa2-4af8-454a-ae89-af6f34d35eff" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:EffectiveIncomeTaxReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_092089ea-cefb-41f5-8c6c-aed26e0f9786" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_339db504-1233-4344-8cad-fb1491ab5643" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="rxst:EffectiveIncomeTaxReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d01c3532-7b09-40ca-a333-30790c24486a" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax effects of items that give rise to significant portions of deferred tax assets are primarily net operating loss carryforwards. The Company evaluates the recoverability of deferred tax assets and assesses all available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all the evidence, including a history of operating losses and the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been recorded to offset the net deferred tax asset as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">realization </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of such asset is uncertain. The Company&#8217;s valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f497fe9-558a-4f14-9eca-f2316f571cef" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbd0fe7a-70b4-4e88-af5d-607844cb4652" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_176b94e9-0ef1-4a7f-9238-5de69e264e60" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">311.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26bb62b-896b-4e4c-867e-8eed3c51e6e2" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">148.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fa1b085-5cd6-40a2-a39e-b0c7a7127a0e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:TaxableIncomeOffsetPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2551e877-77c4-4fbc-b58b-a6ec512d0877" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">311.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in federal NOLs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86aa3561-e3d2-499f-809c-df845627a65b" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:FederalOperatingLossCarryForwardsNotExpire" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">204.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbe6aa76-62a4-426c-9953-dac8428d92b5" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:TaxableIncomeOffsetPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_687a85ab-a13e-417e-9f45-c6e820ce8d46" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">148.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in state NOLs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9c21800-ab02-44bf-81bd-4cccd0872326" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:StateOperatingLossCarryForwardsNotExpire" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9ec196-f5ea-484f-b9d3-9001040d8d83" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:TaxableIncomeOffsetPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. The remaining federal NOL carryforwards will expire between 2024 and 2037, and the remaining state NOL carryforwards will expire between 2025 and 2043. In addition, the Company also had federal credit carry forwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b81367a8-3ed5-4c52-bba0-c49c33e8c47f" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:FederalOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state credit carry forwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17f15938-b2c9-42bc-929c-20d5e134ba41" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:StateOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which may be available to offset future tax liabilities. The federal credits will expire between 2037 and 2043, and the state credits do not expire.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act 2022 which incorporates a Corporate Alternative Minimum Tax (&#8220;CAMT&#8221;) was signed on August 16, 2022.   The changes will affect tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability.  The CAMT act is not expected to have a material impact on the Company's consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards may be subject to substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7339555d-a5fa-4b3f-9de3-f50ef0487466" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss and R&amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has not completed an IRC Sections 382 and 383 analysis regarding the limitation of net operating loss and R&amp;D credit carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company has not completed a formal R&amp;D study but has estimated the federal and California credit for purposes of the tax footnote as of December 31, 2023.  However, the Company has not reflected a benefit in the consolidated financial statements due to the recorded valuation allowance.</span></p><div style="font-size:10.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7f699c5-1f08-4a9e-9129-492fb0972584" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"/>
        <td style="width:6.661%;"/>
        <td style="width:1%;"/>
        <td style="width:14.483%;"/>
        <td style="width:1%;"/>
        <td style="width:3.341%;"/>
        <td style="width:1%;"/>
        <td style="width:15.543000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b84c2273-c54f-429b-8b67-a2ebb8b4ca9c" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98b06947-798e-4e91-8285-a3e2db25b1c4" contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,013</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ee935af-e60e-45fe-bcec-4c9372e61171" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3b2a546-cfeb-4439-b49d-46988960a09a" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8d9fb7a-222b-4458-8d5e-92dad76057b8" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b0a5e88-17aa-4168-b4a8-21788d219bce" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e7039b-8c5f-40db-8474-6fd0dc3cfcb4" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bf1335c-460f-4754-97ce-90f069a40c00" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the unrecognized tax benefits, if recognized, would impact the annual effective rate, due to the valuation allowance. The Company&#8217;s unrecognized tax benefits are recorded as a reduction in deferred tax assets. The Company does not expect any significant increases or decreases to the Company&#8217;s unrecognized tax benefits within the next 12 months. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.  The Company has not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to U.S. federal and various states' income taxes. The federal returns for tax years 2020 through 2023 remain open to examination and the state returns remain subject to examination for tax years 2019 through 2023. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. All other state jurisdictions remain open to examination.  There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0e26e0a-5905-4235-8be9-b2f75501dc52" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:ForeignEarningsRepatriated" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_772ac3b8-fc6e-4179-8075-1bb568374a81" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:ForeignEarningsRepatriated" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cumulative earnings in our foreign subsidiaries as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that would be subject to U.S. income tax or foreign withholding tax. The Company plans to indefinitely reinvest any future earnings of its foreign subsidiaries.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_83d5d0e7-6484-4705-8e6e-d5e952eb3912" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12 &#8211; Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operating and finance leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not combine lease and non-lease components in the recognition of lease expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s leases have remaining non-cancelable lease terms of up to 3 years, some of which include options to extend the leases for up to 15 years. The exercise of lease renewal options is at the Company&#8217;s sole discretion. The Company recognizes rent expense for minimum lease payments on a straight-line basis over the expected lease term, including rent holidays, rent escalation clause and/or cancelable option periods where failure to exercise such options would result in an economic penalty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b345c2d4-44d2-49d6-af6f-512c15600bd2" contextRef="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd" name="rxst:NumberOfLeases" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> leases for office, manufacturing and warehouse facilities in Aliso Viejo, California. The four leases are for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_846f3fc7-0cf6-4b73-9c12-e0acf4dce166" contextRef="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">121,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in the aggregate and expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a68a6cb-8637-434e-8e4c-98c27229dd34" contextRef="C_0ec5af07-2372-4042-a3f4-8511845cf529" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14c7f72b-89c1-4cd2-867e-79adb2f1db98" contextRef="C_35054392-155d-4fc2-92bb-5c95eec04e48" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For one of the facilities operating leases, the lessor provided $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb4c37ee-cb7b-49c8-8ceb-5b2242e388f0" contextRef="C_0ec5af07-2372-4042-a3f4-8511845cf529" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in tenant allowances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2022, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8001d05-2055-44de-ba74-62c0296abc4d" contextRef="C_38073016-ce8b-4023-8081-103f403ab2bd" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thirty-four-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sublease agreement for a portion of the 5 Columbia Building, in Aliso Viejo, CA. The sublease commencement date was June 13, 2022 and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46c04677-a8f2-41a4-adaa-9c6f0cc8cbe8" contextRef="C_06262739-6be2-40d0-a27d-2ee73ccd9a32" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The base rent receivable is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af39106c-bb38-43ff-b791-56ce913d73c4" contextRef="C_06262739-6be2-40d0-a27d-2ee73ccd9a32" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,410</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month.  On January 4, 2023, the Company amended the base rent of sublease agreement to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dc22757-606f-484d-8607-fd0e129ac4d8" contextRef="C_2848131a-3718-4555-b34d-a2e75cc52c9e" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,319</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_293caa62-80a9-4523-af35-4bc521799f04" contextRef="C_2848131a-3718-4555-b34d-a2e75cc52c9e" name="us-gaap:OperationsCommencedDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f06aefa3-4e4e-489c-9185-f1daccf23632" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SummaryOfLeaseBalancesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the lease balances within the consolidated balance sheets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:16.06%;"/>
        <td style="width:1.66%;"/>
        <td style="width:30.48%;"/>
        <td style="width:2.9%;"/>
        <td style="width:1%;"/>
        <td style="width:24.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1.66%;"/>
        <td style="width:1%;"/>
        <td style="width:19.06%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38b06810-8b57-4faa-939a-5c96c7d6492d" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01a08618-fe8d-44d1-8714-28c4f1fbbbac" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,943</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98a9eb22-5875-4665-9fe4-7da6a3667f55;"><span style="-sec-ix-hidden:F_4215fd74-502e-4548-a8dd-7b80b1cd43f0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a57c4d8-3bed-44bc-b33c-e575dc365579" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a61b4aa-793a-41d6-9138-6c7e84e57947" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2edacc39-8e5c-4cd2-99c5-0b705d1d60cc" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:TotalLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12e0e052-c88c-4cdc-8ab1-d75a4309071f" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:TotalLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82;"><span style="-sec-ix-hidden:F_c8f26f61-f9dd-4949-8795-ad61341c192b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48c4de07-0004-45bc-b25d-332b76637a52" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,764</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_514cb479-ed54-4f08-87ec-33cd6d125a6b" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,818</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426;"><span style="-sec-ix-hidden:F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a98a796-ee8a-48d8-a766-43c27e720c7d" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5ae7213-1f71-45c7-b471-3ace3a2d2d12" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b14603c8-a5d6-41d8-b49d-2b04b4c22671;"><span style="-sec-ix-hidden:F_cfa28257-8c04-4096-a2b8-5d3340f0d040;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df2a724-a38e-41df-b59a-824972a3358b" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,093</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca0637d7-2885-48a6-9a22-431a0e864453" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,813</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_1c8ef374-722f-4dc2-918b-df585e24ce25;"><span style="-sec-ix-hidden:F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3986596-82ab-4a10-925c-3d02a9b0405a" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f86685a-62ef-44ea-a3b5-c9568a2ba004" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4072fa1b-89f9-4df7-9141-6d7d933c75a1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="rxst:TotalLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,012</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02d6ffb1-301c-45b9-83cf-a8da9316f277" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="rxst:TotalLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,826</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the implicit rates in the Company&#8217;s leases were not readily available, the incremental borrowing rate was determined based upon information available at the lease commencement date in determining the present value of future lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2316454b-8316-4a60-8b53-6c91b4dfda55" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_2316454b-8316-4a60-8b53-6c91b4dfda55_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands): </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2316454b-8316-4a60-8b53-6c91b4dfda55_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.94%;"/>
        <td style="width:2.18%;"/>
        <td style="width:28.14%;"/>
        <td style="width:2.02%;"/>
        <td style="width:1%;"/>
        <td style="width:12.16%;"/>
        <td style="width:1%;"/>
        <td style="width:2.8%;"/>
        <td style="width:1%;"/>
        <td style="width:10.76%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6995bce3-12f3-4ae0-afda-62dc2c835a2d" contextRef="C_3836ee42-99e1-4b4c-b3f6-d7a829aa62e2" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96eb1da7-7dc0-4715-946e-e7e951b28539" contextRef="C_2f291850-e62c-4bcf-9ff7-f62a97675a66" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55539ce4-a953-42e3-8e81-b5bbc3eb7b9b" contextRef="C_613e254a-d190-4764-a1ac-1d0b1edcfaae" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979d1a91-46c9-4b07-87fc-00847a7722c5" contextRef="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_090f86f6-b4dd-4441-b78b-5643c7b16319" contextRef="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5e820ae-b11a-47ee-85f6-a06ed3589faf" contextRef="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a408fbc8-8baa-4d2a-a544-6f4ba90e6531" contextRef="C_613e254a-d190-4764-a1ac-1d0b1edcfaae" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fee05fdd-3c68-41fe-89cd-691d75a5f54a" contextRef="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2826552e-38c0-4837-a27a-80118ee07ff5" contextRef="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca5acff2-76e3-4ed9-83c5-85819f6daf67" contextRef="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74742e89-d434-4978-9087-35aa9912af13" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98a68587-09ad-4b47-b796-fee84e41592c" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8350fd3b-a6e6-4901-b458-7ef583af4b7a" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of the Company&#8217;s operating and finance lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.86%;"/>
        <td style="width:10.48%;"/>
        <td style="width:1%;"/>
        <td style="width:39.06%;"/>
        <td style="width:1%;"/>
        <td style="width:10.48%;"/>
        <td style="width:1%;"/>
        <td style="width:18.119999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Finance Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e7132da-d09d-4be9-92c4-793db1dcc806" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbdebf16-5e9e-4ecd-819e-6db26107e39d" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25e59c00-eb62-43d0-993c-7ddc29692ad9" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9133f64-96be-4f5e-9f25-a2beb30020cf" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1edc3474-4c64-4bb9-bf32-4186dc59bcfa" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea23637a-6715-4091-8a72-72c12b8850c7" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7c0f342-98cd-42d4-b46e-603d98bb4236" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46c17b2d-4d01-460b-bdeb-13a5d0934a38" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1806871e-1777-4d45-ab7e-38ddf8ec4094" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac3610c4-796f-4b8a-bdae-6ac9b7bd8029" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_849d0d28-b87d-4b05-94a7-0cd9126c3985" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,135</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e8c161b-b369-49ea-86fb-2bb2d9f5e4ac" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1a3ff79-7900-451c-939b-311ba7e541b9" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed6393a2-4c5f-4e67-9b26-3eae0cd36c08" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd1e15e3-4719-431c-bb9a-e03f75f3019e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,857</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d321c96d-8945-4d21-b43e-1a5c6928b633" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a1cb4d3-332c-4158-9b5c-1367252ff208" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="rxst:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company&#8217;s operating and finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.949%;"/>
        <td style="width:2.1%;"/>
        <td style="width:1%;"/>
        <td style="width:31.806%;"/>
        <td style="width:1%;"/>
        <td style="width:1.92%;"/>
        <td style="width:1%;"/>
        <td style="width:15.222999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Term and Discount Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6972ee16-d74b-4384-94d5-99325e8718b1" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e40a6b39-4ba5-45ee-a0ee-faafd1b26862" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4e40927d-e449-4f02-a1e5-4782aa7a1cbb" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.37</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f3ebdb84-8ebd-4b8c-8e47-566178d680bd" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27e9a162-e66e-4ce5-80e0-d0a85920442e" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2db1da16-1e4e-4b73-b9f7-eadbca0c8ff0" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_043b973f-6eef-4456-9222-46426a0b20bd" contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">14.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d00190d-77dd-4a24-9edd-db1895dc2b01" contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5daa239-383d-4cb2-9395-3404f932263e" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 13 &#8211; Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Letter of credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a standby letter of credit, expiring September 30, 2024, issued by a financial institution as required security for one operating lease. The aggregate amount of the letter of credit was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1078a566-fce0-4663-8580-c4b144c845c2" contextRef="C_6b82dab6-564a-4b17-993f-52bc89ea5908" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f891c13e-8187-4ad5-80c0-afb197de92f0" contextRef="C_300d62ab-2d34-4a7f-a559-6b38f6978705" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time-to-time, the Company may be involved in certain legal proceedings or regulatory matters arising in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any legal proceeding or regulatory matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome. At December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9c98113-4422-4dce-9b52-77308ef09a31" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:LegalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_825b1c90-50a9-4d54-a426-38003d28bc31" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:LegalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the outcome, legal proceedings, regulatory matters, and other disputes and claims can have an adverse impact on the Company because of legal costs, diversion of management time and resources, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07411dc8-166d-4957-9ff0-72ce0879e87f" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 14 &#8211; Employee benefit plan</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">401(k) retirement savings plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution 401(k) retirement savings plan for the benefit of its employees, including its named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.  The Company makes matching contributions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07d0e293-d74b-4770-92d8-c70b0c2b0335" contextRef="C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of eligible compensation, as contributed by eligible participating employees. Employer matching contributions vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9533bf-e071-4122-b782-612812a1dc71" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year over four years. The Company contributed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_188ad66e-41b3-4215-842d-7e283b81ab17" contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">900,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c5a6d6f-9d98-4396-88d7-4290779e537e" contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">688,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, net of forfeitures, to the 401(k) plan for the year ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 9A. Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of disclosure controls and procedures</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our management, with the participation and supervision of our principal executive officer and our principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).  Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in internal controls over financial reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting and Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our chief executive officer and our chief financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of the end of the period covered by this report based on the framework in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP, our independent registered public accounting firm, which audited the consolidated financial statements included in this report, has issued the following attestation report on our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on the effectiveness of controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of RxSight, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited RxSight, Inc.&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, RxSight, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholder&#8217;s equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes and our report dated February 28, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Irvine, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 28, 2024</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9B. Other Information.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information called for by this item will be set forth in our Proxy Statement for the Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023 (the &#8220;Proxy Statement&#8221;) and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information called for by this item will be set forth in our Proxy Statement for the Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023 (the &#8220;Proxy Statement&#8221;) and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors has adopted a Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company. The full text of our Code of Business Conduct and Ethics is posted on our investor relations website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">https://investors.rxsight.com/corporate-governance/governance-overview.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We will post any amendments to our code of business conduct and ethics or waivers of its requirements, on its website.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 11. Executive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the applicable information set forth in &#8220;Board of Directors and Corporate Governance&#8221;, and &#8220;Executive Compensation&#8221; which will be included in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the applicable information set forth in &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; which will be included in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 13. Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the applicable information set forth in &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Board of Directors and Corporate Governance&#8221; which will be included in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 14. Principal Accountant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the applicable information set forth in &#8220;Ratification of Independent Registered Public Accounting Firm&#8221; which will be included in our Proxy Statement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 15. Exhibit and Financial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)  List the following documents filed as a part of this Annual Report on Form 10-K:<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements:  The financial statements included in Part II, Item 8 of this document are filed as part of this Annual Report on Form 10-K.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules: Schedule II &#8211; Valuation and Qualifying Accounts and Reserves.</span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All other schedules have been omitted because the information either has been shown in the financial statements or notes thereto, or is not applicable or required under this section.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exhibits listed in the following Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit Index</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Description</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000095017021004155/rxst-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 7, 2023</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022026362/rxst-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 12, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521223690/d237930dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen stock certificate of the Registrant.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 26, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022003135/rxst-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of common stock.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 8, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521223690/d237930dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Equity Incentive Plan of the registrant, as amended, and forms of agreement thereunder.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 26, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017021004155/rxst-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2021 Equity Incentive Plan of the registrant, as amended, and forms of agreement thereunder.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 10, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017021004155/rxst-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2021 Employee Stock Purchase Plan of the registrant.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 10, 2021</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement by and between the Registrant and the California Institute of Technology, dated as of July 28, 2015.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License and Maintenance Agreement between QAD, Inc. and its subsidiaries and the Registrant, dated as of October 29, 2015.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">QAD Hosted On Premise Project Proposal between Strategic Information Group and the Registrant, dated as of October 29, 2015.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000119312521211793/d237930dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cloud Services Agreement between QAD, Inc. and its subsidiaries and the Registrant, dated as of May 28, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated as of October 27, 2015, by and between the Registrant and Accuride International Inc., as amended by that certain First Amendment to Lease, dated November 23, 2015, that certain Second Amendment to Lease, dated December 22, 2015, that certain Third Amendment to Lease, dated January 18, 2016, and that certain Fourth Amendment to Lease, dated November 12, 2016, for premises located at 100-150 Columbia, Suites 100 and 200, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated as of March 27, 2020, by and between Pacific Park Investments, Inc. and the Registrant, for premises located at 75 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated as of January 10, 2018, by and between the Registrant and Clifford D. Downs, as amended by that certain Commencement Date Memorandum dated as of February 22, 2018, for premises located at 5 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022007878/rxst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sublease, dated as of April 4, 2022, by and between the Registrant and Compass Bible Church for premises located at 5 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 5, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022007878/rxst-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Addendum, dated as of April 5, 2022, by and between the Registrant and Clifford D. Downs for premises located at 5 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 5, 2022</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022015528/rxst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #1 to Sublease, dated as of June 8, 2022, by and between the Registrant and Compass Bible Church for premises located at 5 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 8, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017023006237/rxst-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #2 to Sublease, dated as of January 16, 2023, by and between the Registrant and Compass Bible Church for premises located at 5 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Confirmatory Employment Letter, by and between the Registrant and Ron Kurtz, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Confirmatory Employment Letter, by and between the Registrant and Shelley Thunen, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Confirmatory Employment Letter, by and between the Registrant and Eric Weinberg, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Confirmatory Employment Letter, by and between the Registrant and Ilya Goldshleger, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change in Control and Severance Agreement, by and between the Registrant and Ron Kurtz, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change in Control and Severance Agreement, by and between the Registrant and Shelley Thunen, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change in Control and Severance Agreement, by and between the Registrant and Eric Weinberg, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001111485/000119312521211793/d237930dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change in Control and Severance Agreement, by and between the Registrant and Ilya Goldshleger, dated as of July 8, 2021.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-257790</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 9, 2021</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:39.56%;"/>
    <td style="width:9.22%;"/>
    <td style="width:12%;"/>
    <td style="width:11%;"/>
    <td style="width:18.22%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022003135/rxst-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated as of March 7, 2022, by and between BML Management, LLC, and the Registrant, for premises located at 125 Columbia, Aliso Viejo, California 92656.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 8, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000119312522214924/d383901dex12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ATM Equity Offering</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline;font-size:6.7pt;position:relative;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;"> Sales Agreement, dated August 8, 2022, between the Company and BofA Securities, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-266651</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 8, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26+</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017023006237/rxst-ex10_35.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Incentive Compensation Plan</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27+*</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rxst-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Outside Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1111485/000095017022003135/rxst-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of the Registrant.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40690</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 8, 2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rxst-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><a href="rxst-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><a href="rxst-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><a href="rxst-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><a href="rxst-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rxst-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Compensation Recovery Policy</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.99%;"/>
    <td style="width:90.01%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with embedded linkbase documents.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover page Interactive Data File (embedded with the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:22.5pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:40.5pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furnished herewith.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indicates a management contract or compensatory plan or arrangement.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portions of the exhibit were omitted pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish to the Securities and Exchange Commission a copy of any omitted portions of the exhibit upon request.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;"/>
    <td style="width:2.7%;"/>
    <td style="width:5.54%;"/>
    <td style="width:46.38%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RxSight, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:  February 28, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ron Kurtz, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ron Kurtz, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Shelley Thunen as such individual&#8217;s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual&#8217;s substitute, may lawfully do or cause to be done by virtue hereof.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30%;"/>
    <td style="width:1%;"/>
    <td style="width:46.36%;"/>
    <td style="width:1%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ron Kurtz, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ron Kurtz, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Shelley Thunen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shelley Thunen</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:right;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ J. Andy Corley</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">J. Andy Corley</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ William Link, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">William Link, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Juliet Tammenoms Bakker</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Juliet Tammenoms Bakker</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Julie Andrews</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Julie Andrews</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Palmisano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Palmisano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Warner</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Warner</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Shweta Singh Maniar</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shweta Singh Maniar</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Tamara R. Fountain, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tamara R. Fountain, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>rxst-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.27</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RxSIGHT, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OUTSIDE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted and approved  July 1, 2021</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as amended December 14, 2023</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RxSight, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) believes that providing cash and equity compensation to members of its Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and members of the Board, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This Outside Director Compensation Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is intended to formalize the Company&#x2019;s policy regarding cash compensation and grants of equity awards to its Outside Directors.  Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#x2019;s 2021 Equity Incentive Plan, as amended from time to time (or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted) (such applicable plan, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity awards and cash and other compensation such Outside Director receives under this Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 9 of this Policy, this Policy, as amended, will be effective as of December 14, 2023, except as otherwise provided below (such date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Cash Retainers for Service as Outside Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Effective as of the Effective Date, each Outside Director will be paid a cash retainer of $50,000 per year.  There are no per&#x2011;meeting attendance fees for attending Board meetings or meetings of any committee of the Board.  Notwithstanding the foregoing, if the Board or any one committee of the Board meets in excess of 8 times in a year (measured from annual meeting to annual meeting), such Outside Directors will be provided a fee of $1,500 for each additional meeting attended. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Annual Cash Retainers for Service as Non-Executive Chair, Committee Chair and Committee Member</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective as of the Effective Date, each Outside Director who serves as the Non-Executive Chair, Lead Director, or chair or a member of a committee of the Board will be eligible to earn additional annual fees as follows:</font></div></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:5%;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:72.38%;"></td>
    <td style="width:27.62%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Non-Executive Chair:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$50,000</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Lead Director:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$30,000</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audit Committee Chair:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$10,000</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Audit Committee:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:5%;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:72.38%;"></td>
    <td style="width:27.62%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Committee Chair:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Compensation Committee:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nominating and Governance Committee Chair:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$5,000</font></p></td>
   </tr>
   <tr style="height:6.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Nominating and Governance Committee:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.4479166666666667in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$5,000</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarity, each Outside Director who serves as the chair of a committee will receive both the additional annual fee as the chair of the committee and the additional annual fee as a member of such committee while serving as such chair.  Additionally, an Outside Director who serves as the Non-Executive Chair or Lead Director will receive the annual fee as an Outside Director and the additional annual fee as the Non-Executive Chair or Lead Director, as applicable.	</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each annual cash retainer under this Policy will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant capacity at any point during the immediately preceding fiscal quarter of the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fiscal Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and such payment will be made no later than 30 days following the end of such immediately preceding Fiscal Quarter.  For purposes of clarity, an Outside Director who has served as an Outside Director, as a member of an applicable committee (or chair thereof) during only a portion of the relevant Fiscal Quarter will receive a prorated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during such Fiscal Quarter such Outside Director has served in the relevant capacities.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan, including discretionary Awards not covered under this Policy.  All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards, except as provided in Sections 2(d)(ii) and 9 below.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each individual who first becomes an Outside Director on or following the Effective Date will be granted an award of Restricted Stock Units (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) covering a number of Shares having a Value (as defined below) of $ $217,500, with any resulting fraction rounded down to the nearest whole Share.  The Initial Award will be granted automatically on the first Trading Day on or after the date on which such individual first becomes an Outside Director (the first date as an Outside Director, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), whether through election by the Company&#x2019;s stockholders or appointment by the Board to fill a vacancy.  If an individual was a member of the Board and also an employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to an Initial Award.  Each Initial Award will be scheduled to vest as follows:  1/3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Restricted Stock Units subject to the Initial Award will be scheduled to vest on each annual anniversary of the Initial Start Date (or, if there is no corresponding day in the applicable month, then the last day of such month), in each case subject to the Outside Director continuing to be an Outside Director through the applicable vesting date.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the first Trading Day immediately following each Annual Meeting of the Company&#x2019;s stockholders (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that occurs after the Effective Date, each Outside Director automatically will be granted an award of Restricted Stock Units (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) covering a number of Shares having a Value of $150,000; provided that the first Annual Award granted to an individual who first becomes an Outside Director on or following the Effective Date will have a Value equal to the product of (A) $150,000 multiplied by (B) a fraction, (i) the numerator of which is the number of fully completed months between the applicable Initial Start Date and the date of the first Annual Meeting to occur after such individual first becomes an Outside Director, and (ii) the denominator of which is 12; and provided further that any resulting fraction with respect to an Annual Award shall be rounded down to the nearest whole Restricted Stock Unit.  Each Annual Award will be scheduled to vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next Annual Meeting following the grant date, in each case subject to the Outside Director continuing to be an Outside Director through the applicable vesting date.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Terms of Initial Awards and Annual Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The terms and conditions of each Initial Award and Annual Award will be as follows:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Initial Award and Annual Award will be granted under and subject to the terms and conditions of the Plan and the applicable form of Award Agreement previously approved by the Board or its Compensation Committee, as applicable, for use thereunder.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the grant date fair value as determined in accordance with U.S. generally accepted accounting principles, or such other methodology the Board or any committee of the Board designed by the Board with appropriate authority (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Designated Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as applicable, may determine prior to the grant of the applicable Award becoming effective.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">iii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Revisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Board or the Designated Committee, as applicable and in its discretion, may change and otherwise revise the terms of Initial Awards and Annual Awards granted under this Policy, including, without limitation, the number of Shares subject thereto and type of Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Compensation and Benefits</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Directors also may be eligible to receive other compensation and benefits, as may be determined by the Board or its Designated Committee, as applicable, from time to time.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control, Death or Disability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Change in Control, each Outside Director will fully vest in his or her outstanding Company equity awards as of immediately prior to a Change in Control, including any Initial Awards and Annual Awards, provided that the Outside Director continues to be an Outside Director through the date of the Change in Control.  Additionally, in the event of an Outside Director&#x2019;s death or termination due to Disability, such Outside Director will fully vest in his or her outstanding Company equity awards as of immediately prior to the Outside Director&#x2019;s death or termination due to Disability.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Compensation Limit</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Outside Director may be granted Awards with Values, and be provided cash retainers or fees, with amounts that, in any Fiscal Year, in the aggregate, exceed $500,000, provided that, in the Fiscal Year containing an Outside Director&#x2019;s Initial Start Date, such limit will be increased to $1,000,000.  Any Awards or other compensation provided to an individual for his or her services as an Employee, or for his or her services as a Consultant other than as an Outside Director, will be excluded for purposes of the foregoing limit.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Travel Expenses </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Outside Director&#x2019;s reasonable, customary, and properly documented, out-of-pocket travel expenses to meetings of the Board and any of its committees, as applicable, will be reimbursed by the Company.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code Section 409A</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (a) the fifteenth (15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) day of the third (3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) month following the end of the Company&#x2019;s taxable year in which the compensation is earned or expenses are incurred, as applicable, or (b) the fifteenth (15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) day of the third (3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#x201c;short-term deferral&#x201d; exception under Code Section 409A.  It is the intent of this Policy that this Policy and all payments hereunder be exempt or excepted from or otherwise comply with the requirements of Code Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Code Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply.  In no event will the Company Group have any responsibility, liability or obligation to reimburse, indemnify, or hold harmless an Outside Director or any other person for any taxes imposed, or other costs incurred, as a result of Code Section 409A.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise required by applicable law, , the Policy will not be subject to approval by the Company&#x2019;s stockholders, including, for the avoidance of doubt, as a result of or in connection with an action taken with respect to this Policy as contemplated in Section 9.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Revisions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason.  No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed in writing between the Outside Director and the Company.  Termination of this Policy will not affect the Board&#x2019;s or the Designated Committee&#x2019;s ability to exercise the powers granted to it with respect to Awards granted pursuant to this Policy prior to the date of such termination, including without limitation such applicable powers set forth in the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*          *          *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>rxst-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Arial;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements:</font></p>
  <p style="margin-left:3.333%;text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-266651) of RxSight, Inc.,</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-258292) pertaining to the 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan, 2015 Equity Incentive Plan and 2006 Stock Plan of RxSight, Inc.,</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263374) pertaining to the 2021 Equity Incentive Plan, and 2021 Employee Stock Purchase Plan of RxSight, Inc., and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270301) pertaining to the 2021 Equity Incentive Plan;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our reports dated February 28, 2024, with respect to the consolidated financial statements of RxSight, Inc. and the effectiveness of internal control over financial reporting of RxSight, Inc. included in this Annual Report (Form 10-K) of RxSight, Inc. for the year ended December 31, 2023.</font></p>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.44%;"></td>
    <td style="width:5.06%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Irvine, California</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>rxst-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Ron Kurtz, M.D., certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this annual report on Form 10-K for the year ended December 31, 2023 of RxSight, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;  </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:4%;"></td>
    <td style="width:45.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ron Kurtz, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ron Kurtz, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>rxst-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Shelley Thunen certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this annual report on Form 10-K for the year ended December 31, 2023 of RxSight, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:4%;"></td>
    <td style="width:45.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Shelley Thunen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shelley Thunen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Accounting and Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>rxst-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the annual report of RxSight, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:4%;"></td>
    <td style="width:45.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ron Kurtz, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ron Kurtz, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>rxst-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the annual report of RxSight, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:5%;"></td>
    <td style="width:44.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Shelley Thunen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Shelley Thunen</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>rxst-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RXSIGHT, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As adopted on November 1, 2023</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RxSight, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is committed to strong corporate governance. As part of this commitment, the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this clawback policy called the Compensation Recovery Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Policy is intended to further the Company&#x2019;s pay-for-performance philosophy and to comply with applicable laws by providing rules relating to the reasonably prompt recovery of certain compensation received by Covered Executives in the event of an Accounting Restatement. The application of the Policy to Covered Executives is not discretionary, except to the limited extent provided below, and applies without regard to whether a Covered Executive was at fault. Capitalized terms used in the Policy are defined below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section 10D of the Securities Exchange Act of 1934 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with Exchange Act Rule 10D-1 and with the listing standards of the national securities exchange (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on which the securities of the Company are listed, including any official interpretive guidance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Persons Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is binding and enforceable against all &#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Executives</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; A Covered Executive is each individual who is or was ever designated as an &#x201c;officer&#x201d; by the Board in accordance with Exchange Act Rule 16a-1(f) (a &#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 16 Officer</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board </font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">may (but is not obligated to) request or require a Covered Executive to sign and return to the Company an acknowledgement that such Covered Executive will be bound by the terms and comply with the Policy. The Policy is binding on each Covered Executive regardless of whether the Covered Executive signs and returns any acknowledgement.</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Committee has full delegated authority to administer the Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to the independent members of the Board or the other Board committee. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatements Requiring Application of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Committee must determine the Excess Compensation, if any, that must be recovered. The Company&#x2019;s obligation to recover Excess Compensation is not dependent on if or when restated financial statements are filed.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy applies to certain Incentive-Based Compensation that is Received on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), during the Covered Period while the Company has a class of securities listed on a national securities exchange. Such Incentive-Based Compensation is considered &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Clawback Eligible Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; if the Incentive-Based Compensation is Received by a person after such person became a Section 16 Officer and the person served as a Section 16 Officer at any time during the performance period for the Incentive-Based Compensation. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excess Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been Received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts. Excess Compensation must be computed without regard to any taxes paid and is referred to in the listings standards as &#x201c;erroneously awarded compensation&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide that documentation to the Exchange.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&#x2019;s right to recover under the Policy has lapsed (provided that this Policy is not intended to have an impact on the Federal or state tax or accounting treatment of such compensation).  The following items of compensation are not Incentive-Based Compensation under the Policy: salaries, bonuses paid solely at the discretion of the Committee or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period, non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure performance goal and vesting is contingent solely upon completion of a specified employment period (e.g., time-based vesting equity awards) and/or attaining one or more non-Financial Reporting Measures.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; are measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; under the Policy in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#x2019;s fiscal year.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement Determination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earliest to occur of: (a) the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Repayment of Excess Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover Excess Compensation reasonably promptly and Covered Executives are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Covered Executive to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Covered Executive). These means include ( but are not limited to):</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation or vest based on the achievement of performance goals; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Covered Executive, including (but not limited to) payments of severance that might otherwise be due in connection with a Covered Executive&#x2019;s termination of employment and without regard to whether such amounts are Incentive-Based Compensation; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">cancelling outstanding vested or unvested equity awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation; and/or </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">taking any other remedial and recovery action permitted by law, as determined by the Committee. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The repayment of Excess Compensation must be made by a Covered Executive notwithstanding any Covered Executive&#x2019;s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to clawback.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce a Covered Executive&#x2019;s obligations to the Company or to discipline a Covered Executive. Failure of a Covered Executive to comply with their obligations under the Policy may result in (without limitation) termination of that Covered Executive&#x2019;s employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company. For avoidance of doubt, any decisions of the Company or the Covered Executive&#x2019;s employer to discipline a Covered Executive or terminate the employment of a Covered Executive are independent of determinations under this Policy. For example, if a Covered Executive was involved in activities that led to an Accounting Restatement, the Company&#x2019;s decision as to whether to not to terminate such Covered Executive&#x2019;s employment would be made under its employment arrangements with such Covered Executive and the requirement to apply this no-fault and non-discretionary clawback policy will not be determinative of whether any such termination is for cause, although failure to comply with the Policy might be something that could result in a termination for cause depending on the terms of such arrangements.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limited Exceptions to the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below is met, and the Committee determines that recovery of the Excess Compensation would be impracticable:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange; or</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Important Information in the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements, rules, or pursuant to the terms of any existing Company policy or agreement providing for the recovery of compensation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the terms of any of the Company&#x2019;s organizational documents (including, but not limited to, the Company&#x2019;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Committee or Board may review and modify the Policy from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of the Policy or the application of any such provision to any Covered Executive is adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Covered Executive, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy will terminate and no longer be enforceable when the Company ceases to be listed issuer within the meaning of Section 10D of the Exchange Act.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGEMENT</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that I have received and read the Compensation Recovery Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of RxSight, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and acknowledge that the Policy applies to me, and all of my beneficiaries, heirs, executors, administrators or other legal representatives and that the Company&#x2019;s right to recovery in order to comply with applicable law will apply, regardless of the terms of any release of claims or separation agreement I have signed or will sign in the future.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree to be bound by and to comply with the Policy and understand that determinations of the Committee (as such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and agree that my current indemnification rights, whether in an individual agreement or the Company&#x2019;s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that my failure to comply in all respects with the Policy is a basis for termination of my employment with the Company and any affiliate of the Company as well as any other appropriate discipline.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for good reason (or similar concept) by me under any applicable employment agreement or arrangement.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my responsibility to seek guidance from the Compliance Officer or my own personal advisers.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Please review, sign and return this form to RxSight, Inc. Compliance.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Covered Executive</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">print name</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">signature</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(date)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img50815396_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50815396_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K!8X# 2(  A$! Q$!_\0
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M_&G?VK??\_<__?QO\:S\FC-=/*CDYF:/]JWW_/W/_P!_&_QH_M6^_P"?N?\
M[^-_C5#-*#1RH7,R\-4OO^?N?_OXW^-+_:E]_P _<_\ W\;_ !JCFE!I\J%S
M/N7O[3OO^?N?_OXW^-']IWW_ #]S_P#?QO\ &J5+FCE0<S[E[^T[W_G[G_[^
M-_C2C4[W_G[G_P"_C?XU1S1FCE0^=F@-2O#_ ,O4W_?P_P"-._M&\_Y^IO\
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M_,IKXAUS_H+W_P#X$/\ XU.OB#6R/^0M??\ @0_^-92"IU&:[N2/8^?56?\
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ME)2TE4:"4E+24 !I*4TE A*0TM(:0"4E+24"$I*6DH 2D-+2&@0&FFG&FFD
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MEN/W@Y*_WJPV!4D$$$<$'M7H0J*:NCVJ-:-570E)2TE6:@:2E-)0(0T4&BD
M4E+24 !I*4TE "4E+24""@T4&@!*2EI*!"4444 )6CHW_'XW^Y_45G5H:/\
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M1JQNA#24II*T-1#10:*0!24M)0 &DI324 )24M)0(*#10: $I*6DH$)1110
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MT/3_ &?_ *U;E>?.#@[,^AH5E6AS(6DHI*@U%S249I* %S249I*!BTF:*3-
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M3=\=]IY_$TR.\T2)Q*E[ OL>OXBNUG2.*%FF=40#DL<"LL:= MUM,<>6&0P
MP:>P)7V,MM9TUV66,3W;CA%MXRW/UZ"I-.L)[;36N[R'R[J>Y>YEB^]L4YPO
MX*!7006L=NI\M0HZG Q39D:??$.&*,%/H2,9_6BYFXZF=*#)</<(X:"2.,)C
MU!;/]*Z/23FV%8,=B;#288&?>P=F+>N:V]&/^CUM!6@8UFG4=CHH_P#5BN:\
M1/MN<>N*Z2+_ %8KE_$G_'^@]5!K2)S,AL.)TKI%^Z*YJR.)TKI5^Z*&,7O0
M:.]*:0#:Y_Q%X=CU2,W%N EVH_!_8UT%!JHR<7=%PG*$N:)XY+&\,K1R*4=3
MAE/44RO0O%.C6MU9O>ET@GB'WST?V->>UWTYJ:N>U1K*K&Z"DI:2K-@-)2FD
MH 2DI:2@04&B@T )24M)0(2BBB@!*M6"L\YVG! S56KFFG%PW^[_ %%8UU>F
MS*M_#9T:9$8SUK.U[_CQC_ZZ+_.K%Y<_9-/EN-N\QH6"^I]*X&?Q9?:E*L95
M5B! P$/WNM>6EH>5?4T_$<)/BOPS<?\ 3?8?S!K:\?8,-@#TRU<O)K1O[BS:
MX51)93B1=HQD^];6J:A#XA2)9B4\K.-GOCK6D8MK0SE)+<\ZNSLUVV8<9RM4
M]:_Y"JG^\E=K/X,CNKB"9;]DVG('EYR?3K4%]X&-Y<K*FH $94*4ZUIR2,_:
M1,L,'T9,X^Y7*R P!=P.3T/]*](7PF;?3"LVH1+%&IW2L, #WKS75)D:X$2.
MIV.<.I^5L<9%+EMHRN?JB-Y0[')J[9S?NBA.5[K6>\WEP0HXW(7.X^O/7\JE
MAF1Y=RNH8DC8O& .E9N+-^9;,ZS3M0B5EP1\^,@#@?6NT\/2PBX!0)(^0K/G
M@@>GI7DLI> >;&[*6[CC-5K'5=7MKS-C-(9#_".1^5)*^PI:;GUS82*\2?=X
M&:S/'D4,WA"]>3 =8_D/J?2O-/!/Q!U>]2:"YM(9)XEZ!]IQV_6K-S\0?[3U
M:.PO8##\VPQ.-T9/H?2MU%G,Y),Y:3=):1;5)X'05ZQITROX5$18>88 -O?/
M%<=-XI@TZ::S?385N$DV HW /LO7'O5)/&=S_:,<4UI)/ WREH2"JCN0P';W
MHLENRDI3^%7/2-&D^R,DDI^53D@]:Z :_:SOA(Y/KD<5P,C3)8+>P2?:+)NK
M*VXKW_$>],L[M78-&<$?-G/;M3:1%Y(]*LI8KAS-&P=#QGT/I7*_$ J39X&/
MO_R%3V5S);SPW<;?NY"([A!WS]UQ]#Q]#[55\>=+(YSD/_2LN5IEQ=T>>R]Z
MM^&P#XBMLCH'/_CAJI-UJYX;_P"1@@/HDG_H!H9:.\^'D$;>$+=V ),DI_\
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M)3=SWSZ?C5:&UMH;?[5<HC.WS+"@_>?7/113M-MQ<70N=)DG6^CRZI* <MW
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MK4O+*UU,J)HQN3A2O!%076EI;0J8D^4'D#O4JMR2T,JDU4IV:.?GNI[MB6)
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M=F$P;K/FE\(6]NEM&$0?4^M2T4E<#;;NSZ",5%<L=@I**2D4%)124 %%%)0
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M(:6D-(!*2EI*!"4E+24 )2&EI#0(#333C332 2BBB@!#333C330(*]3^#?\
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M9D )?<' ZUS,>@_8[W49UV>5<L'&.JXZUUX;$^S5G\C-KGEJ9]SX>F29;FV
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MI6P %& ,"HPV&=9\\_A_,YW+2PU$6- JC %+2TE>PDDK(S$-%%%,!*0TM)0
M4E+24 (:**#0 E)2TE !24II* $HHH- "4E+24 %)2FDH 2L/Q$<&V_X%_2M
MRN?\2M@VO_ OZ5I2^-'-C/X$OZZF2K5('P:JAQWIPD&:[D?/,MAZZ7P8GFZ^
MLAZ11LW]*Y(/QQ72^"[L1:^L6,^=&5^G?^E16O[-V-L+;V\;]ST36+!=3T2Z
MLF_Y:QE0?0US45G<RV*Z;_JWM8MK?[7'!'L:[->5JNUNN]'QEE^7/M7B3A=W
M/K(2L>1W_@QKG28IHT+R.[,Y RWTKBM<\+3VEP(0Y(9"R_(>".<'T-?0@LOL
M5\TD?S6TQ^:,_P #>H^M&H:3;WD+$1KOVD D>M9JFUL:.:>Y\KOI]U)IP?<<
MQ2;1">O/<5?T_1)E,:$'?(P.T#))]*]GTGX:0QR2W-\^2[%EC0=!V%3^'?!3
M)=SZI<H$E\TBWB[(@Z'ZFJM)D^ZM2S\/_#T^DV;_ &I"LLAR,GG;V!]*F\<:
M&RLFL6R9V@).!Z=FKJH-\>!(O3N*ND)-$R.H9&&&4]"*N4$X\HE-J7,>16ES
M\PYYJS//F-OI4GB+0GT*_P#,C!-E*<QM_=_V34V@PQZCJ<4+<HG[R3Z#_P"O
M7!R/FY3O51<O,;>C>%K<Z0TE['FXG(=6'#1 ?=*GL>]<EXXL-1N;"5;B/ST"
M[1+&F=RCID?PGZ>M>I3S?N]J]^ *I/ I&9.?:N]025D<#FV[L^7;[2;JTCAE
MCB+JT.YVQ@!L_,/PJ31=/9_$$>G$Y\Z0,&[%<<'Z8.:^@-0T739I&,ELC%\A
MD"\-GCI7*3_#\VE]'J&GS+ 8S\D<HW%?H?2CE$V;%DD>F7$]Q.VV"QB"+VXQ
MS^@%>6:KJDFKZM<7TI.97R >P[#\JZWQ]JAM[2'3U8":=0TP4]%';\3_ "K@
M%->CAH<JN>)F%7GER+H7X6K0LK22]FV1CC^)NP%5-+L9K^XV1C"C[SGH!7:V
MUK%:0B*(8 ZGN36U2MRJRW.7#8-U7S2^$+:VCM(1%$.!U/<FI:*0UQ-MN[/<
MC%15EL%)0:#2*$I*6DH 2BBDH *2BDH *2BB@ I**2@!:2BDH 7-)1FDH 6C
M-)1F@!<TOVS[%!++SG;P*9FJ]U%+/Y<<8R2>:F;LBHJ[..UC5=2U)'0LRIGC
MFJJ^&S-;1JH_>OQD^M=1<Z%--,5;$>/2JKVL]O*$\[E#D&L7/R-'#S,>?PC?
M:%Y4\TG[M^:Z>PU2PLK7?(VX@<CUJIJTES<V"R74Q:.,<#/6N2DF8L>0,],>
ME"BY^A2<81U5V=3J7C*X>/R;%%MD/_+0?>_^M7*3W+R2,7^8D\L3DG\:C).,
M$$^_I321D9&3TK9))61BW?<1I,=#SCD,.#4#D]3T)[5,QSG QVYJ'^+@]Z8#
MU/R[1@9ILZC!R *?&VYN^>]#@E",<46$4LXZCFI8FW#J>*85&<9R:8"$/UJ1
MFC&WE3PW*IG:<X!Y]ZMZGKQU"\MI(U<"",1AY"/,D&<_,1U/8>U482'C*GL.
M!BIM.T2XU;6+73;51Y]TX2/<<#/7^E,1VMM*MWIWG1@NDB\$]B.QJOKP$BPR
M+T:,$^QIVFV%WX3U\Z#J4D3I.@EB>-MRDD=C_GI1XFD6*#$;  -M&/?_ ":Y
M'#EG9'I*JIT[LX.^DV3,R=>@-4$'S9-:5S 'E&#P%!_.J<D?ER8'2NGEMH>?
M>^I;M =C$'@=JMEQMZ9Q[U6LL[9!CM5J,JN"1D&J0B/=M;WK2TBTN;ZZ6&U!
M+=2V>$'J34-CI=SJE\+:V''\3D<*/4UZ7I>E6^DV@@@&6/+OCEC6M.FY/R.K
M#89U7=[%N!98K6*&2>28QKC<YR:?1178DDK(]J,5%60E)2TE P-)2FDH$(:*
M#12 *2EI*  TE*:2@!*2EI*!!0:*#0 E)2TE A**** $J6!MOF$_W/ZU%2YV
MQ2?[M8U_X;,JW\-FG;RJ8%^E2';)$Z]B"*H6[?Z*OTJ57]Z\D\LXC4]/#.<(
M3R>G<US]RTEJ'==[9!3..2#Q@^W:NEU24Q74A9C@,1Q^?]:S407,J1%U?)X/
M<9K9/0RV9R?F?9I2/LZS,<YW<@#V%6],E:.Z\N>+RHI%*,8Q@@$5O7^DI#CR
M1T'3N:H[ E^NY> R@_I52L$+W#3_  ^NH7(5+T$L"I4Y#*:FBT"_LY<3'[3:
M-]YD;YD/J:=:SI;^(!*K8Q.?;C-=AIS[;Y.\<F1[=ZVI:W,:ZLSR>X672-8D
MC971HWR >M;NK:L-2\J\@7YI%&_=U#C@_P!*K>/5">*Y% ^41)@5C6LLVTQQ
M_+GG/H?K6<M&:TVVK%JXB"XGN&*AN0G<GN/:G&YN+N 1LX@MQV)Z_P!36>9"
MKG<QD<GDMSS4EN"T^Z8G ZCO2U8](G2:)<6VG)+/##&;@+MBFG;[K'N%]JRG
MA03L6,DTF<@_=!]_6EF4RM#L7RXU'.#R<]S4R[$0KT/OWIZ+04I.6QUO@J_L
MKUWL;^W7?& RA!C<IZMZ@@]>U:D]Q%:7DMM'8PQA7;+8Y('>N#TO4#INJP7T
M<9?RF^9.FY3U%>K&QT'Q)IZZGINH#,D9%PCGYHR?;\*TA*Q%2/-'S'V&G7-_
M<"\NLY48B7LH[?G4^M6EC9:=*TFU;BZX;'WM@Z@?G6M8ZQX>TK3XTNK_ ,YT
M4#:/:LS6?&7A&['G7D3321_ZORUVL/8^M#K0O9DK#5&KH\W70]%O]9CFU"^?
M3K.$ %"O[R8YY ]L5V$?BCPCH$)CTVRN+QP,!I7VBO,->U-]2UB>Z@8I"3B)
M#U5.PK*433R!<N['MFN=SU]TZ5!I6EJ>Y^&_%6H:NT]S;V5G8Z79C=,Z1@EO
M]G)ZG%9FLZV^KZFSI\L*_+&@Z*HKB/#]]JB:>^DQRXM+A_,:-3W'<UU$$ A3
M'5NYHC2E6=GMU.FA1UN2EB< G@=J;2TE>A&*BK1.VUA*2EI*H -)2FDH$)2&
MEI#2 2DI:2@0E)2TE "4AI:0T" TTTXTTT@$HHHH 0TTTXTTT""O4_@W_P Q
MC_MC_P"SUY97J?P;_P"8Q_VQ_P#9ZSJ?"S&O_#9ZI7E/Q'G,?BJW4=1;(?\
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M\^E'/I7=?9H/^>*?]\T?9H/^>*?]\T6 X3GT-)SZ&N\^S0?\\4_[YH^S0?\
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M_P#H5I_^^F_PH_X7;=_]"M/_ -]-_A1RL.9'L%%>/_\ "[;O_H5I_P#OIO\
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M:AYH4QG(P.^0>W%<76B=S:$N97M8****984444 %%%% !1110 4444 %%%%
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M' ;'KUKVV**.")8H8TCC485$& /PJ"XTRPNWWW%C;RO_ 'GC!-/FU#ET/!?
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M4 ,\J+_GE'_WP*/*B_YY1_\ ? I]% #/*B_YY1_]\"CRHO\ GE'_ -\"GT4
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M4 -\J/\ YYI_WR*/*C_YYI_WR*=10 WRH_\ GFG_ 'R*/*C_ .>:?]\BG44
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M^=<C11[*/8/J]/L==_PF_P#U#(?SH_X3?_J&0_G7(T4>RCV#ZO3['7?\)O\
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M'U>GV/2?^%M?]0&V_P"^O_K4?\+:_P"H#;?]]?\ UJ\VHH]G'L'U>GV/2?\
MA;7_ % ;;_OK_P"M1_PMK_J VW_?7_UJ\VHH]G'L'U>GV/2?^%M?]0&V_P"^
MO_K4?\+:_P"H#;?]]?\ UJ\VHH]G'L'U>GV/2?\ A;7_ % ;;_OK_P"M1_PM
MK_J VW_?7_UJ\VHH]G'L'U>GV/2?^%M?]0&V_P"^O_K4?\+:_P"H#;?]]?\
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M5#4NL7XU?JAJ76+\:<=P90HHHJR0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LO6_]1%_O5J5EZW_J(O\ >JH[F^&_BQ,6BBBMCV0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q)_R#H_^NH_D:V*Q
M_$G_ "#H_P#KJ/Y&@#EZ***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% CZIJM/:^>^[=CC'2K-%<!XA1_L\?W_TH_L\?W_TJ]13N
MPL4?[/']_P#2C^SQ_?\ TJ]11=A8H_V>/[_Z4?V>/[_Z5>HHNPL4?[/']_\
M2C^SQ_?_ $J]11=A8H_V>/[_ .E']GC^_P#I5ZBB["Q1_L\?W_TH_L\?W_TJ
M]11=A8H_V>/[_P"E']GC^_\ I5ZBB["Q1_L\?W_TH_L\?W_TJ]11=A8H_P!G
MC^_^E']GC^_^E7J*+L+%'^SQ_?\ TH_L\?W_ -*O44786*/]GC^_^E']GC^_
M^E7J*+L+%'^SQ_?_ $H_L\?W_P!*O44786*/]GC^_P#I1_9X_O\ Z5>HHNPL
M4?[/']_]*/[/']_]*O44786*/]GC^_\ I1_9X_O_ *5>HHNPL4?[/']_]*/[
M/']_]*O44786*/\ 9X_O_I1_9X_O_I5ZBB["Q1_L\?W_ -*/[/']_P#2KU%%
MV%BC_9X_O_I1_9X_O_I5ZBB["Q1_L\?W_P!*/[/']_\ 2KU%%V%BC_9X_O\
MZ4?V>/[_ .E7J*+L+%'^SQ_?_2H+G1A<;?WNW;GM6K11=BL8?_".C_GO_P".
MT?\ ".C_ )[_ /CM;E%/F861A_\ ".C_ )[_ /CM'_".C_GO_P".UN44<S"R
M,/\ X1T?\]__ !VC_A'1_P ]_P#QVMRBCF861A_\(Z/^>_\ X[1_PCH_Y[_^
M.UN44<S"R,/_ (1T?\]__':/^$='_/?_ ,=K<HHYF%D8?_".C_GO_P".T?\
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M44>UGW#ZQ5[G'_\ "!0_\_K_ /?(H_X0*'_G]?\ [Y%=A11[6?</K%7N<?\
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MS+_A3UI_T%)?^^!1_P *>M/^@I+_ -\"O3:*/:2[A]8J=SS+_A3UI_T%)?\
MO@4?\*>M/^@I+_WP*]-HH]I+N'UBIW/,O^%/6G_04E_[X%'_  IZT_Z"DO\
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MN#)P!G'X?K5.*L]-!)L[6N8\1ZYK>B^?<P:?;2V$07]X\A#<X'3ZFNGKGO'
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M<****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,WBO6Y-4C9+ORT67*XR1Q_2JE&.MBITX)2:Z(VM9\4:Q;^+!H6E6%M<2& 3
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M0!*%4$D* 3WQ2U'!/%=0)-!(LD;C*LIX-)!<17,?F0R!TR5W+TR#@T 2  #
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M &!2;%W;MHSZXIAFC6=82X\Q@6"]R!U/ZU6N]6L;&80W-RD<A7<%/7&<9IV
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M9C:8\HI;<5&[UQ3JS(O$6DS2K&E]%O<A5!.,GTJ]<7$5I;R7$\BQQ1J6=VZ
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MV%.HH :41CDJI/N*4*J_=4#Z"EHH 3: 20!D]Z,#.<#/K2T4 (RJPPP!'N*
M !@  >@I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+Q'91ZC)IEK
M(2 ]PV&'56$3D$>X.#6[4$]HEQ/;2L3NMY#(N/4J5_DQIIV=Q,P#J5UJ%G%I
M!RFHNQANBO\  BXW./J",>[>U:'AJ*.#0XX8EVQQS3(J^@$K@5HK;0)<O<K$
MHF=0K.!R0.@_6FV=JEE;^3&25WN_/JS%C^IIMZ6"QSMREUINH/I-GQ#J1+P.
M/^6!ZR?IEA[YK7O(VTSP]/'IT7SP6[>4GJ0./QJS/91SWMK=,3OMBQ0#H=PP
M:LT.6P6,O0+>VCT&R\A5*O"KLW4LQ&22?7.:K:4!#XBU:WMP!:J(G*CHLA!W
M >G !J8Z!'&Y^R7=S:Q,Q9HHGPN3UP.U7K&PM]/A:.W4C<Q=V8Y9V/4D]S0V
MM0L8;:E;:?XGU,3I(Q>. C9&6[-5C1X9I-:U#45A>"TG6-4C==I=ESE\=NN*
MU(K*.*^N+L$EYP@8'H-N<?SJS0Y!8QK#_D:-7_ZYP?R:JWB"\MY=1LM+G<"$
MG[1<<$@JOW5./4_RK9BLHX;^YO%)WSA P/3Y<X_G3;?3XK>\NKH%GFN""S-V
M & ![475[A8R?#=Y"MQ>Z7$Y:.!O-@)!'[MN<<^AR*Z&JDMA%+J%O>@E980R
MY'\2GL?YU';VD\>LWMT\A\F146--V0,#DX[4.SU!%^N022_C\<:R;""*8F&#
M>)'VXX.,?K77U2@TR&#5KO459O-N517!Z *.*(NUP:,"WDOY/'5J;^"*)A8R
M;1&^[(WK6IKL#Q1IJUL/](L@7(_YZ1_QJ?PY'N*N/IT3ZO%J)+>;'"T(';!(
M/]*GN8%NK2:W<D+*C(<>A&*.;5!8S-"1[N-]8G7$UX 8U/6.+^%?ZGW-4KV_
M@L/&#/.KL&L$ V(6/^L:M^TMDL[.&VC)*1($4GK@#%1BQC_M-K_)\TPB'';
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img50815396_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50815396_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $]!0L# 2(  A$! Q$!_\0
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MZ"+_ /?*_P"%.'CSQ'C_ )"+_P#?*_X5S0%/ KWE2I_RH\OVDNYT@\=^(O\
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M_P#OE?\ "N; J0"NOV5/^5'-[2=]SHQXX\0_]!!O^^5_PIP\;^(3_P Q!O\
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M",4XJQTX:I*4G=G@X%/44@%2**]%'**!4@&*0#%/ H$ %2 4@%2**! !3P*
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MIW:/&?\ :;^=:M<QX U ZGX3ANB,;I' ^@-=/0U8:.#^*PSX;M_^O@?R->3
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M&E!&,JDF,;4;UCGS3^=31:U?1="&^M,\BCR 35\L.Q%Y=R_;^))PW^D(-O\
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MZ5A.I<T4;"T445 [AQ12$@#)JI/.3D)32N%R2>]2!<?>;T%8]U=7-WPS$)V
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M/,_+#'-)%)++(L8')-9\S8KEVSLQ=3A%1=HY) KJHHEBB6-!A0*KV%HMK;@
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MYZ$C\:[VWCS;+@8XK%1YMS%7;.*6S:"5TR>O-,DMH5F663 ;H,]ZW+R(&Y8
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MHDB5H_9:AS>/]^X=OJ:EXB/0N.%FSMWGLB/GFB_X%5K1$TA_$=A/-+!Y*/\
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M5:XN;?3K1KJZ8*@Z#^\?2FY<J'&#D[!>Z\FA61N+L@C&%3UKSK7/&4NI3L\
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MO%S[4RX8++C'2@!Q.3FBFJ.,TZ@!#2'H?[HY/M2FL_6;O[+ILA5@KD<9].]
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M7M69+=MC:OYU7.Y^&.?<UC+#W/=PF#E)<TS2_M&"$;8X%R/XL4S^T%>:*4Q
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M'-1G)/\ LU(P<C+=*DL[<W-PB?PYR:A*[L(W-#MOLUL9&^_)^E:ZN3FJBX4
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M]602#773A9#3+?F<4Y7JH&J17Q56+4BWN^7)Z@9KYZ\;ZM_:_B>XE0GRXSL
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ME6-(TK&!;Z>[XPM:UMI.<;A6Y%9I&.E6%4#C%<TJC9T1IHI06"1_PU<2-4X
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MJI$SZ*T/L2^H_(_XT?8E]1^1_P :/JU3L'M(F?16A]B7U'Y'_&C[$OJ/R/\
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M5U;_ /00?_OU_P#7H_X5U;_]!!_^_7_UZ/JM7L'UFEW//LT9KT'_ (5U;_\
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M.1:KT^YXL4!%1O"".G->V_\ "D+3_H-S?^ X_P#BJ/\ A2%G_P!!J;_OP/\
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M^O\ Z]+ZI5[#^LTNYY[2UZ%_PKJW_P"?]_\ OU_]>C_A75O_ -!!_P#OU_\
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6B,8#$8S73A:%2G)N2,,16A.*43__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img50815396_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50815396_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" Z@%? # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHICS11?ZR1$_WF H ?15*36=+BXDU
M&T4^AF7/\ZJOXHT./[VIP?@<_P J!V9KT5S[^-_#R?\ ,0!^D;_X5 _C_P /
MK_R\R'Z1FBX<K['3T5R+_$CP^N?GN#CT0?XU$?B?X?'477_?"_\ Q5*Z'R2[
M'9T5Q!^*>@#.$NC[[5_^*I!\5?#W]R[_ .^4_P#BJ+H.278[BBN''Q6\.'M=
MC_@"_P#Q5/'Q3\-'&9+A?K&/\:+H?)+L=K17(I\2O##G!O'7ZQG^E6H_'WAB
M7@:K&#_M1N/Z470N278Z2BL:+Q9X?F.$U>T_X%)M_G5V+5M-G_U.H6DG^Y,I
M_K3N*S+E%(K*XRK CU!I:!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ:#?2#YY7!^M6(_"K-]]F.>N>?YUM'+:SW9S3SC PZW.\NOC5?L2$D@A]-B
M_P \UBW/Q;UB?(^W7 _W/E_D!61'X6A7&XY/UJTGART3[RJ36RRI]9'++B'#
M1^&-RO<?$#5IP0]S<R'_ &I2?YFLU_%.HR'*QMD]P:WUTBSCP-JBI1962<G:
M,5HLKI]68RXD_D@<K_;FKR9^1A]!3?[0UB0=&+>X(KK0EDH[4AELDZ[<5HLM
MH(R?$5=[0.1WZTPX)SZ$4"#66/+8'L*ZW[99+_=S33J=FO91]*KZCAUNC/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5#Q4.YHL-6?V3P$K+_M4NQSR-U?1$?P;T51AKNX/T51_C5A/@_X=&-TMVW_
ME'_LM3];B5]5K=D?-_E2$_=-*(I<<!A^%?2J_"7PTO\ S]G_ (&O_P 33Q\*
M?#0_AN2/0R+_ /$T?7(A]4K>1\SB"7H$/T(I?)EV]#TZ"OIC_A5?AP=!=#_M
MH/\ XFF'X4>'"#@W8_X&O_Q-+ZY$/JE;R/FKR)">0PHVR#!^:OI!OA)H)'RS
M7(^NP_TJK+\'-(?[EY*I]XP?\*:Q<1/"UNR/GC]X/X3^% >0?A7O<WP7M6)V
M:D"/1H<?R:LVX^"ESR8+NU8>C%E_H:I8N'<EX:MUB>,BZG4\.U3+J-PASN.*
M]*NO@YK48)BBBD/^Q*O]<5A7?PSU^US_ ,2RX(]4C+#]*T6)B^IC.A)?% YN
M/69D/)S5J+7SC##%,NO#&H6K[9K=T;T=2/YU0?3;B(G,3 ?3-;1K]F<\\-2>
MZ-M-8B8_,/S%6?M5I*.2.?45R9AECZ T@>5!D$C/O6JKF+P4'\+.I>QLK@=%
MS]*I3>'+=S\F1]*R$O)D/WCZ5<BUB5#R<CWJG.$OB0*CB*3O3D5Y?#L\+;HF
M8'V)J6WO-3TX@.&95Z<5HQZTK ;CQ5I+JVF&& K*>%H5#JAFF,I?&KDEEXL*
M[1-D#U-=KI'C6ZB %O?R!1T1CE?R/%<))86TX)48/M58Z9- P:"4C'2N.>7R
M7P.YW4LZHU-*BLSW>P\=S,J_:;=)1_>C.T_ES_2NCM/$FFW8'[XPL?X91M_7
MI^M?.=GK%_8-A\L!Z\5UFE^++:8!)QM<]0:XIT90?O*QZ5.4:JO2:9[JK*ZA
ME8,IZ$'(-+7FEAJ84![.Z:(GG"MQ^(K?M?$UW&=MQ$LZ_P!Y/E;_  _E6?)V
M!NSLU8ZRBL^TUJRNL 2&)S_!*-I_PK0J+6&FF%%%% PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:JX%O:2R#N4C) _'H*^B]*\!^'=)"F'3TE<?QS_.?RZ?I71JJHH5%"J.  ,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM%<[DY:LZ(PC!6BK!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_NYU'S1$\_4>HK3K,84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(^C**X/PUXQ "6M_)NCP DQY*^Q]1[UW:L'4,I!4C((/!KE-A:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *0 #H /I2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQZ;=RC:<"%R?NGT^G^?IZ77EGKM6"BBB@04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %17-M#>6TEO<1K)%(-K*W0BI:* /GOXB> I-&NC/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9FO:':Z_IDEG<C&>8Y,<HWK6G10G832:LSY7\6^
M&+C0M1FBECVLAYP.#[CVKFX96C8 XXZU]4>,?"T/B73&4*HNXU/E,>_^R?8_
MI7S1KFCS:7>O&\94JV"",$'T->EAJ]]&>5B*'(_(L6\HD7WI98QC<O;@XK+M
MK@HP.>*UXI!(OUKT=)JS/)G&5*7,CIO!WB:?1K^.56^[PP)X=>X-?0&GW\&I
M6,5W;-NCD&1Z@]P?>OE8!H)-RG'I7IOP\\7_ &&X%I=/BVE(#9_@;LW^/_UJ
M\;$T'3EIL?183$JO#7='LM% ((R.117*=04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7GWQ(\&1ZO8R:E:Q_Z0@S*JC[R_WOJ/Y5Z#
M13C)Q=T3."FK,^.;VSDLKAHV''8U)9W&/:O5_B?X'6U<ZA9QXMI6Y"CB-O3Z
M'G'Y5X\P:&4JP((/(KU\/6YD>+7H\KY6;N5D3&.M/M)VM9@<U1M)\X4GFKC
M$@CK735IJI"S.*C5EAZET>[_  ^\3KJ=BNGW$F9XE_=D]67T^H_E]*[>OF?P
M]JLVG7D4L4A1XV!4^AKZ'T/5X=;TN.[BP&/RR)_=;N*\&I3<'9GTU.HJD5-=
M31HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAYATZ9_W<QS'G^%_3\?Z5X^*H\DKH^@P.(]K3L]T>GT445R':%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>)]!B\0Z++9N )0-T+
MG^%O\#TK9HH3L)JZLSY.UC3)=-OY89$*.C%64CD$=:K1,00?SKVSXI>%%N8?
M[9MX\L,+.!^0;^A_"O%6B:)RA'3VKUL+6YE9G@XR@Z<O(L\,N/RK5T6_>VG4
MHQ1E(((/((Y%8L3;3M].E3(YCD5@?2NFO3]I"QS8:LZ-5/H?3>@:LFM:/#=J
M1YF-LH'9AU_Q_&M.O(OAMX@^S7PM)7_<W.$Y[-_"?Z?C7KM>%*/*['TT9*2N
M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1117 >H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y=\4- "
M2)K$"?++B.< =&'0_B!C\!ZUZC5/5-/BU73+BQF'R3(5SZ'L?P.#50DXRNC.
MK!3BXL^6[F(QOGH<9I 0RUK:SITME<S6TRXE@<HR^F#6,ORG;TKWJ<^:-SY>
MK!PDXLZ'POJLFE:K;7*'F%PV/4=Q^(KZ/AF2X@CFB;='(H=3Z@C(KY5B<QRA
M@<<\U[_\.=7&I>&E@9LRVK;#S_">5_J/PKS<;3Y9<Q[675N>'(^AU]%%%<)Z
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1\
M4M$\F^AU:)/DN!Y<N/[XZ'\1_P"@UY-<1F.0U]->)=*&LZ!=68&9"N^+V<<C
M_#\:^<;^(@DXY7(->G@JGV3Q<RI6:FBEU&<UZ%\+-9^R>($MG;$=TAB([!AR
MO^'XUYVAQD5>TNZDL;Z.:)L2(P=6]"#Q73B:?/!G'@ZOLJJ[,^I:*K:=>)J.
MG6UY']R>-7'MD=*LUX9],%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>%_$#1QIOB6Y5%Q%<_OTX['K^H->Z5PGQ0TK[3HD.H
MHOSVKX8C^XW_ -<#\ZVH3Y9IG/BJ?/3:/"&&Q_:ER1AAU%6+Z/#[@,9YJLIR
MM>XGS1/F&G%^A[Q\+-6%]X;>T9LO:2<#_8;D?KNKNJ\+^$^JFS\3?9';$=TA
MCP?7JOZ@C\:]TKP\1#DJ-'T^%J>TI)A1116)T!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %5-4L4U/2KJR?&V>)DR>Q(X/X'FK=% -
M7/F34;1XC+$Z$21$@CN,<8K&7Y6*G&:]&^(.F?8?%5P5 $=T!,H^OWOU!KSR
M9#')@]17MX:?- ^9Q=/DJ-%K2[V33M5M[N+AXG5U^H((KZBMKB.[M8;F(YCE
M19%/J",BOE$GH>X-?0GPUU/^TO!ELK-F2V8PMGVY'Z$#\*YL?#:1W974W@SK
MZ***\T]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X+XH:<)=,M+]5RT+F-L>C<C]1^M>*:A&5?.."*^D_$EA_:7AR_M0,LT1
M9!_M#D?J*^>+^/,9/]VO0P4[.QY&9T]%)&2O(.37J'P:U,I?WVFN<"6,2(#Z
MKP<?@WZ5Y<O&170>"=3.D^,M.N-V(S*(Y/\ =;Y2?PS79B8<]-G!@ZGLZR9]
M)T445X9],%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?/WB;3QIWB"^M,8C20[1_LGD?H17T#7DWQ/L/*UJ*[4<7$(S[LIP?T
MVUOAY6F<N,ASTF>32*4D(/Y4F=KANF"#Q5B^3;,3TZ?TJNP^3BO;WB?-+1GU
M'H=^-4T*QOLY,T*LW^]CG]<UH5PGPFU#[7X/%LQ.ZUE* '^ZWS#]2U=W7@5(
M\LFCZRE+G@I!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<7\2[/SO#\5VJY:VE&?]UN#^H6NTK,\16?V_P .W]OC):%BH]2.
M1^H%.+L[DS5XM'SCJ,7[O=W'!K,!XK=OHR8I.,\9K#Z,<5[U&5XGRU:/+-H]
M+^#&HF+6=0TYV^6:$2+_ +RG_!C^5>T5\V^ [_\ LSQOILI;"-)L8]@&^7^M
M?25>7C(VJW[GNY?/FHI=@HHHKD.X**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#SGXI6F1I]X!_>B8_D1_6O(-33#AAZ=J]Z^(=K]
MH\)RR8R8)$D_7;_[-7ANIJ#"",_+FO2P4NAXV9QZF.1NC./2O7_@K?%K+4;%
MB!M*2J![@@_R6O(1]TUW7PCO!:^+UAW<7$+Q?D-P_P#0?UKHQD;TV<V ERUD
M>]4445XI]$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9^NVOVS0;^W R7@<+]<<?KBOGF]0&V?OCFOI;J,&OGG6K06U]>VA&/
M+E>/\C_]:NS!RM*QYV8PO3N<D <GK6OX1O3I_BJPN"VU8YT+#VR ?TK(88E-
M$,ACNE8'IWKU*JYH-'C4)<M12/K.BJ6D7?V_1K*[SDS0(Y^I S^M7:^?/J@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ/QY
M;?9_%MZ,860K(/Q49_7->V5Y7\4;?R]8M;D# EMROXJW^#"M\.[3.;%J])GD
M<R[9B*BZ3)GH2!5J_79.0*JN<#/IS7MO6)\U'1ZGT7\.KO[5X*LP3EH2T9/X
MY'Z$5U5>;_!^\,FC7EJQYC=9 /\ >&/_ &45Z17@5%:;1]52=X)A1114&@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_%&WW:58W
M('^KF,>?]X9_]EKO*YCQ_;^?X1N6QDQ.D@_[Z _D35TW::,ZRO3:/ =44>:I
M[8K/;&S/%:FJ*<*>QSBLSK$17OPUB?+2TDSTOX.WACUF:V)XE@/'N""/TS7M
M-?//PUN_LOBRR.<!G\O_ +ZRO]:^AJ\7$JU1GT>#E>B@HHHKG.H**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X+XOMS!XEU2,+
M_P MG8#_ 'N1_.N(/$QKTWXAP>3XOF?H)HT?]-O_ ++7F<XVS$>E>WA'>"/F
M\;'EJL;"P6Z5B#QZ=Z^C/ -S]H\(6G.3&60_GG^M?.!_UJGN2*]X^%-SYN@7
M$!/^KE#X_P!X?_8US8];,[<KENCO:***\T]<**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \N^*D&W4K*X_OP%/^^6S_P"S5Y+?
M*5N6SWYKVWXI0;M.L)_[DC)G_> /_LM>,:HN+@'M@5ZV"E>-CP<SC:I<SI<$
M CM7L'P@N?WMW;D\O"KX^AQ_[-7D,@RF:]&^$]WM\0Q)G'F1LA_[YS_[+3QJ
MO ,ME:I8]NHHHKR#W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U:'[1
MHU]#C/F6\B_FIKYWO%W6[J>#C.:^DR P(/(/!KYUU* PO<1$ E&9?R__ %5V
M8-VE8\[,8WIW.7'WB/05/IC;+\<\=3^E0XPS4L#>7<\_C7J55>!XU"5JB9]3
MZ9-]HTJSG_YZ0(_YJ#5JL;PE-Y_A/3'SG]P%_+C^E;-> ]SZE;!1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X-XHA\CQ'J40
M!'^D.0/8G->\UXOX^@,/BR];LP1U_%1G]<UT89VF<F,5Z1YO*-LK+Z&H@?WP
M)]<5:O%V7+#WJK*,N!7M/6)\Y#1GT9\/)_/\&6G^PSK_ ./$_P!:ZFN&^%,W
MF^%)%_N7!Q]"J_\ UZ[FO FK29]9!WBF%%%%04%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5Y5\2K?;KT4O:2W7GW!(_PKU6N!^)-M
MO2RF YVNI_0C^M:T7::,,2KTF>+:@I%SR,<#^0JG*<+D=N:T=54_:"3QP*S9
MO]7TKW8ZQ/E_M?,]J^#DV_1;Z+/W)$./3((_I7I5>3?!24F+5(R>HB/Y;O\
M&O6:\*NK5&?489WI184445D;A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M45'%/%.F^&5)%]48$?I4E !1110 4444 %%%% !1110 4444 %%%% !1110
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MH1:+:Q]$%:.0.])N%+G8_9QZE=+"W0Y$:_E4XB1>BBEW"D,@]:5V4H170<%
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M@ HHHH **** "BBB@ HHHH *YSQS_P BM<'T=#_X\*Z.N?\ &R[O"EW]4_\
M0A51W1,_A9X/JQS&..<UB-]SBMW5QB#T).?I6&?N'CCI7O4O@/E*GQL[CX.O
MM\8,/[T#C^1_I7O5?/?PE?9XYM5[.D@_\<)_I7T)7D8O^*SZ' _P4%%%%<QV
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%(2%!)( '))[4 +02 ,DX%<MK'CK3-.W1VQ^USCCY#
MA!_P+O\ A7":IXIU'5\B>8K$?^6,9VI_]?\ &E<?*>@ZMXTTO3-R1O\ :IA_
M!$>!]6Z?EFN$U?QSJ>H;HTE^S1'_ )9PY!(]SUK$BL[F\?$:GZXKH=.\'LV&
MF!IJ+8I3C'U.=A2>ZD&U6.>];-EX9GG8._'X5VECH,%L!A ,>U:T5ND:\+C\
M*JT41S3EY'.6'A6"'!903706^G0P+PH'T%6=RCBF-*!0YL:IK=D@54X %!D
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M9KEY#B.8F5/]OK^==-;7D5TF4R#W!I6&6****0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6'XP_Y%6^^B?^AK6Y6'XP./"E]]$_]#6G
M'=$R^%GAFLX-N2/K7.'_ %9%=%K'-N0.U<]QM(' KWZ/PGRM;^(S7\#/M\7Z
M:W8747/_  (5]-5\P>$&V^)K)O[EPG\Q7T_7E8S^(>_@/X04445R':%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45DZQXBT[1(_P#2
M9@9B,K"G+G\.WU->;:[XTU'5P\,;?9K8\>7&>6^I[TF[#2.[UOQKIND[HHF%
MU<C^"-OE!]V_PS7G&M^*]3UF0I+-MA/2&,X7_P"O^-94%A<73\ CWQ74Z3X7
M)PSC\Q0HN0G-1.<M]-N+MAA3SZUTNF>%B0/-4?2NJL]*A@4?+@BM%$2-> *N
MT41><MS-L=&@M0,(!BM5$6,?*!3#( *C,HZ=:3E<J,$BP9,=Q3#)5<R&F[SS
M4EV)FES3/,]ZCSDTF,DT@'%^:!SS0* >:8"CJ<TN:2EQB@ &33@*0<$4X#F@
M  _.E I<48P:0!BE'TIV*!TH .U+0,TE "XI0!0*<.!Q0 E %+[TN.M 7$Q0
M!Q2]:7I0 VCITIW-)CF@!*,?G3L4G(- #<&C' Y_&G8HQ0!'BC'/O3\#'I1V
MH C(Q[48_2G &D(H 812$8I_TI#0 S%)CG-/(IN.U #",<4QAS4M,84 ,//'
MM3<=*<!@4$<4 ,P>E(13C_*FFF V@]:6DH ;TI.]./>D/'6@!O-(1VIQQUI#
M0 T]:3%._&DZ4 -[4VG8Q32*!#32"GDY_P#K4P]: $)YH#'/6DQ@]:3O0,E$
MI%3+<$8YYJF30#@\\4#-1+@T\A)!SCFLI9-OL*F2?'>B]A.*9;:SC?&.HJQ9
M"6V<C&4JI'<<5>M[M>C4[WW(::V-$7JCK^1JQ'.DG0X/H:S9%25>#5*0RP-@
M9(II"4K[G1T5A6VK2)A7^=?0]:UX+F*X'R-SW4]:&BB:BBBD 4444 %%%% !
M1110 4444 %%%% !1110 4444 %87C'_ )%2^^B?^AK6[6%XQ_Y%2]^B?^AK
M3CNB9_"SPW5O^/<^U<[_  GBNAU<_P"CM[USPX4FO?H_"?*U_P"(R[X9;;KE
MNX/252?SKZDKY5T-O+U-6 Y4Y%?50.1FO*QGQGO9?_""BBBN0[@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3STIIX/T%,!I'6FT2' -(AR*  TG0TO%)CVH 2DYI<<4AX]: $[TVG=*3'-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_X9K4445QG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:2E%,0#K2^U%* ,4##%+0!10 4M%% !11FB@84M)12 6DHHH&+1244 %%%%
M!1113$%%%)0(*3%+10 TT4II.] "$4G>E-)0(81Q3:D-,(YX/-(8WK333^::
M: &<@TTJJG(7!Z4\BFG_ .M3 8>M,-2$4PC'/Z4@&&FDBGGCK33Q3 ;BFD?R
MIQZ4A^M #328IQ'6FT -X'-(>N33J3ZF@!.]-(IU)^E AA'/TI,T[&.*:>M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ$:\S&?$>[EW\,WZ***XCT HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM !1110 4444Q!24M% A#WIM+WHZ4"$I#2TE ##Q333S330 PTTCCI3R:8:
M&FF]:<>#330,:::>GK3C3"/K0(0TT]:=330,;^.*;3NG%(?Y4 --)WI>AI.G
M- "4AYI?TI#0 TY_"DI<9Q2=/:@0A/M3<8(IQXYIO^% QI_6F&GFFD<=OSH
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M0:7\: '"ES31ZTO7\: %I:2EH&+1244ABTE%% PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 6BDHH *6DHIB"BBB@0A^GZ4AZTXTAH$-I#2^M!H :>E-
M-._E3203F@!IZ4TGDTXTPB@!IIIX-/(IA':@!IXIIZ=J<3UIIH 8>M(:4TE
MQM)3_K2&@!AIN*>:8: $YI#FE/6D/6@!K>U(32GBF]302%-/3-*>*3U]J"AM
M,/7%// ]J8?TH$QIXIIXIYIC"@$,..W2HS3SW_6F-_G%(!K=*1FR,$4K<'%,
MH 0\<4=Z*:QQ@#TI +@YIA I>_'6FR?*.N,T -8@#\* QQGO2=>]!Z4Q!GGD
MY-'3I0.N*!TI#%4<'&*<HP1UI!UI0: )T]*MQ$U34'/X5:C^4]*0S0ADV\]J
MGO+PK;$ G.*HQMBDN&RF,U2)9B3W,D1<MT)SUK@/$T0O)"Z\D#G%>E75KYEN
M3@=*X+5+<P3NI''7/I7KX.*E$^8S2K*%70Y;25/VD(X/IS7T5X"OH;CPW#:H
M<2V^0ZGT))!_7]*^?UB$-T).F?:O0_"&M'3[V.=&RN-LBYZKZ5SXN#3/2RRI
M&47W/9J*9%*D\*2QL&1P&4CN*?7$>J%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5GZSJL.CZ=)=2X+=(T_O-V%7W=8T9W8*JC))Z 5Y=K^
MKOKFIED)%M%\L0]NY^IH&C/+SZC>27-PQ>1SN8FMJTMQ$@)'-06-H% )%7I&
MV# [4;(G=C99 HK/FERV!1//DFJN[/-1>Y>Q)FD!]*;FE!% $@Z"GH.<5&.G
M'2I5QUYS0 ]>Q]J>/;_]5-7/2I%''6@!ZBE'6F[B3BG+D8- #QTJ0=.M,&.U
M.':J >![TX<=:9T_PIXH!#AB@?YS1^7O0.M #L<=:6DS1ZT"'9]*7O2 \4M
M #3Q3!@FGB@8X>]+30:4=* '"G>M-_&E!H </K^%.%-7BG#\* '9IX_.HQ4@
MH$.'%+G]*3I2T#'"E%-IPYH$.]J!3:44 /'(IU,'L:4=* '4M-[TH- #Q2TT
M&EH&+1244#%HHHI#"BBB@ HI** %HI** "BBB@ HHHH 6BDHH 6BBB@ HHHH
M **2EIB"BDHH$%(?:EI*!"4E!H^M #3Q2'I2M3>E "4P_C3Z830 W./>D-*>
M^*:: &FF4\]Z8WUH ::/\YHS24# TE+3>] A":8>*<QII_*@8T]*0TZD([T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIN:4=* 'T4@I10,6BDI:0PHHI*!A1110 4444 %%%% !1110 4M)10 M%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M##M2946>S*RN@92"K#(([BEK \*:E]KT_P AC^\AZ?[O_P!;_"M^D:!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>N.:=3!CBG T /%'2D%% #Z*0<]J6@8 &EHHH&%%%%( HHHH&%%%% !1110
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ML9;,D.%/T[?X?A4FQM4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 57O[R.PL9KJ7[L:DX]3V'Y
MU8KC/&^H%S#IL;?]-)<?H/Z_E0".3#R7U])<RG<[L7)^M:T*!!TYQ5:RAVBK
M<C;4_"C9!NRM=2@# .*S';)S4T\F6)_R*JDCKFLUKJ6]- SSQ2YYP<4W/ ]*
M<#CFJ)'#GVIPIH(Y_P *<.*0Q>?7FD'4]>*=G!Y%-"@O]:!#T'X^M/SSBF@8
M%+G!H&/&>M2+@C)%1J>?:GKU[T R4#G-/'MQ48XQ4E "@T\?2F#@G&:<#S3
M?FGC'?K48IPH$2 \TH--Z<]:</2F,<*</K3!P*<*!#A0*3/44#CUH <.O-*.
M#FD7.:*!C@:=V]Z92C'2@!PZ\4X?6F@_A2B@0]33AUIBFG"@8X4H.*:.M.!]
M* ' ]Z<*C'%.!Q0 _N*7^E-S2@D]J!#LX-.'6FYI1TH >#2@TP=*=FF X=>*
M<#WI@IPH <.@XYI::#2T +]*<"1UIOO2@C-(!X-+30<<4[M0 HZTX'--I0:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=:!#::1TIQ^E-/\ ^J@:#//2DR,D_P Z7C!II^[@G% Q:0CJ/QH[Y)I#SR.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445E>(K[[!HLSJ<22#RT^I_P#K9H X?6KW
M^T=:FE!S&#L3G^$?X\G\:(%QD^U4K9#GGTJ\&VJ2?2@&174F%(STK*=B6-6+
MJ7)X-4BV"34;E[:"'GUH]QZ9I,^W/K2@Y;H<TQ#NH'K3@3S3!C/M3AUH >.!
MGI3P.GK4?.<4_.#0(=C!Q3QR,TW.:<!2&/ !YI1]*;VP:=0(7/6G+332CCF@
M9(OM3U/:F=Z?VH >#S2@G/--!_6ESTI@/_BIPY_*F9^F*<#G- APX-/'!I@X
MIPQU/:@$.!ZTX'BF#]*<#@X IC'4O--'!ZTO?I0(<,]:7Z?K3>U+F@0HXI12
M<>M+SWIE(=GFESCM312CK2 </6G#WXIO>E!]!0 \=*44STIW>@!^.]+FFYYI
M1UH >".M+TI@-.% AW:@&DS10 \'%+U%,!%.!YYH <*4$TT&E'7FF(DI0:8#
MSS3@<^U Q_%**:#2@^U #NE*#3:4'TI /''6E!IH.*4'BF \<44@Z>U&: '9
MYH!YI**0#@: :;2YI@**,\4F:* #-&:2C- A<T9I*3- "DT4G:DSS0 M'8\T
M@-'TH 7H/I2=,4A]*3- "^])TI*/6@ HHI.XH ,TAH)R"?TIM Q<^U-[G%'U
MI,FD $\TTT$]J:30 A/&*:3SWI3UIO>@ .:;GI2]S3<T (:;2GK29H&(329-
M'3Z4AZT"#M3?:EIM "9XZBD/6@G@TAZ"@89I,XHY-(3P:8A"<TA]A2GI[TVD
M("<#-1G@T[.*;0,:<CO3"<C^M./6F&D TD9Q3>_]*<?K3/\ /% !C_(IA[T\
MU&W7/7- "4T\CK3A33F@!"?3M2$4N:;C% P^GYTWDY]*4YY_G3: %R!_6G=O
M_K4T<C X]Z,XH .G&>M.'KVI.AZ=*!CGK0 \<$4]2140/6G ].QH$R96P*D'
MWASZ5!TIZ-R!G'--B1T<?-DQS@A<UY7XH_X_7Z=:]1B?_0N>N*\N\4Y^V-]3
M7HX+<\/-]C-T,DW)'XBNU/$:\<UQ.B\7))Z#%=J/]6.>,<5.,^(UR[^$1 X<
M<CFIU/&*J$G<?6K"$A17+'<]"IL3@X;WJ=3Q51>IQZ587@<T3(I;DRC J*1>
M?0D5/'@KSBFN.V*S.DSV!CE#=J]"\)7HN-+,!.6A;CZ'G_&N"F3J<$5M^$KW
M[-J<<9/RR#RS^/3]:!]#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KAO&=[YVH16:GY85W,/\ :/\ ];'Y
MUV\DBQ1/(YPB*68^@%>47-PU]J$URY.7<M]/:DQHE@7!''2G7$F%(]J=$-B=
MJIW<G7GZ4GV!:E21\L214!/K2LQ/^%-'+$>U(;%'4G-.'7GK[TT<?UH'7M3
M<. !3UYP:9GG]*=[8P* 'C'7TI3G;[TT>F<&GK0 Y <5(.F#4:MSTJ7OCVI
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MR<F)LCZ'_P"OFNAIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_H@YQ7F_BS_ (^FKT<%N>)FVQB:5C[7GIS7=)_JACIMKA=)_P"/KGI7<IQ
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M0P^HX_K^E,9UM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q_CJZQ':V@/4F1A^@_K785YQXGN?M7B"8 @K%B,>V.OZYI,:
M*=HNT TMTX5#]*= ,#GKBJUZ_P I%*01W,N5LL3^50],YX%.<_,?2F#[V,TD
M-CAWSTQ2#@]\?6D7'7(I>W!XI@.SDGMB@$=.:0=Z7UX/I2 </SIP[^HZ4WIC
MK2@X'M0 \=..#2CZ<4WGO3NG _2@!V>>>E/''/.?6F#BG*?4T 29YIPQ3.G^
M-/![4AC^!TIP/..^*9_#STQ3NV?YTP'YI<TW/IS2]O>F2.!_.E!Q2#K[4HH
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M(91-!'*.CJ&'XBGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWI1GIZTTG\N]&>?YT"'9/K1GDTW([4=* '=!29^:DW9I,T#'9YXHS3<T?D*
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7B@!0:4>N::,=<<TX'/'<"@8?PCCFE%'4_2@'!]!2 <OK3E8@4P'I_.GC.*
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M.X_YQ58'.,5*V&Q>_M2C@\?E3:4'/>F(?VQ1P*;T/6EH 44N<=J04JDYQS0
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MZYH$/W=:0-3,T!NV: 0_.?\ ]5&:CS_*DW<T#)2W7/-(6_R*C+=P:3>?3I0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYX'- /:FYYZT#%)I.N:3UHSP10 9YQ2'TH--;VH "<#--)&* 2,]::Q]>M(
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!W6BD%% #A2YIN:,T .S2YIM% #J6FTM,!U+3:6@!U%)2T +2TE% #J*2EH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%\=$F^
M@4=H?ZG_  KNJX+QQ\VJ1#_I@/\ T(TF-'/P'(S^55[PDC-3V_"CZ56O>/I2
MD.)F-UZ4WZ4YL@T@XZ&@8HZGZ4#UQS2=#VI0<4 +SGIQBE!YSG@TF>O\Z,T"
M'=#FEIHZG_.*5:!"YP*7OZ4WIFE[T .&,TH QU%--*#CK0 X#)XZ4Y<9SW^E
M- P#^='09_G2&.Z8%*.M-'4 4[&!UH 44Y>!C-,!]_RIPZTACQQ]*7(SCTIN
M>0:=G\_2F(<.OTJ05&.,TO0T@)!C'X=:<"2#4:GTQ3P<G\* 'CZTZF _A3\T
MQCLT9IN:6@0ZEIM+0,6EIN:6@!U+3:*!#J6FYI<TP'4M,S2YH ?FC--S2YH
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MNE\+D?VHF!_ ?Y4#.VHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P7C<?\
M$VA'K #_ ./-7>UPOCD8U"W/K#C]328T<W$,+]!5.\SDXJY#DCG&<52O,%N#
MS2D.)G$$\<4T "GM@?AUIH.3T_/M0 9R>F*48W<\4A^]1DB@!>@//:ER2>/2
MD![4O'Y4 .SZ\?2CG./:D4<D\XQ2@8Y)I .'I2]J08_*E%,0HZ_2E'!SUI!P
M:5>#F@!PX/'I2CJ1VI.G7I2]Z0PY'7@8IP]O2D'K^E+G_(H !Z8_&CI^/6CB
MCL<4@%!YI>AIO3ZTN>GK0,</;]:4=^W%-SCBESSQTH D!Y]^*<"#U]*C&,].
MHQ2@_P J ) >.*<.G3M48/\ ]:G=#[4") ?>G U&#UIP_G0,>#2BFYI0: '9
MHI*6F M+3:6@!U%)2T +2TE% #J*2EH 6EIM+3 6EI** ' TM-I<T .HS249
MH$.HI*,T +2'D=Z*6@!._P"%)QF@^])3$+VXHSP*3%% #J4'U[4S-&3ZT .S
MS2YIE*.* '9Q2YY&*;NXHSZ4@'9XZ\T#I_6F"E!'3M0,=FES^=-S1G)%,0[M
MCVHSFFD]*,\<T .H![4G7O29Q0 [/>DI.1UHH =GC-)G'6DSQ_\ 6I,D4 .!
MHS3<FC./:@!<T9&:0XI"?2@!>O3TH]N])G%)GB@!<CM1FFY_SB@$<#H<=* %
MSSUHW8Y_"F9/&2*0G- #L\X/7WHS@X)_^M321QS^=(2.,=: %R,G.?K03Q]*
M9QBC/6@0ZDS_ "I,_EVII. >>@]*0"D\TF>PHI 1@=*8[!D<'-&>G;--/UH!
M'X>F:0PYSQ2 X[T>U-)YS0 N<MBFT'\<TPME>.I]:0@)YYP*;D &@$TW./K0
M 9P.>]-_$T'D$=Z;D#&:!@3CWIA/\J<>">:;GN: $SU]Z:>12D^P_*D)]^:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'OZ49 -)GCM1T/O0 =2>U+G/%-[_ *TO3\.M #NV0*.I[TT'(QWI>HXH 7H
M*4''2DSS^%'0\=J '<YXIP^7J?\ "F9I1P.:0$@-.!]*C''7K2C(Y!- $JFG
M _A40/-*#S3 E%+N[TSH<]J<I'4=*0#P>:7/6F T\' Y_2F [/RT=Z;GGFER
M<T .I::.E+3&.HIN:7- AU+3:7- #J*2B@!V:6FTM Q:,TF:* '4M-S2B@0N
M:*,T4P#VHI!UHH$+2&COUI#U]J "DI:*0"4GKG'2CI0: #/Y^] XZ9IIZT=.
ME #\GIB@'C/?TI@/;O2YY/% #B031NX)[TW=FD]Z ),Y&:-W/TIH.#UI,]J
M'[OR%*""2/2F9I ,&@"0X7G.12 9QG@TW=SD4N>: %8^G([4F>>*">](3S0
M9-*3GUI,YH)H ":0_2D_G29ZTP%)//K29_*DR!S2$T@%R<49SR*3/.#^5(#S
M0%A2<'WQ2$YYI/I^M'/3H:!B^_%)G/TI,\]J3OF@!<\X_G0>""*3..GI2'BF
M [)S29ZFFEN]&['KTI" \?2D!]31NP?7%-Z>E  3UYY]:0FFL>:,T *3STI"
M:3--) S0 $\_UINX#H*"<C'''%-]>V*  \Y-!/..]'(/M32W/:D N::3^GZ4
MA/4^E-/Y4 +G)Y[TW/(%&>::30 $^]-)Z9I2>.F*;GL1]*!AT)YI,<\"DXZ8
MI,\Y.: #\Z0$$TN<'K^=-Z4"%XQGBD'3/2C( (-&>.2: $S@4'(YHY QS29.
M.OXT '7V_"D]OQH^E)R1S0 9./\ #UI#[T>A-)Q3  >W8TF<9[\4N"/ICBD/
M% AR@],5,G!P<XSVJ%!TY/6K* X&13 DC P*L(N1UZ>M1(#CMUJ9,C!]Z )0
M-O''2E ].E)SGE12@8Z4"%'?BCK2 <^G%+^/% "]J!]*3\/TI<]^E "\].]"
MGWI ?FI0,T .SMQZ>M.5N_X4WIZ4#*T 6%(SQTI<@^QJ!3CI3MV:"AV>>:4G
MIZ4Q1\V!UI_&0!ZTF"+D8V0C%=;X07_1;AP.K*/R'_UZY23Y(03C%=EX53;I
M+,1C=*3^@H0,W****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0\&EIH^5?6C.* '4M-%% #J*2C- #A2TT4X4 +FC/2FY.:,T"%I::*6F O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZTF?PH /:@XI">>>E-)Q2$+T.1UIISTX]J"<GUI"<]Z8!G\Z:3[T=:;GOF@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSA^SV4$/]Q OZ5-5DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3_.G$#'I@48QS1CISV_*@!.^/:@<''M2G.[&.U!4 >], ' [TH)ZBD'N*0C
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MH\;3G]*?&?F]B*Z'L<D=R0CKS^512L/+YJ9ACUJ"XR(&],=ZF'Q(TGI!G)W
M'GFM31/^/I?I_45E3G]ZP/K6IHV1/_P'_"O8J?PSYV/QKU.O!PHZ=*4?K3$)
MV@=\"G5X3W/J([(7.#[TO<TW\:7VJ2@[\CI1G!SG%&3FDH&*?K1GWYI ?UH[
M]*!"@\]>U ./>CH?ER?>C)% "CC- P!UYI/I0>#TH ,# HQUH& <XI>O'04
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*3Z^E HX]/RH$+GY?\\4H.!SV_2D/7B@$<X':F [ACD<FC [=:3Z8S1G!I
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MHSSTH 7=S@=*.M)NR>E!/IQ3 7/0^M+FF>I-'OF@0I/&#2>^3THR1G'%)VH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M24&1^%&>>]&<],4GUH 4<'_/%+WQ2=!UYQ2=Q0 N3G(!Z4O3K2#/MF@<#Z4
M'.12_P"%-'''K3LGOZ4 +GC-)FCM]*._>@!>]+2<DT<=NE A<\T TG7M1]:8
M"_B*7MUY%-7TQ2T *.U*.3[4T?=R<#\: 0/:@!V<9(XI>X]J;CC%*#[<CTH
M7ISF@@'G]#2#@?X4N3_D4# #\*4C&,4@Y'0C%+D@#.*0A"/_ -=&*.3ZBE]N
MU QHQCZ4[IUZ4AX%)G)I@.[X_P BCOQUH& /6CZ]:!!]:7COWI. 0.]'\7UH
M 4<BEP<TG?%.&./3VI (00,=Z3O3FYQWXII.10,3OFC.#0>Q[TG\J! 3S]/:
MD/K2YP.U'XT (:3/&,=*=C/;'K1SCF@!G>E]1QQT-*>G&*3UI@)CY:0CM2XH
M(X_"@!K=,#(I??GFE(XZYHZ8/I0,3I0"#Q1[TWJV3TH 4G%'![]*:"<TF?\
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MOY=*]BI_#/GH_%'U.I7J,]!^E28.>?Y5$IZ<5+ZC/'K7ARW/J(;"]@*0=>M
M].*0<#VJ2A1Q0#UY%)G@<T9_.@8OT'Z4<=\8I._O1GC!- "@Y)]J."/2DQCB
MCI0 N>>HQ2YZ\4@Y./6CTH 7//6CVSBFCVZ>]+[B@!?7TH!XR*3J*7.X$=Z!
M"Y.2*!V%'_ZZ >!0 OO[4O44G0T9.<TP%&,49I* <#K0(7UZ8I5//0=*3I0>
MF!0 HZC'>C^5)D@=/QI>@H 7OSVI1P*:#W- //M0 X'KP* >?2D'^<4HR3CI
M[T#"@=<]* .:,<CZ4  X/H".E ."?YTN<GI2<D]J!"GKFE[C%-7T/6@'GWH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+ G Y- [>E'5?2@'# T##.!1T[FD!(P:.!R>E #L\Y/X4#KD4F?F^E (_"@
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M*:IZ=^*7.,9].* %SSZT9/7."/TIN>,]/6@\<=*!"Y"MCI29..HQ[]J,X(-
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M]SZ_E_.M(W%:R.EL+-+"QBMDZ(N"?4]S5FBBM2 HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M([_6@!2.O--[T&C@?X4"$)],4W.1^%+T%)QUH&-YZ=33>G84X]?I33V/^30
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD#VII(&2*,\4 ._.C/\ ^JF=,9I=_(&*0#LXZ8X]J4$9/^<TS."/\*7..30
MH/3% (Z#M3<X/MUI>W7_ .M0 [..,C-*&&>,]/RIF<#W ZT XZ'- #]W8"E)
MXZ_4TP8 Q2D\$]\4 .!'OTI<]Z;^AHW8QUH 4\@$4A.>:7''X4F,9IB ]*:<
M_04[MTIOXT#$(IA.#G]:4X]<4A'<&@!N>/\ &DZ<$9HQ@FFY)&* $/?' I,Y
M_#BCU!//4TW) H =G!/%)GGH>M)DD9!Y X%&>?QZ4P' Y[T!AGBF]!^G-(<\
MY_2@"=6 //7%3*1C/YU54GCKSS3T;% BXF#BK")VZ?457A/(/X\5=CQV-# >
MJ[1S4J]>G--4#_Z].W #WQ4L0YW" G.#6%>WKS3K;P\LW'%.U;4O*C*IUZ=:
MM^%--,LWVJX'?(SVH_NK=E*R7,]D=+X>TV/3+3SI0 Y )S67K6JR7UR88V^0
M<<5:US5TV?9X6 P,<5BVD6&'.6/4T[):((MOWF:6GVY.$ R>N:]>\*Z(--L1
M/*N)Y1P#U5?2N:\$^'1,XO)T_<QG@$?>;_ 5Z-1%=6*3Z!1115DA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>;^)M(6WU:=5'R3#S5 [9
MZ_J#7I%<EXH53J*$G_EB!^IIK<SJNT&>*ZQIN+UACJ <5+ID30DQMG!' K4U
MR9$OB3_=%8QU&-&R",CUKUG3YZ5F?'?6*L,0Y16S+E_:F,[T]*6RN\ *QX[^
MU26U_%?QG&W./6JUS:M;R;X_N]?I7S\KTY-2/M:,U5@FC7/SKQ4#C':H+.YW
M##<&K;#<,U917(PW'/:FGK4C#'X5&0,\<4 '3UI>:;D]#2YXXI@*,GC/-*/3
M'-,7 X]*=P>/RI@+WZ44G3O1W[8H&.SP,49Y/'XT'V]** %/&*.?PI 30.AH
M$.'7&<F@=*;G//K2@C- !W]*. ?6CC/-)QGVI@._I1FDXSFEXSC(H !03SFC
MN:7('- !T&.E&.,9Z&D% (/UH 7OSUH/I2#/44H/S'GD4 ';%+N&>])GD^WH
M*3C'>@!W\5'?'?%!]:0?YS0 H/&,9Q2] <TT^_>EYW4P%H)R<@<^U)W/K2Y]
M* %)X'M0,4W.12@XS0%Q>U!Z')&*3Z49H ,D-ZTH/.>>E-SQ@]O>E!Y]L4 *
M"0>M!QCD\TVEX[GM0 9'>DP>:7/J*0]/2@!?6E( Z]Z9DJ:4'K0 X<<=:-P_
M 4T=?:C(YR!]:07 YS0?KS2'CK1_*@0[ODFDXYI./T]:,C@CTH 0MS1T.<TO
M2D_6@!,X/7H* .^3Q12<9ZY/6@89]::?6G9QDYIA]Z8@/?%)G/44<D\=<4G2
M@ .Y3MI,\TI.>]-S^-(8=S3<_A2DCH.O8"F]R,GK0 I/![TPY.X=>*=GC/X4
MG?% #3TH!^49'Y48&/2FGD<T )G&.<]Z3/6AL_=XZ4A/(Y[4#&GGM2-U[?6@
MXSTII.>G% A,]SWJ////3UI[=C^%-).<4@&D@J1S30?;%.[G/!IA]:8"\T9]
M:3@#KD#VI"2%XY![T .![YI<C!'Y4W/J>U&[ )[@4@'9(_&@L#SUI"<#)' Y
MZT9XH 7.<]*.]("<^I(I#UXQ3&.!Q_C3@W_UJ9N[#(]J >] #B<<8Z4Y7P!Q
M3!TQVI0?SH$/X SGGBESSS3,\=?UHZDG(H >2,8IG.._K2]>#1[4 ,(X!].U
M-(QR/2I"*9C ]J (R*:3@4]A^%1L*!B'':DSC@<TG.>XI.I/]: %R0V,_6C!
MYQ3<Y&3V%'3V]*8AP]#P*,C!SUZ\=J;SZ]: 1D8XH <.3QR:4/WZ8[9IBX!R
M#BESC(- R=)BI.<9-78[CH!UK+ /IQ5B,X'H!WI6 UDF!')JEJ.I+!&W/('&
M*JW-ZL$7+8XS7--<OJ-V!N/E@]:JUA)79NZ-8/JUYYTH.Q2" 3UKJKZ[33;?
MR8?O8K%LM0BTZTV*,-MQP*KK-)=SF23D>AI\LD]=Q?'+R18B)E8R.06Z^M=A
MX3\/S:M?H,$*#EVQPJUC:#I,NI7<<<<99F("@5[GH>C0Z+IZV\8!D/,C^I_P
MJ-_0MNQ>MK>*TMHX(5VQH, 5+115F84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MESF@08SC%&<C&,4H.32=1T_^M0,,\8]!2YY_"D_R:",4"#/I2^U)UZT<?XT
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MX0\-)HMBLLR#[7(O(_N#T^M=-110E8R;N%%%%, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M><XI/<9I2<&DQP<'I0(3H!2'GJ<<4N,\^@I!P>I.:  >N>0*;VI:0G/?GWH
M#TQBFDD'I2D^YZ4WH<_KF@!,CK1G&!Q2X^8TF.?_ *U QHZ\=*:WH>U.)YZT
MG ;G- #2Q)QCBD)R>!3NYXXS3#QVI )GVI,D&E;^5-)H :<DXIASVIS?>ZBF
M^U "$Y/44G/'<TI]*3OU[G^= #3G&>U-Z<C-/)^4G%1@C!Y[T@%R&%1YXI3Q
MQGBCH,'\Z8Q#Q[4?IBDXR.,4AZ8]J %SSP.:7KCO3/QS^E+GKUI .]30#C.3
M31T.#^-*"-WO3$+129]L"@>F>30 N<-_]:G#@G&:9G/7K2YQC'% "^G)S2\_
M2F@_RH!()P3F@!X^49/I06!''YTP'CCI]*=G<10 _.>V/QHSQ@\8XIF<$X_6
MEW?,#0 H([D<=L4G4D$T9(8@^U(3R ?TH 8R\>U0GGL.*L'@D <GKQ4;CGO0
M!#D#@= *3D?_ %J5A]*3'./>@8#&>.F.E*H YX]: ,D^PS3T7Y>1U]:8F*JD
M9).!]:KW5W'!'G(&/SI+J]6$8X&*Y'4]2:9RB9_PJK6U8)-["ZEJ;7$A1"3Z
M'/2H[6U(P6Y)[>E,M;7+[WSG%;MG8L^"5P/3%4N[+MI9$MA9%V#'.,#KVK:B
MC/RPPCGI5>/Y/W40^8\5ZI\// INMFI:@A%NOW%/60_X4I2MHMQ6ZLM_#SP-
MM5-3U"/]T.8HV'WCZGV_G7JM(JA5"J % P .@I:E*Q#=PHHHIB"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOWQ0 4<=,49I.<T &>>!2#W_ %H).">_:D)['J10 8QP*;T/-*>F/>FG@T#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP!XJ]K&C& M=6H/E]60?P^X]JS+>YR-K=17).%M&:QEU1PNL:'+92F2)>.O
MZUFPW./E8'(X.17J,]O'=1%2!S7%:SX=:-S+"#Z\5,)N&CV-&E->9F$!C\M1
MD8'O5>.5H7\N08(]:N9#C([5TIWU1BU;<9C/':AEST_G01@4X=*8B)EZ9IK#
M!P*G(&<^G:HV4D^],"$DYYSQ2[L]:5N3DFF@<8QB@0O;@4E'Z?UHH 7(S_*@
M'GI]:3H*.1_C3 ?U.:3D9XZ4F:!^= "^Y]*.]-XIW4<T@#(H)Y'-(#TH)&:
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MI6QCL?J:9]<T#%X .<<4%CTI.@H&!TQCTH 7/ / Q2<GK^=)]2<49.#D\^]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHQB@",Y!XHY/6G[<G..:3&6P10 G3FD/44['X8I",>M !D\4T]Z<1BD^GXT
M'>D/K2C]10?84 &: >^:3ZTHSZT 'X44AR/>C)S]: #'0\#BE!]:/QH&,4
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MP&".WTI<9[4 0[3V&?:DVGIT'\JFQ@@8/'Z4G2@"(+SGVI<<_6EP1QQ[T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7F/Q(&-;@/_ $ZK_P"A-7IU>9?$OC5[8_\ 3L/_ $)JUH?&
MC'$?PV>57&/M#UF2?Z\8'?I6I./W\GM6:5S=@'(&:]R7P(^5C_$9]%?#W_D4
M;?M\[5U-<I\._P#D48/]]OZ5U=>#4^)GUE+X$%%%%0:!1110 4444 %%%% !
M4-S:PW<)BF0,O;U'TJ:B@#C-1TB?39#)'EX>S#M[&F6UYGY6.*[5E#*58 @\
M$'O7/:EX?P3-99]3'_A6,J?8M2[D8=6'-4[O38+E"&49QZ56CN'A?8^01P<\
M8JVMP'Y!YK%Q+4K'%:QX9>W9GMP=O7@5S^^2"0I(I!'!KUS8LZX<#I6#JOAJ
M*Y5F10#24G';8O26YQ$<@?IUI^/ES1?:1=6+'"G'TJO'<8;#9R.N:WC-2V,W
M%QW+&.3VI,4H.[@'BEQW/\JLD9Z\TF,?4^M. P/2CGUI -VXIO04Z@<Y^E A
M/PQFFXYSVIWM0.<C!-,0S YQ1MYIQ!#48]>W% $>#NY' '2C'/2GD9'J:3OU
MIW :1C_Z](1S3\8X% &.U,"/&*0\'I^-28%)L[]!0(9M%(,YZ4_'M1@]* &8
MQU)HQWS_ /JIP&0<T>GN* & $'BG 8//-.Q@].:,4#$(P>M&T^G44['MVI..
MU(!N,#O05Y]#3^^*;T/O0(: <X[CO1@].<TX^]'KR: &;>*/?@T[\.<4@]/2
M@8W&.G)HP/2G$X%!X% #3UXI,\G''X4[&!U_*F^@SWXH 3!_#O28 /?D4[IW
MI">10 F#S]*.G(H(YZ\THP.__P!:F $@9&.OM1GG&:3Z"DSS0 OKBC/M2>E'
M2@!#TSUV\T@^^?3M3N/3BDSR?2@!",#D?@:;]>M.QC&?R]*#SQB@!I')II R
M-W6G4G []*0QIXXIOW1[4Y@%SCZTAZD4"&\'CFF<8Q3^^*;C'?B@9&1[\XI"
M !UX]:<>^>U-..@Q0 UAP1GK4!4[L=_Y5.>_:HG&"=H^M #,9)('3TII !]*
M4CFC.#U_"@ [_3FC\^*.G44=,YQUZT  X[<'D4HQW[4TG'&,#O0>@]/Z4 .S
MC'!YI1U/!I 3C'ZT9/7T[4 *"=QXH!P>AI!D'&>U'IF@ Z$]<4'WSCC%!Z<_
MI1WQVH :?0?E32N/>GD8']*4CG.:+ ,"DGK^=*5 Z^E-EF2(?,:Q-0UH1 J"
M0/2FHW"YJ7%_';CJ"<5S>HZYC(0\^U8]WJ4MPY^8@?6J1R3ECFJO8+(EFN9;
MAMS''M4-.&?PJY;:;/<'(&U/[S"IN.Q62-Y&"J,L>@%=/I>F1VL6^8C?^>*B
M@@M]/7*C=(1UZFNS\'> M9\7S!XT^SV(.&N''RCUQ_>/L/TI74=R[.UT8]K!
M>:K>1V.G6\DTSG 5%R2:]L\#_"6UT@QZCKH2ZO<96WZQQ_7^\?T^M=?X5\&:
M3X2L_*L(=T[#$MS)R[_X#V%=#3U>LB7-)6B &!@=****9F%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7F?Q+ &JVAQ_RPQ_X\:],KS7XF_+J%FW_3$_^A5K0_B(
MQQ'\-GE-Q_KG/MTK-;)N%XZ'-:$Q/G/6<Q/VM<>H->Y+X$?*P_B,^B/AW_R*
M<7M(W]*ZNN3^'7_(IQ_]=&_D*ZRO!J?$SZRC_#04445!H%%%% !1110 4444
M %%%% !1110!GZCI$&H*6(V3=G Z_6N5N+.YTV;9*I [,.A^AKNJ9+#'/&8Y
M4#*>H-3**8T['(VUR"!FKP;</:FWV@O QEM,NG]SN/\ &L^*X:,E6[5A*%BT
MRU<V$5RI!0'/M7):KX4!9GA&#[5V<<H89!J3 8#."*R:-%)H\@GM+NQ8AU.!
MWQ35N"1SQGUKU6[TFWND.Y!^5<IJ7@[YR]N,-]*T522W$XI['.1D.!ZTXJ1U
MJ.[L;O39<2(2!QFEBNE?@Y![YK5-2V(E%H-IH-3':02#S4;<-CVIDK4C!'2@
MGT';FG8]/2D&>E,+"?E3<=>*6C_(H$'^%(1S2XPV*3IU.:0!VYI*7H:._O3
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MDC'2@!^><9YI,GUY]*3J>E '2F [&<&C&1CM3E7D'L.U2;,<GTI 1JO0TK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>>?%($)IC#C_ %O/_?%>AUP'Q17-
MGIQ']]QGZA:UH?Q$88G^$SQR4'SGS6>HS=*/]K^5:$W$K^F:SN/M2_7BO<G\
M"/EJ?\1GT-\.O^17X_Y['_T%:ZVN2^'/_(L''_/<_P#H*UUM>#4^-GUE'X$%
M%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 13V\-S'LFC#K
M[]JP[O09(B9+1]P_N'J/\:Z&BDXIC3L<6)Y8)"DJE2.H88JY%=*_?GZUT-S9
MP7:[9HPWH>X_&L&[\/S1$O:/Y@_NGAA_C6,J92D3(X/0TK1JX^8"LA;B:!]D
MJ%6'4$<U=AO$DX)Q635BDR&[T:WN0<H.1Z5S&H>#PV3&"/I7;"0-R*=D'K4\
MJ+4F>17>B7EDY(4[?:J/G21-MD4CT)KV.>RAF!RH_*L&_P#"UO/G;& ?4"J4
MY1\PM%G!PS@XS5M55U^]5R]\)S1,6BZ8XK(>VO;/JC "M(UHO<ETWT+3P%?F
M XJ#;BHQ>R#*N&X]:!<JW'K6FCV(U6X\+[\TW'X5*A4\9I6CXXH$0=?I]*.E
M2"/C\*;M.3QR* L,P,>U)[4_;]::1SQUH 3&#W-(3G%+R.M!'/'% "9 .,TG
M7D=*4C.#Q0>O2F F#D'.:0\'O^=+T&/2CH<X[4@&@@>H% I>0..M)GKUH /;
MDD4@ HQT.:08_ 4Q#LTWFC-&: #&:3M_A2Y]*;D]*!A@D]:0=<XX]^U+TY]!
MVI. !_,T )WH _/^5';/J*#QV_\ K4 -SZ^E'&12\<G\,4G0]* #N<"DZ=>*
M4Y!)I#Z4 &:3)..U*?>D_"@ (P<\T''4BC/%-S^5  >PZT$<T8_^M1B@8T<"
MDSCN!2CGK28ZTQ#3P./\BFY[&GXSP>A[>E(>ASQ2 B8<<GI51P 2.E72I(//
M%0/&=W3-- 5SGO28!R,]*G\@@Y/-.6,#G@"F!7V9Z?G3@F/:I6:-.3V]JJ2W
MRH3MY^AIV%<LJ@]O>D9XXP>0/UK)EU'(."% XK-GU'@DL<=.#1=#46S=EU*.
M,':0,5EW6KX4E6P,>O6N>N=3/3/-9LMV\G'0>E.Z'9+<U;[5I&) 8 ?6LF6X
M>0_>-0DYZFI(X)93A$8_A4L$[Z(CQ3@AXSQFM>UT&XE.9CY:]_6M*.SL[!"Q
MP7[%N30DV.R6YB6NE7%RP 3RP>A85LP:99V9WRN&8<Y/-*EW<7DBPV43,S':
M,+DGVKT/PO\ !37=;*7.LO\ V?:GG;(N9"/9>WXXH;BM%JRE&6[T1PT4TES*
M(K.(NQP% '>O1_"_P<UC5BESK$AL;8C.UQF1A[+V_'\J]?\ #/@70?"D*C3[
M-3.!@W$H#2'\>WX8KI*7O2^(GFC'X487AWPAHGA:W$>F6:)(1AIW^:1_JW]!
M@5NT44TDMB&V]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X7XG+G2[)L=)6'Z5W5<5\3%SH-LWI< ?^.M_A6M'^(C'$?PF>
M(R#$C^]9^=MTA]&']*T9>)'XK. /VL =0<C->Y/X#Y2E\;/H7X<\>&2.G[X_
M^@K775R/PZ/_ !3A_P"NO_LJUUU>#4^-GUM+X$%%%%0:!1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDVO38/RIATJUP3L%6"Y[4WS">E%EV"[*C:3:G^ ?E2)IMK'_ ,LU_ 58+$5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#
M>)YEE.G]Z-A^E34$9!!Z&@#YNOE"W 'M65=':P;H*W=639.5 Y5MN:P[Q<IU
M KZ&+O3/C*RY<0STOX3S;M0D!X)@88^C+7K5>+?":8_VVJD\LCC'X9_I7M->
M+B5:HSZG!N]),****P.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \"\21>3J5XF,!9F''L:YJZ&4KLO&<>S7-14]YG8?B<UQ
M\X_=FO?H.](^0QRMB#I_A;+Y7BFV3(QEA^)4U[S7SK\/IO)\6V1S]Z=%Z^IQ
M_6OHJO*Q:_>'T&7.]$****Y3O"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><_$>'_ $^V
ME]8=OY,?\:\NN0!(X%>N_$>(&&REQV=?_0<5Y->(%FXQDBO8P#]VQ\[F\=;F
M/D)=J><9YKZ;T&;[1X>TV7.2UM&3]=HS7S)<C$H],]?2OHKP+<?:?!>F29Z1
ME?R8C^E88Y;,WRB6Z.AHHHKSCVPHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#D_'T6[1X)/[LV/S!_PKQJ^!%P#ZC%>Y>,XO-\
M-S$_P.K?KC^M>*ZD@W$XP1TKT\!+H>)F\+QN<_=C!_SQ7N?PKN/.\%QI_P \
MIF3] W]:\/O%R#Z=Z]:^#5T)='O[?H8Y$?'U!'_LM7CU[MSGRB7[RWD>F444
M5Y)]&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 9GB&+SO#]\GI$6_+G^E>':HFT/GVQ[U[]=Q>=93Q8SOC9?S%>$:FGWE[@<?
M6NW!2M*QYN90YJ9S5T,I[UW_ ,&[K&K:A;9^_ &Q_ND?_%&N#G&8ZZ+X6W!M
MO&L"$_+,KQG_ +Y)'Z@5WXR-X,\;+)6JQ/?:***\,^K"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$->@$-]=1$8V2,IQ]:]
MOKR'QG;^5KUZ.Q</^8!_K73A7:9R8U7I'!2KE6'&14OA.Y^Q>*]/G) "W"9^
MF1G],TV9<,ZCM6=$S1W\94X.[->Q65XGR^$ERU/F?5-%065P+NPM[D=)HED'
MXC-3U\\?9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:\
M<0&70?,7@Q2JV?8Y']172UF^((/M/A^^C[^46'X<_P!*<79W%)731X/J"=_0
MUBW:\9KH=24A6&./Y5A7(RG3M7T%/6F?'8E<M<]"^$%\5U"YM&88DAW8_P!I
M3_@37KU?/OPZO18^*[,[N&?8>?[W']:^@J\?%1M4/I<!/FHKR"BBBN8[0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR()(VC;[K @
M_0TZB@#PC5('AEEA;[R,5/X<5S4P^5AC&*[_ ,86GV?7[Q0,!WW_ )@'^M<+
M,,2.".Y->YA)<T#Y7,X<E2Y7TJ5[?48G1L,IR#[@\5],VEPMW9P7"?=EC5Q^
M(S7RZK>5<J<]#FOH7P->"\\*6G.6AS$?PY'Z$5Q8V.S/3RJ=TT='1117 >N%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >??$"
MWV7L%QC"R1%3]0?\"*\PO4(E)QVQ^->T>.K7SM$28#+0R?H?_KXKR#4$.QB:
M]/ SZ'B9M3O&YS]PN'!KUWX3:AYEI<V;-DX$@&>G8_S%>37"]#_D5UWPTU#[
M'XB@5CA9"8V'^]Q_/'Y5MC(7BSDRRIRS1[K1117C'TP4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!1UBV^UZ/=0XR3&2![CD?J
M*\1U"')*G@5[Y7C'B.R%IJ5U;D8"NP'T[?TKJPLK3L<6.AS4SB)E."#3M&N&
MMM11U8JRD8P?3%2W4>V5AWQG%4$)BN PXP:]:JN:)\UAFX5+=CZ>L;I;VPM[
MI>DL8?Z9%6*Y/X>ZB+WPXL)/SV[;?P/(_7-=97@R7+)H^PA+FBF%%%%24%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YSX^LO+U%;@
M+\LT8R?<<?RQ7HU<WXUL_M&BB8#YH'S^!X_GBKIRY9)D5(\T6CQ6_3# XYK(
MG7#9(_\ K5T.H1X##'_UC6',N5KWH/F@?(XA.G6OW/0OA;J8AU'[(S_+.FT#
M/<<C^OYUZ]7S=X9U![+5(I%.'CD#+^&#7T;;SI<VT4\9RDB!U/L1FO'Q4.6=
MSZ/ 5.>G;L24445S'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5!>VPN[*:W;I(A7\>U3T4 >&:G;-'(ZD8(/(-<Q<H!(RCH*]*\9
M6'V?6)F ^23]X,>_7]<UP%_"00X^AKV,'4NK,^=S2C9N2]3)B?R;E3G'O^5>
M]^ =3_M#PZD3-F2W.T_[IY']1^%>"3)\V?7BO0OAAK'V?4UMI'^6<>6>>_;]
M>/QJ,93NAY76M*Q['1117E'T(4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!RWC6R\ZPCN5'*'83['_ #^M>4:A >0#^=>[:C:B
M]TZ>W(Y=#CZ]OUKQS5K<H[#T]JZL+/EE8XL=2YZ=SBYERO3FK.BW;6E\CHQ5
MU8$'/2ENT"S-Z?\ UA6>?W<H?.,=Z]:JN>-SYJC)TJENQ].:7?)J6F6]XF,2
MH"0.Q[C\ZMUY_P##'6!<V$M@[Y*_O(_IT(_E7H%>%4CRR:/KJ4^>"D%%%%0:
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:^+]/\
ML^HR,J_*YW+^/_U\UZ57/^++$7.G>>!\T?!^A_\ K_SIQERNXI14E9GBU]$-
MC$=16+,N5R.M=5?0[68$?6N<GC\MRE>[0FIPL?*8VDZ=3F-;P7K+:5J\,HX"
M,,CU4]1^6:^A(Y$EB22-@R. RD=P:^6XG,%PK#MUKWCX?:T-2T(6SMF6V^7G
MNIZ?ER/RKS\93L^8];+*_-'D9UU%%%<)ZP4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7NGP]U]=4T<6DC9GMU&.>J?_6Z?E7FXNE9\R/9R[$<RY&=C1117">J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^+H75T=.6XKE?++9GN]%-CD26-9(V#(P#*PZ$&G5Y1] %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPZM-P=CZNA6C5C=#J***S-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O-_'?A<(6U&U3$;?? 'W6_P->D4R:&.>%XI5#1N,,I[BA-
MIW0:-6>Q\VS1;6((Y'%56 (P>#[UVWC/PO+I5ZSQC="_,;>H]/K7&8)Z#D5[
M.$Q"G&S/G,RP3IRYHF9/&T9W#@CH:],^&7CT1.NB:G)MB8_N9&/W">Q]C^G\
MN">,2+T[5D3Q26\PDCR"#58BBI(QP.*<)'UO17GWPW\6RZGIL6GZBW^D1KB*
M0]6']T^_\Z]!KQIQ<79GTT)J<;H****DL**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6WB6W$$Q6+4$'S)T#^X_J*ZVO+E%Q=F>[&2DKH****104444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 444V21(8VDE=411EF8X 'N: '45QFJ_%/PCI3M&V
MI?:77JMJA<?]]=/UJ_HWCC2-;C#VYFC4]#*H'\B:T5*;5TC-U8+1LZ2BD5E=
M0RL&4\@CO2UF:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 57N[*"]CV3QAO0]Q5BB@#S[Q#X+1H
M9'10RX^\!_.O)-8\.3V,S-$I 'M7TYU&#6!K/A>UU&-FB54D],<'_"JIU)TG
M> JM.%:/+41\XP7TEN^R3(K326WO$VN!GUKI?$'@B2&5OW6UQ[<&N(NK.YTR
M;&UL#C%>Q0QL*BM+<^=QF4RIOGI_>=+I&O:KX<F1K:5I(!UC)XQ[5ZOX<\<Z
M;KD:HT@AN /F1SBO"K74P2%D_&M!8XI6$D+E)!T93TJZV%A55T<^'S"KAG:>
MQ]'<,,\$4]7(Z\BO'O#OCZ_TDI;:HAGM^@D7EA7I^E:W8:S!YME.L@[KGD?A
M7D5L-.D[]#Z/#XRE72L]36!!Z45""1TIWF@?>X'K6%SJ<22B@$$9!R**9(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'(XHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV.-(HUCC4*BC"J!P!3J**0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@>E<U+87=H^1N]LUZ5+&TZFC/%Q&3U*?O1_ L3:(H(>W<J3TP>E1K<ZO8/\
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MBN.4Y2=Y,[8I15HJP4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<ZZ6:47I=H]ST_XNZ3=!1-$4)')1P?T-=%:>.= NP,7?EGT=3_3-?+C>';B
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M:EIJ%RV7E<D_A6L<(CGGF-NJ1[G??%BP@5C#"O'=W_IBN8O_ (RSD'R62/\
MW$']<UYU%X=E<Y<L:NP>&T Y'7CFMXX3M$XJF;17VB]J'Q-U2]RHFG<'MN./
MRK!FU[6[TG!9?3-;T6B6T7W@*L"&S@XXXKHCA9'%4S5/X5<Y$6&IW?\ K)GY
M'/I5NW\,NQ'F$D^]= U_:P9QMJE-X@BC!"X_"M5AX+XF8/%XJI\"L.AT"&,
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M7H=%<<ZTY[L[H4X4_A5BK8Z98Z9#Y5C:0VZ>D:!<_7UJU116984444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<8%3]47<?]I5EO XT1:TI_U[T%=;_P">[BNS^U69/0?E0+FS'.![T?5?,?\
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MS_8UYZ/Q[4JZ/>,<?O,#T%?41TG32<G3[0G_ *XK_A2?V-I?_0-L_P#OPO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img50815396_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img50815396_3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" Q."#0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !114<]Q%:QEYI$B3^\[ "@"2BN:O\
MX@Z19Y$<CWC^D"Y'_?1P*YJ^^)VH396RLH+8?WIV,C?7 P/UIV8'I5075];V
M*[KBXBMU_O2N%'ZUX[>>(-:U'/VG5KH)TV6Q6$?^.C/ZUFK80;B[1B23/^LE
MR[?7+9I\K ]7N/B%H,&0E]]J8?PVR-)^H&/UK.G^)UMG%OI]S+[R%8Q_,UP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI%%%%64%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ",P52S$!0,DGH*XGQ!KCZPS6UNQ2R4X:0<&7_P"M
M_.I?$6N'4I'M+=L6BG$D@_Y:'T'M_.L9V"J%' Z 4%+03Y8P%' Z4PL3WIC2
M9'-,+9R* )&?=3&;O[TW=U.:0_K2&#-4;L?_ *]*?R]:C<COUH$-S[]:C<T-
M(%JK),3S0 Z1^^*J33CD\TLDWI5"XE+9';ZT ,FF+9YQ6?<2;FJ>1R <<_A5
M&9AP>] %:9OE]ZH2'YA5J8]^M59/N^E" HW!Z\X_E69<, IZ_C6E<+\I_6LJ
MZ9MIYQQ3 SI/<YJS9X5,]^>_Z56=LL,U=MP$A[ YIDGB_P"V%<O#^SKXS2,$
MF865J2HR KW<6<^@X_E7P%=&-))G/S)&A?KU %?<G[:UWY'P1> G:;O7M.M^
MG4*TDF/?[H_*OA6^17AG9SLC5"TGS=03TJ);DLYM?&%Z4RLQ1?0 4-XRU''_
M !]R#Z'%6UAT!&.ZT=NW$@%31W'AN./G2BY]3/Q4ZD6,O_A,]1X_TV8?]M#4
M;>,M088-W,.,8WD5MC4?#B<KHJM];CBG#6M!CP4T.W!'4^>QS1J%C!_X2V\[
MW$F.^'-,_P"$JO& _>S?BYS70MKVBJ/ET6V'I^^:FGQ%I&T[='MDY[RL:-1Z
M&#_PEE\V,RRGTRQH_P"$HNF(!DD/MNK>'B32LX.DV8XZLQ)-.7Q-I."!I-D,
M^Q_QHNP,FU\2W=Q/#"DGEJSJNXG/4XK]7/V$].,?AGX/QE0/->^O3CH2TDQS
M^@K\P;+Q!IDUW!$FFVNZ1@OR1\ >O)K]9/V)=+%G;_!^U(Q]G\-F8C'=HV(/
MY/3C>^I43[LHHHJR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KF/$^M,6;3[5\-_RWD'\(/\(]S_ "K1\0ZS
M_9=L$BP;N7(C'7'JQ]A7%L/)0@DL[?>9CR3ZTBEW$8B- J\ >E5G;)ZTLCYS
M3,>IH&)13AS12 2FL<?6AV]Z@D?<>*! \F>.U022]>.:;))U']:KO)GGWI@+
M))QR>*@D?KSQ2.W;I4$C?6D R1CZ55DYJ:4]^WI4!]10,K3?-QG/]*I3^N:N
M3=^:IS=OI0(J3'MFJ\GW>O;L*GDSNZ>U5INF?YTP*%SD+N':LBZQTZ]JUKIO
M4#%9%U\QSC/XXIB*+89^F>M6QD6XXYQ^-5.L@]S5J?<(QGIC&!31)\Q?MU7A
MC^'_ (.M5;'VGQ \I[\16KG/YO7Q7JD,EW9SVT6W=, I9C]WG-?6O[>UXWV7
MX<6JMUN-2N"I/I'$F?UKY"UR\:#29 C?OI)!P!DE1UJ);B,]/!-XPYO+13TY
M<"IAX!E;!;5;%?3][FL/[9<MR(V)/^R:/-O'_P"6,GTVU.@C<7X?HWWM:L /
M]F0_X4X^!+5<%]<M/7Y2Q_I6%_Q,#R()/8A.W^-+Y.J,V1#+G_<I ;B^!=/P
M0=<MQ^#'/Z4?\(7II8@ZW;G;T.&(_E6,;75FP!;S8]P>:<-+UD_=MICQV2C0
M#7_X0S2MH/\ ;D+'OB-C3AX.TK^'6=Y_ZY''O60NAZV?NV-P,=/W9J5=!U[/
M-I<?BIQ1H&IMP^&[+3-US!J1>>.*1T1H_O84\8K]EOV4M-%IXL\'VP3:+'PK
M"N/3]S"/ZU^,.A:+J-K=O)=VTF'A:$,W4,^%!_6OW$_9PM0OQ0OU ^6UT2*(
M'Z&-<?\ COZ542D?3E%%%6,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444C,$4LQP ,DT 97B+5/[.L2J']_+\J>WJ:XY5\M0.I[G^M
M6=0OCJE^]P3^['RQCV'>JKM04,9N3Z5$S4,W'Z5"[XI#%9N]5Y'S1)(,U!))
M[^U @DD]ZK-)NI)&W5'NZCO2 )&J%GISM\Q_G41;OWH &/;K3#CL,49]*:2<
M#-,8W^+!'XTQSG&?SIS-NX]:8S<Y(^;\Z &D_@/Y5 Y]OSJ9AA?ZU ^.AXXI
M 59/?C_/6JLN.:M2U5D[GIS3$5I/UKS/XE^/+_PY/'::==M932#YI8^) !_=
M/8FO2Y/NGG%>?_$;X>CQA"S0S?9KH >7<8W!6 _B7N#3$9GP_P#B1>^,IM3T
M;6+C[?JNGV<5_!J#J/-FMVD$<D,I'WBC,I5CS@D'-;]UW]^*YKX8_"W_ (5S
M;ZS>W^IC6-?U=8[>6>*,QPVMK&V]88P3EF9SN=S_ '5 X'/173?O,Y[T(!]E
M\WUZ]*AU#[Q''/\ =J:TR,C';\*J7Y&YN3MSWXJN@BJ/T^E68H_FYY]JKQYR
M>.G\/>K<*DD=!2 MV\.[Y0>V>U:"1ENO;GK5:W7:HP<CJ:N1YSCJ*0R18?E&
M/6K$";)(RI/## IB_=_VL<'.:E4[1G&-HS],#- S \)0[-'ED.<R7$K8/;YV
M/]:TV"]^M4O# V>'[,DGY@9#SZFM!N&R <?G^%,17DC!SPOM5::,;<8X]<5=
M;L#ZYXJ";YL<4 9L^%4X7 ]Z]J_9/B_XE_BR?KOO8T_[YC_^O7B]Y\JD^O2O
M=OV4X-O@[6Y\?ZW5'_1$%2![;1113$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7/>+-2,<*V<;8DEY<CLO_P!>MN\NX[&U
MEN)6VQQJ6)KS][F2^N)+J7AY#D#^Z.P_*@:$.$4 #%5Y'Z]*?+(?IQ5623IF
MD4-DEVU7DD[YI'?KS4#-[F@0LC\GFHF:FLQ_ 4UFH 1C49;DC%*S<=>*BS_.
M@!&;WS4?4T\D^OYTPM_^J@8G\5-/L<4ISR!U]Z3 H ;RRG%,8'G/7.:D;KT_
M/^M,..?2@"-N1S4$GZU,W/>HI.<_3I2 J3=#C/X54D;''XU;D4<U5D_&F(K2
M=!SBJ4_4]^^:NR=#^54[@\8[TQ&3==<9./>LB;[V<Y[$&M6\.YN#FLJ3YG)!
MX[&F@+%N1Y1/H.<=JS[K+9[\YJ\G^I.1QCGC]*S)F.[.<"J)"*/OVJ]#UQCC
MZ53AY]SV-7($[ GK^52,OP_+RHQ5F/)89-01>_4581AG@C.:!EA>XZCUIE[(
M([&[;/2&0Y_X":<F?7ZX%5-<;RM U)CT$##\^/ZT@&Z+'Y>B:>#P1 OZBK/\
M6>O;@<4ENOEV=LG3$:@_E3VZ#I_2J$,;YCFJ\H^8_7 -6F!52>GTJM+T..A_
MPI#,N\P!TXZY[U]#?LMPF/X8NY_Y:ZC<.#CMD#^E?/5XORGJ3C_.:^E/V;8?
M*^$NF-_STFG?Z_O6']*74?0]0HHHH)"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/Q0\)+_S,6GGZ3J: .HHKE#\5?" _P"9AL?PDS3#\6O!Z_\ ,?M3]"3_ $H
MZZBN.;XP>#E_YCMO^"N?_9:8?C)X.'36XV_W8I#_ .RT#.THKB/^%S^$.<:K
MN^EO+_\ $TW_ (75X2Z"_F;_ ';67_XF@1W-%<&?C9X5[7%TW^[9R_\ Q--;
MXW>&1WU _2PE_P#B: .^HK@?^%V>'N,0ZH<]/^)?)S^E)_PNO0C]VSU=NW&G
MR4 =_17 ?\+HT8YQINM-_P!N##^M-;XT:6N<:/KC'T^Q'_&G9@>@T5YV?C5I
M_;1-:Z$\VH'3K_%36^-5F#C^P=8S_P!<5'_LU%F!Z-17F[?&JW!P/#^JY]U0
M?^S5%_PNY/X?#>ID^[1C_P!FHL^P'IM%>7GXWCC'AN^&>FZ>(?\ LU,/QRZ8
M\.77/K=1#^M'*^P'J=%>4_\ "]3V\.S=<?->Q"FM\=)NWAQ@/4W\7-/E?8#U
MBBO(_P#A>EVQ 7PXN??4(_\ "D;XWZG_  ^&XS_V_J?Y+1RL#UVBO(6^-&M8
MROAJ$C_K\_\ L:8WQF\0_P /AF#/I]I<_P#LE'*P/8:*\=;XO>*=N5\-VH!Z
M?OI#_)*;_P +<\8-]WPW:_G,?Y)1RL#V2BO&S\5O&O;PU;?39.3_ .@TA^*7
MC?'_ "+]FO\ VSG./KQ1RL#V6BO%W^*'C?'&DZ>AQD9CE_QJO)\5/&Z]+725
M&/XD<8/H<O3Y)=A77<]PHKP5OBUXT# ,=#C^I']9*K-\8_%ZDA[WP[&?0RQ@
M_D9J.678+KN?0=%?.K_&CQ4K'?K7AN(=!NN+=?YS50G^/6N6[E;CQAX3MCZ-
M>V8/ZS4<DNP<R[GTS17RC=?M)7T1Q_PLKP8CC'RF_L2"?3_75ZO\(_C)<>,M
M4FT'6[:"WU>.'[1#/:,3#=1\9(!)PPR#P2"#D5+3CN--/9GJ]%%%( HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M65K\/]-N;I] \0VJ6VGRQ336S73R7MV716+)/%!*-D)Q(% (!.5 !\GA2P)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O._'$F[Q$J_W(
M5_F:]$KS3Q@V[Q/<]]L:#]*3&9$AV@BJ4AY]JLR-QUJG(:!D4G?GZ5'["G,W
M4]J8?4T )R&X'-)MYZ?A1VH]._XT )Z9H_G1@T'CF@ [4GIG@]J7I]:3.?SI
M (?5CTYQ2<J3VX[]Z7=_A36;T]/2F X'(QR.?K2,.G\C28/3/6FMSD8S^-,
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M-P701]3T5G>']9B\0Z'9:E#Q'<Q+(%]"1R/P.1^%:-9#"BBB@ HHHH ****
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M[$?L*L?^%2? 8_\ 3M*./^OBXK:/P2^1G_R]C\_T/T#HHHJ3I"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#D_UKT:O-OV?@5^'B9Z_;+C_ -#->DUF,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L[Q%_R =0_P"N#_R-:-9_B 9T+4!_TP?_
M -!-- ?D[_P4\Y^'_@$'@_\ "0ZATX_Y=XZ_.B3VQUXK]%_^"G6/^%>^ C_$
M/$-^ >__ ![Q_P#UJ_.F3J?Z5D]PGLOZZE3ELX' XR.WO6?=C%PWX?RK1D;G
M.1Z[L5G77^N:G$SCN144459H%%%% !1110 4444 %%%% !6[X%\42>"_%VE:
MW''YHLY@\D7_ #TC/RNG_ E+#\:PJ*-@/OC3=!\/?$3X9ZIX:O[]GL;RWC>P
MOR"\DNYMUO,B]R&^5EX/$BU\7_$#X;:]\--9.GZW:&,-EK>\C^:WNDS]^)^C
M#]1T(!XKHOA;\8[CP.B:;J GN='60RPO;D?:+*0_>:+/!5L#=&<!L @J>:^D
MM(^)6G>+-#N[>)['Q7%.H;[.HC8;@-H\RVF^9>/0'H/F->E+DQ23O:7X,\N*
MJ81M6YH/[T?$=>P? ']G_4/BOX@M+K41_9GA.)]]S?7#>7]H5>6BASRS'H6'
M"C)/8'WB/2_"%AJ"W,'P\L/O# _LDY3'\1\SY.?IQBN;^(7QIM+&!H=4U)#)
M#Q#9Z9(CWF!T0NF8X%YYY)QT3/-9K#QAK5DK>6YJ\1.HK48N_GLA_P ;/B!_
M9=MJ5W'<+Y-IOT_34B/R&Y*;/W7^Q#$2>G5HAU-?)%;_ (R\9WOC34EN+E4M
MK:%?*M;*'/E6\>2=JYY))))8\L2236!6%:I[65[670Z*-/V4.7=]0HHHK W"
MBBB@ HHHH **** "BBB@ H'6B@4 7@V".!BG+D>V*:OO3N!69D6['Y9D/3![
MU^P?[![;O@[\"CV$<PSG_IZGXK\?;3/G)R>".>QK]>?V!F#?!7X'-CI+<+_Y
M-S"MH_!+Y&?_ "\C\S]$Z***DZ0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G^(/^0%J'_7!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3)N8G'^R:?39.8V'M0!XS'(0JLH*^@(P1[5PM]9FXOKUEZJY)
M%=TWS%^_)KD,@7VH9'&<9I1'(RELFV^PHCC K3>/]WPO&>M4EX/-6230ICFI
M?+X]J(1QFI&Z5!169??-1LM3N.>G2HF&.],"(KC/%)ZG'XT]L=.E-(__ %4"
M&[?P'O3O7^='W>M QT-,!XI1],TG4]Z%/3%,0NX#'.!3E--X%/R/2F!(N*D
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M5K7C%=/O6(QBVES_ -^VK.\+(%\/:</^F2_R% S68>G3%1GWZ]JD4=101^5
M$#56FQM]:MR?+GCFJD[#[N.?3%(91A&?-/7GK4D3 MFHX/NOGUJ6+KG'3WH0
MBW"O;I4Z+R/K4<28[_XU,H)ZBJ ][^ HQ\/8O^OJ?_T,UZ+7G?P'_P"2>P_]
M?,__ *&:]$K,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %4->_Y >H?]>\G_H)J_5'7/^0+?_\ 7"3_ -!- 'Y-_P#!3C_DG/@/
M!X_X2*][_P#3LE?G1,.O4<\"OT8_X*:?\DW\!\9_XJ*]_P#29*_.>;J?UXK-
M[A/9?UU96D;=@ Y/K[46?B"]T.74!92B$7L"V\K; 3L$D<HP3RI#Q(<C!XI'
M&XXRV>P/\JS[K_7'M3B9QW.P\>?&#Q%\1+BQFU)[2VDM)Y;S.FVJ6WFW<I4S
M74FP#=,YCCW-_L+@#%="?VEO&+:];:JT>C,\:W!GM3I</V>\FG,;3W$\>,/*
M[PPL6]84P !BO*:*LT/I3X.VOCCQOX1U'Q/!XBM?^):NKVP@NM-\Z)EFMVN;
MM[N=<"W23 6-V)S)D# 4FL#QAH_B+Q5\0?A-\.=0\7V&H_9[#3+/3KQ;98UT
MJ.[V3""7IN,32DL7/4MD@=/$(;ZXM[>>"*XEBAN %FC1R%D .0& Z@$ \]Q4
M3.S-DL2?4F@#ZUU;P_\ %;7/%7C2S2_T.:P\2>*;OP]/K5O9)YCW\=K()C;Q
MD&:(3PED8H-K>85'I4NCZ;\5O$FE> _%*W_A])/$UOK=JUG#I\9N69K0M)+=
MQQCS#+=I;'8_!)A+#!))^2TOKF.1'2XE5XV#(RN058="#V(KIO FD"^U*SU"
M\G=[!+V.">"TU!+:\^96(D0E6*J,8,FTA<@'J* ,;1?#MYKT=W):B$K:JCRK
M).D;D-(L8V*Q!<Y<9"YP,DX )'TO\$_V;=;^(6M7FC^&["XM6L;\WMKJUPGV
M6]@3&PQW$R,1&,?, I/S X)S7IO[,O[(>K?$^&SN?%J/::7H^VT34&C7?L4D
MM;1C&).7)#G.W=R2"!7Z)>&O#.E>#M&ATK1;)+&QB  1>7<@ ;G;J[8 Y- '
MR!X^_8,T?PW\+9M9L-2N+[QCI,*3RR0*$MYHDX8(N-V]5P=Y.3LZ5]*_\$V_
MB[%KGPVF^'%W*HU'PR-]DO +V3L< ?\ 7-R5^C)75^)/$^B^#=&GU7Q%?V^G
M:1&"LLEP>) 1@HJ]78C(VCUK\CM8_:%U'X1_%B^U[P!JMWHWE7$ZV-PH7S1;
MLQ 1U(*G*[<@@]!W% '] .K:UI^@V;W>IWUMIUJGWI[J98D'U9B!7C7BC]M3
MX0^%PP_X2E=7D#%=FCV\EUD^@91M//'!K\7?&7QY\4^,)HK_ ,8ZOJ>OZE.I
MD^RW4S2-$N,@R G"[AT10*X#7/&VJ7Z7&IW6HRVKX$<=C  98UX&=P. JY
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M\:>,_AG9VOBC4=#T^T\.GQ/KUG'I5AJT@:&YF@@2[%LRLQ@$97]W*O(9V'S
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MZ(NMW@SZG[8W%:1^&0OM1]?T9^EE%%%!L%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %4M;YT:_'_ $PD_P#035VJ6M?\@:_ST\B3_P!!- 'Y._\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%ED+"0LNP^9(-I]G8?TKE;CY=:O.#SC^5=C?+MO+H>DC?S-<A??\ANZ'7]
MVI]3TI1'(O6\:W-N^>#CD5SUQ^YD/85:M-4:U:1>S#%9FHWWFR%MWTK1[$EN
M.ZV]6IMQJX53@].K5AS7A5< X/M74?#;P6?&_B#RK@-_9EJ!+==M^?NQ_CCG
MV%9%EWP;X)UKQ]B>)_[,TD'!O9%W-)ZB->_^\>/K7K^@?"_P_P"'U5EM/MUR
M.MQ>MYKD_CP/P%=1!!':PQPPQK%%&H5$08"@= !4E,DCBMXH%"QQI&HZ!5 %
M2444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COBA-Y>AVB9YDO$7\
M@Q_I7FKY]:[KXMS;5T.'^_<2/_WS&W^-<)UZ=:DH3Z\49[4Z.%VQ\N!4HM>F
M33 @W;J%8?2K'V8 =<FCR$';]: (,].E*?TJ1HE/:FF/KCGTH B]J/\ /-.*
MD<"F_3\J %V_,:7;[9Q1M-.QZ\?6@ V@9&*._P!*4XP>WI2>V?I0 WWI,XYZ
MT>WYT@ZTP&-[U&1MXS@9]>E2MT%1MC@^O>@ 5?8XZ4J_,>.N*7@= ?Q'%"C"
MX[=J (V^4?TJG<9Y&>>M7\;JH76-I.?:D!@7[ Y%8EW]YNY[UM:@?_UUAWGU
M[=:8BHN5E]NPJU<?,@[C&.*K0K\V:L7.%4G/U%:(1B29+8QSG&![4^$Y8>I]
M*BDZMVR:FA7YLXSBD27H^&QD$U=AZ<^M4H?FJ]!GN._/%,"TH.W.:?@CU]*:
MOUR*>%]__KT@*7B+Y/#>KD_\^<GW>O2K&FKML+8'_GF!]*J>)O\ D5=8[9M7
M_7%:%HFRVA'/"@>](9/T%-;./J:=SR*;M.!CM3$5Y!U_K5*Y^Z<'VJ_)_P#6
MJC=?ZL^E)E%2$8A7G/6K-NH89[U6M_F@4^Y__74EW>6^E:;/=WLH@LX(VFFE
M;^")%+.?P4&HE*,(N4G9(=KNR-'"%05=9 .I4\#U!IRCD5\[_L]_%KQ#K/BI
M++Q=,OD>,K)_$/AKC;]GA5R'L#ZNL7DS#U$A]*^B>W& /3UKDP>,I8ZG[2EM
M=KYK^OONNA4X.F[,]]^!/_)/X>_^DS_^AFO0J\]^!/\ R3Z#_KYF_P#0S7H5
M=A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]8
M_P"01??]<)/_ $$U<JGK/_('OO\ KA)_Z": /R<_X*8_-\*?!!#-_P C+=8&
M/^G45^<LW4=J_1S_ (*7Y;X2^"FSP?$USQ[_ &05^<<V,MCZUD]V$]E_75E=
M@>,#^H_&LVZS]H;-:'!R,9YP,&L^ZR)FSUJHD1W(J***LL*]:^&WA6=KFWT:
M2#7+2XU1?+U.R>)8DGB+12VQC##+\X8@@ _)@\UY_P"$='?5M6\PZ>VJ6=BA
MO;VU6Y6W9[>,@R .<X... 3SD XK]"/^"?\ \'3>:[-XDN[@WVC::%GACE9F
M_P!(/$*,'&0449XZA5[<4 ?6GP!^$-O\%_AW::,$7^U+C%QJ$@&/WA'$8] @
M./\ >+&NF^('CK3/AKX0U#Q%JS9M;1<)"#AIY3]R-?<GOV )KHU5I' &69CC
MZFOSA_;Z_:%&N:])X>TNZW:1I+-"GEGB:;I))[\C:/8>] 'SK^TC\=M5^)OB
M_4+Z\N?,GN'Y"GY$4<*BCLJC@"O"&8L22<DU)<W#W4SRR'+,<FHZ +FC0FXU
M.W48QNR2>@ ZFN@AM(I(9)7D"V\T<KQ1N,;=K!1DCH,DC/O69X3A$VI2[L[$
MMY';;UP!V]ZZ6QTU[R::W6,O+YP@^0'8H<.X&>PQ&M;16AR59>\5;G^TH;BZ
MF6&5GE_T=K=4.UCGYAQT&U0<@\9]J-2T=-/TBQGBO(8C=B12\S%FB"29*$J#
MELG/T ]2*VY-->\T&>RE+1G5I(]0A8,0L;.KB($>CL)%/NRGM70^%_"*-JL%
MEK*QZ7HD,$6^YN4)(N($,K,D8^9^2Z.%' )YR,51DGI?L<WKGA.WLXI&@!UF
M*$^=<K;Y2.WE< N)%^_A> #@+QUY-2PR&SAL](N;L6=K<QK<7'DA5BMI7&8F
MV]PJ[2V<\.W<5U.F::FEZ];WRV;2JS27DNO3R":,QK\\AC"'8N3P-Q9OF&15
MG5[S6?$]W;:M#<>5<:M-Y,\4<:!(;O(RHPO"D,KCVW>E2WU1I&-[)ZF)X8T6
MWL=0^SZ]IMK/<WK2VD,21+YBLHR9_EP& =55 1AB2>@KF]<T&R6^:2]%]#,0
MLT=W;3K/&\1&4D3?M;&/?C!'!!KUS4KZ?6-:TZ^DE2YTNSC:.7[1#'*4CLB
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M<216[$;Y &Z849^4JQ*X##-?B1J5JMCJ%Q;H[2)'(RI(R%"Z@\-M/3(YQ[T
M5J*** "@44"@"[UIRY[_ ("F_B/7K3ZS,BU:MEUXYSV/)]J_5/\ X)]R?\8[
M>!/^F?B6\'3'_+PAK\K;;ATQQSWY-?J9_P $^V/_  SGX/!/W/%-X,?]MHJU
MA\,_3]49OXZ?K_[;(_4&BBBD=(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML'(7  /)S\N5]=?M':C<3:'XD@NKAKS_ $=)7DE8EX4>[!MQZ98K,#@\!$]
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M02"K<#D=#Q4%(84#K10* +W3\:4<G_"DY/Y4X=>!]*S,BS:XW ],GTK]0?\
M@GNW_&..G G&SQ?=]O:WK\OK? =<\#OS7Z>?\$]?^3<8,GA?&-U@Y_V;>M8?
M#/T_5$/XX>O_ +:S]4Z***1T!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Y<VWPO?X]:KXKAO?BQI<\EMJMT;?2?$.D7=O=H"\GV
MB$S,Y4^2@Q$T1<'&&4<"OU&KXJ_:R^"/_"F_#?C/XN^$+Y8?)N_[<O=%N5/E
MO<.H@9HG!R@+.LK*0064C(#&IDG*UAG@3^!;#PKIZ>)-0^+'@?P]8Z?&DKZA
M9:;=SZG'"5"_)MD5O-((#(K8.6ZCBO(?A3>:;J7Q0^*]SH5Y/J6D78\Q+R:W
M^S&]8'F81;F,8.&."23U/)Q7$6OP[BTW1](UV35;?4]#E62"]EM=2C74+&\!
M8F%[-_GW$#>)5#(5<<@UZ+^S?X<\G1O%.HPPR6VGS6[PVZSR;[B92=Q:0XQQ
MT&/4UMA:?+.-NYTJ%KM]CQ;7@#JCDC<=YR?QZU>C_P!3&3STJMXB4?VI+M&T
M!B!S[U?MT'D19XY[\9KJG\;''8P=<Q]MB^; STQ7Z1_\$F?^1'^(_K_;%M_Z
M2I7YR>*H1'?PXXR.E?HY_P $F\_\(3\1R?\ H+VO_I*M<E3XD*7PL^\:***@
MY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#-H_M;6W4[A+JET
M^?7Y@O\ [+5@=ZS-#NA>Z7!=@Y6Z,EQN['?*[ _D16DN?2I6Q;W%QUYI#CKG
MVI?YTW%,0A[TG\J7[O'04E,!NVD-.IM AO'X4J]>E)3UXH 5J8>O%.)]N*C+
M'<* &MVXIG7O3FZ=O6F]Z!B=/_UTWC=Z4;1D]C01S0 =>V?2G <<<_RI M+0
M(=TYZ4+][WI?<_\ ZJ7@XH&02?=/T]:R;X94CC\:UYL[3Z&L6_\ F4CC=0!S
MM]\S'^M8MTWS$=2>/2MF\;YV]_PK&NOO'U[$U1 MB,L>W/./2G:DNY#D\8^M
M-M/O<<'''I1?.K!N,_+WJD!BM_K".WK5F$GCT]NE5N3QR>:LPL3[FD(NPGH>
MF>A]:O0\8XP.@'I5&/\ O#@YJ]#Q@^],"W&.>M3+^?H:BC'8_E4R^G?O0!D^
M+<_\([*.I,]N.N.LJUJJ.>WU]>*S/%R_\4_R<9NK<#_OX/RK86,=^#CN*0";
M=O?\*&Y&<\?UI^T*N<Y'K3'7 Z<>E,"O(>?P[UG7F!&Q]ZTI.AQTK,O&^4@\
M]^>*0T)M;*#V%785'K57&-H/H,^M7(U^7I2 D"YYZ9IX7I2*O;^5/7L.W6F!
M[K\#,_\ " Q9_P"?F?\ ]#->@UY]\"_^1!B_Z^9__0S7H-0,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFK?\ (*O?^N+_ /H)
MJW535O\ D%WG_7%__030!^3?_!2QO^+1^"AG_F9ISC_MU%?G--C<?K7Z,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9&#5.BK+/T"_P"">/BBRL?BJ^E6SQW"W"75H;Z"1S%<'!*NB%5V(Q3*@@$
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M?4'%1#J*=-*\\KR.=SNQ9F/<FFCJ*U$7NO/O2_B!V^M)RV._'!I5^HJ#(M0
M+@,>2>E?I;_P3O.?V<=6);.WQA-[X_<P5^:-NNTX^Z ?7K7Z3?\ !.@_\8\^
M(N,X\7M^'^CPUI#X9^GZHA_'#U_1GZT1_P"K7Z4ZF0\PQG_9'\J?2.@****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ.;.W/\ TS7^53TCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKPM_I7)^\.*L_P 7O4@6HL_K4WZ_SJ"$=NHJ<<+Z4 >Z_!'_ )$*'_KXF_\
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MZDU"\2[$Y@^<3HL>U$28GRQ%S(B@,P+$KX]9ZA;^'?$PNK>&SUNUM;AC$E[
MQ@N%!(4M&2#@C!P3F@#]T_@_\2(/BIX$LM:62$ZBF+?4H87#^5<@<CC^\/F'
MU([5X=^WIXT\*?\ "MW\+7#+?>+%G2XMHX2#]A7I(93VWKQLZ]"<8KX2^$_[
M17BGX1VYTWP3K-U-=:I;Q6]U=V\+;,E=WDQJZ\.A)!EZ\';\O)^^/V&?V/=)
M^,7A^P^*OQ#OH?$5C=32FS\/B0R(9(Y&1GO&S\[;E)$?3&"Q;.* /R>U[PKJ
M5K-]HDLYHHIU\^(R1,@DC)P'3(^921]X9'O7.D%201@U_2'^TA^RWX1_:,\
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M<K@,$4_WW7'2OC7]K[X!:[^Q'XBT?XE_#OQ--9V,EVT-FX<"\M'VLYBD'2>
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MM_(T ?DW_P %*./@SX17G_D:93^5J:_.*;D'C/\ GI7Z._\ !2@?\69\)?\
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MTY^TQK7[1WC-/%&MZO=:%HUI<-96_P!EMGGM]-5D9XTB((61W"CS-Q#'J 4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Q_Y:H!\A/WU&/O+\W+)<KOT,YQOJC]"Z***DP"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYJUH[3:3>0ZBBL;H6R1HR-S#D>43D=&Y./0#/I1%/9CG)-76_P#PW]7/1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \[\=1[->#?WX5_0FOC7_@
MHAX=6X\ > _$ZC][IFM3Z5(P'(ANH-Z@GT\V ?BU?:?Q"CQJ%I)V:,K^1_\
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M/>MA&W6\1Z_(O7Z5CWGW2>U:L+ V=OQG,8_&I <,9ZT\'\S4??)_*G*NXC-
M'O7P0_Y$2/\ Z^9O_0J[^N ^"'_(B1X_Y^9O_0J[^H*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\_P"/2?\ W&_E4U0WG_'K
M-_N-_*@#\H?^"EF?^%)>%AG&[Q6^1CKBU:OS<F(WG%?I-_P4L'_%D?#(Z_\
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M /016Y4K8ZWN%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\56W@?PY/:G[@?N^GKBK1!+(O3C@G XQ56XASTS5D-N49''\J23!X]NG2I:
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MHI* &D8YQ2'-.]*-OYTP&X_.F_2G]#CI^-&/Q% #**7CL*.G6F E'\Z/X:*
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MFUT^W'[FWC"+[^I_$\U>J2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *BNO^/6;_</\JEJ*Z_X]9O\ </\ *@#\IO\ @I@O_%D?
M#1.,#Q:?K_QZM7YK3]3@  ^E?I7_ ,%,25^"?AD=O^$M)/X6K5^:MP/F)[>H
MK)[L<_AC_75E5LJV/T_SUK-O.;AJTI-K,1SUSQ_.LRZ_UQ_#^55$RB,CE>&0
M/&[1N.C*<$4>8YC"%F* E@N> 3C)Q^ _*FT59H%?0VEZQ\";SQ%XNFFT^;3-
M%\^-;"&<7+SO9+;LCK;%&PMR\P1MT^4VD@_Q!OGFB@#T_P =7?PSN+?X:?\
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M>]GKC2\J9,^QKF(V^Z*TV8UL3QO\X/0_6IU8=2"2#FJFX=CGO]34JO\ -@G
MQBF!;1\@'G).>G-2!B"#BJR-GG..V.U6%QP>HZ52$R7=MY[>M.7+9%,2-I,
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M3X/^%9?&C2)]\=W;6WV."^FQS#=6WW$D<='3Y)0>A!JE<6GF1M&ZK)&PPR,
M01Z&B[D;7-/MM/U"4LUFGE:;J,N6DLU'_+%FZM;D_P )SL/S+C&*TC6^S/8M
M2[GUS\'?BM;?&CP&=8%HND:]I\WV#7M%&<V-V!G*@\^5( 60]N5[5]'_  C^
M&%GXF\)VFIWUY,8Y'D MH<(% <C!;J>GZU^9'P^^)5Q\*_B-:^+=069;611H
MWBZV)R9K-F 6ZXX,D#E'W=USZU^M7P(C:W^'L$#,KF*YF4.ARK N2K+[$$$>
MQ%5).+,91Y6=#IGP^\/:3M,&EP,Z_P#+29?,;\VS6_'&D*!(T5%'15&!3Z*S
M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,U\$1XSG/.:^]?\ @F"3]G^+*\_<TH_DT]:TMWZ,B>R]5^9^NWP[.? ^B_\
M7LM=%7-?#=MW@713_P!.X_F:Z6I6QU/<****8@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOQ4?#%];77B^2TL+:SB1Y/)MY;,P17D\;$8?[9YK2HN/E$$N<944<S#V5/\
ME.7_ .&R/&?_ $+?P]_\(;2O_C%'_#9'C/\ Z%OX>_\ A#:5_P#&*Y'X+W'A
M:*'Q_'XI33R)O"EZNEM?(Q9=0#1- 82/NR95@">,%@>M5?AMH_AZ;QAX(DN[
MW3]3$U[YFIZ3K4K:=9JD;@K#)=_, LJC:7P F[DCJ#F8>RI_RG<?\-D>,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFD_^#NR_^/5O> ?AWJV@>.- U/4;C1[33[*^AN;BX?6;0B.-'#,V%E). #P
M2>@%>7T4 27#"2XE93E68D?G4=%% !1110 4444 %%%% 'U!'8^"?C)^S?\
M"?P]-\4?#?@K6_"4FL17]EX@AO S_:;I9HGB:&"167:.<D$'BN7_ .&;O!W_
M $<'\.O^^-4_^0Z\'HJ^;NC!4W'X9?EU/>/^&;O!W_1P?PZ_[XU3_P"0Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L;Q5H8U[2WC4#[3'\\+'^]CI]#TK9HH \'OK,7MK);R+L?.,-U5A7F_BO
MPGI?BJSN-.UO3TO(G0Q$YVR*O/ ;T]CD>U>__$#P^;:;^U+=?W<A G51T;LW
MX]Z\R\1Z?O N4'/1L>O8T1;B[C:/ACQ]^P@[7DD_A#Q1:Q0MRNG:Y;M&5]EF
MBRN/JHK@E_8I^*AFP;/2[B+.#)9Z[;8//82 ?RK[[O;?S%Z'>.IS6=&QC?8>
MY[BM.=E*4EU/CS2?V$?%]XRQS7VC:&K9W7&J:J+PK[K#:1#/XO7N?P1_8@^&
MG@WQ-;W?Q O9?B&LN(UCN;,66GVDF>'\H.SR G _>' ].>/883NP0:T$Q(I#
M ,".0>AI.38FWW/I;0?#^E>%]+@TW1=.M-*TZ$8BM;&%8HD'LJ@ 5HUY5\+_
M !X8?*T/5)LKPMG<.>2/^>;'U'8]^E>JU!(4444 %%%% !1110!G:]X?T_Q-
MI[V6I6RW,#<@-U4^JGL:\4\2?LVW44SS:!JB.F<BWO1AA[!P.?Q%>^44 ?(G
MBV&?X0Z?!=>-[BR\.Z7<7"V<&HW=ROD&9@65"W.TD*W7CBM[P!XWT;QA'?PZ
M/KVF:Z-+:.*9M-N%G\@R LBN5Z$A20/2L/\ X*=*7_9WTW'3_A([/.0#D>7-
MZUX'_P $\YE75/B]:(JH&_L>YVJ .=LR$FH<K-(M6:9]CJ34R\]#5=:G6K()
M<<&EQSUI%[>]*/2@!:**#]:8"4C=O6G?YS1^&* &]J,?G1BB@!/K1SCI2[1U
MH_2@!*3]!VI:*0!_#FDYH/6CKGL<]*8"?Q>]'84OZ4M "8Z&G+QZ8]>M-Z=*
M>!_^N@!:/YTH_*CZ4 138;\JS[C[AYK1D'RXQ6?<<)U(- &)>_-61=+VQS6O
M>+U]ZR[A3R3V'-,3,F986:0W-REI:0QO/=74GW88$4O)(?HH)K\^/C+\2?\
MA9'Q0U7Q-<PXTJP,9M=/D.5"H"MC:X_V03+)_M.]?4G[67Q$7P7\/8M%C<&_
MUU!=7B>EDCXAB]O.F7)'=(3V-?#EM&US<I'(3,8G:XG;G,MPQZ'Z=/SK:FOM
M&].-ES':?#'PC-XKU^."^D>9'D^W:M<L 6?)W;3[L3^OM7M7CS4 8R@58E1=
MD<:]  . /PJE\/M$C\)^'"LFTW<Q\^Y?;R9,<+_P'I^)K'\6:@9F<EN 3P:R
ME*Y#?,[G :@Q:1N<D\]:J+UJ>Z?S),XQ^M,C7@>GO6+$6(%SSU]?_K59&>G4
M^]1)W.,>E3@?*>W%0,: ,\<5<LT_>#C/I5;&!Z=OP%7]/4F123W'O0MQGOWP
M3*V.FZ[=XP+?2K^8<=-MI*<_I73?LHP_9_V;OA\"02=+#GZEF-<;X3N!I'PE
M^(FH [?LWAG4W##J,V[K_-J],^ =C_9?P-\ VI&WR]'A/YDG-7$&8OQC;;HL
MXSSMS^-?*?'VPL#W)V^M?37QTNO+TPJ/O,>-M?,\)W7&,9Y(YI2W&=/8_= '
MIQ7G/Q53.@R/C.Z=5X^N/ZUZ/9_=)/3!K@/B);FZTFUM^K3:E#&O?.YU']:J
M.C0UN?MQH,?DZ'IR?W;:-?R45?J.WB$,$<8Z(H7\A4E48A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D_U;?2G4UONGZ4
M ?EA_P %,&Q\#] [G_A+P?\ R6DK\TIOO"OTK_X*8-_Q9/05Z@>+MWU_T63_
M !K\U9 =Q!&>U9?:?]="I;1_KJRMQCTXYINWCD8YZBI67UZTBKS\QX[T&%B(
MKN7I@],4SH3QQ4[=3]?I2;0><]N*!$/IT%)M&.@/UJ7;\W.:3RSSSC/O0!%C
MYL $CJ>*%.#V.#SZFI/+/8<=3DYIP4A5^4=>_?ZT 1;3D$GO@>E-V[V;T)YJ
M;:!@#@=Q1M'^30 S:>3@;2._->U>%?V./B[XV\/Z5K>B^%X[W3=2MDO+:5=2
MMU9XG&58H6RN0.A%>,JN3@GC]*^X[SX;Z9\6/@]\#M$N_&Y\$Z@-#W6"I&=V
MI$JF^-6WHN]<*0I.6W<>E;TXJ2=R)7ND>"^*OV,/C/X0T6\U74O \_V&SB>>
MX:UO()V2-!EFV(VXA1DG ) !..*\17:V=C(6Z_*0<<=:^W/"L7@W]CWQ%XBN
M_$'Q"\1Z[KLNES6=OX=NM$N8/M#MRKI([-&PR -X. &;N<5R/[/MU+\9OA'K
M?@/QUI%M-X+\-6XN;+QJBPVL^@S[N(3,0//5MQ&UB=H//&W#=-7LMPNTKON?
M+6GZ=/K&J6NFV43W>H7,J006D(W22R,P544>I) _&O>+;]@OXYW4D*1^"HS)
M(RQ^7_:EMD,3@*?GX.37>?&SXDZI\$?'G@GP-I7@F/0/ 7AB]M-8M;)8XY+K
MQ$R,2;EKH*68G<V$!P"WS#IB/Q9XU^!/C;Q5J?B*]M/C#:7NI3FYEBM/*CCC
M8\[57<<#(P #@=J:A#5/^OP9-Y?U_P .CY^\&_!?Q=X\^)4W@'1].B?Q3!/<
M6TUE-=QPI&\!*R@R,=O!'KS6K\/?V;?B/\4I-27PUX9DO8],NGLKJ>2XBABC
MG4X:)79@'8?[.>",]17T_P#"'X7>%OA_\>_A5XJ\(7NN2:+XMT[4Y19^( AN
MK=T1<EF4#.[?T.2,9R017+>,OMR_L>:RNF"Z$@\=W@D6RW[Q']H?<&V<[?N?
M^.T_9**O+S_-?YAS.4K+;_@-_H?-/Q/^%/B?X-^+'\,^+=.72]86WBNS LZ3
M Q2KN1@R$CD=NM2+\'_$S?"MOB,;& ^$EU$:6;K[7%YOG^GDYW[<]\8KT/\
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MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_O,U4?AOH@>\AFE7>(#O_P!^0CK]!S^-<9;R3ZSJTES-EI9)3,Y//[QCG'T
MKUSPC;+:K#&@^2,_FQZFMJC44HHWF[*R/0YKD+:^6&R ,DGFN&\17 +L-W0]
MZZ*:X*PY) XSSV]ZXK6K@/(1GOSDUS-F!BS,=Q]<XXJ6%3R>H[8J#G//XU<@
MC/3H?3O4C1/&IW8J55[#@]/K21IUR.U2JIZ _P#UJDH;M. >YK1TE"UP@_VO
M6J.T8Z8Y[5JZ+'^_08SSBD@/5/$#_P!F_LP?%:YY&[07MPP_Z:2Q)^NZO>/!
M%H=,\ ^&;0C'DZ5;)_XX#_6O OB@WV3]E;Q1"#DZA=Z;8@ ==]VA('X)7T9
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MX)U"ZAM+7X?>$[BXDR$B30+7)P,G&4[ &F]=V_Z^8)2Z)?U\C\2O"'C&_P#
M7BG2_$6AZC!::QILOGVTSB.55;!'*-E6&"1SZTW7O%E[XE\57WB2_P!0MY=8
MO+O[=-.BQQJ9MP;(0?*!D#CI7[DM^SKH+#!^%'ADC_L 6G_Q-'_#.NA;=O\
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MY%/VY(S^% Z]_P#/M4@7TJ1B 'OSVK9\/Q@W"YZ9Z_TK+1>1[C'K6YX?0_:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'IT[4O?%,!*0^].III@%)BEI* "BBB@ HY_&D]:/Y4@%S2-Z4N.F>M(&YH
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M?"?P\OA/X8^%M(48-IIL$;?[VP%O_'B:_+72=/;6O&?A[3E&3=7D4(7_ 'G
MK]=(T6.-44;548 ]!5HSD.HHHJB0HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2=MG,ML@]@(U6HYET':Q^QE0W-Y!9ION)XX$_O2.%'ZU^)FH>+O$^MRB6_\
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MZI_P5 \0R*?[/\#6\&>!]HN@<?7!->31_LXZ#%@3:EXAO">1Y(B0?F$-1?\
M#,=O<2.(+O7FC8@KYUO%O0?W5;(X/NM'O/8.9=CK]4_X*0_%&[W+:Z;H]F#T
MZL0/^^:X_5OVZOC'J'77[6P!Y_T>,CC]*U[7]DT74@9+37F!/W%GCC0'';"L
M?UKMM"_9;GTZTAM[7P?8MY8Q]HOU-S-(>I9W8<G/T ]*.63%SGS_ *K^U5\3
MM7)^T^.[H9ZB-A_(DUS5S\4/&.M9$GB?6KS<>1&6.?R4U]I6/[.NNQ8$=GI-
MB.S):Q*?Y5O6G[/NLK@3ZW% O_3(A?RP*.1AS,^!A:^+=8Y$/B6^YZE9_P#
M<583X9^+[[G_ (1S5'[?Z4^W_P!#>OT#A_9WADQ]I\07$G., L1^'2K\/[/'
MAN-AYUU<SM[@]?Q/%'LPYF?GM%\%_%#@^9I-G;@=3<7L0/Y<U=A^"NN+D2WF
MBVV!\W[]GQ_WRM?HA!\#_!]OR;.:8C^^X']*U+;X;>%K+_5Z,A_WF)JN05V?
MG9#\#]0/^LUVU0GM;V,TA_4BM.#X F3;NU35)B>HATY4_P#0B:_1"'POHEJ,
M0Z/9IQU*$G]35E+&S@XCM+:/C^&%?\*.06I^>5Y^R\/$&FR636VO7:RE2294
M@!QT^ZN:AA_8(M]44;?#-XC8P)3?S%OQPM?HSY[+)A3L/4;0!BHY))&8_,V>
MV235<J%9OJ?G]I__  3;CGY>/5+>,GYD:_?']":Z?2?^";^@6<ZM)YD4H.<F
M_EY_$/7VKNY!(RP[TQB.@..XI\J%R=V?+.G?\$_?!EO\\RPLY_B9RQ)[]CG\
MZZ.Q_8D^&UGS-I=C<G_:@+Y]>M?0/H.>:;S@G:<#G-.P>SCU/(K/]E?X9:>P
M9/"VF2-V9M/B)_4&NM\._#;PMH4UY#::#8)&;.3&8$&P@9!4@#!![UUKX^F.
M#5:#"W%\?2UD_'I2N^@_9PWL=-\!K2.WUC7?*B6%1%$"J*%&2S'/%>S5Y)\"
MU!OO$#8_YXC/_?5>MU*-&%%%%,04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&,G/:KMLH.,_RJK"O3D$9]*T(OE'I4C%U34?[&T6_O%7]Y;V[N@ZY<C:@'_
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MW#U!(.#WQ7I%2M@>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW>] Q>O3DTF1SZ4=.W%(WM0 A[_TIN1Z_7BE;'KUIN[O^5 "\>].XIOO0QH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^GUKT!$6-%1%"*HP%48 %.HJ1-W"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(O$LF.3=W46F0$^T< =R/K(*ZK1=/TOPW@Z#H&BZ%)C!NK.Q62Y/MY\WF/\
MB"*?WSCZ_P"%2[>W.<_>-%V/E78??33:I,);ZXFOI.TEU(92,=AN/ ]ATI-N
MU0?7N: O4BD?IG]>_P"-(H;(Q]3_ "KA_C!JQTOP'>A3B6Z>.V4#KACEL?10
M:[5^@ ''8]J\7^/6K&74-*TQ!N:)#=.H_O'Y5'UP#^=5%7=@CN?>7_!(WX;#
M3O!?C+QS/%F34KN/2K24C!\F$;I./0O(!_P"OT$KRC]E;X9?\*A_9]\$>&)$
M"7MOIZ37G&";B7]Y+GW#.1^%>KUK+<R>K"BBBD(**** "BBB@ HHHH ****
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M^T_@K ?I7,-I]I+)YMS&;R3_ )Z7+F5OQ+$TN9BO$_<+Q%^V!\%/#DCV]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW,*2W)Z9C4\BJMOH]C;MN2UB#Y^\P+'\R:OHGR8)X_NKQ0HE#UU:Y;F.R\O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_UTC&<>Y2MRRD75DWV96^7:69K%UG  ]0OS#\0*7*3JCV70OVK=8M65-?\
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M%GS0?IT'&*42>^/QJH9/_K4HDQWQ]*0%WS-PX%&^JOF$8YX]!1YF6.3CGUH
MN"3&![5*K^O/I6>LGS97ISQTJ=)/2D!=#_-G/M4BMTP<\\XJJKC%/\PGY0,G
MITS0!9WX]N<?_7K&\0>*+?P_&0_[Z[896U0X/^\Y_A7]367XA\8?86>TT\K)
M=_=>8898F] .[?H*Q]#\+RZG.UQ<N51FWO(Y)))]SU-+<?P[D2PZKXQO0T[F
M0+]U0NV.,>@'3\>M=IHOA^UT1%(59KC_ )Z'H/I5FWBBLH1# FQ<=NK?6I?,
MS]*>G0G?<D9CDECGZTUF8X!YJ-I.>O.*CDF"*26"@=<]*0R<N3P.365J&M"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^[_3\O\ ,\VT+X+>!?!B$Z'X.T>TD4<7$EN+B8^Y>0L<_2M+4K"6?"O(S1]
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M:4^%2>GB"%_^^4=OZ5^TE8RW,)[A1114$!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?F9^WS\8/$_BSXJ:CX*AU"XL?!FB^5;R65LYC6\NFC$C-.0<LH#*%4_+P3@
MFOTSK\I/VPI'T7]JGQX!'YT5PMD\T,@!BE5K9  1U)R.O:JBKFE-7D>N_LC_
M !5T"\\&^'?AE>9TCQ/I=M(NG0S )%JEOO:3]P>AE0,=T?WL#(R*^A)(VCSD
M9^O%?GII6F:5XDT7['-'*]O'*)8V\S9=6,P.4D21>593]UUZ]^]?17PA_:.N
M--N++PM\4-2C>XG=;?2_&#IY<-XQX6"^(^6.X/&)>$?/.#UQ:]GZ?E_P//[^
MYU3C[25U\3Z=_3S\NO3LOH!)@K;&Y'8UL:3K4FFR!6)DMCP4)R #Z5DWEJUO
M*RR1E67JI&#_ )]ZA2<QX!RR_K3.0M>*_AY;ZY&VIZ L<<I^:2S7A7[Y7T/M
M7E\T+PR/&Z,DBL592,$'TQ7K.FZM-IK[X&W1G[R=C5KQ!X7TWQY;M<VY6UU1
M5VK)T5_9Q_7K6B?-ON9.+CK';\CQGGIUHZ^]6M2TJ[T6\>TO86@N$ZJQR,>H
M/<>]5-U T[ZHMZ;J5QI=U'<6TSPRQG(:,\C_ .M['BNM2&V\73?;-(:#2/$6
M")(-H%KJ'J".BM[5PW^%.AD:)@RG##G\J16^YK36'VJZN(+>TDT_4(/^/C29
MCAD(ZF+/WA[<^WI6:&XR/ICWKJX=9L/&%O!::^S6U_#_ ,>FLQ<2Q'L)/[RU
M0UO3[FSOH[371#:W\O,&J0G-M>KV+$=&]QSZY%!.VG]?UY;^IA_>H_AST%/N
M()K6=H9XS%,O5.O'J/4>]19'4&J ?NQ[=Z7_ "*9G&.P[T?C0 \T*1Z_TIO3
MMS1US0 [_.*.PI,_EVHSVH =[4OYTS=T_2C\>/K0 _USQ1[=J;N[4*W.,T .
MSGMS1^'Y4W=^= (H =N!]S2[NO&!2=Z3GKGD]* '9]L&C/'8CWINXY]:7TR/
M:@!3BCL3GFFC&X"E/6@0O'/]*/<TE'7KQ0 >W4FEY["F^_;UHSGVI@+T[\TO
MM2<TN>"!R/K2 /8<#I2]1G'UI.>>*/PQ0 [CC^5'\Z3CUR*=TH&'YXI?XO0]
MZ!U.2/\ />EZ?X_UH$ __53OQYI/O?\ UJ5>H'2F \=??K4\?7\*@7U[5/&N
M><\Y_'Z4@+D.>/Y5<B; S6?"2OYU:1^_\Z0RUN '//K3&?OVSTJ/S*8S=2:
M$D9O7\*K2-UX.*DD;-0MCZ_6F(AD_P#U5%CMGVXI[?TJ,M3 1F_+T]:A=0WO
M4^*;Y>XY/7UH S[B(@XY_&J<GIS[5J21X4XZ?D?K63J5P%Q$GWV].U,"C<RL
M<A 3VZUCWDUPK;CQQVX%=#% (E.<<^HJG>6H920,C_/6J YEY&)RQ/3^*F+(
MR2*Z-M=6W*P/0U;NK4QL>I7UJFRD$]JL#PCXF>"U\+ZZ+RRA\K1]29GBC4?+
M;S=9(?9?XE]B1VKF8(_E'I].*^B_$&A6OB32;G3+MO+@N=I67O#(O*2#Z'KZ
M@D5X)-IMSI=_<V%Y$8;RV<Q2Q^C#T]01@CV(K*:UN9[:"6H\MAQD=*ZK0[X1
MLHR<_P ZYR"/##'TK3M6VLN#COFH11Z;I\PDCR#T'XUT%G>2  @GCWS7#:'>
M%AY9.#BNLLY-R@]^E6M1G56>L2Q$%9&0<?=.*V;?Q [*#*JR ?W@.?QKDH>X
MX /6K:';T/'K18+G;V>L1CE'DMV_O1N<?7!J]]JEN(\$PW:=A-&":X*.X9#V
M/O5^UU(KQG H#<Z.:QLI,^;IPC/K;R%?Q JG)HMBS'R[F:W/3;*@(_,4MMJ8
M("YR?3WJX)5F4$\YX% 6,IO#+O\ ZJXMYOJ^W\.:IW'A^\0L3;/CL5&[^5=
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M^]ZCWKBMIZGIV-4U8F+N.CRO(X/ZUT>B>*%CM6TO5;==3T>7A[>0?<_VD/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIS(O%=!(K)<WY;EOM3KP,=,#'TXKC?C!?+9_#VZA=@)+ZXCMXE[G:0[$>H
M_.BL^:4C3J>"W%Q)=93)CASQ&.<_6M+PWX8O_%6I)8Z9;^;(?OR'_5Q#U<]J
MU/ _@&]\;7AV'[+IT9_?717(_P!U?4_RKWS3=-TSP?I)M+*)+6V3AI,99V/<
M^I)K-12U9S:O1&7X,\ Z9X)A$D>V\U)P/-O)%&1ST3T KO\ P'X#\4?%GQ)_
M87@W19]<U%2IF9/EM[4'^.:7[J#GOR>P->]_L\_L+^)?BPMOKOC?[7X/\)2
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M<D1^,7YV_P#(+MQG_P C4<\1>SE_37^9]"[>G'7GKD4A7U'>OGQ?^"@7P88
M_P#%7+Z@Z7"3_P"CJ<?^"@'P8 SN\7/GCY=*A_K-1SQ#V<O+[U_F?0!3VI=O
M7UKY[/\ P4$^#.<"'QE[M_9EOC\O.IO_  \"^#G_ #Q\8^X_LR#\O]=3YX_U
M</9R\OO7^9]"!><#F@QYZU\\?\/!/@\4_P"/?QA_X+8.?Q\ZI(?V_O@[,V&3
MQ?!S@&32X6_'B:ESQ_JX>SEY?>O\SZ"VX/&3SZTI4>[5X<O[<WP4DC!_MOQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQIB^'=%B16&D:=YI8G:($X'OQUJ_&N[:QV*&PV[;\QY_04NV1E;S%**7 *J
M6V\\"GRKL3RQ[&;>Z+IUQ;R6S:59LC_(5-N@)SZ<9!&0?PKRGP-X?T[6O.2[
MLUG,9P,-L[XY(KVE59ID8N=AD4#S&R,9QDD\XKR#X;J&O+M& (5VR.,?>X('
M?FL:D5>.A/*K[&V/!&A[6VZ:4<'@-(3P!_6K">!]$7:?L*L2.BR-S[''05M&
M,R222 L"H.[WR:E"HJQ>4PCZD,O5CZ>_XT<L>PN6/8R5\%Z)"V6T^.1<$$"1
MNIZ8Y_A]>F:E'@W1HU11ID<C'< 0S$''?K6S&XN) 2JJ?XF8<+[BA58QHI#
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MD.W=\^-OS*5P,9X'?\J;M+Y1"Q/IG:3P!@\<Y_6D/E78Q+SPWI)4#^S[1"P
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MS;ZD#Y1_O+QZUMW&E^'?%UF3<6]OLE!_?6Z+-"^1U*<X_ T)0>UX_P!=F/\
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MGF70+,Z%=,N&&6V1^F]A3Q8HN?,N!QU\M<UR33>);U?WEY8V SR(86E<?BQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9T^T*[8$A;IGZ?C3X]0CDM96:)5R^ I)_#C&,#KDT(-25F::$Q1/YL>25W'
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M02!T [C%3(J^7N95+,A(8\'CT]JT0 =R!0#QC(9L\DGD<4J.RR84>:2/E4=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,)_>2^W<#U)_4FI? WPW_M*6!KP"VL5&!$OR[@!@ "OH3P_#;Z;:P6MI"MO
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MOE C=0!D@8P1VQ5:S_X\P!ECGF-#EL8Q^9-3H8YH0\>2I(#;N#GW]Z98WQ4
MO@Y IQ))?9*XY^5#T/IS7$^&;=9KQ0Q8,S_=7@Y]/I7;^,&<^%-+M]O[GSKB
M<MC!!PJC-<KX3^69F3&5##D=,BN:7Q&3W9W,&U8650!$PY=<8#+T_#MSWI3'
MYD+;D)8\-&<[AQZ>M65400PJK0Q_:%\S;N&Y1C'S#/R@D9P>2,FJ7GB&?&_)
MD4[BQ+!C_?&._P"-:@+/,R*GR;LJ3AP!G'5AC)]LFJEPCR,&\UH9IH@!&4W$
M _WN>NWO]*FW"YC,B[AC/RJ0-QZ8R!P*@ \D']XCR,,@(,N3TY/3C^E,!C/;
M0^://8!E$*LRCH.0/4?7J:9-<":W5Y$989E"-O)1<@\ #IM"_J33X6,<2@%$
MVY)VX+;ONL<@=357=#M,:J?+64%H6)(0^Y/)/< >E(9,UTMTVZ>3<WF':J@9
M&>!T[^WO4=Q(EO)(/)V$@J[$DDDY! .> 1ZT) T<?E1J$)R0S$!NN>?0X].H
MIMPX:3?*50K_  J,A^.@/>@"63$B227#-<3!P^YF&1\N% '?& /H*AV_9E6/
M@%>5P^$5>Y_/\ZF9VN%$QC:[53NC4C[W(!Y]*A8I]H"Q%'&<(I8_*,8XIB!9
MEC7Y%\P-\PDA;!()X//&*-K-(?."8P2& !">P/3Z^]+,&C78S*K*"P?;R_8*
M0?2D0<Q&1@X/R[B<D<<@ <?C0!+(WEJS%F(1%!VC(;'09%1S,VT;D926W.X
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M,4NWKUXP?I2L ([QGAY%;'\+D9J2.\N8_NW,Z$=-LK?XTPJ>I7/.?6EV[6R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M95'(/J*\N^T2\<G_ +ZH-Q*W4DG_ 'N:OVI7-$]*D\1121K$\NY?XV&/F_\
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT;X<_!/Q%\1M2-GH&DW.IR XD:!?W4?_ %TE/RK^>:S<DC"591V/+]-T.-7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_;0D?I7KEO;Q6D*0P1)#"@VI'&H55'H .E244A!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#R+XNZ;]DU^SOU'R741C?_ 'EZ?H?T
MKA_7L:]D^*FE_P!H>$Y9E&9;-UG7UP.#^AKQI3W'2J0F)CO_ "IIZ_K4C#/O
M49&>U,0B^W2N:\:?+)I'I]NML?\ ?RNG51_^NN6\=9_XEN,C;=VK;NW^N'%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#&NOKWK.DSS_/%:-TOR\^M9\W.3T]ZH"E,3QGK["HOU![5,Z[OX<'O4/\
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MJIJ7_'J?7(R?Q%2,^@[/_CTA_P!Q?Y5-4-G_ ,>L/^XO\JFJ0"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2>M*<;3]*0Y[F@!LG"^U9UUT/-:+_<-9]R.".O.!BF!CW*_*PK-D^8GO6G=
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M6>2PSUJKJ7S0_BN!^-2,^A(/]3'_ +H_E4E,A_U,?^Z/Y4^I **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX_7VI?I36]N:0";?Q_K3?KSWIWU'&/\ )IK?3O3$'7J,'\Z;FES^-+[_ -*
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MX_R>U AR^_4\>U'//'%(O/Y<4@SP?Z4 .R<^M"\'Z=Z3V/ [ 4N?\F@ !P,
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M>U-7M^?M2 G=_/- $F?7FDX'_P!CVI#CZ4+GO^- AVX]>I[TOZD4S^+WI?\
M(S0 HZ\=*7^'CK2>N1@T=_Z4 .XH[CN:;ST[_6G#M]>* '#L*/3M_6F^E+Q_
MA0 _/H>*7W[4S-+D\T .'7.:=VYIG3O]*7.* 'YP?6ER<_A3-V/Q[4N<YSP,
M4 3*WX4R;IBE7WILW3U/M2 JC[PQUJOJG^I7(_B7^8JQ]YL]*KZE_J5&>=RC
M]14C/H6/_5K]!3J;'_JU^E.J0"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;*3BEC^;Z?6DEYSC\:D"!1\WO574>(0.AW+_ #%6E&6Y'/TJMJ6/*4'NZ_\
MH0I#/H1/N+]*=34^ZOTIU2 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/6?^0/??]<'_
M /035RJ>L?\ ()O?^N#_ /H)H \!'RKQTK!\>_-X6N^,_NYAR>_E-6\IXK#\
M=+GPO=CK\DA_\A-5H3V-;2/FT/2CS_QY0?\ HL5:/7CI[=JJZ'\V@Z2W;[%
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M&?IZ4P,ZXSR<'TK*N2,UJW/TK)NL],TP,^XSBJ;9Z'\JMW#=">1Z53?KCK3
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MAG]UU/[U?_0A2&?0J_=%+2#H*6I **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %,F_U+_[I_E3Z;)_JV^AH ^>9/\ 6/\ [QK,\1@G1Y0!GYEX
M_ UIRK_I$@[;S_.L[Q!_R"9#_MK_ %JT)C?!NX^#=#PW'V*/&T^U:S8//KQ6
M1X+X\&Z'C_GS7^M:[>O6I*$_GC&,TW^7:E/&,4GX4P$'Y>F*9SGU-/IG?IP*
M0@&#GL:4X'3K0,MD_A0><]J8";?>FXZC^5/P<#UZ4U@>E ##_P#7I.-P]/\
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M:CZ]*KWV=]OW_>I_Z$*D9]"T445(!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!X!KP']NZE_U\2?\ H5<]
MK2;=-NB!U3GGT(KI?$2%?$6IJ1M;[0YPW!QGK6#K6%TJY+=  /S8#\JH3,OX
M;G=X-L_^NUP/RF85TGZ5R?PK8MX'M"1M/VFZX/\ UW>NL_E0,9<6T-Y$(KB&
M.:/<K[)5#+N4[E;![@@$'L15*\M=0D\2Z7>0W@73([>YBO;-ADRR-M,4@/JI
M!!SV-7_P-'/'&<4P,^+4]/UC5-5T8JLUUIAMY+B"900-XWQ2+ZX(//8BG7EK
M?R>(]*O8;P1Z;#!<Q7MHP/[YG"F)U]"K#OV-7X5BCNOM'E(TK;5D?:-SJIR%
M)[@9./K6-I:7GAKP[J$FJW;ZD;62[O%F1?WGV;)D2,CNRKE?3@4 6(]4L-5U
MC5=#95FN]/2WGGAF0%"LF6C9<]<,O7L13-3T_4;CQ)H&H6]_Y%E:&X74+-P2
M+N.2/"$?[2N%.3VSBKFE75KJ5K::K:HLD-[;13I,% :2(C>H)].3].:H:-:W
MNAZ9JOV^\;4PEU=7ENR@^8EL?G6$YZE?F [8Q0&WD.A\064_B>_\/*SC4[.R
MAU!U885X9&9 RGOAEP?J*U8I6M95D"JQ')21<JZD8*D=P02"/0UGZ+J=GXDT
MC3-;L0LMMJ%FDT$Q4;S$WS;2?0'.1TR#47AW2;^RO-<6XOSJ$-]J<E[8QLIW
MVT+HN8/<!U8C'9@*/0/)GA_CCP#\3_!O@W6_ '@71M-\>_#K5XVATNWU*Y$.
MH>' T@D$0=F7?%%( \4AR4P/3GUOX,^$YOA3X.\.:5>WYU?5K.:34M6U#<7^
MU7T\WG7#@GEAGY03UQFKW@_Q1I_COPOI?B#23(]AJ$;/")!AQM=D96'8AE8$
M>HK5QVZ ]JQC2C&7,OZ]#MJXRK5IJC*UD[NRU;VNWU?Y[N[U/*?"6AP1_L_Z
M[X(;3)]8_L:X\0:-=:18?+<WDD-T][$L/(_>/'-#(#W..:\G\7?V?X5_:R^
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M/K56[_X^+/\ Z[Q_^ABD!]"4445 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME0 <8Z'KWI?3'.:;S2]!T H #SGTI%'MS2_2EQ[9H 3 _&C^7:E7"\=*.G-
M ,__ *Z7^(G%';U'^<TO^- !CCI1QQ@9]J,?B*& X(_#WYH 7V/TI>OI^%)W
MYX'TH Z\T +FEVG!!ZFDYP.>:4=L"@ S2^^<>U)G-*O;(Q2 D3IBG8I%.*4\
M\=_I0(09!)JK=?\ 'Q9Y/_+Q'G_OL5:ZU5NO^/BS[#[1'C_OL5(T?0E%%%2
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2,H=2K ,IX((X-+10!Y]XQ^'=KY$^HZ<RVCQJ9)(#_JV
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M_#C(I>O2@8GIZ]*,]_RYI5]^30M A<&E"_C1BCCG% Q#V_*A<T[ICB@=CVI
M.7Y:<S'K2(N.G Z4XCB@0W[U5[K_ (^K+'_/Q%_Z&*L^OTJWX>TI]<\4:?;*
M,I"XN9CV"*<C/U.!^=2QH]OHHHJ0"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC-,H=['I28Y)Z#'%'U-.YSR.: $5>>@HP#[XZDTO% ]<?I3 ;@MP<4\K[X%
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M:GF8]#OGNI&8C(&#QMXJ/:LA&Y5<=1O&?Y]Z;_>]<TJ_-CGG%(0^;_CUN?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEN$B)_U, *K#&/\ =C"CZDUO7%BT=A;&/*G[0O*\<;)*SU>J9ISQCIRI_?\
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M^*/@P8Z7N>/9&JZV<<^E5?#0W?%3P>/^GMS_ .0WH ^IJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?K7?50@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGW$8YXHZ*>.M(,T4B@[^]9^L_<L\\_Z5_P"TI*O_ ,76J&L']W9]/^/K//\
MURDH$1>'_P#CZM/3RSVX_P!1#71#.?:N=T#_ (^K3.?]63U_Z80UT*GYAZ_K
M0!EZ]_Q\6O\ NK_Z.CJ3P^<PS\X&8^ISGY!4'B XN+0G^X,?]_HZFT'_ %,_
MJ/+[_P"Q0,U%-.IHZ\THY]S0 -FN;U*X2W\8:&TC[$+NNX^IC;%=&QZ8'_UJ
M\9_:8\6:AX#^'6K>(M+9$U*PC3R'D4,%,CK&6 ]0')'N*"HZM)GM6"IYX(I.
M_)KQG]DOXO3_ !8^%K0:K<FZ\4^&9ET_49W^]=0N"UM<GU)4,C>Z>]>S^^*S
M3NKCDN5V$'';\Z-H92",B@\4H[=J9)GW=N._*UB7EOMR!R*Z>5!(I!K*O;?Y
M2".@S0!SVT@GM1[X]ZGFCVM[]*B(_P#K4AB?7IU%.]Q31P22/?BO/_B[\4+G
MX7:*;Z'2EU264;;=)'*)OSSN(YX'.*948N4E%=3T+K]T<4FT?W1_C7RUI?[<
M%SP-5\%VTG]XV5ZZ'ZX8$5UNF?MI>"KL*+_1-<TYCU9!'.H_ $&C7L=3PE3I
M9_-?JTSWGZ?E2,O .3]17F>E_M._"_5, >)VL&Z;-1LI(_U (KL-)^(7A'7U
M!TSQ9HMX3P%2\5#],-@TKHS>&KK7D?W,V98R=K*[1R(0Z.A(9&!R&![&O1O"
M_P"UM!X.U[2M ^)(73=-U206VF>+N%M&G[6UW_SPE/57/R.,\J1@\ T9C(5A
MU 8>C \@@]Q6?X@\/Z9XKT+4=#UJRCU'1M1A-O=VDG1T/((/\+*<,K#H0#5H
MY=C[G219$5T8.C#(93D$>M.K\MOA%^TMXR_8<\;6_@'QU<WGC+X5W(,FD:D0
M9+NTMPV,Q?WQ'D"2'.5^\G!VG],O"7B[1O'GAO3_ !!X>U*WUC1=0B$]K>VC
MAXY4/<']"#R""#R*>VA<HZ*4=4S7HHHH("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\2_^"C7B":S_:^^(=RBHYM6TFU8-U\IK)6&/^!!OSK]M*_"?_@I
M!?36_P"V-\3 ZG[!=_V?"7XXDCM(B/RS^1J9;"/-?#_B2UUB-GMG9)$ $L;
MXCSTRW3G^=:&J8.EZBH&"\#$C& 3CK_]>J/[..O:3I4GC.VUD0W%C>6EM(;:
M=0T<QCEW?,#Z$@UU/BW0+'2]!U;5].N9;O0HU>&7SVW26DF2 C/UD+ %LX&
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M^O-*>II.AI#T]:0PSS5'6/\ 5VF>GGM_Z*DJ[_$>U4=6XCM#G'[]N<_],I*
M&:%_Q]6O;]V<8_ZX1"M_^(9X [U@:$ MU:^GEG'_ 'YBK>Z?6@1F:[_Q\6G/
M\*_C^^2I- ):&?([Q]_]@5%KG_'S:G_97_T<E/T'_57'/>/_ - % S5'MZ4J
MXI,^_-+_ !'-  Q_ U\\?MN6\UW\!?$T%NRK,XM0C-Q@_:8R3^6:^ANF2.U>
M"?MC9'P7UP^CVN??_2$HZ ?FZVAWMJTGF 2!NIC;)-?H_P#L#^,CXJ_9GL--
MF=FN_">JW6BMYGWA Q^T6^?;$DBC_=KX/O-FYP<\FOI;_@GSXG&G_$GQEX79
MPL>N:.NHQ)G[UQ9R?-QZF&5O^^:RV%%O9GV[VI<Y..U(5_7I1G.:LL#106Z=
MZ3\:!%/4 ?+)/2N;GY)(P.U='J3B.$]B17.2=Q4C&J,JN!2[>H'4T]5&W'04
M[C..OI[U0CR[]H;PN/$GP[NBD>ZXM3Y\9[\=:^#[Z$QS[NSCFOTL\368OM!O
M(&"L'B92I'J#7Y[>.=,^PZI>Q ;1')D#'13S_C6D7T.JA)W<3EU.>OZ4N.V,
M4U3C_P"O2_3\ZT.L9(!Y:@+AESN8GEO3CMBO9/V4?B$W@SXE)HUQ+LTGQ(HL
MI-S +%=+DV\G/3)+1GV85XYV^E1'>K*\4ABF1@\4BG#(X.58?0@&I:NA-75F
M?J4K9&<,,<?/U^E/V\<9%<Q\.?&B?$+P3H7B2/&=3M1+,JCA;A?DF7\'4G_@
M5=1]!]*R/,:L['S%^V!\!QKEC>?$GPY:L^LVJJVOV5NN3=VRC'VQ5'66,8#_
M -Y!GJM>>?L9?M?:E^R[XP6WO7FU+X;:Q,K:I81_.UF[8_TV >H&-ZC[ZC/4
M"ON2&1X)(YH\"13E20"/Q![8XYKX(_:H^ J_"CQ*OB+0+01^"=:G8+#"/ETJ
M\;+-;GTB?EHSV^9>PK6+YM&52DH_NY;/;R_KI]Q^V^@:_IWBK1+'6-(O8=2T
MN^A6XMKNW</'+&PRK*1U!!K0K\@?V!?VS&^ &NQ>"/&-ZS?#G5)\6UU(Q8:+
M<N?O>UNY/S#^ G=TW5^O<4J3Q))&ZR1N RNIR&!Y!![BI:L*<7!V8^BBBI("
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OP^_;LL8M;_:V^*,,K+',M];"&1DW&,BT@R0.AR,
MBOW!K\3?V_(]-TC]LCQ^+6XP+C[%+,96X%RUM'N4?\!"'\34R)DKZ'S'#I<N
M@WL@@46,]X!$T9;=!/ELJJ-V?C)!XKM+77HM4\%ZKX=E=X[J_82M:,F"-F7(
M//)YSGTR*58X+R(VMY&)(&5E*GL",''<'&>E4K7PB\/B&PO#<*\-D_FP2=)
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M./D',DO/=5P>QKFOVSO&VL^)/B5X,^#NF/\ 9+77(/MUW-(_EQ7"B1E6)GZ
M#86P>N17Q9XT^!FI^$=!U6VEU?4+'Q$VN[H;F&%426S=2?WLK'*.C_*%^ZR8
M*G-1+F^R'M*4&HSW?]??Y'O>I?M=?$WXB:M%H^E:]:Z)>W<P@MK*QMUADDD)
M^51+,.">@R1FO@?]L*^NK[X\>-;B[GEN+P:]-YDLS;I ?)BV@D>@&!]*]:\!
M_#3Q%X;TK7$N?%$U];ZG\LFDW S$\B',<SMSRI)(P<Y)KR#]K[3;B#X^>,+A
M")(+JXM5\H EMXM(CN_')K-<WV@E4C*SB]/2QP_PYU34M<\066@0".>:YW+
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MTOPG:-->7"J5_A) _P#UT[I;CC"4W:*.B8A5W$X'?-<5XT^)VE>%[5S-<H"
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MVB-?_9K^(B>)M&C:^TNY"V^M:.S86^@!X(])DY*-[E3P36DES:H[]*\$UO\
MUH?NI17.?#OX@Z'\5/!.D>+/#5ZM_HNJ0">WF48..A5AV92"I'8@BNCK(X H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^1_VCKU;[XM2)]D6:"/2X[:19U!2?$A9E7N"-PZ$&N<@UC3]<TO[
M'JME-J>F0H8WMPJS7EFG(.S</WT6.2IYY_&O5?B/I-GKGB+68+V'SH6GX(.'
M0@#YD/8UX[X@\#WGAF47T4\EUIZL"E_&,/!Z"4#H?]H<5&J=T9R46G&:T?\
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M"=K#NI(K\S]5T?4O"^N:EHNLVYL=9TRX:TO+8_P2KU(]01AE/<,#7ZN'Y@>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^??
M%DF_Q-JY)X^TL*RXI#&6*G[PVLI&00>Q'<5-XDG+>(-5;J!<N3CG'-9R7 ;
M4YI#,#7?A_%<*9M! MYB<OI;'$<A/_/$G[K'^Z>#7YT?MXV_V3XF0P2^;%=3
M:+92B.8%77RGE1E(/0@$=/>OT\1N<Y^E?"/_  4^T$ZYX\^'UTJ*UZ_AF>.*
M0ML+&.](^8]\*^*3M8S:Y?0^&_#>IM8Z]8QF>2WM9[B..?8-Q",V"0/7G->S
M7>A:GH<P6Y@8PLJR)=0D/'L9F5/,(X1V*/A#SQ7B-E:&SU/3[R=W^PB9&>ZA
M3+(N1S@]&]">,UZ_'KL[> +'_2@UK?\ B6QBC5?O'R()6D7/H#+&">Y)-9=1
M_$KG#:E,8;RY1AOGDF<A1R>O4^@]ZSKB.10=SC/)*H.*GAM4L803S=*#YTW4
MNQ)8_@!@54N6\N)I'DPY_GV %6!T/@-8?^)F&.+@QIL]-F>1^>*ZBS<88?G7
M$^$?DUQ #@-"^1G&>,XKK;$MYC \@TGHR)'1Z>P*@]<'^M=EI?W5P<$'KBN&
MTS]<UV^E9Z\=:L$>G>!QBZ8]%^S3?^BFKO0"WEMV,P_G+7 ^!_\ CX8]3]GF
MZ]_W35WH8_NL'/[WIGC.9:HI&U8L-H&>XK1B;G.:S+)L8QSSD5HQL H('/OT
MH+)\EFZXYJC>?\?"_4"KBMN<<?6JMYS,HY^\.#UIH#4TG_7*._3'3%>@:8NV
MWD)_BE8\]\@5Y_I>/.4=1C'->@V>1#[$YXX]*&(M\LO]:;_#35?TX%#?C^%(
M8B]3SC%4-8;]W:^\[#V_U3\5='.>>>_O6?K6/+M#_P!-V_\ 13T &BL!>6W^
MZV?KY4=;V?\ "N<T1O\ 3+4YP=C?4_N8ZW@W3\J ,[7F'VJT]E7_ -&K2:&V
MV.X^L?\ Z *A\02?Z1:XZ[%^O^M6FZ)(%AFRQ(S& ?\ @ H$;1DZFE,P&>>.
ME4?//7//M369CQV^M RVUR,8]LUX7^U5IK>)OAKJ&EI,MN\UQ;.LC+N 9)0P
M!'7!Z>U>PW320J>#T!KQ3XV:@\T$5N3A6D4D#V_^O28=#@_V<?V5-#U>QM/&
M/C'4;/7C$_F0>&[)R8;9P3@WC'#,W&0@ 3'7-?4^I>(;:QC4NR1JH"*HP$50
M.% '08Z 5\AZ/JVH>&]2%[I=S)8W'=X^%<>C#^(>QJE\3/'7B[6K(O8,H39F
M>*'(E]RN>H]AR*CF;T'1HT8RYI2U??\ )=+?=YW>I[)\1_VB=+\,QR1I<I+<
M'I&C9;/T[5\N>//C=KOC"25%N&M;5ND<9^8CW->?7$DUQ(TDC%I,DEFSGZ'/
M>H?+['C],5K&"W9["E&"M37S$DE>;+$EF/4L>:9Y>U<D8/2I]GTZ=QTIR*5.
M<G/IWK8SNV]2MY97 (P.Y[?2G*F[T&>A'2IR!&1D[0.<YJ6*WDFXC3=SC@55
MRO4A50IX7D<4N N1G!.:U;/PY-,!YS[!G/!ZUKVNBVMKAA&&]SUJK,=^QS=M
MIMS=?ZN(A?5ZV+7PSG:UQ)YG/0#''O6R L? &/:AIB.G4\>M59%<K>[$AL;>
MU0!44GZ9-*\GEY&,>V*CDF"KN<[1VSW_ ,:[GP3\$_%GCSRY;2R^P6##/VW4
M,QKCN53&YORQ3N*=2E05Y.W]?B<)OW9;/N3_ %KK/A_\--?^(5]'%I-HR6F<
M2ZG,I%O"O<Y_B/L*^A_!?[+7AO0_*N=;FD\17"_-Y<HV6X/L@ZCZYKV.TL8-
M/M8X+:"*W@086.*,*JCT %9.2Z'GSQ4YZ4U;S?Z+_/[C&\(^$-/\$^&[/1-.
M1A;VX^:5^&ED;EY6]R?RZ5L>7N./O#/-2GFF[<C&<BL'J<J5E82,84 #%6%[
M#H:B533\<?E2&2?7KU^E.ST(SBHE;TJ1.Q- $JJ<^C9X-*\<4J217$$=U;RH
MT,T$HRDL; JZ,.X*DBD'?\Z7C^M >I^;7QK^#[_!KXD7_AU3))H<J_;M%NG'
MS2V3,0$)_O1-F-OH#WK \'^(=8\#>*-&\1^'K@V>N:/<K=V4Z]!(O56]5895
MAW#&OO+]H[X2K\6/AYBW0'Q!H+OJ&F,>K*1B>#/HZ#(]&5:^8-#^%T7DQ33$
M,K@,OH?Q]:ZZ<746AV4JC<>7=H_8/X,?%'3_ (T?"_P[XRTP>7!JMJLKVY.6
M@E'RRQ-[JX9?PKM:^._^">_B"+3=/\3^"XYA)%;NFJ6\8.0F_P"23\V53^)K
M[$KGJ0]G)Q.:<7&5F%%%%9D!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5YW^T+\5O\ A2'P5\7>.%M!?3Z/9&6"V8D+),S".)6Q
MSM+NN<=LUZ)7S3_P47NS:_LD>+T56D>XGL(0BXRV;R'CGZ4#6Y^?&N?M4?%+
MQ5J'VJ]\3BQE,GF?9].MU@@W'J"!DD9[,3FO<?@Y^TU8^+7BTGQ,T.C:\WRQ
MW(!2TNST /\ SR<_]\GVKY1^)'A.#X>^,+708]>LO$WG:;;7TFHZ>N(([B6,
M226BG)WF-6C;?QG?R 1BLJ&; "2_.G^]\P_&BR:NCO\ ;<RY:D=/2S7X:>FQ
M^HUI>ACM=2D@'(8=O6ODO_@HQH]YL^&?B*&UE?3H8[_2KB[ !2*=Y(YHHV]"
MRK(0?]DUC_![]HW4/!<<.E^(&FUOPZAVQ3J<W5D/]@G[ZC^XWX5L_M\^/(-6
M^ W@-=(O(-3TC5-:NK_[1#\P9[6TS&C#JK S,2I]*E[69SU:-ES0=UW_ ,^S
M_I7/B^^T2+4E>6U(@O<<-CB0@87>O1@!GBN4UBWO='6VCM0UH+.Z%\+%FS%-
M)@)YB-V9@H_=^G2M;P[XK75)!!.K1W(1GW("05&23@>@Q76[HKM8O/C20QN'
M3<,[6[,/0^]0<=G'8X77'A&H7;JA6)]KA&X*AD!QCUYQ7--:Q1LMP6:8C[H<
M_=/3I75>+DW:_>QLQ;.QBV>^T5SL\*PP?(1N .W<?RIH9T'P]ADU+Q-;1HGF
MOLE9E]$"\G^5=TNGFWF;:IR?:N7^ NL6>A_$'37UBRN=0M;BWNK2<V=QY,Z>
M9&0)8S]TLA&=C#:W0^M>^:UX;L(+$:M97%OJ6A3MLBU6V0QQ12?PPW,1):WF
M/]UB4;JC'I4NU[&<K[VT/-K)=N>,<XKL=)<;5].#67J&C_99.FT9[>ON.U6M
M.E"X ;GTJD..IZSX'?\ TH\$#[/-GU_U;5WN[YD'0^:._O+_ (UYIX'NA]HW
M$X7[/+RW_7-J]"CF#E/^NO7_ (%+5]"S?L^0/6M*-AU!X'OTK'M9"RC!R<]:
MT8I#C/7W-!9=5OF6JMXW^D+QU([4\/M=>3G//-5]08+,.^#WJD!L:7(!-'WX
MQ7H%BV+=02>>17FFES#S$.>A'->C6S[88^>,<T,1:W;<'.,T-*!GFHO,^;K4
M;.!GTH&2L_S&J&M2#RK3O^_; [?ZEZG:7YN36;KDO[FTP<?OF/\ Y">D!)H4
M@-U:#_IF?_1,72MYI &QGWKE-$D/VRW&?X&R#W_=1UT&6=Q@&@1G^(Y@+JUY
MYVK_ .CEJ/P^QFCN, DAH_RV4SQ) ZWUBIZLJ8X]9U%:OP_T[[1974C#/[V$
M#KWA0_UI7"Y9M;.21P,<;<ULVVD=\<8[UL6.FQ+]\  +DD\ <U'<:U90[TM0
M;V3.W;#@*..<L>/RJ'($FRC-HJ3*HVGH,>M?/'Q^T:/3[RVCWKYTCY\L')4<
M]0.GTKZ)NKJ\NH<2S?98F&/+M>./]IS\Q_#%?./QTV07MLD2>4BYX')'X]_K
M2YM;"MU/)4@=Y!%$C2R,3B-!DGC/;V'Z5A7VNP6VH-96]O>:K>+")W32+=KW
MRT(R&8QY[>E7]5M/[2T^ZM&DE@6>,QF2%MC*#UP?<9'T)K$UJS\96L=G'X.\
M8WGA"&RN?MBQZ6?(WS#(61G7#$JI*@$D 9P!DYG7H%XKXORO^'7\#-OM,T'Q
MQ=21V]T-.UO;O6.XB:&68=_D<#?CN!\P]*X36- O-#F6&]A\MGR8Y%.4E _N
MGU'IUKK+[0;O4=#U6/Q?XGGUG4KR\74+C5)'\RZ216#DQ,>0QQUSD[C7L9^'
M<GC7P_JFD:KH][H?B6,/?+INKQF&1K=QB":)3@IG#?,>I&#6T7+J5&JJ;TU7
MZ=[;GRXRA6( RWH!5B'2[FX/*B,>]=#::3#9VZ/M#,1@R8_.I3UPOW:ZU%=3
MU$FS.M=!B3#.#(P'\1K4CMXX% 48/TJ+S".*&)8')J]MC=11.),-TYZ4UIOF
MHL;.XU2\2TLK::]NW/RP6L32.?; _K7LO@?]E?Q'XB\JXUVZ7P[9-U@"B6Z9
M?<?=3\<TK]3&KB*='23U[;O[CQC<S,D:[GE<X2, EG/H!WKU3P'^SGXK\7&*
M>^A_X1W36P=]TN;AA_LQ@\?5ORKZ7\"_!SPM\/8U;2].0W>/GOKC]Y.Q_P!\
M]/PP*[>.,;L 9["LW42V//GB*M32/NK[W_DOQ/.? WP%\)^!V2:WT_[=J"@?
MZ9?GS7!]5!X7\*]%\L9.!_2I-I5>*&'&,9/<^U9.3>YSJ"3OU[[O[QFWC';W
MIH4]^?PJ?8>_&.U-\L#@<^HJ2R!EYZ8IJQD#WJUY?&./RI&CW$9YQT^E $ Z
MY!./>G;._;USBGF,]N!^E/";A['U[4 1A>1VR>M*O;@XJ3:=I')]:3;U_A]Q
M0(=],X]*7&[WH51QG\LT\ T "L5=64_,#D'T-?(G[0VF7_P_\<LEOO30M8C:
M]L6[(V<30GW5CD>JN*^O","O//CY\/W^)'POU&SM(C)K>F9U73"OWC+&I\R+
MZ21[A]0M:0ER,VI5'3ES')_\$X=4N)OC_JD9<L)-!F\P>N)HB#7Z8U^>?_!*
MSP;+J%YXV\=LK?83%#HUH[K]\C][*0?;,8/O7Z&45'>1=>7-4;"BBBLCG"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MED:8N?7)<_ECM7K5>#_ W5O[/\57-@S$1W\&Y5_Z:)S_ .@D_E7O%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_A)__56+<7B_97VY0XSQ4-]"'.+7N_U_7F2QWTGE#+D<<'T_QJ^TT%]";>>
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M.M176O7C0KLAM[,-P/,8RN/3T'\ZI2,@P$& HQM'KW_S[TU;<SLO!/MW%"D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7_EH DB'Z'!_0UZ-XV^%K66K.B2JCG+>9"-R-Z9'8UST/@D6>\SS,VY2IVC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR0.35>XD^S1;MDDK\*L<8R[L2 % [DD@#ZTAG2^!?B!KOP]U<W^A7?V:1O\
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MW'K^&:JY5FS1\]8HPSMM'<D\?6DM+UM2F\C3K>74)<X_<K\B_5N@KJ-'^$L
M99];O)-2F[P(2D(]L=37<V=C;Z?;K!:P1V\*\!(U"@?E2YAZ(X?3?A[>W@5M
M5NQ;QC_EWLSS]&<_TKK]*T&PT2/996L</JP&6/U)Y-:%%2*X4444""BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \G^+&BVFE7=G?V\?E/=NRS!?N
MLP (;'K7#JPXY]Z]*^-*_P#$ITU_[MP1^:FO);;4%23RI&QDX5B?TJ2D:5)S
MGVHW#Z\TG.?7VH&+DK@C.?UK<TS44O81;7'$@^[(:PMW3'-'W3D'!'2@7DSJ
M)(QS;W*@^A[&L#4M-DM6.!E.S>E:^DZE'J$?V6Y.)1]UZL,"N8+@<=%;L:JQ
M+33..D4YX'%0DGMG%;VH:48SN7[IK&DB*GW_ )5(BK^/Z4UF(]<]JE?&>E1%
M>3CM0,.M'3VIK8^N:7/\_K3 7C@=?I4N[.*8O?M3U' R,G\\T .0]"1^%2[O
MS]JB'7/6GIV/6@"15W<4K0AATYJ6(?-C'&:LHH(S_3K0!E2V?7CFH;&:]T#4
M$U#39VL[Q.C#D,.ZL.X^M=%Y",,\8QTJ*;358DXR#U_PHL2>E^"_BQI_B'R[
M34-NF:H>/+=OW<I]48_R//UKO*^:+K1!)D;=ZYSBM?P_X\\0^%-D:R_VC9#C
M[-=')4?[+]1^.: N?0%%<5X?^+6AZSLBN9&TJ[;CRKO 4GV?H?TKLXY%D0.C
M!U89#*<@TRAU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !115/4-8L-*0M>WMO:J.<S2JO\S0!<HKA=4^-'A7
M3<A+U[]Q_#:1%Q^? _6N2U3]H5N1INBGVDO)@/\ QU?\:5P/9Z:\BQJ6=@JC
MJS' KYMU/XR>*=1W*M_#8H?X;2$ C\6R:Y74M:OM48M?7UU>G/6:9F'Y9Q2N
M!]-ZM\1?#>BDK=:Q:B0?\LXW\QOR7-<EJ?[0&B6V1965Y?MZE1$OYG_"O!/E
M52%0+C^Z*1FR>>M%QGI^J?'_ %NXRME8VEBO9I,RN/Y"N/U7XA>)=8+"YUNZ
MV'JD)$2_3"XKG^5!/3Z]Z;M/([^] !,QFD\R3,K?WI&+']:BYV]<\D__ %J?
M]X=013=A]2.* &;MW?YJ8RU+M"@@>M(V<#C\J8B 1\],4>6>AZU)^'Y4*OKS
M0 PKU[<_E33G\/6I"NYCWX]:9CC- #=W2D8D$>N:<P&.GO36&5[>WUI#$W;<
MTTR'=P?E^E&[\3UHW<CU^AH 591N .<TOVG:?3C-5F!QZ]Z;@KGUIB-FWOMN
M",UTFD>(O)(21@T9ZK_A7#QR%3T!.>I-78+C:>3C-,=STTPK-']HM&W1GDQY
MR1[51EMO,D$L#&*=#D;>"#GC!]:YO2=>>SF7#GMGFNOM[BWU= T;>3<#G;G[
MU4)QZH^<?CI^RSIWQ&FN=;\,"U\/^,22]Q&WR6>J'_IH!Q'*3_RU'!XW#O7Q
M9K&D:AX<UF\T;6=/N-,U6S/DW6GWB;73/MT96'1AD'/%?J[=6ZW#>7<*(I%'
M##TKS;XO?!/P]\7-,CM/$,$EOJ-NK+I^N6F/M-KQTS_&F<91N/3!K7FON<:C
M*C_#5X]O_D?_ )';M;K^785_ ]PLB,SZ#,Q!5C\UHWIG^[Z'MTJ?5[.;3+D^
M(=+0.I4&]MU_Y:*,?O%']X#J.XKTOXH?"?Q!\)=:.D>)+..6TN@5M=2MU+6>
MH1^BG^%_6,X([9ZUY8DTO@F\",6ET*=\)(QRUJW]TGT]#2VT9W4ZD:J4HO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"/:KG^>:8P4AAQ36;:,C@]:7ITYQ2-]W&>>IH ;W-/[Y_E3% /!/Y4Y5/X4
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ME1,S=,BC<9-YPSC'&?2F-,2>GMC%0[>^>?:FDXP!DGUHL!*TQP?RS4;3'''
M_E3#CH>,4TMV'2G8=QS3E1R>:C\T]B<]*:S%B.W:HG/4YS^-(1*S'UQCWIC-
MV+9YX[U&S]1R!Z5&1SD=?>@"8MUIOG>@/I3-V/YXI=IR>WKFF(3KP!SGH?Y4
M*NX\#/TIXBZ8X/05*L97WI -$?8C&:FCMA@'&*DAC]LUH6MH2P(&..QI@00V
M?3C\:OPVIX!&*T;;3\<]JL>2%44",[[*%7E<=J7RPK=*MNI&.]1[1R/2@"!E
M"C]*3RQSWJ8IN;IQGTIFT=3P/:@9"RX'%,;CG&>XJ5@!UZ5&WU[T@(F7!)YY
M[=JC(Z^E3-FF&F!%SUSBHV^Z:F.,XQ4;9SP<"D!"QX/>FR$]2.:>R^],V]1B
MF P_=ST%-W%>G?UIYSN'3I^%,;J>GK3 3.#DG/TIK,>WYT?I1W':D C9['BF
M9Z\=J5EY)!Q@4W*KQ@#WZ\4AC9/O#G/OUS^%,QMZ>G/'2G?=[>PH^]D8&[KB
MF!%UII)I[=<8IOK0(:5SR:8R^M2'OS2''IFF!!Z@=>U+D\CM3F7KC_\ 53<?
MEZXH D609W=:LPWAB;V'=:HCCMQT_2G+)R".M '9:#XE:UD09XZ$YKL(9HM4
M43PLL5PO5,\&O(8I&7!SGO[UMZ3KDMK(O[Q@1Z4RM&>@7$"Z@Q20&&[4 !LX
MZ5X)^T-^RYHOQFAN;I1%H?BYX]OV[9^XO\?=6X _B])1\P[Y%>[Z=JUOK4*Q
MSD)*#\K@=:L3Q#FWO5W _P"KE!X%6I'/5HJ=K[]+?I_EL^I^/7BCPKK'P[UB
M]\$^.-.GL7/"--R2 >)$8<,!P0PZ_F*K:'J5QH=_'HVJR*Q(S:W?:9#TY]1W
M%?J'\</@9X>^+WA670?$UKY\:#?8:O;C%S82?\](V]/53\I[BOEKXN?L-SZ7
MX5C_ .$/U*]\1_9E,DT%^4%\&'(DMRH"GWC.,\X-6M=C..)E2TKKUDMO5K=/
MONO/MX:K%>#CUQ06VL,#J>N>>:YCPWKTI9M,U$;+Z'A6;(# ''?D'/&#R#P:
MZ/(^89P*#OW5UL3%OF)['(^M*Q#-PO3FHERIP_)]AWI[$;CD\=<+VIBL#<9(
MYV]5]:KR]L>OKR*M.0V,C&?\\U!(NY0,8]O2@HX_Q=")!(I^ZUN5QVZ$5^CG
M[.&L'6/AOHTYR3-8V[_CY2@_RK\\?$R;3;N>1AES^-?;7[%>J?:OA;I$+$YA
MB: _5)'7'Y8K*1FSVG6DVRL>U2Z:Y6:,D_>6EUU-LA^G:H-/;_5'\*D@[[3'
M_=8ZUHCIC\*R-(D^10#QCO6L&[BJ0QV.YS367)Z9%/Q@=J:RG/\ G%,!NWGI
MDYQ@BGY'/?CBFCMD_G1]#VS0 OOS2'Z\XZT9RW/Y=Z.,?RH 4\\\T=>W-)GO
MW]*,X/''K0 HSTQS[4G*\]J%]<G/UH) Y]:0"_Q<TG3(S^-)G Z8I-QXYQ3
M<WMTH& 3GC\:0?=_"E7L: %[8'%!;TI/I3=QZ]J (M0MQJ%C=6[#<)H7BQ]5
M('ZU\\0J3"FX_-C:2?;CFOHY<*R'K@@UX/KUC_9^O:C;@86.XD"CV)S_ "-0
MP,Q?F(P<=JM0H>WY5#&A;D 8J[!&0O8=Z0$D8P <]3Q5C@+CI_*HE3.><'WX
MIZ_F?2@"16W=_<'TKM?A?\3[OX=ZH58-/HUP^;FU7JI_YZ(/7U'>N(_SBC[W
MS4 ?=&E:K::YIUO?V,Z7-I.@>.5#D,#5NODGX3_%2Y^'NHB"X+SZ#.W[^$<F
M$G_EHG]1WKZNT_4+;5+*&[M)DN+:90\<L9RK ]Q0!8HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\2/VXK:_\
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M!8$F.?0TOF<=<>IJMN^N*=N]^M("?S#GW]N]-\S@ '\JA+'U]NG-&\^N/04
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M #ZTG<8X[<5(5ZX&.^*8W8GCC- ">A_2DQ[4OXT9_P#UT -7M0?;BE_&DQP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG9/F/KG_ /53#'EA[\4 1_6EQZ]:7&>?U^G>D"XYQ^-,!>U+QGI2#OQ[4O\
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M'\6^%UCNY-^IV!$%P2>7&/DD_$?J#7=T#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *JZIJ=IHNFW6H7]Q'9V-K$T\]Q,P5(HU!9F8GH
M3GVJU7Q9_P %+OBY+X?\'>'_ (>6$YCG\22/=:CL.#]BA*_(?9Y60'U"L.]
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MDT#*[1\^WK3&C/4\^_TJPRXSV%-\OY@0,<T@*VW@''Y]Z!\IZ'\:G\OU&?\
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M]'^$-;'B3PMI.J Y-W;1RM_O%1N'YYI@C7HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MECUH$9[6Y[C/>F?9B,96M3R_Q_"E$8SF@#*^RD=L'H.*<+1E^8+EO2M%H\X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%'@2?:$XXVJ&/\ZT\Q>S=[+4^A=%D 93GCOBNFCF'D,XZ(5#<@#+, HY[DD
M>I-?/1_:-\,Z/H-UJJVMY=QVJ@2+E8AST)8\ 5\I_'7]IWQ+\:X5TUV31/"R
M2^;%I=A(RB9@<K)+)]YV'4= O:E:RNS:%%6YJDK+[V_1?YV7Y'[MVJE;:(%=
MI" %?3CI4M?%W_!,_P#:DU/XW?#_ %7P;XLO6O\ Q=X2\I1J$S9EO[%\B*5S
MW=2I1CWPI/)-?:-0<["BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%R1TZ4Q#, 'GJ.]&#UIVT-U--X],^F: #H>1^%(<9)_6E'R]J<%PI&1^'?\
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MO4!H<GH?PRT/1665K?[=<C_EM=?/^2]!75JH50J@ #@ 4M%(+A1110(****
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MJMQ<A=W-1S7@W.N2%'?U^E9\LQD;G]*0"S3F0XIB+N;K2JNXU<B@XSC/<TD
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MU?ZU]C44 ?%=U\#OB#9_>\/O*!_S[W$;?UK.N?AQXRL5/G^%]44#^)8-Z_\
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MB:] T/X9Z%H>UQ;?;+A?^6UT=Y_ =!^5=710%^PBJ%4 # '0"EHHI""BBB@
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MX3N&EL9G!U3P_<2D6FHH/;^"4#.V0<]CD9%>7Q$2(&0=^">N>]"QLK;NO?\
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M5XK^R)\=A^T!\%]+URZ95\16).G:S",#;=1@9<#LLBE9!_OX[5[55FH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ'I0,D)QCG%(S=@,4W/K^M(6_P : '?Y%,9^>E+N'/;-5+^^CL;=YI&VJ :
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_":R^$?A*/3XBMSJ=QB;4+W',TN.@_V5Z*/3ZFN_HHI$!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+%HRIZ=_>J4T.U\XJ+6,K&3]C*L.IQTSQ7.>(O!<.J-]HMU\BZ_BVX D^O\
MC792-\Q!P?PY]C2/ WEJTFU4/W3GKZTQ-=CSVSTE+7]WM(=3W'0X[U:DC_<E
MCP&&00.F>H%='J5C&[-,B#<%PX_O**R+B$*O"!8\?*,_I]:6Q2/-M9B:*[YS
M@'\Q3X46>VPW;C-3^)(S]HY4@YSC\:9H>9)=O!!]:HLRM0L=HSU';'7%=#X
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MHH _F<O(@T8N80WDL<,",&-NX(['/'X52'RG&?SK](?^"D7[$Y\&ZAJ?Q?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!^;7_!5V9W^(GPN@SE%T_4
M)0O;/F0"OSZ_UCR.<?,Q)_,U^B'_  5?TYT\7?"K4=O[MX-1M=W^UF!P/YU^
M=L>3UP3S42W,WN/7G%+['I2<8&1^%*R\XJ (Y(]S;LX;'TJ?3;Y[&[25,;H_
MX?[R]Q4+=L=<_C]:8_R8<'+'T^M(1VM\L=Q;Q75N=T3J#GI^%9IR<+Z] :?X
M5N_-6YT^3&PY>,-G_@0_K3+J)H9V7H1[5JM42P4;F/TJ_8LP8'H_450C96S@
M\=#FKEO(%QG''/UH YGQEI_]G:PS+Q!=H9%7H-W\5>2:E']CU!ATYX_PKZ \
M;:7_ &AX9>9!NFLW\U>^5Z,/R_E7AWBV%6D$R# X/RG/%!2V-+3[C[1ICQ%E
M"\_EUKD=2^6X.%^K5:TO42BD9('0U2U217D##MV!Z"@HI,1R":[;P%JA6!X&
MP#$VY<GC!]?QKAO<FMCPK<F'554$_O%V@8SDCFA >\Z;=F2%'W#ICGK6K#(&
MQ^=<EH#3K"!-&RGJ-W!(]A6W]O-O@-&P3.=V>:9&A[9^R?XQ;P1^TY\.-4$@
M6*YU(Z3<'/!CN4:/GV#[#^%?M!7X":?K3:9>:=JUL^U["\M[Q&SR&BE5\_I7
M[ZV=U'?V<%S$<Q31K(A]5(R/YTS2)-11104%%%% !1110 4444 %%%% !111
M0 4444 %4]6T>PUZQDL]3L;;4;.3[]O=Q++&WU5@0:N44 <GH_PD\#>';H7.
ME>#/#^FW .1-9Z7!$^?7*H#76444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4R:&.XA>*5%EBD4JZ. 58$8((/44^B@#Y)^,G
M_!-CX:?$:_N-5\,RW/P\UB=B\O\ 8Z*UE*QY):V;Y03ZH5KY]N_^"4_CZ.Z*
MVWCGP[<VV>))[>>-\>I4!A^M?IQ12L0XIGP3\.?^"5.CVMU%<^/_ !A=:W K
M9;2]'B^R0R#T>0DN1Z@;?K7VWX,\$Z#\._#EIH'AG2+31-&M%VPV=G&$1??C
MJ3W)Y/>MNB@I)(****8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>rxst-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-27T16:27:42.3494+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://rxsight.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:rxst="http://rxsight.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5" id="DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5">
        <link:definition>100050 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details) 5</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies" id="Role_DisclosureSummaryOfAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments" id="Role_DisclosureShortTermInvestments">
        <link:definition>100100 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories" id="Role_DisclosureInventories">
        <link:definition>100110 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1" id="DisclosurePropertyAndEquipment1">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>100150 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" id="Role_DisclosureStockBasedCompensationExpense">
        <link:definition>100160 - Disclosure - Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiability" id="Role_DisclosureCommonStockWarrantLiability">
        <link:definition>100170 - Disclosure - Common Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1" id="DisclosureStockholdersEquityDeficit1">
        <link:definition>100180 - Disclosure - Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrants" id="Role_DisclosureConvertiblePreferredStockWarrants">
        <link:definition>100190 - Disclosure - Convertible Preferred Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStock" id="Role_DisclosureNotesReceivableForRedeemableCommonStock">
        <link:definition>100210 - Disclosure - Notes Receivable for Redeemable Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100220 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100230 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100240 - Disclosure - Employee benefit plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100250 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables" id="Role_DisclosureSummaryOfAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Summary of Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" id="Role_DisclosureShortTermInvestmentsTables">
        <link:definition>100280 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables" id="Role_DisclosureInventoriesTables">
        <link:definition>100290 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>100300 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100310 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables" id="Role_DisclosureTermLoanTables">
        <link:definition>100330 - Disclosure - Term Loan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityTables" id="DisclosureCommonStockWarrantLiabilityTables">
        <link:definition>100340 - Disclosure - Common Stock Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" id="DisclosureStockholdersEquityDeficitTables">
        <link:definition>100350 - Disclosure - Stockholders Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsTables" id="Role_DisclosureConvertiblePreferredStockWarrantsTables">
        <link:definition>100360 - Disclosure - Convertible Preferred Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables" id="DisclosureStockbasedCompensationExpenseTables">
        <link:definition>100370 - Disclosure - Stock-Based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100380 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100390 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Summary of Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100420 - Disclosure - Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100430 - Disclosure - Summary of Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails" id="Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails">
        <link:definition>100440 - Disclosure - Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails" id="DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails">
        <link:definition>100450 - Disclosure - Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails" id="DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails">
        <link:definition>100460 - Disclosure - Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails" id="Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails">
        <link:definition>100470 - Disclosure - Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" id="Role_DisclosureShortTermInvestmentsAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Short-Term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails" id="Role_DisclosureInventoriesScheduleOfInventoriesDetails">
        <link:definition>100490 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails" id="DisclosureInventoriesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Inventories - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100510 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation" id="DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation">
        <link:definition>100530 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails">
        <link:definition>100550 - Disclosure - Fair Value Measurements - Schedule of estimated fair value for the warrant liabilities measured using significant unobservable inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100560 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" id="Role_DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails" id="DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails">
        <link:definition>100580 - Disclosure - Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails" id="DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails">
        <link:definition>100590 - Disclosure - Term Loan - Schedule of Cash Interest Paid and Effective Interest Rate On Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails" id="Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Common Stock Warrant Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails" id="DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails">
        <link:definition>100610 - Disclosure - Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails" id="DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails">
        <link:definition>100620 - Disclosure - Stockholders Equity (Deficit) - Summary of Preferred Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" id="DisclosureStockholdersEquityDeficitAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Stockholders Equity (Deficit) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails" id="DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails">
        <link:definition>100640 - Disclosure - Stockholders Equity (Deficit) - Summary Of Common Stock Equivalent Of Preferred Stock Due To Anti Dilution Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100650 - Disclosure - Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" id="DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails">
        <link:definition>100660 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails" id="Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails">
        <link:definition>100670 - Disclosure - Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Convertible Preferred Stock Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails">
        <link:definition>100700 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails" id="DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails">
        <link:definition>100710 - Disclosure - Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails">
        <link:definition>100720 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails">
        <link:definition>100730 - Disclosure - Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails" id="Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Schedule of Income before Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100750 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails">
        <link:definition>100760 - Disclosure - Income Tax - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100780 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>100790 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100800 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails" id="Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - Notes Receivable for Redeemable Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100820 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails" id="DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails">
        <link:definition>100830 - Disclosure - Leases - Summary Of Lease Balances Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" id="DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails">
        <link:definition>100840 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100850 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" id="DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>100860 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100880 - Disclosure - Employee benefit plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100890 - Disclosure - Subsequent events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="rxst-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="rxst-20231231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="rxst-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rxst-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="rxst-20231231.xsd#StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="rxst-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="rxst-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:href="rxst-20231231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments" xlink:href="rxst-20231231.xsd#Role_DisclosureShortTermInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories" xlink:href="rxst-20231231.xsd#Role_DisclosureInventories" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1" xlink:href="rxst-20231231.xsd#DisclosurePropertyAndEquipment1" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="rxst-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="rxst-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan" xlink:href="rxst-20231231.xsd#Role_DisclosureTermLoan" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:href="rxst-20231231.xsd#Role_DisclosureStockBasedCompensationExpense" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiability" xlink:href="rxst-20231231.xsd#Role_DisclosureCommonStockWarrantLiability" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficit1" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrants" xlink:href="rxst-20231231.xsd#Role_DisclosureConvertiblePreferredStockWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStock" xlink:href="rxst-20231231.xsd#Role_DisclosureNotesReceivableForRedeemableCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="rxst-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="rxst-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:href="rxst-20231231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="rxst-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" xlink:href="rxst-20231231.xsd#Role_DisclosureShortTermInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables" xlink:href="rxst-20231231.xsd#Role_DisclosureInventoriesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="rxst-20231231.xsd#DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="rxst-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="rxst-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables" xlink:href="rxst-20231231.xsd#Role_DisclosureTermLoanTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityTables" xlink:href="rxst-20231231.xsd#DisclosureCommonStockWarrantLiabilityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficitTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsTables" xlink:href="rxst-20231231.xsd#Role_DisclosureConvertiblePreferredStockWarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables" xlink:href="rxst-20231231.xsd#DisclosureStockbasedCompensationExpenseTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="rxst-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rxst-20231231.xsd#DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails" xlink:href="rxst-20231231.xsd#DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails" xlink:href="rxst-20231231.xsd#DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureInventoriesScheduleOfInventoriesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#DisclosureInventoriesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rxst-20231231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation" xlink:href="rxst-20231231.xsd#DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails" xlink:href="rxst-20231231.xsd#DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails" xlink:href="rxst-20231231.xsd#DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails" xlink:href="rxst-20231231.xsd#DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:href="rxst-20231231.xsd#DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails" xlink:href="rxst-20231231.xsd#DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:href="rxst-20231231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails" xlink:href="rxst-20231231.xsd#DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails" xlink:href="rxst-20231231.xsd#DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" xlink:href="rxst-20231231.xsd#DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="rxst-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:href="rxst-20231231.xsd#DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="rxst-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5" xlink:href="rxst-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5" xlink:type="simple"/>
        <link:roleRef roleURI="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="rxst-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DebtFromCashReserves" xlink:label="rxst_DebtFromCashReserves"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StateOperatingLossCarryForwardsNotExpire" xlink:label="rxst_StateOperatingLossCarryForwardsNotExpire"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedCustomerDepositsCurrent" xlink:label="rxst_AccruedCustomerDepositsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" xlink:label="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfWhollyOwnedSubsidiaries" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AugustFourTwoThousandTwentyThreeMember" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CompassBibleChurchMember" xlink:label="rxst_CompassBibleChurchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesFWarrantsMember" xlink:label="rxst_SeriesFWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockInExchangeForCancellationOfNotesReceivables" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BofaSecuritiesIncMember" xlink:label="rxst_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesNoncurrent" xlink:label="rxst_LeaseLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" xlink:label="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStock1Member" xlink:label="rxst_RedeemableCommonStock1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PriorPreferredStockholdersMember" xlink:label="rxst_PriorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TerminalValueExitMultiple" xlink:label="rxst_TerminalValueExitMultiple"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockWarrantsMember" xlink:label="rxst_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExpirationOfCommonStockWarrants" xlink:label="rxst_ExpirationOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmployeeStockPurchasePlanMember" xlink:label="rxst_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TermLoanMember" xlink:label="rxst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeniorPreferredStockholdersMember" xlink:label="rxst_SeniorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PublicOfferingMember" xlink:label="rxst_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod" xlink:label="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock" xlink:label="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PercentOfTaxableIncomeOffsetInFuture" xlink:label="rxst_PercentOfTaxableIncomeOffsetInFuture"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" xlink:label="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants" xlink:label="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FinanceLeaseObligationsIncurred" xlink:label="rxst_FinanceLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionsMember" xlink:label="rxst_RedeemableStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseAssets" xlink:label="rxst_TotalLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGAndHPreferredStockMember" xlink:label="rxst_SeriesGAndHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TaxableIncomeOffsetPercentage" xlink:label="rxst_TaxableIncomeOffsetPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RxlalMember" xlink:label="rxst_RxlalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" xlink:label="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LDDMember" xlink:label="rxst_LDDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LiabilityOnUncertainTaxPosition" xlink:label="rxst_LiabilityOnUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InvestmentMaturityPeriod" xlink:label="rxst_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchaseCommonStock" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FederalOperatingLossCarryForwards" xlink:label="rxst_FederalOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesMaturityYearEnd" xlink:label="rxst_NotesReceivablesMaturityYearEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareTable" xlink:label="rxst_EarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="rxst_SignificantAccountingPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AmendedTermLoanMember" xlink:label="rxst_AmendedTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:label="rxst_DeferredOfferingCostsIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockConvertibleConversionPriceIncreaseShares" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_COVID19PolicyTextBlock" xlink:label="rxst_COVID19PolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RightOfUseEquipmentMember" xlink:label="rxst_RightOfUseEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemablePreferredStockAndWarrantsMember" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerThreeMember" xlink:label="rxst_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareLineItems" xlink:label="rxst_EarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SummaryOfLeaseBalancesTableTextBlock" xlink:label="rxst_SummaryOfLeaseBalancesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingLeaseObligationsIncurred" xlink:label="rxst_OperatingLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NewLoanAndSecurityAgreementMember" xlink:label="rxst_NewLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredOfferingCostsPolicyTextBlock" xlink:label="rxst_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" xlink:label="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsOutstanding" xlink:label="rxst_WarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OfficeManufacturingAndWarehouseFacilityMember" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetDepreciation" xlink:label="rxst_DeferredTaxAssetDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerFourMember" xlink:label="rxst_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" xlink:label="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNumberOfCommonSharesIssued" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FederalOperatingLossCarryForwardsNotExpire" xlink:label="rxst_FederalOperatingLossCarryForwardsNotExpire"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="us-gaap_RegistrationPaymentArrangementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncreasedDecreasedInRestrictedCash" xlink:label="rxst_IncreasedDecreasedInRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageCostOfCapitalDiscountRate" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageGrantDateFairValueExercisable" xlink:label="rxst_WeightedAverageGrantDateFairValueExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableAggregatePrincipalAmount" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithholdings" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShelfRegistrationStatementMember" xlink:label="rxst_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FairValueOfWarrants" xlink:label="rxst_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" xlink:label="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesInterestAmount" xlink:label="rxst_NotesReceivablesInterestAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfDeferredCost" xlink:label="rxst_ReclassificationOfDeferredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableMaturityYearStart" xlink:label="rxst_NotesReceivableMaturityYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OtherComprehensiveLoss" xlink:label="rxst_OtherComprehensiveLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021PlanMember" xlink:label="rxst_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OneCustomerMember" xlink:label="rxst_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGCommonStockMember" xlink:label="rxst_SeriesGCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingLeaseRightOfUseAssets" xlink:label="rxst_OperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EffectiveIncomeTaxReconciliationTaxCredits" xlink:label="rxst_EffectiveIncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShortTermInvestmentsPolicyTextBlock" xlink:label="rxst_ShortTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseLiabilities" xlink:label="rxst_TotalLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossFromChangesInFairValueOfCommonStockWarrant" xlink:label="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" xlink:label="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignEarningsRepatriated" xlink:label="us-gaap_ForeignEarningsRepatriated"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsMember" xlink:label="rxst_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfLeases" xlink:label="rxst_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" xlink:label="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RepaymentOfTermLoan" xlink:label="rxst_RepaymentOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantMember" xlink:label="rxst_CommonStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfLiability" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BmlManagementLlcMember" xlink:label="rxst_BmlManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LiquidityAndFinancialPositionPolicyTextBlock" xlink:label="rxst_LiquidityAndFinancialPositionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerTwoMember" xlink:label="rxst_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageDiscountRateAbstract" xlink:label="rxst_WeightedAverageDiscountRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InterestPaidOnTermLoan" xlink:label="rxst_InterestPaidOnTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExchangePaymentOfNotesReceivablesForCommonStock" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForRegulatoryMilestones" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingSegmentsPolicyTextBlock" xlink:label="rxst_OperatingSegmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedInterestCurrent" xlink:label="rxst_AccruedInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StateOperatingLossCarryForwards" xlink:label="rxst_StateOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfAsset" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchasePreferredStock" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockMember" xlink:label="rxst_NotesReceivableForCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalCashProceeds" xlink:label="rxst_TotalCashProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMember" xlink:label="us-gaap_FutureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesWCommonStockMember" xlink:label="rxst_SeriesWCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_UnexercisedWarrantsExpired" xlink:label="rxst_UnexercisedWarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetAmortization" xlink:label="rxst_DeferredTaxAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OptionalConversionsMember" xlink:label="rxst_OptionalConversionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsToPurchaseConvertiblePreferredStock" xlink:label="rxst_WarrantsToPurchaseConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionMember" xlink:label="rxst_RedeemableStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationTaxCreditOther" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAbstract" xlink:label="us-gaap_DeferredRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="rxst_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossOnExpiration" xlink:label="rxst_GainLossOnExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharePurchaseAgreementMember" xlink:label="rxst_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EscrowHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" xlink:label="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredRevenue1" xlink:label="rxst_DeferredRevenue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStockMember" xlink:label="rxst_RedeemableCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableInterestRateStatedPercentage" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CashInterestPaidPercentagePeriod" xlink:label="rxst_CashInterestPaidPercentagePeriod"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantLiabilityMember" xlink:label="rxst_CommonStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccountsReceivablePercentage" xlink:label="rxst_AccountsReceivablePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageRemainingLeaseTermAbstract" xlink:label="rxst_WeightedAverageRemainingLeaseTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021EsppPlanMember" xlink:label="rxst_The2021EsppPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:label="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InterestPaidOnFinancingLeases" xlink:label="rxst_InterestPaidOnFinancingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfCustomer" xlink:label="rxst_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedDeferredRevenueCurrent" xlink:label="rxst_AccruedDeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InvestmentCreditPercentage" xlink:label="rxst_InvestmentCreditPercentage"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExercisePriceOfWarrants" xlink:label="rxst_ExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExerciseOfPreferredStockWarrants" xlink:label="rxst_ExerciseOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesCurrent" xlink:label="rxst_LeaseLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesHWarrantsMember" xlink:label="rxst_SeriesHWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableDisclosureAbstract" xlink:label="rxst_NotesReceivableDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClosingStockPrice" xlink:label="rxst_ClosingStockPrice"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainOnExpirationOfWarrants" xlink:label="rxst_GainOnExpirationOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsToPurchaseStockPolicyTextBlock" xlink:label="rxst_WarrantsToPurchaseStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoteReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesReservedForFutureIssuanceTableTextBlock" xlink:label="rxst_SharesReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingIncomeLoss1" xlink:label="rxst_OperatingIncomeLoss1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGWarrantsMember" xlink:label="rxst_SeriesGWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShelfRegistrationStatementPolicyTextBlock" xlink:label="rxst_ShelfRegistrationStatementPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoCustomerMember" xlink:label="rxst_NoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClassOfWarrantsExercised" xlink:label="rxst_ClassOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TemporaryEquityNoteReceivablesCommonStockIssued" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost, Depreciation and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, Depreciation and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D expenditures capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Weighted Average Remaining Lease Term and Discount Rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Term And Discount Rate Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Term and Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriters discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DebtFromCashReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DebtFromCashReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DebtFromCashReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt From Cash Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DebtFromCashReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt From Cash Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State operating loss carry forwards not expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Operating Loss Carry Forwards Not Expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State operating loss carry forwards not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of estimated fair value for the warrant liabilities measured using significant unobservable inputs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation, Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options issued and outstanding under the 2006, 2015 and 2021 Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful lives of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value, Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vendor invoices</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Trade, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedCustomerDepositsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedCustomerDepositsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Customer Deposits Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedCustomerDepositsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Customer Deposits Current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue from Contracts with Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities Noncurrent Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities Noncurrent Finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Accounts Notes Loans And Financing Receivable [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue recognized during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment and other fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Other Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Proceeds of Common Stock under ATM Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs of $12.4 million</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of wholly owned subsidiaries.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Wholly Owned Subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of wholly owned subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 4, 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August Four Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August Four Two Thousand Twenty Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CompassBibleChurchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compass Bible Church [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CompassBibleChurchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Compass Bible Church [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WarehouseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warehouse [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WarehouseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warehouse [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesFWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series F warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesFWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesFWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Surrender of common stock in exchange for cancellation of note receivable, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Surrender of common stock in exchange for cancellation of note receivable, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock in exchange for cancellation of notes receivables shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock in Exchange for Cancellation of Notes Receivables Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for at-the-market offerings, net of issuance costs 1, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for at-the-market offerings, net of issuance costs 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for at-the-market offerings, net of issuance costs 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BofA Securities, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BofA Securities, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BofA Securities, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Option, Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 (remainder)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - operating leases (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease obligations recorded for right-of-use assets abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Obligations Recorded For Right Of Use Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligations recorded for right-of-use assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStock1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Common Stock1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStock1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStock1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Common Stock1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential Aggregate Payments For Sales Based And Operating Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Aggregate Payments For Sales Based And Operating Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential aggregate payments for sales based and operating milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PriorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior preferred stockholders member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PriorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Preferred Stockholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PriorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Preferred Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TerminalValueExitMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terminal value exit multiple</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TerminalValueExitMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Terminal Value Exit Multiple</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TerminalValueExitMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Terminal value exit multiple.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExpirationOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expiration of common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExpirationOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration of common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExpirationOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Of Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExpirationOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration of common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Raw Materials, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee stock purchase plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities Current Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeniorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Senior preferred stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeniorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Preferred Stockholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeniorPreferredStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Preferred Stockholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Term loan, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value of Vested Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision at the federal statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities Current Finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of converted shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued upon warrant exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Production Molds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tools, Dies and Molds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Saving Plans Matching Contributions During Period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Saving Plans Matching Contributions During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution saving plans matching contributions during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrants Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Preferred Stock Warrants Disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal proceedings, regulatory matters, legal costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PercentOfTaxableIncomeOffsetInFuture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percent of taxable income offset in future.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PercentOfTaxableIncomeOffsetInFuture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent Of Taxable Income Offset In Future</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PercentOfTaxableIncomeOffsetInFuture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of taxable income offset in future</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of redeemable common stock to common stock options assumed in non cash investing or financing activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of redeemable common stock options to common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (Loss) from Changes in fair value of preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From Changes In Fair Value Of Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FinanceLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FinanceLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance Lease Obligations Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FinanceLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Obligations Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options issued and outstanding under the 2006, 2015 and 2021 Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total lease assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Lease Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of the letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGAndHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined class of G and H series of preferred stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGAndHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G And H Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGAndHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G and H Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized expense related to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for the exercise of stock options and vesting of restricted stock units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued for the exercise of stock options and vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued for the exercise of stock options and vesting of restricted stock units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financing Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financing Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses for investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity, Ending Balance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity, Beginning Balance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision at the federal statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for the employee stock purchase plan, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Short-Term Investments Available For Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TaxableIncomeOffsetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Income offset, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TaxableIncomeOffsetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Income offset, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TaxableIncomeOffsetPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable Income offset, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Other than Long-Term Debt, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Other than Long-Term Debt, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of preferred stock to common stock upon initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable common stock reclassified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock to common stock upon initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs and premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RxlalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LAL</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RxlalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RxLAL [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RxlalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RxLAL [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering and reverse stock split.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering And Reverse Stock Split Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering ('IPO')</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) available to stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LDDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">L D D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LDDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">L D D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LDDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LDD Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 900,000,000 shares authorized, 36,139,513 shares issued and outstanding as of December 31, 2023 and 28,268,389 Shares issued and outstanding as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock after reclassification of redeemable common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiabilityOnUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liability on uncertain tax position.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiabilityOnUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability On Uncertain Tax Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiabilityOnUncertainTaxPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability on Uncertain Tax Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions for prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of dilutive securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Issued To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Indexed to Issuer's Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign exchange rate on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value of Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock for at-the-market offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in at-the-market offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of common stock in at-the-market offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument face amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for the public offering net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock for at-the-Market Offerings, Net of Issuance Costs, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock for at-the-Market Offerings, Net of Issuance Costs, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal operating loss carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Operating Loss Carry Forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-Kind Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment-in-kind interest income added to principal of notes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock, price per shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesMaturityYearEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivables maturity year end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesMaturityYearEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivables Maturity Year End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesMaturityYearEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivables Maturity Year End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on short-term investments and cash equivalents, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for lease obligations abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign income before taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years), Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Revenue Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shareholder Representative Holdback Of Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholder Representative Holdback Of Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholder representative holdback of exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings Per Share Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Rent Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SignificantAccountingPoliciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AmendedTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended term loan member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AmendedTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AmendedTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Component of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Convertible, Conversion Price, Increase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price, Increase Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Stock, Convertible, Conversion Price, Increase Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fair Value Less Strike Price of Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of unexercised warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_COVID19PolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_COVID19PolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_COVID19PolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-Of-Use Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of use equipment member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RightOfUseEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Proceeds of Common Stock under ATM Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock, consideration received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years), Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable preferred stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Preferred Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Preferred Stock And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for excess and obsolete inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer three member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases,tenant allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Of Preferred Stock Warrant Net Of Shares Withheld For Exercise Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Preferred Stock Warrant Net Of Shares Withheld For Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for the public offering net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in at-the-market offerings, net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in at-the-market offerings, net of issuance costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Notes And Loans Receivable [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings Per Share Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to common stock, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the limitations on the use of all operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Balance Sheet Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Lease Balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Lease Balances Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease obligations incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Obligations Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NewLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NewLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NewLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Offering Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assumptions used to determine the fair value of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Assumptions Used To Determine The Fair Value Of Warrant Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of assumptions used to determine the fair value of warrant table text block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk adjusted discount factor, Weighted average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk-free Interest Rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Structure used in the manufactOffice, Manufacturing and Warehouse Facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Manufacturing And Warehouse Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Manufacturing And Warehouse Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer four member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Cash Interest Paid and effective interest rate on term loan table TextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Interest Paid and effective interest rate on term loan table TextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Interest Paid and Effective Interest Rate On Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of common shares issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number Of Common Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional common shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal operating loss carry forwards not expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Operating Loss Carry Forwards Not Expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FederalOperatingLossCarryForwardsNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal operating loss carry forwards not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calhoun Vision Inc 2015 Equity Incentive Plans And Calhoun Vision Inc 2006 Stock Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calhoun Vision Inc2015 Equity Incentive Plans And Calhoun Vision Inc2006 Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shelf registration statement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncreasedDecreasedInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increased (Decreased) In Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncreasedDecreasedInRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increased (Decreased) In Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average cost of capital discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Cost Of Capital Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average cost of capital discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reconciliation of cash and cash equivalents and restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Cash Equivalents And Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageGrantDateFairValueExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Grant Date Fair Value Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageGrantDateFairValueExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Grant Date Fair Value Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Short-Term Debt [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Short Term Debt [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate principal amount of notes receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable Aggregate Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Warranty, Service Contracts, And Accessories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Warranty Service Contracts And Accessories [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service warranty, service contracts, and accessories [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares redeemed for employee tax withholdings, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares redeemed for employee tax withholdings, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares redeemed for employee tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares redeemed for employee tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares redeemed for employee tax withholdings, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shelf registration statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shelf registration statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Inventory Valuation Reserves, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Inventory Valuation Reserves, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: reserve for excess and obsolete inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustment of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of common stock equivalent of preferred stock due to anti dilution provisions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Equivalent Of Preferred Stock Due To Anti Dilution Provisions [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Common Stock Equivalent Of Preferred Stock Due To Anti Dilution Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesInterestAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivables interest amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesInterestAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivables Interest Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivablesInterestAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivables Interest Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value (USD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dilutive Securities, Effect on Basic Earnings Per Share, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of deferred financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification Of Deferred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Deferred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period for recognition of expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableMaturityYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivable maturity year start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableMaturityYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable Maturity Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableMaturityYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable Maturity Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield, Weighted Average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected dividend yield.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OtherComprehensiveLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OtherComprehensiveLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The 2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The 2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OneCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OneCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OneCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series G Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax reconciliation tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Reconciliation Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock, date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Transaction Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Transaction Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvoting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (Loss) from Changes in fair value of common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From Changes In Fair Value Of Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of shares of redeemable common stock to common stock, assumed in non cash investing or financing activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of 4,093,995 shares of redeemable common stock to 4,093,995 shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Options Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-Vested Restricted Stock Unit Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Redeemed For Employee Tax With Holdings, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Redeemed For Employee Tax With Holdings, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares redeemed for employee tax withholdings, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of the Status and Changes in Stock Option Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets or liabilities measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignEarningsRepatriated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of earnings from Foreign subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignEarningsRepatriated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Earnings Repatriated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease beginning date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Anti-dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities issuable value under self registration statement form</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities issuable value under self registration statement form</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities issuable value under self registration statement form</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-deductible permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-deductible permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number Of Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification from warrant liability to additional paid-in capital for warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification from warrant liability to additional paid in capital for warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification from Warrant Liability to Additional Paid In Capital for Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RepaymentOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RepaymentOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RepaymentOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RepaymentOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Right Of Use Of Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset right of use of liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_BmlManagementLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BML Management, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_BmlManagementLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BML Management, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiquidityAndFinancialPositionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for Liquidity and Financial Position.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiquidityAndFinancialPositionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Financial Position [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LiquidityAndFinancialPositionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of discount on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest paid on term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid On Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Finished Goods, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. loss before taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange payment for notes receivables for common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Payment Of Notes Receivables For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange Payment Of Notes Receivables For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Annual Principal Payments Due Under the Amended Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential Aggregate Payments For Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Aggregate Payments For Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential aggregate payments for regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingSegmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Segments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingSegmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingSegmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future sale under the ATM offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares available for future sale under the ATM offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future sale under the ATM offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Loan Originations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Loan Originations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price, Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion Factor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedInterestCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Interest Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State net operating Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State operating loss carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Operating Loss Carry Forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StateOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State operating loss carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash Received from the Exercise of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use of Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Right Of Use Of Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset right of use of asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Number of shares, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued To Purchase Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued to purchase preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding used in computing net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivable for common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable For Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable For Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable for Redeemable Common Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable For Redeemable Common Stock Issued [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivable for redeemable common stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance under the Equity Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Issuance Under The 2006 ,2015 And 2021 Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Available For Future Issuance Under The 2006 ,2015 And 2021 Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued and Outstanding Under the 2006, 2015 and 2021 Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Issued And Outstanding Under Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options Issued And Outstanding Under Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalCashProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total cash proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalCashProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Cash Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TotalCashProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FutureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FutureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash raised under the ATM Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesWCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series W common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesWCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series W Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesWCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series W Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_UnexercisedWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unexercised Warrants Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_UnexercisedWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unexercised Warrants Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_UnexercisedWarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unexercised warrants expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calhoun Vision Inc2015 Equity Incentive Plan And Calhoun Vision Inc2006 Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredTaxAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - finance leases (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash - end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash - beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Debt [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock sale underwriting discounts and commission deducted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sale Underwriting Discounts and Commission Deducted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sale underwriting discounts and commission deducted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OptionalConversionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Optional conversions member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OptionalConversionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Optional Conversions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OptionalConversionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional Conversions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsToPurchaseConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants To Purchase Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsToPurchaseConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities and Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable stock option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Tax Credit Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credit Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number Of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock, number of shares issued or sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options issued and outstanding under the Equity Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options issued and outstanding under the 2006, 2015 and 2021 plans[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options issued and outstanding under the 2006, 2015 and 2021 plans[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Hardware and Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average fair value, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value- End Date Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average fair value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future sale under the at-the-market offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares available for future sale under the at-the-market offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk adjusted discount factor, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Short-Term Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk adjusted discount factor, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossOnExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossOnExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainLossOnExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain Loss On Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for employee taxes related to stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for employee taxes related to stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for employee taxes related to stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for employee taxes related to stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Purchase Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for the employee stock purchase plan, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued for the employee stock purchase plan, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued for the employee stock purchase plan, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Escrow Holdback Of Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Holdback Of Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Escrow holdback of exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning Balance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value (2) Share Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Sublease Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred income and obligation to transfer product and service to customer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_DeferredRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_RedeemableCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The stated interest rate for notes receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable Interest Rate Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable Interest Rate Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CashInterestPaidPercentagePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Interest paid, Percentage, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CashInterestPaidPercentagePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Interest paid, Percentage, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CashInterestPaidPercentagePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity, Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity, Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk adjusted discount factor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement, Gains and Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized issuance costs and exit fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: unamortized issuance costs and exit fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_CommonStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccountsReceivablePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable, Percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccountsReceivablePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccountsReceivablePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021EsppPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The 2021 ESPP Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021EsppPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The 2021 ESPP Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_The2021EsppPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The 2021 ESPP Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) available to stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable for Redeemable Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation limitation and credit carry forwards subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnFinancingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest paid on financing leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnFinancingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid On Financing Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InterestPaidOnFinancingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest on financing leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ATM Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AtmOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive Officers and Non-Employee Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officers and Non-Employee Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officers and Non-Employee Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory held on consignment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income before Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 3, 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Three Two Thousand Twenty Two Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May Three Two Thousand Twenty Two Term Loan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Non-Refundable Payment Upon Extension of Expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Non Refundable Payment Upon Extension Of Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional non-refundable payment upon extension of expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedDeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedDeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Deferred Revenue Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_AccruedDeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Deferred Revenue Current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable for Common Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable For Common Stock Issued [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivable for common stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentCreditPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment Credit Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentCreditPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Credit Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_InvestmentCreditPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment credit percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExercisePriceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercise of preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_LeaseLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock from public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesHWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series H warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesHWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series H Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesHWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes receivable disclosure abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NotesReceivableDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to common stock, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ClosingStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ClosingStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation limitation and credit carry forwards subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-deductible permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainOnExpirationOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain On Expiration Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainOnExpirationOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain On Expiration Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_GainOnExpirationOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on expiration of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsToPurchaseStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsToPurchaseStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Stock Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_WarrantsToPurchaseStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrants to purchase stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Note Receivable For Redeemable Common Stock Issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Receivable For Redeemable Common Stock Issued [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingIncomeLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Income (Loss)1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingIncomeLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_OperatingIncomeLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Losses from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_SeriesGWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible compensation, contributed by eligible participating employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Other Income, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shelf Registration Statement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shelf Registration Statement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ShelfRegistrationStatementPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shelf Registration Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_NoCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_ClassOfWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity note receivables for common stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Note Receivables Common Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes receivable for common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares issued under ATM Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs of $12.4 million, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Preferred Units [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Preferred Units</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DebtFromCashReserves" xlink:to="rxst_DebtFromCashReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_StateOperatingLossCarryForwardsNotExpire" xlink:to="rxst_StateOperatingLossCarryForwardsNotExpire_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AccruedCustomerDepositsCurrent" xlink:to="rxst_AccruedCustomerDepositsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" xlink:to="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NumberOfWhollyOwnedSubsidiaries" xlink:to="rxst_NumberOfWhollyOwnedSubsidiaries_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AugustFourTwoThousandTwentyThreeMember" xlink:to="rxst_AugustFourTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CompassBibleChurchMember" xlink:to="rxst_CompassBibleChurchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WarehouseMember" xlink:to="srt_WarehouseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesFWarrantsMember" xlink:to="rxst_SeriesFWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CommonStockInExchangeForCancellationOfNotesReceivables" xlink:to="rxst_CommonStockInExchangeForCancellationOfNotesReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_BofaSecuritiesIncMember" xlink:to="rxst_BofaSecuritiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LeaseLiabilitiesNoncurrent" xlink:to="rxst_LeaseLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" xlink:to="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemableCommonStock1Member" xlink:to="rxst_RedeemableCommonStock1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" xlink:to="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PriorPreferredStockholdersMember" xlink:to="rxst_PriorPreferredStockholdersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TerminalValueExitMultiple" xlink:to="rxst_TerminalValueExitMultiple_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PreferredStockWarrantsMember" xlink:to="rxst_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExpirationOfCommonStockWarrants" xlink:to="rxst_ExpirationOfCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EmployeeStockPurchasePlanMember" xlink:to="rxst_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TermLoanMember" xlink:to="rxst_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeniorPreferredStockholdersMember" xlink:to="rxst_SeniorPreferredStockholdersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PublicOfferingMember" xlink:to="rxst_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod" xlink:to="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock" xlink:to="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PercentOfTaxableIncomeOffsetInFuture" xlink:to="rxst_PercentOfTaxableIncomeOffsetInFuture_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" xlink:to="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants" xlink:to="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_FinanceLeaseObligationsIncurred" xlink:to="rxst_FinanceLeaseObligationsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemableStockOptionsMember" xlink:to="rxst_RedeemableStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TotalLeaseAssets" xlink:to="rxst_TotalLeaseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesGAndHPreferredStockMember" xlink:to="rxst_SeriesGAndHPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CommonStockOfferingCosts" xlink:to="rxst_CommonStockOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TaxableIncomeOffsetPercentage" xlink:to="rxst_TaxableIncomeOffsetPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:to="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RxlalMember" xlink:to="rxst_RxlalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" xlink:to="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LDDMember" xlink:to="rxst_LDDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LiabilityOnUncertainTaxPosition" xlink:to="rxst_LiabilityOnUncertainTaxPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_InvestmentMaturityPeriod" xlink:to="rxst_InvestmentMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsIssuedToPurchaseCommonStock" xlink:to="rxst_WarrantsIssuedToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:to="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" xlink:to="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_FederalOperatingLossCarryForwards" xlink:to="rxst_FederalOperatingLossCarryForwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivablesMaturityYearEnd" xlink:to="rxst_NotesReceivablesMaturityYearEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" xlink:to="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EarningsPerShareTable" xlink:to="rxst_EarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="rxst_SignificantAccountingPoliciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AmendedTermLoanMember" xlink:to="rxst_AmendedTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:to="rxst_DeferredOfferingCostsIncludedInAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PreferredStockConvertibleConversionPriceIncreaseShares" xlink:to="rxst_PreferredStockConvertibleConversionPriceIncreaseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_COVID19PolicyTextBlock" xlink:to="rxst_COVID19PolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RightOfUseEquipmentMember" xlink:to="rxst_RightOfUseEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemablePreferredStockAndWarrantsMember" xlink:to="rxst_RedeemablePreferredStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CustomerThreeMember" xlink:to="rxst_CustomerThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" xlink:to="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EarningsPerShareLineItems" xlink:to="rxst_EarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SummaryOfLeaseBalancesTableTextBlock" xlink:to="rxst_SummaryOfLeaseBalancesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OperatingLeaseObligationsIncurred" xlink:to="rxst_OperatingLeaseObligationsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NewLoanAndSecurityAgreementMember" xlink:to="rxst_NewLoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredOfferingCostsPolicyTextBlock" xlink:to="rxst_DeferredOfferingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" xlink:to="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsOutstanding" xlink:to="rxst_WarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OfficeManufacturingAndWarehouseFacilityMember" xlink:to="rxst_OfficeManufacturingAndWarehouseFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredTaxAssetDepreciation" xlink:to="rxst_DeferredTaxAssetDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CustomerFourMember" xlink:to="rxst_CustomerFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" xlink:to="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AdditionalNumberOfCommonSharesIssued" xlink:to="rxst_AdditionalNumberOfCommonSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeExtensibleEnumeration" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_FederalOperatingLossCarryForwardsNotExpire" xlink:to="rxst_FederalOperatingLossCarryForwardsNotExpire_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementTerm" xlink:to="us-gaap_RegistrationPaymentArrangementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IncreasedDecreasedInRestrictedCash" xlink:to="rxst_IncreasedDecreasedInRestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WeightedAverageCostOfCapitalDiscountRate" xlink:to="rxst_WeightedAverageCostOfCapitalDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WeightedAverageGrantDateFairValueExercisable" xlink:to="rxst_WeightedAverageGrantDateFairValueExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableAggregatePrincipalAmount" xlink:to="rxst_NotesReceivableAggregatePrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" xlink:to="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesRedeemedForEmployeeTaxWithholdings" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShelfRegistrationStatementMember" xlink:to="rxst_ShelfRegistrationStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_FairValueOfWarrants" xlink:to="rxst_FairValueOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" xlink:to="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivablesInterestAmount" xlink:to="rxst_NotesReceivablesInterestAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:to="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ReclassificationOfDeferredCost" xlink:to="rxst_ReclassificationOfDeferredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableMaturityYearStart" xlink:to="rxst_NotesReceivableMaturityYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OtherComprehensiveLoss" xlink:to="rxst_OtherComprehensiveLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_The2021PlanMember" xlink:to="rxst_The2021PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OneCustomerMember" xlink:to="rxst_OneCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesGCommonStockMember" xlink:to="rxst_SeriesGCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OperatingLeaseRightOfUseAssets" xlink:to="rxst_OperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EffectiveIncomeTaxReconciliationTaxCredits" xlink:to="rxst_EffectiveIncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShortTermInvestmentsPolicyTextBlock" xlink:to="rxst_ShortTermInvestmentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TotalLeaseLiabilities" xlink:to="rxst_TotalLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockTransactionDate" xlink:to="us-gaap_SaleOfStockTransactionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant" xlink:to="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" xlink:to="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignEarningsRepatriated" xlink:to="us-gaap_ForeignEarningsRepatriated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsMember" xlink:to="rxst_WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" xlink:to="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NumberOfLeases" xlink:to="rxst_NumberOfLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" xlink:to="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RepaymentOfTermLoan" xlink:to="rxst_RepaymentOfTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CommonStockWarrantMember" xlink:to="rxst_CommonStockWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredTaxAssetRightOfUseOfLiability" xlink:to="rxst_DeferredTaxAssetRightOfUseOfLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_BmlManagementLlcMember" xlink:to="rxst_BmlManagementLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LiquidityAndFinancialPositionPolicyTextBlock" xlink:to="rxst_LiquidityAndFinancialPositionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CustomerTwoMember" xlink:to="rxst_CustomerTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WeightedAverageDiscountRateAbstract" xlink:to="rxst_WeightedAverageDiscountRateAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_InterestPaidOnTermLoan" xlink:to="rxst_InterestPaidOnTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExchangePaymentOfNotesReceivablesForCommonStock" xlink:to="rxst_ExchangePaymentOfNotesReceivablesForCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PotentialAggregatePaymentsForRegulatoryMilestones" xlink:to="rxst_PotentialAggregatePaymentsForRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OperatingSegmentsPolicyTextBlock" xlink:to="rxst_OperatingSegmentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AccruedInterestCurrent" xlink:to="rxst_AccruedInterestCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_StateOperatingLossCarryForwards" xlink:to="rxst_StateOperatingLossCarryForwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredTaxAssetRightOfUseOfAsset" xlink:to="rxst_DeferredTaxAssetRightOfUseOfAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsIssuedToPurchasePreferredStock" xlink:to="rxst_WarrantsIssuedToPurchasePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableForCommonStockMember" xlink:to="rxst_NotesReceivableForCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableForRedeemableCommonStockIssuedMember" xlink:to="rxst_NotesReceivableForRedeemableCommonStockIssuedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" xlink:to="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TotalCashProceeds" xlink:to="rxst_TotalCashProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FutureMember" xlink:to="us-gaap_FutureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ConvertiblePreferredStockWarrantLiabilityMember" xlink:to="rxst_ConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesWCommonStockMember" xlink:to="rxst_SeriesWCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_UnexercisedWarrantsExpired" xlink:to="rxst_UnexercisedWarrantsExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredTaxAssetAmortization" xlink:to="rxst_DeferredTaxAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:to="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OptionalConversionsMember" xlink:to="rxst_OptionalConversionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsToPurchaseConvertiblePreferredStock" xlink:to="rxst_WarrantsToPurchaseConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemableStockOptionMember" xlink:to="rxst_RedeemableStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IncomeTaxReconciliationTaxCreditOther" xlink:to="rxst_IncomeTaxReconciliationTaxCreditOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="rxst_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_GainLossOnExpiration" xlink:to="rxst_GainLossOnExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" xlink:to="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharePurchaseAgreementMember" xlink:to="rxst_SharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" xlink:to="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EscrowHoldbackOfExercisePriceOfWarrants" xlink:to="rxst_EscrowHoldbackOfExercisePriceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" xlink:to="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_DeferredRevenue1" xlink:to="rxst_DeferredRevenue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_RedeemableCommonStockMember" xlink:to="rxst_RedeemableCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableInterestRateStatedPercentage" xlink:to="rxst_NotesReceivableInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CashInterestPaidPercentagePeriod" xlink:to="rxst_CashInterestPaidPercentagePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_CommonStockWarrantLiabilityMember" xlink:to="rxst_CommonStockWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AccountsReceivablePercentage" xlink:to="rxst_AccountsReceivablePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WeightedAverageRemainingLeaseTermAbstract" xlink:to="rxst_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_The2021EsppPlanMember" xlink:to="rxst_The2021EsppPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:to="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_InterestPaidOnFinancingLeases" xlink:to="rxst_InterestPaidOnFinancingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AtmOfferingMember" xlink:to="rxst_AtmOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" xlink:to="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" xlink:to="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NumberOfCustomer" xlink:to="rxst_NumberOfCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" xlink:to="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_AccruedDeferredRevenueCurrent" xlink:to="rxst_AccruedDeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableForCommonStockIssuedMember" xlink:to="rxst_NotesReceivableForCommonStockIssuedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_InvestmentCreditPercentage" xlink:to="rxst_InvestmentCreditPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExercisePriceOfWarrants" xlink:to="rxst_ExercisePriceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ExerciseOfPreferredStockWarrants" xlink:to="rxst_ExerciseOfPreferredStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_LeaseLiabilitiesCurrent" xlink:to="rxst_LeaseLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesHWarrantsMember" xlink:to="rxst_SeriesHWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NotesReceivableDisclosureAbstract" xlink:to="rxst_NotesReceivableDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ClosingStockPrice" xlink:to="rxst_ClosingStockPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:to="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_GainOnExpirationOfWarrants" xlink:to="rxst_GainOnExpirationOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_WarrantsToPurchaseStockPolicyTextBlock" xlink:to="rxst_WarrantsToPurchaseStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NoteReceivableForRedeemableCommonStockIssuedMember" xlink:to="rxst_NoteReceivableForRedeemableCommonStockIssuedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SharesReservedForFutureIssuanceTableTextBlock" xlink:to="rxst_SharesReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_OperatingIncomeLoss1" xlink:to="rxst_OperatingIncomeLoss1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_SeriesGWarrantsMember" xlink:to="rxst_SeriesGWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ShelfRegistrationStatementPolicyTextBlock" xlink:to="rxst_ShelfRegistrationStatementPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_NoCustomerMember" xlink:to="rxst_NoCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_ClassOfWarrantsExercised" xlink:to="rxst_ClassOfWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxst_TemporaryEquityNoteReceivablesCommonStockIssued" xlink:to="rxst_TemporaryEquityNoteReceivablesCommonStockIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesNoncurrent" xlink:label="rxst_LeaseLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesCurrent" xlink:label="rxst_LeaseLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="rxst_LeaseLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="rxst_LeaseLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStock1Member" xlink:label="rxst_RedeemableCommonStock1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStockMember" xlink:label="rxst_RedeemableCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockMember" xlink:label="rxst_NotesReceivableForCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockMember" xlink:label="rxst_NotesReceivableForCommonStockMember_3"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionMember" xlink:label="rxst_RedeemableStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithholdings" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionsMember" xlink:label="rxst_RedeemableStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OtherComprehensiveLoss" xlink:label="rxst_OtherComprehensiveLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_16"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableCommonStock1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_NotesReceivableForCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxst_NotesReceivableForCommonStockIssuedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_NotesReceivableForRedeemableCommonStockIssuedMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxst_NotesReceivableForCommonStockMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithholdings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_OtherComprehensiveLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" xlink:label="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingLeaseObligationsIncurred" xlink:label="rxst_OperatingLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FinanceLeaseObligationsIncurred" xlink:label="rxst_FinanceLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RepaymentOfTermLoan" xlink:label="rxst_RepaymentOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InterestPaidOnFinancingLeases" xlink:label="rxst_InterestPaidOnFinancingLeases"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredOfferingCostsIncludedInAccruedExpenses" xlink:label="rxst_DeferredOfferingCostsIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InterestPaidOnTermLoan" xlink:label="rxst_InterestPaidOnTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" xlink:label="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" xlink:label="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" xlink:label="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ReclassificationOfDeferredCost" xlink:label="rxst_ReclassificationOfDeferredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" xlink:label="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" xlink:to="rxst_OperatingLeaseObligationsIncurred" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" xlink:to="rxst_FinanceLeaseObligationsIncurred" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxst_RepaymentOfTermLoan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="rxst_InterestPaidOnFinancingLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_DeferredOfferingCostsIncludedInAccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="rxst_InterestPaidOnTermLoan" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_PaidInKindInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_ReclassificationOfDeferredCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiability" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock" xlink:label="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableDisclosureAbstract" xlink:label="rxst_NotesReceivableDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_NotesReceivableDisclosureAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingSegmentsPolicyTextBlock" xlink:label="rxst_OperatingSegmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LiquidityAndFinancialPositionPolicyTextBlock" xlink:label="rxst_LiquidityAndFinancialPositionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" xlink:label="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShelfRegistrationStatementPolicyTextBlock" xlink:label="rxst_ShelfRegistrationStatementPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_COVID19PolicyTextBlock" xlink:label="rxst_COVID19PolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="rxst_SignificantAccountingPoliciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShortTermInvestmentsPolicyTextBlock" xlink:label="rxst_ShortTermInvestmentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsToPurchaseStockPolicyTextBlock" xlink:label="rxst_WarrantsToPurchaseStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredOfferingCostsPolicyTextBlock" xlink:label="rxst_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="rxst_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_OperatingSegmentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_LiquidityAndFinancialPositionPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_ShelfRegistrationStatementPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_COVID19PolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_SignificantAccountingPoliciesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_ShortTermInvestmentsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_WarrantsToPurchaseStockPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_DeferredOfferingCostsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_EmergingGrowthCompanyStatusPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" xlink:label="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" xlink:label="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPreferredUnitsTextBlock" xlink:label="us-gaap_ScheduleOfPreferredUnitsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" xlink:label="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesReservedForFutureIssuanceTableTextBlock" xlink:label="rxst_SharesReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfPreferredUnitsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rxst_SharesReservedForFutureIssuanceTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" xlink:label="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SummaryOfLeaseBalancesTableTextBlock" xlink:label="rxst_SummaryOfLeaseBalancesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_SummaryOfLeaseBalancesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfWhollyOwnedSubsidiaries" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShelfRegistrationStatementMember" xlink:label="rxst_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNumberOfCommonSharesIssued" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingIncomeLoss1" xlink:label="rxst_OperatingIncomeLoss1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_NumberOfWhollyOwnedSubsidiaries" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_ShelfRegistrationStatementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_AtmOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_AdditionalNumberOfCommonSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockOfferingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_OperatingIncomeLoss1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OneCustomerMember" xlink:label="rxst_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerTwoMember" xlink:label="rxst_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerThreeMember" xlink:label="rxst_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerFourMember" xlink:label="rxst_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncreasedDecreasedInRestrictedCash" xlink:label="rxst_IncreasedDecreasedInRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoCustomerMember" xlink:label="rxst_NoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LiabilityOnUncertainTaxPosition" xlink:label="rxst_LiabilityOnUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfCustomer" xlink:label="rxst_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccountsReceivablePercentage" xlink:label="rxst_AccountsReceivablePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_OneCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IncreasedDecreasedInRestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_NoCustomerMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_LiabilityOnUncertainTaxPosition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_NumberOfCustomer" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_AccountsReceivablePercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionsMember" xlink:label="rxst_RedeemableStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockWarrantsMember" xlink:label="rxst_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGCommonStockMember" xlink:label="rxst_SeriesGCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemablePreferredStockAndWarrantsMember" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxst_SeriesGCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemablePreferredStockAndWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DilutiveSecuritiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DilutiveSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareTable" xlink:label="rxst_EarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareLineItems" xlink:label="rxst_EarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemablePreferredStockAndWarrantsMember" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmployeeStockPurchasePlanMember" xlink:label="rxst_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_EarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rxst_EarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_EarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_RedeemablePreferredStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_EarningsPerShareTable" xlink:to="rxst_EarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LDDMember" xlink:label="rxst_LDDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RxlalMember" xlink:label="rxst_RxlalMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_LDDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_RxlalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAbstract" xlink:label="us-gaap_DeferredRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredRevenue1" xlink:label="rxst_DeferredRevenue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredRevenue1" xlink:label="rxst_DeferredRevenue1_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="rxst_DeferredRevenue1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="rxst_DeferredRevenue1_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InvestmentMaturityPeriod" xlink:label="rxst_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="rxst_InvestmentMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RightOfUseEquipmentMember" xlink:label="rxst_RightOfUseEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rxst_RightOfUseEquipmentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantLiabilityMember" xlink:label="rxst_CommonStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_ConvertiblePreferredStockWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_CommonStockWarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsToPurchaseConvertiblePreferredStock" xlink:label="rxst_WarrantsToPurchaseConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="rxst_WarrantsToPurchaseConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExerciseOfPreferredStockWarrants" xlink:label="rxst_ExerciseOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExpirationOfCommonStockWarrants" xlink:label="rxst_ExpirationOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossFromChangesInFairValueOfCommonStockWarrant" xlink:label="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants" xlink:label="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="rxst_ExerciseOfPreferredStockWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="rxst_ExpirationOfCommonStockWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedDeferredRevenueCurrent" xlink:label="rxst_AccruedDeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedInterestCurrent" xlink:label="rxst_AccruedInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedCustomerDepositsCurrent" xlink:label="rxst_AccruedCustomerDepositsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="rxst_AccruedDeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="rxst_AccruedInterestCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="rxst_AccruedCustomerDepositsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AugustFourTwoThousandTwentyThreeMember" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TermLoanMember" xlink:label="rxst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NewLoanAndSecurityAgreementMember" xlink:label="rxst_NewLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AmendedTermLoanMember" xlink:label="rxst_AmendedTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DebtFromCashReserves" xlink:label="rxst_DebtFromCashReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="rxst_AugustFourTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_AtmOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_NewLoanAndSecurityAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_AmendedTermLoanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForFees" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rxst_DebtFromCashReserves" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CashInterestPaidPercentagePeriod" xlink:label="rxst_CashInterestPaidPercentagePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="rxst_CashInterestPaidPercentagePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchaseCommonStock" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesWCommonStockMember" xlink:label="rxst_SeriesWCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharePurchaseAgreementMember" xlink:label="rxst_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGCommonStockMember" xlink:label="rxst_SeriesGCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExercisePriceOfWarrants" xlink:label="rxst_ExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EscrowHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForRegulatoryMilestones" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainOnExpirationOfWarrants" xlink:label="rxst_GainOnExpirationOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsIssuedToPurchaseCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesWCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SharePurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesGCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ExercisePriceOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_EscrowHoldbackOfExercisePriceOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PotentialAggregatePaymentsForRegulatoryMilestones" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_GainOnExpirationOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TerminalValueExitMultiple" xlink:label="rxst_TerminalValueExitMultiple"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesWCommonStockMember" xlink:label="rxst_SeriesWCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageCostOfCapitalDiscountRate" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_TerminalValueExitMultiple" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesWCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WeightedAverageCostOfCapitalDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PriorPreferredStockholdersMember" xlink:label="rxst_PriorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OptionalConversionsMember" xlink:label="rxst_OptionalConversionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGAndHPreferredStockMember" xlink:label="rxst_SeriesGAndHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeniorPreferredStockholdersMember" xlink:label="rxst_SeniorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNumberOfCommonSharesIssued" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="us-gaap_RegistrationPaymentArrangementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PriorPreferredStockholdersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_OptionalConversionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesGAndHPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeniorPreferredStockholdersMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_AdditionalNumberOfCommonSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_CommonStockOfferingCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementTerm" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMember" xlink:label="us-gaap_FutureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021EsppPlanMember" xlink:label="rxst_The2021EsppPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockWarrantsMember" xlink:label="rxst_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantMember" xlink:label="rxst_CommonStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmployeeStockPurchasePlanMember" xlink:label="rxst_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_FutureMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_The2021EsppPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PreferredStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_CommonStockWarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_EmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClosingStockPrice" xlink:label="rxst_ClosingStockPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_ClosingStockPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfStockLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesFWarrantsMember" xlink:label="rxst_SeriesFWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGWarrantsMember" xlink:label="rxst_SeriesGWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesHWarrantsMember" xlink:label="rxst_SeriesHWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesFWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesGWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesHWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesFWarrantsMember" xlink:label="rxst_SeriesFWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockConvertibleConversionPriceIncreaseShares" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGWarrantsMember" xlink:label="rxst_SeriesGWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalCashProceeds" xlink:label="rxst_TotalCashProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsMember" xlink:label="rxst_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossOnExpiration" xlink:label="rxst_GainLossOnExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesHWarrantsMember" xlink:label="rxst_SeriesHWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_UnexercisedWarrantsExpired" xlink:label="rxst_UnexercisedWarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchasePreferredStock" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsOutstanding" xlink:label="rxst_WarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FairValueOfWarrants" xlink:label="rxst_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClassOfWarrantsExercised" xlink:label="rxst_ClassOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesFWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PreferredStockConvertibleConversionPriceIncreaseShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesGWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_TotalCashProceeds" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_WarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_GainLossOnExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesHWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_UnexercisedWarrantsExpired" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsIssuedToPurchasePreferredStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_FairValueOfWarrants" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ClassOfWarrantsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021PlanMember" xlink:label="rxst_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021EsppPlanMember" xlink:label="rxst_The2021EsppPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_The2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_The2021EsppPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageGrantDateFairValueExercisable" xlink:label="rxst_WeightedAverageGrantDateFairValueExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_WeightedAverageGrantDateFairValueExercisable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetAmortization" xlink:label="rxst_DeferredTaxAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfLiability" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetDepreciation" xlink:label="rxst_DeferredTaxAssetDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfAsset" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="rxst_DeferredTaxAssetAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="rxst_DeferredTaxAssetRightOfUseOfLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="rxst_DeferredTaxAssetDepreciation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="rxst_DeferredTaxAssetRightOfUseOfAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:label="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EffectiveIncomeTaxReconciliationTaxCredits" xlink:label="rxst_EffectiveIncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationTaxCreditOther" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_EffectiveIncomeTaxReconciliationTaxCredits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_IncomeTaxReconciliationTaxCreditOther" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FederalOperatingLossCarryForwards" xlink:label="rxst_FederalOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StateOperatingLossCarryForwards" xlink:label="rxst_StateOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FederalOperatingLossCarryForwardsNotExpire" xlink:label="rxst_FederalOperatingLossCarryForwardsNotExpire"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InvestmentCreditPercentage" xlink:label="rxst_InvestmentCreditPercentage"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PercentOfTaxableIncomeOffsetInFuture" xlink:label="rxst_PercentOfTaxableIncomeOffsetInFuture"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StateOperatingLossCarryForwards" xlink:label="rxst_StateOperatingLossCarryForwards_8"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FederalOperatingLossCarryForwards" xlink:label="rxst_FederalOperatingLossCarryForwards_9"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StateOperatingLossCarryForwardsNotExpire" xlink:label="rxst_StateOperatingLossCarryForwardsNotExpire"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TaxableIncomeOffsetPercentage" xlink:label="rxst_TaxableIncomeOffsetPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignEarningsRepatriated" xlink:label="us-gaap_ForeignEarningsRepatriated"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_FederalOperatingLossCarryForwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_StateOperatingLossCarryForwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_FederalOperatingLossCarryForwardsNotExpire" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_InvestmentCreditPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_PercentOfTaxableIncomeOffsetInFuture" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_StateOperatingLossCarryForwards_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_FederalOperatingLossCarryForwards_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_StateOperatingLossCarryForwardsNotExpire" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rxst_TaxableIncomeOffsetPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ForeignEarningsRepatriated" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableAggregatePrincipalAmount" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoteReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableDisclosureAbstract" xlink:label="rxst_NotesReceivableDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableInterestRateStatedPercentage" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExchangePaymentOfNotesReceivablesForCommonStock" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableMaturityYearStart" xlink:label="rxst_NotesReceivableMaturityYearStart"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesMaturityYearEnd" xlink:label="rxst_NotesReceivablesMaturityYearEnd"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesInterestAmount" xlink:label="rxst_NotesReceivablesInterestAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TemporaryEquityNoteReceivablesCommonStockIssued" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockInExchangeForCancellationOfNotesReceivables" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableAggregatePrincipalAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="rxst_NoteReceivableForRedeemableCommonStockIssuedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxst_NotesReceivableDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_ExchangePaymentOfNotesReceivablesForCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableMaturityYearStart" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivablesMaturityYearEnd" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivablesInterestAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_TemporaryEquityNoteReceivablesCommonStockIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_CommonStockInExchangeForCancellationOfNotesReceivables" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfLeases" xlink:label="rxst_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OfficeManufacturingAndWarehouseFacilityMember" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rxst_NumberOfLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rxst_OfficeManufacturingAndWarehouseFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_OfficeBuildingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_WarehouseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingLeaseRightOfUseAssets" xlink:label="rxst_OperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseAssets" xlink:label="rxst_TotalLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseLiabilities" xlink:label="rxst_TotalLeaseLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_OperatingLeaseRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_TotalLeaseAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_TotalLeaseLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageRemainingLeaseTermAbstract" xlink:label="rxst_WeightedAverageRemainingLeaseTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageDiscountRateAbstract" xlink:label="rxst_WeightedAverageDiscountRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_WeightedAverageRemainingLeaseTermAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rxst_WeightedAverageDiscountRateAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LegalFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod" xlink:label="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BofaSecuritiesIncMember" xlink:label="rxst_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PublicOfferingMember" xlink:label="rxst_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BmlManagementLlcMember" xlink:label="rxst_BmlManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CompassBibleChurchMember" xlink:label="rxst_CompassBibleChurchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_BofaSecuritiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_BmlManagementLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_CompassBibleChurchMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockOfferingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStock1Member" xlink:label="rxst_RedeemableCommonStock1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableCommonStockMember" xlink:label="rxst_RedeemableCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockMember" xlink:label="rxst_NotesReceivableForCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NotesReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" xlink:label="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionMember" xlink:label="rxst_RedeemableStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithholdings" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionsMember" xlink:label="rxst_RedeemableStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" xlink:label="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" xlink:label="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" xlink:label="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" xlink:label="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OtherComprehensiveLoss" xlink:label="rxst_OtherComprehensiveLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableCommonStock1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_NotesReceivableForCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxst_NotesReceivableForCommonStockIssuedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_NotesReceivableForRedeemableCommonStockIssuedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_OtherComprehensiveLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfWhollyOwnedSubsidiaries" xlink:label="rxst_NumberOfWhollyOwnedSubsidiaries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShelfRegistrationStatementMember" xlink:label="rxst_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNumberOfCommonSharesIssued" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OperatingIncomeLoss1" xlink:label="rxst_OperatingIncomeLoss1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_NumberOfWhollyOwnedSubsidiaries" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_ShelfRegistrationStatementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_AtmOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_AdditionalNumberOfCommonSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_OperatingIncomeLoss1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OneCustomerMember" xlink:label="rxst_OneCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerTwoMember" xlink:label="rxst_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerThreeMember" xlink:label="rxst_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CustomerFourMember" xlink:label="rxst_CustomerFourMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncreasedDecreasedInRestrictedCash" xlink:label="rxst_IncreasedDecreasedInRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoCustomerMember" xlink:label="rxst_NoCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LiabilityOnUncertainTaxPosition" xlink:label="rxst_LiabilityOnUncertainTaxPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfCustomer" xlink:label="rxst_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccountsReceivablePercentage" xlink:label="rxst_AccountsReceivablePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_OneCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_CustomerFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_IncreasedDecreasedInRestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rxst_NoCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_LiabilityOnUncertainTaxPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_NumberOfCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxst_AccountsReceivablePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableStockOptionsMember" xlink:label="rxst_RedeemableStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockWarrantsMember" xlink:label="rxst_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGCommonStockMember" xlink:label="rxst_SeriesGCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemablePreferredStockAndWarrantsMember" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemableStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxst_SeriesGCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_RedeemablePreferredStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DilutiveSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DilutiveSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareLineItems" xlink:label="rxst_EarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EarningsPerShareTable" xlink:label="rxst_EarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemablePreferredStockAndWarrantsMember" xlink:label="rxst_RedeemablePreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmployeeStockPurchasePlanMember" xlink:label="rxst_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rxst_EarningsPerShareLineItems" xlink:to="rxst_EarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rxst_EarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rxst_EarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_RedeemablePreferredStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LDDMember" xlink:label="rxst_LDDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RxlalMember" xlink:label="rxst_RxlalMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" xlink:label="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_LDDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_RxlalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_InvestmentMaturityPeriod" xlink:label="rxst_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="rxst_InvestmentMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RightOfUseEquipmentMember" xlink:label="rxst_RightOfUseEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rxst_RightOfUseEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_ConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantLiabilityMember" xlink:label="rxst_CommonStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_ConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_CommonStockWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsToPurchaseConvertiblePreferredStock" xlink:label="rxst_WarrantsToPurchaseConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="rxst_WarrantsToPurchaseConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AugustFourTwoThousandTwentyThreeMember" xlink:label="rxst_AugustFourTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TermLoanMember" xlink:label="rxst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" xlink:label="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NewLoanAndSecurityAgreementMember" xlink:label="rxst_NewLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AmendedTermLoanMember" xlink:label="rxst_AmendedTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DebtFromCashReserves" xlink:label="rxst_DebtFromCashReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="rxst_AugustFourTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_AtmOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLoanOriginations1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_NewLoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rxst_AmendedTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rxst_DebtFromCashReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchaseCommonStock" xlink:label="rxst_WarrantsIssuedToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesWCommonStockMember" xlink:label="rxst_SeriesWCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" xlink:label="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharePurchaseAgreementMember" xlink:label="rxst_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGCommonStockMember" xlink:label="rxst_SeriesGCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExercisePriceOfWarrants" xlink:label="rxst_ExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EscrowHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_EscrowHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" xlink:label="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" xlink:label="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PotentialAggregatePaymentsForRegulatoryMilestones" xlink:label="rxst_PotentialAggregatePaymentsForRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainOnExpirationOfWarrants" xlink:label="rxst_GainOnExpirationOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsIssuedToPurchaseCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesWCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesGCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ExercisePriceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_EscrowHoldbackOfExercisePriceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PotentialAggregatePaymentsForRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_GainOnExpirationOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TerminalValueExitMultiple" xlink:label="rxst_TerminalValueExitMultiple"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesWCommonStockMember" xlink:label="rxst_SeriesWCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageCostOfCapitalDiscountRate" xlink:label="rxst_WeightedAverageCostOfCapitalDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_TerminalValueExitMultiple" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesWCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WeightedAverageCostOfCapitalDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PriorPreferredStockholdersMember" xlink:label="rxst_PriorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OptionalConversionsMember" xlink:label="rxst_OptionalConversionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGAndHPreferredStockMember" xlink:label="rxst_SeriesGAndHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeniorPreferredStockholdersMember" xlink:label="rxst_SeniorPreferredStockholdersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AdditionalNumberOfCommonSharesIssued" xlink:label="rxst_AdditionalNumberOfCommonSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" xlink:label="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" xlink:label="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="us-gaap_RegistrationPaymentArrangementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PriorPreferredStockholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_OptionalConversionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesGAndHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeniorPreferredStockholdersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_AdditionalNumberOfCommonSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_CommonStockOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" xlink:label="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FutureMember" xlink:label="us-gaap_FutureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021EsppPlanMember" xlink:label="rxst_The2021EsppPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" xlink:label="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockWarrantsMember" xlink:label="rxst_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockWarrantMember" xlink:label="rxst_CommonStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_EmployeeStockPurchasePlanMember" xlink:label="rxst_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" xlink:label="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_FutureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_The2021EsppPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_CommonStockWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClosingStockPrice" xlink:label="rxst_ClosingStockPrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rxst_ClosingStockPrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesFWarrantsMember" xlink:label="rxst_SeriesFWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGWarrantsMember" xlink:label="rxst_SeriesGWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesHWarrantsMember" xlink:label="rxst_SeriesHWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesFWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesGWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_SeriesHWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesFWarrantsMember" xlink:label="rxst_SeriesFWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PreferredStockConvertibleConversionPriceIncreaseShares" xlink:label="rxst_PreferredStockConvertibleConversionPriceIncreaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesGWarrantsMember" xlink:label="rxst_SeriesGWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalCashProceeds" xlink:label="rxst_TotalCashProceeds"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsMember" xlink:label="rxst_WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_GainLossOnExpiration" xlink:label="rxst_GainLossOnExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SeriesHWarrantsMember" xlink:label="rxst_SeriesHWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_UnexercisedWarrantsExpired" xlink:label="rxst_UnexercisedWarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsIssuedToPurchasePreferredStock" xlink:label="rxst_WarrantsIssuedToPurchasePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" xlink:label="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WarrantsOutstanding" xlink:label="rxst_WarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_FairValueOfWarrants" xlink:label="rxst_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ClassOfWarrantsExercised" xlink:label="rxst_ClassOfWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesFWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_PreferredStockConvertibleConversionPriceIncreaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesGWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_TotalCashProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_GainLossOnExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rxst_SeriesHWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_UnexercisedWarrantsExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsIssuedToPurchasePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_WarrantsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_FairValueOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rxst_ClassOfWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" xlink:label="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021PlanMember" xlink:label="rxst_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_The2021EsppPlanMember" xlink:label="rxst_The2021EsppPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_The2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_The2021EsppPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_WeightedAverageGrantDateFairValueExercisable" xlink:label="rxst_WeightedAverageGrantDateFairValueExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_WeightedAverageGrantDateFairValueExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" xlink:label="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" xlink:label="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" xlink:label="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableAggregatePrincipalAmount" xlink:label="rxst_NotesReceivableAggregatePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NoteReceivableForRedeemableCommonStockIssuedMember" xlink:label="rxst_NoteReceivableForRedeemableCommonStockIssuedMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableInterestRateStatedPercentage" xlink:label="rxst_NotesReceivableInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ExchangePaymentOfNotesReceivablesForCommonStock" xlink:label="rxst_ExchangePaymentOfNotesReceivablesForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivableMaturityYearStart" xlink:label="rxst_NotesReceivableMaturityYearStart"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesMaturityYearEnd" xlink:label="rxst_NotesReceivablesMaturityYearEnd"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NotesReceivablesInterestAmount" xlink:label="rxst_NotesReceivablesInterestAmount"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TemporaryEquityNoteReceivablesCommonStockIssued" xlink:label="rxst_TemporaryEquityNoteReceivablesCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockInExchangeForCancellationOfNotesReceivables" xlink:label="rxst_CommonStockInExchangeForCancellationOfNotesReceivables"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableAggregatePrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="rxst_NoteReceivableForRedeemableCommonStockIssuedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_ExchangePaymentOfNotesReceivablesForCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivableMaturityYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivablesMaturityYearEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_NotesReceivablesInterestAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_TemporaryEquityNoteReceivablesCommonStockIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="rxst_CommonStockInExchangeForCancellationOfNotesReceivables" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_NumberOfLeases" xlink:label="rxst_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_OfficeManufacturingAndWarehouseFacilityMember" xlink:label="rxst_OfficeManufacturingAndWarehouseFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember" xlink:label="srt_WarehouseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rxst_NumberOfLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rxst_OfficeManufacturingAndWarehouseFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_WarehouseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperationsCommencedDate1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AtmOfferingMember" xlink:label="rxst_AtmOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BofaSecuritiesIncMember" xlink:label="rxst_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PublicOfferingMember" xlink:label="rxst_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_BmlManagementLlcMember" xlink:label="rxst_BmlManagementLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CompassBibleChurchMember" xlink:label="rxst_CompassBibleChurchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_CommonStockOfferingCosts" xlink:label="rxst_CommonStockOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rxst_AtmOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_BofaSecuritiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rxst_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_BmlManagementLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rxst_CompassBibleChurchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rxst_CommonStockOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesCurrent" xlink:label="rxst_LeaseLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesNoncurrent" xlink:label="rxst_LeaseLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="rxst_LeaseLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="rxst_LeaseLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="rxst_LeaseLiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="rxst_LeaseLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebt" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesNoncurrent" xlink:label="rxst_LeaseLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_LeaseLiabilitiesCurrent" xlink:label="rxst_LeaseLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxst_RepaymentOfTermLoan" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_RepaymentOfTermLoan" xlink:label="rxst_RepaymentOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" xlink:label="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" xlink:label="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rxst_AccruedDeferredRevenueCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rxst_AccruedInterestCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rxst_AccruedCustomerDepositsCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedDeferredRevenueCurrent" xlink:label="rxst_AccruedDeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedInterestCurrent" xlink:label="rxst_AccruedInterestCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_AccruedCustomerDepositsCurrent" xlink:label="rxst_AccruedCustomerDepositsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rxst_DeferredTaxAssetRightOfUseOfAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rxst_DeferredTaxAssetAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rxst_DeferredTaxAssetRightOfUseOfLiability" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rxst_DeferredTaxAssetDepreciation" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfAsset" xlink:label="rxst_DeferredTaxAssetRightOfUseOfAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetAmortization" xlink:label="rxst_DeferredTaxAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetRightOfUseOfLiability" xlink:label="rxst_DeferredTaxAssetRightOfUseOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_DeferredTaxAssetDepreciation" xlink:label="rxst_DeferredTaxAssetDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="rxst_IncomeTaxReconciliationTaxCreditOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" xlink:label="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_IncomeTaxReconciliationTaxCreditOther" xlink:label="rxst_IncomeTaxReconciliationTaxCreditOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseAssets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseLiabilities" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rxst_TotalLeaseLiabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseAssets" xlink:label="rxst_TotalLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="rxst-20231231.xsd#rxst_TotalLeaseLiabilities" xlink:label="rxst_TotalLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rxst_SeniorPreferredStockholdersMember" name="SeniorPreferredStockholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_NotesReceivablesMaturityYearEnd" name="NotesReceivablesMaturityYearEnd" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_PercentOfTaxableIncomeOffsetInFuture" name="PercentOfTaxableIncomeOffsetInFuture" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_EarningsPerShareTable" name="EarningsPerShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" name="PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" name="ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_TotalLeaseAssets" name="TotalLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_OneCustomerMember" name="OneCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_RedeemableCommonStockMember" name="RedeemableCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ShelfRegistrationStatementPolicyTextBlock" name="ShelfRegistrationStatementPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_MayThreeTwoThousandTwentyTwoTermLoanMember" name="MayThreeTwoThousandTwentyTwoTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_NumberOfLeases" name="NumberOfLeases" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_GainLossFromChangesInFairValueOfCommonStockWarrant" name="GainLossFromChangesInFairValueOfCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NumberOfWhollyOwnedSubsidiaries" name="NumberOfWhollyOwnedSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_RedeemableStockOptionMember" name="RedeemableStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_AccruedInterestCurrent" name="AccruedInterestCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm" name="SecuritiesIssuableValueUnderSelfRegistrationStatementForm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_DeferredTaxAssetAmortization" name="DeferredTaxAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" name="StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_TerminalValueExitMultiple" name="TerminalValueExitMultiple" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" name="ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_SeriesGAndHPreferredStockMember" name="SeriesGAndHPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_WarrantsOutstanding" name="WarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_EarningsPerShareLineItems" name="EarningsPerShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_LDDMember" name="LDDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_NoCustomerMember" name="NoCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_DeferredOfferingCostsIncludedInAccruedExpenses" name="DeferredOfferingCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" name="IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_RedeemablePreferredStockAndWarrantsMember" name="RedeemablePreferredStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_AccruedDeferredRevenueCurrent" name="AccruedDeferredRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" name="ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_FederalOperatingLossCarryForwardsNotExpire" name="FederalOperatingLossCarryForwardsNotExpire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_SeriesGWarrantsMember" name="SeriesGWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_WarrantsToPurchaseStockPolicyTextBlock" name="WarrantsToPurchaseStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" name="CommonStockSaleUnderwritingDiscountsAndCommissionDeducted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_SummaryOfLeaseBalancesTableTextBlock" name="SummaryOfLeaseBalancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_AugustFourTwoThousandTwentyThreeMember" name="AugustFourTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_NotesReceivableDisclosureAbstract" name="NotesReceivableDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CommonStockWarrantMember" name="CommonStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock" name="ConvertiblePreferredStockWarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_DeferredTaxAssetRightOfUseOfLiability" name="DeferredTaxAssetRightOfUseOfLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_NotesReceivableAggregatePrincipalAmount" name="NotesReceivableAggregatePrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SharesRedeemedForEmployeeTaxWithholdings" name="SharesRedeemedForEmployeeTaxWithholdings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ServiceWarrantyServiceContractsAndAccessoriesMember" name="ServiceWarrantyServiceContractsAndAccessoriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SignificantAccountingPoliciesPolicyTextBlock" name="SignificantAccountingPoliciesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_InterestPaidOnFinancingLeases" name="InterestPaidOnFinancingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" name="ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NewLoanAndSecurityAgreementMember" name="NewLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_DeferredTaxAssetDepreciation" name="DeferredTaxAssetDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" name="SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_InvestmentCreditPercentage" name="InvestmentCreditPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" name="ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ExercisePriceOfWarrants" name="ExercisePriceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" name="SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_TotalCashProceeds" name="TotalCashProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ShelfRegistrationStatementMember" name="ShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_EffectiveIncomeTaxReconciliationTaxCredits" name="EffectiveIncomeTaxReconciliationTaxCredits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount" name="SharesIssuedForTheEmployeeStockPurchasePlanAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ClassOfWarrantsExercised" name="ClassOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_OtherComprehensiveLoss" name="OtherComprehensiveLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_RxlalMember" name="RxlalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_RedeemableStockOptionsMember" name="RedeemableStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_RightOfUseEquipmentMember" name="RightOfUseEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation" name="PaymentsForEmployeeTaxesRelatedToStockCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_BmlManagementLlcMember" name="BmlManagementLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_WarrantsMember" name="WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_NotesReceivableInterestRateStatedPercentage" name="NotesReceivableInterestRateStatedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_RedeemableCommonStock1Member" name="RedeemableCommonStock1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" name="IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SeriesHWarrantsMember" name="SeriesHWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember" name="ExecutiveOfficersAndNonEmployeeDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_COVID19PolicyTextBlock" name="COVID19PolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract" name="LeaseObligationsRecordedForRightOfUseAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_DebtFromCashReserves" name="DebtFromCashReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_The2021PlanMember" name="The2021PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember" name="RedeemableConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ClosingStockPrice" name="ClosingStockPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_DeferredTaxAssetRightOfUseOfAsset" name="DeferredTaxAssetRightOfUseOfAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" name="ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SeriesGCommonStockMember" name="SeriesGCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_OperatingLeaseObligationsIncurred" name="OperatingLeaseObligationsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_TotalLeaseLiabilities" name="TotalLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ExpirationOfCommonStockWarrants" name="ExpirationOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_PotentialAggregatePaymentsForRegulatoryMilestones" name="PotentialAggregatePaymentsForRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_DeferredRevenue1" name="DeferredRevenue1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_WarrantsToPurchaseConvertiblePreferredStock" name="WarrantsToPurchaseConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_WeightedAverageCostOfCapitalDiscountRate" name="WeightedAverageCostOfCapitalDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_WeightedAverageGrantDateFairValueExercisable" name="WeightedAverageGrantDateFairValueExercisable" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_OperatingLeaseRightOfUseAssets" name="OperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ReclassificationOfDeferredCost" name="ReclassificationOfDeferredCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" name="CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_WarrantsIssuedToPurchaseCommonStock" name="WarrantsIssuedToPurchaseCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NotesReceivableForRedeemableCommonStockIssuedMember" name="NotesReceivableForRedeemableCommonStockIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_LeaseLiabilitiesNoncurrent" name="LeaseLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_FederalOperatingLossCarryForwards" name="FederalOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_The2021EsppPlanMember" name="The2021EsppPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_OptionalConversionsMember" name="OptionalConversionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" name="SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants" name="GainLossFromChangesInFairValueOfPreferredStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NumberOfCustomer" name="NumberOfCustomer" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_StateOperatingLossCarryForwards" name="StateOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_WarrantsIssuedToPurchasePreferredStock" name="WarrantsIssuedToPurchasePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_IncomeTaxReconciliationTaxCreditOther" name="IncomeTaxReconciliationTaxCreditOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" name="SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_LiabilityOnUncertainTaxPosition" name="LiabilityOnUncertainTaxPosition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" name="ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NotesReceivablesInterestAmount" name="NotesReceivablesInterestAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_AccruedCustomerDepositsCurrent" name="AccruedCustomerDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_BofaSecuritiesIncMember" name="BofaSecuritiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" name="ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_TemporaryEquityNoteReceivablesCommonStockIssued" name="TemporaryEquityNoteReceivablesCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod" name="DefinedContributionSavingPlansMatchingContributionsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_IncreasedDecreasedInRestrictedCash" name="IncreasedDecreasedInRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_InvestmentMaturityPeriod" name="InvestmentMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CommonStockOfferingCosts" name="CommonStockOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" name="ConversionOfPreferredStockToCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_FairValueOfWarrants" name="FairValueOfWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_NotesReceivableForCommonStockIssuedMember" name="NotesReceivableForCommonStockIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_LiquidityAndFinancialPositionPolicyTextBlock" name="LiquidityAndFinancialPositionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" name="SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NoteReceivableForRedeemableCommonStockIssuedMember" name="NoteReceivableForRedeemableCommonStockIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CommonStockWarrantLiabilityMember" name="CommonStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SeriesFWarrantsMember" name="SeriesFWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember" name="SharesAvailableForFutureSaleUnderTheAtmOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount" name="SharesRedeemedForEmployeeTaxWithHoldingsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" name="ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" name="IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_AtmOfferingMember" name="AtmOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_NotesReceivableForCommonStockMember" name="NotesReceivableForCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_PreferredStockConvertibleConversionPriceIncreaseShares" name="PreferredStockConvertibleConversionPriceIncreaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_UnexercisedWarrantsExpired" name="UnexercisedWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SharesReservedForFutureIssuanceTableTextBlock" name="SharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_OperatingSegmentsPolicyTextBlock" name="OperatingSegmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_RepaymentOfTermLoan" name="RepaymentOfTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" name="SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_TaxableIncomeOffsetPercentage" name="TaxableIncomeOffsetPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rxst_CompassBibleChurchMember" name="CompassBibleChurchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CustomerFourMember" name="CustomerFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_GainOnExpirationOfWarrants" name="GainOnExpirationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ExchangePaymentOfNotesReceivablesForCommonStock" name="ExchangePaymentOfNotesReceivablesForCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_InterestPaidOnTermLoan" name="InterestPaidOnTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_SeriesWCommonStockMember" name="SeriesWCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_EscrowHoldbackOfExercisePriceOfWarrants" name="EscrowHoldbackOfExercisePriceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_ExerciseOfPreferredStockWarrants" name="ExerciseOfPreferredStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_AmendedTermLoanMember" name="AmendedTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_StockOptionsIssuedAndOutstandingUnderPlansMember" name="StockOptionsIssuedAndOutstandingUnderPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_FinanceLeaseObligationsIncurred" name="FinanceLeaseObligationsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_NotesReceivableMaturityYearStart" name="NotesReceivableMaturityYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration" name="AdditionalNonRefundablePaymentUponExtensionOfExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_AccountsReceivablePercentage" name="AccountsReceivablePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_LeaseLiabilitiesCurrent" name="LeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_PriorPreferredStockholdersMember" name="PriorPreferredStockholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" name="ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" name="InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_OfficeManufacturingAndWarehouseFacilityMember" name="OfficeManufacturingAndWarehouseFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" name="EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_GainLossOnExpiration" name="GainLossOnExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_StateOperatingLossCarryForwardsNotExpire" name="StateOperatingLossCarryForwardsNotExpire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_CommonStockInExchangeForCancellationOfNotesReceivables" name="CommonStockInExchangeForCancellationOfNotesReceivables" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" name="SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" name="CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CashInterestPaidPercentagePeriod" name="CashInterestPaidPercentagePeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" name="SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_CustomerThreeMember" name="CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_ConvertiblePreferredStockWarrantLiabilityMember" name="ConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rxst_AdditionalNumberOfCommonSharesIssued" name="AdditionalNumberOfCommonSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" name="IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" name="IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rxst_OperatingIncomeLoss1" name="OperatingIncomeLoss1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901365904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RxSight, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001111485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3268801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Columbia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Aliso Viejo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-7830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RXST<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,987,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2023. Except with respect to information specifically incorporated by reference, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901169952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,692<span></span>
</td>
<td class="nump">$ 11,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">117,490<span></span>
</td>
<td class="nump">93,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">20,281<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">17,421<span></span>
</td>
<td class="nump">14,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">168,407<span></span>
</td>
<td class="nump">134,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,841<span></span>
</td>
<td class="nump">10,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">182,550<span></span>
</td>
<td class="nump">150,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,863<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">15,239<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_LeaseLiabilitiesCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,903<span></span>
</td>
<td class="nump">17,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_LeaseLiabilitiesNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,188<span></span>
</td>
<td class="nump">60,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 900,000,000 shares authorized, 36,139,513 shares issued and outstanding as of December 31, 2023 and 28,268,389 Shares issued and outstanding as of December 31, 2022</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">754,971<span></span>
</td>
<td class="nump">636,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(594,640)<span></span>
</td>
<td class="num">(546,032)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">160,362<span></span>
</td>
<td class="nump">89,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 182,550<span></span>
</td>
<td class="nump">$ 150,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_LeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_LeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_LeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_LeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900036928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">36,139,513<span></span>
</td>
<td class="nump">28,268,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">36,139,513<span></span>
</td>
<td class="nump">28,268,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099895524208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 89,077<span></span>
</td>
<td class="nump">$ 49,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">35,312<span></span>
</td>
<td class="nump">27,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">53,765<span></span>
</td>
<td class="nump">21,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">74,799<span></span>
</td>
<td class="nump">58,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,051<span></span>
</td>
<td class="nump">25,981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">103,850<span></span>
</td>
<td class="nump">84,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(50,085)<span></span>
</td>
<td class="num">(63,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,308)<span></span>
</td>
<td class="num">(4,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">6,574<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of term loan</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(48,588)<span></span>
</td>
<td class="num">(66,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(48,608)<span></span>
</td>
<td class="num">(66,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation income (loss)</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (48,518)<span></span>
</td>
<td class="num">$ (66,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Attributable to common stock, basic</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Attributable to common stock, diluted</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Attributable to common stock, basic</a></td>
<td class="nump">34,455,111<span></span>
</td>
<td class="nump">27,661,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Attributable to common stock, diluted</a></td>
<td class="nump">34,455,111<span></span>
</td>
<td class="nump">27,661,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896416352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Beginning Balance, Amount at Dec. 31, 2021</a></td>
<td class="nump">$ 138,242<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 617,511<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (479,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Stockholders' Equity, Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,366,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares', window );">Shares issued for the exercise of stock options and vesting of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount', window );">Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesRedeemedForEmployeeTaxWithholdings', window );">Shares redeemed for employee tax withholdings, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount', window );">Shares redeemed for employee tax withholdings, Amount</a></td>
<td class="num">(643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">11,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued for the employee stock purchase plan, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount', window );">Shares issued for the employee stock purchase plan, Amount</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare', window );">Issuance of common stock for the public offering net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount', window );">Issuance of common stock for the public offering net of issuance costs, Amount</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="num">(66,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Ending Balance, Amount at Dec. 31, 2022</a></td>
<td class="nump">$ 89,902<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">636,001<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(546,032)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Stockholders' Equity, Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">28,268,389<span></span>
</td>
<td class="nump">28,268,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_OtherComprehensiveLoss', window );">Other comprehensive loss</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares', window );">Shares issued for the exercise of stock options and vesting of restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount', window );">Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</a></td>
<td class="nump">8,352<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesRedeemedForEmployeeTaxWithholdings', window );">Shares redeemed for employee tax withholdings, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount', window );">Shares redeemed for employee tax withholdings, Amount</a></td>
<td class="num">(1,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued for the employee stock purchase plan, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount', window );">Shares issued for the employee stock purchase plan, Amount</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare', window );">Issuance of common stock for the public offering net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount', window );">Issuance of common stock for the public offering net of issuance costs, Amount</a></td>
<td class="nump">53,600<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">53,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1', window );">Issuance of common stock for at-the-market offerings, net of issuance costs 1, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,142,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount', window );">Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount</a></td>
<td class="nump">41,582<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">41,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="num">(48,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,608)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' Equity, Ending Balance, Amount at Dec. 31, 2023</a></td>
<td class="nump">$ 160,362<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 754,971<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">$ (594,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Stockholders' Equity, Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="nump">36,139,513<span></span>
</td>
<td class="nump">36,139,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_OtherComprehensiveLoss', window );">Other comprehensive loss</a></td>
<td class="num">$ (90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for at-the-market offerings, net of issuance costs 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for at-the-Market Offerings, Net of Issuance Costs, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in at-the-market offerings, net of issuance costs, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_OtherComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_OtherComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued for the employee stock purchase plan, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued for the exercise of stock options and vesting of restricted stock units, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued for the exercise of stock options and vesting of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Redeemed For Employee Tax With Holdings, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesRedeemedForEmployeeTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares redeemed for employee tax withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesRedeemedForEmployeeTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896044928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (48,608)<span></span>
</td>
<td class="num">$ (66,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use lease assets</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and premium</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on short-term investments</a></td>
<td class="num">(6,122)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,746<span></span>
</td>
<td class="nump">11,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,325)<span></span>
</td>
<td class="num">(6,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,749)<span></span>
</td>
<td class="num">(7,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(562)<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,593)<span></span>
</td>
<td class="num">(58,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,814)<span></span>
</td>
<td class="num">(2,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturity of short-term investments</a></td>
<td class="nump">255,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(272,315)<span></span>
</td>
<td class="num">(212,657)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(22,129)<span></span>
</td>
<td class="nump">39,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from term loan</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_RepaymentOfTermLoan', window );">Repayment of term loan</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock from public offering</a></td>
<td class="nump">54,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings', window );">Proceeds from issuance of common stock for at-the-market offerings</a></td>
<td class="nump">42,434<span></span>
</td>
<td class="nump">6,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">9,473<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation', window );">Payments for employee taxes related to stock compensation</a></td>
<td class="num">(1,423)<span></span>
</td>
<td class="num">(643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease liabilities</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(622)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(2,235)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">61,524<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,192)<span></span>
</td>
<td class="num">(12,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">12,595<span></span>
</td>
<td class="nump">25,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">10,403<span></span>
</td>
<td class="nump">12,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_InterestPaidOnFinancingLeases', window );">Cash paid for interest on financing leases</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_InterestPaidOnTermLoan', window );">Cash paid for interest on term loan</a></td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">4,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract', window );"><strong>Lease obligations recorded for right-of-use assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_OperatingLeaseObligationsIncurred', window );">Operating lease</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_FinanceLeaseObligationsIncurred', window );">Finance lease</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredOfferingCostsIncludedInAccruedExpenses', window );">Deferred offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ReclassificationOfDeferredCost', window );">Reclassification of deferred financing costs</a></td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredOfferingCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredOfferingCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_FinanceLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Obligations Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_FinanceLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_InterestPaidOnFinancingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid on financing leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_InterestPaidOnFinancingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_InterestPaidOnTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid on term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_InterestPaidOnTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease obligations recorded for right-of-use assets abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_OperatingLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_OperatingLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for employee taxes related to stock compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in at-the-market offerings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ReclassificationOfDeferredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Deferred Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ReclassificationOfDeferredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_RepaymentOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of term loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_RepaymentOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for lease obligations abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901029904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 &#8211; Organization and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RxSight</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc. (the &#8220;Company&#8221;) is a Delaware corporation headquartered in Aliso Viejo, California with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> wholly owned subsidiary located in Amsterdam, Netherlands (&#8220;RxSight, B.V.&#8221;).  The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany (&#8220;RxSight GmbH&#8221;).  The Company is engaged in the research and development, manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products, which include the light adjustable lens (&#8220;LAL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and a specially designed machine for delivering light to the eye, the Light Delivery Device (&#8220;LDD</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), are approved by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) primarily for sale in the U.S. and have regulatory approval in the U.S., Europe, Canada and Mexico. The Company began marketing its products in 2019. The LAL is a premium intraocular lens (&#8220;IOL&#8221;) which is partially reimbursable under Medicare. The Company competes with other IOLs in the premium market.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of RxSight, Inc. and its wholly-owned subsidiaries, RxSight, B.V., and RxSight GmbH. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All significant inter-company balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company&#8217;s chief operating decision-maker (&#8220;CODM&#8221;), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.  The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, the Company filed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement on Form S-3 (&#8220;shelf registration statement&#8221;) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital.  At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million dollars of common stock through an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, through the ATM offering, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,617,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, have been issued and sold, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,142,089</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were sold during the twelve months ended December 31, 2023.  As of December 31, 2023, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million authorized under the ATM offering was sold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 7, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock in a public offering (&#8220;Public Offering&#8221;), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">days from the date of the underwriting agreement to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock on the same terms and conditions.  The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023.  The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">53.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Public Offering, after deducting underwriters' discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022 the Company has cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">127.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company&#8217;s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the years ended December 31, 2023 and 2022, the Company incurred losses from operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.  Based on the Company&#8217;s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company&#8217;s products and achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements.  The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and meet its future capital funding needs, as needed, through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901447872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Summary of Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict.  Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span></span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents. Cash equivalents are recorded at face value or cost, which approximates fair market value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company&#8217;s short-term investments, which are government securities, are classified as available-for-sale and are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company&#8217;s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders&#8217; Equity on the consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the investment has been in a continuous loss position for over 12 months; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration to maturity of investments; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the credit rating, financial condition and near-term prospects of the issuer and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type of investments made.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had an unrealized gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrealized losses related to short-term investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023  and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an allowance for credit losses for these investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.   For additional information see Note 3 &#8211; Short-Term Investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of cash held as collateral for a letter of credit as security for future facility lease payments and corporate credit cards at the Company&#8217;s bank. Restricted cash decreased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">711,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as required for these operating activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.92%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.5%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,692</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,403</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,595</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company&#8217;s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company&#8217;s business and may impact business in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are presented net of allowances for credit losses. Accounts receivable are typically due between 30 and 90 days after invoicing.  The Company does not have a high concentration of business with any individual customer as of December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company did not have any customer who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. The allowance for credit losses is calculated quarterly and is developed using an aging of receivables where receivables are segregated into various categories based upon due date, and a historical loss percentage is applied to each category that is adjusted for current receivable composition, counterparty and specific risk and prevailing economic condition and supportable forecasted economic conditions. If a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the allowance for credit losses. The Company closely monitors the credit quality of its customers and has yet to experience a write-off of a receivable or uncollected receivable. After evaluation of the collectability of accounts receivable, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any significant allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company does not generally require collateral or other security on receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.  Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable and operating lease liabilities. Cash, cash equivalents, accounts receivable and accounts payable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company&#8217;s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and amended term loan at December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of that date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment and leasehold improvements are recorded at cost, net of accumulated depreciation and amortization. Property and equipment are depreciated over the estimated useful lives of the related assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, using a straight-line method. Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or their estimated economic lives. Repairs and maintenance costs are charged directly to operations as incurred, while renewals and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All long-lived assets are reviewed for impairment whenever circumstances such as events or changes in the business indicate that an asset or asset group&#8217;s carrying value may not be recoverable based on undiscounted future operating cash flows to be derived from their use. Factors that are considered important that could trigger an impairment review include a current period operating or cash flow loss or a history of operating or cash flow losses and a projection or forecast that demonstrates continuing losses or insufficient income associated with the use of a long-lived asset or asset group. Other factors include a significant change in the manner of the use of the asset or a significant negative industry or economic trend. This evaluation is performed based on estimated undiscounted future cash flows from operating activities compared with the carrying value of the related assets. If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized, measured by the difference between the carrying value and the estimated fair value of the assets. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (&#8220;Commencement Date&#8221;) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.332%;"></td>
          <td style="width:1%;"></td>
          <td style="width:17.684%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.48%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.504%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,860,328</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926,226</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">685,029</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">543,538</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock issuable in offering period under the 2021 Employee Stock Purchase Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,189</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,594</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. Canada and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company&#8217;s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer.  Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer&#8217;s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer&#8217;s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation.  Revenue for training is also recorded at a point in time, generally 60 days after installation.  Revenue for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales are recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the years ended December 31, 2023 and 2022, credits related to returns and rebates on list prices were not significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company&#8217;s contracts. Revenue for service agreements is recognized ratably over the term of each contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from contracts with customers consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDD (including training)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,091</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,515</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LAL</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,092</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,965</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service warranty, service contracts, and accessories</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,525</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,077</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,005</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. the Company did not have any customers who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:40pt;vertical-align:bottom;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions during the period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,422</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,052</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,721</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,405</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,888</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Sales </span></span><span style=""></span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales consists of materials, labor and manufacturing overhead incurred to produce the Company&#8217;s products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as royalty and license fee expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses are expensed as incurred. Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities for new products and technology. The expenses include personnel-related costs, including compensation and benefits and stock-based compensation, consultants hired to perform research projects, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs related to FDA premarket approval submission preparation, various laboratory and research supplies, write-off of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of manufacturing processes in excess of capitalizable value, fees paid to contract research organizations and direct FDA related costs. The Company also accrued the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for equity-based awards on the date of grant to employees, board of directors and consultants based on the estimated grant date fair value of the award Equity-based payments include stock options, restricted stock units and employee stock plan purchases. The fair value of the option awards are estimated using the Black-Scholes option-pricing model and recognized in expense in the consolidated statements of operations and comprehensive loss over the requisite service period, which is generally four years. The Company amortizes the stock-based compensation for equity awards with service conditions on a straight-line basis over the vesting period of the awards. Compensation cost for stock options with performance conditions is recognized based upon the probability of that performance condition being met. Forfeitures of unvested stock option awards are recognized as reductions of expense as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company&#8217;s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;), and its shares being traded on the Nasdaq Global Market, the fair value of the Company&#8217;s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company&#8217;s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company&#8217;s common stock. For all grants subsequent to the Company's shares being traded on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#8217;s expected term; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the lack of historical exercise history, the expected term for options granted is calculated using the &#8220;simplified method&#8221; and represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is derived from the historical volatilities of a select group of comparable peer companies, for a look-back period commensurate with the expected term of the stock options, as the Company has limited trading history of common stock. </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in tax rates is recognized in the Consolidated Statements of Operations and Comprehensive Loss in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history and reliability of forecasting. The Company recognized a valuation allowance on deferred tax assets as of December 31, 2023 and 2022 after evaluating that it is more likely than not that deferred tax assets will not be realized as of those dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the accounting for uncertainty in income tax recognized in the consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax positions where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States, United Kingdom, Germany and Netherlands. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect on such jurisdictions, which could impact the amount of tax paid. An amount is accrued for the estimate of additional tax liabilities, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The accrual for uncertain tax positions is updated when more definitive information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of accounting standards updates (&#8220;ASU&#8221;). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that are of significance or potential significance to the Company.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900934080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3 &#8211; Short-Term Investments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.94%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.459999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.259999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.471%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.066%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.089%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.828999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All available-for-sale securities held as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> had a maturity of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ad232f5c-7ce0-4d92-95b3-b3019e7d245b;"><span style="-sec-ix-hidden:F_1f005e07-66a8-4957-933b-b4aede44a4d8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company&#8217;s ability and intent to use any and all of those marketable securities to satisfy the Company&#8217;s liquidity requirements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company&#8217;s intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer&#8217;s industry, and any significant deterioration in economic conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest expense in the consolidated statements of operations through an allowance for credit losses. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Unrealized losses on available-for-sale debt securities as of December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Further, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an allowance for credit losses with these investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900830656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.74%;"></td>
        <td style="width:1.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.94%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,092</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,408</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,680</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,145</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,567</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: reserve for excess and obsolete inventory</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">496</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">634</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023 and 2022, finished goods included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of inventory held on consignment at customer sites, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901019632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5 &#8211; Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,824</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Production molds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,005</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in depreciation and amortization expense for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900740144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6 &#8211; Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below (in thousands) present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value. The Company did not have any assets or liabilities measured at fair value on a recurring basis within Level 3 fair value measurements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. U.S. Treasury are measured at fair value using Level 2 inputs. The Company reviews trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099995159376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7 &#8211; Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.9%;"></td>
        <td style="width:27.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,637</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900774496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8 &#8211; Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Refinancing and Payoff of Oxford Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 29, 2020, the Company and Oxford Finance LLC (&#8220;Oxford&#8221;), as collateral agent, and certain lenders (&#8220;Lenders&#8221;) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the &#8220;May 2022 LSA&#8221;), pursuant to which the Lenders provided to the Company certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the &#8220;May 2022 Term Loan&#8221;).  The May 2022 LSA increased the loan and security agreement to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was fully drawn upon as of May 3, 2022 from the original term loan.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2023, the Company entered into a new Loan and Security Agreement (the &#8220;June 2023 LSA&#8221;) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate Term A Loans (the &#8220;Term A Loans&#8221;). On that same date, the Company prepaid the May 2022 Term Loan in full which included approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in final payment and other fees using a combination of cash, primarily comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Term A Loans and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash reserves.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 4, 2023, the Company repaid its outstanding June 2023 LSA of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million early which included outstanding accrued interest of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in final payment and other fees using $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, net, raised under the ATM Facility and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash reserves.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900771264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9 &#8211; Stock-Based Compensation Expense</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has three equity incentive compensation plans: the 2006 Stock Plan (the &#8220;2006 Plan&#8221;), the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) and the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;).</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2006 Plan was originally adopted by the Board and approved by the Company&#8217;s stockholders in 2006. The 2006 Plan was terminated in 2015 in connection with the adoption of the 2015 Plan and as a result no new awards may be issued under the 2006 Plan. However, the 2006 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2015 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2015 Plan was originally adopted by the Board and approved by the Company&#8217;s stockholders in 2015. The 2015 Plan was most recently amended in March 2021. In July 2021, upon completion of the IPO, the 2015 Plan terminated immediately prior to effectiveness of the 2021 Plan with respect to the grant of future awards. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2015 Plan.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2021, the 2021 Plan was adopted and approved by the Board and stockholders prior to the IPO and became effective on the business day immediately prior to the effective date of the Company&#8217;s IPO registration statement.  The 2021 Plan provides for the grant of incentive stock options to employees and any subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;), and performance awards to employees, directors, and consultants and subsidiary corporations&#8217; employees and consultants.  The number of shares of the Company&#8217;s common stock originally available for issuance under the 2021 Plan was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,420,135</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock plus any shares subject to awards granted under the 2015 Plan and the 2006 Plan that, after the effectiveness of the 2021 Plan, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by the Company for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest, with the maximum number of shares to be added to the 2021 Plan from the 2015 Plan and 2006 Plan equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569,530</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evergreen provision</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common shares reserved for issuance under the 2021 Plan will be increased automatically on the first day of each fiscal year beginning with the 2022 fiscal year and ending on the ten year anniversary of the date the Board approved the 2021 Plan, by a number equal to the least of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,260,406</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such lesser number of shares of our common stock as the administrator may determine. The 2021 Plan is administered by the Board.  On January 1, 2023 and 2022, the number of shares available under the 2021 Plan increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,130,735</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,094,670</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively pursuant to this feature.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 ESPP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2021, the Board and stockholders adopted and approved the 2021 ESPP. The number of shares of the Company&#8217;s common stock originally available for issuance under the 2021 ESPP was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">664,976</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and the initial purchase period began on November 1, 2021.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 ESPP provides eligible employees of the Company and its subsidiaries with the opportunity to purchase shares of the Company&#8217;s Common Stock at a purchase price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the common stock&#8217;s fair market value on the first trading day or last trading day of each purchase period, whichever is lower. The 2021 ESPP provides for two six-month purchase periods every twelve months: May 1 through October 31 and November 1 through April 30. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the number of shares of the Company&#8217;s common stock available for future issuance under the 2021 ESPP was equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">577,847</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evergreen provision</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common shares reserved for issuance under the 2021 ESPP plan will be increased automatically on the first day of each fiscal year beginning with our 2022 fiscal year, by a number equal to the least of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,081</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such other amount as the administrator may determine. The 2021 ESPP is administered by the Board. The Board determined that no additional shares would be reserved for issuance on January 1, 2023 pursuant to this feature. On January 1, 2022, the number of shares available under the 2021 ESPP increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">273,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock pursuant to this feature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purpose of the 2021 Plan and 2021 ESPP is to provide a means by which eligible recipients of stock awards may be given an opportunity to benefit from increases in the value of the common stock in order to retain or procure the services of the employees, members of the Board and consultants and provide them with an incentive to promote the Company&#8217;s success and accomplish corporate goals.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows, subject to the optionee&#8217;s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activities related to the Plans, as of and for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.549%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.342%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.922%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.102%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Avg<br/>Remaining<br/>Contractual Life<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,339,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,465,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">841,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">120,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,777,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.51</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,237,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.30</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of restricted stock unit activities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span></span></p><div style="font-size:10.5pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.472%;"></td>
        <td style="width:1.7%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.163%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">492,862</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">430,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">262,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">650,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the intrinsic value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">121.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and of all options outstanding was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">185.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. During the year ended  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the total cash received from the exercise of stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The total fair value less strike price of these options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the accompanying consolidated statements of operations and comprehensive income (loss) as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.031%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,539,445</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,447,687</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unvested options, respectively. Total unrecognized expense related to unvested stock options was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amounts are expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized expense related to unvested restricted stock units was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amounts are expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.81%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant date fair value</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.91</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39.71</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.60</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.74</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.52</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.73</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900810240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10 &#8211; Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, the Company filed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement which became effective on August 12, 2022. The shelf registration statement is effective for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and permits the Company to sell, from time to time, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate value of our common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.  Included in the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million dollars of our common stock through an ATM offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Offering</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">475,875</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common shares for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and other offering expenses.  As of December 31, 2023, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,617,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for total gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million), have been issued and sold pursuant to the ATM offering, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,142,089</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were sold during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which was the remaining authorized value of the common stock under the ATM offering.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,777,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,339,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">358,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">865,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">492,862</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under 2021 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">664,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future sale under the ATM offering </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,454,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,816,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The ATM offering was completed in July 2023.</span></p><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as reported on the Nasdaq Global Market on December 30, 2022.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900804384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before income taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. loss before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,588</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,266</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components that comprised the Company&#8217;s net deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D expenditures capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,292</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes with the expected income tax computed by applying the federal statutory income tax rate to loss before provision for income taxes was calculated as follows (amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.98%;"></td>
        <td style="width:4.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.120000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision at the federal statutory tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,992</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired tax attributes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax effects of items that give rise to significant portions of deferred tax assets are primarily net operating loss carryforwards. The Company evaluates the recoverability of deferred tax assets and assesses all available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all the evidence, including a history of operating losses and the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been recorded to offset the net deferred tax asset as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">realization </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of such asset is uncertain. The Company&#8217;s valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">311.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">148.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">311.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in federal NOLs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">204.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">148.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in state NOLs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will not expire and will be able to offset </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income in future years. The remaining federal NOL carryforwards will expire between 2024 and 2037, and the remaining state NOL carryforwards will expire between 2025 and 2043. In addition, the Company also had federal credit carry forwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state credit carry forwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which may be available to offset future tax liabilities. The federal credits will expire between 2037 and 2043, and the state credits do not expire.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act 2022 which incorporates a Corporate Alternative Minimum Tax (&#8220;CAMT&#8221;) was signed on August 16, 2022.   The changes will affect tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability.  The CAMT act is not expected to have a material impact on the Company's consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards may be subject to substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss and R&amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has not completed an IRC Sections 382 and 383 analysis regarding the limitation of net operating loss and R&amp;D credit carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company has not completed a formal R&amp;D study but has estimated the federal and California credit for purposes of the tax footnote as of December 31, 2023.  However, the Company has not reflected a benefit in the consolidated financial statements due to the recorded valuation allowance.</span></p><div style="font-size:10.5pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the unrecognized tax benefits, if recognized, would impact the annual effective rate, due to the valuation allowance. The Company&#8217;s unrecognized tax benefits are recorded as a reduction in deferred tax assets. The Company does not expect any significant increases or decreases to the Company&#8217;s unrecognized tax benefits within the next 12 months. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.  The Company has not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to U.S. federal and various states' income taxes. The federal returns for tax years 2020 through 2023 remain open to examination and the state returns remain subject to examination for tax years 2019 through 2023. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. All other state jurisdictions remain open to examination.  There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cumulative earnings in our foreign subsidiaries as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that would be subject to U.S. income tax or foreign withholding tax. The Company plans to indefinitely reinvest any future earnings of its foreign subsidiaries.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900801952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12 &#8211; Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operating and finance leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not combine lease and non-lease components in the recognition of lease expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s leases have remaining non-cancelable lease terms of up to 3 years, some of which include options to extend the leases for up to 15 years. The exercise of lease renewal options is at the Company&#8217;s sole discretion. The Company recognizes rent expense for minimum lease payments on a straight-line basis over the expected lease term, including rent holidays, rent escalation clause and/or cancelable option periods where failure to exercise such options would result in an economic penalty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> leases for office, manufacturing and warehouse facilities in Aliso Viejo, California. The four leases are for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">121,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in the aggregate and expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For one of the facilities operating leases, the lessor provided $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">900,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in tenant allowances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2022, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thirty-four-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sublease agreement for a portion of the 5 Columbia Building, in Aliso Viejo, CA. The sublease commencement date was June 13, 2022 and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The base rent receivable is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,410</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month.  On January 4, 2023, the Company amended the base rent of sublease agreement to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,319</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per month beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the lease balances within the consolidated balance sheets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:16.06%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:30.48%;"></td>
        <td style="width:2.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:24.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,943</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98a9eb22-5875-4665-9fe4-7da6a3667f55;"><span style="-sec-ix-hidden:F_4215fd74-502e-4548-a8dd-7b80b1cd43f0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82;"><span style="-sec-ix-hidden:F_c8f26f61-f9dd-4949-8795-ad61341c192b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,764</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426;"><span style="-sec-ix-hidden:F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b14603c8-a5d6-41d8-b49d-2b04b4c22671;"><span style="-sec-ix-hidden:F_cfa28257-8c04-4096-a2b8-5d3340f0d040;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,093</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_1c8ef374-722f-4dc2-918b-df585e24ce25;"><span style="-sec-ix-hidden:F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the implicit rates in the Company&#8217;s leases were not readily available, the incremental borrowing rate was determined based upon information available at the lease commencement date in determining the present value of future lease payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands): </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.94%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:28.14%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of the Company&#8217;s operating and finance lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.86%;"></td>
        <td style="width:10.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:39.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.119999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Finance Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company&#8217;s operating and finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.949%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:31.806%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.222999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Term and Discount Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.37</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900739856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 13 &#8211; Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Letter of credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a standby letter of credit, expiring September 30, 2024, issued by a financial institution as required security for one operating lease. The aggregate amount of the letter of credit was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time-to-time, the Company may be involved in certain legal proceedings or regulatory matters arising in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any legal proceeding or regulatory matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome. At December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the outcome, legal proceedings, regulatory matters, and other disputes and claims can have an adverse impact on the Company because of legal costs, diversion of management time and resources, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900830656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 14 &#8211; Employee benefit plan</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">401(k) retirement savings plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution 401(k) retirement savings plan for the benefit of its employees, including its named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.  The Company makes matching contributions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of eligible compensation, as contributed by eligible participating employees. Employer matching contributions vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year over four years. The Company contributed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">900,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">688,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, net of forfeitures, to the 401(k) plan for the year ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901189152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of RxSight, Inc. and its wholly-owned subsidiaries, RxSight, B.V., and RxSight GmbH. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All significant inter-company balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company&#8217;s chief operating decision-maker (&#8220;CODM&#8221;), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.  The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_LiquidityAndFinancialPositionPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2022, the Company filed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shelf registration statement on Form S-3 (&#8220;shelf registration statement&#8221;) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital.  At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million dollars of common stock through an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, through the ATM offering, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,617,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, have been issued and sold, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,142,089</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were sold during the twelve months ended December 31, 2023.  As of December 31, 2023, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million authorized under the ATM offering was sold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 7, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock in a public offering (&#8220;Public Offering&#8221;), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">days from the date of the underwriting agreement to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock on the same terms and conditions.  The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023.  The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">53.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Public Offering, after deducting underwriters' discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022 the Company has cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">127.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company&#8217;s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the years ended December 31, 2023 and 2022, the Company incurred losses from operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.  Based on the Company&#8217;s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company&#8217;s products and achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements.  The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and meet its future capital funding needs, as needed, through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict.  Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company&#8217;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents</span><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents. Cash equivalents are recorded at face value or cost, which approximates fair market value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company&#8217;s short-term investments, which are government securities, are classified as available-for-sale and are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company&#8217;s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders&#8217; Equity on the consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the investment has been in a continuous loss position for over 12 months; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration to maturity of investments; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the credit rating, financial condition and near-term prospects of the issuer and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type of investments made.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had an unrealized gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrealized losses related to short-term investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023  and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an allowance for credit losses for these investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.   For additional information see Note 3 &#8211; Short-Term Investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of cash held as collateral for a letter of credit as security for future facility lease payments and corporate credit cards at the Company&#8217;s bank. Restricted cash decreased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">711,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as required for these operating activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.92%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.5%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,692</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,403</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,595</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company&#8217;s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company&#8217;s business and may impact business in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are presented net of allowances for credit losses. Accounts receivable are typically due between 30 and 90 days after invoicing.  The Company does not have a high concentration of business with any individual customer as of December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company did not have any customer who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. The allowance for credit losses is calculated quarterly and is developed using an aging of receivables where receivables are segregated into various categories based upon due date, and a historical loss percentage is applied to each category that is adjusted for current receivable composition, counterparty and specific risk and prevailing economic condition and supportable forecasted economic conditions. If a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the allowance for credit losses. The Company closely monitors the credit quality of its customers and has yet to experience a write-off of a receivable or uncollected receivable. After evaluation of the collectability of accounts receivable, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any significant allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company does not generally require collateral or other security on receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.  Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable and operating lease liabilities. Cash, cash equivalents, accounts receivable and accounts payable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company&#8217;s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and amended term loan at December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of that date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment and leasehold improvements are recorded at cost, net of accumulated depreciation and amortization. Property and equipment are depreciated over the estimated useful lives of the related assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, using a straight-line method. Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or their estimated economic lives. Repairs and maintenance costs are charged directly to operations as incurred, while renewals and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All long-lived assets are reviewed for impairment whenever circumstances such as events or changes in the business indicate that an asset or asset group&#8217;s carrying value may not be recoverable based on undiscounted future operating cash flows to be derived from their use. Factors that are considered important that could trigger an impairment review include a current period operating or cash flow loss or a history of operating or cash flow losses and a projection or forecast that demonstrates continuing losses or insufficient income associated with the use of a long-lived asset or asset group. Other factors include a significant change in the manner of the use of the asset or a significant negative industry or economic trend. This evaluation is performed based on estimated undiscounted future cash flows from operating activities compared with the carrying value of the related assets. If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized, measured by the difference between the carrying value and the estimated fair value of the assets. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (&#8220;Commencement Date&#8221;) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.332%;"></td>
          <td style="width:1%;"></td>
          <td style="width:17.684%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.48%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.504%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,860,328</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926,226</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">685,029</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">543,538</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock issuable in offering period under the 2021 Employee Stock Purchase Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,189</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,594</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. Canada and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company&#8217;s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer.  Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer&#8217;s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer&#8217;s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation.  Revenue for training is also recorded at a point in time, generally 60 days after installation.  Revenue for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales are recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the years ended December 31, 2023 and 2022, credits related to returns and rebates on list prices were not significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company&#8217;s contracts. Revenue for service agreements is recognized ratably over the term of each contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from contracts with customers consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDD (including training)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,091</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,515</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LAL</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,092</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,965</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service warranty, service contracts, and accessories</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,525</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,077</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,005</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. the Company did not have any customers who individually accounted for greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:40pt;vertical-align:bottom;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions during the period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,422</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,052</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,721</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,405</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,888</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Sales </span><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales consists of materials, labor and manufacturing overhead incurred to produce the Company&#8217;s products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as royalty and license fee expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses are expensed as incurred. Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities for new products and technology. The expenses include personnel-related costs, including compensation and benefits and stock-based compensation, consultants hired to perform research projects, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs related to FDA premarket approval submission preparation, various laboratory and research supplies, write-off of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of manufacturing processes in excess of capitalizable value, fees paid to contract research organizations and direct FDA related costs. The Company also accrued the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for equity-based awards on the date of grant to employees, board of directors and consultants based on the estimated grant date fair value of the award Equity-based payments include stock options, restricted stock units and employee stock plan purchases. The fair value of the option awards are estimated using the Black-Scholes option-pricing model and recognized in expense in the consolidated statements of operations and comprehensive loss over the requisite service period, which is generally four years. The Company amortizes the stock-based compensation for equity awards with service conditions on a straight-line basis over the vesting period of the awards. Compensation cost for stock options with performance conditions is recognized based upon the probability of that performance condition being met. Forfeitures of unvested stock option awards are recognized as reductions of expense as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company&#8217;s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;), and its shares being traded on the Nasdaq Global Market, the fair value of the Company&#8217;s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company&#8217;s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company&#8217;s common stock. For all grants subsequent to the Company's shares being traded on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#8217;s expected term; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the lack of historical exercise history, the expected term for options granted is calculated using the &#8220;simplified method&#8221; and represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is derived from the historical volatilities of a select group of comparable peer companies, for a look-back period commensurate with the expected term of the stock options, as the Company has limited trading history of common stock. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in tax rates is recognized in the Consolidated Statements of Operations and Comprehensive Loss in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history and reliability of forecasting. The Company recognized a valuation allowance on deferred tax assets as of December 31, 2023 and 2022 after evaluating that it is more likely than not that deferred tax assets will not be realized as of those dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the accounting for uncertainty in income tax recognized in the consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax positions where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to file federal and state income tax returns in the United States, United Kingdom, Germany and Netherlands. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect on such jurisdictions, which could impact the amount of tax paid. An amount is accrued for the estimate of additional tax liabilities, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The accrual for uncertain tax positions is updated when more definitive information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of accounting standards updates (&#8220;ASU&#8221;). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that are of significance or potential significance to the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_LiquidityAndFinancialPositionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Liquidity and Financial Position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_LiquidityAndFinancialPositionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901364496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash Cash Equivalents And Restricted Cash</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.92%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.86%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.5%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,692</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,403</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,595</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.332%;"></td>
          <td style="width:1%;"></td>
          <td style="width:17.684%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.48%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.504%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,860,328</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926,226</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Equity Incentive Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">685,029</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">543,538</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock issuable in offering period under the 2021 Employee Stock Purchase Plan</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,189</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,594</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue from Contracts with Customers</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from contracts with customers consisted of the following (in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LDD (including training)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,091</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,515</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LAL</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,092</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,965</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service warranty, service contracts, and accessories</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,525</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,077</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,005</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Deferred Revenue Activity</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.039%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.369999999999997%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
          <td style="width:1%;"></td>
          <td style="width:18.127%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.821%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:40pt;vertical-align:bottom;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions during the period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,422</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,052</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,721</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,405</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;">
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of period</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,888</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187</span></p></td>
          <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reconciliation of cash and cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900731184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Short-Term Investments Available For Sale</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.94%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.459999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.259999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.619999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.471%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.066%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.089%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.181%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.828999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss, Net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900890448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.74%;"></td>
        <td style="width:1.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.200000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.94%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,092</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,408</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,680</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,145</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,567</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: reserve for excess and obsolete inventory</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">496</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">634</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900801952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer hardware and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,824</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Production molds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,005</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900855984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level I</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level II</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,968</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900885664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.9%;"></td>
        <td style="width:27.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,637</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099900780672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesReservedForFutureIssuanceTableTextBlock', window );">Summary of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,777,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,339,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under the Equity Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">358,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">865,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units issued under the 2021 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">492,862</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future issuance under 2021 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">664,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future sale under the ATM offering </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,454,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,816,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The ATM offering was completed in July 2023.</span></p><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as reported on the Nasdaq Global Market on December 30, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901227840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Status and Changes in Stock Option Activities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activities related to the Plans, as of and for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.549%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.342%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.922%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.102%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Avg<br/>Remaining<br/>Contractual Life<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,339,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,465,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">841,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">120,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,777,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.51</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,237,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.30</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Non-Vested Restricted Stock Unit Activities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of restricted stock unit activities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 is presented below:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.472%;"></td>
        <td style="width:1.7%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.163%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">492,862</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.08</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">430,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">262,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">650,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the accompanying consolidated statements of operations and comprehensive income (loss) as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.031%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.81%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:17.467%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Range</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant date fair value</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.91</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39.71</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.60</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.74</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.52</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.73</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901252960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before income taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. loss before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income before taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,588</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,266</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components that comprised the Company&#8217;s net deferred taxes are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D expenditures capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,292</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes with the expected income tax computed by applying the federal statutory income tax rate to loss before provision for income taxes was calculated as follows (amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.98%;"></td>
        <td style="width:4.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.120000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision at the federal statutory tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,992</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired tax attributes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits [Roll Forward]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.971%;"></td>
        <td style="width:6.661%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.483%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.543000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance of unrecognized tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions for prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901130368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SummaryOfLeaseBalancesTableTextBlock', window );">Schedule of Lease Balance Sheet Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the lease balances within the consolidated balance sheets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:16.06%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:30.48%;"></td>
        <td style="width:2.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:24.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,943</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98a9eb22-5875-4665-9fe4-7da6a3667f55;"><span style="-sec-ix-hidden:F_4215fd74-502e-4548-a8dd-7b80b1cd43f0;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82;"><span style="-sec-ix-hidden:F_c8f26f61-f9dd-4949-8795-ad61341c192b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,764</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426;"><span style="-sec-ix-hidden:F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b14603c8-a5d6-41d8-b49d-2b04b4c22671;"><span style="-sec-ix-hidden:F_cfa28257-8c04-4096-a2b8-5d3340f0d040;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,093</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_1c8ef374-722f-4dc2-918b-df585e24ce25;"><span style="-sec-ix-hidden:F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Component of Lease Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands): </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.94%;"></td>
        <td style="width:2.18%;"></td>
        <td style="width:28.14%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of the Company&#8217;s operating and finance lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.86%;"></td>
        <td style="width:10.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:39.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.119999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Finance Leases</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company&#8217;s operating and finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.949%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:31.806%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.222999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Term and Discount Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.42</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.37</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SummaryOfLeaseBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Lease Balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SummaryOfLeaseBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Weighted Average Remaining Lease Term and Discount Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896155248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Subsidiary </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted', window );">Common stock sale underwriting discounts and commission deducted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.2<span></span>
</td>
<td class="nump">$ 105.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_OperatingIncomeLoss1', window );">Losses from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.1<span></span>
</td>
<td class="nump">$ 63.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of stock, date</a></td>
<td class="text">Feb.  07,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD per share) | $ / shares</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_AdditionalNumberOfCommonSharesIssued', window );">Additional common shares sold | shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted', window );">Common stock sale underwriting discounts and commission deducted</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockOfferingCosts', window );">Common stock offering costs</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="nump">$ 53.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_ShelfRegistrationStatementMember', window );">Shelf Registration Statement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_ShelfRegistrationStatementMember', window );">Shelf Registration Statement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember', window );">ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember', window );">ATM Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,142,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_AdditionalNumberOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_AdditionalNumberOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_CommonStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_CommonStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sale underwriting discounts and commission deducted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_OperatingIncomeLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income (Loss)1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_OperatingIncomeLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxst_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899947376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IncreasedDecreasedInRestrictedCash', window );">Increased (Decreased) In Restricted Cash</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">711,000<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_LiabilityOnUncertainTaxPosition', window );">Liability on Uncertain Tax Position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit losses for investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_AccountsReceivablePercentage', window );">Percentage of gross accounts receivable</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred Revenue, Revenue Recognized</a></td>
<td class="nump">$ 2,721,000<span></span>
</td>
<td class="nump">$ 1,405,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rxst_NoCustomerMember', window );">No Customer | Customer Concentration Risk | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_AccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable, Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_AccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IncreasedDecreasedInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased (Decreased) In Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IncreasedDecreasedInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_LiabilityOnUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability on uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_LiabilityOnUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rxst_NoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rxst_NoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896197056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,692,000<span></span>
</td>
<td class="nump">$ 11,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">711,000<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash in the consolidated statements of cash flows</a></td>
<td class="nump">$ 10,403,000<span></span>
</td>
<td class="nump">$ 12,595,000<span></span>
</td>
<td class="nump">$ 25,172,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901406144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">685,029<span></span>
</td>
<td class="nump">543,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">98,189<span></span>
</td>
<td class="nump">48,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_StockOptionsIssuedAndOutstandingUnderPlansMember', window );">Stock Options Issued And Outstanding Under Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">6,860,328<span></span>
</td>
<td class="nump">1,926,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_StockOptionsIssuedAndOutstandingUnderPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rxst_StockOptionsIssuedAndOutstandingUnderPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896336144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 89,077<span></span>
</td>
<td class="nump">$ 49,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rxst_LDDMember', window );">L D D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">32,091<span></span>
</td>
<td class="nump">22,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rxst_RxlalMember', window );">LAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">54,092<span></span>
</td>
<td class="nump">24,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rxst_ServiceWarrantyServiceContractsAndAccessoriesMember', window );">Service Warranty, Service Contracts, And Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 2,894<span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rxst_LDDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rxst_LDDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rxst_RxlalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rxst_RxlalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rxst_ServiceWarrantyServiceContractsAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rxst_ServiceWarrantyServiceContractsAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899916480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredRevenue1', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Additions during the period</a></td>
<td class="nump">3,422<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized during the period</a></td>
<td class="num">(2,721)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredRevenue1', window );">Balance at end of period</a></td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899880624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details) - U.S. Treasury securities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Total</a></td>
<td class="nump">$ 117,480<span></span>
</td>
<td class="nump">$ 94,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss, Net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 117,490<span></span>
</td>
<td class="nump">$ 93,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901321408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit losses for investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeExtensibleEnumeration', window );">Investment, Type [Extensible Enumeration]</a></td>
<td class="text">US Government Agencies Short-Term Debt Securities [Member]<span></span>
</td>
<td class="text">US Government Agencies Short-Term Debt Securities [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column C)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899875888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 8,092<span></span>
</td>
<td class="nump">$ 6,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">5,680<span></span>
</td>
<td class="nump">6,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory gross</a></td>
<td class="nump">17,917<span></span>
</td>
<td class="nump">15,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: reserve for excess and obsolete inventory</a></td>
<td class="num">(496)<span></span>
</td>
<td class="num">(634)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 17,421<span></span>
</td>
<td class="nump">$ 14,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901353200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Inventory held on consignment</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894501712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 33,539<span></span>
</td>
<td class="nump">$ 30,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(22,698)<span></span>
</td>
<td class="num">(19,898)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">10,841<span></span>
</td>
<td class="nump">10,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">14,638<span></span>
</td>
<td class="nump">12,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">11,553<span></span>
</td>
<td class="nump">11,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Production Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxst_RightOfUseEquipmentMember', window );">Right-Of-Use Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxst_RightOfUseEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxst_RightOfUseEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899374512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894526032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 121,965<span></span>
</td>
<td class="nump">$ 102,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">4,475<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">117,490<span></span>
</td>
<td class="nump">93,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">4,475<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">4,475<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">117,490<span></span>
</td>
<td class="nump">93,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 117,490<span></span>
</td>
<td class="nump">$ 93,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899863056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 10,637<span></span>
</td>
<td class="nump">$ 8,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_AccruedInterestCurrent', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,557<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 15,239<span></span>
</td>
<td class="nump">$ 12,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894384032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,473<span></span>
</td>
<td class="nump">$ 1,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=rxst_AugustFourTwoThousandTwentyThreeMember', window );">August 4, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DebtFromCashReserves', window );">Cash reserves</a></td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember', window );">ATM Offering [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rxst_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Proceeds from Loan Originations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Net cash raised under the ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DebtFromCashReserves', window );">Cash reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rxst_MayThreeTwoThousandTwentyTwoTermLoanMember', window );">May 3, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Proceeds from Loan Originations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Final payment and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rxst_NewLoanAndSecurityAgreementMember', window );">New Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Accrued interest paid</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Final payment and other fees</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DebtFromCashReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt From Cash Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DebtFromCashReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rxst_AugustFourTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rxst_AugustFourTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxst_AtmOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rxst_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rxst_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rxst_MayThreeTwoThousandTwentyTwoTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rxst_MayThreeTwoThousandTwentyTwoTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rxst_NewLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rxst_NewLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099906356608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901408544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Warrant Liability - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901147616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901404208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity (Deficit) - Summary of Preferred Units (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894295648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Deficit) - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 07, 2023</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted', window );">Common stock sale underwriting discounts and commission deducted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementGainsAndLosses', window );">Registration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm', window );">Securities issuable value under self registration statement form</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementTerm', window );">Registration Payment Arrangement, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common Shares issued under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm', window );">Securities issuable value under self registration statement form</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale of Stock, Transaction Date</a></td>
<td class="text">Feb.  07,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_AdditionalNumberOfCommonSharesIssued', window );">Additional common shares sold</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted', window );">Common stock sale underwriting discounts and commission deducted</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_CommonStockOfferingCosts', window );">Common stock offering costs</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="nump">$ 53.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxst_AtmOfferingMember', window );">ATM Offering [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,142,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm', window );">Securities issuable value under self registration statement form</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common Shares issued under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net Proceeds of Common Stock under ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_AdditionalNumberOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_AdditionalNumberOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_CommonStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_CommonStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sale underwriting discounts and commission deducted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities issuable value under self registration statement form</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementGainsAndLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (gain) or increase (loss) in the carrying amount of the registration payment obligation that was recognized in earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482804/825-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementGainsAndLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the term of the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482804/825-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxst_AtmOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxst_AtmOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099899954208">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,364,218<span></span>
</td>
<td class="nump">11,816,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">650,357<span></span>
</td>
<td class="nump">492,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_The2021EsppPlanMember', window );">The 2021 ESPP Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">577,847<span></span>
</td>
<td class="nump">664,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember', window );">Stock options issued and outstanding under the Equity Plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,777,404<span></span>
</td>
<td class="nump">6,339,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember', window );">Shares available for future issuance under the Equity Plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358,610<span></span>
</td>
<td class="nump">865,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember', window );">Shares available for future sale under the ATM offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,454,064<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The ATM offering was completed in July 2023.</span></p><p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as reported on the Nasdaq Global Market on December 30, 2022.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rxst_The2021EsppPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rxst_The2021EsppPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099995199728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ClosingStockPrice', window );">Closing Stock Price</a></td>
<td class="nump">$ 12.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901411744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility, Weighted Average</a></td>
<td class="nump">64.90%<span></span>
</td>
<td class="nump">63.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield', window );">Expected dividend yield, Weighted Average</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">64.90%<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk adjusted discount factor, Minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">68.60%<span></span>
</td>
<td class="nump">64.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk adjusted discount factor, Maximum</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected dividend yield.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099902813200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,364,218<span></span>
</td>
<td class="nump">11,816,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,139,513<span></span>
</td>
<td class="nump">28,268,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Compensation, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Stock-Based Compensation, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee&#8217;s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-Based Compensation, Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,357<span></span>
</td>
<td class="nump">492,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested at December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_The2021PlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="nump">2,420,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,130,735<span></span>
</td>
<td class="nump">1,094,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">7,260,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_The2021PlanMember', window );">2021 Plan [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="nump">4,569,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_The2021EsppPlanMember', window );">The 2021 ESPP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Conversion of preferred stock</a></td>
<td class="nump">1,452,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">664,976<span></span>
</td>
<td class="nump">577,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_The2021EsppPlanMember', window );">The 2021 ESPP Plan [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember', window );">The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic Value of Vested Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.3<span></span>
</td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value of Outstanding Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Total Cash Received from the Exercise of Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total Fair Value Less Strike Price of Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested at December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539,445<span></span>
</td>
<td class="nump">2,447,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_The2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_The2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_The2021EsppPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_The2021EsppPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099895458704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Stock Option Activities (Details) - The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning balance</a></td>
<td class="nump">6,339,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,465,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(841,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(120,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired</a></td>
<td class="num">(65,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending balance</a></td>
<td class="nump">6,777,404<span></span>
</td>
<td class="nump">6,339,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">4,237,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Granted</a></td>
<td class="nump">16.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Exercised</a></td>
<td class="nump">9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Forfeited</a></td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Expired</a></td>
<td class="nump">18.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending balance</a></td>
<td class="nump">13.02<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Options Granted</a></td>
<td class="nump">10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Options Exercised</a></td>
<td class="nump">4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Options Forfeited</a></td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Options outstanding</a></td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099893879008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at December 31, 2022 | shares</a></td>
<td class="nump">492,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">430,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares, vested | shares</a></td>
<td class="num">(262,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(11,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested at December 31, 2023 | shares</a></td>
<td class="nump">650,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, beginning balance | $ / shares</a></td>
<td class="nump">$ 15.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Options Granted | $ / shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, vested | $ / shares</a></td>
<td class="nump">14.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average fair value, forfeited | $ / shares</a></td>
<td class="nump">15.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 15.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894509424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,746<span></span>
</td>
<td class="nump">$ 11,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,963<span></span>
</td>
<td class="nump">3,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,609<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894527104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility, Weighted Average</a></td>
<td class="nump">64.90%<span></span>
</td>
<td class="nump">63.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate', window );">Risk-free interest rate, Weighted Average</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife', window );">Expected life (in years), Weighted Average</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield', window );">Expected dividend yield, Weighted Average</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue', window );">Grant date fair value, Weighted Average</a></td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="nump">$ 12.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">64.90%<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="nump">$ 10.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">68.60%<span></span>
</td>
<td class="nump">64.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 39.71<span></span>
</td>
<td class="nump">$ 15.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected dividend yield.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901374336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income before Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss before taxes</a></td>
<td class="num">$ (48,590)<span></span>
</td>
<td class="num">$ (66,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign income before taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (48,588)<span></span>
</td>
<td class="num">$ (66,747)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099901412416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit), Total</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(9,527)<span></span>
</td>
<td class="num">(11,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3,266)<span></span>
</td>
<td class="num">(3,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit), Total</a></td>
<td class="num">(12,793)<span></span>
</td>
<td class="num">(14,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">12,793<span></span>
</td>
<td class="nump">14,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894122336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 73,600<span></span>
</td>
<td class="nump">$ 70,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredTaxAssetAmortization', window );">Amortization</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D expenditures capitalization</a></td>
<td class="nump">10,923<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,292<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">11,271<span></span>
</td>
<td class="nump">9,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredTaxAssetRightOfUseOfLiability', window );">Right-of-use liability</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredTaxAssetDepreciation', window );">Depreciation</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">103,888<span></span>
</td>
<td class="nump">91,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(103,242)<span></span>
</td>
<td class="num">(90,471)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_DeferredTaxAssetRightOfUseOfAsset', window );">Right-of-use asset</a></td>
<td class="num">(646)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(646)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredTaxAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredTaxAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredTaxAssetDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredTaxAssetDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredTaxAssetRightOfUseOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset right of use of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredTaxAssetRightOfUseOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_DeferredTaxAssetRightOfUseOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset right of use of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_DeferredTaxAssetRightOfUseOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894254496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at the federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other non-deductible permanent items</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration', window );">Expired tax attributes</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.30%)<span></span>
</td>
<td class="num">(22.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_EffectiveIncomeTaxReconciliationTaxCredits', window );">Income tax expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at the federal statutory tax rate</a></td>
<td class="num">$ (10,203)<span></span>
</td>
<td class="num">$ (14,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(1,992)<span></span>
</td>
<td class="num">(2,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(1,805)<span></span>
</td>
<td class="num">(1,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other non-deductible permanent items</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration', window );">Expired tax attributes</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_IncomeTaxReconciliationTaxCreditOther', window );">Other</a></td>
<td class="num">(239)<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">12,793<span></span>
</td>
<td class="nump">14,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Income tax expense</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation limitation and credit carry forwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_EffectiveIncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_EffectiveIncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation limitation and credit carry forwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_IncomeTaxReconciliationTaxCreditOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Tax Credit Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_IncomeTaxReconciliationTaxCreditOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896269888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 12,793<span></span>
</td>
<td class="nump">$ 14,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">311,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">148,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_FederalOperatingLossCarryForwards', window );">Federal net operating loss</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_StateOperatingLossCarryForwards', window );">State net operating Loss</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_FederalOperatingLossCarryForwardsNotExpire', window );">Federal operating loss carry forwards not expire</a></td>
<td class="nump">204,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_StateOperatingLossCarryForwards', window );">State operating loss carry forwards</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_FederalOperatingLossCarryForwards', window );">Federal Operating Loss Carry Forwards</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_StateOperatingLossCarryForwardsNotExpire', window );">State operating loss carry forwards not expire</a></td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_TaxableIncomeOffsetPercentage', window );">Taxable Income offset, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Description of the limitations on the use of all operating loss carryforwards</a></td>
<td class="text">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss and R&D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignEarningsRepatriated', window );">Amount of earnings from Foreign subsidiaries</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_FederalOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_FederalOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_FederalOperatingLossCarryForwardsNotExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal operating loss carry forwards not expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_FederalOperatingLossCarryForwardsNotExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_StateOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_StateOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_StateOperatingLossCarryForwardsNotExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State operating loss carry forwards not expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_StateOperatingLossCarryForwardsNotExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_TaxableIncomeOffsetPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxable Income offset, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_TaxableIncomeOffsetPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignEarningsRepatriated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign earnings repatriated from subsidiaries outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignEarningsRepatriated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896358160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 3,494<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current year tax positions</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for prior year tax positions</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 4,244<span></span>
</td>
<td class="nump">$ 3,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099902883968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">34 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease Rent Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Base rent</a></td>
<td class="nump">$ 5,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Lease beginning date</a></td>
<td class="text">Mar.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Office Manufacturing And Warehouse Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_NumberOfLeases', window );">Number Of Leases | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Operating leases,tenant allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Maximum | Office Manufacturing And Warehouse Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxst_OfficeManufacturingAndWarehouseFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxst_OfficeManufacturingAndWarehouseFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894492400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary Of Lease Balances Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">$ 2,444<span></span>
</td>
<td class="nump">$ 3,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets Finance</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_TotalLeaseAssets', window );">Total lease assets</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Liabilities Current Operating</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 1,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease Liabilities Current<span></span>
</td>
<td class="text">Lease Liabilities Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Liabilities Current Finance</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease Liabilities Current<span></span>
</td>
<td class="text">Lease Liabilities Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Liabilities Noncurrent Operating</a></td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease Liabilities Noncurrent<span></span>
</td>
<td class="text">Lease Liabilities Noncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Liabilities Noncurrent Finance</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease Liabilities Noncurrent<span></span>
</td>
<td class="text">Lease Liabilities Noncurrent<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_TotalLeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">$ 3,012<span></span>
</td>
<td class="nump">$ 4,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_TotalLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_TotalLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_TotalLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_TotalLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099902803936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease cost</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease cost</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease cost</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099902802688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894493360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases</a></td>
<td class="text">1 year 8 months 8 days<span></span>
</td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance leases</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rxst_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases (as a percent)</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance leases (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxst_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxst_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099906231984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal proceedings, regulatory matters, legal costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Aggregate amount of the letter of credit</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099896133328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of eligible compensation, contributed by eligible participating employees</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140099894799136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriters discounts and commissions</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">36,139,513<span></span>
</td>
<td class="nump">28,268,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 9,473<span></span>
</td>
<td class="nump">$ 1,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPT9V=KE!0B5'7RGYRY@?[-6-T9TB/P1E?@B.R@\%NN*LG0C^3%ED[GMVS>'
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M<ZPG13FDTY](XL#5F+@.FXFY20YV97Z@]7/S*7$VL C!:3K69YO% 9EJ"\E
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MFO[(OK_1<M.=>M]*K6757:XY ]G& +Y?24#U[L8<I.__<;+\%U!+ P04
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M 'Y?,R9/#^H#S3\6%O\#4$L#!!0    ( %*!7%CI>]9%L@<  #DX   8
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULQ5MM;]LV$/XKA%=L+1#7(O7J+@G0
M.A)68%N#IML^*S(3"]6+)]%)^N]'2HIEDC(MK9<M'V+9NGN.O(='48^H\\>R
M^EIO*&7H*<^*^F*V86S[;K&HDPW-X_IMN:4%/W-75GG,^-?J?E%O*QJO&Z<\
M6Q#+\A9YG!:SR_/FM^OJ\KS<L2PMZ'6%ZEV>Q]6W#S0K'R]F>/;\P^?T?L/$
M#XO+\VU\3V\H^V-[7?%OBSW*.LUI4:=E@2IZ=S%[C]]%=N/06/R9TL?ZX!B)
MKMR6Y5?QY>/Z8F:)%M&,)DQ Q/SC@:YHE@DDWHZ_.]#9/J9P/#Q^1H^:SO/.
MW,8U79797^F:;2YFP0RMZ5V\R]CG\O$7VG7(%7A)F=7-?_38V5HSE.QJ5N:=
M,V]!GA;M9_S4)>+  =M''$CG0,8ZV)V#K3@0_XB#TSDXBH/C'7%P.P=7C7"L
MTU[GX#6Y;Y/59/HJ9O'E>54^HDI8<S1QT-#5>/,$IX4863>LXF=3[L<N5V51
MEUFZCAE=HQO&/_BP834J[]!GNJ9\&-]F%*W*/.?#X(:5R=>S]@-]VHJA49_Q
MD\4#K5@J#*_YN*!5U6 )H[CHCC9EMJ95_1,*_]ZE[!MZ?47OTB1E;] <_7%S
MA5Z_>H->H;1 7S;EKN9N]?F"\?Z)5BZ2KB\?VKZ0(WWY4K(X&W!;F=T..S?@
M?67V?K]>IR(1<8:NXW0]YUU8Q=MTN"7A":PDV>6[K.'B$]O02B2>3Q@;4<D/
M%'TLDC*GZ/6O95V_&8"/QL-WZ9=!%GSP[$<0V8\@TJ Z1U"'Z#U#'^A]6A1I
M<8\^Q%E<)/0,O<_+7<%0S'CPY"VR\1DB%L%#/+<1W2:BF!L?+K$=$(><+QX.
M>=7-B"^;7.DF'O9=C&6S4#>;$TNVB09L''])?&]O)^7/WN?/ALG?S2:N:#TJ
M?\:(XF+UKM[&";V8\<%5T^J!SBY__ %[UL]#U=.">5*6;<_S'4_)-634$!(L
M @*3^'7V_#IF?EO:TKK>\;KC:P'$*QO1)UHE:4W%1%LW4V79SJ?-E/E :R:X
MYR>Y+ZO21-1L:[<K4E8_CX8A\HW-F4J^HY'/"]&U5.HA8X:08!$0F$2]NZ?>
M_3^H;R?2(>I=C:W 4::ZE:O/K0J90RC*9!@:.SZ5(R PB2-OSY$WAJ.J6>QT
M+-%\FY7?*$4L?N+K,;81TS,GY;GLAE)OC#*UZCR-@;FS=%RUZB!CAI!@$1"8
MQ*B_9]2'9/1X-?DZ"YYC*^5D;,O$M%V-B1A"1HR P"2B@CU1P>F5SUS<%ZX1
M7]CRF^4Z;FXWZ9,X'BRS0,L0QO926?6MC'&GDC(J9 @9,@("DUA9[EE9_IN+
MUG,!M5>B[:Y*-IPXM.6+4\.L: PU=59<:D3PU3<.E$D1,F0("18!@4FL8JN_
MT;? >3T^-W;!)#)LM0S-+9I:AV-"AJ A(R@TF;(#;08;*?O(N1+W?F(QF+0J
M14O3,WO;W6V6)OST':W$HK&@3-BFSWY)69OO%<P-F%J@'=HA0X[O!KZKE"AH
MU! 4+8)"DRGOQ11L5E.@*#=4+M%(<I?N4BU=8S,GE^Z8F"%HS @*32:R5W6P
M6=;YG?.2MGI=5M;#Q:<K*W//\]5E_LH<:3(7H#(-*%IT.B,R&[T&@T^(,(,B
M6UBL1RB49) [1[N-#I9+2U4H!\R(NF#!NL;BV9YEJ1KE@-U\J4RMT9"1ZWB6
M38ZDL-<R\ DQ8U0*AT7*X13J.@,)B!?8@389C;6\,O=A\N &53F@T&3^>IT#
MFX6.]H%"(CU0.#HS>;K6K5[%5^9XDZ<E4#$##R@H:@<BJ) R(;U,@4?I%/^=
M,&QNS^3%GBY68&SQ&V-'K4G(L"$H6@2%)@^!7@#!)Q20_UH@QKJ8$=BN=M4*
M3FK$PT#:)0M4%8%"D\GJ=1$\2ACY;J78'&9R&>JJR-PCEJ>M,D!U$5"T" I-
M?G[=*R-DE#+R_8(QT16*.7:(*AF;FS/UPCDN: @:-()"DQGKA1%B%D;^C7),
M='$"N]I#[)4Y\F1R1@4-08-&4&@R.0?[04YL"($4D,VQIDZ61-<A A\3]2X"
M-&@(BA9!H<GD]K(&.;%;!51%)OK]/L9$?6)M;M+DDAP3,P2-&4&AR:3UZ@<Q
MJQ\OKR.;&S"Y3'41P_$L\:<6*NB^$U"T" I-YKR7:XA9KGEY(9GHJHPK="NU
M>O4-)^KS@$$D5]6V0G./)_/S$G(,Z>488I9CC/S$;,XIFN=Q];5AI:6(LS%(
M$L+&T@3=F4)T887PU::E*7&@84-0M @*3::^%WZ(6?@Y2GU:3&0>&^M3%V@<
M[ ;:)EI?EZA5+H>1U#UAYFY/)NDEI!G22S/$+,V,>'Y#= UD[@2>%:@9!MV.
M HH6@J)%IS,BL]%K+^2$]O(=SV_L0>Z6NL3E6;:G58=N9ZO;\ 9L?-=9^MJ:
M<D"J437I :RYNW2\@PV8\B[S7N6P3Z@<W_'\9C"%MBX\V!ZVERY6!8_1EE?F
M/DS>0PZJ>4"AR?SUFH=MUCRF/+_IH*11M%079N9X4Z<E4+1P3 <BJ) M(8N#
MEZC$2W6_Q=5]6M0HHW<<WGKK\\94[7MJ[1=6;IOWJFY+QLJ\.=S0F)>7,.#G
M[\J2/7\1KVKMWQ:\_ =02P,$%     @ 4H%<6,Q]?8$="0  0BL  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RM6E%OXS82_BN"KSBT0+V62$JV]Y(
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M(P#OUU+JPQ?S \.UV9O_ 5!+ P04    " !2@5Q8I.IU&G$,  "F(   &
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MX/G:8CZ)7UA ][\F7/P74$L#!!0    ( %*!7%A2%VY9."D  /B%   8
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M3%F#FCEX$L'ES.:W)? EP-3#:?)+#3*[*G^'0VR  S$G )VD<V,D@[\3%()
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M+_W,O=6ER/@1;AT+U#  =;;::UXLR4E"(4F/-V@GQ,=+1#K58':@?8$4_.(
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M"Q4<%%'G<<,&E++=2KD^,.T-VOD(1WI*([>>$ZNIPYL\MI\29425#VQ$_S8
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MBY2<ZJOKK)"B1 Z1I=I,-\[W#G@E<J:C(B6*&'*^LD@=40(E-5ERA"0/7*P
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M6,"2RX6AT2^P<3!$Y@BTVN\#\?X>4<&<!SEV,L1IRN1JJ?)&ZHWK:V1V27H
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MPORPU08^BO_@"J_0C_5/W*J>7J9HRH/O[A1]_O&9^='_ML>PL]/ #52TQXN
MN  Z%^C[Z-%L//5M)PD4Y%<HXY/0KIZ=_.G0Y>"G4X6LUOP#,9J?$-KV5U3=
MT^XW:%?VIU?]<OL#MO=)M4:[@9JXPE;(,+FPWT7;FUIO^8=82UW7NN#+C4PP
M3],"O%]I#+7NAAATO\Q[]6]02P,$%     @ 4H%<6&ZE(L"(!0  +0T  !D
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M@@EXW)7%_(]75$Y2UAW6<KO@L&DLXF Z"GM?D%VDF:\8CJFZ1P7=H!["6M!
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MY:&TM,\K^^G77P ,:AR3CIW_3E'V5<<^9[=&D"$2WM\HQU=./W1_0O[IF.'
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M$YLV<<Z$MLK4,4_+;65T!8TB*D@)9B$R :5$3<DR7X=B@\&=T8,5-4!\5TK
M&--;OT4KA<Q7A=*B2??A[&-1_*@ZB<X]>7FJ=/JDH"MUPX?1-B@[E$O?T_LJ
M7-U5=^=9^YB 7QJQDBF$G5HYW%>E._/HSIZ04PQ4S=]P6<.#ER%P[*,_.;BT
MU1PV^6HJT48<N_O;L#K<?B^[2]_=\>[J_$&%#3Z)H+R&Z73\R[,1A>XZVKTD
MW^0KX,HG7"CS8X4;/ <Y@/VUQ^>^?Q$'P]\$RW\!4$L#!!0    ( %*!7%B\
M][,=^P,  '\)   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;(U6VW+;
M-A#]E1TFS<0SBDA1LNLZDF8L.YWV(8G';MJ'3A\@<BEB# (T $K6WW<7I&C)
ME>T^V,)E]^S9*SC=&'OO2D0/CY72;A:5WM<7<>RR$BOAAJ9&33>%L97PM+6K
MV-4611Z4*A6G27(65T+J:#X-9S=V/C6-5U+CC0775)6PVP4JLYE%HVAW<"M7
MI>>#>#ZMQ0KOT/^H;RSMXAXEEQ5J)XT&B\4LNAQ=+"8L'P3^E+AQ>VM@3Y;&
MW//F]WP6)4P(%6:>$03]K/$*E6(@HO'084:]25;<7^_0?PV^DR]+X?#*J+]D
M[LM9=!Y!CH5HE+\UF]^P\^>4\3*C7/@/FTXVB2!KG#=5ITP,*JG;7_'8Q>'_
M**2=0AIXMX8"RVOAQ7QJS08L2Q,:+X*K09O(2<U)N?.6;B7I^?F7JE9FBPA+
MU%A(#[42>AI[@F:!..M@%BU,^@+,*(6O1OO2P1>=8WX($!.GGEBZ([9(7T6\
MQFP(X]$ TB0=OX(W[AT=![SQBW@%G>2PZ/R\(3\=")W#=U^BA1OCO$4O+5+)
M^6=BU])ERKC&HH._+Y<D2=7TS[$PM20FQTEPAUVX6F0XBZB%'-HU1O,/[T9G
MR>=77)ST+DY>0W_*Y0'Y8RQ?Q_EF/,)H A_>G:>CT6<X6B,P248?[T]@+V9.
MK*5>N?;ZCQ+ARE2UT%O@X>#IC^+-'1/RD%&Y6+EL0F^^@46S!RA)O7U3@/0.
ML./E!B!UIIJ<-,*%%A59P$?,&NYYDB]DAI;D-J4A:"]=L04Z85* 2J[D4BKI
MM\3@H>DHN"'\H%IN+7<$F<V@4U#X1( \W$*8-. -NTAJ FIC@W=$ES"D)9\K
M&J9LWQ#,1OJ2S#.\DA7SYIK(*"A$?KD-%U<FQP'P].++3UX\ L5"%!YMV'R\
M-;X\X;DDR3M?6M.LRH/8.F;TS(5AR,[> 4A'(?3(O<OR#XU0DD+4A #<M1/4
M!0UQ$IKFM%VVK@6:0[CD_!*K3ZVZ)*R]C+:QVWGQ%L5@!(75H0H,A\DX?$%=
M6 1M/-L6G)<.[BD]C?9202Y=JT3$"FNJ_V;VN5&.[ANV-B7J-Y&'S]KA/I2,
MSTJNV$-\BFA3LP<I_,2;OM@.BT>X)[VV7'K!6E#99;(F24+O@S#<];%]R?0:
MG8?TE.S6)+2E0(!9TZHP3;MUAW[L$W@/OR3)($F2$,/W<'9^'G8#T!@:EGJX
M0.EYA Z.Y7O7X\%L6XCT!&"U) *[9R!@TR(E6,*I,3SI:CL\-CSCO4>Q0KL*
M3S]'C8JA?1_[T_[KXK)]5)_$VT^3K\*N>'HI+$@U&?Y\&H%MG_MVXTT=GMBE
M\?1@AV5)7TAH68#N"T,CM=NP@?Z;:_XO4$L#!!0    ( %*!7%@%X !@MC0
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MBB!\&G8+N5*,[GD^&)C=B!Y'H[NN"D%B^) $L,@DKQ(%T*H[.E*SP;"#A1(
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M>7GIY[.4=0E]_U?+C?_?"/#H&C=I,M_R!QK^1X,F^I,T=S/-7TW91[#7@X]
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M2P!O;!:![@\W*A]<M+:-+J;AJB=UXZA> ^6H]WL\+)'3VC:MM*O!(24/8G#
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M+S).?[UU$R^YX6N"6 YK"*#7!(];*2X3^/\=AT8"W(>L"V)G,>1EB[#D9<]
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MHTRLIEU.>3:>9$K;XP?4.=S(!1I+!VX-'#ZPJ4!S-/0M%7&A?K("/*\!PQV
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M)S9HYX#GI5)V9[@$_3\@_0M02P,$%     @ 4H%<6&AA-<YX P  M0<  !D
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M-!/H^T8(O>^8!.-+O?@74$L#!!0    ( %*!7%@N%P"LNP4  &8.   9
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MAI7]3=]S,^ 3NBE@W!F9?WV#K;RPNH.;VUL0:1DEU,UBS[D%ZS&5KZU/"OX
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M'>HE)<!% 1"\ ^ '<"N%F6OX)E),=P%ZQ*:B%*PI702-B%>8="'T.Q!X0=B
M%U8AA@XO; [QK_.)-HI4\'==D 5$5 ]A=\:)7K $S]HD?8WJ&=OC+Y_\V/O:
M0#"J"$9-Z.,'VFGI,D.04W!DX8)E3"0(#VY?7HMB\Y&*ZZ@W@M=3?YPC3&5&
M.Y*+&1B[]N!&A=%@:#!S-"8%#4V:-',NW$@BA9893YG!=&T 3G^D(F<CEYJ)
M5!^=M&@E,9^@<JNYW6F5:W*9,:WYE"<N.+?@]A&TSK4FP-9O"U0T1!PWK:R8
MJNQV.Y;3XR419<X</D/0B:*(WF%G%(6M[UPX>G>*BI@RKT"\ '\N^8+*BNF
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M^K'M64%X_0@BS_8&,/+*YI#6O&S2\GL01CO59,%><[>7PHX?]B$@?=R@UB?
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ME:;2:++M/*SZX(&;8!7LU':2]M^O;0@#&8(Z6O(2L+GW^)SK$[B>'KCX+E,
MA7[F&9,S)U5J>^.Z,DXA)_*:;X'I)VLN<J+T4&Q<N15 $IN49R[VO)&;$\J<
M:&KG[D4TY3N540;W LE=GA/QZQ8R?I@YOG.<>*";5)D)-YINR096H+YL[X4>
MN15*0G-@DG*&!*QGSMR_6?B!2; 17RD<9.T>&2E/G'\W@T_)S/$,(\@@5@:"
MZ,L>%I!E!DGS^%&".M6:)K%^?T3_:,5K,4]$PH)GCS11Z<R9."B!-=EEZH$?
M_H92T-#@Q3R3]A<=REC/0?%.*IZ7R9I!3EEQ)3_+0M02_-&9!%PFX-.$P9F$
MH$RPE7,+9E;6DB@2304_(&&B-9JYL;6QV5H-968;5TKHIU3GJ6A5;!_B:S2/
M8[YCBK(-NN<9C2E(]"=::>,DNPQ,Q /L@>T ?10\1PO.E-"[(-$C52E:6*X@
M)'JW!$5H)M_K["^K)7KWYCUZ@RA#_Z1\)PE+Y-15FKHAX,8ES=N")CY#T\?H
MLUXOE>@OED#2!'"UYDHX/@J_Q9V(2XBO4>!?(>SAH(70XO?3<0>=H-J'P.(%
MY_"H))N-@ VQ[JX5^]\['8H^*<CEM[;"%;B#=ESS%KB16Q+#S-%_<PEB#T[T
M]@]_Y'UH$]T36*,$@ZH$@R[TZ"AX;=P55^XZ&'?%1W>U5:" '5I8\]K:1Y/0
M&X^G[KXN[674(/2\8175X#RL. \[.=^A)5JV<>I,>^VN] 364#BJ%(XN9,Q1
MGR7H":Q1@G%5@O%EC%G CFJ6"[ 7^B?&?!F%\= _8\Q)Q7G2;<SY71NCSJ37
M[DE/8 U]8:4OO) MPSY+T!-8HP2^]_SM]BYCS!*W[KGAP OQB3-;PO @')VQ
MIE_K.?Q.WBM="1H#>B1"$*9^7:'C3-547*$Y2TQ+ E)RH5N15AF=R[QV+_M"
M:Q8%/Q<%7\C1)7!?9>@)K5F&YS[([^PQ_H>G@Q<?>#P)!Z>6?AGE#_&IH]U:
M0ZW7V]ASAD2V/RY:S&JV.LO,;0=_,G]KSCBV47^&*0Y(GXG84"91!FL-Z5V/
M-251G#F*@>);V[8_<:5%V]M4G]- F #]?,VY.@[, M7)+_H/4$L#!!0    (
M %*!7%@$/1N?W0(  -T'   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;*U5R6[;,!#]%4(-B@1HHLT;4EN EQ;M(8 1-^VAZ($6QQ81BE1)RD[Z]24I
M6?4B&SGT(I'4O,?WR-',<"ODL\H -'K)&5<C+].ZN/=]E6:08W4G"N#FRTK(
M'&LSE6M?%1(P<:"<^5$0]/P<4^XE0[<VE\E0E)I1#G.)5)GG6+Y.@(GMR N]
MW<(C76?:+OC)L,!K6(!^*N;2S/R&A= <N**"(PFKD3<.[Z=]&^\"OE/8JKTQ
MLDZ60CS;R5<R\@(K"!BDVC)@\]K %!BS1$;&[YK3:[:TP/WQCOVS\VZ\++&"
MJ6 _*-'9R!MXB, *ETP_BNT7J/UT+5\JF')/M*UC P^EI=(BK\%&04YY]<8O
M]3GL <+>&4!4 Z)C0.<,(*X!L3-:*7.V9ECC9"C%%DD;;=CLP)V-0QLWE-M;
M7&AIOE*#T\FBNCTD5FB<IJ+DFO(UF@M&4PH*W:*%R1M2,K 1,UB!E$#0(VR
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M0E-GLL.4_ATH#8#VET+HEXEI3\W?*/H'4$L#!!0    ( %*!7%CZLG?,K@(
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M<$Y*9N[DZCO6>GJ.+Y5,^U]8U;%1 &FIC>0UV&; J:B>9%W[L 'H?7D#$->
M^+V ;@WH>J%59E[6A!B2#)1<@7+1ELT-O#<>;=50X:HX-<KN4HLSR327RIS<
MH^)P+9:HC:V0T7 "HRRCSFC"[$9U6ISMAQ,TA#)]9$,>IA,X/#B" Z "[G-9
M:B(R/0B-S<NQAVF=PT650_Q&#A-,3Z';.88XBKL[X./WP^-M>&C=:"R)&TMB
MS]=MLP2\)1.<&7C\80/@VB#7OW>)J]C.=K.YK_!<%R3%86 _,XUJB4'R\4.G
M'WW=)75/9%O"NXWP;AM[,F+VFR8B1;#UAE2A/0' I-:H_0I]/2"[?*C(>Y[<
M71[+)!J$RTUQ;1%;&9\U&9^U9GQ#UI27'!YOD,]0[2Q/*\._EF=/9%MB>XW8
MWE[/96^?PO=$MB6\WPCOMU;Y]6(ZAOOG N'Q<FU<(YDQA$M1<E3^<MKI0COU
MPQ2^R24JX=AAM$"14GO:-VY%;_44TU+9Z]!NM1RU\?]Y5^5AN''GNWY[0]2"
M"@T,Y_;MT>DG6S%5];!J8F3AV\!,&MM4_#"W;1^5"[#[<RG-R\1UEN:/1/(7
M4$L#!!0    ( %*!7%A^C!5CW0(  #D(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;*V674_;,!2&_XJ5H0DD2KX_VK61H!4:TC8A.L;%M LW.6TM
MG#BSG1;^_>PD9*4U'1>[:>SXO*^?<^*/CK>,/XHU@$1/!2W%Q%I+68UL6V1K
M*+"X8!64:F3)>(&EZO*5+2H..&]$!;4]QXGL I/22L?-NUN>CEDM*2GAEB-1
M%P7FSU= V79BN=;+BSNR6DO]PD['%5[!'.1]=<M5S^Y=<E) *0@K$8?EQ+IT
M1]-$QS<!/PALQ4X;Z4P6C#WJSDT^L1P-!!0RJ1VP>FQ@"I1J(X7QN_.T^BFU
M<+?]XG[=Y*YR66 !4T8?2"[7$RNQ4 Y+7%-YQ[:?H<LGU'X9HZ+Y1=LV-O8M
ME-5"LJ(3*X*"E.T3/W5UV!&XP1L"KQ-X[Q7XG<!O$FW)FK1F6.)TS-D6<1VM
MW'2CJ4VC5MF04G_%N>1JE"B=3&_*#922<0("#=!<+9*\IH#8$NV.G,Y 8D+%
MF8JYG\_0Z<D9.D&D1-_7K!:XS,78EHI&>]I9-_-5.[/WQLPSR"Z0[YXCS_%\
M@WSZ?KGW6FZK&O2%\/I">(V?_X]"/*,9$1EEHN: ?EXNA.1JJ?TRY=<:!F9#
MO?U&HL(93"RUOP3P#5CIQP]NY'PR9?N?S%[E[O>Y^\?<TVM2$K6$<K1BS/PI
M6WW8Z/7!L$D39ZC*OME-X3 H"IRD#WJ%%O1HP5&T.[Q5RUT")Y@:R5IYM#-I
M&"7.'MEA4!0, S-9V).%1\D>U/$T(.6@XBP#860+#Z8-W"#<8SL,\L(H-K-%
M/5MTE.WO8EYQ9F:+#J9UXZ$;[\$9HL(@&IKIXIXN/DKW195KA+IEC-1-A.!)
MEQ"I@P2QA6 4)*C3I<O!1!\?< V"8;0';PB*_#>^>M*S)^^K[#GZ!M*$EASL
M C<./'>/S1 5)'ZX!V?O'.SZ4OV*^8J4 E%8*IUS$2L#WEY4;4>RJCGK%TRJ
MFZ-IKM7=#EP'J/$E8_*EHZ^/_M]"^@=02P,$%     @ 4H%<6)W@_M\N @
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M+@@3H,=SSM6V8P[U[@Y/?@-02P,$%     @ 4H%<6)3IB! J!@  13@  !D
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M(8(2E[R5=*LW-]C[.?-\A98V?&'3Y\81%*TE7?=@IZ 6JOOSQ[X.6X#1Z1Y
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M2J;1I-2ZF#PSS=OW;YKWXQ/O3S#O0=+_"'$4)T?@X[?#X]=PZI3HY(@[.>+
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M=W.+VLMLALU.M-C8,7 N- Z5]G"-<S](8X#7ET+HXXFY0?%/PO!_4$L#!!0
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M<SFTM!9O0$9KXPL9L64W!#0Z?KJE"<<N2VMG]NQ]I56)00VEO6:,I%.0'Z-
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MAOH=-]Q0AXG*"M#WE93F.+$.JIYU\B]02P,$%     @ 4H%<6%IH;:RJ P
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M%9NF3>V_Y5E^L>/Z??@:GNUC9=>QUV34??L>ZSW 6S<9'X/)HUCNWC&83([
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M]96RWCFW_\_QT[/L;3N\Y+/I?Z3K/U!+ 0(4 Q0    ( %*!7%@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 4H%<6"$C2,'N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 4H%<6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !2
M@5Q8F%@Y4^8(  #X-0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 4H%<6(,""RSZ!0  1!D  !@
M         ("!*1$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( %*!7%C? 2@=_@(   $*   8              " @5D7  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !2@5Q8M5,,)]$%  !D&
M&               @(&-&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 4H%<6.E[UD6R!P  .3@  !@              ("!E"   'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %*!7%C,?7V!'0D
M $(K   8              " @7PH  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !2@5Q8I.IU&G$,  "F(   &               @('/
M,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 4H%<6%(7
M;EDX*0  ^(4  !@              ("!=CX  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( %*!7%C&7>3>&08  /(.   8
M  " @>1G  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !2
M@5Q8W6]__ 0#  "!!@  &0              @($S;@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %*!7%A$8CL!9 ,  %8'   9
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M970Q-2YX;6Q02P$"% ,4    " !2@5Q8;J4BP(@%   M#0  &0
M    @('ZC@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M %*!7%A19(L:T0P   LC   9              " @;F4  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 4H%<6$$BWN&2!P  )1,  !D
M             ("!P:$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !2@5Q8KJCR*A<%   ?#   &0              @(&*J0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %*!7%B\][,=^P,
M '\)   9              " @=BN  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 4H%<6 7@ &"V-   C[,  !D              ("!
M"K,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !2@5Q8
MKIMG]G8%   Y#@  &0              @('WYP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( %*!7%ANYXGTT (  & &   9
M      " @:3M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 4H%<6*O,XD#! @  X@4  !D              ("!J_   'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !2@5Q8>LX&?"0#  "^!@
M&0              @(&C\P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( %*!7%@ :CEZVP(  ,4&   9              " @?[V  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 4H%<6$B;_GR]
M @  #P8  !D              ("!$/H  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !2@5Q8:&$USG@#  "U!P  &0
M@($$_0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %*!
M7%@N%P"LNP4  &8.   9              " @;,  0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 4H%<6+W?\F^C!@  GQ$  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( %*!7%CV<C<W: ,  &T,   9
M  " @50B 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M4H%<6/^PM2QF P  !0X  !D              ("!\R4! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !2@5Q8!#T;G]T"  #=!P  &0
M            @(&0*0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( %*!7%AH+;]IHP(  )D&   9              " @:0L 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 4H%<6/JR=\RN @
M5 @  !D              ("!?B\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !2@5Q8?HP58]T"   Y"   &0              @(%C
M,@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %*!7%B=
MX/[?+@(  !<%   9              " @7<U 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ 4H%<6-T?H]2"!   I1D  !D
M     ("!W#<! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %*!7%@.7^*4/P(  "P%   9              "
M@0Q- 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 4H%<
M6+P9-Z\[ @  ,P4  !D              ("!@D\! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !2@5Q8+VCE)=T"  #3"0  &0
M        @('T40$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( %*!7%A++?N]B (  "L'   9              " @0A5 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 4H%<6"0NHG2=!@  <S
M !D              ("!QU<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !2@5Q8>ZT.$Z0$  #Y%   &0              @(&;7@$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %*!7%@;S6<E
M)P(  %0$   9              " @79C 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ 4H%<6%<PFMS> P  51   !D
M ("!U&4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !2
M@5Q81 CA0(8*  #D7   &0              @('I:0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %*!7%@P-8Y_Z@0  -86   9
M          " @:9T 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#
M%     @ 4H%<6'>=SE^+ P  OPH  !D              ("!QWD! 'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !2@5Q86FAMK*H#   U
M#P  &0              @(&)?0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;%!+ 0(4 Q0    ( %*!7%C][="*FP0  $$4   9              " @6J!
M 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 4H%<6'KZ
M07:G @  %P<  !D              ("!/(8! 'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    " !2@5Q8?4>YT%L#  !A"P  &0
M    @($:B0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M %*!7%@.V5YNZ@,  (X-   9              " @:R, 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ 4H%<6'IQH7")!   ]1$  !D
M             ("!S9 ! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !2@5Q8K+LX5'D$  !=$   &0              @(&-E0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( %*!7%AX-LUZ[0(
M .L'   9              " @3V: 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ 4H%<6#_-Z%E'!   S18  !D              ("!
M89T! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !2@5Q8
M %%PTN4#  #3$   &0              @('?H0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( %*!7%@G9>-Q@P,  / .   9
M      " @?NE 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ 4H%<6-6.!OXD P  A@L  !D              ("!M:D! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !2@5Q8JP8A\[\"   ]"0
M&0              @($0K0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( %*!7%BHA^B/W@(  '\(   9              " @0:P 0!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 4H%<6*RE;,,0
M P  L0D  !D              ("!&[,! 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " !2@5Q8_H?KL,T"   N!P  &0
M@(%BM@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( %*!
M7%A&;-@ 1 ,  ,H4   -              "  6:Y 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ 4H%<6)>*NQS     $P(   L              ( !U;P!
M %]R96QS+RYR96QS4$L! A0#%     @ 4H%<6(D>G^>A!0  ?#    \
M         ( !OKT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %*!7%BW
MQP,P0@(  $(K   :              "  8S# 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( %*!7%CXPP(=!@(  $\J   3
M      "  0;& 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !1 %$ +A8
' #W( 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>412</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies</Role>
      <ShortName>Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1</Role>
      <ShortName>Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Employee benefit plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee benefit plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables</Role>
      <ShortName>Summary of Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables</Role>
      <ShortName>Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails</Role>
      <ShortName>Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails</Role>
      <ShortName>Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails</Role>
      <ShortName>Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails</Role>
      <ShortName>Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Short-Term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-Term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Inventories - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails</Role>
      <ShortName>Inventories - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation</Role>
      <ShortName>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails</Role>
      <ShortName>Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Common Stock Warrant Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails</Role>
      <ShortName>Common Stock Warrant Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails</Role>
      <ShortName>Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stockholders Equity (Deficit) - Summary of Preferred Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails</Role>
      <ShortName>Stockholders Equity (Deficit) - Summary of Preferred Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stockholders Equity (Deficit) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>Stockholders Equity (Deficit) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails</Role>
      <ShortName>Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Stock Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Schedule of Income before Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Schedule of Income before Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Tax - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Tax - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Leases - Summary Of Lease Balances Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails</Role>
      <ShortName>Leases - Summary Of Lease Balances Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Employee benefit plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee benefit plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="rxst-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Subsequent events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="rxst-20231231.htm">rxst-20231231.htm</File>
    <File>rxst-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img50815396_0.jpg</File>
    <File>img50815396_1.jpg</File>
    <File>img50815396_2.jpg</File>
    <File>img50815396_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="657">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rxst-20231231.htm": {
   "nsprefix": "rxst",
   "nsuri": "http://rxsight.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "rxst-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "rxst-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 350,
   "keyCustom": 62,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 21,
   "hidden": {
    "total": 19,
    "http://fasb.org/us-gaap/2023": 15,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 152,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 779,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 657,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "100040 - Statement - Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Redeemable Common Stock, Stock Options, Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_295809f3-db7b-4e78-a9ef-56ea3cb4a075",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_295809f3-db7b-4e78-a9ef-56ea3cb4a075",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation",
     "longName": "100080 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies",
     "longName": "100090 - Disclosure - Summary of Accounting Policies",
     "shortName": "Summary of Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments",
     "longName": "100100 - Disclosure - Short-Term Investments",
     "shortName": "Short-Term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories",
     "longName": "100110 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1",
     "longName": "100120 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan",
     "longName": "100150 - Disclosure - Term Loan",
     "shortName": "Term Loan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense",
     "longName": "100160 - Disclosure - Stock-Based Compensation Expense",
     "shortName": "Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1",
     "longName": "100180 - Disclosure - Stockholders Equity (Deficit)",
     "shortName": "Stockholders Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100200 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "100220 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100230 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan",
     "longName": "100240 - Disclosure - Employee benefit plan",
     "shortName": "Employee benefit plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies",
     "longName": "100260 - Disclosure - Summary of Accounting Policies (Policies)",
     "shortName": "Summary of Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables",
     "longName": "100270 - Disclosure - Summary of Accounting Policies (Tables)",
     "shortName": "Summary of Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables",
     "longName": "100280 - Disclosure - Short-Term Investments (Tables)",
     "shortName": "Short-Term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables",
     "longName": "100290 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "longName": "100300 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100310 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "100320 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables",
     "longName": "100350 - Disclosure - Stockholders Equity (Deficit) (Tables)",
     "shortName": "Stockholders Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:SharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:SharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables",
     "longName": "100370 - Disclosure - Stock-Based Compensation Expense (Tables)",
     "shortName": "Stock-Based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100380 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "100390 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:SummaryOfLeaseBalancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:SummaryOfLeaseBalancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "100400 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "U_Subsidiary",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "U_Subsidiary",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
     "longName": "100410 - Disclosure - Summary of Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "rxst:ShortTermInvestmentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "rxst:ShortTermInvestmentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "100420 - Disclosure - Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details)",
     "shortName": "Summary of Accounting Policies - Schedule of Cash Cash Equivalents And Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails",
     "longName": "100440 - Disclosure - Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details)",
     "shortName": "Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails",
     "longName": "100450 - Disclosure - Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details)",
     "shortName": "Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_22015c87-a9d7-40c9-bba3-3d510e3d5d06",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails",
     "longName": "100460 - Disclosure - Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details)",
     "shortName": "Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_81ab6b37-2ec1-4387-88a2-59b62a95b01c",
      "name": "rxst:DeferredRevenue1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_295809f3-db7b-4e78-a9ef-56ea3cb4a075",
      "name": "rxst:DeferredRevenue1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails",
     "longName": "100470 - Disclosure - Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details)",
     "shortName": "Short-Term Investments - Schedule of Short-term Investment Available For Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
     "longName": "100480 - Disclosure - Short-Term Investments - Additional Information (Details)",
     "shortName": "Short-Term Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails",
     "longName": "100490 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails",
     "longName": "100500 - Disclosure - Inventories - Additional Information (Details)",
     "shortName": "Inventories - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "100510 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)",
     "shortName": "Property and Equipment - Schedule of property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "100520 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation",
     "longName": "100530 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details)",
     "shortName": "Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "100560 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
     "longName": "100570 - Disclosure - Term Loan - Additional Information (Details)",
     "shortName": "Term Loan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfeaa0f9-8a0e-4a4c-af2e-cbfcae368f77",
      "name": "rxst:DebtFromCashReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails",
     "longName": "100580 - Disclosure - Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details)",
     "shortName": "Term Loan - Future Annual Principal Payments Due Under the Amended Term Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
     "longName": "100600 - Disclosure - Common Stock Warrant Liability - Additional Information (Details)",
     "shortName": "Common Stock Warrant Liability - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
     "longName": "100610 - Disclosure - Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)",
     "shortName": "Common Stock Warrant Liability - Schedule Of Assumptions Used To Determine The Fair Value Of Warrant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3910fa9f-eae3-48ac-b145-d6273c7505d8",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
     "longName": "100620 - Disclosure - Stockholders Equity (Deficit) - Summary of Preferred Units (Details)",
     "shortName": "Stockholders Equity (Deficit) - Summary of Preferred Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
     "longName": "100630 - Disclosure - Stockholders Equity (Deficit) - Additional Information (Details)",
     "shortName": "Stockholders Equity (Deficit) - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a",
      "name": "us-gaap:RegistrationPaymentArrangementGainsAndLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "100650 - Disclosure - Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details)",
     "shortName": "Stockholders Equity (Deficit) - Summary of Common Stock Reserved For Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_023ec558-5797-47a9-a985-808a5dc77077",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails",
     "longName": "100660 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved For Future Issuance (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_25a0e726-e847-4009-b9ba-5e81ccb68e86",
      "name": "rxst:ClosingStockPrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "rxst:SharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25a0e726-e847-4009-b9ba-5e81ccb68e86",
      "name": "rxst:ClosingStockPrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "rxst:SharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
     "longName": "100670 - Disclosure - Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)",
     "shortName": "Convertible Preferred Stock Warrants - Schedule of Probability Weighted Assumptions of Convertible Preferred Stock Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
     "longName": "100690 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)",
     "shortName": "Stock-Based Compensation Expense - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails",
     "longName": "100700 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activities (Details)",
     "shortName": "Stock-Based Compensation Expense - Summary of Stock Option Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_1d8556ea-ac49-44a5-91dd-da0264eccc3e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
     "longName": "100710 - Disclosure - Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details)",
     "shortName": "Stock-Based Compensation Expense - Summary of Non-Vested Restricted stock unit Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_b77127b8-810a-4edb-a388-e4c235f9b291",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b77127b8-810a-4edb-a388-e4c235f9b291",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
     "longName": "100720 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_4afc0d75-e45f-41c5-a746-3f9e2d736cce",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4afc0d75-e45f-41c5-a746-3f9e2d736cce",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
     "longName": "100730 - Disclosure - Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details)",
     "shortName": "Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails",
     "longName": "100740 - Disclosure - Income Taxes - Schedule of Income before Income Tax (Details)",
     "shortName": "Income Taxes - Schedule of Income before Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails",
     "longName": "100750 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails",
     "longName": "100760 - Disclosure - Income Tax - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Income Tax - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100780 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "100790 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_81ab6b37-2ec1-4387-88a2-59b62a95b01c",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_295809f3-db7b-4e78-a9ef-56ea3cb4a075",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "100820 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_06262739-6be2-40d0-a27d-2ee73ccd9a32",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_06262739-6be2-40d0-a27d-2ee73ccd9a32",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails",
     "longName": "100830 - Disclosure - Leases - Summary Of Lease Balances Sheet Information (Details)",
     "shortName": "Leases - Summary Of Lease Balances Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SummaryOfLeaseBalancesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
     "longName": "100840 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "100850 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
     "longName": "100860 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "shortName": "Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4cc92432-cf1e-4695-bc70-b0ff049a2abb",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rxst:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100870 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
     "longName": "100880 - Disclosure - Employee benefit plan - Additional Information (Details)",
     "shortName": "Employee benefit plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "100890 - Disclosure - Subsequent events - Additional Information (Details)",
     "shortName": "Subsequent events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_01f8a67f-a74e-480a-abb3-13c58f494e3f",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rxst-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts Notes And Loans Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r883"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor invoices",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r25"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307"
     ]
    },
    "rxst_AccountsReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AccountsReceivablePercentage",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable, Percentage.",
        "label": "Accounts Receivable Percentage",
        "terseLabel": "Percentage of gross accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on short-term investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "rxst_AccruedCustomerDepositsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AccruedCustomerDepositsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposits",
        "label": "Accrued Customer Deposits Current",
        "documentation": "Accrued Customer Deposits Current."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_AccruedDeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AccruedDeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Accrued Deferred Revenue Current",
        "documentation": "Accrued Deferred Revenue Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "rxst_AccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AccruedInterestCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Accrued Interest Current",
        "documentation": "Accrued Interest Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilities and Other Liabilities, Total",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r204",
      "r690"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r120",
      "r210",
      "r686",
      "r713",
      "r717"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r38",
      "r557",
      "r560",
      "r633",
      "r708",
      "r709",
      "r935",
      "r936",
      "r937",
      "r949",
      "r950",
      "r951"
     ]
    },
    "rxst_AdditionalNonRefundablePaymentUponExtensionOfExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AdditionalNonRefundablePaymentUponExtensionOfExpiration",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Non-Refundable Payment Upon Extension of Expiration.",
        "label": "Additional Non Refundable Payment Upon Extension Of Expiration",
        "terseLabel": "Additional non-refundable payment upon extension of expiration"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_AdditionalNumberOfCommonSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AdditionalNumberOfCommonSharesIssued",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of common shares issued.",
        "label": "Additional Number Of Common Shares Issued",
        "terseLabel": "Additional common shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r883",
      "r1039"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r732",
      "r949",
      "r950",
      "r951",
      "r1013",
      "r1041"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r461"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r506"
     ]
    },
    "rxst_AmendedTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AmendedTermLoanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended term loan member",
        "label": "Amended Term Loan [Member]",
        "terseLabel": "Amended Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and premium",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r607",
      "r864",
      "r865",
      "r942"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Redeemable stock options",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r206",
      "r242",
      "r282",
      "r296",
      "r300",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r546",
      "r550",
      "r588",
      "r681",
      "r774",
      "r883",
      "r896",
      "r972",
      "r973",
      "r1022"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r214",
      "r242",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r546",
      "r550",
      "r588",
      "r883",
      "r972",
      "r973",
      "r1022"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_AtmOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AtmOfferingMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering [Member]",
        "label": "ATM Offering [Member]",
        "terseLabel": "ATM Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904"
     ]
    },
    "rxst_AugustFourTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "AugustFourTwoThousandTwentyThreeMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 4, 2023 [Member]",
        "label": "August Four Two Thousand Twenty Three [Member]",
        "documentation": "August Four Two Thousand Twenty Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss, Net",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r362",
      "r680"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r362",
      "r675",
      "r961"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "rxst_BmlManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "BmlManagementLlcMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BML Management, LLC [Member]",
        "documentation": "BML Management, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_BofaSecuritiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "BofaSecuritiesIncMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BofA Securities, Inc. [Member]",
        "label": "BofA Securities, Inc. [Member]",
        "terseLabel": "BofA Securities, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_COVID19PolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "COVID19PolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19.",
        "label": "C O V I D19 Policy [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan.",
        "label": "Calhoun Vision Inc2015 Equity Incentive Plan And Calhoun Vision Inc2006 Stock Plan [Member]",
        "terseLabel": "The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calhoun Vision Inc 2015 Equity Incentive Plans And Calhoun Vision Inc 2006 Stock Plan.",
        "label": "Calhoun Vision Inc2015 Equity Incentive Plans And Calhoun Vision Inc2006 Stock Plan [Member]",
        "terseLabel": "The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      },
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r202",
      "r851"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, cash equivalents and restricted cash in the consolidated statements of cash flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r129",
      "r237"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r129"
     ]
    },
    "rxst_CashInterestPaidPercentagePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CashInterestPaidPercentagePeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Interest paid, Percentage, Period",
        "label": "Cash Interest paid, Percentage, Period",
        "terseLabel": "Cash interest paid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r207",
      "r208",
      "r209",
      "r242",
      "r266",
      "r267",
      "r274",
      "r276",
      "r280",
      "r281",
      "r342",
      "r379",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r418",
      "r419",
      "r422",
      "r425",
      "r434",
      "r588",
      "r724",
      "r725",
      "r726",
      "r727",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r762",
      "r783",
      "r802",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r910",
      "r944",
      "r952"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r280",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r432",
      "r434",
      "r724",
      "r725",
      "r726",
      "r727",
      "r866",
      "r910",
      "r944"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of converted shares of common stock",
        "verboseLabel": "Number of shares issued upon warrant exercised",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants Outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants exercised",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "rxst_ClassOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ClassOfWarrantsExercised",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrants exercised",
        "label": "Class of Warrants Exercised",
        "documentation": "Class of warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ClosingStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ClosingStockPrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing Stock Price",
        "label": "Closing Stock Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r102",
      "r682",
      "r761"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r373",
      "r374",
      "r836",
      "r969"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Conversion of preferred stock",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "rxst_CommonStockInExchangeForCancellationOfNotesReceivables": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CommonStockInExchangeForCancellationOfNotesReceivables",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Surrender of common stock in exchange for cancellation of note receivable, Shares",
        "terseLabel": "Surrender of common stock in exchange for cancellation of note receivable, Shares",
        "documentation": "Common stock in exchange for cancellation of notes receivables shares.",
        "label": "Common Stock in Exchange for Cancellation of Notes Receivables Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r887",
      "r888",
      "r890",
      "r891",
      "r892",
      "r893",
      "r949",
      "r950",
      "r1013",
      "r1038",
      "r1041"
     ]
    },
    "rxst_CommonStockOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CommonStockOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock offering costs.",
        "label": "Common Stock Offering Costs",
        "terseLabel": "Common stock offering costs",
        "verboseLabel": "Stock issuance offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (USD per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "rxst_CommonStockSaleUnderwritingDiscountsAndCommissionDeducted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CommonStockSaleUnderwritingDiscountsAndCommissionDeducted",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sale underwriting discounts and commission deducted.",
        "label": "Common Stock Sale Underwriting Discounts and Commission Deducted",
        "terseLabel": "Common stock sale underwriting discounts and commission deducted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r762"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stockholders' Equity, Ending Balance, Shares",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance, Shares",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r111",
      "r762",
      "r780",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 900,000,000 shares authorized, 36,139,513 shares issued and outstanding as of December 31, 2023 and 28,268,389 Shares issued and outstanding as of December 31, 2022",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r684",
      "r883"
     ]
    },
    "rxst_CommonStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CommonStockWarrantLiabilityMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant liability.",
        "label": "Common Stock Warrant Liability [Member]",
        "terseLabel": "Common Stock Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CommonStockWarrantMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrant",
        "documentation": "Common stock warrant.",
        "label": "Common Stock Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CompassBibleChurchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CompassBibleChurchMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compass Bible Church [Member]",
        "documentation": "Compass Bible Church [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r220",
      "r222",
      "r228",
      "r676",
      "r696"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Hardware and Software [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r94",
      "r95",
      "r305",
      "r835"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r94",
      "r95",
      "r305",
      "r718",
      "r835"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r94",
      "r95",
      "r305",
      "r835",
      "r912"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r179"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r94",
      "r95",
      "r305"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r94",
      "r95",
      "r305",
      "r835"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r449"
     ]
    },
    "rxst_ConversionOfPreferredStockToCommonStockUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ConversionOfPreferredStockToCommonStockUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock upon initial public offering",
        "documentation": "Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering",
        "label": "Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of preferred stock to common stock upon initial public offering, shares",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Redeemable common stock reclassified",
        "verboseLabel": "Conversion of preferred stock to common stock upon initial public offering, shares",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Common stock after reclassification of redeemable common stock",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r422",
      "r890",
      "r891",
      "r892",
      "r893"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Aggregate shares of common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r70",
      "r110",
      "r141",
      "r429"
     ]
    },
    "rxst_ConvertiblePreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ConvertiblePreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ConvertiblePreferredStockWarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ConvertiblePreferredStockWarrantsDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock Warrants",
        "label": "Convertible Preferred Stock Warrants Disclosure [Text Block]",
        "documentation": "Convertible Preferred Stock Warrants Disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r671"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost, Depreciation and Amortization, Total",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and Amortization",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales [Member]",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r947",
      "r1010"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r947"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current Income Tax Expense (Benefit), Total",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current income tax expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r528",
      "r536",
      "r947"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r947",
      "r1010"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r305"
     ]
    },
    "rxst_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer four member.",
        "label": "Customer Four [Member]",
        "terseLabel": "Customer Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three member.",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two member.",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r239",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r404",
      "r411",
      "r412",
      "r414"
     ]
    },
    "rxst_DebtFromCashReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DebtFromCashReserves",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from Lines of Credit",
        "terseLabel": "Cash reserves",
        "label": "Debt From Cash Reserves",
        "documentation": "Debt From Cash Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r415"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101",
      "r389",
      "r608",
      "r862",
      "r863"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r99",
      "r407"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r608",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r945"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r70",
      "r73",
      "r98",
      "r99",
      "r101",
      "r103",
      "r140",
      "r142",
      "r245",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r608",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r945"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r947",
      "r1009"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r154",
      "r185",
      "r535",
      "r536",
      "r947"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r163",
      "r522"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "rxst_DeferredOfferingCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredOfferingCostsIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities",
        "documentation": "Deferred offering costs included in accrued expenses",
        "label": "Deferred Offering Costs Included In Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Policy [Text Block]",
        "label": "Deferred Offering Costs Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Total",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "rxst_DeferredRevenue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredRevenue1",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "negatedPeriodEndLabel": "Balance at end of period",
        "negatedPeriodStartLabel": "Balance at beginning of period",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer.",
        "label": "Deferred Revenue1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueAdditions",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions during the period",
        "label": "Deferred Revenue, Additions",
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Revenue Activity",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfDeferredRevenueActivityDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revenue recognized during the period",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1009",
      "r1010"
     ]
    },
    "rxst_DeferredTaxAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredTaxAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Asset Amortization",
        "documentation": "Deferred tax asset amortization."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_DeferredTaxAssetDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredTaxAssetDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Deferred Tax Asset Depreciation",
        "documentation": "Deferred tax asset depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_DeferredTaxAssetRightOfUseOfAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredTaxAssetRightOfUseOfAsset",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use of Asset",
        "label": "Deferred Tax Asset Right Of Use Of Asset",
        "documentation": "Deferred tax asset right of use of asset.",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_DeferredTaxAssetRightOfUseOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DeferredTaxAssetRightOfUseOfLiability",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use liability",
        "label": "Deferred Tax Asset Right Of Use Of Liability",
        "documentation": "Deferred tax asset right of use of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "R&amp;D expenditures capitalization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureIncomeTaxScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "verboseLabel": "Less: Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution, net",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contributions",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of eligible compensation, contributed by eligible participating employees",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_DefinedContributionSavingPlansMatchingContributionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "DefinedContributionSavingPlansMatchingContributionsDuringPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Saving Plans Matching Contributions During Period.",
        "label": "Defined Contribution Saving Plans Matching Contributions During Period",
        "terseLabel": "Defined contribution saving plans matching contributions during period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r286"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Total",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Redeemable stock options",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r463",
      "r494",
      "r495",
      "r497",
      "r878"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904",
      "r906"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net income (loss) per share",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Attributable to common stock, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r266",
      "r274",
      "r275",
      "r276",
      "r278",
      "r575",
      "r576",
      "r677",
      "r697",
      "r855"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net income (loss) per share",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Attributable to common stock, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r266",
      "r274",
      "r275",
      "r276",
      "r278",
      "r575",
      "r576",
      "r677",
      "r697",
      "r855"
     ]
    },
    "rxst_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Line Items",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "rxst_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Table",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rate on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax provision at the federal statutory tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r514",
      "r538"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "rxst_EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired tax attributes",
        "documentation": "Effective income tax rate reconciliation limitation and credit carry forwards subject to expiration.",
        "label": "Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other non-deductible permanent items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1011"
     ]
    },
    "rxst_EffectiveIncomeTaxReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationTaxCredits",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax reconciliation tax credits.",
        "label": "Effective Income Tax Reconciliation Tax Credits",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for emerging growth company status."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition of expenses",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized expense related to unvested stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Share-based Compensation, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan [Member]",
        "label": "Employee stock purchase plan [Member]",
        "documentation": "Employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r195",
      "r224",
      "r225",
      "r226",
      "r246",
      "r247",
      "r248",
      "r251",
      "r259",
      "r261",
      "r279",
      "r346",
      "r352",
      "r436",
      "r498",
      "r499",
      "r500",
      "r531",
      "r532",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r574",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r633",
      "r708",
      "r709",
      "r710",
      "r732",
      "r802"
     ]
    },
    "rxst_EscrowHoldbackOfExercisePriceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "EscrowHoldbackOfExercisePriceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrow Holdback Of Exercise Price Of Warrants",
        "label": "Escrow Holdback Of Exercise Price Of Warrants",
        "terseLabel": "Escrow holdback of exercise price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExchangePaymentOfNotesReceivablesForCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExchangePaymentOfNotesReceivablesForCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange payment for notes receivables for common stock.",
        "label": "Exchange Payment Of Notes Receivables For Common Stock",
        "terseLabel": "Exchange Payment Of Notes Receivables For Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExecutiveOfficersAndNonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExecutiveOfficersAndNonEmployeeDirectorsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officers and Non-Employee Directors [Member]",
        "label": "Executive Officers and Non-Employee Directors [Member]",
        "terseLabel": "Executive Officers and Non-Employee Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExerciseOfPreferredStockWarrantNetOfSharesWithheldForExercisePrice",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Of Preferred Stock Warrant Net Of Shares Withheld For Exercise Price.",
        "label": "Exercise Of Preferred Stock Warrant Net Of Shares Withheld For Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExerciseOfPreferredStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExerciseOfPreferredStockWarrants",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of preferred stock warrants",
        "documentation": "Exercise of preferred stock warrants.",
        "label": "Exercise Of Preferred Stock Warrants",
        "terseLabel": "Exercise of preferred stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExercisePriceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExercisePriceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Of Warrants",
        "label": "Exercise Price Of Warrants",
        "terseLabel": "Exercise price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ExpirationOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ExpirationOfCommonStockWarrants",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expiration of common stock warrants",
        "documentation": "Expiration of common stock warrants.",
        "label": "Expiration Of Common Stock Warrants",
        "terseLabel": "Expiration of common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrants",
        "negatedLabel": "Change in fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92",
      "r93"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r580",
      "r642",
      "r643",
      "r644",
      "r862",
      "r863",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r158"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r451",
      "r456",
      "r580",
      "r642",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r451",
      "r456",
      "r580",
      "r643",
      "r862",
      "r863",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r580",
      "r644",
      "r862",
      "r863",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of estimated fair value for the warrant liabilities measured using significant unobservable inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r91"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r642",
      "r643",
      "r644",
      "r862",
      "r863",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r583"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Assets or liabilities measured at fair value",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "rxst_FairValueOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "FairValueOfWarrants",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment of warrants.",
        "label": "Fair Value Of Warrants",
        "terseLabel": "Fair Value Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option, Disclosures [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591"
     ]
    },
    "rxst_FederalOperatingLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "FederalOperatingLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal operating loss carry forwards.",
        "label": "Federal Operating Loss Carry Forwards",
        "terseLabel": "Federal net operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_FederalOperatingLossCarryForwardsNotExpire": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "FederalOperatingLossCarryForwardsNotExpire",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal operating loss carry forwards not expire.",
        "label": "Federal Operating Loss Carry Forwards Not Expire",
        "terseLabel": "Federal operating loss carry forwards not expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease cost",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r622",
      "r882"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liabilities",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Liabilities Current Finance",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Liabilities Noncurrent Finance",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails5": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "rxst_FinanceLeaseObligationsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "FinanceLeaseObligationsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease",
        "documentation": "Finance Lease Obligations Incurred",
        "label": "Finance Lease Obligations Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance lease liabilities",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r624"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets Finance",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease cost",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r622",
      "r882"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance leases (as a percent)",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r882"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r882"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r354",
      "r355",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r413",
      "r432",
      "r564",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r695",
      "r860",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Financing Receivable, Allowance for Credit Loss, Beginning Balance",
        "periodEndLabel": "Financing Receivable, Allowance for Credit Loss, Ending Balance",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses for investments",
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r190",
      "r191",
      "r192",
      "r211",
      "r353",
      "r356",
      "r358",
      "r1032"
     ]
    },
    "us-gaap_ForeignEarningsRepatriated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignEarningsRepatriated",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of earnings from Foreign subsidiaries",
        "label": "Foreign Earnings Repatriated",
        "documentation": "Amount of foreign earnings repatriated from subsidiaries outside the country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FutureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FutureMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future [Member]",
        "label": "Future [Member]",
        "documentation": "Futures contracts are forward-based contracts to make or take delivery of a specified financial instrument, foreign currency, or commodity at a specified future date or during a specified period at as specified price or yield. Futures are standardized contracts traded on an organized exchange."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r771",
      "r776",
      "r791",
      "r797",
      "r818",
      "r886",
      "r887",
      "r888",
      "r1012"
     ]
    },
    "rxst_GainLossFromChangesInFairValueOfCommonStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "GainLossFromChangesInFairValueOfCommonStockWarrant",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) from Changes in fair value of common stock warrant.",
        "label": "Gain Loss From Changes In Fair Value Of Common Stock Warrant",
        "terseLabel": "Change in fair value of common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_GainLossFromChangesInFairValueOfPreferredStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "GainLossFromChangesInFairValueOfPreferredStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueForWarrantLiabilitiesMeasuredUsingSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) from Changes in fair value of preferred stock warrants.",
        "label": "Gain Loss From Changes In Fair Value Of Preferred Stock Warrants",
        "terseLabel": "Change in fair value of preferred stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_GainLossOnExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "GainLossOnExpiration",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on expiration.",
        "label": "Gain Loss On Expiration",
        "terseLabel": "Gain Loss On Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_GainOnExpirationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "GainOnExpirationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Expiration Of Warrants",
        "label": "Gain On Expiration Of Warrants",
        "terseLabel": "Gain on expiration of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of term loan",
        "negatedLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r65"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r242",
      "r282",
      "r295",
      "r299",
      "r301",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r588",
      "r857",
      "r972"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r904"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. loss before taxes",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r537"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r121",
      "r168",
      "r282",
      "r295",
      "r299",
      "r301",
      "r678",
      "r692",
      "r857"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign income before taxes",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r537"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372",
      "r786"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r786"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r509",
      "r515",
      "r519",
      "r526",
      "r533",
      "r539",
      "r540",
      "r541",
      "r729"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "negatedLabel": "Income tax (benefit) expense",
        "negatedTotalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r186",
      "r260",
      "r261",
      "r287",
      "r513",
      "r534",
      "r698"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r511",
      "r512",
      "r519",
      "r520",
      "r525",
      "r527",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "negatedLabel": "Income tax provision at the federal statutory tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "rxst_IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired tax attributes",
        "negatedLabel": "Expired tax attributes",
        "documentation": "Income tax reconciliation limitation and credit carry forwards subject to expiration.",
        "label": "Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-deductible permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "negatedLabel": "Other non-deductible permanent items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "negatedLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "negatedLabel": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "rxst_IncomeTaxReconciliationTaxCreditOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IncomeTaxReconciliationTaxCreditOther",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Tax Credit Other",
        "label": "Income Tax Reconciliation Tax Credit Other",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "totalLabel": "Income tax expense",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxReconciliationTaxCredits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research and development credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Taxes Paid, Net, Total",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "rxst_IncreasedDecreasedInRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IncreasedDecreasedInRestrictedCash",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increased (Decreased) In Restricted Cash",
        "documentation": "Increased (Decreased) In Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "InitialPublicOfferingAndReverseStockSplitPolicyPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering and reverse stock split.",
        "label": "Initial Public Offering And Reverse Stock Split Policy Policy [Text Block]",
        "terseLabel": "Initial Public Offering ('IPO')"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest and Other Income, Total",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r170",
      "r227",
      "r285",
      "r606",
      "r787",
      "r894",
      "r1040"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r235",
      "r236"
     ]
    },
    "rxst_InterestPaidOnFinancingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "InterestPaidOnFinancingLeases",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid on financing leases",
        "label": "Interest Paid On Financing Leases",
        "terseLabel": "Cash paid for interest on financing leases"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_InterestPaidOnTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "InterestPaidOnTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid on term loan.",
        "label": "Interest Paid On Term Loan",
        "terseLabel": "Cash paid for interest on term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, Finished Goods, Gross, Total",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross",
        "totalLabel": "Inventory gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r852",
      "r883"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r201",
      "r212",
      "r366",
      "r367",
      "r369",
      "r670",
      "r853"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, Raw Materials, Gross, Total",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Inventory Valuation Reserves, Ending Balance",
        "periodStartLabel": "Inventory Valuation Reserves, Beginning Balance",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: reserve for excess and obsolete inventory",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r932"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventory",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "rxst_InvestmentCreditPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "InvestmentCreditPercentage",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Credit Percentage",
        "label": "Investment Credit Percentage",
        "terseLabel": "Investment credit percentage"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_InvestmentMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "InvestmentMaturityPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment maturity period.",
        "label": "Investment Maturity Period",
        "terseLabel": "Investment Maturity Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r746",
      "r747",
      "r749",
      "r751",
      "r807",
      "r810",
      "r812",
      "r816",
      "r817",
      "r819",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r888"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r746",
      "r747",
      "r749",
      "r751",
      "r807",
      "r810",
      "r812",
      "r816",
      "r817",
      "r819",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r888"
     ]
    },
    "us-gaap_InvestmentTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeExtensibleEnumeration",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Type [Extensible Enumeration]",
        "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r749",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r817",
      "r821",
      "r822"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-Term Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r171",
      "r172",
      "r189",
      "r310",
      "r311",
      "r584",
      "r585"
     ]
    },
    "rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for at-the-market offerings, net of issuance costs 1, Shares",
        "label": "Issuance of common stock for at-the-market offerings, net of issuance costs 1",
        "documentation": "Issuance of common stock for at-the-market offerings, net of issuance costs 1"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for the public offering net of issuance costs, Shares",
        "label": "Issuance of Common Stock for at-the-Market Offerings, Net of Issuance Costs, Share",
        "documentation": "Issuance of Common Stock for at-the-Market Offerings, Net of Issuance Costs, Share"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount",
        "documentation": "Issuance of common stock in at-the-market offerings, net of issuance costs1, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for the public offering net of issuance costs, Amount",
        "documentation": "Issuance of common stock in at-the-market offerings, net of issuance costs, Amount",
        "label": "Issuance of common stock in at-the-market offerings, net of issuance costs, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_LDDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LDDMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "L D D",
        "label": "L D D [Member]",
        "documentation": "LDD Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Rent Payable",
        "label": "Operating Leases, Rent Expense",
        "totalLabel": "Operating Leases, Rent Expense, Total",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Component of Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_LeaseLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LeaseLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities current.",
        "label": "Lease Liabilities Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_LeaseLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LeaseLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities noncurrent.",
        "label": "Lease Liabilities Noncurrent",
        "terseLabel": "Long-term lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_LeaseObligationsRecordedForRightOfUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LeaseObligationsRecordedForRightOfUseAssetsAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease obligations recorded for right-of-use assets abstract",
        "label": "Lease Obligations Recorded For Right Of Use Assets [Abstract]",
        "terseLabel": "Lease obligations recorded for right-of-use assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal proceedings, regulatory matters, legal costs",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of Contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease agreement",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r242",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r547",
      "r550",
      "r551",
      "r588",
      "r760",
      "r856",
      "r896",
      "r972",
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r165",
      "r688",
      "r883",
      "r946",
      "r966",
      "r1015"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r200",
      "r242",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r547",
      "r550",
      "r551",
      "r588",
      "r883",
      "r972",
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "negatedLabel": "Total liabilities at fair value",
        "negatedTotalLabel": "Total liabilities at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liability:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Liabilities, Other than Long-Term Debt, Noncurrent",
        "totalLabel": "Liabilities, Other than Long-Term Debt, Noncurrent, Total",
        "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_LiabilityOnUncertainTaxPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LiabilityOnUncertainTaxPosition",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability on uncertain tax position.",
        "label": "Liability On Uncertain Tax Position",
        "terseLabel": "Liability on Uncertain Tax Position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Line of credit facility, expiration date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit, Current",
        "terseLabel": "Aggregate amount of the letter of credit",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r162"
     ]
    },
    "rxst_LiquidityAndFinancialPositionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "LiquidityAndFinancialPositionPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Liquidity and Financial Position.",
        "label": "Liquidity and Financial Position [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]",
        "terseLabel": "Notes Receivable for Redeemable Common Stock",
        "documentation": "The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Term loan, net",
        "label": "Long-Term Debt",
        "terseLabel": "Term loan, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r401",
      "r416",
      "r862",
      "r863",
      "r1034"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months",
        "terseLabel": "2023",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling after Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022 (remainder)",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r63"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r869",
      "r976",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum [Member]",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r458",
      "r669",
      "r705",
      "r752",
      "r753",
      "r809",
      "r811",
      "r814",
      "r815",
      "r821",
      "r846",
      "r847",
      "r859",
      "r866",
      "r877",
      "r885",
      "r974",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "rxst_MayThreeTwoThousandTwentyTwoTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "MayThreeTwoThousandTwentyTwoTermLoanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 3, 2022 [Member]",
        "label": "May Three Two Thousand Twenty Two Term Loan [Member]",
        "documentation": "May Three Two Thousand Twenty Two Term Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r458",
      "r669",
      "r705",
      "r752",
      "r753",
      "r809",
      "r811",
      "r814",
      "r815",
      "r821",
      "r846",
      "r847",
      "r859",
      "r866",
      "r877",
      "r885",
      "r974",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Securities",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r305",
      "r869",
      "r976",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net income loss",
        "negatedTotalLabel": "Net income (loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r131",
      "r169",
      "r198",
      "r218",
      "r221",
      "r226",
      "r242",
      "r250",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r272",
      "r282",
      "r295",
      "r299",
      "r301",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r576",
      "r588",
      "r694",
      "r782",
      "r800",
      "r801",
      "r857",
      "r894",
      "r972"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) available to stockholders, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r254",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r273",
      "r276",
      "r282",
      "r295",
      "r299",
      "r301",
      "r857"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) available to stockholders, diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r262",
      "r278",
      "r308",
      "r309",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r371",
      "r498",
      "r499",
      "r500",
      "r529",
      "r530",
      "r531",
      "r532",
      "r542",
      "r543",
      "r544",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r586",
      "r587",
      "r592",
      "r593",
      "r594",
      "r595",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611",
      "r612",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r672",
      "r673",
      "r674",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r262",
      "r278",
      "r308",
      "r309",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r371",
      "r498",
      "r499",
      "r500",
      "r529",
      "r530",
      "r531",
      "r532",
      "r542",
      "r543",
      "r544",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r586",
      "r587",
      "r592",
      "r593",
      "r594",
      "r595",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611",
      "r612",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r672",
      "r673",
      "r674",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NewLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NewLoanAndSecurityAgreementMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Loan and Security Agreement [Member]",
        "label": "New Loan and Security Agreement [Member]",
        "documentation": "New Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NoCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NoCustomerMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Customer [Member]",
        "label": "No Customer [Member]",
        "terseLabel": "No Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Nonvoting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NoteReceivableForRedeemableCommonStockIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NoteReceivableForRedeemableCommonStockIssuedMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Receivable For Redeemable Common Stock Issued.",
        "label": "Note Receivable For Redeemable Common Stock Issued [Member]",
        "terseLabel": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableAggregatePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableAggregatePrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate principal amount of notes receivables.",
        "label": "Notes Receivable Aggregate Principal Amount",
        "terseLabel": "Notes Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes receivable disclosure abstract.",
        "label": "Notes Receivable Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableForCommonStockIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableForCommonStockIssuedMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Receivable for Common Stock Issued",
        "label": "Notes Receivable For Common Stock Issued [Member]",
        "documentation": "Notes receivable for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableForCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableForCommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes receivable for common stock.",
        "label": "Notes Receivable For Common Stock [Member]",
        "terseLabel": "Notes Receivable For Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableForRedeemableCommonStockIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableForRedeemableCommonStockIssuedMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Receivable for Redeemable Common Stock Issued",
        "label": "Notes Receivable For Redeemable Common Stock Issued [Member]",
        "documentation": "Notes receivable for redeemable common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableInterestRateStatedPercentage",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The stated interest rate for notes receivables.",
        "label": "Notes Receivable Interest Rate Stated Percentage",
        "terseLabel": "Notes Receivable Interest Rate Stated Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivableMaturityYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivableMaturityYearStart",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes receivable maturity year start.",
        "label": "Notes Receivable Maturity Year Start",
        "terseLabel": "Notes Receivable Maturity Year Start"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivablesInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivablesInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes receivables interest amount.",
        "label": "Notes Receivables Interest Amount",
        "terseLabel": "Notes Receivables Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NotesReceivablesMaturityYearEnd": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NotesReceivablesMaturityYearEnd",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes receivables maturity year end.",
        "label": "Notes Receivables Maturity Year End",
        "terseLabel": "Notes Receivables Maturity Year End"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NumberOfCustomer": {
     "xbrltype": "integerItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NumberOfCustomer",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customer.",
        "label": "Number Of Customer",
        "terseLabel": "Number of customer"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_NumberOfLeases": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NumberOfLeases",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of leases.",
        "label": "Number Of Leases",
        "terseLabel": "Number Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Operating Segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "rxst_NumberOfWhollyOwnedSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly owned subsidiaries.",
        "label": "Number of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office [Member]"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044"
     ]
    },
    "rxst_OfficeManufacturingAndWarehouseFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OfficeManufacturingAndWarehouseFacilityMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufactOffice, Manufacturing and Warehouse Facility.",
        "label": "Office Manufacturing And Warehouse Facility [Member]",
        "terseLabel": "Office Manufacturing And Warehouse Facility"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Customer [Member]",
        "label": "One Customer [Member]",
        "terseLabel": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r295",
      "r299",
      "r301",
      "r857"
     ]
    },
    "rxst_OperatingIncomeLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OperatingIncomeLoss1",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income (Loss)1",
        "label": "Operating Income Loss1",
        "terseLabel": "Losses from operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r882"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Liabilities Current Operating",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Liabilities Noncurrent Operating",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "rxst_OperatingLeaseObligationsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OperatingLeaseObligationsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease obligations incurred.",
        "label": "Operating Lease Obligations Incurred",
        "terseLabel": "Operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r624"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": "rxst_TotalLeaseAssets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use lease assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "rxst_OperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right Of Use Assets",
        "label": "Operating Lease Right Of Use Assets",
        "terseLabel": "Operating leases right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases (as a percent)",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r882"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r882"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Base rent",
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the limitations on the use of all operating loss carryforwards",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_OperatingSegmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OperatingSegmentsPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Segments [Policy Text Block]",
        "label": "Operating Segments [Policy Text Block]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperationsCommencedDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperationsCommencedDate1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operations Commenced Date",
        "terseLabel": "Lease beginning date",
        "documentation": "Date the operations of the entity commenced, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityDescriptionTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Indexed to Issuer's Equity [Text Block]",
        "terseLabel": "Common Stock Warrant Liability",
        "documentation": "The entire disclosure for freestanding contract indexed to and potentially settled in entity's own stock. Includes, but is not limited to, strike price and number of shares to which contract is indexed, settlement date, and settlement alternatives."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r563"
     ]
    },
    "rxst_OptionalConversionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OptionalConversionsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optional conversions member.",
        "label": "Optional Conversions [Member]",
        "terseLabel": "Optional Conversions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r155",
      "r719",
      "r720"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on short-term investments",
        "verboseLabel": "Unrealized loss on short-term investments and cash equivalents, net of tax",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12",
      "r156"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation income (loss)",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12",
      "r156"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of unexercised warrants",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12",
      "r156",
      "r219",
      "r222"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_OtherComprehensiveLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "OtherComprehensiveLoss",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive loss",
        "label": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureInventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Inventory held on consignment",
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Payment-in-kind interest income added to principal of notes receivable",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "rxst_PaymentsForEmployeeTaxesRelatedToStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PaymentsForEmployeeTaxesRelatedToStockCompensation",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for employee taxes related to stock compensation",
        "label": "Payments for employee taxes related to stock compensation",
        "terseLabel": "Payments for employee taxes related to stock compensation",
        "negatedLabel": "Payments for employee taxes related to stock compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final payment and other fees",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Operating leases,tenant allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r127"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of deferred offering costs",
        "verboseLabel": "Underwriters discounts and commissions",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "rxst_PercentOfTaxableIncomeOffsetInFuture": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PercentOfTaxableIncomeOffsetInFuture",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of taxable income offset in future.",
        "label": "Percent Of Taxable Income Offset In Future",
        "terseLabel": "Percent of taxable income offset in future"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "rxst_PotentialAggregatePaymentsForRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PotentialAggregatePaymentsForRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Aggregate Payments For Regulatory Milestones",
        "label": "Potential Aggregate Payments For Regulatory Milestones",
        "terseLabel": "Potential aggregate payments for regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PotentialAggregatePaymentsForSalesBasedAndOperatingMilestones",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Aggregate Payments For Sales Based And Operating Milestones",
        "label": "Potential Aggregate Payments For Sales Based And Operating Milestones",
        "terseLabel": "Potential aggregate payments for sales based and operating milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Price, Increase",
        "terseLabel": "Conversion Factor",
        "documentation": "Per share increase in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r435"
     ]
    },
    "rxst_PreferredStockConvertibleConversionPriceIncreaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PreferredStockConvertibleConversionPriceIncreaseShares",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Convertible, Conversion Price, Increase shares",
        "label": "Preferred Stock, Convertible, Conversion Price, Increase Shares",
        "documentation": "Preferred Stock, Convertible, Conversion Price, Increase Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation Preference",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r422"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value per share",
        "verboseLabel": "Preferred stock par value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r418"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r762"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r418"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r762",
      "r780",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r683",
      "r883"
     ]
    },
    "rxst_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants [Member].",
        "label": "Preferred Stock Warrants [Member]",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "rxst_PriorPreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PriorPreferredStockholdersMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior preferred stockholders member.",
        "label": "Prior Preferred Stockholders [Member]",
        "terseLabel": "Prior Preferred Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from public offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "rxst_ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock for at-the-market offerings",
        "documentation": "Proceeds from issuance of common stock in at-the-market offerings",
        "label": "Proceeds from issuance of common stock in at-the-market offerings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Total Cash Received from the Exercise of Stock Options",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from sale of stock",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r724"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash raised under the ATM Facility",
        "label": "Proceeds from Lines of Credit",
        "totalLabel": "Proceeds from Lines of Credit, Total",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r945"
     ]
    },
    "us-gaap_ProceedsFromLoanOriginations1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLoanOriginations1",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Loan Originations",
        "terseLabel": "Proceeds from Loan Originations",
        "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Notes Payable, Total",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from term loan",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Short-term Investments, Total",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Maturity of short-term investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of preferred stock warrants",
        "terseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r671",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r849",
      "r867",
      "r884",
      "r913",
      "r970",
      "r971",
      "r976",
      "r1036"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r671",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r849",
      "r867",
      "r884",
      "r913",
      "r970",
      "r971",
      "r976",
      "r1036"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r218",
      "r221",
      "r233",
      "r242",
      "r250",
      "r260",
      "r261",
      "r282",
      "r295",
      "r299",
      "r301",
      "r342",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r545",
      "r548",
      "r549",
      "r576",
      "r588",
      "r678",
      "r693",
      "r731",
      "r782",
      "r800",
      "r801",
      "r857",
      "r880",
      "r881",
      "r895",
      "r937",
      "r972"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipment1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r180",
      "r183",
      "r184"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r203",
      "r691"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r679",
      "r691",
      "r883"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r180",
      "r183",
      "r689"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives of property and equipment",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r357"
     ]
    },
    "rxst_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r450",
      "r458",
      "r489",
      "r490",
      "r491",
      "r645",
      "r669",
      "r705",
      "r752",
      "r753",
      "r809",
      "r811",
      "r814",
      "r815",
      "r821",
      "r846",
      "r847",
      "r859",
      "r866",
      "r877",
      "r885",
      "r888",
      "r968",
      "r974",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r450",
      "r458",
      "r489",
      "r490",
      "r491",
      "r645",
      "r669",
      "r705",
      "r752",
      "r753",
      "r809",
      "r811",
      "r814",
      "r815",
      "r821",
      "r846",
      "r847",
      "r859",
      "r866",
      "r877",
      "r885",
      "r888",
      "r968",
      "r974",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r958",
      "r959",
      "r960"
     ]
    },
    "rxst_ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from warrant liability to additional paid-in capital for warrants exercised",
        "documentation": "Reclassification from warrant liability to additional paid in capital for warrants exercised.",
        "label": "Reclassification from Warrant Liability to Additional Paid In Capital for Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ReclassificationOfDeferredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ReclassificationOfDeferredCost",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of deferred financing costs",
        "documentation": "Reclassification Of Deferred Cost",
        "label": "Reclassification Of Deferred Cost"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of redeemable common stock to common stock options assumed in non cash investing or financing activity.",
        "label": "Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity",
        "terseLabel": "Reclassification of redeemable common stock options to common stock options"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of shares of redeemable common stock to common stock, assumed in non cash investing or financing activity.",
        "label": "Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity",
        "terseLabel": "Reclassification of 4,093,995 shares of redeemable common stock to 4,093,995 shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemableCommonStock1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemableCommonStock1Member",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Common Stock1",
        "documentation": "Redeemable common stock.",
        "label": "Redeemable Common Stock1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemableCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemableCommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Common Stock",
        "label": "Redeemable Common Stock [Member]",
        "documentation": "Redeemable common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemableConvertiblePreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant liability.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemablePreferredStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemablePreferredStockAndWarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable preferred stock and warrants.",
        "label": "Redeemable Preferred Stock And Warrants [Member]",
        "terseLabel": "Redeemable Preferred Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemableStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemableStockOptionMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable stock option.",
        "label": "Redeemable Stock Option [Member]",
        "terseLabel": "Redeemable Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RedeemableStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RedeemableStockOptionsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options issued and outstanding under the 2006, 2015 and 2021 Plans",
        "terseLabel": "Redeemable stock options",
        "documentation": "Redeemable stock options.",
        "label": "Redeemable Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegistrationPaymentArrangementGainsAndLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegistrationPaymentArrangementGainsAndLosses",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement, Gains and Losses",
        "terseLabel": "Registration amount",
        "documentation": "The decrease (gain) or increase (loss) in the carrying amount of the registration payment obligation that was recognized in earnings during the period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegistrationPaymentArrangementTerm",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement, Term",
        "terseLabel": "Shelf registration statement term",
        "documentation": "Describes the term of the registration payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r635",
      "r1021"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RepaymentOfTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RepaymentOfTermLoan",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of term loan",
        "terseLabel": "Repayment of term loan",
        "label": "Repayment of term loan",
        "documentation": "Repayment of term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r508",
      "r1030"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r943",
      "r1031",
      "r1035"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r924",
      "r943"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Stock options issued and outstanding under the 2006, 2015 and 2021 Plans",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r143",
      "r687",
      "r712",
      "r717",
      "r728",
      "r763",
      "r883"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r246",
      "r247",
      "r248",
      "r251",
      "r259",
      "r261",
      "r346",
      "r352",
      "r498",
      "r499",
      "r500",
      "r531",
      "r532",
      "r555",
      "r558",
      "r559",
      "r562",
      "r574",
      "r708",
      "r710",
      "r732",
      "r1041"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contracts with customers",
        "verboseLabel": "Revenue from contracts with customers",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r294",
      "r297",
      "r298",
      "r302",
      "r303",
      "r305",
      "r447",
      "r448",
      "r671"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r848"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r882"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r882"
     ]
    },
    "rxst_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for lease obligations abstract",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RightOfUseEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RightOfUseEquipmentMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-Of-Use Equipment [Member]",
        "documentation": "Right of use equipment member.",
        "label": "Right Of Use Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_RxlalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "RxlalMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LAL",
        "documentation": "RxLAL [Member]",
        "label": "RxLAL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Proceeds of Common Stock under ATM Offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of stock, consideration received",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of shares",
        "verboseLabel": "Sale of stock, number of shares issued or sale",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock par or stated value per share",
        "verboseLabel": "Sale of stock, price per shares",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockTransactionDate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of stock, date",
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Sale of Stock, Transaction Date",
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r911"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of accrued expenses and other current liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "rxst_ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assumptions used to determine the fair value of warrant",
        "label": "Schedule Of Assumptions Used To Determine The Fair Value Of Warrant Table Text Block",
        "documentation": "Schedule of assumptions used to determine the fair value of warrant table text block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Short-Term Investments Available For Sale",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reconciliation of cash and cash equivalents and restricted cash.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents And Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Interest Paid and effective interest rate on term loan table TextBlock",
        "label": "Schedule of Cash Interest Paid and effective interest rate on term loan table TextBlock",
        "terseLabel": "Schedule of Cash Interest Paid and Effective Interest Rate On Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ScheduleOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock equivalent of preferred stock due to anti dilution provisions.",
        "label": "Schedule Of Common Stock Equivalent Of Preferred Stock Due To Anti Dilution Provisions [Text Block]",
        "terseLabel": "Summary Of Common Stock Equivalent Of Preferred Stock Due To Anti Dilution Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Future Annual Principal Payments Due Under the Amended Term Loan",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from Contracts with Customers",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-Vested Restricted Stock Unit Activities",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfPreferredUnitsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPreferredUnitsTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Preferred Units [Table Text Block]",
        "terseLabel": "Summary of Preferred Units",
        "documentation": "Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r462",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the Status and Changes in Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule Of Short Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r140",
      "r142",
      "r143",
      "r207",
      "r208",
      "r209",
      "r280",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r432",
      "r434",
      "r724",
      "r725",
      "r726",
      "r727",
      "r866",
      "r910",
      "r944"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1006"
     ]
    },
    "rxst_ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ScheduleOfWeightedAssumptionsUsedToRevalueConvertiblePreferredStockWarrantsToFairValueTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value",
        "label": "Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value [Table Text Block]",
        "documentation": "Schedule of Weighted Assumptions Used to Revalue Convertible Preferred Stock Warrants to Fair Value."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SecuritiesIssuableValueUnderSelfRegistrationStatementForm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SecuritiesIssuableValueUnderSelfRegistrationStatementForm",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issuable value under self registration statement form",
        "label": "Securities issuable value under self registration statement form",
        "terseLabel": "Securities issuable value under self registration statement form"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r745",
      "r748",
      "r750",
      "r810",
      "r812",
      "r817",
      "r822",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r850",
      "r868",
      "r888",
      "r976",
      "r1036"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r858"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SeniorPreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeniorPreferredStockholdersMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior preferred stockholders.",
        "label": "Senior Preferred Stockholders [Member]",
        "terseLabel": "Senior Preferred Stockholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "rxst_SeriesFWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesFWarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F warrants member.",
        "label": "Series F Warrants [Member]",
        "terseLabel": "Series F Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SeriesGAndHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesGAndHPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined class of G and H series of preferred stockholders.",
        "label": "Series G And H Preferred Stock [Member]",
        "terseLabel": "Series G and H Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SeriesGCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesGCommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series G Common Stock [Member]",
        "documentation": "Series G common stock.",
        "label": "Series G Common Stock [Member]",
        "terseLabel": "Series G Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesGPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock [Member]",
        "documentation": "Series G preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "rxst_SeriesGWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesGWarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G warrants member.",
        "label": "Series G Warrants [Member]",
        "terseLabel": "Series G Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesHPreferredStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H Convertible Preferred Stock",
        "documentation": "Series H preferred stock."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927",
      "r975"
     ]
    },
    "rxst_SeriesHWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesHWarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series H warrants member.",
        "label": "Series H Warrants [Member]",
        "terseLabel": "Series H Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SeriesWCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SeriesWCommonStockMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series W common stock.",
        "label": "Series W Common Stock [Member]",
        "terseLabel": "Series W Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ServiceWarrantyServiceContractsAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ServiceWarrantyServiceContractsAndAccessoriesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Warranty, Service Contracts, And Accessories",
        "label": "Service Warranty Service Contracts And Accessories [Member]",
        "documentation": "Service warranty, service contracts, and accessories [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock-Based Compensation, Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at December 31, 2022",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk adjusted discount factor",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk adjusted discount factor, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk adjusted discount factor, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield, Weighted Average",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected dividend yield."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years), Weighted Average",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Life."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk adjusted discount factor, Weighted average",
        "terseLabel": "Risk-free interest rate, Weighted Average",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk-free Interest Rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility, Weighted Average",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r462",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "rxst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Number of Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Options Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic Value of Outstanding Options",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Ending balance",
        "periodStartLabel": "Number of Options, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic Value of Vested Options",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Stock-Based Compensation, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r467",
      "r486",
      "r487",
      "r488",
      "r489",
      "r492",
      "r501",
      "r502",
      "r503",
      "r504"
     ]
    },
    "rxst_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement Member",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested at December 31, 2023",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Unvested at December 31, 2022",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Number of shares, forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Options Forfeited",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average fair value, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Grant Date Fair Value, Beginning Balance",
        "verboseLabel": "Weighted Average Grant Date Fair Value- End Date Balance",
        "periodEndLabel": "Weighted average fair value, Ending Balance",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total Fair Value Less Strike Price of Stock Options Exercised",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfNonvestedRestrictedStockUnitActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of shares, vested",
        "negatedTerseLabel": "Number of shares, vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShareholderRepresentativeHoldbackOfExercisePriceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Representative Holdback Of Exercise Price Of Warrants",
        "label": "Shareholder Representative Holdback Of Exercise Price Of Warrants",
        "terseLabel": "Shareholder representative holdback of exercise price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future issuance under the Equity Plans",
        "label": "Shares Available For Future Issuance Under The 2006 ,2015 And 2021 Plans [Member]",
        "documentation": "Shares Available For Future Issuance Under The 2006 ,2015 And 2021 Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesAvailableForFutureSaleUnderTheAtTheMarketOfferingMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for future sale under the at-the-market offering [Member]",
        "label": "Shares available for future sale under the at-the-market offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesAvailableForFutureSaleUnderTheAtmOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesAvailableForFutureSaleUnderTheAtmOfferingMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future sale under the ATM offering [Member]",
        "label": "Shares available for future sale under the ATM offering [Member]",
        "documentation": "Shares available for future sale under the ATM offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value.",
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life.",
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life",
        "terseLabel": "Expected life (in years), Weighted Average"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value.",
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value, Weighted Average"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfRangeAndWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate.",
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate, Weighted Average"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesIssuedForTheEmployeeStockPurchasePlanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesIssuedForTheEmployeeStockPurchasePlanAmount",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for the employee stock purchase plan, Amount",
        "documentation": "Shares issued for the employee stock purchase plan, Amount",
        "label": "Shares issued for the employee stock purchase plan, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for the exercise of stock options and vesting of restricted stock units, Amount",
        "documentation": "Shares issued for the exercise of stock options and vesting of restricted stock units, Amount",
        "label": "Shares issued for the exercise of stock options and vesting of restricted stock units, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for the exercise of stock options and vesting of restricted stock units, Shares",
        "documentation": "Shares issued for the exercise of stock options and vesting of restricted stock units",
        "label": "Shares issued for the exercise of stock options and vesting of restricted stock units, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesRedeemedForEmployeeTaxWithHoldingsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesRedeemedForEmployeeTaxWithHoldingsAmount",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Redeemed For Employee Tax With Holdings, Amount",
        "label": "Shares Redeemed For Employee Tax With Holdings, Amount",
        "terseLabel": "Shares redeemed for employee tax withholdings, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesRedeemedForEmployeeTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesRedeemedForEmployeeTaxWithholdings",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares redeemed for employee tax withholdings, Share",
        "verboseLabel": "Shares redeemed for employee tax withholdings, Share",
        "documentation": "Shares redeemed for employee tax withholdings",
        "label": "Shares redeemed for employee tax withholdings",
        "terseLabel": "Shares redeemed for employee tax withholdings, Share"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for future issuance.",
        "label": "Shares Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf registration statement [Member]",
        "label": "Shelf registration statement [Member]",
        "terseLabel": "Shelf Registration Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShelfRegistrationStatementPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShelfRegistrationStatementPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement [Policy Text Block]",
        "label": "Shelf Registration Statement [Policy Text Block]",
        "terseLabel": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Short Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r933"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_ShortTermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Short Term Investments Policy [Text Block]",
        "documentation": "Short-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SignificantAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies Policy [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r238"
     ]
    },
    "rxst_StateOperatingLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "StateOperatingLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State net operating Loss",
        "documentation": "State operating loss carry forwards.",
        "label": "State Operating Loss Carry Forwards",
        "terseLabel": "State operating loss carry forwards"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_StateOperatingLossCarryForwardsNotExpire": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "StateOperatingLossCarryForwardsNotExpire",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State operating loss carry forwards not expire.",
        "label": "State Operating Loss Carry Forwards Not Expire",
        "terseLabel": "State operating loss carry forwards not expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsScheduleOfProbabilityWeightedAssumptionsOfConvertiblePreferredStockWarrantsDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r207",
      "r208",
      "r209",
      "r242",
      "r266",
      "r267",
      "r274",
      "r276",
      "r280",
      "r281",
      "r342",
      "r379",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r418",
      "r419",
      "r422",
      "r425",
      "r434",
      "r588",
      "r724",
      "r725",
      "r726",
      "r727",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r762",
      "r783",
      "r802",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r910",
      "r944",
      "r952"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSummaryOfAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r195",
      "r224",
      "r225",
      "r226",
      "r246",
      "r247",
      "r248",
      "r251",
      "r259",
      "r261",
      "r279",
      "r346",
      "r352",
      "r436",
      "r498",
      "r499",
      "r500",
      "r531",
      "r532",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r574",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r633",
      "r708",
      "r709",
      "r710",
      "r732",
      "r802"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r745",
      "r748",
      "r750",
      "r810",
      "r812",
      "r817",
      "r822",
      "r834",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r850",
      "r868",
      "r888",
      "r976",
      "r1036"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r279",
      "r671",
      "r722",
      "r743",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r781",
      "r784",
      "r785",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r889"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r279",
      "r671",
      "r722",
      "r743",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r781",
      "r784",
      "r785",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r889"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r110",
      "r111",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued for the employee stock purchase plan, Share",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares issued under ATM Offering",
        "verboseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs of $12.4 million, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r143",
      "r724",
      "r802",
      "r828"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r143",
      "r473"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Proceeds of Common Stock under ATM Offering",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs of $12.4 million",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r143",
      "r732",
      "r802",
      "r828",
      "r895"
     ]
    },
    "rxst_StockOptionsIssuedAndOutstandingUnderPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "StockOptionsIssuedAndOutstandingUnderPlansMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Issued and Outstanding Under the 2006, 2015 and 2021 Plans",
        "label": "Stock Options Issued And Outstanding Under Plans [Member]",
        "documentation": "Stock Options Issued And Outstanding Under Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options issued and outstanding under the Equity Plans",
        "label": "Stock options issued and outstanding under the 2006, 2015 and 2021 plans[Member]",
        "documentation": "Stock options issued and outstanding under the 2006, 2015 and 2021 plans[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r134",
      "r764",
      "r780",
      "r803",
      "r804",
      "r883",
      "r896",
      "r946",
      "r966",
      "r1015",
      "r1041"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableCommonStockStockOptionsConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stockholders' Equity, Ending Balance, Amount",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance, Amount",
        "totalLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r195",
      "r196",
      "r225",
      "r246",
      "r247",
      "r248",
      "r251",
      "r259",
      "r346",
      "r352",
      "r436",
      "r498",
      "r499",
      "r500",
      "r531",
      "r532",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r574",
      "r597",
      "r598",
      "r602",
      "r633",
      "r709",
      "r710",
      "r730",
      "r764",
      "r780",
      "r803",
      "r804",
      "r832",
      "r895",
      "r946",
      "r966",
      "r1015",
      "r1041"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r241",
      "r417",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r565",
      "r805",
      "r806",
      "r833"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r637"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r638"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SummaryOfLeaseBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SummaryOfLeaseBalancesTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Balance Sheet Information",
        "documentation": "Summary Of Lease Balances.",
        "label": "Summary Of Lease Balances Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Weighted Average Remaining Lease Term and Discount Rate.",
        "label": "Summary Of Weighted Average Remaining Lease Term And Discount Rate Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TaxableIncomeOffsetPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TaxableIncomeOffsetPercentage",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxable Income offset, percentage",
        "label": "Taxable Income offset, percentage",
        "documentation": "Taxable Income offset, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r66"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary Equity, Ending Balance, Amount",
        "periodStartLabel": "Temporary Equity, Beginning Balance, Amount",
        "terseLabel": "Carrying Value (2) Share Capital",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r505",
      "r685"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockEquivalentOfPreferredStockDueToAntiDilutionProvisionsDetails",
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfPreferredUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TemporaryEquityNoteReceivablesCommonStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TemporaryEquityNoteReceivablesCommonStockIssued",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureNotesReceivableForRedeemableCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity note receivables for common stock issued.",
        "label": "Temporary Equity Note Receivables Common Stock Issued",
        "terseLabel": "Notes receivable for common stock issued"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan member.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TerminalValueExitMultiple": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TerminalValueExitMultiple",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terminal value exit multiple",
        "label": "Terminal Value Exit Multiple",
        "documentation": "Terminal value exit multiple."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_The2021EsppPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "The2021EsppPlanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2021 ESPP Plan [Member]",
        "documentation": "The 2021 ESPP Plan [Member]",
        "label": "The 2021 ESPP Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_The2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "The2021PlanMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan [Member]",
        "documentation": "The 2021 Plan [Member]",
        "label": "The 2021 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1020"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ToolsDiesAndMoldsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Production Molds [Member]",
        "label": "Tools, Dies and Molds [Member]",
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TotalCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TotalCashProceeds",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cash proceeds.",
        "label": "Total Cash Proceeds",
        "terseLabel": "Total Cash Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TotalLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TotalLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total lease assets.",
        "label": "Total Lease Assets",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_TotalLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "TotalLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfLeaseBalancesSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total lease liabilities.",
        "label": "Total Lease Liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r413",
      "r432",
      "r564",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r695",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureShortTermInvestmentsScheduleOfShortTermInvestmentAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Short-Term Debt Securities [Member]",
        "terseLabel": "Government Securities [Member]",
        "verboseLabel": "U.S. Treasury securities",
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae)."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892",
      "r893",
      "r1033"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "Government Securities",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisAndTheFairValueHierarchyOfTheValuation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r874",
      "r876",
      "r1033"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureTermLoanFutureAnnualPrincipalPaymentsDueUnderTheAmendedTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized issuance costs and exit fee",
        "terseLabel": "Less: unamortized issuance costs and exit fee",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_UnexercisedWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "UnexercisedWarrantsExpired",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unexercised Warrants Expired",
        "label": "Unexercised Warrants Expired",
        "documentation": "Unexercised warrants expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r516"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reductions for prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r177",
      "r178",
      "r181",
      "r182"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "srt_WarehouseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WarehouseMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warehouse [Member]",
        "terseLabel": "Warehouse [Member]"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants exercised date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants exercisable term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "rxst_WarrantsIssuedToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsIssuedToPurchaseCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureCommonStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued To Purchase Common Stock",
        "label": "Warrants Issued To Purchase Common Stock",
        "terseLabel": "Warrants issued to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WarrantsIssuedToPurchasePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsIssuedToPurchasePreferredStock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to purchase preferred stock",
        "label": "Warrants Issued To Purchase Preferred Stock",
        "documentation": "Warrants issued to purchase preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants member.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Warrants Outstanding",
        "documentation": "Warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WarrantsToPurchaseConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsToPurchaseConvertiblePreferredStock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants To Purchase Convertible Preferred Stock",
        "label": "Warrants To Purchase Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WarrantsToPurchaseStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WarrantsToPurchaseStockPolicyTextBlock",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureSummaryOfAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Stock",
        "label": "Warrants To Purchase Stock Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for warrants to purchase stock."
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WeightedAverageCostOfCapitalDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WeightedAverageCostOfCapitalDiscountRate",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureCommonStockWarrantLiabilityScheduleOfAssumptionsUsedToDetermineTheFairValueOfWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average cost of capital discount rate",
        "label": "Weighted Average Cost Of Capital Discount Rate",
        "documentation": "Weighted average cost of capital discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "rxst_WeightedAverageGrantDateFairValueExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WeightedAverageGrantDateFairValueExercisable",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value Exercisable",
        "label": "Weighted Average Grant Date Fair Value Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Attributable to common stock, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r276"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding used in computing net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Attributable to common stock, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r276"
     ]
    },
    "rxst_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://rxsight.com/20231231",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://rxsight.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)(1)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482804/825-20-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482804/825-20-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815-40/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-24-022073-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-022073-xbrl.zip
M4$L#!!0    ( %.!7%A@7$8<LZ8  !7    1    :6UG-3 X,34S.39?,"YJ
M<&>LNW587,_2/S@XP4EP39 $U\$MN 7W08,[P2TP"03)!'<(SN#N#L'=-6AP
M"Q#<AQWRO?>^]]UG_]C=YW=@SG2?KNK352WUJ>Z:Q_G'7P \!1EY&0 "(@"
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M7)_1"22BLRH[GM%RJ_\A-'69P""B Z[1GSR)]E>R_W>"!?S_DNP_@OV/7 L
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M.9_M+GI1N)[T,K>"NQ6:VQB', 69I&%(*)"N =O;LB&VN%?LVY+OW$MQ-+1
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M $B+@$71WNG2 (W^&$;"BWHDI&I?G2BRPWR--(,+1BTMPF[XQ"O%_CO]D*'
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MLTA+,L'PR"I9_/ES@"5)4VO U(MPDXKFA.5V*0 ^\_&V-.[ZIF<K0H2FS$!
M0]E-E?5VPH&R48?#^I[\5S=XZ>9B*TZ[S,EP!Z:90%,K>E^&B:G_Z13-[/_
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M;[5;S0[ /KC7Q.>EUO?6FWW@YJ&MF^1!N!N"F!*MY)DA_#5N.P^UN+!' 9>
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M=1=6.M><F KA+TCF\WLKL*YG6?X25.B_%BG^YS.ZO(S]&6XSQE6)N%M@U0B
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MML-"/L),74PU)5B-E-6D9I^UIJQQ'^MNHD*+=]SDC7/UYK."+)YYW$\/^*#
MQ)7M[)S"Z8G6\"(_%4=O>O.\P/O5XZ.-/$ O3\4Q G"/.T8[?L0\V$6+&X*^
M -><Y$UT5?/$Y !"BZXJ#5+:9[R)7[3%5,5^^N3X"N7!9F2ND\B3XXB4G"O?
MR;8-P1:!E[,UXM']^/S#S1;>LNH^Z,-6L?"$9M1;5FU';5=K,;N#-)Q/W%*C
M9X*A5ZM:E%1HZEN.K^#5288K6RY C/D=>^K0%,VDM0_I88_ -,I7/^7<Q:X
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MQ+!WG;Z%%TL^K?:6557&&[6G"Q%?/0\A4$)12[X1B[I\?G@YG8#?M+V^X_O
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M#.](%>:L=BM%>.;+X@S1.>Z.!I"7-70B.)U6@.WF;CMM%+E\M6# V/<E<$Q
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M.N$8\TUCEK D#8'C+40F6)BU)?:9V,Y]5*EO0CAN@%ZI-7-'[R+O4&W#[,K
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M(-/+^)\]____]O^^,?Q9^"]02P,$%     @ 4X%<6%QG,+(0R0  A<P  !$
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MOD.>#^P%85W7PF<U:BU2@C'O?H/'$R-+=^X4")!9=Y'6PCK@7>FRPYO$D]U
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M('++SF''._IN8:)J7W10)[T0]-'OOC/! 6GSX_KW]03><$9?Z([Z^45Q":@
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MRC!KIC+J>-6H..C+OARR;3]'2W;^%V/ZUK5!:'-N#[FIZQF[R;'!6BD5;_\
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MV4-P+<.N[T':IYI<@Q)QV-<MK>A2(INH,ECR<=:0'81S+*,BJ&KP_P"C^:H
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M#?Q3>SW$VD3?-$%WAN]>L?8+>:Q*':Q8<BN1N[]TW=>K2E:;/(V&\*"3M4Y
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MAUCQ"MI&3Y:G8/K3DQ)$WA'2S<2M>S\@GOV]ZZ.YD#RD?PC@5-! NFZ3'$
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M1NU02V2GHN:M!\4\-FE89BS:8,'CY3UKE=4\)2HK3Z9(89.I0?Q5Z+M!J-X
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MVJ4KD\\TX)@5VK1%6*^*3%2LO6H99$@A>9S\J#<U5<FS/-/BEJDQ$&EP,O\
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M7!*HJ4+O20.]H*E_A,))KAD(;)\CNLF[Y_J27Q'(0!2!=BU^7RQ-[ J"-D^
M29W%S5C;6G:J+$\+OXK$DPS'[RE\/43+/S(859>M"3Y!LWD& !3Q/0OJ<NX
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MAY>YM81[<YAWD,5I2[Z5+\PG/C35HFEF4^"N(^=D6R?;UG#(AZTE4HZKLL#
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M7.S,]DA'V@%;?]NT<76V)TPA<A@ITZ+!Q%JPLT=D3=L*J.@1M+!@#^4RHN6
M*>1X_ZE^Y9G>&]794&JX[LCOA>CH<F7#=^JE0[9S6Z=@L'KBBZXBL@/.$(=K
M?=<#R3[09T& 'TAK=/]$ C1WDWXQR7$4$R*6W\MO\SQ &^"MF:0-LDZ*V<B%
M<^BI8-I,0UF+1L>.*_%"M;;\O8'NW,,U68PG'"A421I@4Y58387U#;=U>M3G
ME_]LW(!0_]+"A"6*G!]S[1.?;^$GP9AI,AS&>OPX]!2K!>:VE<^;&439> A=
M,C>E9Z;VD=U7EL]T_JI>AW#= 7[/]]>2K]>#[@!TO1+[54>%@0VU$BT1:2O:
MYY/0XZ77EX-!S"S(X%:VVQ,&)A;]HF\=>?3XH=IXO_ZZ0$'$0X'I;YIA:T]/
M\HWTY!]]?15$ SVL0]EPV&=6?:+F"1TOZ@X@K_Y#9N/S)@WH,M1XZ^8LGVZV
MFYI,,WH[8L^Q8O(AU"EYJ99"KGZRW9M V>O>979O!YY<^&^(C*.LMZ#M0DF.
MA\R,I:'V)\3#^B0W <3E.E*_8LBA[Z0'3>J3<?B6Q"5&QS4/1 (V<0\[ST [
MXV<2%B.%;W!TE]G9FBSQO#XZN<[4%T*+"XX'WT/X5U<>(39VES90(PU:)553
M&7A=:+MTXG8A,3B"+3[!E&NO05'1U)W5A'D=DV%&_-*>V(TQN3Y*OG';H.@[
M7P9O-F9BB;N%:*[6%&L^.B<@,,#.!?JQYFE%3>N[+[+>7168.T"I/7V@3_V;
M3R;"_AK?X_ @U3&FLDIG? -=% :=PU40,3$V/7DI:\]#ER)Q&QHUS[<M\@U#
MYM7EUFNRE&>TEQ!T>\B*D*>7JL+%UY9;MK%K#@^*295V;+OVAY\TC6X6]A%(
MU6!ZPAFYRC-)GZ;^Q[XHOC?ICM8;KT(H!1ZYH^7H-MM45]^]#29DP[I_OHCS
MX2E%20*(TZ-B7%.Q>"VC$ "#,9')RNRV+9B7I6Z;A=%LBXT#Q^SH%T%S,G85
M9CR#G#P8!/DFA>]F!A'9GAF:G#/\&W9 7>>T%.:M?Z%[81))GMQ<<?UQV:9>
M)X\";M:5W>J(NKD#N!BLEM-R*G0[ETP'9GBXZWX12\_)U&[,T>'QL"I18<%9
MEH4]4U"R2AZE8.!@M&8*3<;6+QG):O !:(M$*RB_ZLI%_9#"FA'4H@ESY8?"
M&E/-.6;&IA5QT1E 5(IW;4G !2K937]B&:4] "YY!%D@B!5N)]E6W534%7"A
MP&5>BT-(OB8N5^/*\7(H^]0^>;/CI*E'^G*7>M7C?0JWZOYRU;(A?]A22$B#
M AM%'=RJ-+X2-X[VH=4%YD?HAPQWGD3D&'UD>CG?M&Z!6T^/M2!""%=]<U?O
M/!?6WY;CYL3<]H:Y[5524,O !7#&;YQSVRC2R.GOV:UT%<W)/YL]CJ._W3X7
M[=4Y>)C^Z4^8HKK0R@T\C[+W@Q2OEV:;JM2*-I,IKZG!] KE>))GCCQ<,:)"
MY@_;"5:%=T7KJSJW@H]]?)P_IKMK=$215?N$Y5SU>%G$9<+?NHXD\)+')JAK
M,K_@[G(,XS;B?@6HJ3)<CH0CB9B<F%,UQG 55.V/<[)TDM6)[5ANB9 ZCR(D
MSD.<3A-^F;V[+0JD/NF::CG""H_%S$[RU[B(?.WAA\33!%J45L)#)OD?7$O,
M%0IW-1#.O&9A;LVRPY53RLG;8 F5MS5'*S+X%^=S9518;0F$6#U1<V$CP#E)
M)RH5#_]&'YB90.;EC;-'YY0<A*S(V$BQ=6+H.KP:Y_Z0T^?AL<9&-=G%-Z6[
MY0&U-;6(Z%?OR'(?@8A2*LMK1\?V%>UTFH9Z^7P$#M145L=<J+ONJ\V<#RA$
M$,XJ<&3:?T7;;T3KSG\^/6->.(J:2,]2M#97B'9 RGPH3&)X;Q^ZO@EE(S,"
M+M6"@[7,5QVRZ*=EEM<45BOZZR:: 00Q.Y _$W97'-P%A,>"Z2T:,M9MKZW]
MK/Q&5(>CKP3O  ,*$!INF9\@CRO>?QH29:K7Q^DM:RSJR-^\"\*5,*D/A%L\
M*DW]H6T:NP%D?)_PI$CG:;N.42R/G%(B'7UA*B[@[\ZTEI&WNNW8?.S4,C?+
M9FB?_*RI]P#OX@+4 ,D&U'W1S2>_I7@MC+#@DORO;@N--K[OUN&%>[?>I+FQ
M9F/1F]'?7%/-1FQL-"*E7<@E/D[R[<OB*!;[21._"TL18) &<X5RV=1)$94U
MDN#E1W^&L)&>%9U?\'OH=?/5K7_IMS%DM>HJ&FE@P%^J(+,T<'O0!].W"?B^
MC%A+<O%49\:UK/G5PT826UNR#XU#Z@FRLZG,J\J-1_89O@<*%LJ/U8R1N[,U
M69>$QUH#N%@\,Q!M9?IX"&X9ZSQ2LQ_#0TJ/TI,TH5W$ BSL)5[YB=_$2$]Q
MIK[1O:#X1J#^)3E4]O$/X(XKA[N=<B%[A>!"U*#D0"2I,2>-P@H%18+#;%?'
M<*&Z/&,\=[1==N 2 LJ*]P#3 &^1..28^/?.YUV2*SKH<_@MN(?F<OU&V6WA
MM\"&\](ML76[<WJ*VG1B;AX*(]H3%BG 83D#KLJ":?'( $=":X'J@BG$FQ)V
MI5?O%>/-5JX0O7\AT>N&8BMYK;X\VX;U)2]BVZ46$%%3& I!?,?L015E&S/.
MK*#$9=XIE^>?8N+SWS^Y)R^.;Q*>.HG7[ZNOP*U<G+/OH@VO#R^L^Y*Q'<MT
MDV!;OK/RS156ZAO&'*>"V]:?;)._9ME+$2*><=TL3U4\"]24JQ @<7[LL*BN
M%\%XNORW4!"M<EV'UR<@Y$IGKR^19&D\6U[P*G2!X/>)^YK4<Q ..VPN."UD
M\WTXP0QF*'@DO'5S9TDV8Y.6:8J1%&!A6??LF<UOU_8E\(7L;/Z('DTY^ .-
MTA%BQQ:-P4RJX9M M+.]CC-&$Q>UF"FU7"V0;/W1HUOA_HKRBL@?0.8^LE13
M,*-U'X"#.#Z#]Q]LP67>E'D+>_^]Y#0_5/\Q%XLYPH47,D26X_B]02\"%%WH
MB5+X>U/'>\36C4.4M\ZW,C40?)(",@#-8$XE_Z*:Z.<JU=5T(AUS6,-G">K:
MC)]CZ$Z%6;W*J/%#.D'-4ME]'HX.;F1*9=S]3_I9^Y)"(8UV:OHU8LK&@),"
M&,27H%.:=RR=CBYW03//,[WFC/H*FUA=$4*RP4$<4][(W$:L 4B/0Y@P8KM>
MIEQ_1\K>>#BLP)':[$TR;U4>P_-&TYXNW(B/6?GG!$H?TOZPP"?'((>- K4%
M(O*ZA^3!%C .X@?__'M#L\GXD+WE]LI/> .>\M?J.L3Q#E!_CRW TXT[ (%X
M4*3.\@<JM:59B;GLJ4I(F,'2I-]<;L$T*UL:IVO3-7CJ&:^ZQMND7J&ULC=V
MF*4GM#]\"KB/T6MJ+<C^ZI"G;5 +7J_*E,5-U>" C+S##)&CR;@&9KKT1^H!
M1CC#"?C E 96@<C0Y43-^)K--HWWE:\R4X>T),O#P+*OF@=Y33V;=].&&,(E
M&CB[92N\E%Y.4[XBI1U/WW;FV\NB9.M.7='4;'8/<AOM(/*/ _7H';-%-A#U
MZC:_-:S&&T[B>>D">;,6EL6&.TTJHK.I9;_W'/-P]VQ@%I1H:O?,[PG8-,]%
MT86^E3P#VG1J_>GJA/X<GEQ<QM,5/9+'6&FWJZ]9>W'!<((6LVR?EQU*=KW0
MIP"[M0_)1G]'L8X(AL'6!VKT=>\ 8^"6!S-CZH33C6UO04PN5>P=T1! (7ET
MG0B+ICJ"5='^&:V+EA%.<&MD5 &!,P&;=2H?12-Y5*1SCDO&WS]M:)>6CNYZ
MCH\X#[0C9D$[OVG.48N[MN_P#+X7SKB0+8..#"I_CVDU'OS>Z()0C7]AT^9Y
MHB8^%+Y$YC>F$G&[C:6QQW=P&KG4X"<9TV7NLW(IYZ%CFNUC.[Z;^?CZR:@;
MD%N[-]20/R)3=%A$DQK2#B@B4YUZV$D[GZFD7]-G#I>@+-IK,F2=F*9NN\CI
M5?AJ>XK6AY0.LZ_4_:G679**CAY8-<(^P%EB^,WT\TI"Q0SI32UW!XB+[8)3
MO\+XR#M;C=KK_?JKK4)RF']ZNF".Z-<4SE.SVQ*>FL\&&[^?8@Y[B(@&??40
M@[D.2R\A6$1<-/K#"+/#%;&QA#81R+E^>#H_@1@\K7AXL1(0.W.;G:XI%S^J
M:!:8E%9?';<<L/.[8AC\4,9?6SHW2[L#Q 1;B95E=%:QUP^48.4>J'@8E[8A
M%V-QJ;'V#ZTK0 ',&??U(/12A;?I!B5\F'*P$W0^/[[!&IYL]_*2__=SOFJA
M#Q&HCSKOW/P6X5T^779%75C 1[^ 8H!=Z CBO#!T[5)W[77L>NQJ;(C<CE[P
MGK( GXM&,N9CJ6T:MSXS$#'[*6<N#^/@C&E6E[%QDK,R_7OT?VDET4>,=,Q>
M8OOG29%LD?Z3:P:O7T5+V-+K:Q)09*K#2="VH=R:J;PBF!O_ SYN?CM7@8H0
MZOV"9:II,BR]R]J_=H35[-N( N0G3\E+H8Q(%=,J9, *5H-(,&-'E!B<22\F
M*\%NRQ-EYUC3[I4_(FW_G2FF[_UD>AC"F^\S@DNNZ:1 E1@6N+:_4U+518(S
M,P[.G\W^F</S4*!X*KW^T$9U@"VQ2A.Y_CLG[TOZSWT&R)]1\Y&%MT(75QS.
M87ZO=_LO"!2IQ5 *1P(NSY?%XU'DJD'#B]<M/[ =@%;\/"^WNGLL;#<VB?E;
M!&=@JS>MD-,B$5?U$4P^?ZP;T<WTP_2:^>?RG[3M7I*1R3*DHG(OZ)R'$8D5
M@GUF[J.<<Y94M\:FVFG)>Y/^B#6+C@_.;.IH"\WX5Q\N$0&I2B>@QBTAZDSK
MK+0<T^4[ )%-*NX;*:RKZW&PZ4$(Y+O9)5^,7W%%"X6)+TO@9)WZ+NE'[(D3
MW4]\$Y\?U=JV7B+&R\_+TF<)R7&").;XEA[/!LC\70[,7[>HEX@\-C 2_WO]
M-6%B9 O6>% 4V#EP6D"3Y#,3][RGUU&>]@Y@H?FGU %'8O+H#C#/F"(DH1/A
MLOGL7.E:(.4";_J^3VMH6?G!M 4T5.4FAORO,F?35'CV\@UH*:).D*[.5Z(Y
MSIO]5:C^2L<<S&=-,X?T1(SC6MZ4\F//;<57OP-.Y5(&/*OHFQ$#ZCR?F?3$
M9[!UAJ/7]D&@YP7!83Q#;SZ]86-Y61D>5+FUOB_.Y(E8B'S1'GR[S]<;(F ^
M.-IETGI<D*0S,Z;Q\LAPS.VYTKASZ"F$+@\W,V&_3.*J@Z^((,8@%#%6-4QH
M3E<::RXW7.+OD%.WC ?%3*DX54-6(#:DFQ"0Y#*HCS4LB2@;H:;+X->B\YQ/
M!9"C@5&NM([]2FP6AWCW@EACF;<<,'=<G94Z^/"^AQF0F87RMBDF0=UD1E54
M$OAD?'G*6[CS#.SBT2*<E' ':$W>Z^9DW5ZQT1$)WD6N%^T&9*<YV1*\UP ]
MKA"]H5&IN8(DGPD\+U129 W0$@O><]+=&V!'TR>6/>_UE4<S<;J!]T)3&]8&
M>S4"<NQRS!&MH]9&8.^.P#O BF'IOU_BQ/IW%FG_7;\.P1C_<[[C3I./P^!*
MFP]S&6Q2"I*+&#(C?433> <(4R[^J%,P5;.6V9F'VY7G_@PF6K*KL,S<1?H4
M&1QF_8OX\M.?927^[[X2Q@=HXN%7;64BQ+_:K&_"Q/X8'Z1.OJ+Z0W_+>S%$
M&=J?'=VT5JZ,2%X^E%A6$H:E+--$W@'(?0[(L_M==)PK;?.]8$49D[CI,RV/
M0I&;KP>7?GT9=CV56%9\$UH$^]O!&:=K[F@0>8G1\)C <(]K]M7+YB7TC.!;
MG3D=G!2ZK^WH9^.\@0^KME3CO;P=]$GV&_,[V8KY T2O^JYK_Y0X:?4+DS8<
M4,AF)<SJDD]VL^SS<":JZ=HVBLYY!\KZ@?=9,N_X#A"(J>3\LSOPZBR"!E,I
ML?@RPG[(]1X$7>X 19#9H=6/??%0L9*XQ3WC0D\T1BR_K3"6JD":SV1B_^LM
M'W>IAG=$Y[W'',=RA,2(1DB(0R_9WNVP;$G<>\ WV%=VQ:^]Y+)!I2T_DF<#
M_:R$,_<ZXGSH]/7)O_P@CM8L_B@7?PP)FO@Y^DGVVOKJ^>6_M-% \B;$,I7^
M7U5B_ZB*0&GM4 \S>O VW$O8_BT)^)<D( @UAE,>G-(G9FZYVV:L_]Y8=?P:
MQH9BL0K("%R0E+MJ>NN79. XO,6D+D:4Y)NKNPG9Y9MMIE5/RCR$]_'M!^L(
MAS04AI')U9)1?#W74<V]YA0NF/NPU^#$><5(%'$#3*!IA@LVXN6)X]QPTRQ#
MA5TBFL-,6=7'ZI)U*TL-E=?GY$;D5)P[^/*(!;&LBV2- _GS1M3\KD[NB3I/
MMB7$Z;^-0B^U@DN*&\L4E_XQ+I:Q#>._A1QW@(W[1>-L^][CDN<N]A)K_VWI
MW4"J3/\9.Y!;)'T'"'!SN -(X=P!_AC?>$LL&NK? 0:E[@#[XW< HXC\L1T:
MO9R9HV;FAPUXMZ"^/S>/:&YO_$XV_18-IO]_ WLU48-^_TO)N0[D#G!,^&]3
M,[8J/N)@;#Q$+Q''-/]3<@L:^Z_^C4NT4=,)TG! O(^L2.H_1DKLWP$^_;D\
M]FNNK;H#I)S]VV1QE$ZQ[S^S*9,W"K@# +?F;_WF_V.CX;V- U?W:V/1;0.-
M-FI"O$RU9CU5LW(\-2(H;OG6^'[<'>"?@49-_U%_![@\_IWW'XW-(Y\+KVY!
MQS1'M_>^NQ<7*=[?X/;9Q:W?U=F_YA);=S^7,]YKBCL W8K$OL 1^C(C<Q.5
M9;-I74KV,,J#*+S"NP&J[O1%Z2B?=V6*QRTC!'P'\$;I5MC,0?&JO_"88"7'
M4@I[OQOROWYVCCF(4B\)446N?,T"<<:)Y1YV5("[2TB\$1\>H[W,IR+3GVY>
MCBB1\Z04G^9V=J'I;8.*;_S:HW>"=R_OXQN*Y'&TM'M<_JD]>?Z?1'AGD5-]
MGQ@CZ]*GMGU]4J+^ZA%9L"0^U0/_<YJ#W'DYV4=DPG> 4K_V(+Y!&'FB;VQ1
MPD?V?N%*L.Q2DNS.:9<564L5$W7LU+N,=[C-D1<T!P4B\P\[?%V/>G+%=?^*
M_DZ>A9/DC0>NA%YD[WB%M35/2P]W#?V?QLP]G.D]CN,[K2<B[:BHCMB1+FJI
MIU.+T'YT<U MLF084I%;1,CBYY**<HFD='&_C-$IM,18;G%8*[<]R?V486&5
M96:V\W6IUGGJ><Z?W^?[_GU^G]_O^WF_?N_G^>TW4#WH12,F,)GU<0;/C"<,
MATF=WKS'76^CVJG!B[LLP3RDQO2J1CXYC5T>N[A648P]_,[ZT8=;MPF^T<]E
M>NNUJAWN!O<_+",'K7L2^F+'W[_<?)Y/7I:\J.CS88VGSA^F6B0(;IMJ]S.,
M:2GMB;N')_--O0Q:P->-PJ8R38U)1E=2&(SL$-(+W(+VF(EHI@01##[3D9E@
M@E1/@S$OJ>"M@C\0Z@;K1@F4<7W'999%<&5,T7/1I7X)@N$E0=28@1/&-8O#
MO.$>'0FBCT+>J9S7/.+_T&#??EZHKC<)3)3<[F_[.:"RNA.H3*D894ROW]XB
M!]BRY%W-!IF[W0/SNO",R3T2Q-;9&ULD\]+=H8&=VF)DC'ACTL7P8>=Q?97W
MY2WOBOE*(__TN*=P"P[ PQU 6<%+IP(+:\]*HZVB"*G=/'V<GKU.C94%LIB,
M%VV0UW><=#DCDD&+"&A>!JB+G14G%MXN\](YQ^8Y1<F9>Y'J@A82X9<>L\*=
MN(6O-S2X+M6FQ4*"W$23P*@@NJ$;2R5:^T9PY"%R6W[6C91+B?$#&+:&P,CI
MU\JALZC)XU M-;N2:S&84P</)X(3+$S8^."$H[[/VH?]L=:Y"$4#M5;W(Y%C
M!(&[6\6G.3=G2Q"5)5(VK3WFPGQ_DI]$[OA4?MJK)@ MPMR!A;+0%!A=[JOO
M?!MX](&]D(GCW#=GI\(S15+"9CV\7OJB)F$FJ4K(W,RYWS2MDV;"#S&6V?&I
MG3C'G!E#3\/02(3)@R<DB)_!Z7OAUW[Y1'H8=WOI?7*2#3L%/.E3J2;1O()\
M*?@:M;I\1E&;1\Y_=D9B!Z"93<[47&=W<6K6,1/P=W<?UQ^3\U0:0/,>:,TI
MNX$R<89#HB\<&DH@RW.W3][N1M5B36?^B+["R.SA50>L;6A,U%(_]R;TEKB8
M3HK^;4FXGJEW9%D+QS_\J.-DO[ U*:9>I<&KON!BXTJT"S&^0:T%H.5JB&)_
M;.8!#633O2(S3^=<\_1S#*R??5:12=5\5%O>+9LLI4[&M55)+UP9'4AK&G&C
M+=Q@F[R/Q<^E]/J_Y RO >Z!A&/>*C5'WK4.>;.7S]=64BW/W+0D+NCD&+;)
MN-<Y@^MI)$*"ULVTP_I.,IXZC!:"A7EG]83M]1JNG];Y'1S]+8:#-L6-:<9R
MT19JY<6#[&Y4T\?7:;8'^]8++EI!+Q[U"0ZL5CE4NFU]*@V,LJ(O-M_JK*;A
MW7F,N*<Y(ZZES=OW7<6;ZUXG@G-3T.I)L!G:_.:0Y_%:F#AX_&5?Q+P(W46!
MS6)LD=,R3Y,E)=7,K+K@V+*C@71JE^M*C35.T7J6Z;@(E5#]1J>I9#'==$'\
MHA63^7P[,?V@%<69H/EDB(5S7UU[AM]F6#A4; [+#A3Z%.Z%3/C;'.47_:$.
M^-VBD&Y54A\!VWTH"-I[+I>I9K2^JG.'7>D&?$H.O@JC+$$DCJ/# R9>4B=_
M1R<+6IP,P@1VZ!# ZN135X]=[O@("0AMN_@RSYORB1=TF_)/H# 3/;X.I%0)
M0G;,[A/(3]W05( /<;[L:[^N7;(:PN:WZ#:K^F."@)H56O<BU866QJ=[W_@<
M;DZ+GVK">&#\4VT?IN5DQ"G'VNL@!^!:"F:%2=XIG\_M%Q3=MJ[30V!892<=
MU_AF]37?&"E/&&!E1"PFNH&3Q M:72L4JLZ[KE'8C+SF= ;?EF7\UU5;_'WB
MEJTT[74)]G8C;&K,Q9OI!7GJ$L1C#4!82GPO(4V":-P/8.=6(>37;\2B]U (
MV1T?_8?]8 7K2]4G3EA2'E3I$0:#YHQACKJL//L-AOE<[=VTXU/%FSEWC-PH
M[5ER,BYC>('ECF_A( -PUELJJ%R^1!4J\2-M6;O2Z"CI8 +UVDA;/ZZ2\!Z:
M=M_PJO_"9,L/'1V@.?HE1H2BI//&5WO/Y C3$DY+PG3.^L[J/V8$4^G_"0.-
MF0'+19@<Z*O.5)J+<YDHD+7K6:8\"70C-R(5=7Z68!@%@@NX8+AA.@55B.F:
M A@!QI #WB(,LA/%>D874J.CY5?!"P9O#6+-U0#+Z9+Y<\M <YK]-&P7R&BT
MT4VKTL4;)J%QB$)-[=&4$973ID!]+MO(P7[3)H=B*_DKM4C%:^Q#RN$F9SW^
MK%(D+HTT@R2O_P502P,$%     @ 4X%<6"<]ZJ)\;@$ 7"8& !$   !I;6<U
M,#@Q-3,Y-E\R+FIP9^S<9U134;<H[" "4@1!0$ @*"@E4J0H/2)2I0@"H2/2
MN_1.* (2Z4B7WFND=Q#I73K2>V^!T$NN[[E?^7/'=[][WG.NY[[NG?'\RAX[
MF6,G8ZXYUUH;,X&9!]V1E921!&'= (&P?K] F"F0..@6+BX>+LXM/#P\?/Q;
M!$3DMXD("8FHR>Z2D-/1@.GI:&AI&9@XF!D>/F&DI65YSOJ$ZRDO+R^864"$
MGUN8@X>7^Q\7P<+'QR<B)**Z?9N*^P'M ^[_Y0/S'41ZBSB58A\;ZR'H!BD6
M-BD6IA4$_OT]<;#^[0#]7P?6#>R;.+AXM_ )"'^?4'$'= ,+&_O&36P<G)LW
M?[_K^?M]T$U2'+('3\5P[RKIXSVT)>?VB4B[Q?BRI)E">7"?B>>]G2\^ >4]
M*FJ:1X^965C9>/F>/><7$!1_)2$I)2TC^U9%50VFKJ%I8&AD;&)J9F[OX.CD
M[.+JYO?1/R#P4Q B,NI+=$QL7'Q">D9F5G9.;EY^:5EY1655=4WMCY;6MO:.
MSJ[NH>&1T;'QB5^3"XM+RRNK:^L;FZB#0_31\<GIV?D_XL("86/]W\?_,"[2
MWW'=N'D3^R;>/^+"NN'\CQ-(;^(\>(I+)J:$IV][]R&WSRWREQ%I)<WXC#S*
M^Q3O[08)*)EX%QZA_A':OT7V_R\PWW]79/]/8/]O7),@(FRLWS</FQ0$!9V<
MLZ1[$P
M
M
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M!CG,2HEK*41JA8S91X.G-YNB76X7]6CI%ZVP2659_W(94"GKB%M5I<^N-E^
MB,V.2^6(W_=K]>!>B36Y-ODF@8SKG^HD"#O; #,>;%UNJ<WNSNX\;V:3%MH1
M$<VH<'4,"]FQN5'43OII7=Y2Z@E9A$CA"JV#H27-R@=%*^(.Z@Y8OM Y)+H"
MA;-32;F!TPJ?T[U_>=M&PSS&>>F$+.1JL%K_5(6_HOI+%(>2!,4C''*E%P
M /#7H @I<BF0^JD4LC.)CW=9HA@_L#"%:G/E#+I^IM V/Q1A-9R- =6OG9,<
M]D&V#+7-NC63>_(L:)S"2!+ASN2$$T^7K_#>ZMHN<@:/.<D.;CA=3)67P27
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MP&A[UD*63R+W9&7+P'XR[#SL1_VTE:B&/?V8CE8R;5C:^* $Q0\WL3^]TQ(
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MH["P!A^$8T!$U0.CBJ<P#>V!T&'G@ D,R$D5F@8>*TYI#=Z\)-HO,GTOA^B
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M7%L!,96C1",!)%^/C'!/3%HT%T(OLI%B&G2T;1($;7@C$A J8836(-M$3!4
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M;-M+6V<1J5EK5TD8Z;2\S)#TC"<=6<NR<0ZR&5CE)_'>PZ.898-EH%]?,M-
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M;\H #?NRZOOR:;$\@T"DS"S/[23BYQ .J: _D"5N24"D&1,4JA'5B/HLL8)
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MUB,Q.) G/QV07VK+B.LO@RMP(GD&L5(1(V:F1$&?,X2W!P4USHRCEMY"9(8
MH!=>@H2)J,OSY2IL-XK1=I"E=4*^DAM*%5?P0T )GO.#K6J IU??<_=63;IT
M4E;78"AN*;4JX6@=,A3KBBO<W4B9;+9J]A=$7HD&+QN3:H0]!!E#R9>6B=UK
M^E@NR/(>N(%IX 9'2FYZ5/$(".AB63;G':X<A$X3)ONHVWH+UQ:B-VY=ZD9Z
M22-PC@J,\T,!!GCA5M[JJY=)7H<SOT_O.=![<.7MZ[^?\E=TV/O)7+:-0%ZU
M(+7;X@]MRO^5G6'553*Y/%[_FV#/ZMXM*S>]X*;TS_1_OM22&#R[4< ^L5<N
MM&GSP-H3G=,O_U9:XY;DDVG3'C.2AM/F(_=J!D[J*4C\GIQ[?0'ON>SCRH,_
MW<L3<FLRZ;=F/"B70<RL /:V9T_;8XV%ZF[QUWE@:EDY$_EJMBKL6YCTH%N,
M4:$F:7;_/+!CVT"P@^F'ET]2FVDT>)EIZS^?(EIDD446^<^4>0L3UD\OOU\8
M- ](?K-<ESRW+]-I>*9847=5#%OX!"?^.%E@=L7[PSQP.&Z*]?%EQKU[L1S#
M0+^K5R]M3!\?/K"I@%&;3-76B S\N'/5[EN*6ADA=8U4S"P"^N.LRJ[+SE(/
MN:D-;TQN+/8\>HW)4&A$<<,R6[AP&TD'PPJOI$B%V1'3(*V.&Z*LO-2TB ^)
M;FK(:AQ@5\+7ZLO2L15E=B3I&&&C;,4NJ&AVD$@<(\7/D!42Z$5\48X4:]NJ
MF"Y^"!.T-4"^ J$2O"I#EPMGJRGAH27)I>C(J;\DV4V"AP!%OX@I2&+QTFK$
M;!.2,MZ$TI*[W\CM5ZD0 Q+6%Z.)B",0:*H0 =W'DLQI@J1N6O\_+H%3%/T]
M8FJYX(O/9K6YRA65(B).B[45EXX@JO2Y)T&.CZ(!R(^2X.3^%.3#M)&MEJF,
M.$-Q,UC*(BNDE9-.)6+#)+13!VNI2\64""X'[:/D/<:9X!O5,^*+%1"/^IB@
M-F!.\9H.RIU!6&)2HV80B%=6<T@F1;ZCC#<+OI?Q%J:,JYZ;0:2UBB\A6[7
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MZV*&Y8P]1]_[*9LE&SFW%O_CK? 76621?P4VIHX6#!<4NQSE?TZ)MI@'R//
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M4Z');!PA?2 O9;B3N\E<28*UG1 "J,",6+Z.*\X"%LL?L1W%"(>'O-58B=C
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MI62@(.]QZP;+T&X[CP#]0+4TOE'.[XGVN\?'!,_5WSZ)EB6HXQME!L2,*&Z
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MVGS*!Q;:Z/,K![-6A/=6W(Y%NSG7Y ^BV[TGC+R?[SU5[COT;4#T<FN-P['
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M4N@$I.%PM?P WO>VE+;O,,?=3R EE[.3E/^&$Y;A$\O@PZ*LE7ZY>#[CSDD
MMUI4D*M*^I 7P\=P1OD8=@+B<8GA)!0I?5317=UA J&475PY[E6N@A@;S>SD
MNC@(/9@"*G+EMEU6&:R$9AJS196:;@YR2L\["+XV0%KT]19*+?0I" S&IC*?
MB[ DN*453:SQ71_7S_%P]!+'B->G,D(;@,!FX-WLA)#)=_T9HHRN/B-U7 V1
M6"6#Z4\-5$N2\4X[4=("L4U>;"<^UR5V G+D8-7+?MY!G#M4S]F-[0)_O"$Z
MB,\>5\)XB<Q.X8Z+9!)NAYN/.4*"X8Q-T8HT0"#Q407>  .;YNI<7QM%VZ/
MGE&1(\P6R2@P4VVSFRJ)%S>IV1@Z(+!%U<:3W\BR/98/!M!>TJ%?-R;YF$EP
M#>+1%VP@JS" ^D2A<1NB[+3V\UF=9=(4BA$$7G/#HI0[P"1>,#,O;R9&PNY_
M5TMA>U2$)-FGNWHA5W[%LSB=U7T\5^$CHLP: .V/YO!KT@;O7&T*1?<A+USA
M\U;A72TB(4[TS>HB<2K!]/J#6T-R^IPH?8O N!G7S@Q-(6%PBH>HV)V,@&@@
ML%]PM1D5>XB0[-KT8%(EO0C>-BD]QRTDA]PVQJU;'4D>C>*#MAL[872S#%%>
M,5CJ9E#"UD-<6%.T!$36/*.V >",$SNKI+\AABD3JC7M6%+K%HI/,PS(_-A-
MX^GWM$FA93U$_*Y/*N(=+%ZC);SREC][<EB0Q=9!Q\95IVS6H?'.E<$$Q_.3
M']9-)E;@3P?J[$XOMX2\832AYEDAN1:1/3$[EM3QN^[]7Y/MB?ZVYX@1E1(?
M";)!9^'5N+&P W.\DJMIC!W22"& =9[40'YFFJE;>LM62_+HT)0_1AVMDQ=V
MW=?OJ%%[H5Y\3K@AI&1^_&#JS+?7/"H7 :?!EKG0,S;A2)0L F9@<DB3_6L<
MR<^PUM3-T.B[9)^A>B[JK_O5!AV0'XZ32DX'Y3<S4N%XEXXG4_$?'@^4-#Z_
M'EZNL]8?GJC+F]_\Z3=]^WYY<A>UFA%%\*/7WYWYXV#NS!\G<.[[_;K5_,8\
M6I;;,!DK^G'%4U["K.$41/6PO(-F]V&!ST S:E?^#*'):E_P[Z[JN\3\TP5R
M?3/L7M0-LM?L+ZMGH#O=+NU&T/_VY5266&*)?Q[GMZT+OQS,E-X:O-TULV^(
MY;$C':RC=\8MD!:![WU^[C2MA,5O/B"8O7U7?O5!6Q1HD<_>FG.*.GB@ZKU/
M/NWP?X!#3,-_SZ^71C9Z\OS45]!M#-C7,7/-:$C+J#0EON-QQ./+@^A5?<FV
M+US*PIZF5VC($YS\R>%J,2^^MQ$8\7MZ!?6-PJ,2B3:')8P^\)=E*F -;B8+
MR05J: CSMQ=SGW3D7XZ$\8"<UYB6!:&V%M&7%JB'O&C2UK(+<NWWI&09BE.
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M.#SS,W_N^L<E;<4<U7X1R!-$EKX?0(M;?4V@HPNXZI0Q8]-@Q]0N?W-KU"I
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M&JMDHBXZX^7X.;2+PV[?327.3C]_5]Y5V_!OCO%J;-5VW_Q7=M&?C*K)T80
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M//GM6-ME'PO$TKLE @./>M]TM;,2,ABH=RY2D_R"O0SEYI!@[3&R_097V%P
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MGL3<*7FB3,]5:$+>T=SG)T<I'N\!9WY^$,5^ZJW2I]\DG6>PHB"0GO*M>\F
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M;^%T:@+[K?2'&=T!KKK 4-D\[)9L5^X9&*T)B96P=>[R(2'>O!EDT17GFGD
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MX+K"L_YYM9&,T6([@! _L&6;D4=A1(+K@!#$#J(,K1I,XEU=\S$[!CP0^_5
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MT\6!"6[I\SI3^@N/VKE51=%993,T*TR<)4W,-1OT[&R8L=L<C2^910-Z<W0
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MG<]P:#&AO2ZCCPOJ"]?9A]PFR8TB2A@U;C/&5\=Q:T1G8CLVDJDV2\'@V<[
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M3U4GZL5-0MRE15I@ZJI92(L]"B?_2KR>"3Z2S^*GAS2$5X5ILF#47PR-? ;
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MM:\(H/ C^9S3;8BWGOR6*,*<H4Z*N&%.!0S$.XGWK%[;1AM?^[EGF[X/K/6
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MB@8>0/M"OSCSP!1@X+$HF$_:!^!$[KE=SSJ_R"SQFKWDARPJA/]R BZR-1E
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MVT?AND.9P^^-'>-F%G9QQ0VV<<MN^\!<I,8ZY$^L&DZ-#ZM4F ,(&EMR1 &
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M:)7 M7/T3X\UP6-92QLO.BSV'C=O"=(HH8BZV@L53.Y:(XCRLP(QF)W5#%
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M$U>&_J[B/T0K)4/=K%?:=Y2-NEA$SNI&$K,?:_/<B*2=#-Q)DIFDR&V0=F"
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M?^P0!-W&?STZJKX[4OLGX:9+9L2)]H%.(W5M.[_BBFC^&ZH,'1L'_HH7QG:
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MFZS7H_$_V=.LW3"S8H,28CQ-_6N)'ZSB%U,+WHYE,H5RCX;<F%IEAKOP9_'
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MRI]_'QT
M
M
M
M
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M.6$,3"PQO6QFW\%PL>=6""8L>=&R]RT6']\I#(0K1F",2Z&",]]+N17O\Y,
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M]Y, N"2^L%*6-=7S^U)@OH#;IN'/>1)@42"ZX\@TP7W]L_TV_$?B%,_(\Y;
MAQ?>DX #(\Y"[5^,%G _W8<7*C:<XC?[Q0.'&:TAK "++CK3"2VV#7D]Z_+E
M+X[G'[XN:4;&$E[>X*2BYBWD_GQR5-!/][9N@%L3-F4(_J1UY*%*)CCBBE1V
M^NE4@%%EKL 8Z& ,:^Y>EQ]XH&J:7-!BDKQM\K'1!RWS>"VZ7**.JFI+5$W?
M.7)@!OP)>#;CX($N=:C$3Y!3(VJL&]T_H O7C',-5O9[0;^^WDN(?(94A^?;
MZ_5)*GNEC7UP?95QNE\2H_73G]^[2-!;"3N<L5@^54;EA0PLH#E%CZ/B$4"<
M+57!USZ#B+C$@=U"-":T.2APQ /M. ".?Z2!M*"Z7T\^<E@RQ\:D) /-(^PD
MPG$L7TLU#+W6)BOQIG/8:_&*?7X76$@ ^<!^-OT5@QHMW1L\(<+"NXP?#L 6
M;F""=Y<L7U1:X8UIN>)/4GM>"2F&S]?NVYMF/^CQZ.T)*"]LO:"^A+^Z,]@C
MJSIPW 3"V(@ZEYBB=&$TF3":D]4%>L0$E,/_F9(MX<)U_!@8E?I0X>1&3MB_
M/-?.IFXR5CW#('D]%^;Z+.IS?8H16#>M!\RJ)(C8DW1:75-( ]9OE#W$F^R$
MDH"/KY$[R=*=6)=V# F0/#7:%R0!#P#,US+YUEO^\K 517><:!;A_0?H;7\Y
M;Q3:_>C96Q*P44VW>:-,@,@.?B7?4]RTYGZ6,UCTSNJET07Q<*+]6?6#LB%>
M#^/M9VO/BL]DV_3PGMN:Z",!7<.6:+_76B&JA)O7SNHQ1_+6G'H0[G$F'YII
M/4H9O&@C!,X7PHNW7"1,*3]N\BCH5>4EL+7!.O[\3O#X@CD[@1L=N%2F5=K)
M)</Q! V"5("P!?;4V;^M?:$R3H1J/9?/2I-AP^58(TNTR0<Y8CM*B@18&<,V
M1LS#_HR8I=?U%+]\J00N6IUY"-L89<>++Q%!].MVI]6VI+-Q_< WOG2-@ #<
MK!SR]?;K0+?,JR2@RH@1*?YA9WE,I<Z $:,END%=^-O:B 30CASN;,QX[%EW
M"9=BA]QF>9XHZ^&MAI=#0@]B1;^3@(7 QQ5DP7(-1R,"9^-Y3=Q<(0E@?(T&
M'Q(+CL5X2A@?YS1'MDJ[//J!<[X,QNR1@(HOLCWN3'_O]&2@8-+J["-^Y_E-
M^74L%H5K6?S48$,_&1H(/5'')Z6?G=RKA_XH6-;E^"<LR>!'V^$#T9Z!;G>N
MPYW1NF&[)1+P1SIJ,37^;-3W%R&-!$S)_U)I_GLW"]'NN<6H>&Q/<L'G'DW;
M5+QS<Q:;DEN+F'<*!U'0(^*/Y_[QM7&SQP,O<YK96L7\!V_1><L1\V#F(E7!
MMMC )+ZCSHHL]9M/B)K.\L_'Q9NR[OZV44#TP-E$>4_&7B_R4F'>^!"]3"X1
ME5W>;YFB>_A8:E7B@^P9,3(\21L\?0W[_6R[\6.;UT*8D?B;Y50"<<%?B%WA
M(> QLV*\ *[7 RUFZ$IM61L^9Y8 JE97SF6A'PFV"]7NI(MHYX](-!Q.0.LI
M?US?-]#@_R^?5?IWIOFD2%N./,G)1;'+#&P[Z'.I*OR;BDH]/[2:;"70]7NS
MRT=MPE*R=&70E6>=^]T6*156#N'NSQNQ=?%/7[P)NE9=$Z_,&=R/Q"XVKJ7E
M558/C(QJ<_OH2!&AHR9PZ2Z9!$D]L:P?B=&]9_>]"]08D-S.(K8(&6F_S54N
M5/3IS;LE/;S?+R9[</CE*C0JPZ><G%#8+%P:_ #KUPXB^P.51#73RT8?Q#\5
M&O66%V2Y./_-O#9%2PTM/)AY6R]H0LFG/!WLLDVV/L?:'+##T@$%88V)M&/;
M!R FG:>EEO?_'.YV%@@6[EVE*_KYF3/LNYD0=?Z%YV :O *N\%01_PSWF*\8
M6VR!2YF'LV-N^WON:8U]3K&X<Z=2A_O+L2!9V$-U80HF:OZT VZ;29;VS9U4
M$US8UWB=>Q6_#^2EQ2#J]9'71UUK[J4\.[T8R7WY1_=HJE.[FG;/L/6E4WY_
M6DOL7)>HJ\,B8]< )RYB$=RIIV;7@/-:%+I->+VE.MCMGR0=]2NT6)S3.'C*
MT_?;S7ZU/;51A%L?A+/?Q?OLN88M7(_J+"_FKB"D>*'];WY\UNS(2"$>_&W^
M2?U,$T5X>7;BNE;W''?PT]-[SH<JS'4[!'@'B-;% II<)H9_2 *<=/EFN=_D
MT%Z8?592TF3P^B)@%^Z"P,'1C]4[5 1P1@5K%19ZU&^4K%M!")</?946Z;[O
MJK4$[$*_'C?L=P>,=<$G+*VPL&Z)R[BJ-AL^'T3DY!9"Z;:+ E^69Y+FF$%/
MQ?8NNEZ+(O(7RO"N4(8MCT.$3SF'M7_N@M9KO,MB/K:G:@$4[Q=(XX+C+K_Z
M1L?<)&,OU4A*N%?0N[?'N6:=VF0G]3 <%X.-6/04S]K)?Z%"WYH?5% >?RU3
MZP,M3/)>GOM%O_NQ]1>-K_1H4[6((EM55"A1K=QK:'W+/33HLE"4;KP\?.-I
MCL0J'7ESG*U36YGZ(7=%TRC8C@1<.&:23W/YY"%P[=*C%5?->2T$,$\M JD)
M/EITCT9P* 7,E[_>M?H251QLOC/7PWW6U8XCW5UXKK!,6YIG<]>FF-K<0@SL
M)A74"@=49)G@G^ B779@"_!HO$O(4Y7"YSF=/-O/W46Z!=M7[H?2M87U10SN
MRZ!AK&<Y"4(5? U[F+^@9]O>>K/Q?5<'MV'E'1+@\%:;YD&33F*F('FY@;71
MJ8'_WF%&(XX2K2R+S+K4+).#TU_D,#,<\S:G*'6C[)#VO[#<1L^O(>2T4/PG
M:^KR[C+"%AQ]I\=PISS*NUD3*7+K,"/N-[1C9)7(1!R;)<>MH>^=;9*>NSR^
M/N D,^]JC;JQ,'%YZVF#W3-]!0]4BS-&41_,!8NR] O'7VMX-MU(E28;/7*'
M/L/\./27<.HG><QLV(<ZH:RS1%#:*LLD7RP+"DK<[+Y+@T<*1!B'AHR=E-7+
M'91$[$FVXXM-=^(SZTLZ&+3;>E?S;VM_QB"%OLE\9E>3BC/A8/>EUL>5<IS2
MJ-_4VO/>-AV%_/#(/+"@) $J-4[4T%R^:C*10NN,O0ASZ^M7<X=ROA]O#X;"
M)DQEBA0\S"TFMT>E6??K$P=48N[3WP%)V8X,!7FS\JTJK81*;@2- KTJ&"8%
MOR)/NZ5]&5]=2GDEAM$'3Z3B;%%A']+V*(?=0H)KUZ4F6P=VQ! 32BS9:N#P
MCK,S?W>QN8*+6AEV8_4T]QA L!U113%.[#]6D3A>=><B/J#4>BAAH,':Q6J@
M ?QGL1F9-BOX?O3QIK*X,=&F_)W'I/$']N',0LM]V# 5T9ALQV%3[Q2BL<-'
M#[9"#(DW0PI=9(<G+2Q+,!3.WXJJ$X8J:U5P'9$'2[996:E$FG<"/= K]_7E
M24!LN H"QV@*GB\@)PK#H^+'7;@^J&1TL^/,5O%Q4MMJA3?^A!MHS9* G0-A
M+=J=O,3A%>SE!#!M8#P)F"\R([ L^-1;[<.86V'8<<I@EA4VI"#<R]PL=;CS
MY8\D-FLYO/"IMI1TX@FS$)Y-QRSY'>[YLXM$$A#MX+[,]'6*2/.Y'+V,<\\O
M/YW<'",!ET7WQDX?8(A!LFM:ARD#^ /PVX(!<?0R6'69!(1_]<]/7\(%Y4A\
M5NA>(.84ZY  2EUL[>#5'7"440;^)'*/SH\H:7/AK#,Z*V(&C$X,"/E>)$ 9
MLJ:E=!HE?!2<M6,,C];K@C+N?" !@4&')&!RU-0&)\+>=:RR&HGGRB5\ALZ=
M6K=R$8<:2$!F_XDAK]I2;3"J7R4@2O@0 VN'J-R\@KZ[\T@YIJ[YK&[+9R.'
MM>M#Q2NQ>;AKRCV?/)$'F:W"Q,'ZLS<7@.YJ'48B;:17\\4#CAAL,$:;[&<Q
M? RV=H,BY_],<1Q[.W$?_SRK@W8,L^(,;Y UWWCED;)S EHYP)X-'>3YG'(W
MA\^B4#^FL1K>XBD8-X*U:[7>1N@,T/7 )G8V>*#V1;)X5B.T[L>>JNPR6--"
MGTU?HHU@2"/L^ _LJM94P=H*Z+M!O\K"CQ!S,)Z5&_TBRZ_KQ,[Z-\[W)TRZ
MR!,Z9\,SI1CLX7YI7:F%JNLLG*MC9V6R6Q;''N/:V=O/8GB=X'3$+KS?29P%
M\7'P(ICSX<2&/X>B)*#:^0JA444181/3&'UH2:M!-##K1[AE$0.YU(/DT3_E
M\@/\0!*)^R[0:1"OX#5X-Z^K-L^QTP7&(84"V<UT;"U:D2B,2Q>$]2FFV'1&
MLNT=35UOYWO:#7J1?G8("?'%9>59R.0V^E[H%JYP<:[30 "[9B(.=H;%L9,S
M8B$]%+!QB[L)(<5=Q E94+-T2*7[\9_ E2SITRB)1,P0]'<6FWW/=LRLE)P\
M"*N8!<<'%FECT8MV?5&X%+0L>:8/)@/VQV<YZQ]G@]3J#6S3BP[4>XHC\Q ]
M8)!V5Z8RUNXCILFJ 7RJ;.H>:RWY-FE6$BNP>CK9@B0![-:PPP9$J^.I,6).
MNF4+O:SHAPM;U($?9%Y#+?'J$_2]<(230J%8&>T 5S.#MYGZF D(L=_J8^.[
M R_5QA1/]42MEFFK JWK%3Y7*;>VIF;*[,"G,G>OH4A \]ZMH\2!/9FHP\)
M=YG#N5#8DW0PAQ-6_>S+H27O5FAI_50PZYSL[Z<S_+YG5J?O_A8ZC&]E5_9M
MB=?UE4DJKZ'X(/@[W-JK:^F2PB_V$$+':7?:J&]IJF2;S9P]P)NT R=75,08
M55$*(# $]V'/6OU4E?C]+%M<4F(I7T=M+Q)$+7?P:=ZIC5JQWE./?J)22U\F
M6JF+E7;U12:A-)[@EE\S/BOI^'G<Q!1' G*1QS0/O^WO/@/M,)OX\04Q/O#L
MS<QP^.)A**9SLT+Z=M9UI8T73X$-E\/A0_GXQ2K<G;+N#_Z:(^^5'Z7?'1NK
M6[:)$?B0_WVU[P51$^$&LVV0=4)0<0NN=ER)*" HH!)QH"*"&KC+&KZO,I(3
M>T/ZO[QX_7>VB@^X/D WG8T1%;3%/GU,Z8E@RI_*G^PFG(;"^/6N2[T>VK=\
M?/W(HKF.?F7]Z-F6*PGH4*.\B-A(@.!I\NNA+46>XP:3A0/7A>F*K_9^Y:T_
M*!24OYZ=/(?Z<+%_+W#8?RW)Z^YV0O4,,M-+E0;)DZ:[OQ+1SZ_2/ B$2'8+
MZ4_D*C$LIHWS>AT_)$]WMS)1[!> M(Y(;ZIA(#6-(]*HQ/W3P@6SM-X\O20.
MJ]W(X>47/CPF"/W<#'*K*'@PQ&-!65V[7O3KI]OK2.,:L8*UW5E^Q&Z."UA:
ML\0H41S%?_TN12SPNWE'XK4/F',"UXI6JW9GGYA*EPN^2ZM-/Q^:>S4F\\Y#
M3,7$R_D,YH0(3A8\YXX,LL-KIR58GJT\]%:3=)#Y4GR.3_JORWD3XM<N!\\^
M%=Q+R#![:XX/Q"X71+[(J1BL@7'A6OL>C-2 6)$P!X84OA3O"G+>$JB=8^5%
MFM2+<?U_51S#V?ZD\OV%]8M2 L%4"M PVH&O9Y^D"5^D:[GSY(5'3H>HY;NW
M(9?UPR9ZVQ2'*1):;@P&9CATE8]#YH^ZX5><^6Z,E0;K@:)]."GJ9 \#?T2(
M1M(V%]_3O&^0I) $"5Q3HCV]C9-82$B95Y;M-')&O<]DPK+."KV:T>/979=-
MZERJF^1VCGP8ICJN<&,[60\GBT6M+KXO?_X4EM.>K[S50$BD'_V:O'%=NM8A
MZ5Y](O9FTOW(7+@S<2WJ9H#T 612SHF/2W8(YR9:^MS-9$ZG;L3<4/FVWAOW
MK]69EG>02?>B<W)Y%]I^3=Y\%7!8=7JISW91S.8A+@A;U0-CD#X];9"YN*]X
M:]O=53I.)])Q-:[RD*)L'J#(L&^<HX3VF<(8]FTBN7Q3%K7=I]I;1=.[&_,/
M\VDO^00LQPF\ K[%A191+?IS"LF7]F5-&G7^QE69#:&'),2K]20M7+*8+.8L
MF]1=>23U/'S$,SU\>"21XIO=VA[<KCRA@<HVBRE?XK_\D3WBX\$J#:ZC4KFR
M4IX_2>XO&.^P[1\="H@UX'P>WU&V2C-==A?X5CW=0\AIY78&<ZA0X1#M@4HH
MW\FR"@KF*;VO]VW#S,4%WFT]IX@K8I)32M0C9#?3%N-U"5G--O/]E\2FK$:E
MWRAR^]1G:%Q*$@I%_/(G9[YSJ<=_S?*$O6N;SO^C]-H+G]NU)Y]'N"$-S?#>
MV"U%?OJNK]K?X4]O7R?D)W*$==LYD0">9K(2/2>V@IA[E3. J>QPV=AWJ[=<
M"\VEM>LO[SL]",_U>P#\D0[2KB8!](YWS$0*?1SR)\RG;SJ(7(N=E9LFGW8S
M&O#H-VM6#GI6ZG12DQI=[:)LJ5M_:I\:POD>]4=#T.4VE6C#O=C2N(@1KQ$[
M)N=/JVK^V726$:_=YKT,IO#3"2.G<5O*A5<[MGBI=XO4.(-]R_P\S%VF! HL
M!EO=4SF.D =%HNV_8!;/Q"Q/R,,I;>#EUBGZ4^ ;[>AOQ;^7 T'Y5]]_MJ9F
M>VXV^SENE7__X*!P;"Y,E79 ?Z5*YB_NKLF;-ON_G*2.:49Y89_LK.YL<TP4
M_K+]9@\R7,4+TPT_I\O>A;@Y31.5]^Y+UJ%2ZY'E#SXS:X^\="X9?\'0.NJF
ML39-3#%T;\GZ\?8GKY/2GV=W^[1O.E-#K6A.BZ29>Z(5;EQH!4D>3]8F,AYM
MEXZ0S=T6=]D243TKEB_\2SUC'U8+_Z813GCIOFR1DKJ8$*Q82$X"E$#'1N2[
M9D0:CX$((A^^$S05^);<';R>N[TV\ !_#$4+E4(C2$"[7JL-5; 2J)O04)C!
M>()F@P9IOW;NW9+?%[A>*8% KR$8ERU^P@@.QZ9ZV/YA= 'H1X;?[82ELZLT
MS_Y7?T WVP1M-&"[5=C7_$X^(5Y+--OF^D=I[^!1%N\CBIPBR2W_'**&N_^"
M^+#DQ=S4SW]P6-[]XP;YD8T:#IV_!I5+[5:("H?^Y9]V<CW]5&3NT6@UY]7?
M248?3:=IY[6?W=\3O+G^(?Y!-C_^]-0]V-=5O1U\I5GK>N@LK\T5QT;V5QO>
M!!?#RJ2M^6Z?$"\O)0^+ 8D^KEZ:Y6A.6#8XQ9BAF@P&'!2R4CZ43,R$5O>
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MJ+DN;>9E,K5M_"NDB&H?<]]66?[+T8![(*-U0#[1FTX?02SBGHRSS>>+*KW
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MH/%WWJ:CX:+CM^P]/<4'FG4F58\+GM]3'X *,Z>0#$9,((H#$;A^KMH:'RU
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M+*RQ<!"?">JEK^*)=]#GH?D;FQKZ9J[LKB]#LLZ0X1O[*;Q[FCAK-A']X$S
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M0WK8&AML:-(_LDD.S\^E$5!>/5F&$6U9$/\N&&TP9:NKBP'(_'V9<5IFJYJ
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MT<F+9DSTU]JUO%8P#?)"&;]A@Q.RU]G0]4D@?^TDX&&@F<'W58HN?]]4RSV
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MU[[50\2;%EMNYA&9K4)F+KN^/W=)UEXX\ 5S&_:T]_19.!!+;<Q\O!QS?ZG
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MO)::$5C(<O5+.]Y(Z9L]U+>OF!QC"TW7Y!5=+7LF1!?#%@NYX-NMUYL;PD_
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M_.T+ML?CS!3=.,V+:=B\B$._ZE2FWUA8N6ABLF CR"-%EU]F^3;1(5C)>8/
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M2"_= ]8=/H'/#'6V3R*JOR>N>0H112+I'BRIXG#EZDD$3UQ;:V$^T673/>"
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MMF-S%$WL!*^+T"DN3[0*1H516O8GUOQ]<9["FQ/H+RPMLOGTA!(0!1ZDXR,
MPTP7/=$OAC1<CP&N36E=E%TLI&'>Z*P;RZWLTYO!(E=5H)-M=?GUBB2N]R5B
M%C/?L,39AE[NU +U*P:EGP& ,R6)-OVN@')%G[(/M7T4@03&]X 0W9CPV[MI
M>JY'GCE;>QJL8^#1\AY9P-ZN0FERN^AO7J,E)![7(8UG$3LX<P(98/,H+L+"
MOAI_OR2?JW&$+=KR..X9VCT@=B:3_(D'AA V2"'9DB8[FD\Y0EV!B,)1]H;"
M]W,7RB-M36UD[>#E'\0IN\$KB9+>AZF)_8TY"RWFS_^-],XSH/DP7F>#-HA5
MR/HA[K<:5K7AN31 B@*Q_R9V(<((S);F7 ?4KWX*+G0%G:Y7W /(V^7)OH\=
M:("@H[E?//?97'[>JF&U(HCN 0DXP%MXQCU 6F!%!_U4#O5.&'RP[H3$G0WX
M/_![.RBAI&9-+G\]_%RY@(G: X /&$.Z.OT+P'^@>)BUUZMS7C35$=NJW#2T
M,X$[I_T')IF3?J9^E]7C8W!60?+5XB]!3.!>K>=]X+VIV1V2I?,#E++EM=D_
M4UBTPM!9+JIF5XVR?P3 M"> ^'86<M-4HQ?4743IFF&'B1&(DMGM1 WR;T0Z
MVQR:N!Y5G#6BT;@[Z7-P'Z$P!X0++HJU=8JCX9MI<\81E8%#JU)(T/QBGR_F
M^9< 9W%YFNEWX3E*>R <>!IFC$3&=^_B[E/E-9_*]SH:<]0.ZNL3,R,0 ^?]
M@Q3=5T%K(NX.@6&:@Y.GX"\(J75;,>F"7:JBST6VJ!>3[K^6E[N[ZTGJ6J'!
M-LGF'YJ[@%^M%*I</[P+1$ML/D>JSZY.KUP='4JPSZ 66"+6L_O80U)4A126
M2YTG%:*1A8B^>*+LYR[34QJI/9)8!3,>W(?-$"?\/2_CYRD4FT+7W*ZME(UF
MFX+CD.2BIU-D75T#E.4<YP01=.+3;5YEMALZ2M@K<G5Q"D'NNUJ,9]\YT#CX
MVA(5%A4V *8 +(O3L+[45N5-T<*0@D0[;5>6><CKJ'&.D*QITS,S<_RM/EZA
MC<]G0082Y!.@9[^J_(7C-))41$E[?]"Z[BN_A7'U;!-DJD313;W[EL,A,QR>
MR_>HISI.;Y\,10M[U=H4.F8 @31;/#/N['L:@A'"24F_&DU#G Y 3L(E80P$
MD=D8=3,I\BK?OS5-Y85TW^C0NPJC3F_"IF*GUU::BF/$6.\!.$L(3N>A@/7>
M+"[._"^?KTCWGG^]6F[[=/ [T[SC&5SU3L:[>(VV9=*?N&))V:/,H-?)P\OI
MZ:=?1LOO[0ZZ\Y@H?4\]$6TY'9)F.7^N%>"]:W<$D5#"DSP8:<S41(8D001N
MN&6LK*Q?W]CHPM<$X'O3VD_K@9(LD!.<?>WZ@.]*(M\C/<[7>=\-,$5G8KV/
M2U, >EOZS8I*J4M1"""?HR: =2M?P#9C@**04OWN8CM!HH0"NY33JCNROD>!
M/-_" ?P!V.@4]$1PVSLYT+ $&YQZ@[V=VGA2?_18K,WUA3YU27T0AVI<&L$V
M 0;ZFSBL[UE,#D^_>K!UE_ ?>(/&74BDX7^XMVTHE^QPS>IJ6O6>*A4MO,,_
M?MMZ; GP1:<'A@@IP62V4MI)&H7.#?:)7GD7X)TMR7:2173=Z*[&\^++#;KU
MFJT8*7O0E3!8F7%V1CFZ&EK3@S<@>+-)]@[V_"5-;H=GM3E+>1JQ+M>QV%>W
M,ZDB4^[UXHEC/2D@MCO+U-]_;$5KM&,WAM]P'J_BH]?*WI6-$B;$:Z7ZTCBJ
MV7GJ4&$D+.KOS9[M#U)Y1BZ]N_*R&\;^UM-]G>AR_D+Q&N,\3J!E&C^O6L9S
MXG#**E3 VA@C-U=='/V11+3PP4Q?QCH[DFK2_YE\(V9 ,+DJCP,0H_8-Z)@:
MER<Z5G3ZG.).L%%4\G#DM=H#"8#,*,MX>"\(E0VN6#<\]^.W=EYU(#HM [V/
M9\]%S4Q=MK]=O[S\\92:\^W8X-3'R=,$O?G']-W4&(!Z!UQ-.E^ZHN87L*+<
MF@S[< >R?6WS.K;7P 0#"]IAZ9C^Z&!A <5[@%;KS*2*D>RV$@027U_>--0>
M;/8(^9OWS:JGG6'WII-;!VK!B$4WX^[%-ON(\=[[V^QBWFUY!T3[;A0U06L9
M258+NEVLB[&'4P7M6V79$PY3R+N7S"+6W2=#=(>CZ,2+.86RU[//! L]B.7G
M0ZX99$970_HP_:P=08&^4UZ*'\>M_I@;+)3JC(0RGG5T)>K06'/P8A73?<UH
M<8F,\+TZ7?(&:S][+78/V-T?EM,"M";=U"#*HZH2>Y?W\#+]EJHY;V*DF-,T
M'V] V>SQQU2S42XD+_4B^A4CJ*65OK_V\^$J(.HK_'9%.FN#>CQMGL!%QD -
M5V+M-!<>"6"YHP?U=C# E]9UOT,:[R1RT-E-[)+R7LV7[N2<B  ]L%A*.[>A
M'\58[@01$J?%/\=/D6*O;<%K-^1""CX4/ER%XE:>JS=IN]W4WD\#'ROD=:'^
MJE2":+WK5U7#&H"/H'\<^5\+KTTUV']_O$F.E<84#Z9(&'H5[[SP@U#3&K4"
M;##W?PI_[6%=K!SW[*!D9@:E=U-9.8HQF>G:C$ND>KWD,M$A@*SN0+.'U@+#
M&\ 18'R$LD!6=*H#7D;8H[/QJ_IO!;0L@66-"A0;N")X)D!_,V2NOQZL6SUC
MG3L*H@"ACDAHB./J6V>7MN?MT2>BD781O&'^1GH386K 1&5Y0^<&>]I#.%"G
MKZO*5GG D7KK<!D946$5L:D9\\*L/=7>47@NJY,W,7#6KU0/03H=%@$:^EAE
M^\P [CJ#QSX8JY=\21JM('"QUB*O]_4-H75:SS> J;?#)7*TU$=@ZZAGULNM
M)5%OQ_5,OC]QN#]1M;2Z1(P2=M=KS#O5\=)[6HS;P@6O3O] QQXS]]-&D+EJ
M;3=&5+!CKMG+)2SJ\%_TUB_SDWYS2^ O>O]0G+JL9-AY_YM:8U):SHYKA@RB
M1'[G2,$G<0*AZ-@;H%P(ZK4P O\L=@JYUB'2VW>!S\]M\<ACQ!4MDW6\3:#3
MRO> Z.'[X .Q[$M8?G>,KS?SKV O[8/0T\^Z%9J3.E,%G0\&&Z]3GRU0B)7;
M"#;-'5.QBO4E>Y7S.3$FXCD!;3H$8"S!'O> )R;>BJ/=6E'KI(=.CO/-?+K+
MW[*V@X5YT=[6GO.180V]:?ZUB-8Y4@$G T;[SA0B PFZ?4*+^.U903,,TIOR
MG&GR2<,#W]X:</CM1(:M,_=WE^>$M2KM,E/W%,R3LW$I3Q*C"55Z3X!VDYQU
M?IV!M[*]SB.O[@%/O:/6<3W!.*%A:S&"._JQUPKV]H*S&^ZA'^N_VNX<5I_-
M!12]L/V6J*VM-M+D2=TE(6YLGYK-,4$0+L;GL$;]I\& 0D<9HA[)J'L5@6NY
M+>CZE$3\R2I:T!L:*J1W8>? "+]UYN8MCNMEY]_>5-\,MBG6?)'L%Y]13[J#
M3H%];ZSC2+GI<G8C3#(>[B-OE\G/!R;Y*Z<JP(Q5DUBL:W]E2@3> TD)L?VO
M_$[4233@@; 7*2%"],K2%98*YW)NS7-NL<O=:?\M?>;_&X9RHD"*H)S:0#=N
M!2^V>.F4&M::56'>$H(5GK?!C4-OYE&X[Y7^]GLT>4RAA#%6JZC%@9:_]9TD
MO/Y-0\:'J8M?G)536TV$BI_WL11OE5 XG*LLIRQ'/(7PUKX7\FT*Q7(!4 II
M/\O!6.']]PYH"#Q?@EY5OG6YP+PI!VJ'CN+BPFYY88SX)^B[KNS?>;<3/_\Y
M_II13%FM>@"3>'9J$EZ-$!$<HEQ>UJ;@B&EL'3JAM6]*($WZD"TCKC,L+*F_
MQI7GP*V=0D93$")/-UV5Q)$0 ZWT>%OPO46#N:/7#ZE_M;;@A^NG+19^DGE=
M^;K<?#&Z,:!5B_6Y\);?>EV&ZV+2.-1:<EZU%UAW$L,TXTX_7QSFE&5@<+H@
M\0PFBY5%).FZ)B>[N^+Q@^A.X+1_W3H,],J;7 $&#O' F&I05B'BX./&+<YG
MK-;RH"]GW224 >$J$$R*]_J9',;=:=A)UC7%6J7#BJ%PGPK%8L-)BR%(_NGC
MBZ?(U5>T<BL?D%ND0R_;QWGC>.Z49#[\OAR1[)GGC*TN6.XNV4O]7=@+6:H/
MB[7Y\ZBJ0C08NWP:ZW^K2J/S&*:NFOH^KGCTZ!;GQ'X4]$)IVYZ,,%;QW7!
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M%_TB1R)JHV/!;!!JW+@A^NDB1BE#GI\;+ L"VKI#/%B4]P!KB(1@YZA+?[4
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M60D0@I! 0T@ 80<RG,P $H]\!$R.'^![54A14$CC=YUK$2+NO9YVJS&;D-V
M;8\/P*R_1 O_M1G +M/J9U6RPJ6Y,3D1*(Q4D+("HLIV'.O'=MD+IV8Q;L&B
M.XY?7QQO% +4/IR[P6'S!1X#%.(UK%'7H:""J16_S)GP)#8/ZCCQ>P !>*8L
M\QCA.Q,SY><6%%?XP=]1_,<D88G456E"AS$TZPU%E<C& BE;=INS+^S]TZ"F
M#1KKE<ADE\F+LK*%.JDK =&-VJ+'(6/&67M6#49O9_RT10S"L_%]_0<U0449
M=++88I?;13H\K:V7VKB2Z.F86J>5:U-B0H6+/!Q'CD$1J%-JU7V"+?T?\AO%
M8C/<H1MD"?N"%L?S^\1]@6"7C&&3\0.[>&QOK(7"Y_W&T)G,)>R# X5^4GKU
M-G$^E$]EA'B G%.AQ0I!TI1Y8P9^> \86P3!]L;\^I*A*'K+>W6C_6V!+U@Q
MS6"+I1+@U]0%O"%<O[A[OW)+677;3!"T(X$>]T]5RP/H_T'N_],3^'GS SIV
M0)3YAIZCQ';^\;D$_<P/A:-+@&!UPO$%_]1$_ .'CAS$I;7L-.*!$L%=2@_,
M'4?GY]+#VQ.#4SFD* 3DJ"*8LL-RH"<9$>LG=[L_6$<[*(YU,%_O6+_3Z%WY
M8M^UN-!J"5QEH44L_*^&I/_ERA$5XAFH*L8MII^TR260;X71E;K0(C,6%1QL
MO<V);YP/S_WKOYVWT:PF_8[SAQF0DZ>/%GJ4K40-89]4+XQH01)6$Y?IH^L*
MR+H::0?E2JDQ>9(,-2=T5_JL:W[$J23W6<:^YT]CS!39H;S8T^(\<N0_/7_B
M<'S,E(!M<TP:^]N+)G/3<M7MQ$C41,MM)([7^*#^7,Y*@OW5N$=Y +^)KD&W
M'^Z58.)@_?<%Q.X!'^%3Z'"8,SJ+R\;3V+_)R85V5,<_P$656UN5/?$<GCID
M^Y,-#-R7L5HU5?@3I-)87)TUG6,IAKI11=!/)<V$-2S#ABHMZI6S)[>Q2-_M
M2ILCP20?_.^1?;L&3#8#B]T)6\0)XRW"%^@27V7$O^TP3<_< TY7IL<>S-:7
MT%FY>D)=NR@F7X<+>ZN)M[5/PRW.GS0G>]7G!ZI]VO0OP+PT&(N4O=.?<CP"
M:B6N2#LTNAG+!R[JQ]S-?S1<7S<:%&)W>#/\REM@^\!]*'_9-K6WJ#FK*PV6
M1I24B3ZUX:E+!U5CFSX;*EZ(<D7S^:GJ4AM*(XQ#GIUORAG;VU^HDY8\/PX]
M@&[KM\(N9GT+4LA2GCCA36^U+]7..W)Q"K*>F3[NT&,T&HH?2F%[(EX"K9_5
M<PRYCK!H:;1OX;*JF]QY]K:^IKLIA8>*QK\-/Q _N,XJ<.\VY,^7?HY!;-L4
M&;9.O+)(MU%OIKCWOCLBA];I\HXI9]0*8A ]O2IRT-:--V!S$V GN$3MYJ8_
M.C!I/^? OS"0'RP4D<_!G+CX _-PL/.Q]*\=RB/#C^ZS2;IZ>^<W2<R7B/ /
M5(2$+WQ3%JZ;#_W2M^W8W(6^-WS:1='9:K?V1U68=H0=D2EUZ.4O:I*^XPR6
MDXI'NYW]?=7!!YW SE"9XN*?>XN!.2J-C8/Y*+"8 CWPM<Z(!/5LP>ER16K$
ML]$,?9'GYF\2*,Q"Y>A7+VGQO!+@._)M;[5O_8CC+KW4G!!IHO> %88Z4:_%
M0S$/&&-/!U.M'Z=&CV]1GN6*[[)?$4_-!=LK@@UCG?4U9%[A@IUKE9/856.Z
MV8P:Z?]B[SVCFGK^_=^-J"@*B/0:E [2E-Z"(EVZ]!(4!.D"TDM I I$0(KT
M7J2)]"XU(+U++Z&'%FJ D-Q\?W>M_[KGG'7O.N<^.6?]U__!YT&R]V1FS\R>
M]^L]LV?'"*]6L^VL,K\WTU)&FR=/4J.2IKY5F"K9LPIASF!3#==0\]KFJLB>
M#@G]&:MGTG6TQ^RNP):X%A'@-A'GSWP5P<Y$'J) J4/[C_/3DAR5V^&Z@0/J
M=%6%X(5EG '-])!A)LDI:X5D#4:W8-CQY?26)X9"[_BP?]5XLZ#2 BKEK1#@
M+7_>(C0G<HFGKYNC%ZU,&(V;?DNSC2Y('/"*H\SVND)SDD[3ZQ(;=>URV# <
M>I*+ S0JH5LWJI&<'7Q-';-XWUJHW'9";CP14TNIK7#COWU+XO^0D#Z :^].
M!T,#J*[O5D1#EW.8F4Q@@!=9UP[8M\!>=UM'D#'<*6LQ*U-3E !=XU^((I:V
MHX[S>/\'JX0#*B"R 5,!#,[4 4,9_+^B[R?I;S5&UY(]MH<N?@(O<R%0A621
MG1OKU; D6<HE:(?*H:K]78:/*3*=G=@=L8'<T\>M;U$)V3]13[9CQ#* "J?K
M[^YZ39,BUR"/+7<UJOH()=131JR7R":(03AS%P>0-P=]N(M@U#\,0)K%7*9H
M7 \]GL\@51HK@\<DPV5\]3\Z$.Q $XSU=SK;Z*3UPS]=M@U(L)&-Y:M(G6_K
MZ<MYW2ZX[T6+V1EGRWC5ER$^K!%://!]"-@HK1!G+;N??;&-:=FRL#)5O.UZ
M]]+ ^9 &$=IT)8;1_(7*"&5KKNF80TJ^J*71J1I2O;RKRQ[;Q!CS.7+=^K,D
M(E\[96DZS26E0[L>U (A#7BT!:;"4.2BJSIIMHO?^Y3><W'\D/[!IX1LY=V_
M5NR?;YNQ!T@'=.* &GOL8(:$)"C<*15+51'.3S3;_]! N=F!JU%[5G19F2C+
M"0[^6=D;K_A+\0_JY_W20I;@D6#3Q5>;W[S]B? W4^__:LGL"@C4>JNN3J(]
MAH,5&44V3170H!EA8*X9]I)E>?Y5!)HL&0?P $>.4*4DX\.A[#?W%.N>O?"K
M$*IE598 ZAPNQ]!*\K)TA^4)^56\_8ZWV:VN"A39,YEGV&QF:VCV(SV/A.\[
MKZAMJ\%Z ENB!6_(H+-."BTKL1]=INN,;XIMJS15&'LV4*:Y9]W&?M19_;J:
M?(N=[Q%2CF#?165;U><D-U*.G38?!\APRWX# B@#JK4O1PA4N47'_BF5J4]
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M5*;8(4=OA'9V=U%9:2M%#;:3[*QB 6E'E.(M7?Q[" =\<_)COKUOWZ6_=%=
M&$:UC:7/$'<W&917H>?;R#[['+,XDPURN#]PYQ8'^)G8X2?=Q\VJD< YT43
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M)H6$Y63;D !HN] Q_C98ZG;O"#I+Y]I$MZ[#MR$$\M-TFR/32Y##5_K@OSB
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MCAH**K 3?'^>XK]W(CI-??2^]HU5]#POOSZ+XG/I3W=V2.W[D3_0^ 9CE^J
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M21QU=T8K87P/CPU-+V:AX4_>L7G.N>96C$Q].Z]4*[X*4J#4%?HO36E9+>U
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M<SZQ]9Z'!K78Y\]:)@>?5^J-W!V9Z#\I,D#J%/6(+VL1AJVK^A)K=B(U*.]
MM,?BZRHHJ[4()61//G_L+1S3(I2ZRO@68*';4BPD=S>ZI6BS3."Y$M3'0@R$
M4!"_#OCFB-R6(SG-AP=\BF+.33%U@8]]O0\/.+%$J@TS:F.V@+-"?E?N6Q+0
MOJQ;H'1V*5@9<QH>&P19OP:XJSKLR=:?E/S"IMM]6RJ0R+K/L'Z" Y!3[+U(
M+)1XOI4P0_)*GP\.KA#N>J?1<G5R4O2F)O%H0YPENC#%X$YLA<%;+RKK=Z<]
M_D@XV+8M$G)8$D SSY[>;VR/98FTM[?-!LLDA#,XE2>-SGWX!#[+>RN[KC76
M5+D,K5:*SKW.PCXQ0C]3F:+N7%GZ/+6Z<V6JF]SFGM Z<4W+!;*N W7!60^F
M;TZ/>TUW:9EMS]J..V;0GE20;C7]$AX4(=M'G,=&V+(YE;$VG)0>_,0!%EO<
M*TQ?;%R*O"4SPYM;7PIFD;RS(#O75DZ G\\07-7L@DDP8CC@SD%8(<IQ]XUS
M.4+(MG:WN9.<=BEFAI$,V^)PW6WIN<]':M*E_^#] WB^B5CRSSCV5*R/ROPU
M;[K64QFDI>&WEK60/H?L3>E]&21[0";"5-/M\?NP2LPM(^UJ4KL[$_NGJV4\
M"-J-KYWCC(S'^GQN+02]$D6?$("+_I,>0P^L'NN6+VP7![P[@U';]D5A+U3@
M!7<''0/Z/*PA@8WR"22M1X?!X^!F)FA']G4:PA#S_":ZHZ?BT<G%6P]L0M,5
M2S<.H$6LW$8\Y>N:D;[>5BF!3"_?@D32>]6-KSDXWF260Z(-!CVA*#1\L?4'
MNC[WBL/U]8GT1JM>_0:JZ>OU#ZMG.6.H]6RXPW2:U[&HZ.A\B<7LCM ?\$&-
M!53UI$P$ZI$%]8P\AD3*E<=[:2&>%6]G]%2'=84Q#2_<DV@=M[FY=#Q*A0.$
M4E*J,)(]FF3;43XUI4HX@)$J^U77?V5MG#L.6@+-+ARWP@'Z2_)RH 0<<*C+
MB ,ZX@\/APA0MB#(B0$2DB)&<DQ\+8 #/B59^)&/Q!""T&JA9#K@4:M>Y@7>
M8\45>X%J'% >_*^5<5YQK!?2<'H)A>_$84=E!2?2B/JB7G'.3VY3*2/=4K2O
M]0_AC\+D8WO<Y.;J/P6?% X8" 4K."702?/+?EO(BO^L\QR^D)LL$:7*ZVQW
MPD,V0:P> ?_3</"[<("QAX_JE[8!FJ8P*TLQZB]Q,P[XQ;5!:DD?.7.TBJR4
M@YOJ7 BAC@2NCR^T_W5RU9G7.3=Y]CD.H'>.!8$?[\,)@5'\$06J\I'N:K](
M%? "(TJ9+\<A.E-^3TG0C4Y8OZ$V_'B]"%&/_=;N# (W:6\OQEAL/-TJ4ZR-
MLO*VT#Y[S1)+'^63-CH@:\D?.49=Z7H'B!'TXH#]PO<)Z=^881]^QM[!G&IL
M_P,+8@%3]RU;V4&R\_<;I%;6H\:0=^&(->18_.[AD4?07OP_&4[H)\T\PAY@
M993^KDK?0I3O8C^Z$0FE*MCRI3W1I#/O5K\]Q-1 B .8D4I/\;\Q(CF57/D9
M#Z"@:+%=H4W ;2Y%XJO;XP#,\0O^W6N?2"=/4CJ7J#WX#H\Y):)@)_CI2R3,
MSV >>OA*%()6">#@E+^.?JNT\E'IM"),MPA.=88#,!0DE:MM$<KB>)O"_GUO
M]@ '5)AH_S/K]CT!$N(#QP&J2LBE#K=, ELHOHN-S#;N(+ 4T-Z(0M@+''!)
M5]Z1[^ ATQ')5<#R7UDT^=\]2IVIWEN:CRV*$.X)80XKL6>2_F2J,SF!TLR7
M ^:S?<Z/=_T0)).&!JGHB@X?2&3IOO">LZ9:;_K]EYL.D<V'#.-_UWP-VC!R
MAQ>UJ5<Z"U#/1S?<M4>;Q!"+S?U=/@&'_%INHY7(OZ/4J_NBL%!I_ZL[4N8J
MX,_2VO:4?'^V9]>;% UFK+_PPGY$+B>=<:.+K-NKQO8?#]U/]-FK)9/Y'(C7
MZ/VSI0'S,*\=-Z/1RN@SYLWZ,HD951TS39APYE^E[O.HRD'_W/=V,PLN/^QR
M#BL:.VT?#*^>[D-O0M^2A6:0H$1:EKKNS00\*JV/MFRHHC;VS_N^@LG:/;KQ
M >SU048"\?>-U,_G93>[(N6!WS'/MVPE1#F6W+8=B3HO#4).ZH47:#2JQZJW
M%!_75(:\C2#Z503H1WL;=."[.JU?&=GK5-Z.F7F)-=C%!GS"0^;2X,?$P_\G
M@]K8+X+&,>J%+8GY#G6"8BQB>K(_?.E1F@\#!NNT7QV_I\^1M'F\>/(F[.<'
M"8R"[SHEP1'GES>9*Z29MZ:C]Y\T2^7/F_*ET4<O_+FX;7TKX9Y;]=>RZ1A>
MW]_,8J/-;Y@PDK(M!?:Y:N]7OU?/A63V/KW16VZ0_4B%< RO<<N%JI SSW&7
M<>Q#*>DUPMCU0:0Y$0ZX>?S=X#6ZY7UD$<,5\Z9=H,3<TX=VC*5C?$8%_C%Y
M$_W#\GI3A<:_[KJTY\-E;&GJ6KA.LF[E1))-)=]57FBQ7=H4#J#-NGV6"TJG
MS0FD0"J);ZM5N^>>9-W,NR:R,^8&H*2V$EFGN>6^C"<%-Z T+4PA MMJ<G=C
M0M.:?2RGR\0*5;U V$; &)S.A2FZU+JI^Z:-9[C^*BQE]*M??;?-_(=T96&"
M"-]C?86Q,[A(A5>+/Y)_19/MC'&<XJFUH5&>F!BWK>U]9YG)B4P/6G*UOD>7
M7!QMLK)/,2IX4HE%R>NA1 ;$QTKO6T]K?EU_D<5K:0\[>_ZT#SO>XJ]R9>3W
M$G(+(_-%(;J];5K+S)PS/T[VT9>YH>^N2A\_GXD<KE<[NKG&]K[JX;2/F$OK
M_P#/OOR(0=K9[S&,1R<)S?H)'48M\DXC/ETJ?6?6K+.;?D)@T[=0?54)KJCQ
M-8") )9<5&]?F\7VM "$@6#B_,.KE[". $9>CG%/H>-]B#/'JP]MA\R9$:50
M:KO;UJXF@9JW?WTKE_<;VB0H$K)E2(L?-BYJL?,M/&8;$KH<9S4G*FQYVV48
MY#8,@6!KC.BV)ZXF5.81S GB(.Z];KF>P&=P*M=!L)?X<+Y^#U&A\V^]:QF5
M6!49>,L]EXSKPU=E,:GE"X@;2ZIMR2[CCGF%X/R/2[^BP#;7J:V@&\\YU4@#
M\I.G&5:D@O+\V-$1181UNXMT$_.".\^<D)C9EF?+3+ SR.\E8#:VKG]T!?R=
M4\3E]EN,I6/C$X3TWC "PHTZZ_A]SNE<YB^"&D/VCQ/#FN'1-<?2G.X]0AG*
M&]_JZ,;_7H\0%5)M@JET)>_#HO;3#6#EX#(?F<P%MI/V<L)5]H;&,4?'R^K9
M;T(5?OONH*D?DL(B#5<N6?"U+1]7J,>L".:;WF7,XJ/[Y#V2CT,P(2JOW_Z7
M;. ,>+)N+%W=N3'@&\'%&QQP2]#!CVQ$*A.MUHX#^FQYCU6=FWE/*K#$%DLH
MJQ.J':(O=?[043QFT&,FOS)UD6=,)LU"IU_D5T/+2\MZ9,0W4NMB%"5V>/0A
MYM61S1AXS FM87CY^G;P..709U2WQH+F]+9*-;/;7.1-^>T1'4?:+;*I_+EC
MMQ3-)\=#SP[DR"TW?M^,*8RD7#X3E[Y,B>^7"6/2T+!M5]:[4#*_QE834(]_
M53D(VE:?:TD=R;!SS+(@)7)1',6J \]LUY8=6=M$]LRIKF-D^=%SG9?Z=3EH
M<ZD%,9U:M7Y; YTZ?:^T=X;9#N5R6PI>?\HU[B).*NH/9!FV,ZEER?Q(1_DQ
M3GX4121D[I_R;#SR5 O0DW4Y!Z;<Q!HFGLP)+>+%G*[LOGE> I%MEF11V >C
MSB)F:K^/KT.'.#-6RIQ9TN.$Z:S_1M>'T'$"7PG$5YL5/&H]GE(CC[ZZP(VO
MW#HJO<3.9% TX>68YZA[73[[3?Q)(NEM84[5:LFR(WM_&I5W1W_V$GJ)$Z0V
M=+N"J_8FVNA:R9$!A*BI6$>Q3Q@1)WZ'9KLO)*67]Z_J/P_('4_6D==$S)))
M.W9^G-RMNU==?I7)9WOY\;*GV+Y@YN6Y3\A \4WJK]%C:JR">@K,>5_!].=?
MG/\*(-(GON8%$$?UL3X)@)SEU\I3!!9N+J]->Z.J5C6*#Y7@&7</11.6DT_(
M"+S>GHT;UOPR1,0ANUY%J3389^4GIP]^)@+J!B3?@JF]II<UHYOUBM&19^,(
MDOS]?(F&1%Y-'G&$Y="D&9R0%2 ,FDWY+*)YB:$32SK% :2PS&:&0TCWHC0Z
M02SPH[\D)^H5Q;R)^CN1^0]YS@2\7$^%YMJ9FZ<J.I=FZE;!W=PB[(?3H58M
ML%>-OKS%:_61M+GI&O3L'A9,85<2RU&G5'@P[0"%+%*CH:B#%8/(YD>^Y2HY
MZ#J-B77J )8[3F4+Y*Y&W^[O+XVL1=FPD9O61;7.MU5N_&JT:'Q(QK1XE[H_
M  6:!7UP3-N[RD3O@:UR*@3 @]!D-PG5?F<T"39L$$R!I41G+B]] 77*\HTG
MJ4U1+_)6W1B*)Z0L::!]^E""J7'BRR&T:_"PK)65@9;L<Y(VO5'CE:FY<^;V
MVF; _'D/[P@.L&X+Q3*@LU',ZD3PQ%;>] H6O9^9FM;A;.'+]1DJE"O2/]M=
M,"])3W=G-9*682380=G'H\WF[@6'^JF(U#FMV5?AT]UQ9C_C- @8&3,DVF\4
M".^7_X/D\J[GI6UE#+(O#@4^N4/#%X7&_(2R.ZFF*G^\LJB--$JDM ;J^.%V
M4813+?*=T$I8=R;U]F7(?L)*O\D7-1(-I$J&_L2R7)+HWB\K.B<YS@-2,N-3
MS6#'PQO@R$4JYUO@F+#(UFELH'L0S8S?8'17^J&!#&]/ !]$S?E*T:M<W,DF
M9@G[\%,/^_=)4NM7<01PV6K7'M'6.AP0R'R\X6N\5)$9A]&( ?U50HBL-Q^W
MKY3PAN?$J*3G3N[%4%%606G.7T\/!]__O]A[SZ FOWY=.(**HH@*2"=2! %1
MD-X2$&DBO2DM*@K2I?<$1 %IH4@OH2-=I/=.1'HH03J$'DKH 5(._[WG_?3.
M[/V^<YZ9?<[,\^'ZDLFL];O7_2O7=:]6]&=>T$7>;@,\':>3 82C/\\M^;KY
M/QVIZ12]SW?K^GU@1XO+7S+ ;^V2JG:>M2R_6,.]&NWZ6R.-M?(*8AZ4-4]%
MAGSB#0YV1",PN#S^C4&JHY(>Y< ,UZ-#PL/?"QFP>/5:)B0'XH4NQQR5XJC8
M)49613:Z,0QSP1.Y0S%B/:2Q46[I>X_TJ<K'2VFW<FD/)N+X"G2D+]@+!)4W
M)8IP_#Y;4+^-I@>TA9S/'(*R$9]A'8DV:QGJZ^#XQ\,#&<H =:8=F$7U\3R!
MC@Z,2R*H@E(8RDGQ8?AXK[=#BU,M$Q=BRU(=SNZG% [V[3S>1E8OD0&1#AI+
M4/B^E3N4 0LD\@/+6Z^1 <O*O]B%]VD)?N@/9I .X.D=!S V%W'!RU%Y[$Z?
MLL/X0_^G3XK_/PU12]=VLKP^*.S5"?R9O2:^;,$S#%%L\36^LOWA<M=:M/'P
M>=@QRR"ZZI7XMOQV/I.\GM;Z;&BNZ)J0OK:$*YO_Q(J6K!'[>+F1R:&FI6H"
M<_[H#KHOG99F\NS.)HTSVF/@<G]4HYI<A%OV@J4BOU&[G%55EIPS>L-@1^A%
M>IMGH= '@2SU(DI=CS]UW!O;%A6XW27)*;ET;N,X(M].NQOQ 7M\,^LI.E;E
M;SLP_>5DC()C""Y3=?30.-8+N!2^0;) E$G'SN]T^ZB\\ 77GD/2?;I<<D=*
M8AH:A/_\2OLLKYA)-:),'_#_/.VI((G:OIZ8M@5_NR3(1M*C/BTG73]QKUUR
MZCI_YF*%(W[!'_UU_0SC Z;[B_]3R!7F*TTJUAN. LD 9!+,Y%3TF*I^'PKR
MRKCU>;=#[[8L\+&=!ZGZ.XG'P--Z3D/_R>R0;:#JBV1:V['G?2]R$:1F<=C9
MX0Z8^K*4+D))64B8;EC/5V\$JW =_B<QC/\AX(C>N2;P* >= M#R%U65ESE0
M9?4O=,T0&0!(SL7M%?B2W+X#W#+UB/.VVIWT ;HIGJ#O(Q/IV)=7(*COY?27
M5$T P1\>^!C>*&\ +)4/1.8Z&SP.*<@#6)I_<ATVLN]SJ)\Z7GB]@>LZ,4Z\
M^8FS-E+C]T4L!1V)%\M$J:\+=H)MASB4%X'!-[)/DQKV[ON&HV20>:8_'[7,
M^<V901<M4K:"$T75\!C,4%<?_!OX]I/J0HQP[CXQ3^@&#-GDZV&B2 ;8+U*K
MD0[$=?%.V51-P3;&7@$7JAGZ3(9(!8YT3MC7+ME$F0TD)*B_'-0&-UFF^0/*
MS7"1OZ9*1#)/N<&I'/DU/\;TPB13?_V2OV477=/RRC[@J?IJG=,=,XHM23=Y
M;';*0HDTSRW1(2>?I>KB@/T[&81EM*C5U4?]GD S3%@"@UQ&3HW +=<AC/']
MB,-U?]FQ2+J> @\!0XO.H%&L.HO[[VV]HHR ?_:XO6"M6N!8K7+[+O0IB%AN
MDE-EF2^];=+P"-:J&'$0ID9KL$=Y46I(_4"&,F_6*L;:F^"-W H^;$,SIOU>
MR$L<;;##-61<GBD?28KVJ)P"GSG_GAC?I'M-6N;K7.H[ +OG;-9]Z'6(BL)G
MM%I%"'BS]#Z<NX9;UR@P@V%O]5Q6QYT9:T'W#HQ2M?<L-\%C_%"V]JG-Q7_<
MJF=%-F66\G9$LROU5UJD']@E-8P.5BQ!*%]ESJ S!'Y]>;B;G#.T86YPHX81
M4WNZFHNWSF.WQ*RU^SYRG%UJ_]0Y_E9;F Q8%W?&1P-_7C!2W>C_K]<:_P,]
M20%E(?I+IY +?W\,MVZG8<_E>!7>30;(_EP4=7C(+%\9=&J\FAL[?4"*IP(>
MCL$B8<^!MUMNIGN<[6SVH#7''^V:6]6CQ,/=4R@%#F.4*.J/N4L_/3E_.M7+
M&=/"AG_8R-X/^[7M#6K=W-.(-V\,T_S+ V_/X:$B6;Q!$MT@>_FGT6^ 54K1
ML+5L]*X4,7E[_!.(W4NTS NU#<;/2I$&))"[?C(X.P[D^>-1.,$%\<@WS@8&
MP2$7*M4=9QTYR8#6<))8ZO:YF1*65 'K:?5N74PN263"VRWTG]L8(0C*4M !
M";FUQ8(@=3DRX+? *!D0FI,@3P:4-UF<."%)E_!"#1RJ4UQKI!3^(:QZ ^TI
M/@1\-&)WDJW]-T<K1B%N$1X$Q.9.D0%[8D-X*WE!3T(L&7!UCPS02;6'K8NY
M(.M\9Q/GR0  @5F(ED!0@FMB26*.07)#]V#8[(M2!=V'=8ILL'KA7R\L1B'V
M^&L(I&W*XP\CYP1!'%3FPB2N:3+@VX5)W3;'$!B!$N?DQD8B ;6/+I[K:A!\
MOC,.>=9=/@?&6_FS^_@)X$)(U[=A1:/PK>G<!>M%IR]14I3G+&-PXM6H5R?L
M>7_]R0 <;7OK4\JXM<X@,D"3D6!7LF?=K>G4,W<'5QOL'GY^(QW8J5/%8N_<
M2:\5IG!9MKR?2,6'>$&L 5="XT[@'4/4=!&PWRQH[ND=U).MV1SN>T!J/][K
M.V*FVB3>]$08=O>&AN^3UHN1NS"<1@@3CJ"H#7)WL-/<DPRI$7.>QG_^<V/C
MOI[P35?P[NURPS>*5"U2)>:N&,EO<HHXK KN04_Q6Z=%=OXO,38>]X:G'^W3
MGMK(\K)8#VJ9I<5=V%$&^3NM^N4V@IKP.(>8?FL4#9XMI&IC%W*&?YUC7HLC
M ^X*@DE<&?!B4LM;&P\(^C?A_6BKC3:'308K;N)+!G=EW2_<^*%)5*30=B[=
MS*0&\X/GKC_G*]/H>0H!%%),FZS'2_@.E(3?AW>>P#.J:4LTJO7UD?;G#,81
M(<W!+-Q0QW%TXK7W#A1CGY$%S\NLC7[BU1?_4MBVL..T$/Q?RSS4%]<UO.W&
M>R;A;,#?(X,YQZ5$GV_/-#<8B'[PW@EB(8AK"#,@V&/,(5A;CW:K6PG^/6#C
M.('C"3H)4(JL=]SR7O Q@@7"/L+9"9*)!K!;^ I[R[&=E+.=V:7@5^_3>V>Y
M<N Q4<[[F !YP:,_$\ O,E]*V<N^+A37,QC^Z5R<? 7H-]3R*W%I"SP4+R0#
MJ,F Q1,!N1N+]Y#_K&'UN7@ID2@];<,GV%W6B(9N&(1[__/Y\3"^V=^.AP93
MEW5+^$-M98TZ54/-4]JZU3H@WH3$Y11"AZ<Y*O:6$[DH?,=I"?NJ="_1S%2P
M])-3[HE6F]1%VB"6&2TH.UZM39J6&&2'7/R568G77TA_MLFJ 0F9HZNKB^/D
MTJ1 \U'R,6NUL3B93Y-:WGQO>' Q)%WEU[QZR( V"WX403EK4]C$CL6^Q;]J
MD#O>\*?JP[]&3#RN6$UTTVO?)0@#Q.LBMG1J$U\U-9Z[C68C69)KK_Y6W ^,
MEMJ U N=RZP_$H;2>[V'GP-,8'MBL$Z9=5./"PU3B)OK7Z;=8KWPS_R1G8O0
M3C(Q3SS:!]]IX?)3GV@1]$JN)@/H-A-JIXH5V2M2'BX%OK1)SWGWAK)WM3Y]
M^ ZIY='AJO*%(B?../T=?28'ZRC _:4D94JT$C1O7'0:EJ7:@:"YA*94N&AF
MZ6.5[]>"_PRSCB<S?JT;=ZSK[S[!HW9"2% NX/'X10[R;%W,.'P[N@@)H1KM
M/$80-(&XH08E2_ -/UDD4>.?'QZ_.KGUVN,_PCW$S8RVZB+CPA@)-F#7H;/G
MX).]?]J 7;0!S5FT#H'A,JHN^N6'+2+<HA"XXB9PU/S>_7],>;@"_[22^!])
M3+F!(WN)^R@&UA,Y?%(7"C];;\5 &H.._5$,GT",7OZJ9C04Z(O4ET\&=,IM
M4!9T"M' =BCMR( NW8__F$* +0"_M-;SD4!OD?^1>JS88,BN_S3%@_78<V1>
MEL2TKL?F<%IU T+B"CR7_5A$#?\Z10UWN(K^SY3:F6#>"L13+8+650FU(<"C
MBY$(]G(FM0#/S_ZQ1?U<;H,Z2[63_8KQ>8Y"-9(4J$D&!'N.#(K@6A69F*C.
MKZ*YR0#VO#X.3%4C%'PQNO%>*C#8!;&O*2:)'\,(='Q.A$=/0N\*[AKBMAZ:
M@)-=G&X'O/ITBXJR5?SLVGQE?H3B4 ?Q,ADP0X%&$#P:(-<)C'4H\[<H@HAE
MUM2WRZ4TI;D2GRIO?>VR? 2FG"L34I[Y]DQ/W;O@1#:C&.=&!G3341SRRQ6I
M%@S:U90@;GX47&SF$!3A2^==37A=$;DO\@C)'JQ-.<I0JE<CZ?N57O>EXO_T
M=;/_!^(J;;C?$\;0K18S56]&$378(=V6'5(\G5>=1<U*6^#XKF%\'=_T!D0!
M+;LT=%UYZ9K?9$TWC.F49VM^J[::$R&G<?U;V,\>69:BX[Q7#'+6J$8:.]6X
M_EAI3N&Y[LZN^6Z2OUU:[-,OA4QKE^]H+0E.#P1<PAK'K;87"=W;37+6ZY3H
M#!H0?G16N".8B2N// )>5[MW]=PPV&7"19)REA:'<(P?HC)B(OKS>V#D-T+/
M*#M!4J@F?0XAJ_T=A=-MJ]/WD,ZZ$X9AX[YI[:2R&SSA?QK8A,\XQO]^!-\3
M3V>T-PYKJ/Y).IT6@)\T 'O"+VT?&HLL[H:>,8;6J#),5C<XG;HW$&<0P5[@
MP-+SOG,'$%!B<TGP8VNKZ%=@<B'SNS",4\MCO%YWLDI1HE:ST3B+_FD@?**^
MCPR8$NR<2+XS:1N'.#NY1KMJ<VD%@M-;(0,B+)J<=NQDO"^80AO,!-]WS%XG
M,5]UE&N=APX1OZ9=?V]/B@P8MEMOG2[&&,*[: -.H, 0Y?'M#(QN5;QCPJ!&
MTHAEM&SB?I#]@N5JFW1Y"MC2=$".- JZ75<U7OK81,.N493E1?8SDX%$1Y0G
MQ8O#;DOYT4/"G^#=LW5H:.%EYP&M^A_<LHD\QX6)A)29Y[^=M2GS5!#Q:LT/
M;R].)3;?SRFO%KX;9N:#8GG#+JOGXZQ!_'CFEDNAJRP$X*2'W?/50T'= $EK
M1P/TS?6Y@P\OR>-S< 66\_1S7O2 9I8T_N)YQ)_TN0!&A(G%F*MBYC6KW92<
MI\O %>/W^DC;8JZ=I0!1:#MOEJN3-?.-!WU;,SX"1U:@MO=K4ZU28-O=,%V"
MPEXS<3O'6KLUWO*G;LS*AD=>3@WP>$+[J3XV!N)$\-FS;V'$.Q6J6CL?FT.Z
M]& =X()^UB3#X>:5ML,[IL4'DS_+^VDL#2$,7BF;I+DG H,JK[;?;K,WO>$1
M "_<!W9-C$WL2^:7U$=JWYB,YWH&<IAQ[=$V.=QFORR0$[^-JB-R#)L6/9[9
MPCP"FV"W3.T%G(?>IG3W]LXFR[^&Z=9U.02911XDY[W3%IJJKA;L_!,4&-8>
MWU<_**)[7XG; E8F^(QA*H<RS_ S2'4#:W(G,I,,."M2"1$X LTOZQ\O1Y#H
M;S63 4/5:HRHW'< WX.I&C\PD^2-C&0L45"(,69'!&N: 50Z#J!RK+HTZV?=
MY\>*@WYO=G=BM,%M7V@:J95H,D $HH:]Z\V[J*HLRXC#G!D/D %W*GYXQ2UH
M1:@\3QF?R-ZDQ?7$/+\.Q'%;["X)J;KGS7Q9J!2]-U2F:3(;>*#:W3=4A8VC
M;1X$-:&!.2K,O6METJ40=G/_\E?)!X@D'"Q==\1R^KH41ES^A7AJN"<HZ+#L
M@DJ8C/24GK_R$XW,.>"NJ!T_HB/UOC)Z $[[W$3R*TW%M%)1EHOOSO\<#*MM
MK8+F^>G$HP@/-TO_6OBVDP&_.FPGEIOAPSX/LW_T_RL_>P3O[\]K56;L['AM
M.[Q127B]^ND;RZ78?F0 @)D'W0]]],_T/G0(>J<^=@["*I$GP ;KJM2N2S>=
M?<4[P;$0LVL1?FYN26(.60IX&P\"-E[V616%!(/8:R%WO:R[[V[J(MW<[,1]
M)6+HW+S]''C@R9]\C/3BM'XWW]5$Y)T <;J[U_Q\\-_L%IRN;S!^RTJ5WEV9
M$'\@W+_?15^D3"OG\M=*&A,XUS2]5!LE-CW$<N=XZ[NIKY%Y^2^I(+&D3U<W
M*,5>:G7^EEH77$!08NGPJGJ0VQNZIE.VQ_>3>.[<TTX-OMGX4Y'-6',1<O>B
MOM]N\F0UMZN]QVBL]Z',04&(0Y%)V9$B0)O]EYU =+P&SXN4L#CK=;X M[X!
MT6X9Z^.\Z)^,'!]FX[]YZ#MRZM//<YK]ZN6WIHF]JLHN./%H5T^=R8DJP[N\
M'\(,L_,"+HD=I\#"CZ:GX\,>R'P=F+[^VYX]AXJZ_O"0H=?<[]W>LF=EC]R'
MDNA8X=,==:G+4<V;A7-W7K1-V1,+8IDQN(*T-\[WV@]^13?[K-:E,RXAOC31
M8=*I(;?Q!:HCEC'+.FC/B@)"I2.M'%2*X;07-\5Z035,>.*\0KHY^%J^@;9N
ME/R)V2/]ED**+[.T[<L9>UOQ)F@81O]0AT 5P%W:O%7?\WQ?.7]::2DXY%P$
M,G\$@8;?3#2)ETQBIYZO?#&><N\8NA'/(WPS-^+S->X*ADH(/QG0_E0H=OY8
M;?B%2L5U<7;EX\PV,@!> $2UE)1>TUJ\*''"_]-3ZO^7@I*V:XZA=H^AKG??
M<1BZ\X$-;KDIB/137CP/%ZRDZ;=07CIT6OSN$V1!-!!/OSMJ425QXNQD4=09
MK+1):ZL$LDFY&Z%X65@NZNC>[-S?37^[EKV0P+)#CT>G&>AL\Q\;ZVPPDR7K
M6CL/SD2F-7EX,\!8[\\D%C^VUS=XG7!%-;*3:C]WTB<LZUXPDQNA2"&[*.?P
MM[A,LS"[4&B=&;TQ\,^O(X<[3W)I7!\=R-Q\F&+TB2J3*L^.)P_Z]L('G-X;
M"5!>^NP\D9%P9[ ,SL;C5PILD+Q:IC('8?:T2'T/F"@M+3%.-HYYQ]U(':PA
M'AGZVQ[&:)MA(!N?F?)PFDN4JMBT0E^[&D=*Y NM(KZMF@5I:DV]P6W2?KC>
M$+'_]-?VG!2/^ZY^B8"L):[PK7FL2F<E!5CFW:;[=:36N,P_%8&!#6$VUA?Q
M)B7V&V-8C(_/*./!KI[^[>R$&/]"_XT /;VE,(#3HF*>/&TIT 2@;?)P*6HL
MX&%V%'_ =UC&=W=;E6.L&F6!KFHS!ZG*58'ZBA#PA;PF0$I/#\6!, &$*;4S
M%WD^6>E:OEFKS'XP:;AFME0_Q.K501O20H^6,W1F1'"$6)T47I6N0WRM_>+;
M-,!"$KMY04>6\:'O)W8/4U_WUJ*X08S5DS.LA11FMG'P$^/>VJ%&ZE/]3@D*
MNZ1>O6(.UA4BU5%I:P3+=_2<N /OYMIVW,>B80NSXO?:,.[D\CR.^O2_JE7O
M2M9E?$VF(LD +.LJ="9C/F"I*G4Y,G)EITS?:E"XCFE0=J*C+HR-%BF>2GM3
MP/<;R S&:%$=^,WH[%V_C\^XLOE\HH]?Z<'[H[ROZI9H7"&SU9QHU*SMEMT\
M\X^WD.^68+/Q4/0E50N\6( 9Y6?P399D8P\II-@X).F@1^"#>5]4SG3I%2XU
M#*>6]&%I.@W5E*YKU1I%Y9N(0TH^ JFZ.#^&O>/-)=+NZ6J 3''?4"UT&$&K
M4SB=LT[SZ:\%Y8#L3ZDS%<$Q@GGQM:IDZ9ENYXSQI1;V)D8$"T$5>DG0TMKA
M36Y,3]\G;9+<:L,NBYWJN>@[X1YYF_6 ?2$7)8DL;@Y%.:@[3 -N?S\&G=*;
M=)HH+1<L;^?1(5_Q<$=6C\*TQ/N:+"-D#0*YR%7@P]L-B5T.[CDK<TC-*.V/
MF%@5RFG1L%-J=YH'O^Y";>).T>N26YJ+QR@0E2GD=Z9&"61F/J'GNA[)!(:I
M@ ^6WCV6WP][6'3_7UE@]\JG.6N@?6!Z6J)"&=5J77GG/%4%BD"+N>IQZG3W
M(;(OVMA;ZG@#4@NLF0D&_I5="J(,(D;>)_R!8R$A)LK]KGZ@/5.M?D?4YKB0
MN19%UF,SX1UMMN.2#WO@9Z0_1_PV>Q>Z->Q<:C;"6 -W5^1)5R2_&L;#+G$T
M";G8>-P^:/ ^8WR"-+1INB2!P :3#$L\5<5:[ETH/)9:6,?"^#+?(Y:;UH@7
M>XU#"(-&N3?]:V0 A_@6D#D)UC$Y 5A4:@,K6LA_FJX6#!H[+86?KT\X3TY
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MW/-&\6=@M$& L.*NN1UF(XK&*.B&LY^_T'N"CU[C.MB:9LMM_E(I=^V$^+S
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M[YARZ#D9 OQ6E@6J1N(?:T[%HS)PE*?"9<VV*EH%3(7WLLQB]!S%KL45'.:
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M'?44Z4L"NT$9/$<SZN4.?XCYLB:7^JV&Z>TWOMC2^7'Z#9LQB5S1;)D0:W[
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MN^O9':N67-_N1W)'WI,:OF*@&Y#I!O"@/_OWZ6G_$I2)(N."&RJ#RL8?PSC
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M SBV)S*FN=P23</S_6A&Y< \GG0?]WGF?230CKHB\"7JK9P#ALHB/_F6O=H
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MZK1 /I#L">4:^ON_V/O*H"BC/]Q%4 0$1$":14)*0+I942F)19$NI;N[%D1
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MSCU(E_1UIPLD&H6M#/RICI^TVZ7<O7AGO@A!_)E?++%S9]X0WB/+F2Z] M:
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MQ^([K&RW@$\I(?"6QR?\ YZ.S^[Y[!E9_YF_'.L"&67;7?&GF$)+[& 1%[<
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MB!B:>\V5>4G-V[]0(;E,=3%'^Z\UYMGGBZ4A F6L/JJJOTIJ/R29+AU0E-7
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M!U=%(!$>*Y>W&8#$3(A",>"J@_(O8K;---\ GF0WJRX_/ZCNIYCN.LKQ\5\
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M_M,WDNRB2F-+]_.]?ITE'\QTC-YURRGEFP].O5?@ #5*RWXEF@BWSK&O0#'
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MC^.E&LX+SD3P3,U3[4ENI]I;@,S^SQG&P3YB[6K5=;N!KE_L)OPL34X5T8K
M"$61>8W^SE_.4[]<7(7X",;\ &N>"RF;67P-YM>W@ C#N$Z. Y,#A[$)'NT:
MVT_TMJA*,N<W.QX1IQX!QZ]>,70"&V1F!N)R3=&_=";/R>6H(96FKPH7[S(H
M6!US$+,NCH30?K7E #UR/B/H7IQHAUZ:TZ-Q:Z5Z\U5%D<:ESI?5;XE6;1+8
MFRP"*IS6:Y8V)A*X]^EZ7"GG[&=D3.MS#>J2_*[>Q@:5%\^]%JA4&3\DWYMI
MSO(U=$7K7[6T%<3D4#MXF@5>D_19HNBK.HUUD=#0B[EG UR1*[,]Z1"I9VL$
MO+> CJSF6X!-D_E7,F96MHGS^S^4&J".+*V>@[];5UF3BPXGK6QVG^-2?M^H
MO,<M"<]''IP)GW'A[D 'FEK+.\\A#QV>[<O-&-_/H.?(K &&5C6^;Y,QC[!(
MCDI]\A7&0KI9KO8;BED3\.#02CR2D_T9^]4E YXA+_DF $^6I*<(\R_^M:M
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MBH.;F,/&>F@$('B/T^4K8[PA%*"G$A4D6^)HU)!3L.<CLB\S\%/&:-[@A:A
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M1L[ XJ+I?=N0?V#:H5*V_R/.P19]C.#!ZJ*KR6.A]N>[]JW'5)U7*!N#I25
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MY95HG$)GP#3A&.2R6&:I/"9^D'W\<;&VMIBV]BV)5OWSI33 MV')P,$ UP<
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MT3,@8;,Q\8^OG8\$IDM^HO>\G5DP?(%I8 ;_M5-1*",G[\J"9)K\F/_C3?\
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M:B;/@V0D*!T^9+FYNB*8G J]OUON:2L1<17H3OHL'!\+2;SY%N37K/A:9*3
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M",&HH4HOUT?+9;E^(MOG""RJS?4S/UVBUZ@KWSW2O2QJ8#V[1+#GV'06?:]
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MR79CYPMAE_O>/^L<X?C&GY<Q-NP&X..IFGM&Z*KL^FSZ21I4(;@I\B5J*%W
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M?0['S8;KJFK.D=?/0\6^!&+W$@F/5EC!PSA0A>.5)U)1SY8 Z-IX1U8V\YB
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ML4<K%PBGD7QGKBQ<R-"OVG8-@M=[F7FG.,1 )"I/7&>^M_5T-5Z;^/#^/W:
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MG]]\X(5[TM1B.R\93Z.+-$<,/RR%4RY-ATP'\IT5]CU;*U(V\#R.JZGCY,E
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M1LZ)K#J8D*MO:4N"56=<O#;ZO,*'U"0T-DV4_ N$>OP,%_UMF026BM_47'0
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MWX7L]86"LSS3DLL&U)5(C;?Z/_,F0NV 0JKH1>4RR$?ZN$&TKX;9CK7 U?M
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MEK$4B)B=]0FJ":0@\;9(*JFX_FCL79:G_;#:5_I#Z 6T\$1TJ"8Q_ZZN#/7
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M-)T!5^S]KUAX9HZ/Z!W$4(IA\9>A)(T\J3FA2[POUO*%DN.J]@1G0/Z8 <^
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M7G2C2SZ]:@MVKC(U=XAA((X1QG5@RZ(:)(0GA<MEK@C>QOFO?*__/+@?4EG
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M3S_F8SN>C2-RLSK[UYHTO 6&(C8'-JAQSA<=>, ?:'*/+A-U1NXS6= K=-Q
M\>T/&H-^'0%L/D $FU=$$.G:I0@-2?XGW1(>Z4)L?XSKY*<X4>[.'X,%]Q6C
M&XIZK<G\GI^;KD^"Z[GU27*5[JF1KPWBJ"8;&+3O6;8.BOQ-&"<ZVOY@$Y>2
MS-<ELI:;[-[%)+A,D)=-K<0H,NV2=^B9XX,%]>8YE5?%HKW#PJ[T&,E!*11L
MGKE^)D,*)(O2U==0G>?<"CX;'VC$/_V(2]<F8F7-%*5#ON%*QD1$E+GEAFOK
MUOF8B\K/V!L#4Y+/SRJB%")G^=;$B1\^8YVK]@D7D&-4]J/T^R*5:7<(+/^0
MUC1.@V[ 4M]65 @9E;H]P%KX5EO'6E1A(A*'6[PU?.^K$(@]X66]K)YJ*ZEM
M_5-+ZIT^W9W^>DB-D"UA1SW%7%Z.WA%[@Z']RKWGW2I!;$UI(D?WIG%!FS"^
M87_ZK(+@I#>USR2DNKNJ\>J3"YHH;'Q&+QTUF&_Z)5!LT.#PPFP=6E01AS;O
M"; 3!77Z/8$R"JNU4;>'G'E\!S"F/(O8<CI&*C4]W0&_+GOEBKJU +TR#]@W
M?-R*-=M!6Z^L%'1_HB/BJ"S0_'SQ3D(;#_A^NWP$'C^\?.\C@KQF1 !/A]8G
M7J\.RTL=5B=#L)_U-FK3>@)OOFK/7:;I1P]L*"^/9("M+DI]QU%VT7OSMPR]
M;2RJ^0!:[6]X@$A1\_$-'K!",3.^#>H,^7[]84YG(DC(&9&[(#$18IEQ Q_,
MU$,7M.]S8)Z !Q10>,"C=WZ>Y=YF8A?F(<JS=;<5;>R_NRF8EOH"GME^I*=8
M$_'),^-MD?X, ?_SO B9PQON$@$K,62A0[M=FOV0-00SU<;QZ[9&AETA/.3Q
MS&*H0- ^#PT2(<OE.'J^C#EVH6R/< 5S.*>;W[TF9X0*.<T?TT[>*$%!Z\$!
MZ]D"C>=4&<'R@,IO+B#7RB?<]G9'H^&\)N%*L8BO?J=6EU.+E?N3(INT;03C
MQ"-$"24#^7C LK*\3/+9'F_I8)[9='E<KK++EH"#R.G5SY!1ZM7S]OK[X0N+
M6,G6&/+"9=W(WF ^J_(,LWF&CFG.PI 'E^&SBC=_P6XOK\D__ZVTNWA\!LDV
M@_SSU\FJ^D;6NH<,_D@QYL72T>>WI3*T N&IP,<&Q?3L)D(B2QY87D.5F_=8
MCH2H_LIE@WIZHRQ.&R0]8\S?6Q_:G\7S9U@8TC40-?.GI9X%,!GFAH&OOD<O
M7'XJ>"?M*C73T3<BT&^8VB9TQ/RCTR4H<'6V>KOH^5'($G)7:YAY=<\1#V"]
M^>Y0/8X'3,H=W$$MU3RK'W<#.)EX*342 >@.5]VZ(DH'5VZNDK^I#PE.28G=
MOEJD;V@X@/DD@?A.RYG$P1J98;JV1W4_8D^,E"E:7'3W@B2#RKO)9U ,2D+]
M33PSL/L2(1)[4L_?]/]+V$0*Q^Z?1Y/G B[K +\9QWG_:(4C9YLSWD?VU]##
MY.C2AL[1GT3B6$ZFA'S+]7UJK[HY05C;Q.8S*\D^LV* 7O2N6<U%J-!9<-OS
MQBE@TL:V+ZRKTM;E1P.3T7E'%0 /L+Z4L82>>CK1KA)2V,0 T?*5UJY%X)*J
MTUU'W9\K],EQYY[+Y:1%0M^= HVB0XEX]$CC()>ENK=E00Y% 7#;#/"?-2G$
MK(M<@D18JJ?76:48AJ@'_NCR*_64%+C44>J OLE;+>^2*FQW6MKIO9I;WZ3%
MM$'P\AA(UF>4V2$;>'<G?2HI?Q_MTC-'SQ]W\!&\;1I0#ATWO3?.,*CJB0<8
MI-5 7)+N28/);Q109B1*:Z3VULM4RH*=-KAG2,+Q3)R/)JI[;/C"OX,A0(H1
M#XC5^V5B;8A0D\0#S*:+SZ;*;TP-PZT*_%41<^XVD[RXK;-YNK.+"J#N;4F+
M3Q#LIXD#Y/E'!:R*<Z?-W1@^!U(@'F 2M#YW-G[_SA%QGT4_4:M6XK$#?Y."
M1;:>V/WR-Z2Y?I]]54ZP!Q#T5QRO4]-N_RUB[;7:54JX5?HVM@7B8DP.34'&
M41F]T7J0'U;/8GVVFS2BN-9(KL)8S7<NQ/EES@M6^Z,&2D5>6@L+#Z$>&1BD
MV3#[QD,!>#*^K6V+H5[/3WJIA13?4H",S/F>,GF=>"D3:;XY78/9+<!\952V
MUQ/J^X9(K3,OBNHIVP-)MZ,T):S7-2LD4$L)K^L;LFXRO<:CW 8OF9.Q*#KF
M+O9/#6@$2HY5Q\\NMT"GHW][?W=;#0F=H @ZP1;= 44S HO6DMS:7H%-Q=EC
M%\%HY/UXHCN!C_?E#[+X5?O_D5;XE:<DJC*D " )2F$_\'^>MWABG4V\%ML)
M.6"ZW8Z!W#KXW=_MZ UY]L$MF1)BE0B!^A@R7+K:/IKG;\F"W17I&%J_=E%7
M?<;$W)K7Y7:4<#@;-)@Q+)>7$"%C[)C#>;KR3\J(*@V/HV/Y*_=6?GVASF^
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M>TZ0*VN)V%6<\J3& PQG=F/0S),%"S;!D00)S9@1$$7%JP7(]W:;#-^[Y7@
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MG.>C:C2!WR?>MWHK'9#=4'M3 &E=0KOP5&VLN>IQVDIKMYK6+YY#XEORE;F
MKY_UUEG7PS3W/BU]T&^&$?F-&%.91"ME[U!SAM^Z!_H]3''J]1<W/OIEH^&4
M&-\#_Z?@T%+CR",9!\\@/88S.$]CTE2=CVAT[&YC-S5H;$\?VBXUUE7&=*B
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M&GY"3H\+",I%7_3-O<^T?MQV-[Y@]U6?I'\BVA% K I\(SA;*TT17!V=9__
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MH>I4<V/.6ZPL<,1?3^=)=VC^OE@=-Y2V]0HEQY])5))\?-%^(5#W<)6@H6,
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MB'%1V#C7,_;2=F1HW$E&4#]5UUA*\' B24R$]NCRPACN4XG:IQ+YSJL*%3V
M31SA- _!13Y,J=S7Y@1!YC3GZ$\KFM3%7[>=6- >S?PJ8WAC:P<%X1[MB>2I
MIJ+'2-V08_4MU8--M^:_U?D5UC7X754(^VM%4;+W%_G2RJ*R;<_MK_4:%8]^
M_'YG.D";$#MOC*VN,1(W&BJIM]0[+:T+B<,I/18"QX)"X</JB&=8WX+@XKG;
MAV^/5/FX6Q,OJQUUNK&)_*SD*_SV$JNC0!^DP9=PP5A@=:2CAW*!'NP@&6?S
M].C?A1X@[$5-&VN[9-:;WG.O8;(Z1%3+4'_] G$+[\6OO20W735=!0K4/6D
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M1K=KK"6T[#D,">=^VUUV+RA\:U@:$Z#<L@G!F;:GW4W$P'M?Q1EO%_!IQQ!
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M@U>I##GC_2BN:)<!+O PYK94.$&>Y3IY-'R8F99"3K35I !ZZ16-!0;K 8<
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MP?>3S"-JD,:2_R&4?L[K1Q?Q(L<4>KMJXSSTFX@N<_(HDM:+*'6WP6,#U96
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MN^ G\1:NKA_9^<Y>)^4,K-<P,"V4@UDP!=\A<XI(G,T"$\T(Y5S8<=KP<;E
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M*PF4&9$'SNZ&U1Z-G\(*@:*3;OP!>3^<@#_O[9>DH8M6&Q7-Y"NS,TOO-<<
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M(:]&0&J^^?91G76^C=5,ZS7K"MPVWL?>8VJT8A/4#P&JNIR+Q'QO-(Y#N):
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M2(4?X8U<)@C;T*W/YU7@:V68'"5_AV#4.3_*=A%'JQC0&UH)E1Z#GH<AT[=
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M[JQ&L4\KG/SI]55Y[OYOX&'^B_\%P'K@F,?(.+Y:/*SCP7Q^0;;)N*>9C*W
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MC"H@;>Z3^H9EQE_CE=IAH6Q,4.!0L3OCWE*K.D0?:O@IN!)K'L3X^W"" 6K
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MWS4I',T6'=K.Q!(!/Q_355R 1;12="DL8*U<Z: @&[#%38T(O6U;8.3L$!'
MJ&Y.!,!:Z8B M-NVSVI7-/F+PM%8-S'O=UD(K$P@R!:#H<_M#-=9:;S]:/*?
M-T:R.&H#I-W<FR*?C#7T:9FD7 90_SYWR,==)+N]U-YU> 8Y>3JO&7UR^W*B
MO7)(+A1Y8F34VWM.*^!6TF@OP,S5G5M/IZO&P,\:Z%VUL%1RMGG*@X]Y.%V
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M2@'$T,FO^(YS?6O'*IQ=0JM"N1:SE#UT<#+")OX[VY$9/97Z\@BHF#Y*?C5
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MDSJ?$3!'44Y7)2I7W;86;\T&WXLWZ93DHK[C6+4QB"VO!='/B7WS/C)_%)S
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M$3S#RSG'N)9Q\[BT*(C6&Y;^H)*9"D%JC^,$EJ4<@O.->HE;B'DVRD7+NFN
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MC80:"#J<JHX6'TL$K:2&9Y=%>)^K:=+/G5P!+U#>6<?B41F  '4?,?4%A'S
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MT1A72;=L]EG_H=_']=R'_<#FJW*55^-DGW9P>$I9@XR/7/XU/;\J9-.A4]<
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M?" !9'V@J^#E3 ([K 2=KJ</BIK#44;5(<GXDLQQ8,+#VR.A+ F?V?\2:U;
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M;_D2Y;"6+["$I.N]9/+PI@!:9C2*,E9G8VQGIJ"4\X/YIV)>Q;W)$YBVY#\
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M9D!-O^+@JO$%OWQ3-L6._(D+E'[#.E27H$[/25)[>!Y3+)AC])V\QBE N$Q
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M9%@KZKNKLH-6ZP>MSZK5]X V;[HJ9UM;+:IIGSP ]6U5';I.-\AB HTY[_X
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MQGL88U@ JXLO4(FOE/U+5N\'*OQ 373?2;N8"8E26*.6VP8Y>W+T%_37X!Y
M2)CO#1ZM4^BDY85/-]BYQ3KK*09!ZQYV$Y,S"JFJVC,+?N2,[VV#A=\ZQ!ND
MXN9\*Y##]G4$4P^:8G?(RD >!L>I.BHSGOM)X<@1XV#'\EBN#]L!;# ?WI&[
M8IC#M%=:V3#D03O[ !*,U;&>^.(I^\?#NNR]SI'U?,+&U"_*<*+A9#<<X>H4
M[P+D.$GFP>V\2-SH8N)&*X*R 70$UOGD)N#<.5@'12]KZ\!T'*H]\4+QT@R1
M8Y%Z[&RY@ C N<+!%+SJ$,-DD),B65.;ZP5L:BFK+0 34IA==^S,*!L!\\77
M4XRW=?A6'O- !T)9DI-@,VGOSR ._;'7KY#[53Q5MXR/6@D_I,#VDE)Z=<=B
M1D!1Y4/P3'AB(+CRK^E7\"=@HV7427KQI #RWA6[BIEQV=E&9=A8Q"'AA]^Q
MEO9/4!.*[L+Z?@\W=P]"*.*OCJX4X6B'J+E?T]N+9N:%&G=,DT]D6QW U(XU
M]4L79[,0<),;FS@[7VR*%(Z7A@6'5?V,45>O.OZCZC]?J&OLR.>ZUHK>_L+@
M':H\/1PL"//*2:NM+#5Y\DE'Z=(W>7'M8>V4OV'6O:2A)C>'2\^L_U8(L8W_
MU7&MG4AN*5FMBWR*K"_Y$H0',QMOV@W=DTYDS(+-U-T>HO9+?'J,5.*GZ1/-
M4SR;<0+3_9:!,AFR G<HV"KAAAK]CIO=["$TC-P4BK<II:0E4#8R>C2[;_*5
M&1%]TE (.8 OY1T.07"@(KBZ@>U._@YP13CA[%0 /PU3%A!A/.AA.% 0=.D=
M4--.\?FL>B HDBG6+OL3862:0)*-E^[B]G-\S#<^Q[*%N1HR=-.Q.6KR437*
M%'-7JPNW3CSCSX0M4Y'@I/"+9[\A/,P.5[(FO 10)T13YO*V9":%MOBJOW*M
MI1E-7V2+.'8Y[HG28R,B6Z*'&CS9?@B:2 TU1LU?QQE8?!.?!2]C+L8&P P%
MJ.N8'JN"-_L>?ONA_ZXV!$[>BNOG_Y?OK/QW4#/[[LKFLZW*U3:B[N?(PJ;A
M%X96TT\KEGE5!([F@$&+%B/531ZP)\W#E8+7GLT\VMW1GN;FT_]RK"&;ABX^
MOF+>\%4@FE>@TM7-:Y_/S:WKY$KCOC_1$/8]-3QR(+K8N BSF\S[[N6JN<NQ
MV^7:/^R\\-$S&U_^"#M::4SMG' Z=<IXC.9RM2-^$U?$4$=>(.5,PP3-$ILV
MW^10\QAG;8</#W[Y>[.&<L*\=;:3_Y4VMV];[NYR%Z)?3(-N+L[(6;7;[5!.
M DJEM<ZO];?\, <GJ53-U$+4!%U.!&(4*\Z\JY]Z>TL/5PPLR2BVEU:9.P5$
M>IT"K@A>F1V7AR6])*-##ZF$#-F/WU2BMGPCIQ[(BOH05=XGL)[X' 6]:ZPS
MJSKS[$8L6N<48%^/$-,ZXN*FD48;L\]Y3 1I!TJI@9@FRNH<2T F;6_88YYL
MV<[-I/I"Q6KK\L!Z! +_DUMT0CY<CXM9+6>LA II<=MNFV-?XY98I6\E5T(^
MI^Q\/TS.\E/NRE!X<'V^3XS]8#DNBO\/7W](+KFQ'-F4/[XR8;FJ7(A"G$</
M[4Y_16D'Q3]2OD*X*0"KK49\MGZ_]N"X8"1XS][&Q['[()KC]1;2I:F.H?^>
MJ@]O#)L&[ G9<$#I<]@YXK@IYB>2FC7(Y+!$Z9>>>:3PJ/.M=P-66JRY)\#Q
M;[1L&+XUNB^!=A#O6MBY1</KC]<SKEQ5[UB7>B;]<#2?2>'2;!\'_S]%&O.&
M8,H%P5"^((&3&@"KUX\WJ%L5,DBVL_?^(M6B:VY#HO\ARSD>6Y /9BA#DH/5
MAVRD=&GXC,#.OCF,C%?=4;]0CZ)+Z=H.QRCO&))XFH)B7K$H.(4?%R\WD'64
MNB1Y\&I)")5A)%3OV+YH<(B!PV=C)NK0-%ZS_W8AHT(EU!#?1]D?;N#;+_3O
MH6"*9!EXOG#WDD=+?RU N$702=_T"$[D+O/$"'EV)HIZ=]\])<!)"[D*ER5@
M>F#Q@3LQPC(RUDL&J92O=[5S#*DRG*[;?2Z@E,>(F9D9 S.5CO4Y+@E[J]DQ
M1VJQ>MF+$RYK]7<:&VO1G"(=F-RICEBD\M,8!"2H&U9"2N93OB5#@)).+N8<
MX?"$JJE9?(M</&S0MZCVW/J%=BK=)8*U082Y5BD''# 0M$LJ5Y1LQPO8Q!XW
M.[79_6X2X=.Q>74?AP0J^Y;6_L(Y ZZAM9S$S\V=)+M.UX:_U0$B+DDJ?^3V
MPSI/9ETV"H*//<_]5<YMGGS&.V! /'K8+GC.J[X;G@"B^Q+(WSP.HGOJNW^?
M!)9?YGOLL=W*L2ZR.""U'V2I\E8^BS[G#7011'F_J$N#]N(!<!;'=O#;!M%X
M(PZ$:UA7*Q&*9Z:6*6W^.?CHA%0>I8T+2/J=-[8 TL59_GKI#NB\4B%(<0AL
M\"ZE_3D<S@>C.I@X>>25Z.*2_-6(T/OF3^-#X?X4,TD6A)$*H2>W!;ARFX9E
M"BY"*YMQ*ROTX4T)/EB./<[+BRUJR2*%2H72+U>4#\TJQV1_J,(."-D::Y0!
M*?4/IFT2D&8"EM9;_%0E%>CJW$[D:PS%Z /2!%R]>H_)'\<*@\QWT-DJ)DQC
MBPY%KMYA.N5R".RTEB0O>V4EQ\;WS$.Z"TR=W0ZFL[U72-LK"JD.>Z02BE+O
M=:<6M MF6/)BR ;,\-_J.(ZF(%J^5&S#G ^U-,.O!E:HT//G/4V;;(G RD>,
M%=Q2?K\P3-O(=EBM"R#6&FH&\=:6@%L__OI8_5-Y3.%+Y:\VB5RR+=PS1B@R
M^&/-T6.@&F1$PW$P%Y&[KO$ NV.*E"?)10.;V+B-_HX8<U?0JL<];ZPIV[7#
M<>@+)\G9OJP*S#\;/Z[N\5V4WG2QSK:*YOB=> PD9P81R;8349%"0E]XAJO*
MZMY5R+2?^ HVF%<>S"<]=#5, VI)W/V&/(XUYXJIYR7$Y!5!DD;,JZ'&=D$[
M&^I7V<?*'X+PKEH'C3?]#_HE.1E6Q>S/D]"$CGB;T$&36Y8XC2=UW#@;Y3J[
M0>-30$D8H]0I8*P0XWHQQ*?;_0BFSO 2#QW-HV#T_<F&[@A#@$(I8C54V45I
MV25DG5G?S0=P\YP@NSO]WN3:0&BOW"UC&6[N8[&15HS0+TZ+3XA&$\.?C_AF
MB 76R/'>29'CK>=JF7.3F>'IS$GUO'4VRP^"084N*X5@DB[F.]!E'.UV?(\H
M>PI@GWJ>N-AMI)RQ<C^8+?'2F)F8OR+%9J/D_=/7]XJ!T'ZG_N!M;VO,:-J!
M[7YZB-PP=3;E7IWDPC53.]<A>:]'$CEE8VEU^P3W:7+*)^2/#2_K;3VUFFMJ
M07O%=?";"F\2<.O'SF]. 7<^2YO;O*B_WZ&#)7*$);69&K@H^Y=FZ$37& :&
M57W]])I,4OS#=6Q,K2!I[2LW/)-S&TW8>SNYZ) +J68@27TSO(44"BR G(%B
MWX"2?94E.H%N5BQ[+!FO14Z"@H? ]-]TMU'9<F;C0>(?L MG_?K/-JE#=&&U
MJ!W;$ZU]Q\_D^U_[KA >,A]7-RPX_8$__0&JT\(ZQ%N),04:?GYD)NF5=[6'
M[6Q(Y-AW3-USM)KTOJL[K]YG21'ZG\EC%V896W[F O("_@H.2!EM5H D=+=)
M&##9"6=#KNM^5>2%<"XKRZRU=X/TO\G"^6-(@!#NB@^9=,[ZM9@%JA+[3V6F
MF4:/V>5?["&B' BYW(KI:\;_"WO$:)9#8WW#'C>.ON2< G!:-E@N4RT.P/\O
M#H:#T%/ 6;%]\"G@/*8[3KQ;_G>@G]J]ZBL#[2\0%5-G01_>Y^Z-NRU<]TQO
MK3FZ<N0:S(\BBK0#(3^[V56>#^F.4$<L^U0'W]I(G1S>,"YE.8;M/$XL"\LN
M8V*E=7!S[Y7EQ^[Z73EHG]9SQ:TE^-VQ .W39$)-NT.J*7([$N4$[QEG8I&F
M6<*=L=BD4&<#Q#:48I<_^]"8/_U.(_ZJKM!(TI5M&9A=V:]RU4CU;J_/Q>^T
M4$V\3K,U4('+G$(MPYV<TU5?9'H7GKK_@C.@'& GG0)?V2-#G3%_*N=YT3)?
MS 7>R[WTR%])S#FR#*^)O9=Q0S!^1N:USXM\WACGO)U'W7/?)=DY"0%OYJI1
M./1SF8.GAD=:(;].I.@IQP$G-[?<&6V?]:FE5MCF7I^(5:<OBJS7]TQS+UR;
MNFQ\([=W8>;1#_IJ!+[&.4;FV+HK6$LB][$@<KPR@(X*=7O@-(<LDS54?U(6
MP+]B+$TQ''A="\9E0XQU^,;R&"+&XUFV?(0-GPDDO'[/>:Q8,"0886@],BEC
M,&[!!&L ,A8O8%Z:97YTTF(9^-CXU-AGUPU_V#@M4#/#OW4]=;Z?!6<WN#$_
M(NNVL/.@\O91A<I;Y5*F#O,>N7PUC,V!R"[[_K6M0YR9V[[/V<W9SOXGI*::
M+5O52UY>+/V>@'./47R\D:S*2ZV-A.JC\ALFG[H/S]75:^[9UJ]JK .[;+<?
MEKUH63$BTRF]IX",V=[E#)" J[$[TH6!^4O!P(R,&2RZ(9\4FV56!S5XTZUT
M>/.%.,P DNV"\(*;P9%)#)8?HHS8KC2.J!3O4LLOF/\R.T\L, ./V*HTF3&F
M@J*'4'SQL/[[I34[,2X;-&J^)-<M%FUP]SF$8@$$BM9=8(GW_]72^C;\8CTX
M/&)JKS 6"4VDY3:N4\@XRBE@-%]$L5^285(P7%LZX)B]G'F'E*'M\4<DX\4E
M9%Z,L<FE,Z< VG('L8V6 Z"O*_%AE4A?"DBC8<R\)'32#Y%I.[\-W:#AS%HM
MJ6*&LH!#WY)O_7]L[V!D,XWM0VHP,ICG/]A:[M5?D/TU11)ID>:J\PXL*EE_
M!4VT^ENGRJB&IH;IYBH.G%=#U]R+=^Y=9K;)-E_L9J#F>Z:'M(B]TSC9(^)M
M/K1N5 HL6*R&6,VQJX=F6T'0;?J *(A"J*JEG]UKN'^I-&)&"E]CA=H0*&>\
MA5H_L@R4AHVI'8^DL_=AX$6"'H>^^=+"I%QFWF'K*[/,H*&HC5DD;.R?C9E"
M1+ #+K%<BQ_R%/';LK&=PQSHV6R P=?@J9 :UVF\.F(EYK*MDM)NZ?5U-BBR
M!?M^N@KUTI*<H(<KA(]I.,FH]D:UL\"0:5W>?ML"R1H]W>)!QFF! 4*  )!^
M-;,#6&J[W8C#AZL[M+=4YDJLE$>+GL-B3$]5VN*-/$ZBR+_R2;-LG_P6=3=M
M@:_Y&I5:RE@P<QPF+PB0AF9T-5ZLY^ %)USRL.MM"ONL%AC2 /IK/7;>@K\=
MS28JQ6WF:,N,#B(X^+<B5GZ< @)":LYD^:I2Y3(9.) 77@#[0?[V,\D"&L/%
M>'T%OOKN"VLQX9\.=TDM2K;,@N6/RP(YZ+B(#=V+8C@^1;JK)9XYI]_22O5R
MJ/Z7YCFDCLTY@_H>V>/=XI$V?139X(+@G-]QR6M/>XQ^Y/FU+GV,%!<UYT*$
M+]'3-3$DBR5.!S(M2C&XP+&S9L07OVAZZ%]4"FX!@&(/AY#HI$%8OXI@I:<K
MP)LX1C8B D4S&U2WC)@GC^\Q]-'R/%L19+6DD]:3ZC#F:5*,@ADOLAH3S0%8
M;[EW$E*=+D+14^\BUMSN].^Z#=%8$7VZG@'X-+$2Q,W4<5MSS7;WD%91RIZ(
MX!=2O1]Q,*:$@\>- 0-QP3#UC=_9AEVQHZXV?UI'W .[X2S]:!ZWO\-]F?5=
MYE]'*GR.WT\EJUX.&D4Y/'.--< L;Q^6,RZNOGR^O&TK]7U1MZ=L*38V=LX7
MU^)[]4(Y ;SW^PAFD1]UL5#%J+M?_ )73(M4._5.5IEQS?.,KM^M#FE!EA[U
M<_'E3%>@E,2,@&-LLT\_:(=)%I"W^)]C7AOZ;_UGRG^.9HN49HA/9MB_Q \K
MA*(,7GTSM\;D%'[SL ^4NU)/0H;B]0&!+P_-%?BA>&JN]S[>B!:"TT5O??\1
MV7)D(KS6H*W8NR*I<K/-*:\_H%V'YUKL'-M,#8'<RE'[3?3N:F9FJ79;@3OB
MJ[BE8UVL=DO]&MGH^QZZ^V'FW"J[-'GWH?13N0;/73ZIMM]_^^ UIAGDA3?W
M27),AAO])H2GSPW%X\ST @8Z!N>QJK@FI]'2E.D-P^F-B<3'Y;=)-;)UY5I+
M(1RC[FQMR;>OIG8I^(4F:PKE>O]2/\P8_!VL4K(?'CU^/S]%]110 ?T*.EH^
M!>@#BI;,3=$N[Z""AJ)S.E=3P/LLU.P;<_.L>J4S_Z!F<M+QZ1:DB%JQIS?H
M0V<3>/A]2-QQW3009$X8XH_^Y-QVD59NZYZJ(5MO[*"PE/"?#P;&/\:"/@=+
M_Y;U>R;T;G9*XKBZ\2!,K6_PJ:T6 [2D]&:D":<.@"%,E&"JJ_&?P9$.[">3
MAP,H;+#%9G\DLLC%O\S:91C1^/U"<F%M7+:^; S[3YZE;H3X$&@NIZT:DGND
M<(+?@Z/#[W3-ET/(L@BQ-]Q'JL@RO)I*DM8KT(1X5NS87WIJ3 U"XD?H9H+M
MRACXN8M-H)Q.6J_J5ZD^F:JC/T"-_ANRIG$M)'JHPUCH;UOMLRCF16:EBF&]
MA#@TAD2K3%*[?C+\:3_]4]_3X=M!-,W6(.$_@Z\_12,1I7]D\;$3' %7$;F*
M1-<HT$#USHUO_E\)AS>T$LZ9HU7F&YV7^#45ER,UO0%]DBQ*ZWH .,H!*#"A
MT*FL%N%;4EZ^..57<N9C\GO88(HJ@X/HL2^]*/C)5@7G\'/4X\VO3Y:Z"L9U
M?PJ_\/[Z1&3&CT]'O05K\W-U@L.RH42_;\/S=VAVZD+(V@36UCG\>?ZMLPA%
MLME8U^RFP2E@ F6^/[UY"K#<]/PH87,*Z)JYNIWD>DW>L:TJ^'T!;)J U09N
MYF\;(O),8%\^Q]R[_-^ Q_[+]92XM]:VR=?*<ORF.8C'0:1335#:5=E<;%YQ
M043A^JPEN$%GSV&B[87;KS9G3#C<>.WB)LYDLS9_UK%1L7ZXAM.N)7DHXJOI
MBM+M:-]78C8-#P2BNPXAMV"]Y9?."0ICZ[>_5.S0EO,.1C?B0W@H#NS'CL7[
MX"YYL^69VU^"#6\B_@=[[QG49+AVC09!4"E1 >E$ :5)[U("(D5Z1ZDJTJ7W
M4 (BH+0(B-)[;Y'>>PD=I4N'T$,)$""$$#[WF3DS[\S99][SS7=F]O[.V3_6
MO^?7_=SWM=:ZR[4&OE[]R>%XF_NV_^U$]KK1!S:^)P/3@@J<4E;Q^[N!*&$-
M<PA4>"<-+7VGVWMNJ07G54Z^PVA/'Y*9>J-H25B1N+DJA^MQ>A) <BOE%C=M
M<TO#QS&MD(I3Z9WXZ=$_1'Q/QP4-=&35[UFV7@.JV[M\Y4CQU.B(CX_85,8_
MW.?]HH*O;?C0,G:8S ";H+VXN@:0#%Y]@\L8KOEKQ[#R_/0/)-->D!%R=$^2
M\+A7"U<%=^2R@?74J4+!15-YNF6ZW0'66-Y5("SC9BOZ1XQHT:GFDW5K[<64
M)?E;K]\%%:$R;IV3/?P*90+; 6<YUR+V+M?ZZB9J^/01&??C+;$_'%/X<K6Y
M-- _A)ZHJ3ZS/:C7@81<)BOI[ 4)!E!> S[:!KS$[I>9.K *U39A;5=5%9[X
M;T><)8ZZ'2-(@Q0(DTEGI.TO"3<(/=!;UP!;P_"M;@N&R!,+A1-'7!\_/.EH
ML)E"92+G)MPWY^OC-V66-+[JVD=.7^I;85MF%_KPY6A<Z!6O0Z3UAX#Y-1?R
M759@VUW+)]@DPNX.V<!#0L1<-6VH[<ROF8EG%0GVY;,#MOXW%DS[!74C=F6!
MK;[&L7*@)=]GBC+6%37A+M\_6.=@@/N$*8!'>FMQ830K9NI=8)\<NM"V34CU
MN<=I04(O-[(08O^/!UA)E"YJQ:YAC1:WQ)R:SXI2-W&_2!TS1<0L?8855EL#
M2Z8FGPBKTI^5I'Z*^,OR7ZEN;#'[Y(VY8>]HKASU^6^&<:1%6E''%J8(*OM>
M<9ORW)+J.-U7Y*?C\-S14!0DVBHZ5 ::>/]:U)2 :>!L@JDBXK!ZS.\SI[\%
MM!9WNN:]#V*Y!N F >F0T]R,A?%@2.P2)@9U;O]9^Y>A7]X=6:#)ZX([;;GU
M8JENKJ^KN.BUQ<^*$D4PN*!O7(\K<8;]V<0?11"RQ;=>.1%T_,!#<^4(T$.J
MV\A9/0XK)XW2$[>04;\=@V"8\Q0]&6OZ-8#1J@C?\(^#RKT@,RO4ODZ]= 0:
M>8HI8+O-M(F:J"\NXJ#?8O(KGC\X&7L'[BH=&)+0L VG"?ZHM259<B+ &3)=
M)KX,=3-\#Q8(&+]!^LXX;G^@I,K611M2R>5,Y6;(,2>H]"CN)8)A,WM4-N:9
M\ARB7-FTWL'JQE)F&%'U/]YVBK#T0-5NRZPE ?LQ:P6Q6AY]VK3&/A;V@]@M
MEA,-Y=J6!>HTHY&T><NWDF97\F/UD,W<)%[6"TSIF0\)G%]8%:QF1S6OU6)@
M^(X^[0T045RNU'CA:NJV,T8!'2MW$T21,ZY:1J-?[LQE>(UY.?=6IDW_4+ J
MR?!VF@^]B5O)+"I+_5+/^[:J3'(,]..XK'V_U^8BW/\*RO@A)664=&MT*4W7
MDZ1Z4+Z;GZ<R(2&:.AI3\-*5*=Z7</IBG'B28)CTI?Y=S+*XE-25PXTKF(85
M6UH5U2?_>Y'!3^&R*@P(T6N 15^6T5,R^GUM8XQ4GG!7'$J?UZJ-U!]3,K@8
MZ&"W'.PV]C.+7*$)-QF)@*E5Q&KK)T0F:[/'<H<\.]$7L,J0=:@".52#G)=J
MB$0#+R=P;I$Q@:[V0X>(58W;QO3,:^FG.'W)0KA%#:!!5DE:]DIZPH?*M]"M
M%W#C&W6*($3ODF 0'+2*R.='8F@Z^]S4,Z#E@JS+@@BVN,K.?4S>GFH^A4@_
M<D&//A#*(U<#O;N2(F&[%'SWO.!TE'LQYDYA;&88@%/6%Z5>7Z_F;=^^50[@
M1"/ALCNQ#0/Z-6>%S)%:Z>!TP#,^-3N#]0UH_C/UA@JIM^'L127C5C!(Z=/7
MHU3 VD<_OJ.+^@.[L\;,##0]X[VN 7*GWX<'??MIJ<T@6SN1;QSN1P<9L89'
M'V5,_6#^J 6+'*]#G^7Z-J^0/^SS#F?H??"XE@5Q$;I,<^!/;,#__5(+RF_-
MU;WMT-B>>/ES_T1'EE+Y71IUZ%R.8US-RCI!WO#6W$O F!EN.J8\^</!GD<O
MX$71":MP("G/:4;LA+CIN@5ARGMTEC<TVK:XU]ZT!$YR#*2A+J;,B*-XJUYQ
M3!4H8D[C0>[[YY&2/,1IK5I/O@&A]E5#BSN&PR3^G2G'%DI']-,I[D27@5)D
M^%!^0)UZ!J5Y(DZ0W67G#)A@?1/Y>I;K,$'U-GX,8G,TL&]<XT*!8F7KG-A[
M[PO#M[P\5L$*H;#&_CEXAC#O@3*+V@'F)+ZV%WAM?9R.M(_,J.PY]5-!I<?#
MPZ[L7]0EUGGAOX,>.)H4&S=SY\M#VT\&H2OL(=B4TU:!%S]_/SHN<V*KU<;9
M-'#N0E):Y>W<(:!N/J"2=6(Y8=$=O%$[,W8AH&!N4F1X)PL@"=#[K?I_B>"3
M(_I;ROMGY\P#R-%F(^Y6DUE'C$QV0IEB&O>_W,9T(+8LX]9>//Q"VC<&N?I;
MFSYV8'^? K]8 -!Y]S=$6X61^M]E\,U;7Y6S+O<_$[PN)B1^/ R(J1:0]B>P
MYN061?AZCQXC>XQRU9H=^126W^OUS;(_C,1<U,! STOH+-0C=%0.'P*BJ9+9
M6F)']MLF<][RA#FS+@:_/1 Q:0HO0H>),[;B/[O?61"BD&V0F>*-:,6/!"3@
M1P]<;F,S>U)8JXL=<*F!$=H\)]V;M]:\]YX?I2#Y3MG=?&C3RP3</#AODW"W
MPE:DC9XO:KMWF"V\%'V_7K'F8=X*ZREMI[)SM[=@K*P?G]MQD^TM,ZTHH-\>
M!R4!W_8*)/F/:3GBMG\L0E&5IYGX^P4X3=!9;M-$5%)A&_IJ;D$IPW3H^P,&
M'//,'FT0:5#W-8"Y1OO/^5FX"R.V9G'$GBK&W_E1K2Y'O-;E'96!C@&R>%=)
MN >V\!IP4Q!;>L1FGXO>&($'>WIS#H5JDKOYU<O0I?>)$-;*)?>+R[B+>>NM
MKR"9/VF,5Z@JCQS[VMC2QDJP,STIGQ"E(R4C\5!2^O(Q,L)O*#6>W(TY!=BC
M?6_VIM3=(<B,8)TT_<9"X7%N,@U2VYKS'-H)]BV"CT _9J(-KDS5,RC!:VT1
MK+EO5/776$CYJA"$R;H_G:Q'&> F1PQO!T$&?=[33O':-ZIKKK>B.<>"?UO@
MZ?I2S"[05<5+DKVA0#'*Y"!FEROGX[_\Q/1?#* @=N=2"LMY]NG76N6144;?
M\2RHTF'::<-\CGKF?49$4UHQ!AX1\+?4D30>797O170MB?PZ305=V#2U")N,
MDETJ$7/+X8UW8FC*>$$)O'\_J\<N0E9-7Z$-XS/*SB6$G<X[HE+.!4*N 6@U
M2PJLK6'-=!L7-JPET,^Y2Q5CZBLWDE]*_-7\I8"X+'W(+F7@CM(#A?=*3BZT
MZ2U&9T<<=U]\E%R+>5["17\'L *0-JC1U7C[7\, =$<H? 1;]'(&J&/*HH5O
M8=CR<H)EC!'7 /+\WSZ[C**:<AER]GPJ K<.C*<"FR)/UK\*AS,7[T3B*EJ:
MUX!=F;4U<P6?0OBUQ\225JU/N;>7%BF)99)A2%4M:%]J0^DSX1IW=J?W;\.5
M#V[MV?'MNLE_<AG/=4XF?#M#I<04W>">%'=D6S5AD(69S+IH"1E4K%(43F+R
M;@)6VPYOI">DE/R):0>9!+B[4H%-%)]Z(R/UEK?$6*]FR2XF0L/[(!-W6ZN7
M"^Q59=97<'H/%@<8LFQW4M[PDVFX;6OR1'M<Z#;;L=>*K9./*<XEA7T@@@V6
M+)B%+8ZHB*TLH.)I?$YQ1@'5#$R9XU_)13<5(]_Q;Z+42ANF^K.0DF,>+P%Q
MSWT?KAP_\S!:C28A9D;B(S_8UX-'"S4\ 8!6(0/BC^@\SVU[>E@S:CKZX)0I
M8F@NN=EY[R1#"K_SV>U-*4+#0T>$=N="+WQ?PZ8?G"[(;GW>]\S0>_30:G^Z
M3,0Z0L8J@Z<FVI@Y+C8Y3_@!2&B++-\P52XX2,P:,4P&=X"S?9=+\QAY1,LQ
M>FOGP"$MV@\DD;T)KQ+W&-,2YDGLCP6W[#:>@O.)N0<:H/XX_5L?W,GJ6SU3
M!(+QBFOAQ&J_3LDW.*_>?,Z#FN^'6(1F$P8)_)-UK5>CF;DJBZ^'CX/4$2AY
M5K%Z;ZF"NJD!OM.!WD#-7$(_CH;>R?CUI!CU9)[T&\M"0.9T<PQH12 88QXN
M0#5OIMK*T<PG D7V_!)978][+&TU'%&5]12J-EF-[FLL%C25I39H&&,?JOZZ
MA8&WEWFRB*CK/*U!F<H_\[O+ WUDO-T "W5JH_9=V_J&_EY"1,"_E<1K.ICB
M@=@0<:'5+Q.<F<*^,R<7I?N[7 Q'T>#JL1ZIGUJP.]!V?WI"K3W8)A/T[,2^
ML,\_U!=X3'OVF,8,"(.N)LOXMK)-_%T@ M> <MV!2TF\ NQ@]O40PG&*4'LF
M1D-T9#[3<?A9'.K??<@%.CET8X*:C#9BW9"\M'+0L%,E8NQW2M0U(':S;>,O
M"]YHJ&RK<L&4\@[IIP7AR+0W>;@V*7K"S<[AO\ABWNM59'\[I1#FI=9#"T1X
MA;&=O/C9<.[H-;85/7[OB-G/6G+,\@1K,+CRWM^FK63RK]MIO[E[,X7W=LVY
M[#ZG-2BNOT+1X.J'#JF30,]][GV6=2+$9@/!@&B5IWL&EJ_. %J?@98&$!T%
M)33T.KD4OVCOM>?ZZ[ "ZBC=4F*C G.&-G:-)$P\<&8]!D&^O0 E!M38EA$=
M;+14N?1COSNXA<<:/R+XE'MK>2Z?_*/0S(6A5\!Q4*)PO9X_VC[D[2LOXDR-
M$SUN##CF>=G+<YQ!Y$BLWWD>"9X@>GJ9DVV\Q7*ULW)^7D"2.9A^WGPRGMR4
MGCX)6.FNG_Z!*=BZ!L#5)TB#0?61<N<6]G*M]KY_;8,\*)_YO1[.37T\^*X_
M!C=N6UE(H/$XS;(2AOA@1%?:O^3)>HQ_LTH!@"W+)61PC-ZK* T;%$K^]D11
M0;7/E:;XRSKX=+&Y@XY)GX4],DSE<9XK(,M>HM(Z]9<!A3+$S>P@^PC4U622
MN\OZ>'S/</Z=6.]@E@V& 86%3.?'P@M1BD'I4*<B_F?S&O##7R U;YO81-4*
M>Z7\;0U40\),NYB%*CJ7/7-#O]J+^8H[^J_$;25]8MYC[:XPPF%\[HU7$<G:
M.2_I[0K3W4FS11G,R[K% ]5N['^P\X,+A_L\U99)B:='$-?JA-2A(898;07-
MZ-_U83Y6XS5O=6CNC-5O RW[:OBN'%Z8QVJ;_"S'GABR(]&E=Q2M9(L8K$W!
M$A#])[*[S:J5QSU<YVMUHMIW'.4X'I4]!0V CY=6_-P(),=0(@WOQO3V-ON'
M)_ G=^=5'@^OKZC<^6&UWPN)_8(VF9.M<J2#>5^MAG*#UB"9X\U7(LJ5O]_>
MG9U3<J1'WBMBP&5@0A7[/2T_X4:+Z]1G-'F(\7R7 ]HKDJ O</E?!(9M$]:9
M!\L?&BPOG#Q],CL\08E>GCIT>VQ%A@ *HE]W3+CR'N;\TQO7'^*?ZE8WWHD4
M?H4!^&0!N^%8+E T++K=T>7S_5+G"(WOE&P/J>2/WYDC"9<V\"2!UZX>OP,=
M<[#-R+,CB1YM>L>PEH%:38<S="7&+Q641;M5SM>[Q5$'9+=;F7ZS5_]D^?Y
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M"\M[]Q^^9\%R5OC_JJRJ.VC]N[I,LJ+3O,%^;21X;W3]/N4*DR4-UF2[Y6E
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MC"]3)<&@5!T0O+G;)FTM=W?F-#?&)5X&5#-#SR?>&'ODXFFFG-&X=(SX[6N
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M=05*-;N=HM10][,Z6H7Q7*X,T4P=KUV<57^P[=!]W[0G[D44LUVVX=TW7,P
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M>NG"5<;RF\&6-+=9?R-V\5\-DF>]+_E.I*N-9(,,9;K"5.3S0HWW:WD=I^:
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M8(.EH&)"[5-Y^@-DIIK4!WWIZ),QFJN+#DS>PS%TYF ]1E-E5-&>EYH-MIB
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M\=/B<^2;[EAW2F_T:'-N!CB9GM0RFU:58?O[I3/?N(Y<N^XT?&=7XL"9YAH
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M[A%B6AE?BC%IY[@&K!2U<1 6K@K*17\:)KQ 8P3C%F3&92*N 2RW]?F"L=<
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MM<.J(XZ>CV,BG]5MR(7'_Z*S6JB["/W(M  QJ)P77OU\7N9RQU'Q]<3#5,D
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M4I'MQ5S DDE8,B%"$ON@XT<T],!X=V#W'FPJQ9(ETZOA.D?5>/R _7<P@J/
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M5VM')!8\(#QPO-!V5<#]P1FUVTZ(3R]1;NS'CN=0XD5.C$=4!X1YOL!C:**
M<[#5DK6#X/=M%P_-7W)6)%&)%\B AVB/N I,61EA8UA)> A4 QO%8VJP9S)\
M+?IQ>BDS=2(OFFHTM"T;0W3]RED_X/@5<.Q?^JC.OF&LP@2S<#FS":R<3ZCG
MQ\2AW'>EG[C.<%/1OJDXX#WEEVDNRVG_PN<"3;'PPU HGWC"\V"S]Q2):101
MU[55(B,9L.%FY&X/RGD:'I$TM#W/!IBW80_S ]\GS(YA#V,Q)KOY+H^'[U\<
M5*^G#;GU$\=6-%%$4HGG7%!.F.,'1*"ZSZ/ #L3@<KPWUE9M0R<61(F@E$D2
M1]Q#BT(11KD+__%I8O,X4='@-,4-G>48.]+!]-M <&RYZPH\ZXT14!D5\[DK
MN#/8#,^7ZP?<D).).\KU54"2T.88 ,,T.!_[IL6^G_A^R,7@[/"-)1^N+BT*
M-@S?2^")02" Z@!3B<L8"7@22,EM7PZSWT2G$OPABXN2CB]33AM-L:K'Y=[!
M_N-"0VL^T/,AIHG&@(]*I5R^I_E$45Y/,(0*U_\#  1+:.1;RM,,UN1%(H+K
M!B$5#B8A8T-VK%&G FP;+XY<WW8YB_A@HT2;2RUZ\!"W*>^Z<0E8RQ%U">PN
M>$:[M&'_88)(/TIX[&-RVW!Y[%L<'.\D* ^712:.1^.RN-)+_FPJ2QPL+5%^
M3 *7^;!*-JR2"$+8KP*;NYX/2N2+=G \F^."W, +.19J"=3E?>ZA$00?660'
MR@-MWQ;/W<OP="E%F[')XDBY4>P '/M:UFA"XH0K$MHJ24(_E%(,-J5HV\KI
M:9R)G/J<"2F)307%[JV*)+&+'[V(!I$?N^'@;+7G4:&^T WBB;KQ8@LHWW,Y
M<20F=CO")33&<XL%2'XBG<!C@ZW<'/[^^BC!F^2I6:7/Y^-).=-R1CJH+W]K
MG@%_M@]H?VD_XQ.6/*WZEZIO/6U2EWOXP[<^2S?'O6-LYL=O?.(L#GOKJ28.
MV_W^C0_&DP3P4 $0E>JCVA\!\3D]++*,EI5VS'7O$^D5\&?_$1\F<#FMBW)Q
M2&E5^*X3[7T^/;QO.+?NQR\/95Z,TGS98Q]*O[E'O)X?_5>H<7IXB[X/G,RR
M13/R<<>*F1^_\9''H)(M?Q[^<O_#TIN]4F;:J*TNT[&5I?F7DR*;1RB\8;<H
M+UZ#C>V]+N'GUWC=*POPH[S_XN:*U^B9(:HHZKRHY2NK+DZDJGY]]?;#V;D*
M X9M>0E+,!]"XD%C0G!B\T@XMD,5D^*5I<IBU-QS'L&^&@O?)F$D\4R6D!(6
MT@!NDR'W>!A%#K?>GGN^").(VD1@F9RO*".,2D5X'/,$%#C0M;&ZX_4"#=IO
MJF)2<EF9CY<2'HZ< SSSV_^RK%_@7ZNJISCY,0PWS2](78SW[-T@S=\ HY%+
MF5Y<ULT7K+@A5?ION&J/%24\B< W;^#EX_8A"B -+Y%[CCVNWXQH>0$/T8]\
MHW]3=)1FT[TS0/?*^B"OK9-B1//V0E;4=3&":Q$7"<W2BWPODZK&=U1CFK>O
MN;X$T2;P#9=[XU*2ZY*.WRR\^][7P;NN4U%?[JFT)AJ'<WS)?_S)">TWO[S&
M=P&5QCU*=5-L9HYS<G?=8%Q;HIBP3+[I$]!I![!Y6JR*%'-$6,/<T#$FR\79
M\2(KRKT_V?I_;^Z>Z[7A4U9DHC_Y\#MG__G#\=G1H75ZMG]V=/JC$N'TZ.#S
MR?'9\=&IM?_AT#KZ[X/_W/_PQY%U\/']^^/3T^./'YX[9;X7)_Y! 6+!N"CR
M'>MP]V#7<NW 3^ZB1C,K%-X]W_Y+!Q3--%>)%1TLMT^VJB)+17M=J:F 8_@J
M9;\"*]X3PXK[M?<]$YEZ^_'DO=5.OS^>;WCV*ZWPY$6NM<R4:P4*] DGCNTP
M\HG+!#:3\T&54,PAGHI<#J:8HY+@E=48':"$/+AIJ953-/:$3/<."ZX['*$Y
M/0R".C;Y6\=.<V3Y[4>2QZ_*QW#D<9D2\SCFB;]S\M9/Z)&S/N;RYV4BN:%!
M+2Q&C8?0+"B?. K4PH&N^"O)Z+28U/"@&RG>F(<ZMKT+?-7<P-'L'5=RKY)C
M"H:IA!?!P^'I9?OHJ[1*F0XQ[[57-Q?!5:)C0_UP_R]O7KV^X[<D['[\Y75=
M+KZF,2@2H,Y2BE[#@ DK)?VRI_]+\(LE VF%5DLQ3-4!^^1*EC5F!S2,!GS:
MR7;9F#'ZN@U8++/7X,SO0' WI%'LBH"$*G8P24KJIC5$.9'KL3"R*?-6A>#[
M>3ZAV8D<%V4-=FE1CFC]ZZL4)E%)#KQ<9(QF65&#A;<"6;T;?I+(#]]\'<"!
ME<03\$"R1A98)=WV/WSXO/_..CGZ]/'DS/KT^>3T\_Z',^OLHP5*^QEHYI;C
M61]/+"?X2?QL?7QKG?WGD=73YSM=?O_@#']V$L]?%00^!-BZY6PA OY%)'NF
MZF#RO=I@45KUI;146@'+6E-)2TOF0HJOJ(A?>]\=^&(G5/(H!ICPI0*L< 6)
MPX@3V_=8 '\EGI.L"E\^:5_WD0E5S ',GH!OR C><HFW$4&G!&=.9#Z(13F4
MW(0@/&=G3>M@>R&-F4MB&=A899M@A[*$>&'DN"H2812YJUJ'MYJU_@?H^Q:^
MJ09!88R4? WR'Z;*OWB$^'BR>LWT>\>RU4P'HIE^U?FR!MV4^BKP[4 2Z2+^
M!,H!)%*@FP:^HUCL8#;_RKP+)<TKW<]Z$/JIO]5/OY5N9R?['TZ/M2+ZP^JH
M@W)U/U9#K3N1M$P6@PYE6DO_5Q?/?KO^[L@ Y@RF%>:M6&]3V!T!*E"5_(K'
M]VMON\M?X#*71[8@?A0%@*\\),P6(8D]JJ0^65L\&I./=.8+SL5,91ADMC&%
MVPX3>^OZ??ZAF)X7^SL%@8=*JH@Q$DD,?3!LU@%6% D9I780Q8&*^&H$H6T(
MD==8\[%28?CJY.]:R).;4WS>CG6<\]V5&5 O8OOZZ>B&\EJOHE4HJ^Q6SZ*5
M58TEQY1$8:6YE=:5Q2]I"4/_^4="CZ<.'&U$97T43MYK]O99@D[JXLWJ[."Y
MI=;/?I1E'-CWF,:]'^\QC?5:?H-M?'OU%M^^8 V9==](T&9>>)9O,UXD640#
M3CSE,M _[( P*2-BR\2)PX"S)%S1-H,5>R68OK/&0P?%)*_+Z4$AY&USN,(K
ML-@+G[,2-^K=SM&,7E-,0?XNB_AYK7=@RTB%L,".C^=?1CZL':P:L1T[$:Y(
MXC!9T7J?T9OC)D/>U&:N3-F^:R$3GWAN&,=8=?3@I;P'&Z+!04,T.'WF3BU%
M2[@%IG8!MG9I_7-2II5(N3:W"]5?B17/<S<*X.XGG6S:AS8]Y_*"YNF_]>>?
MUPX@SX@KCG=/=D]WK:8Y2+E&-GC:B<TCG?6AV%VZ[#^0(O(5,5R^.PGF1#((
M R)\A;W@DHBP0 3$9G84.S3P I^N9G?:%Z*45=7\\R[-I;-&]@"]V#HH,M@
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M5I:0*LU-!OS)!,QIWPY:PO;6 VB\^Q47]=?G<U<1DX@8O)614''0O"+/)DG
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MI"2F+IYO'04\I$I1=T4:6&^I<*4:2-UBZ!9#M_;Q^C!4>P@SF(BT*.> H9B
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MA?6)EK5U?'S<-7IZ"UAD.3;YVZYUBGOD(C7F!_ M],"(3T9K;1M3]#F:'GF
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MXI<^Q-Q"LO/>R2/Z=4&$,%#A"R7Z_< ZWWFOQE23TWDD5NL19*8"<V&*^G)
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M4&VX]'=:K@0H.H2ZFM;C'@2,M]B!DD7=)X4_!%<\CLJN:*TD2N)F,]._KVF
M(5>EV61[Q)3:V9KE%4I,0Z3^U:!#1O*W'P/2&<!"NK48; C^;.,J0OJ\H\W;
ML=]L%)M&^S>;M=L&$7M371""D8!IQ\!KT@5"+4>#B[O&[P)G:.8(.PMW&P']
M(8BKFFBB4;5C!ERJ%PU.L4Z0P(+KTX/IVMBV; D>F)[/A_=1?/-+X?N"BN]!
M6%_E3Y^+D;7Y]1JP'_/ZE5\BWDF5_9^&ZD$97#V4KOJ7BG7+?YTOJ[DS(LR
M/UBU?O/!VR:)L!(N^35#()+?)X-NS? B#:BN*3)O&C.B#F,7.A[?;)U3)A(!
M<I&0*>T@)>H=H<-EO5:SE=:=>C>3@G_6:2J9N8 A$Z9*NOK!H!D("P-*5;^]
MT;EVKAG$7'\X.;E'^WWD__/!0_QG&7[*%IK%GF+W'T[X"Z)Q:0UE8LC.=\'<
M7E%==,Z)K/B/C3+B<ZK[.-NE[/LQ>[/?"I,VE80 3>>K5&PJE-UU\C;58E&L
MF#40TK]&M&ZUIK^3J(@:R82]BGQY*P".0$J#=H5.[?*8X63]#JE5H3=19 9S
M1\T%H"(:8X63A"PNMJQ$VQ'@F!Y]D1D7U\!XQ X'U5OOR[0=@F'\P@9OEV K
MJ0Y*W3;AS$F@P6R/'73=ASN/<W$=,%ZQ_<3ZDZZJKFZW?7HXA,%'U''L%,%)
M"AD:;X-WH:,$KCMZB)1>K!QM$RRSYI,RGS+(E#L .*A(D/DP@X[G@PP%.:',
M%![?K(892MH!KYK4%CY:YF:(!S^-;U81-W1WM0P>]+Z8ZNKJ<R&E@-?9N.Y&
M@<E?;\#YQF_RJM-C)C%X-[ ?GOQZD_3O[XCNP+PD_4?#WG^SO7(&&KPZG+ZQ
M33]\9$Y&BF5/>LD3V#Y]A&WO2A/ R2&+ 'U&)<#9;K9T>H2*AW +\.R:*A5H
MM!9<6R:C>$I^O?;W98[T+$-=)B3VF41\=99,+*&:VRX%E'*%!(< @/_0\B$M
MQ/B.A&YP(31/"3]]>[ZJV;84'5%=%/3%A WP,"2J.&1"% )JE(-_.'UZ?.*#
M/A_(*PSS#Z>/CN^%OQ@#WL[!CP"?\WQ__?%W_C].<VFTX?*9,%!?<L6>W)M
M4!,'W:_JAKS*CC.&)@2=_RK'P@TIF/W[">> V8^GO4,JL?=&$3RLWOYN)!9#
MBL,X.4)3@K?@9S[:;XN_U^Z?;>G]<.\=M%T#Q2$A8YA5J_66T=B"V3]AJR'D
MGC4M)AQZ1K\@1[VX\,& %D?S8__D5#(6&RG-HAO!^T8.[%#6A%'SR;0 JY@M
M5%Q) 66)E8V[D/QD[M^$%H60*9YU]28V6VV\P<EB7BO*A^2GQB.!64(R6NLZ
M],F8YK _B817U]\38?@;EJR?\P?VXPOO':W[K \L15H/?+/*KPW\BC0>(8<
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M&I9*I:"UB(0E41G;]W_E_?R/Z5LL??03C^009&*U8J6'VTO@<-?0-+%?8"1
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MG-=I>]P4[Y.UN*,@?E4SCR#O.![%V[6"#I;NPG]LO] *';]:FZBHI7W\'P9
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M;2+KGK[;/LGW[(:[1O7.) FTW&5'GE&-$L0ME[7S(OI&X0$ 2!#7"U'X?$,
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M(E  LFEIM]2?'1<_D:,IFX0RXQ=DPBN[E=%I)PEYY4\-&6K[\8_\>YP!AIK
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M@J,0Z\3P**1,$1A8K'1<O#0@6S(O/9L%]@*0[/G+_9\)R:^&UU4Q[[PO0,K
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M@.I)#TK=[&D)E+GTK_QNKR@"?J8]T=+T,4I]A'B=H<P"FVG&2-*%2"EWY:6
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M//OP0# ,1-L%OS[X6F#9WZ@N-)NL:(]3VTS+I?;.O_DKU^@AF.:\_39PRQ%
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MF@FZOX@+VARE?_Q4H6G:[.:Z@[1(+WGRPG=;.P^_]3%-(K]4 72J')+?%E(
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MLT)V4ABQT)SZ_W5O S:T()9HC\\L52.!9/)Y="AJ*#4/_!^/&:S/O@:3#1&
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MI4K>;:QUY90W&3FV#:2M)BBQ<UQ>,&V!U^=@!/WTVV=6/#$0:7Q;>W4!SG.
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M??7LV=7JR28^$?D\0AS3OZI=^J=@_T@#)&V%&4=6Q^,?K <0'I(H&EH<W+%
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MZ5H($LJ.WZI[R=XH.U1(E5TH_EEC)'YR8G=![265"JDWJ\R\/)Z2:G@4:@I
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M1IEC9JO.$>ZR7!)-L_+Y[>;>>8_!?-:8@>(Q(2 FU,Y_Z55_:]W'!W9>_4"
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M--&7V)PW!P1M*+#.!N\&>CB$^KK?GU->ZT88?"HO.>^X81 HXPTH]%^M7E
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MR,O)1\82*@1APX)[/\CJ2T,5S9_<7E[^4?<9XS'0#R>SH+.W"6ZRI8_/JM!
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M=FAQW2Z;IZ:%4@Z+6!&4*J%$<[OCTODPJPUD]?J$\F(YR^7A!J1+1G0BLUQ
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MWCC'P)B0#6B-,R7R]+V3NW:DDB SE)?O9D>W.N[Y"\CLY=R#6OU?X@([T#&
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M]>HO_6,#>:S49M9A36^:=)Q8#0\#/?V>29!0 Z6Y&B'<.XPJUO;7#B.J;P^
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M,.<+>E/DCQ=>3#0^QD7W&3[&A 4A%2"#_1(/<;C1RU<TPD41(&D8T>.$.Q\
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M:_<W4TB[.:9Q6R!N#-KB[)]"QAZ,EEF]'[@ HL[A63L&^T.?31-JX)YB?Y3
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MX,#!S?QI=(R2JN$<I(YA_5@K'*P]P%K=8<>M5.+7/7J\(Z8CCF*'R<U/WUN
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M@G7W1=-'XQK] E\4?X,)5(2&G3W!UI0$M_6$46P&,S.*$WM(QYEYK\E!-CO
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MR;MZ /E[Y?.)ST=OL.#W+28T?)^;NG[WQHZ14/4-;EZBJ_Z+.'M/+7/>E\,
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MCRRA4F^AQDW5"U9UM$DTS"-MV;"O=V$]A)-'E%@I,\75SXUGJI467V%:I'J
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MT8/(F2VWN,>,)^]*\M?N@I$I(V =E^*G(MC,'O5==?VG"<,W3\OUYN_]I?<
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M4E<B$\',_6I.8E,12H72EB15("PP>DT>U3W/B^26=[FE Q@P5X=/]KO\5/J
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ME-P^:+E$+B+PX4IRIE0W[0]$I=$(6P8+WNRE)U8MTH1E HY:] MLN4PZ&&.
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M&P^?O7(@S\Q&8)"]?P+YDX _?Y:]>@L;1;U''!3\(U@U,(LH/D,CW)R:U0C
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M5ZF>-+0>7Y  RUE>%!P%FP\ RB'FO$9 I&U%S%ZG8$,_7-?IND[)$:1L0V,
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MMXAU2@]M;!&>8SJ,TTY8+ST 2!YMZ,I\$$KEORIC9G 9EB_%]FU!>E/IV'5
MN*VQ,W(PFJRJ8;H_LZHM9'F(*HPQ#<P@@O.*7H>>.(G4KC=/PZXF5$#RZPB?
MNC-"'=O#9$*Q13%MJIB>W!D>+M&_)6;#?5,$-FUJEVG*: *8)13#F07/,ASZ
M3+T+GD)V'<U4++!Q+SQU8J&N@R/(?WF;.SG+DJ!^H>\QM2O,QA?M2N0XO\^V
M/+S3Y\4R$A]+) J!4B,DZ_(1<P\8/\E@I'"K:5MEU20R?L%QDQQ5.TZZE5:A
MJ#?SK.AD]!?9V75HIWW4<P"33>>]$WA1[MZ9W>W961(RLMD%90 EF7;QUL\
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M209FADD_T1B$[\LJF>%9V5OBKUTZE)= L'O;T MO$DYGFM<XP\B^4)4.G4H
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MC00XR!\P5KAQ@7KY&A'4K:@VD(0U<1-0Y!T>CKZ(=_@C1N;'L6&3V%%OS5[
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M2*2<I1'.1"[ Z$Z R@SW6A?Y;];W7M>L%C,LKBA46$S5"D5M8QN2\TFJ_+;
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MUS>ZC>D;'XLN\M*O6#(TO.[=P&(Q%U8$YK@(2J^UIYTD30SF:81Q-1Q53-=
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ME?I4'%'I#AQ(O1:Z-TCJ@"['UVK5JN3]=[1XUH=_E92E^E5&J:^+U/\^A7&
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MU-DRD;,3R*2YR-CUG71/(0;N*)WG A'H6X++G.P@T-H:1)81FE!.\"[%BD!
M--O@2RU?97_6*BI;%2E7?=05R9RTIL3'*GZD*H^/$O5LM=+23".K1T@L9LR*
MK&0D@VIP4]6T\S+=+YUC^+5,9%HC*DW]0B*[P_S<,8I>B7N!==9H&5 V(7()
M5@=:]6ZB]D5S$94KYG=Z:]::P)^HLD$TL8.T@;\7#5.".RXX3U6S2113C>-#
MZ-L&@HZ:/@+[T:#Q?8O^%!JG$=C:V*(S]=5UQ-4,LP,#!G;3+\3-!^92(-G?
M-WY_*N\HJM3",;*'32M<3JC3\O^ ,@?I3)S;VXSEKV!SL61QE$4EYR]\JAQ)
MP6,84B><,9]0#VK+:[NCNN^'J%.JSN@P!:.J;C4O)8#N@XA%3H(?53:442R:
M;JC;I8S]05G=@25^&L?@HZIKJRJ_&FQEP0H>9!%ED=]JS:L#R90B@KR3%)^/
M9\@-YJ1PV<Q;Q*H:8]-GG&8PT^@/)GD"974&DPU'9/ILP=D,3V8TX,5OFHS@
M^%*54BVN_;,F%ZP/#CH9F[FX4XN(T2&,L'I"<;+R9(+%&IGJG(0P3D:O>I68
MB7B_VB@!%PEFKXA@EJP:(S)DV*(N,?&0S=2\C2"J&CSDX/'H:UN#]D_.L/V3
MXE'7C:J:X+9EB0J<]^ !"T(>05_3L06Y7-#H3$,B!/^.8T0+)D@N^OT^KJ-P
M>>=3&$,\$_'V.1WHDH_0EO5KLJ,LEYPX4R)Y7O/Z:E(DJ-(#E.W$K%&?E@&V
MR9CX+W7&U8Q%4;ZLWY4+BB0I1:$,.TFV7PNW] 1J8VFA0H.B5[*PQ!0L"4T!
MX?9%%P*D\Q<$Q#KE] P<U(9MADVMI3^HB$/%DYIJJ0-'P\76#5#I/2L#5RLC
MHR>"^8ZU($E!-BVQ? H5:!!V+74?4% BFB=@71:6A$QY/%<D4.B[A&4F2'<5
M2-9DTY)R%#SO2=USI495@6.Y#E_C+ 5P3@0EN]XYHWH:+"1BL_HR+0BJ(/X!
M<;A9-5,?(>.%,,DK(ER4,_5TA-LE *%Z&S@*1"6+#$T<CTJ;/,F#YDGV3)[D
MD>1)GN0I5!: CG\T"OG0<E.M(\3N<W15&D G0LO4"">KX;>Z$JHH^#;%5574
MDNC]]:,'ZW>3"<6(%5]Y%0--\ZBHPQ0-<TR<0;;H=K"1Y;'J42E9&L696".O
M:"4SR9AJ$Z:NO%9F:-=_4H=$?55B2_R6AEH@.V_DJH02*1WAB.!->DK!:4:#
M!@>6^PL_YAJGF0P\)3 U!V/RCYXF3(XG4R2WKKJIK5X:Z/=\^EV0J.D45.RK
M\R3K&F^DM3L_=3L$ CV&9U%)>-!P +0O+X?3M#53IQNOCNTU9(]HT K>!EQR
M5J>%4)2ONMN4@Z'ET*Y0F3C,ZRDL)RE5<UK-.Q3EM70%1A&S6[RM(&M'L( V
M(Y6K5RPPCH MP(>H.P8L$Y/6CE(!;ZX"<9EV15SE96FBRF_DS8125\&H1JF.
MZSI^568/=382(3B9$*!:%=>&$@9G,/JFY72V*!<ZCA<5$6(C**B1OXM+7HR(
MDEDIVD%6TU<6D<[PCA]N7%ZKJF8E!N(24D3U1-5PIBLAVL9A&D>IK72 ?DV/
MI,7RV5RTE:1[V4S;RY0R6H7?O!22O&C?Y1[/80=OP=90>(,?4 DVF\_C"AZT
MX(%L*:.VM.KKHC=2@S.+VJOH01/QQ7(^P8R ?&/P K^N.1.Z$R&Y*N7AN>)'
M-#P \DPTT:S70\4OA,M6*P2LC$+@:(*IO>#9IQ2HH2YJ6B5X=195_<AJC(TR
MBC!*_LXB0@>L'A I\V-<P'NIE&L,@K,BR7E>/;%Q DG94)7R2MEU,$0TH1BK
MI."I^I<HWG[ 8_QZ<$\#)?I(X](V+\19K-IS.2J_7XW7KIKKBM4E+FA\!AP(
MA![2]L"(%O7V"SE^Z55].M0O(5"*Z%NTL]?R5JO;[KX:OU;H?,VR,0/8<[[<
MQ7QA7?G%:UM2N(IGB_57;3"$.<&EN-(/Q&J,OG2%Z((,0"U,HGH3+P](+*VC
MLGWK)L0Z-4'+^DM-RBIO?Y89"&R]<]*Z/4AX 4)(=RSXY01IK^FN#SD1PCB]
ME6UPM%(.>8:@V:.8(2XU>_U_0"[J(!$OLLC?->7U*</;0YW!11R0=;/5C&/1
M094<4Y.%D.Y6M3]R2PFV;UA,5.5ZB,A6_;Z$22-BU(SL\*HI&GI/2.8B#+RE
M[DZVRB!;>K"(2HG#&5&_:E$>8/*-* =JF-QZU$[&K55$BL+4= C6\69&-35D
MTJ<U.JDVWM5%1N/N0J6BXN)Q )'E$>3B#@5> F"%YY-:/<7.5A-2JUMP)*19
M\(*88F3'9X8]S04IENR:GHM>6C2R&N#$LHK4",6ET^C1MVZ_ENS?4H4\F]"Y
MLOWD(5GIF$JJU89&2RS;+Z!9_2.B3[I'%"D/!9:+$@;E+;&EC*UUT5-!&L3I
MF!??$OU]-\B72EFI[-,U5SK$)R122VXY>9TY^KS*/A275MC,HJB'""_'6QNB
M'%QN3T5M8Q=S:=;6 EHE>-.QONRTBBN_JG>5,M?'I.%@H))!(XL,]:$L"Y?P
MI.462YG W7^#[8O?RD@@;C,&!@%_\>-.S!9I6<#.W?'@K=A%M]UNM7]27P!9
MB=D\YV]R;'0*NJ/$+:-3B9[] [X?!E %,S$-2,#&&_5]^2'X5%"%!^EU7K?E
M]7^2<<XU?W=W_%N_Y0T/\%CSRGZK>PF3?(%7NB^PE3N_4E^@__Q3D2UC@+R0
MP,-KS/SODPQ\Z\"11T](_UM_]-P"\(B;D#?B/@1_L08^EHJ=Q/&W[NA;XWD,
M#TI>OG9:C[C,*((+G2SVAH>__/D'M_O#AIG/HB"(^=OJ8DM=/\X+BT@"+&76
M',/:[.+B;5HZM#H>*24/KY70PW;G*%;KV=3FL)/;^B;T<$HBYWF12N+M)A-&
M2<[W;#DB\^0T5/+9A&P;K3L3M/8,6"^MW-]= ]7&GC$:<H^&&&/&:(C1D/LT
MY+$^L=&0747'Z-"YZE#7Z) Y98R&&$_%:(C1$..I& TQ&F(\%:,A1D.,'V(T
MY#DUY)Z+.DI#7;VI\V%W0W_K2[EM6)-A<5ZB6'H+3=JTH)10>PVJ]9"X;#/]
M>V7H^<O%GZ8?^B.3]+BFN[^9/;"5:X'ID+.EU. ]RG>O;_;9J.P13->H[+9[
MW1^8?38J>P33-2J[M<J:4]:H[#%,UZCLMGL],*>L4=ECF*Y1V6WWNMLV^VQ4
M]@BF:U1V:Y4=F7TV*GL$TS4J:U36J*S9RK-4V9[Q9<];91]_N:_*<"_Z<O]3
MQ5GU%\F#]4%P8/U*]%=&M'9%B5TK7LX#1QZ57G::)TIWCWD#NQ>JGX>X&&PP
MV'!.V-![F$S)8(/!!H,-EX@-P_U%CPPV&&PPV' ^V-#?8Y:4P0:##08;S@<;
MO*[!!H,-!AL,-JS!AM&#Q:T&&XX7&YZP\_^/ 0D#$MN)2J=K@I(G#!+&@##8
M<,"\\?TECAML.%5L4#DT\%]LWT4_5E.10Z*>7]Y]#>7Z+]BJ\<%F=IO,*(OV
M^PE]-)_6S<[Z2KW@ VN,_><YM:@KV'>.#?\*3,=9Z2UG_=W#5G&>:0*XM@D@
M]IZD)H"O1"=;;$"I=Z/$;N.JH?OKE4Z!44[]_);:_E4=Z6^H_VVC4V591+'L
M8JU:6S;;V;=>4+C.J)5?[T#=V [1_\R\T[SS_-[9W?V=IJG?Y,79V\YMLJ9?
MV5Z;^CW"ASN&U3*DAT9)3%._8U&2,YKL$9DGIZ&2SR9DIJG?B4F&:95QA%ID
M-.1<-<08,T9#C(:85AE&0XR&[*HAIE6&T1"C(<8/,1IB-,3X(49#C(88/\1H
MB-$0XX<8#7F1C.3M6?U,RSYX#J6_FI9]AN7S3-E<W;:]3XJM<]YKH[9GLY6G
MK[:>W7\XV<KLM5';<]K*TU?;CMTW_.E&;8]BND9MMU;;H=T>/'A/9?;:J.TY
M;>7)JVW7=DVO7*.U1S%=H[5;LSK;^Z10.>>M-EI[-EMY\EK;MWNCGMEJH[5'
M,%VCM=ON]<AVS>7/F6OMO51D!Z2VVB\=V<Z43>_++$HF2/#5L:U;;DT94E;Y
M&6<Y#X@=+&<Q/"D-K8%+!%3:7Z\^UW_U1G9O.+)NISRQ_'0V9QE\HDB).LP*
MLW0&\\I2>%7%9K7$7E5P?YK G"<+Y":;9\P'.>,YO3-(_2+-<GSP.$K@P;=1
M,27FK,90F]QE1T2$M85NO)#TZ-E1>YCX.]CY-(&?228RGI>Q^#&=\XQ(R_*G
M[,J>1[O#-KT0Y^".$Q<?Q5>]B4 S(G_C4ERC'K\ P]^1P. 7 "(!9?"[/,J)
M"A&9_O"7%<]?F0M"/Y\5#/')RLMLPK.(YS9]&# HM\(TLP(>1W!0(K+& MQ2
M\0%\"OS,@G^6\ [\5<R3W)JG.<R 'K:PD3\PX3S@@4W@E_/L!I"0?F8^0&*>
MXBM;UE=^PY.2(XE@ "^[@<$)H%68/,_2H/1! >=9!,L."X*CQ[?^GD1(3GA=
ML *?] Y&D\XX("S MO9I!/(LPEF3"D^+*8MGD:^A\ZOJB'@M!C@;ES$#L%[(
MQ8&'D.V''U7GQ>N6]0]N\;LYAS7,Y"Q@612:$VGB.$_CLN" _7',<&0YGD_P
M)7Q-6NU7FDU8H@@1:;GHU_#&+"I2L3<L""Q?3=$^GF,AB&XJQ(GYG1-$&:P(
M3 0Y"LM9\C:(\GG,%F_PKV_G, V0*"W;-!*O4GF*\$\4JRA<J'?2%QV>!&_'
MZ1T.'HD6JZ35NRW-MB=@WM-2=Y^VVL-F<!L6FQ9]6N5WSMF$B]1-AX4PS#<L
MOF6+7!+'Z;NCEIZ,V'7K_I3E/;Q5O(?%7&- JP4]7N/F:5.64(-P252X ('*
M#@4<+ @JBXR1/0K@5>)' )84Z KPE@]AM_#I!*!;6;T5-),EF\!@Q*?AZ,%3
MPZ\!.2%"6?5F,*/@@)E9LY2 .O5Y4(*9!6_'K^E//D;S]_P-"3KA43*F/ ZP
MR[G:22N'%\+V)\+"F"0S^$+C# ?L3R=PE.$Q#C:$L#CF^ 7UB"0%<"=BX#01
M,E@9%5-V@Q3%/-E /6RDX:7,2C20\#=H,I%Y60!D6#-PC*(YV)92H5D"%EXZ
MAO$*+\D:ETD0TR8"MB!3-SP@R1F9!VBA^=R67G <-[XX 9S)X)=@@,%O\C"2
M[C*\%!^SX"QK6;\):Q4LV3DZ!H P.2\(:S(.YAL/R/23GERV5D9)-*7'75M?
ME:RBI3HO<%JV0$G$IWN>A.^+N0H,5-\8+U")8K *"QJ^P$%+ 3-\J(A@_ "O
ML#S%HFDP3S+.4<U((;47@B?*QK! *=CHPLJ7WX#-B-*@95VA.4!_":,,WHR+
M9E>?TG83!&H,7RLS?TI1"$5)C0]'[8/520(6X\CA#(G U*XT'G4\+_WIZG#Q
M4(!-'3?&7(T51C;#)2(><344H]XO,?6/J=@2% \+K&S8IO?<Y\0-WW%MBJJ1
M1&(0S*ZDGYRT6HA(B^L#7SJ@PN<B$00'*+U%97A%WEM:YO#,_/6;4]_SYRYB
M.L#$3Y3AOCMLM3NC>QFTA]ZN[-M>M]7IC[3_#7:F\=Y]$.ZPY7K[>?'C2P,/
M1]%Y+![E\]6.GLS<JO+J_C.55^]M90Y?7_V_>$!^6#D@7[KH^L K:#3G &77
M!ELO2T)>AKKBA+#U&'HOG N0GMULC>(<=S^&$Q*E,SU?UED@QNJX=*EX''B>
M^#S-W$YS;D8^S=R.=&Z&3FTW.K7W[_&2QX]+3#>J;D%?FTS]$RJZ:.[_IGG^
M: IMZL7H>'9[9!@DC/X>PW2-_CY:?SW/[KFFOO6\]7?WNYK+MNFN/AOQ,4AP
MAJC?ZX+59E@VC=H>PW2-VFYMK'7M4=\8:^>MMD<1@#L6'^Y1:WHMT_%52<&:
MO'][N1;7B-RNZ/%PWL$YX\NCLBY.]+2QAZ,'N^OL0URJS(MS%AB##@8=S@D=
M7+OG[<\4->APJNAP%+'%DS17+2,_^X$+K^4A7@1IB25]+WB^//_]TS8+<?)'
MS7!DMP?[:RYR[YJ9T\:@A4&+4T:++J!%^U"6J4&+4T*+"V>(?13)A:*035*-
MT>)VBM1^0703!241TS#?!U.^D$1'1&553&%>;OLG01M*/!G'R&ER='M[<&+0
M=ZD@P\SW1A#Z0A2J3R6VU99!)PF=,3C=(A;GMA6SL:0F@B>5(?,+0:Z,U#U3
M3L3*\-F$5*!()5%;DS1.L%S&2,A$2N>KUTZC^1R?A4\'50EB^$?+^J*>C)_+
M+9$YS!O?_!>H7(3$2'E>9H*.20V9^./*C#B';/@R:!T1=](]1QK;%DP!"46(
M0Y/_JXSF@DP)^3<K.E\K+^=X/Y(K!BB8.YOPZI,  OYW9TSL2,CQQ).<OMBR
MFDL**YBJ"2"?*6R>'PE>*20*37+!F"07BG[=&)$/IPX2:PD.3;D@Q*\$2UDM
MG_@U\5RE"Q9+PBB0?_$"SM7+6M9U\SOCB(BE"QW8D%9*#IG8UF@F.K>IWYCB
M%@RG* N*)FB2I;=BK(20R\2!^')X0'",,'G^IR+L,9@X/G+=TD[EN27&B;LH
M_@T[!=_YTZL8_O':HN,/F<D72DR0'*[QS2E\E2C\<,^) @S?%TERW#&W6!B"
M5(F',.N&91$'"0;!0*Q)L]RVZMH!!M  >FCE@";X;Z*,@T](^9$B.8ON;%VG
M2+?15,6OW" )+7ZG"6>D#_6#%A&/ _@WXA =ZT(=D=$XX^JY>8$T1I-H[;SA
M6S&8 C%\ML3E)'XLP*V,2-C2ZD?! !PA.!%P(FMFDVU3?((8YNFOS8$376:>
M2T[YBF\>!V5TZ.78$8GP.@)X7,S1;1"':K*P9CR@?P=<W+Y+JL(:]NN]1\UA
M5IS>-@3+5J=H=> I/)9DW?A6I.(D4DT\ S,\=G*>$ ?K!)!:T #"PO2$:4H$
M?&FA'@7"68L8G!F?$N2:CE#DJ9M"D")G)P[GNU7.";^)+[L<(S$@,A?&@N\;
MF</I!T1T6W(X%L3MJ;&\"MW!WS7T!V8Q!2N09Y(1$M>A.>5Q6=!'+.(<JPT2
M4N66=24.GJ:V".VO5@M>J@ZOW)9,W'C$X1\;HYFQ!7*09O 2?7'CQ3$JV=%I
MU)X[''P1=AILI[1K+JK] G[Z5/RL:W%.*]V/Q7D6P,<C.CRC&_Z2>[C]1"[X
M0-MF#U_]^[\-/:_]]OJO_\YF\[=7]$_W[6N[VMW*NZS[,& O!W XTB3AL:,8
M>M7G=:OO%DP^\0L\Q) 2.DU*^LPF/XS&.(;QPE3RBOV7>E3HX[8K0U+X>-EW
M3K 2E@E9>.@APF',)#UQ.LG83/;"2*5M"F\%K\G'0TES'VF)P"=>%)$/'PJC
M1#BI44*TR(+JNFX-1/YO"9N S67@T +#H!H"'(]P&F666MIZ195CK+SWV2S*
M<S%JF-\-C[7%A,'/4GP>[A\\^$8ZP/6<!>DPKDKU:QP-9QEZFVH^L(4XYR3D
M&4]4(R-X&PYC"IZ=1HO<6"9T&SB-#@8@4P]S=$UK=S;F$P;N^9RAW,&K)W*;
MB$:9C',982-A9" :!3W UHN+A5N+KR;JY8@8J,E^N!9-**QNN_MJ_%I9 -<L
M&[.$Y\Z7NY@OK"N_ )DMV)U\\CAE&5'6"@<<IH*2[0[>-N14QB#4,)6>^&DV
M3\G@J;8,5ZN./ZP(O>YEK^XW>NF:Z[1+7Y&FF"]W&3D>4\;T$#GD:@^;%\:F
MAXCI(?*H*<,IEC$ YY(<1 KCI("P 79K$N'1<@[()]PH] C]:$XXA\$_^&"4
M5.% ZH,G\$SYF("<\BBH\5["/1TV%3C7P$L@1Z=DC;1YGF*H5;75&W-ZC#4O
MQV#GB69^R5E[;Z?D)WS5#8T 9"-.131DV3FX///[P:71[VUTV[#,,A' E\TX
M1*N*#0^C/CT)S)Z+*&EM(Y(QI0<EFW'&!9B#8$%33"LO0$NEE0'V6]TR;:PL
M4QE%59:9:-FQ8M ^BU=@U]=+8J6PK8V:24%1)FIN8^M36;T&TQ=-VG\:U<TT
MS;GN?F!T.RUS<:E6/[+:EN;M#\)H+.ZIY&41M;_C#IM3)"K0KK?* HQ*U65G
M:1Z-5\Q+L$IIF9;F+YOHZ5(A@I9K@\T1WF#YLO>3C&*"*8FI'S<L+L'7(>-^
MSJ) &J[8-9,EA9(!4754#U4W1F5_5''I]?']E=:_):\>D#<]._P8K(WT7,0*
MX1Y6PH=_I<8#=$_WL%KA593\!\7@U4(UV_P]^!2,X8) HY#BS46="2#E035L
M 3C "T(P2<DT3V0?173C2.$B4F!Y7Z;I8_.U(6Q_(8*NZL85/U^MLO9A>TE,
M*KU%OTNIL3A5U3+7J'#.!^=+ASVW/S8_H0_!\TK<+C>387DEUH>;(O6I"O2H
MVU/ QR#=U,@.93Y)$\=G^;3^N 8S9-+.0,F4WXS! ?@^H%5>7Q0"XI1U2&#%
M&%UY9?4F>&!,MQ%&P8Y*P6HL!-%)9W"\);PPZK9^71Y6/OBD!0=G(C20XE-3
MT"F'VH"A49,7HF<8'?6HBV@9P7F.OS2J<0RJ\1EO1RF/"1WT,LJGRF2D38Q3
MEERN?FRQ.,L]N3&A1B2)W/<E&2M!2W91_16^_>4.#+^ 3J*6D=$ZOW$&;YR"
M08#^(6[*Y8KD%65>5>TOT6MKK [*G^Z[(HZ+WXD^DQC0J[U$%%ZL026;1EQO
MD<>,K=<%<LL/BN:3^"^8&#A*\+O%4N=*3)I<'HEH_QY2&V*5-3IER81N._ L
M*!:@"YF,Z8EWD/)H#45U#P9=+G6<1)E?SG+JXBDU#BV^]#;!?K9T^]98B#+)
M.!.^]81%\JDX1DXJ?L_!!2H)$HZM;C.\+5N(P:F^H@%>2<P:!YJY_7B.VX^A
MN?VX[-N//6?\?.48VA)-T*L4@-/.2#JMC7F<00 .22[[,<L"H/S!"J 7,!OV
M>'WS-/'YK=&M5_:&+6?HV/W!57+_&@V@2/3V2VR#73OA=%A3C(1BT93-4&<Z
M8$8)ES_C][2X:FT=B* [K,4L/Z)FPJ?:4]=K#;Q=&\ZZ+:^[<[/:[LY??;G7
M[KQ2N[]ST-;_M]V#7JP[U OQ'+](0]S+:I5V6;,U,GR.NWI.LSV*%L2;X7YX
M;IIR@9U&3?OS%SACC.*<ON*\(U?5Z,G)G&/'S-NZ3\%\):(G9<Z2@)(.?0Y3
MK(,L^>:6?:8EM^EE;VQTT\O>]+(_4L4YEY"%49/58_O'!UOI&BTQ6G+I6O*3
MT9+3:;)T>ATQKY>H)$^N_YCI$/SH/=\S^[IA2C[:D_4$MM+H[Z/U=\]\Z$9_
MC?X:_7U._6W#^6MZ-1O]/8;IFE[-6YO-;FMXRCN]'5+_=+0MX4[/N=[4K\$T
MXMP=1BZ@$6>G9W?<_=D'IA/G1=D0!A[.'!Z\@=T_6/-$ P\&'LYXLR\ '@ =
M.J:-MT$'@PX&'=89#ZV^ 8=G3Q[0*^[IB;L$//3Z:WJ(_M3V/27\QQ(/^:O6
MB^V\(>NE.T&?)7;U.O:@;TP;8]H8G# X<9^-X]H=;W]7-08G#$X8G#A#G.AX
M=K=C JD&)\X')TRH9'_PX/:\EGONZ/ B22&GS\WU!+%:;0/\9J.0;5T9=1S*
M]A+UU)<PW1,_68T4F^D:*3[7;;VPZ1HI/LMM/:OIFNO,YZF=YG%,7=U5ZW3J
M-Q_ QV4/^)L'Z=*.N5[ 5(9LG7+5M0>CD=EK$R0\@ND:M=TZGV!H]_>83W#.
M>VW4]FRV\N35UNW;;J=K]MJH[1%,UZCM(S*/+^RL/7C5M''#\3E?><Y9YD_)
M_0[X#8_3.3:H-#?]YJ9_2V@:V>W>V5_U&ZO#) (9>-@%'GKV:&C@P<##^9JJ
ME^J4=.SVH&VVVFCM$4S7:.W6$< 39V([PAO]\R1@^RTM6*R:>VL9M\;V-[;_
MEE#3[MC#WOY,!&/\7Y098?#AS/%AV+7[7<.H8N!!G[#<11KJ&J&_9/1XQ-(8
M<'%'MM=^,--ATY)6@&'0QZ"/01^#/H^]]O!:#Y(C&.QY_JR/\PS5?$9JN#!+
M9RI<DR:F+]UEA75?]=IV>WC226+;[?J#+3TOSF8Y_3TUFJQK<K]C=]R3OJ,Q
MFGQ^FFQN6+>./'1LK],Q>VW4]@BF:]1VZW/7:[=.N@YYRU-W3WQD*D?BLOG(
MBBG/K"CQTQFW7LD,B=>VE?#"$)-MUB(SW=,_^XP4F^D:*3[7;;VPZ1HI/LMM
M/:OIFHKH9S'I/Z&<\+Q0^<ZG[!$:YW]KY[]C=]HFYFZ"=T<U7:._6^MOUQ[M
M,978Z*_17Z._SWEG9O<[)WW\FBLSH[47I[6O.IT]=ODYK4/7\(0_KSN.!&6I
M=MUVRF)G$&;;[>_;O8&A*S5VP3%,UVCM]M9\S]U?;]!SWFJCM6>SE2>OM3V[
MW3-::[3V&*9KM'9K%C[PP2_,0C8WX<]759HF%KP@2B9EE$^1&=Q*0PO49&;%
M*4L,U\]>0.@""N)?N?:@O[_T^B.M>#>7>(83S.#$4W#BW_]MZ+G>LPC,:5%C
M&'PP^&#PP=@1QHYX29P8&I@XQ'*<KQ5Q7 )CDA:>DSI]E^)@8_ 8@V?I+K4[
MVM^MS)':.\8=.BXSYSPV^P+0X57'[GK&'3+ND,$)@Q/WR$O7'GFFTX)!!X,.
M!AW6!56[G8?YRD\='IZ7'\T0DZL4DC$/TXRK0$C![O;80^Z<@>?T8:4[M'O#
MDR[K-)Z'R2V]8 7N]^U!]Z1SPHT"&P6^7 5VA[;;.VE28^/3&[6].+5]Y0U:
MWBEO]3'S*IRGI_VI\J[W3EQHPG]G'O[S3(MV8T48:##0L+IF9Y]:8)#!((-!
MAEU""_LC?C/08*#!0,,908/GMHQ+87((]B--O_#"BM/\I',&3!ODG9('^J8E
M@[$DCFNZ1I-WRR+HF>8,1I./:KI&DW=*)^B>])%L?/JST5^33F#2"4QG\T-Y
MW:*SN9_.X)-3GN31#;_?"S<]2,UT3__<,U)LIFND^%RW]<*F:Z3X++?UK*9K
MN-R?Q9S_/8$UBF&$@35A46*]0EO^-;*[Y],T*QQB=(^2&YX72/)^TI=M)C"P
MK50,.V:?32SO"*9K5/81EVFGO-'F(LTH[^4JK]LUM;A&9X]AND9GM[\\\_JM
MD[:3C[D8UWCG^)R/:0:+FEA^F64\\1=6D;$DCUD1@8.N^>LF!=^DX&\G46=/
MYF=L$5.<8Y!A%WOF[$MZ38S!8(3!B"?%*0Q5N($& PT&&M91A0_ZK=ZYP\.S
MADQ,E>_;9LNT9M:Q:J!F(B &J![#7&08"(P-8Z#!0,,:&V9@#!@3 S$@84#B
MWAC(V8.$,2 ,-AALV"TGI+W'BNHCA8=CSALYSR#(N^W+K9\F8U[+0R$+TG(<
M\Y=$I><G8=EF(4X?H+#SFKL_II9[%^U$,<K8,@8W#&ZL4K4-.X=B=C:X87##
MX,8YXH8[M#ON_I+DCQ8V3,3DHM#BA6(F9PH22$/7/7^,V =9'?R7P43HQRW&
M/X1_/F\$@]YV*R(ZXS0.EHML[AN-^"B^ZDU4P"C\C8MTS>)&K_C&<NA%/IU6
MI]/YZ9Y*G_[+K-!V"W+O]#'_)>,LYX$U7E@_=MLMUX*GQ%&:V%::64.W-?S)
MMHK4^G$XJO]FA?"W8LJM!6>9Q6&9 NL]]_ELS#.KX]J6U_8Z5IBE,WCFJ-5^
MS/>\EO7;E%<#LVY9;@4EQS'0[Y!!A,563L-/0\L;V;WAR/I\]3FWYED$:PVK
MH+X!BUK/\//[]_"O'+X=XWSQX?C]?A\^%JQ_^,#%;^5B*GF1I<G$8D$ZI]HI
M^'M:9M;7NVN45*O@_C2!K9LL<"WG&?,!6. Q^/ @]8LTRUN;Q.WRM.]=FA>X
M@OEE:V%C&9:T<=#J-Y013KB^5,9.K]7911GA$8-'*:.]JE.%KIU10O].2OH6
M3(3T$$6>]"8'^8'O91'H#7YNSK,H#5J6]=<LS7-+;(DV;7A\O]WJ_J2>^_"4
MNIU6CSZ.HUT=;#2;9^D-?#V%5[,"QQ%S.//9A-M6R&[2#(]"^%X:E'X!2W,G
M'LNL"0P)[" <,EI$\ 6<7@9?3N#1]"&8J]RX"D!H%F):.1(@(4 @[LCAQ.DM
M/'*&#XX 9WS8?0DN8E4+,0X-73!=$9!$/J1:R&(:98'UKY)EA5AW7!$#+_7I
MQD'&DXEM37@"NQW3#K$ /AX!C(,@W'#5RK9"GZ.<B'6YV/B8/5R"3K>_9,@
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MXN<!+3 OJ&4!P'WDXZQDV<(::+8.76^)& ;)+CWZ%D4++Q]!CJ7.HF*NE3R
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M'A/J'5G:DJ1#="I$\@\B/T./F\,XCJCP3R['ZM48*XM4=3#&8:#A <J*'W?
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ME9"1QPH8,!?VA$R(BS)A4F+8_U]X,1')@EN,'C?.<=NZ@8&E]*HXQOA]KK(
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MHU=I/ 1:_S+LY)71JT7?L=LIEWGU]^A8F(DCH;*A<'_51^SJ&;)*"PP_9%O
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ME76&/6?$N>_W1NZH&ZY@ZRX&(HGA;R"%GVHAW!N4#NSNJ'W96&HLPLO>R(L
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MO:HYS@=G:588X^5T/':SYN+JB\ "N1I8^%%<X5L-CZ76(1H(S+.RH!S *V:
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M7-I.+0V9<X>7MI7M)F[8U%WO.''BQFF7FZP]?M)"+Q(25%+,:ILA:1M!!$K
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M\'[Z9CJI7SJ;CL?EDJ.Z_:GIJA4$5PBH"*@(J BH&QC,++6PK"95B^! &);
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M!6:+63AU3:K#<\]G->(V_]P>U:=_+T;G=>P;>G-[GA.STTE@.^^)U?GN7I(
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MP0J)V1.P$D2%+!B!G)0IB*4)V)I)29G)002M$NW$\MT86.W9O%R, >^.Q5M
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MHCN^N,=,]F$='6RPG52!QU^7=6)(<,^C)1@2_&Y5IS ^A:A!\:1 ")? !2]
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M<_A.X\7$Y5F$5<\>J!X&=BXP;<(]%@++>CP-,\<5S\^ 3GB2'"$#8J$^53Z
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M4W)TOM[1TL<M1G3&)7U[<&@FCN?X0N,8>X<D/,RXYPL6^<I'5:-8&G@) \-
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M3>(P ?$I8O!8DIQE(I,L=]+,<QST9X)M\2D<+U"!'[& 8UO%!&]S$^4S'H/
M%<KW57A$T1MW&7J/[N3,XO,EB,^CNP_Y*AVAQ<Q7AQ<IWHF',D56+9;X/Z-B
M?JYD@]N0XX7JZ-B/W"C%ADEQ(%C@)B[HVURQV)5"15FL OD4K6$>44<GZ=*)
MXZ=5TELL-*OI69S.XO0UB-,<')0D]B1+1.BQ(,H"EH5^RIP\XRK@2B4IWVG.
M&:>2\TRQ)!;@\L0.N$E<>/"O@*>.2-(\/J*(40#BU'EBGV<6IU^K.+U3)[]7
M!,UW-QS&Y\.<.QEAMLI"$JPCX4SB!SVZV.59-6CSL.H:0!@<RU/P63>VQ<C4
M<NXPUX,+;14FCL)6H1[6#029Y[ $$VQY'.:)ZR1.%.W$J0+7<?".DBE?)"S@
M8 AS)\B8X"+Q(M=SXMVJ Y#4J.MT6YU?BN;WGU6-'_!3O.T?2.=U6ZM./#-O
M*)^]&\3S] I=L(!5*CWFN![65;@^X]S)F,_=*)1IDB6!OU-7H93RDSQFF9-C
M[A7\*PME @]&PO?!6W"#Y#E6Z#H3RF>/-GKZ _,-HNL9;-?GQ(I\/+!(X(HX
M$8Y@:8(>8XS]QU6(&2E)YB6!=)-4',)C_*!TSSICZGQ_]:YO-O.A:,2J:H")
M;MM-]#:SIFZBKUP)/1_+7@M#;&S<Q:K0'4\*VXG*("?;;BH]1GPS^JY!.3>*
M[*\:#1-CZ(1JG/$5 38W9TIM[H.4^0P'_.@PC9^L,\.,2;KW6S,FZ1%CD@X/
M9X ON]GE&_(T/3(<P[GF;!^O1_CR<1)F#-,9PW1& 3N.6_.#(X(]4Q7AS#8S
MZN(,8'K\\O:%KGD^2C. Z7R49DC3(]/P+W^%,T#DO,*O:X4SQ\XK_&I6>'1)
M^5\?2-'WYNZ,;Q:9@G>6IE/D6M5%)>>$J*\4YF#&_3MHBA%/O-CC2<H\R@MU
M5,PR3[@LSB(OD+$3AGFRG321N#R+,C]FGH)O!GX2LR3A'@M3>(BG8>;TN'_U
MEV:SG3'A'JS(S4T>/7]^3N6<)=<LN8Y0<B6Q*Y2,8L9SQV%!DODL\[. 24_Z
M89ZZ0@3Q3NI@&B9.FOM,9C%B(,0)XZG*61@I[HLLX$X</H7D"H.I7,&OG<&?
M#X+KQ<?AAE;_W8S[_0A&+]+J?R=E@<>I6<BVM@WC[V+R/XA>+U"CWHH>+U$2
M'8(17JCJ=>,X"%6:,E"FH$:CR&5IS 7S$ADJ+W#S.-NI2SA IG5WM@_5\F 9
M>/=%.)V/Q2P?9T:8Y>,TOE <\RA'X>9Z'@MX$C/P1V*F>!HX'@^EEV6'*+9]
M9/GH+9UPEH\//A;7W9@?S=+GVXOC\F/,D::ZH=,29BKOZ]"\(KZ;D0!G),!]
ME/OVGB5Q=PQ*\M3+/"=@H0#U'_ 8/*.()TSE?IQ($?),[,!L', SZOYCA<6A
M I7>,O8>O2G<D>((WBY>/[?(G*7P+(6/2PKG:1@JG[LL=Z*<!5D4L52X\*]<
M>!&7*DIB]0C^UZ-)87<9/#6RT2R%OW(I/-\E'3*#3)7RKKEC<Z#T'O1X]6B&
MA^":5PQSZ"GI!%QY3.9!P((4&V-(L %XDJ61XJ#[O1W-'PB1>H'O,9&[X']%
M:<@R$3L(+Y4[0<H]CM':ITAG2Y+DV<*M+QK8<);%LRR>9?$3RV)'Y+Y,9<B"
MP)$@BR/,%U 1<Z,4'#"I)$]V8F$O(;5XEL7S!=DAT6?Q4P,:R T;CE%I]U/@
M;DAJD<5QVJ4"'?'A).Z N4CHA=<-X@4B\3,>,?@!!DDS;(P,TD+$RI5Q&O+$
MC?['NV>E_.TPWO17<>0WQ0:6+VZ!;[>[+3?\83C].\SM+]-PER!=HRR5@L4H
M5(,4-B')71"OGA='CE1*^@>!NWQ?-9N?\L\(9_AS!92YNBVRY6TFV/'&<V\K
MKA(]?%KG:(]'!W)W(_\RT@IT,*>Y_-;D. K0Q*<!B[14UV"9!MZRP4_.$96Y
M &6]7*PXZ$/"W(2AVAQTL;X(KT WG"DN%T4I6K0!%IMJL:XKV0HU!-7\?_^?
MQ'/CMXWY&XS/F\6E6JWPO_@]86=Q5JS7.#*^ZPS^M8)?3A8_V??@]QI\VZJ5
M:O3D'RU';$48L&EKC!DMNP7@6V%ZA Z[A(?!3-E4]95&#JU6RP4LR("!+A?J
MC[98XS=I"M5::<#B9M&T:^RKVB [&4KPTVY,@ZD/>P>GDF6\43C9\[4J&WK^
M9#$F-)"ULNMHP"R"+16%YE7U!9]2A(UMZ$4?CR8F0"GSHES( A[<&+HTK3A#
MBM;5%5\A+>"+<.+T:$K9D9OG!!\>:>0]:O6@F,19[HLXCT#"RM1C@4P5 XT8
ML\R/HEAX*HN<@V3*_J(:Q6MQ]JZ4'\ 27E6T63]HDFNQO26MG]9^>&[Q;NE#
M7#F@T,*0J'E\IKR/B7$L$+I/<SR[37H^"8'L(0?L8876@M>=!",,9ZMS3A8C
MUII\UN@UE+_M.J_A92@0&RW("Q#(FZJ$7]>\(!5& +V@\CCH"?VE;J1.TX'P
M!86 +BS*_7K?% S\-(%2@T O8?V]$H3O;I0X*X&PIU<GBU_/U.A%I.3@)4U5
MEFK%:K4B2&H2]D.E,U0T-&BF2@54U6_8IY((.KMI5QM>PC?/"JN^]:+Z%<%T
M_ZVHBWBG?34%..@=T,_H&RXVI&@;8 GX7JU.VQ4G';MK,Z@2V%ZI6D\<![3K
M@I=__/ .WJ?@;/RN@'9K>/<%CMMFYT5#JA?^2LC+M( +7A=5VRRZS=(O[*8.
M.GN](K5^62.W5GE.=TC KGILVD=K#[0;L +^-%TIME8V&G;=UNNJ4;L4(01P
M=23:%92AHEX_:JQ15^H+TV8#T!"QJ-OS\JTLFO6*7[W!O[Y=<XE\-;B(+O0[
M[;TE_/KOMMD4^95].3W(5"G?9M477 7":G=!E"^W#!=$]Y>9#P-S>QC972<>
MF35HQ-C0PG^==;>^:[ 7]4TO.-<PV3=\=<FO&L2B'FZ0I3[%3Z9(_Q */WY
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M%QO9'"KD,[)+J^IWNZV=O[$3QE[N7@Z+]ARM-GS[U%BDEI ,P* D GK#>KD
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MO5Y1-5^3/$@F_ A^^1L$I%7UA0844U_05R> KBH#WU9M-)88G=TYD#<'\N9
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M$IQE 5=,.%&0\%2$B0J>15-X2_^Q"RY?.IO/DNO%;>D+E5R)&SC2!5&5>5$
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MF%.):&AZ&\F C!84*6-<\LRF:.(^.G0]BTAAK"=8*554H*MLZ2N +L4D#9P
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MCMO(89*_#E++2]_]5_8J?U\8Z0XZN\>,-!O-2 \S3WZ+Q;C%O;%IR(_A7'-
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M28C"W?9=AT"]^E&P=W3_&Q@DVXN[%.XZO<D5__W!,$0EDJP'Y*!:4<2-)PB
M@: 0N";!&2J[_OOC:TZW(*3Y,4?DY6"\)A;O67 $]^GV(C0OE-6*VO6,9Q?%
MYW"6RU!"]'9S\"TTPGV[^%X^W)0YOWJ9>1I:Z:.2RYNUW[)&W]U=/N@@.J])
M@7 G, HTZZ].8U!=$T4Q8<T$UU93MQ>=-R?XMP6]?YQ-EG6"VO*(JU46EH"W
MHS-0<]+3YNQ<@0\S_QZ4-E"0\Z1F_ J1\]#VO.4T> UJ9:(*<2PB<C1JY(EU
M5J>DHU4GX1-<8-[)N 5S68ES0\X"'@4\'M,*(&JM-*'(>TH0 (E#CEB%F(Z
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MPVZ[>>_J;MO.=U4]NP1RO<[^W<ERPC (F%:CJE>VG?( G@=(5DTO8I7AJXK
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M&&%)I,#<YY;P+Y%N<'][$L7I /S')7*E7*JZ-:V'L:ZKW%G^'[&ZF@Q\ UL
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M8")U( $%!:H,!S1%VF&%A* 1)R>EH)U26%&98*V+8 UZ,!H43F!0>@K_<&O
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MM)P #%(=N:',.+Q3U9T#N!P;/O@1V&#YXWH++OB8.W3!!?7[]*YQ!]H?<_^
M2=V\9 F>>!4[Z7W]@VG?'#QH?GGD\CR;KQES5C"&3!0YKC *Y"1(/A$]B=QC
M#%NY2QS(V6P^,WVU??,+]A;L?1+V:J-R61!D'<.(1Y-Q5#'DM.>8)"9M$J<=
M0'(D*%9]N5V1+=Q8N/%)W*@"2R%:8"62 TG =#0B_XF#!J4FY9C)78)/SD88
M$MQ7!\_*?F9-*&#F+0T")1I #8Y6(6UD1,& 2LQ MS&L<^;TF "6\]E\T1>T
M8&_!WOTVA&:)F*0\(M'A>4U0+') .L?.1DV<VJF\S]EJ0K2OMK<=O\L%!Y]S
M][X-<3/+7IJ=;^'64^DA^6R]1?.<]]I+-#IM;$@)824TV-P8)$VB!DQP*[6P
M!$B]DWOQI.B&W&?R8CP,<5+_],_98'K]VW@:?QS4?CBN9Y.'M G=OI_Z4?LI
M]]<3=+5J^QZV.R])17#U?_^/IH2\K587K?E.O:W:Q=NE4>>>![W:N?,4_=>/
MF&)[:7[RF\$47NJW3OK#11RFZH_X:5!/)PUN5PV:9HP^?%?MAX]S\^8\"BP?
MQUS/O&/;YOU^5+V;?9K5TTKWJMP]J]?TOLV"UHZNJS08YI;WF[7Y1[Q^_W$P
M$M0+Z@DBU"F 5N.04X0CYSA7E"KXMP/'!  ;KM9(*<VRU:>1-42"6&;$>J\"
MB7)=\XA^-AE,!['^!12(+'<;#>%O0!"3#T#7JV2]I.J?0?"OZQ ??EQJ"7)5
M2T#BOEQIO,>3OWT@&%P]S'M0-UP]6>7J>C'_"M[N+RH7/2QD%5/*#>D_QVJ\
MI#1"6U+K-[V>[WS6H%YY JS5QFH9NPMW26#KC4A(,>H0%Z"=&E!><P W-TYQ
MYW6GV';BVID$:H!CE&0OH$/:@X1WA/LHL/&1V-O"?95@%HKJC1J;$QJ. @+3
MBUS(<#U*>B]AV?N@N=SH^RJWY9ZW_UY TW1<U7$X[%5I,KZLIO"X_%7^;Z^:
M757;7!#'!"T,]*(3 T*)%/1!%04R&*#(2J<HP9):T<T\!%/)4S"QH@D"<1I]
MUCL3\D$+[:.*$?L"6@\!K<&HLI\^ =#DD_AE7_?Q; (K?GG9P YHD;W<;#[%
MR22&Q1<ANBG0VF)9>Q78EMELA$] G'\"5,H+5S\,SG*YT*:Y,!#HU62<HT76
MR/K+8'I1I6'\.F^AGJ\#X13KNK(A#/(#[; "Q3\K-("U<52!8O&/.,UTT_X.
M5TYB9:_@\5>3 ;R[7U6_C/QPEE\+JY!?=W*\X85B02:!L+# &]81I(/*1YR8
M>4QPD*9SIKE_"/Z+'8SJ=Z/PZ[BN8WWN''$7K:[K@3#1\5(9!+JJ<[33K*[J
MV=75L*7M.1[/L==N9+:3HSJ;/,-$410E:Q 9;'4PT5%*N7"UX4IV*RJ H2^P
MTW Y,5E9D!P90;-"&4$9]4"3RIT4(HL3);_0^M$VH3 0WV0\^W21Z>C=Q[_"
M)0#)@]&G_A&'_5C[_:3MP8=;QGGYW\^7_Y4:R3_.\N0;0,Q*<M4*\!^CCY<N
M3BI&-IG.]7@8=C57'H%PZRNQ-4<K"1"0&O#.@>W,=>2@BV*P@Q6V6!E#K-%[
M"6;/3)S1+H9V\7X'^AF'UI4/\VM^6I>O=?/;*K#]\MO/]]5#5:*GE3@E<%N@
M6#.;QF0].:$7D]#6X9#[MTD06SD$D&N.F$\J>*>TPIWX%4VLDXXI! 8($ [3
M"FEM*1+&@=EBA,-DW0SYH5F'A@X^@,QJA-V7+ 5'G[(S>SP#_1D4K7S9H*YA
M<#_&,,L1U'L2>O(T99Y-4T",T,PU8\IL95VJL%B8QNCURZ5I_QX#NDR6DK"*
M7_-16 2SHWK7R-#;>,3 / %5+)L)\.NI$2'0C1,)3%HO0.GG)D@$BE-$T2OC
M'#?1IFXB&U <YY$@XD,N7$8 A 3UR#/F.,?<<<:.A$2T)XGJ&;FW (M]$-T<
MA&#W5P33O]:W[-V,42V9? +%OL[JO8\QU">IL#M!%#<48(L%!68B$)"1,?=O
MT@Q;*H5@W=B[IY -0,[[U!#/#\" 8*6W^OD?P&2#SS&\'WT$H[%NQW;F>OIW
MHS@];:I0A'E'I$).Y\-9Y4"V"1]@:0E3'@MI6*>.S1[!I#'G-F/)TZF!J_Y)
M*39S:OB^5UW8S[%R,<+J-TO12*=&W;V:3<# ;9T!&7)63;=>IISV;.#DR(=1
M37@.($L8+'J30"&./B%&18R$)"LVG.WO!BJ_S;*HAC\:B&Y)ZI>MF/(TB40X
M[6&]MZ9NSRN13AYSL!>!$R^18U)G2620(UHCT%\2B2%0S_>".;_/%^'GR?BR
M\1^-?'P_:4FIC7'8%^"0DP2<7O4E3F*++V&C(7Z\,6Y0N5N$^V+;PZI)O+2#
M41ZSG4TOQA-X6[AQA^8KUKQ>C3700<[^JMMEOT%-@2B-!4<A: MR,]<$=BDA
M'PTV/F$:]4XE6U;B]_Z(=9R XO3S>/+S;#J;Q 4M?\P.T0=$-1W0S;3'0*?=
MZ.F'56*8S%>L@</4K%DC</.BY3VI!W4NNC2GHS0>#L=?@%K>[,P.]R[> V)H
M%N&*3;3B8A3S5<_K^P;X8?S6C2= \,U(\LCQV^9R-+37X]D4GOXUAK?MFT@^
M0_EV<8//GN.K.KZIXY7-??<6&SII(K::9W^S*6OY\Z">GZN]63QC2^9Q^UHI
M^T:J;]]^\Z<[+B)](N^[Y+[?@:+%O>\YR7&<5/VTRT$(PW@:T=O/&J]^!O'X
M0!GYUR9Z^L[=G8/ 8IQ]<37-ZL$@5 N .XG]?TJ8Z8,5C2=0ROVKUS(E9J>Q
M?H5_"O\<BG]HX9_'T-=N16 >(<XWCOED.'8''T+C]*G&;0[2JM\,%-UZ"A^6
MAT&--M\:]M7O0SMZ4"GHTUZW R'YZF-'X].:\GYG=\^6;H2"0\ZX,;,.7A1,
M&1RLY1C%U/2"S?T*'4N($JTE8Y92TNU3Q&,,T1*$DW"YFV4.XF88!9.X4DJR
MZ#K!"BM'U3^T<97WN"SN\<WB^XZF>S"2'L?;SPH+U1<@.Y$I%R#;'<B$S2?3
MFB/'<IJTSB'_G$A$M?2&!NVX[1P5B!@!(2( F0D&\<@-TD(JI"*+QN0NDJ+3
MM^OY@8PQTX.!%"#;@RNLJ,DY7;0Y'[2?[6#8>(XW^;Z+FERD2Y$N2^G"#3%,
MLYA+& G$!09)P8P$Y9=21ST5.'62%YU+UBF2D)0RWT,5,AQ;%)Q,RDBGG O'
MEBY,Z)XD3RL85FB^P-BY;NF9PECDD@6L(G+2\6SM!V1D;G,KA.(!:T=Q)P$0
M:ZRP= YAE@.WL#1P=U HJ, (:,N6*G]L&--2] A]6NVM\Z/YXDG>E7N 3J>3
M0=-O:Q$TE%/CYR[E&]V88DH:S;A(E%?#746BK/F/,9>&@R:,)36YS[W/R6X8
M$>MT EC6BG4DBM7**^4HLHGF",WL/Q;)H,A)C$S:&'6GS_VSNUT$[C&ABD0I
M,%:V]/QAC"KNJ?$.46QH+EO%D+52(T8BHS3AZ(/KUBA0A"JGD29@U?,8'+),
M:X Q3QG@F:/FZ##&#>UI613CXCM^=M]QHQO_].'WWXM0>34,5H3*>L9D#J%P
M$CG59"_E2K:82F2)4BSI9*/K9GY0%KT0&@EE%.+*&F2-%DAC;44 M1G?%$X_
MEE 12O4T+[IQ@;&RI:\ QJ@GS"M0; .AH.?::)&3!B.'O6*!.$-HIQP -XG8
MZ,'$S^$5G,#EUC")6'3"1^HX$>+8,"8E[QDE"XP5I_'!=>/:#N.6S-,'I-;F
M62+>E]JL_D_ ,MR392C["BZZ&M=-S<HWDSBTN<KOUBE\1[[_CGY?)-VN7']_
M]L>+P84G;OJC\E_.25HR'J11%J/@-2CPR3KD;$S(:^U-HHIITO$D2<\BTXDC
MS3!&/!B+#$N@^?L4(X]@+"3ZS-*RR0M&_QLGXTP@FA+Z]K""\B$I/^?.- 4I
M"U*^'J14+D0=.$9218VXD=FNL +9$ $0O50JESM<1TK*18HR:41E](@K2I"F
MF"#BO"&,!HE)I[C+L\?4];C@/7Q'F;H"F,4SOV_KXV-37?"F]I/?5.:DR*O]
M<AWMT\QV83S+]M[KE%B;U^!,918QWBGK6)94#G$N)=(^,,2C)M33R$/NAG#+
M%^:]H9Q1Y!.)B$LCD/,J^\\ H[FQU#IW;)FE>TSR'B4'SC*ZDW)>GM0JL%E@
ML\#F0^HX.HV=LPQI!>C'G?*@Y1.*=,XD]XP0KN,NU="/!9N$]#21/:$/'&%S
M9KBYL=DNK%\:CZ>CW':TH9K?/OYWDL)%'2-R)I^@1ZJ ;H)'.#<2Q,0FEVO9
M?[T<OAG:T:?_]TT<H;]]6%V&U6IXM"]SF;G5&H>(]K'1W[Z]RFV?1I_FU^VO
M6^\^%/Y;%%'/K@ 5;KOX[QS2=F?_$2N/?KQ]#)++>8+1<C6,T[:%UG_,AM=-
M':ZUVIQE:Q^RM?3[(U9LS5O;*0:U,$W7C\>6,6--_5E8"C\;VKS_+O<9S_TL
MF_JMP_'_S]Z;-K=U).G"?^6$[WBN'<%"U[Y(\W:$+-OW^H;;<LCJF9A/';6*
M:(, &P>0Q/GU;]8Y  @0I+C@8"]'-T409ZG*RGQRJ:S,.K-(Z\Q>C_O^,#M=
M!<)29#8"2.43GRHG_"2GP-(75AF5E%]/AJ?"XJBH1%%SA3C&!L#.623 H_#>
M21WU:L/4MRTQ&B7W>R;%CIJIRX<3?O8 'P 6XW@]&D]NN>0W6P?[K^K_#$;.
M#JJ_M0W[X+M;5L2SGJ@K>FE)[_SUN1W?.RT4;"SV6B2*4L#@40ICD:9"HA2#
M#(2#^:36=HY>TOW\ER' ;/Q@OW34\)SLJ=_45OJ=DXUPL^,AS5NOMRM6P9+%
ME1(,G;(?#TQ@";:6<+F_@Z0$.9\,HL9$9P5Q7JX=<7\)^_WA+V.8YLKJ[;1^
MB( \\98IX9\:M.*;8;;6@9[#K12O?IZRUX=2O/I#6\W\>C2,N841*,%!;B?C
M&AJ"T=3PR23S2=N?M)[5K*ZK[YJFI*-I;8>A_G[S M8OA^Y2.[N[VME"](QZ
MK."T!.OXT:+4CWW/>URS#1\"4LDW'HCH"<[P[7_/>^!!5=(^N7C@R<[O\;J_
MZSG IU?5]^4L<!!D*4Q?F+XP_:XK5!?=66#D:3!RAC7S7]AFXADI8 =!LIV*
MS$&FE!:AVJE0O:3WQ!D+53G\M6G>P]][?_168G&3N\':DCAT).<G5[G@H;G^
M6\=K>_29/]^],*[[O"U6+5GB5%G$<(B(BT"0-1XCQVS 'EN"">END^Q7$.C<
M$_8M/*\_G/:'']]=SYJ4UW?V+6(]W[EXL%4L6VD5"Y]J6 ?X[;$:/OI"F-,K
MT?LT,2N'44]W;0N$[@="E7;:9/1DP2-.N$,N1H*\#R291#7/)696(30J$ZQU
M$6GE&>(*)P3V((4?W!KLM4EJK>7/ 4&HE!=*% @]Y$-70)S]D_!9TC5+3YCO
MNA>[OYP++N>".]!/4I@D=)0(S/.LI A'V@B/B @N,>E"$NM%ZG=CXL]$_NGJ
MZ:M:::>'!H[\@/#6A*A@ZV$0Y<#8XD2QE49OL; :L8!]6W/!L."0]B+D5'6E
MR;YL_VZQE15L/<[H__'Y ;\^D(%;G( 3/36\G^C661P?WDT$C%B9, :7@C*2
MSUS%@(R3'&$I+8U!86S7*@_MR,/XZ<MD;&&E^T,[OOEE$J_JWT;#/)+Q:#"
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M"%H)&A%E/AO"4B ; 8Y2D !BGF#IU\J4;& ([P2]MGP \&@XO02)]Q4D;HM
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M,)H;2ZUS#YU@6$11W\T%\5>0P[=V/+Y)H_%G.PYU1SL6BEU(O.4-X*/9D"B
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M0\9;< &4]%%XYXAQ6TG=+9"Z?TA=-O;A=PO3^.N<@+]-K^*X[^%SZ'_ZZW_
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MK:?P@X.%Z;5)*A:;\1!Q[MDVXW%.LYA/>S&?A$N$RT01=A',)YH\TL$9Q),
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M+M/I1W"0P);W'8$-(^0KS1/VK'GJ2?81CY)S/)7.2>K:PZ<\<I\[!(/ZB3&
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MP4>RWIW@.<PT]SC>@-/X+KV/=O!3$][\?9P-LLG-"F?5_TJ3KW'6/6U"*;D
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ML T\GWD(]NP]GY_;8K)%/QS5I%>GGHMZH/X7=-D/(0Y?_?P/HZV)C@)0:27
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ML4A3;A2UC F]MC?>85;/K7O;V?8X-J4R<P&OLJ1G %[>8LE44(AJ+1#75B)
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M8;'3Y7XX3+W/Y3[8BK07@&CU=01*?8J#F]YAE*8];).?;#K#0[ 7?@6M-*A
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M 311E3B8.8LP1;C-@@,WGLS,EM;7]$MXT_J8,Y>]B8EDQQLP!HC2;A^UME$
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MIAFKB_GF*Y 0 +/!S7WOM5-80C#T[0JAEL1Q[MJV^QZC,9 O_PE(^!@-;T4
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MZ:Q%7Y1JS-2%3 <W?+WU8U#VK.$0E#R,17U-:G+R*"LO:Q%'@(C##CC-::=
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M*O]JZ9-_?0B<'OF+.5Z7!8^8?NEE1+4C&-.O4HE3.X(Q_2JC5+4C>-.*)-1
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M^7TA.G_1P#O,>5Z[C"R46\ZZIVN'A%Y04312% 1<%!4,VOO#AV_( F2!%BQ
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MCLGVUDW9F"T:S^ZT]@),$ZM3UU;2N0?G"= :(&[IDY.LMB+_'/\YEM$<5/+
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M@A=? ZM6^=D^'+><R_EC%*9[,D*9PV6N17+8H=JDN!Y,UB(ZGH!WCY>A>%9
MHL0\;&<9@N,N!4QP(2[X2PS^O)D,R;UWP;K5@+<T1E,S6$FOGXBT1B1-X.PZ
MHE"3J]<:'66;FJ;3Y 0>()06@Y/)60#II*.8'></>R(LT"?-*_MO;0#00(HS
MP4YN6+&:PA;C9Z2]DFD'"F[W7%%YZ?EIHI5*NM.9V\-V+)3^J;'Y6T-QL$?2
M/=[#W1YLJ.:T?, T%I]#>ALF9IVER3:,:@3GNAHV\0BP$ZVV($61<\X/*>P4
M5VYK+6IU=>9P?:EDEE8)2>JJSD+;TLX#K*Z&]<"4S#+2[(!46\4Z(QP[06,2
M:F"IH;)E?\U6.*/VI0>EOY", MS%SZA0S^*!_(2#% M@ 1C?7[UD>T'>&62A
M1/5R;$\BAZ>GS"">V$4J694^@F>?::UD4W.F,\!<7NJ5#OF/EA54"JB$INBS
MVEIS$.7JD ,KQ>:F(&2&^8[:05%IUNB$ O"@XNL*$\$VL7!2TZEY#;=B[W[F
MB)[D>*+.>5J';.FK_,'/7U%-]X?A1NQ)SFD4> #-0/I[[;W IWIGP9H*IL]X
M\3Y?!%_(@HK 29%FHF0O<^7)WU!E)H!JM]X_4\^E^X7]@$EGZP[6UM5M;KK2
M!J@/A=.7GTC%(M#=LC2#5P$-6E>H5[1%9R85=I+IIAKGL]3U" U-P(G\JWUU
M8ZX?;5(@2B4MOH/V!50@[4NG5&Q2'>;5"\5 H<>O$C"MMJAU!48_S<7L5!;=
MV)A=]\6XUOF+UI>=I_:X(2JCN:8UMKX$4>;)0A:* *T189"0>AYR<P4;4+"P
MC'=T1TO"F&X"C9">0PQ<W$X355?#YOMY10'>83COO?CWW)FWYO6LKV)/+O4I
M7>RJI:!Z,T[+RC,3 \WZ$#HOEIT8>0?L73Y@#?>>)$?\)@<"?06+3,0.3[K!
MH?RH^KO.XE=;Q;BK"L24P>K@">)?]>"ZVK*&^R1PZICZ;QF*>!V][:1U->N"
M%)_+!A%*E++X,&,!92Y^@:&D0RKB\:18\:8;MC.96=BQ,UW6E\#EWIN &;@B
MXL+9#O[J$DV@I6%9J;U8D]Y0I3*<]0N*%@K_@\EY<GQXM183/%!O,_D+J62M
M8MML2_.,5BP%W-.;]F.D5V?T)'9X\@Z/79:244R2"4O?GFG,YB9K_4UPEBRW
M1)B*?L>)>!JK,]OW)&75N3./5[]V5KCV>-06MW<2<M@%D;"UW;.QJ99]79-I
M Z4!PG/3EPCXJ*)2@]L;AFI,NA(W+=.K#H_K,%*='I_A<P'57I7WV!A9T^BX
M#-@@]RXFE^0%>0:\DFY1G#05'\V5+*8G\-R;X#^\P&U R5 4M"<;4 @LAJQ
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ML06LYT4:)^0D5"[T2ID9W!!Z7^(ZQ]VVU4V_C%RR\FA^@L_@J+%. Y>J])G
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MQRXFTC0$C.:&H??#[2(YW0)6Y+@.82:9*=V($C^RL]>XBCR3_/CU\S*=V]9
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M$Y2UCK+FD6A_4GR)J<>HD$8GUX2HQVD^PW3F_G?*O126H?"0P)\APS*8C2%
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MSSUQVAE2_:6'=8;)3A(#L>*,\@BKQ .G../;QT(YQ]ML>0(4> 87O8](:&>
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M"%8?7CODWT)-3<,0:1N#6*9/".)Y/ $A6M2ZN$D/01*53"%)[;C1$.$X;H\
M%TC%)V(@%.DBLR7ATF4C%BY_=  M7D*-TGY[>1H[YR.$[P?^/S0891:/X "O
M*_UMXPB%$2;\6S4&XF%07A-<E&J"/?'!N(,?'XJ\7 T]7LB6.82XD6&:EG'G
M^HU'_G!K8-#(1I/I&ERZ+<+@7/($F^3T1M7+NYK@AG2.KC'>M()O5/A+N^[E
M'?M6+4]%<\6+>R)5AUB=ETC!R9R(CB+CUU-MAS"@V,,V-ZG$S@\UUW"-4!?L
M:C"%9W:,LBG"?E=L6R;]&.)5HW!PLGO+X'&%SWR)99"Y,<J_X7;NSKM>W_=
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MV!<4A7FK8^\"@\7LV!<0X"A-X4SK*F%*"?2;,=4]GE*V<Q^@\$;ZG1TZ$$G
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M3=F*K?J:]WM/S[^QCW/^FK9D5?OSR.$<90!-"(Q&V'#>O";7[&: /8':^WM
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M(9P3Z%;SPOWXO77=O(1NW.Q*^SU-PU:;G=%(5,HD*%3T$?6TCW4#+#X,TSC
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ME?9T6R^@Q>7/%&@QVWFY! Y('U8F6;U2G!HWM9VJ[QGR39>\+0U]JPD?:*0
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MC@^GF592C[0F'7Q\8*69;40.)0RVZ6JY8\)D&=@F_6.J99(O$?LICO338*_
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M[57\>S*$AT[&D^[H"TTV5+CH6E7_R0A5QD6.!T7)=ZF "*G2?SD>0%7^CIW
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M5;NO,A;S"W-D0X)/QDXR-)71I=Q!K QVAM#MCR#[@Q:7[)XM4MCJWG_]DX,
M(4_'V5+=0.$V#"90[5&[Z_E> >7L-%09Z]]I^I0%Z^=H$6">@8EDYX/]?WG
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MJ-.ZXO[1ZO5QS_.#> =UG J[:8QV_\4@0)F*+Y5%\HI0.6](*JDE,GF?A$&
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MQ">VAB35EBQ$SAD.:,&9/($OBO?'Q8_?L!!K7V@7<@>A(*-2-#_ <[?C\4'
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MM0_VK_^=K-_[N.7>\\?]0YVR'9E9E> 'NDZ#&@K7YJ<&L=2J!L%.7VCCT\,
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M-$UO&]-'P<:V(R2FX6S#O1, *9)O52<!)S#4I!,4^B$X :8T-9-R;B@3\SL
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M&^[Y8#0^\V'XI=A0$:61'L$@H\?0ZPG$;7XO@U)$Z?Z;;"*&>$"VYL5+$$D
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MG6'NM%/O!KJ#@U*:A[<9 C$&;%C\>HDF 9Q$0$4'.$:$@LNG3R*^H06B0L"
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MAY M9,S564!"5U[:HH":X7MW()^T1R<N\,A_A!P_5 5!]]>S!@I\\[[[A^S
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M&,XG\E1-;CGLG'Q595S5M7KG3.\HBF&4/<ECY.[NX6DTE3*5JZMSJ%XGJ7^
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MM_7^!J_ "_Z!/%9@S\G#3@&0V_ >'[['*,#??]U\HN #?8O"](T7O7?RT-,
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M5$M.!$4O8>FF=\ R\K.$I2]AZ1;L E7-K\?_GZ<8+8V[2XUX ^9XNLIUQ+0
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M:P>@2\6%<A'AM,-Q2/'0S#54MALE^YH>#DYT*DSN-XY/I(?X=8](UP& 8;-
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MQ9ZS$E6;O1I2%-:%AA)2P'*%-N$N\/Z'NG=#;2Z,UU W4ZS<76>SG8N0=L=
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M,;AD9_4Y"N-!0+,7L[9RQTCU[2^^3? 9]O)F2+)2!(*EJ.*'(=3YD/T0 =
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M=CI, -F$JPXM<RUS);E9-$D%CC4:-A\FUSHZ%:SWQO')0Q>_[A%*'H-M&!T
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MO!B]1-X&$_57)XJ<(*EP=<X*%B&J;ZK-P>__73-07A G#C%JJ,+DHG<^2,L
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M!61E0%*)5U$M )3/E4YA1_Z/J"+6W?WBP+"EHZ\6)X#[0M#7I#ORQ8GFR$>
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M9@#GT TW]%PGU'\3O/1J#W"#B CRN%/XLP;:@=;M%X6="S@@!P=(?]@BLJK
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MEE@]%Z:#)7W1$^"Q3\)8+2.\[+;P+QE6J-F!>[;9@*XMVQ;8STX\D9.S+<!
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M7QU@7#\>():O<M=F#PS0P>LJP5.1:_1HN$,O=)&U?5O-P9?'X)=6G^J+J/V
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MW/@(*5>$K^)/@<L 1)].A\-0%1(Y.N B-)6#:N7@7[7*EV7U,U<L(KQ#:L
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M<L!O,5*> ^G,0 ?@S8?"^A@!4ESY?K BG$67^0AEN*2>$$42- -UI8A>^%!
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M ;AN..OT":F-223UV%:$,7PH;&:@NB44;Q9Z@Y:U.=S;2ID5;7?0?R;TC[8
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M*8.&ED^]_AKFE$4/" ,)H#:I%?F:A63-Y@F@"XSCIE%&U;5K[;M<;+<8X+@
M*5=DP/G6 )G<!0O MMO^*TE0*W(8H49:CC@F,HH.RUU,4\87GJ123S@\'<>Z
MB"AT@6) B6?F=/5[P#H]L.*0(A3#]^#!^SOZ[7UU.G&&7WB/;^0XX8.':#8]
M3NA.<KJEDC6<Q=.:G?)<)>J"QRQ!=13W 'I0'4+W=YQUIK"L S#+!H! 25/+
M?5NLGTSIZLX6%GV[(Y^@@*E&Q]6<PD/Y5?M2"*38(@N.VO6CX_=HN8.,W2/3
MKC>.'A!Y\'F[WEX0@3_,LM[EH52'B8"&MT.C<\6\DH61^^J,P3!> ([[UG<_
M/;RQGINK<UX\#-MH"M4985X&]42)HP);4]2:\IBL$WV%$[$;>*![2SQ BT_.
M>&!R/+#0^NA.S1PMG()=\[Y^)A.1YQL#GOP(EO@\\;\;,*9GR NMZZUV"BKB
M1@RI=%MKL36S>Y/'2.^SX8$]6#K?N,ZD.\>W!:S>&6/.&(E@3/)M,H8;;?Z@
M]RM!9=L]VLZ;_1 $WAECJXVQ\V;?!SPGL> 1.9NN:UP6R_ [M_9]%U@>\2',
M'X' .QN\01MLNZO:^U(<8@(OU9N=;,(-A17WM?\M_P6_<9WQQ3^2^:H?YE[:
M+W$; ,7NI- *5T#S1"UNF528F2Y1K/U8_-J=!:[83_UY^=C,&#KD1:CS: 3P
M]ZD<TXEU<:U[@/^WX-,OW0/W'P_^#U!+ P04    " !3@5Q8QW<D#78%  #/
M*P  #P   ')X<W0M97@S,E\Q+FAT;>U:ZW/:.!#_WK]B+YETDAEL;!YYV%QF
M*"%SF=Z%3J SO8_"ED%7679E.4#_^EL)&_* I+URS:,P28BME7;WI]^NGJVQ
MBOGI&VB-*0GQ&UJ**4Y/NY^L>LUV6]7Y(PI4"XG6, EGD*D9I[_OQ$2.F/"
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MJ'PF,'2Z5X.+\XM.>W#1NX0/'Z_Z']N7 QCT?B(MGA4@[C%\M/MVQX9^MV-
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MUWIB5EH=$6LW)6JU\*(BJTUK'?L*B&Y*7:OPE)?%J@#'\SNEIV,O0KUGH/N
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MXJ8  &EM9S4P.#$U,SDV7S$N:G!G4$L! A0#%     @ 4X%<6"<]ZJ)\;@$
M7"8& !$              ( !(7 ! &EM9S4P.#$U,SDV7S(N:G!G4$L! A0#
M%     @ 4X%<6,W60\,F%@0 MTP% !$              ( !S-X" &EM9S4P
M.#$U,SDV7S,N:G!G4$L! A0#%     @ 4X%<6*H.>'-;,P0 [H@K !$
M         ( !(?4& ')X<W0M,C R,S$R,S$N:'1M4$L! A0#%     @ 4X%<
M6/UTB)4.WP$ \?D< !$              ( !JR@+ ')X<W0M,C R,S$R,S$N
M>'-D4$L! A0#%     @ 4X%<6(OK<Z.K%   ;J\  !               ( !
MZ <- ')X<W0M97@Q,%\R-RYH=&U02P$"% ,4    " !3@5Q8SPOJ..X$  !,
M*@  #P              @ '!' T <GAS="UE>#(S7S$N:'1M4$L! A0#%
M  @ 4X%<6(5LXZ '"0  <44   \              ( !W"$- ')X<W0M97@S
M,5\Q+FAT;5!+ 0(4 Q0    ( %.!7%BN$OY!\@@  /A    /
M  "  1 K#0!R>'-T+65X,S%?,BYH=&U02P$"% ,4    " !3@5Q8QW<D#78%
M  #/*P  #P              @ $O- T <GAS="UE>#,R7S$N:'1M4$L! A0#
M%     @ 4X%<6(N2Y^%E!0  BR4   \              ( !TCD- ')X<W0M
M97@S,E\R+FAT;5!+ 0(4 Q0    ( %.!7%A^TSZ[-AD  ,ZS   /
M      "  60_#0!R>'-T+65X.3=?,2YH=&U02P4&      T #0 F P  QU@-
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>rxst-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rxst="http://rxsight.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rxst-20231231.xsd" xlink:type="simple"/>
    <context id="C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b64f86a3-1985-43c1-be28-347c081c8c0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_300d62ab-2d34-4a7f-a559-6b38f6978705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fd90b2d8-aec9-4102-be22-34321f15f5b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c0d5359-a0dc-4cfd-ae75-3d2013478591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1c4862f1-51c5-4005-ad1c-acfd1c889569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b57291d-8c21-44bb-84bc-64c21d397bcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="C_25a0e726-e847-4009-b9ba-5e81ccb68e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2022-12-30</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b42dce2-cf09-4fb9-9b81-1ed4c14f7dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_366621b7-b9f6-4be8-a093-a9b4299ad983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:RightOfUseEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0ec5af07-2372-4042-a3f4-8511845cf529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b7350b8e-419b-4564-9523-4be12bc48b7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="C_436ef63d-fc6d-4417-9b9b-5376ba16f03f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:StockOptionsIssuedAndOutstandingUnderPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9fc400ca-bc44-4785-8a4c-ad2af354ffac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bbfab71f-6665-4527-940a-db6f796b7bbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_080706bb-030b-4069-b6d7-d7d31567a27c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:SharesAvailableForFutureIssuanceUnderThe20062015And2021PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f7038cd-03eb-4dd6-8464-7a639831af3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="C_8cad5a80-a737-4f91-a14b-3bb394a8f508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c4dc177f-a41b-4a6c-9a51-c41f851cea5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8cd00306-7aef-4100-8205-c4511dea8fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_9b5f35bb-1962-4ed8-958d-db0a4a14c1cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_bfff9d89-3c68-4d8a-aaf1-ae180ad5659f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_74c21f63-ba1d-48cd-9f91-f41a3325970f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6b82dab6-564a-4b17-993f-52bc89ea5908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_619af7c1-a3fb-4ce4-9615-d637396286e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a53c973f-68a7-4092-8c03-15c10d086cf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:RightOfUseEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_47ec21cb-9507-465f-9a93-95dbd904a764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e670d03-0073-40c0-81aa-a64691a64651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6bd8958d-ac74-435f-a9b1-65f5c5df5463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c024e436-4a63-48c9-b8e3-a71a5ce33e50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:ServiceWarrantyServiceContractsAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-28</instant>
        </period>
    </context>
    <context id="C_e15cdba7-7d58-4afa-a398-ee69435f47e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_5ee404e1-09d9-4e49-8567-7e3e99def558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f255c0ae-0062-4072-976a-b8a141cbb369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="C_f7039d17-9ee2-4e22-b624-e5756e318526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49f1aec2-a4e1-4190-a936-3eb5ce2b4155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9b31877-61d1-447b-9f36-a10b15a4cba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-28</instant>
        </period>
    </context>
    <context id="C_115b5518-d11e-4805-8e6b-f554aae35196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_ec480dfc-096a-4260-9524-3d1d45f8ffe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="C_d24bcbd2-389a-48da-b2a7-d4fe20dbb56e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-28</startDate>
            <endDate>2021-07-28</endDate>
        </period>
    </context>
    <context id="C_9e2c5118-f472-4fd8-bd76-d3936f7e7ba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ab197fb1-568a-479c-8dca-51ebd28598ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f69db501-f7ea-4cc8-80d2-81597ec37696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b78bc7b3-79c3-4faf-8705-31df15a4698c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d126cea-f298-4eca-b4ae-c0648a9c58e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b77127b8-810a-4edb-a388-e4c235f9b291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_1a6bb245-6eba-41dd-bf62-8d7ed791fd8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0769e4e2-f071-4d16-811c-15ab6db50acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_055117f2-9811-4160-9a40-b17c1f912611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4a21676c-9a43-4d66-b8cc-6cd51899920b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="C_0c2cf702-64b7-49e4-996a-cc8a823efe97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18f22b78-7783-4b48-a916-de31acc7d1e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="C_fa175e83-4ae0-4e56-8332-28c4e9813a04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_04d3ef87-f8dc-4a39-8e22-74626d458f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_38073016-ce8b-4023-8081-103f403ab2bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fed1b82c-fcdc-47fb-8e4c-b26548a6ea85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb92c51b-50ce-4557-91aa-51fc17ad1a81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ec88e75c-ff75-4185-a750-95225b1dcd49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_88cb89e8-ba4b-4206-a251-8f43f4a4a237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a4f444db-5996-4c90-8623-059c3f481ab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-28</instant>
        </period>
    </context>
    <context id="C_e78c7069-b653-4177-963e-9d1bbcfd973f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f291850-e62c-4bcf-9ff7-f62a97675a66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_26a351db-d159-4b04-884c-9e54b986cc5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5bc13ab9-a18c-40ae-9c04-bd63e0ed3ba8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_70360018-fdc1-4362-ac4e-ba7f96b09f5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_f491cf28-fab6-4049-bce7-7c1f825422fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_37cd287f-b1fe-417b-bb04-4b5f0d4c6f3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-28</startDate>
            <endDate>2021-07-28</endDate>
        </period>
    </context>
    <context id="C_aa88a57b-a838-484b-b8a6-d0306d09b381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1e80520-b096-4bb3-86ce-8009a5315cb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:StockOptionsIssuedAndOutstandingUnderPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1d1a568f-d394-4720-a1b6-9a88ef02d12b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d19decf9-3310-45a2-abd2-b456a757f5d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5e4f8477-6783-483b-8846-75d4dd7609bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_811fa48d-1349-4d4a-9ccc-b9ad64097210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c3e38f4-8300-4d9a-93f9-acfee4e73ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:SharesAvailableForFutureSaleUnderTheAtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_28619841-2fee-441e-b364-8cc0d0d59ea3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6fa4f2fd-ca66-4db8-b0ed-9ab91076fb17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ffa1d143-149d-4487-a305-e878c9ce191c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:LDDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlanAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84f4cc9e-e25e-43fa-81e5-13a42f6b8d68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cfeaa0f9-8a0e-4a4c-af2e-cbfcae368f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rxst:AugustFourTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="C_f267633b-a252-4c4b-a433-0ca95b359c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3ce3f5e-c938-4989-9d48-abb64a18b225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d583f1d4-bd83-4639-a274-fe28298e7a88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ee2d4d90-23fb-46e2-9141-296d7b75f054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4a7af93b-ffbb-4eba-bf5d-00c6faec0f6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:ServiceWarrantyServiceContractsAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_245fe6f8-26ec-4721-8201-1bc9132d6013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:SharesAvailableForFutureSaleUnderTheAtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_88b18fd6-1484-4233-9ccd-4639da1f1dde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-28</startDate>
            <endDate>2021-07-28</endDate>
        </period>
    </context>
    <context id="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2eee38f7-b0f6-4df6-b5d8-aa6c3374c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rxst:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7e12529e-af41-4c48-9b3a-2cd9a1e05936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e59788db-8615-4e43-8e9d-3d404e52eb66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_28c73d3b-1f4e-47eb-8983-ab2974f6fec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49a84f59-2893-49df-9918-73f7863dfea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_01f8a67f-a74e-480a-abb3-13c58f494e3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f203818c-89e0-4e29-82a7-a9e012aac75d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_062bed15-9f98-4171-bfad-0df8a119278e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:NewLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_5b74aaf6-1816-4ba8-b25b-06f474253518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:NewLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="C_8e853287-f8f2-492f-b2ee-7e9d752ea4ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="C_1bc5a935-0234-4618-aba4-1ab485aa91f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8faa684a-3959-4ad4-91fa-5f5f141cb065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3836ee42-99e1-4b4c-b3f6-d7a829aa62e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0abec27c-e9d5-42ec-8f2f-cd858ce7ee0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="C_613e254a-d190-4764-a1ac-1d0b1edcfaae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_023ec558-5797-47a9-a985-808a5dc77077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:The2021EsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3f2eeece-26e5-4b45-bad6-a36623117435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:RxlalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_22015c87-a9d7-40c9-bba3-3d510e3d5d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:LDDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_271a9f64-d7fb-4c83-8f60-0616504ca74e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_41c727ce-a38b-4fac-af15-b2f7c97ca3f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rxst:RxlalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_34ca7f16-9126-43a4-886f-fec2f9b38b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_08a244e1-1cd0-4f12-b52c-c33b4404b433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxst:AtmOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4100cff0-e3c8-4a4e-a04b-cac826120706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rxst:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5bafa0c3-726b-4976-a24a-5029c3f3ff37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bda624d3-25b5-47d8-97a1-87d5fd21b451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4eedea1-0f5b-4dfb-bc30-d9f477763ebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:StockOptionsIssuedAndOutstandingUnderThe20062015And2021PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_06262739-6be2-40d0-a27d-2ee73ccd9a32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-04-04</endDate>
        </period>
    </context>
    <context id="C_829b96d2-f2b7-4707-8dc5-c513602f5c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2848131a-3718-4555-b34d-a2e75cc52c9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="C_935e5c68-4a2f-4fe7-830e-c64554a43bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rxst:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="C_668f69a7-acb0-43b4-a348-1ac42e4921ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d466df4-3d33-403f-8a77-220f9e7e5b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea603303-001a-4544-b085-bb841cb42c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3910fa9f-eae3-48ac-b145-d6273c7505d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e81e1959-5dc9-462d-a83b-fe7fb4c2dc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rxst:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc1f24f5-960c-4f14-a149-a28449446cd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_35054392-155d-4fc2-92bb-5c95eec04e48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxst:OfficeManufacturingAndWarehouseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2256ad1c-8fe9-4d3b-ad3f-3872402cb7c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxst:CalhounVisionInc2015EquityIncentivePlansAndCalhounVisionInc2006StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7e03f7a2-cd01-43e0-96bd-e479c8471a97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13836f48-52b4-4300-9d56-4f50c234e19e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2536cb31-d62d-4c3e-8731-b705f381e0d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_87f27813-04b4-43a9-89cf-60f99646eed6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ca4cbdee-0ada-4ebf-982e-0a37a5748260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rxst:MayThreeTwoThousandTwentyTwoTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_8c73432c-1e8b-41d2-a8a2-ad9cf9e153b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001111485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Subsidiary">
        <measure>rxst:Subsidiary</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>rxst:Segment</measure>
    </unit>
    <unit id="U_Item">
        <measure>rxst:Item</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_5dd7fb70-dd6f-4dc3-a6d8-55878776b401">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_490b6b1d-3bf1-4eeb-b099-513a5c99a6e9">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_e99068eb-24aa-45a4-aac9-7f3e912cf5c2">0001111485</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_4efa97b4-2f73-48e3-b9a0-8446f86a165b">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_89532d2d-44fa-416d-9656-337fd8e5f25d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_2ed9af09-c8c9-47b5-bea3-2da165653b77"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1a6bb245-6eba-41dd-bf62-8d7ed791fd8f"
      id="F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InvestmentTypeExtensibleEnumeration
      contextRef="C_d19decf9-3310-45a2-abd2-b456a757f5d2"
      id="F_ad232f5c-7ce0-4d92-95b3-b3019e7d245b">http://fasb.org/us-gaap/2023#USGovernmentAgenciesShorttermDebtSecuritiesMember</us-gaap:InvestmentTypeExtensibleEnumeration>
    <us-gaap:InvestmentTypeExtensibleEnumeration
      contextRef="C_bc1f24f5-960c-4f14-a149-a28449446cd0"
      id="F_1f005e07-66a8-4957-933b-b4aede44a4d8">http://fasb.org/us-gaap/2023#USGovernmentAgenciesShorttermDebtSecuritiesMember</us-gaap:InvestmentTypeExtensibleEnumeration>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_98a9eb22-5875-4665-9fe4-7da6a3667f55">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_4215fd74-502e-4548-a8dd-7b80b1cd43f0">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_c8f26f61-f9dd-4949-8795-ad61341c192b">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b">http://rxsight.com/20231231#LeaseLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_b14603c8-a5d6-41d8-b49d-2b04b4c22671">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_cfa28257-8c04-4096-a2b8-5d3340f0d040">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_1c8ef374-722f-4dc2-918b-df585e24ce25">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175">http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_71880674-2bd2-4945-afb1-3f72c4851f95">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_26a782d5-6f81-462e-a366-f1723b670ab3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_09aec78e-44ef-482d-867c-043b58679319">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_0036a8b2-8e50-4df9-bad9-36712f7d6772">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a4f5405e-e24e-45f1-a7f6-f541fb81a83b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_22b2c70d-4775-48c6-b0d6-83afeec0f6db">001-40690</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_c6fef7bb-7ed2-4b4d-ad67-6baa05785f7c">RxSight, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_37eb7a5c-3f2b-4005-bee7-0e91865cb96c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_50e7f6e7-1498-474a-ac58-0109d2d9869c">94-3268801</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_db17e565-d4f3-4097-b5d5-0b0781a5354a">100 Columbia</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_55e6aeff-d596-4980-9b64-85b1828844c1">Aliso Viejo</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_dd5a7f0f-f02c-4359-a369-b29cc1f2a713">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_3aec0577-0f1c-45a5-ba8a-f028893e22b2">92656</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_1182c5dd-2961-442a-be8f-82416ceb515d">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_f81b72bc-2108-4615-be96-1302ee9d1a11">521-7830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a6471bf0-4921-448e-99a4-1bd195327b84">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_1785f41f-89d6-4b8c-b634-1fcafe0324a3">RXST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_985b1dc6-30f3-43df-bb5b-1d3156fe365a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_2d7b405b-6fc0-4730-95cd-81af458bde47">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_533200a4-6133-445c-8b89-672106cc39db">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a97cfd2e-a354-4c01-92d0-a08fef9e9bde">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8d119eb5-2ed1-416a-8a22-ba75c6affa2b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_521454c4-24af-4fc9-80b1-26418b2179cb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8af0ef4a-87b9-41d9-a1a8-cb97f8301e03">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_bf199b2d-3253-4291-880d-9ad80a82a4d4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_1f033c78-4eb6-4197-9e0a-8bc959c5499e">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_cbcdfe00-ee39-4616-bf4b-77063c775892">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_9d725045-37f3-49d8-9216-de69a459d4b4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_b64f86a3-1985-43c1-be28-347c081c8c0f"
      decimals="-6"
      id="F_089af205-4e95-4d30-ba8d-59c30358eb10"
      unitRef="U_USD">869000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_ec480dfc-096a-4260-9524-3d1d45f8ffe9"
      decimals="INF"
      id="F_985981e1-5019-4442-835c-57c389afc035"
      unitRef="U_shares">36987556</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_ce713a58-a626-4177-a386-76c52f3680ea">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the registrant&#x2019;s 2024 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#x2019;s fiscal year ended December 31, 2023. Except with respect to information specifically incorporated by reference, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form 10-K.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_6e011409-d850-46b9-858d-328dc86d68d7">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_1ee1ec76-67b1-4ea4-9360-1aaa29e905f2">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_6e49b727-e06f-4875-aaf4-c38291df2379">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_a4fae2a0-1e83-4aba-8e51-22aa80070a37"
      unitRef="U_USD">9692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_e90a865e-93b3-40fa-8281-a31c2c9cd2e5"
      unitRef="U_USD">11834000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_5f1d6993-5f64-4bfa-a385-9eecc59194f5"
      unitRef="U_USD">117490000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_7d1a6f8f-5395-42dc-aef3-e21deb20e973"
      unitRef="U_USD">93968000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_1f50b246-d39e-4977-a213-da6ca5eb1ea1"
      unitRef="U_USD">20281000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_c335f773-df6a-438b-bcff-bec81ce2c1c7"
      unitRef="U_USD">10956000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_cc7e46b9-5433-4642-bae8-1df7e4dfea56"
      unitRef="U_USD">17421000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_4103480e-2930-4fc8-89a1-0be5e255c3e6"
      unitRef="U_USD">14835000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_2dad4e26-8baf-4e28-a5ec-0f2e13ba8fdb"
      unitRef="U_USD">3523000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_2d44d5d4-7687-4fd2-9998-400879a45902"
      unitRef="U_USD">2962000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_c4f15582-2134-40b3-8ca8-ff3793dd3a69"
      unitRef="U_USD">168407000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_9b52413e-2c8f-45d0-91a0-c4a9105dada5"
      unitRef="U_USD">134555000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_d4038770-c5d0-441c-9dcd-a697ae5d82d1"
      unitRef="U_USD">10841000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_9ebbf07f-9deb-4a12-962e-09ac9d31e800"
      unitRef="U_USD">10138000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_03904796-a1a7-415a-a1f7-4c62bb393041"
      unitRef="U_USD">2444000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_6cbcdad3-ec08-4e6d-841b-5e185dbf1488"
      unitRef="U_USD">3943000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_6996f6b5-7deb-4b4c-b58e-a6ab39b2df14"
      unitRef="U_USD">711000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_55cf1b68-0b07-42f9-840b-8d37178ef302"
      unitRef="U_USD">761000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_2b011a31-e74a-452a-b882-950e6721fd80"
      unitRef="U_USD">147000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_e16d4c9b-cd7d-4688-8ce8-e486c3753256"
      unitRef="U_USD">767000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ad5aeeb8-3e18-4048-9efb-8c22e6cf49bb"
      unitRef="U_USD">182550000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_3755f3b5-31e6-4cea-ae3b-1d7cd70b5cce"
      unitRef="U_USD">150164000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_4b057676-ba46-4f7e-8e4b-35003b16f16b"
      unitRef="U_USD">3863000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_691215f5-dff8-4d7b-a1d2-cbae02f756fd"
      unitRef="U_USD">2595000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_48345122-0517-4d61-bfb0-044a41a78343"
      unitRef="U_USD">15239000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_5f6f01ef-fb4f-4419-a520-6a0ce98d8ba3"
      unitRef="U_USD">12672000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <rxst:LeaseLiabilitiesCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_2d9c526e-4527-4a5f-8107-cd6c1a2da5eb"
      unitRef="U_USD">1801000</rxst:LeaseLiabilitiesCurrent>
    <rxst:LeaseLiabilitiesCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_a2c58354-f7c1-45f0-99cd-e6ba75e3a85e"
      unitRef="U_USD">1970000</rxst:LeaseLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_aabe28d8-9027-40dd-b342-596ff481f811"
      unitRef="U_USD">20903000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_b1918539-5c31-4190-9b6f-6fdfc28c1b7d"
      unitRef="U_USD">17237000</us-gaap:LiabilitiesCurrent>
    <rxst:LeaseLiabilitiesNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_3ed0025f-bb53-4e6b-b380-df30da40dd81"
      unitRef="U_USD">1211000</rxst:LeaseLiabilitiesNoncurrent>
    <rxst:LeaseLiabilitiesNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_37b148e4-a3a3-4757-8ca3-e38c22d7a314"
      unitRef="U_USD">2856000</rxst:LeaseLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_0c9dd094-4ac8-4c56-a0eb-07bb46157e7b"
      unitRef="U_USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_d062a59a-9fc3-4bc8-a1ca-f057ec6960d4"
      unitRef="U_USD">40169000</us-gaap:LongTermDebt>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_98477ac1-8640-4772-a928-9fd4a7dbd27b"
      unitRef="U_USD">74000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_556fa291-f45e-4fbe-acc6-04d95713fd8a"
      unitRef="U_USD">0</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_bb78345c-306c-42ca-bfe7-084a11f18899"
      unitRef="U_USD">22188000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_d0d8b6ca-23f3-40e3-8201-075360ca1565"
      unitRef="U_USD">60262000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="3"
      id="F_f28f8336-53b0-43e5-8c0f-9057055b6b93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="3"
      id="F_69577cd8-c2b2-46fc-b628-24279d55dd15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="INF"
      id="F_18038717-8e0a-4dae-a23a-bb985f1a4d40"
      unitRef="U_shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="INF"
      id="F_d0b2c3e7-d986-4127-9602-733872bd72e4"
      unitRef="U_shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="INF"
      id="F_e1242c0f-fd52-4970-b231-3860e288fc47"
      unitRef="U_shares">36139513</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="INF"
      id="F_d2332ec8-8347-4c63-98fd-f6d1906bd595"
      unitRef="U_shares">36139513</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="INF"
      id="F_51f6a607-bc56-46ca-9310-da7a26cd9303"
      unitRef="U_shares">28268389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="INF"
      id="F_bdeff3ed-0394-4cee-a543-b515ba683eb5"
      unitRef="U_shares">28268389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_704b664d-963b-429c-be4c-6c529a56d137"
      unitRef="U_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_31d6af6c-2302-4f31-8608-8964be1b5cc4"
      unitRef="U_USD">28000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="3"
      id="F_0f0bf33d-5841-4bec-b89a-4c297dae2a4e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="3"
      id="F_4c48ad80-bb78-4603-b646-be94e202b628"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="INF"
      id="F_d617cb93-0329-42e5-af2e-a8a0b4c0bd98"
      unitRef="U_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="INF"
      id="F_78fa0bed-eb2b-41db-bfe9-009bf6a86989"
      unitRef="U_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="0"
      id="F_3e1ccb6c-e59c-4238-b963-de8be6b1daa0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="0"
      id="F_346244c2-85ca-4019-9389-c7f8f407f8d8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="0"
      id="F_454c987d-ded8-42e1-b847-d7c23af95644"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="0"
      id="F_9533f045-4c60-4171-af0b-08f100791914"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_d286e360-fbed-4943-b040-b25b097c67f9"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_eea1ec8d-0c16-4e80-884c-21430af43bc6"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_6a369ad3-cdd3-430b-86fa-31c76cf3e810"
      unitRef="U_USD">754971000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_7117168f-e07e-47cb-ae0a-fcb16e418510"
      unitRef="U_USD">636001000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_dd6bfbdb-1051-47a3-b3fe-512e5703e579"
      unitRef="U_USD">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ec122c86-5e3a-4266-9582-378a2a63542e"
      unitRef="U_USD">-95000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_66a107af-001f-414c-afd2-9efb0ecdd8c3"
      unitRef="U_USD">-594640000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_1c8a7eb8-6560-46fe-8841-2e86d2df42e3"
      unitRef="U_USD">-546032000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_88d1c02a-8d64-4c76-8be5-05451a565bf6"
      unitRef="U_USD">160362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_52ac70f2-284c-45cd-b63a-3f9c8f052bf7"
      unitRef="U_USD">89902000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_a3f9122f-5bff-4421-a2cd-986e4848229f"
      unitRef="U_USD">182550000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_085faa89-a8b0-49f7-9f49-e7a421c34c03"
      unitRef="U_USD">150164000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_6e62979f-e79d-4c10-934c-5f38afeaf303"
      unitRef="U_USD">89077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_3ba0c292-d96a-4884-92d5-43c3011fce64"
      unitRef="U_USD">49005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_35bc45bc-264c-433f-94b1-a9048f12fbdb"
      unitRef="U_USD">35312000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_53aa72ed-2f4b-4870-800d-c73610213f1c"
      unitRef="U_USD">27677000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_14749023-aaae-40e8-bf24-f22471e3b092"
      unitRef="U_USD">53765000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_06271496-51d8-40d9-bde4-b79f22013692"
      unitRef="U_USD">21328000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_05f58b69-828f-4587-abf4-7594c4298600"
      unitRef="U_USD">74799000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_7b87bd24-9ab6-4b81-a837-1efb9176cc1a"
      unitRef="U_USD">58665000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_ac2c6d13-c87a-4d12-af8c-57bde87d63e3"
      unitRef="U_USD">29051000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_8f8c8763-5cbe-4148-89a1-47b07e2a61d9"
      unitRef="U_USD">25981000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_04af8894-47f9-46ab-a981-8c8d0d69a226"
      unitRef="U_USD">103850000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_91cec819-f277-4cf3-9043-6303e2b9f6c0"
      unitRef="U_USD">84646000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_62f1b7e1-7203-40a4-9a14-ed2d5cd36707"
      unitRef="U_USD">-50085000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_5170ea48-3426-44d0-84cb-68013774d112"
      unitRef="U_USD">-63318000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_d5f4b267-88ad-4fe1-a366-9f7949101d84"
      unitRef="U_USD">3308000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_0127fb46-5573-4718-8faa-a1331505456c"
      unitRef="U_USD">4946000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_e02d6e81-2e1b-4179-afc9-c46b87712953"
      unitRef="U_USD">6574000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_23621363-8e82-42e7-ab15-0c7a720d5bb0"
      unitRef="U_USD">1517000</us-gaap:InterestAndOtherIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_a14cbbab-d27d-4598-8d94-7c3cf44a3320"
      unitRef="U_USD">-1769000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_791cea26-8d74-4506-8770-2199d1f3a379"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_b668d942-1e86-49ec-a216-756700b57bee"
      unitRef="U_USD">-48588000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_7965e41b-6800-47f9-9fbf-04997b4df6d5"
      unitRef="U_USD">-66747000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_7a591a7a-9d66-4c09-9dab-11b6818db996"
      unitRef="U_USD">20000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_04f095ea-f648-4813-8995-42b50b0aa88d"
      unitRef="U_USD">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_63080e55-a41c-4ba5-b78f-ea05d9ca2280"
      unitRef="U_USD">-48608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_b839b0ef-4ee8-4dea-a926-a06cb7ad8584"
      unitRef="U_USD">-66756000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_26fc4928-2407-415f-b293-36d498f22030"
      unitRef="U_USD">83000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f5578357-eccb-4213-b289-a419a982e33e"
      unitRef="U_USD">-66000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_ab0102fb-c191-4688-bb82-5c1566160b1b"
      unitRef="U_USD">7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_0853117d-ed41-4084-9948-3d7904b19c95"
      unitRef="U_USD">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_dba38e9f-bc45-45d5-8b57-b6037d08186d"
      unitRef="U_USD">90000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_1d22b930-aafa-42f1-9823-4df9f385374c"
      unitRef="U_USD">75000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_c6066b52-6556-4e0a-a9cc-6681447edef0"
      unitRef="U_USD">-48518000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_6815d5dc-02c0-4c21-bbd2-ef35bbb892bb"
      unitRef="U_USD">-66831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="2"
      id="F_d273af1b-e775-477f-8741-c5f577941215"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="2"
      id="F_10d1b4ff-ed2f-4202-8429-ff130f9f63cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="2"
      id="F_a29b18e9-ca2c-4063-97de-75f07c200afc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="2"
      id="F_f058dd0c-9718-4965-8336-24ab10f3c281"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_674888e9-2207-4746-9cf8-977c226ccf7b"
      unitRef="U_shares">34455111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_adb3ac2b-27ed-4035-9585-c24369a8b99f"
      unitRef="U_shares">34455111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="0"
      id="F_526c80fd-dcae-4d3a-a2d9-64c66ed9271c"
      unitRef="U_shares">27661982</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="0"
      id="F_cafa4137-be1e-43b5-9e65-790822ab14f2"
      unitRef="U_shares">27661982</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8cad5a80-a737-4f91-a14b-3bb394a8f508"
      decimals="INF"
      id="F_3dd3ef6c-71f7-44be-a5d5-4310e8b3f5fe"
      unitRef="U_shares">27366746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8cad5a80-a737-4f91-a14b-3bb394a8f508"
      decimals="-3"
      id="F_345b46d9-cdb6-4b88-adfd-0335a50e036a"
      unitRef="U_USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8faa684a-3959-4ad4-91fa-5f5f141cb065"
      decimals="-3"
      id="F_603833a4-290b-4840-8445-2bddd7ae671b"
      unitRef="U_USD">617511000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d583f1d4-bd83-4639-a274-fe28298e7a88"
      decimals="-3"
      id="F_0a3b7afe-a595-4b6f-a34d-bc286f672bfc"
      unitRef="U_USD">-20000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f69db501-f7ea-4cc8-80d2-81597ec37696"
      decimals="-3"
      id="F_b5785d78-dc32-4d6f-963c-38038d03d70c"
      unitRef="U_USD">-479276000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075"
      decimals="-3"
      id="F_35f47eb0-5920-4ff3-9e9a-60f6a31a7a31"
      unitRef="U_USD">138242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares
      contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"
      decimals="INF"
      id="F_41200469-0694-4f86-82ad-962b75aa90f6"
      unitRef="U_shares">382506</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"
      decimals="-3"
      id="F_eaac4d48-a4aa-4a5b-92eb-54be5a8eb008"
      unitRef="U_USD">1000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa"
      decimals="-3"
      id="F_ce193bf4-c08e-4d78-a4a1-3ba5e72ef032"
      unitRef="U_USD">840000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_574c4463-a3ca-4206-934d-00cb46dd2447"
      unitRef="U_USD">841000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesRedeemedForEmployeeTaxWithholdings
      contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"
      decimals="INF"
      id="F_99c0423f-5536-41d2-85a4-327c0ee36d85"
      unitRef="U_shares">49456</rxst:SharesRedeemedForEmployeeTaxWithholdings>
    <rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount
      contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa"
      decimals="-3"
      id="F_c95ac422-fba4-409f-8a9f-b0ac3f9a29dd"
      unitRef="U_USD">-643000</rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount>
    <rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_c05da786-6ff5-49fa-a48a-c007542c2ed1"
      unitRef="U_USD">-643000</rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa"
      decimals="-3"
      id="F_22f23ed0-fcbf-401d-be93-ed94a8008a8a"
      unitRef="U_USD">11397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_951dd948-f948-47ac-b486-c1f157c62f36"
      unitRef="U_USD">11397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"
      decimals="INF"
      id="F_7b9b16e9-8747-4a05-97a4-bb3da6e82926"
      unitRef="U_shares">92718</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount
      contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa"
      decimals="-3"
      id="F_d6c24e7b-91d7-4d29-baae-b8e613541738"
      unitRef="U_USD">937000</rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount>
    <rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f504fafb-d2b9-485b-a3f7-a1bebe4a64f9"
      unitRef="U_USD">937000</rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount>
    <rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare
      contextRef="C_2536cb31-d62d-4c3e-8731-b705f381e0d3"
      decimals="INF"
      id="F_ef83addf-183b-47ef-a76f-fa38894454a4"
      unitRef="U_shares">475875</rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
      contextRef="C_f491cf28-fab6-4049-bce7-7c1f825422fa"
      decimals="-3"
      id="F_79badad7-afc6-43f8-90e7-81635a85dd3b"
      unitRef="U_USD">5959000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_158afc5c-d3d0-42fe-8243-6e30dd2f016b"
      unitRef="U_USD">5959000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount>
    <rxst:OtherComprehensiveLoss
      contextRef="C_26a351db-d159-4b04-884c-9e54b986cc5c"
      decimals="-3"
      id="F_4a4c0cd1-42ba-4332-998f-38cc447be39a"
      unitRef="U_USD">-75000</rxst:OtherComprehensiveLoss>
    <rxst:OtherComprehensiveLoss
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_00b607fc-4d86-46ff-899c-f3ebe70544af"
      unitRef="U_USD">-75000</rxst:OtherComprehensiveLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a3ce3f5e-c938-4989-9d48-abb64a18b225"
      decimals="-3"
      id="F_add9a189-abea-4c92-b9be-b5fc05b5ed67"
      unitRef="U_USD">-66756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_5f3f0697-ecb2-4e24-8f6f-0ad2e2f1140b"
      unitRef="U_USD">-66756000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e78c7069-b653-4177-963e-9d1bbcfd973f"
      decimals="INF"
      id="F_03b05f0d-04b6-4a14-bac3-3769655027af"
      unitRef="U_shares">28268389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e78c7069-b653-4177-963e-9d1bbcfd973f"
      decimals="-3"
      id="F_22132119-21ce-475b-8ada-7669d71297d7"
      unitRef="U_USD">28000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_619af7c1-a3fb-4ce4-9615-d637396286e3"
      decimals="-3"
      id="F_d52e6e60-8744-4590-8292-a66684661d58"
      unitRef="U_USD">636001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_26a351db-d159-4b04-884c-9e54b986cc5c"
      decimals="-3"
      id="F_7c5587c2-5c9a-4022-b56b-cc05f72a9a83"
      unitRef="U_USD">-95000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fa175e83-4ae0-4e56-8332-28c4e9813a04"
      decimals="-3"
      id="F_ea7bd5e8-63cb-4f8c-ad9d-6c2ff6348b41"
      unitRef="U_USD">-546032000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_34bf62bf-70ed-43dc-8ab3-66caa6900b8f"
      unitRef="U_USD">89902000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="INF"
      id="F_d01da811-65a7-4ae6-a684-41de68ba9629"
      unitRef="U_shares">1103974</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="-3"
      id="F_3a9e09c9-461c-4165-8b6f-9728453ad09d"
      unitRef="U_USD">1000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_d9eeea97-8e25-42b5-9f0a-9d6a35782e8b"
      unitRef="U_USD">8351000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3c513fa1-cae3-4d51-bec6-aabac939a92b"
      unitRef="U_USD">8352000</rxst:SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount>
    <rxst:SharesRedeemedForEmployeeTaxWithholdings
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="INF"
      id="F_aa1fb4af-61fb-407e-ba50-8833f713f0a6"
      unitRef="U_shares">62068</rxst:SharesRedeemedForEmployeeTaxWithholdings>
    <rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_248eb63d-0be1-4d80-8751-a8b1ef37e882"
      unitRef="U_USD">-1423000</rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount>
    <rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_27184c8f-1d0d-43ef-b165-474e6d7ba042"
      unitRef="U_USD">-1423000</rxst:SharesRedeemedForEmployeeTaxWithHoldingsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_406444d7-dc21-4271-b718-9fb3f8940e18"
      unitRef="U_USD">15746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_4e1846d1-8bcd-4ffa-bfe6-a754822b4f81"
      unitRef="U_USD">15746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="INF"
      id="F_5c91dae0-9db0-4611-94ca-b8e2a2db7627"
      unitRef="U_shares">87129</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_a6778b5d-fbbc-4846-b43e-f8fcf23c9b3e"
      unitRef="U_USD">1121000</rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount>
    <rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_608669e0-c2b2-4acc-850e-228019a091fa"
      unitRef="U_USD">1121000</rxst:SharesIssuedForTheEmployeeStockPurchasePlanAmount>
    <rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="INF"
      id="F_09b4f598-9d51-41d7-ab6e-3f425b075177"
      unitRef="U_shares">4600000</rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCostsShare>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="-3"
      id="F_a6c4ba2e-039d-4e59-9b36-a9bff4101a2b"
      unitRef="U_USD">5000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_55be754d-086b-4a4a-a570-e2d2b0f12411"
      unitRef="U_USD">53595000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_5f8de83b-b57b-4308-a795-88d0c3c31270"
      unitRef="U_USD">53600000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount>
    <rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="INF"
      id="F_6d91cebe-72e9-4b4b-84ea-44d7f1c401e5"
      unitRef="U_shares">2142089</rxst:IssuanceOfCommonStockForAtTheMarketOfferingsNetOfIssuanceCosts1>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount
      contextRef="C_811fa48d-1349-4d4a-9ccc-b9ad64097210"
      decimals="-3"
      id="F_f0ee4db6-be59-496d-ba76-fbd47a6585c5"
      unitRef="U_USD">2000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount
      contextRef="C_74c21f63-ba1d-48cd-9f91-f41a3325970f"
      decimals="-3"
      id="F_79e8802f-33a6-47a1-b3e6-b58137ef2737"
      unitRef="U_USD">41580000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount>
    <rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_ea5dbf86-754c-4267-97d1-2388ff79fab7"
      unitRef="U_USD">41582000</rxst:IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount>
    <rxst:OtherComprehensiveLoss
      contextRef="C_ab197fb1-568a-479c-8dca-51ebd28598ff"
      decimals="-3"
      id="F_609df9d7-2c1e-40be-97be-36aca3b98c12"
      unitRef="U_USD">-90000</rxst:OtherComprehensiveLoss>
    <rxst:OtherComprehensiveLoss
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_e755c15c-3e13-47f5-aa6d-23ff8f179327"
      unitRef="U_USD">-90000</rxst:OtherComprehensiveLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea603303-001a-4544-b085-bb841cb42c83"
      decimals="-3"
      id="F_1cef1079-6815-4c27-80cd-fefc3eb1ad58"
      unitRef="U_USD">-48608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_7551c737-fc57-47b9-a068-512e835cb89f"
      unitRef="U_USD">-48608000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1bc5a935-0234-4618-aba4-1ab485aa91f4"
      decimals="INF"
      id="F_f8529229-a5d4-4316-9897-edbeb24b5f43"
      unitRef="U_shares">36139513</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1bc5a935-0234-4618-aba4-1ab485aa91f4"
      decimals="-3"
      id="F_2b769c43-2791-4974-ad3e-11d0c3fc5447"
      unitRef="U_USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_055117f2-9811-4160-9a40-b17c1f912611"
      decimals="-3"
      id="F_05749270-b4ca-482e-803e-7b083640d7db"
      unitRef="U_USD">754971000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ab197fb1-568a-479c-8dca-51ebd28598ff"
      decimals="-3"
      id="F_a71893ed-03d0-41f4-a7c0-8c7bc4848a3c"
      unitRef="U_USD">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2e670d03-0073-40c0-81aa-a64691a64651"
      decimals="-3"
      id="F_da408fc8-1959-4170-87b4-ff7dfd6b4688"
      unitRef="U_USD">-594640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_b5fe6672-e6be-4606-946f-7af4fb95f0e2"
      unitRef="U_USD">160362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_8179f6f8-ccf7-4f96-be11-7c4af3c96d32"
      unitRef="U_USD">-48608000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_42c47a72-6060-4613-947a-e5bf5bfb14a5"
      unitRef="U_USD">-66756000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_5a02ee5f-b900-4cba-8b4c-36a2978b7dfe"
      unitRef="U_USD">4078000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_3d3e39c4-c90e-465c-a665-446ac06a5faa"
      unitRef="U_USD">3884000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_5a563014-d328-421a-a044-d3d1e8806bf4"
      unitRef="U_USD">165000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_414cf562-1b86-4bf4-8f6f-64fe3433782c"
      unitRef="U_USD">138000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_2d745de6-a60b-4821-ba38-5c319beb1b01"
      unitRef="U_USD">287000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_c14610cc-88cc-42e8-9368-80e379e55cf5"
      unitRef="U_USD">552000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_f697672f-19ba-4895-9b35-34a4859a8a39"
      unitRef="U_USD">-1769000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_7bd2506c-fb56-42ab-8a2a-1313022d8214"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_ef40cd1e-a192-4e63-970e-706d763690b3"
      unitRef="U_USD">6122000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_62caf35c-5024-42d2-bae4-d8573e8f33c0"
      unitRef="U_USD">1405000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3e90ff2e-d19d-4db7-bbea-fca021706d8c"
      unitRef="U_USD">15746000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_ec08ed3d-f593-4808-bf72-0d6d573cc72b"
      unitRef="U_USD">11397000</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_9b6081d3-9e3e-421c-85e7-dc4ed7d166bc"
      unitRef="U_USD">164000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_1debe4d6-f8df-4a38-8620-c37858f5fb21"
      unitRef="U_USD">752000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_35cff366-22b3-4af7-b10e-b14e8ebfc6f0"
      unitRef="U_USD">9325000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_a745f78b-91de-407c-b52b-ea787e08a620"
      unitRef="U_USD">6094000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_adf4616b-8545-4511-986d-f20001fb5e38"
      unitRef="U_USD">2749000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f9042850-9074-4c38-9997-ef5a80084c58"
      unitRef="U_USD">7555000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_af7c0c3a-310e-4688-a366-28938d7c42e2"
      unitRef="U_USD">562000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_bae12045-c802-4370-aa5d-a944d7fe58a8"
      unitRef="U_USD">-789000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_c712bf09-c972-443b-9b0e-70efe5a4408e"
      unitRef="U_USD">1250000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f5480c5c-fe86-4afb-bec7-7edd0dae4404"
      unitRef="U_USD">635000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_15d80818-16e5-4f4c-8825-dbd007e835be"
      unitRef="U_USD">2314000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_4f574e15-1f65-4e93-8701-9a28169295e1"
      unitRef="U_USD">4813000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_f19abd42-710c-4daa-b348-ebd32b3d22fe"
      unitRef="U_USD">-41593000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_5cf4d37d-112e-4053-9b10-21b480bd2676"
      unitRef="U_USD">-58850000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_2d82b50c-f3ed-45b2-8f6c-cb60bb130db8"
      unitRef="U_USD">4814000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_ef12c31c-82de-4829-af5f-09de34eba5ae"
      unitRef="U_USD">2393000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_806de204-df9e-4f80-aca6-558f7ee1dddb"
      unitRef="U_USD">255000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_eeaca8d0-03e6-405f-8eb7-ac672ab9a5dc"
      unitRef="U_USD">255000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_8a05242c-d13a-46c3-a875-d2e0882edd26"
      unitRef="U_USD">272315000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_94c538c2-44fb-46da-9f96-8caf7165ea0d"
      unitRef="U_USD">212657000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_bb4c5fd5-0f92-4f10-ab5a-291e142e72af"
      unitRef="U_USD">-22129000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_b4adfdfb-8de8-48f6-9644-fbc6e7d9f105"
      unitRef="U_USD">39950000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_484d8cdf-e2ea-4ccb-b1c2-351034bf5295"
      unitRef="U_USD">20000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_13caca8a-a699-4dca-aa66-dd7e0522d421"
      unitRef="U_USD">0</us-gaap:ProceedsFromNotesPayable>
    <rxst:RepaymentOfTermLoan
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_15beb827-b44d-430f-98f9-a9add83bc88f"
      unitRef="U_USD">60000000</rxst:RepaymentOfTermLoan>
    <rxst:RepaymentOfTermLoan
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_64e19174-46b9-4927-857c-d50f0fb8b4b7"
      unitRef="U_USD">-0</rxst:RepaymentOfTermLoan>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3dbb727d-812d-418e-97db-c11466d560ce"
      unitRef="U_USD">54050000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_d66a4ba5-6835-4a0d-aed1-1adeb8b540cd"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_d8a14af5-74f6-403a-8baa-61fb51c8a0a1"
      unitRef="U_USD">42434000</rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings>
    <rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_91057fd6-b835-4bf3-9e44-653c1d9107b2"
      unitRef="U_USD">6050000</rxst:ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_0556f4f3-7a7b-43ae-b8ab-f8aee9ed9b86"
      unitRef="U_USD">9473000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_01865601-4534-4b54-9fb1-11ac6d16a6c1"
      unitRef="U_USD">1778000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_fd5a48d6-a54c-482e-89c5-cea628bc6706"
      unitRef="U_USD">-1423000</rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation>
    <rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_bf83f3d4-f122-4092-91b5-456c3855e39c"
      unitRef="U_USD">-643000</rxst:PaymentsForEmployeeTaxesRelatedToStockCompensation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_4910d61d-464f-44d6-b32d-6cc30b793db4"
      unitRef="U_USD">153000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_ab3b93cd-5d60-4f7d-8a96-334a033ab4ff"
      unitRef="U_USD">121000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_bed03b35-45db-475d-a82e-c31c80a76eb1"
      unitRef="U_USD">622000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_9be900a7-5676-4909-91f3-1f107e536405"
      unitRef="U_USD">587000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_0cd6e6d5-d987-4058-9a79-b2ade86783cb"
      unitRef="U_USD">2235000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_786800ac-8b48-4c51-b299-18d048a6194f"
      unitRef="U_USD">145000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_fb9675e4-b5c6-4ba7-8985-170f95f57c2f"
      unitRef="U_USD">61524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_2b483a01-fe19-4536-be06-4ead042845e5"
      unitRef="U_USD">6332000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_2ad8389f-615c-4629-bcfe-fbef7045791a"
      unitRef="U_USD">6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_7759d8c6-f17d-44ed-b084-f4c1caa3c86e"
      unitRef="U_USD">-9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3425fb0d-12fe-4a11-bfd9-e7308d650308"
      unitRef="U_USD">-2192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_58c50327-0767-41d9-a524-f5937d33c93f"
      unitRef="U_USD">-12577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_e65b8a0e-9db9-4855-981f-d0f93a389c42"
      unitRef="U_USD">12595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075"
      decimals="-3"
      id="F_e2dddcee-9fc6-45bd-be4b-a3984bb4f187"
      unitRef="U_USD">25172000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_fd3cc35d-4449-4caf-80b7-cf3ea69b4916"
      unitRef="U_USD">10403000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_09a0144e-2300-440f-878e-51c109614f0b"
      unitRef="U_USD">12595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OperatingLeasePayments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_93de472b-27a5-4f89-b97a-3a9fa70b7df8"
      unitRef="U_USD">2216000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_260f8531-7f61-469a-8806-8e735cff6d7c"
      unitRef="U_USD">2187000</us-gaap:OperatingLeasePayments>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_0c5d03a4-4d55-4971-9854-c4d3f1e9a79f"
      unitRef="U_USD">8000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_406cf420-fe68-4d70-99f3-128fc4c76e1c"
      unitRef="U_USD">3000</us-gaap:IncomeTaxesPaidNet>
    <rxst:InterestPaidOnFinancingLeases
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_c267266f-bf3d-4d4d-9756-cc4d4af159ea"
      unitRef="U_USD">12000</rxst:InterestPaidOnFinancingLeases>
    <rxst:InterestPaidOnFinancingLeases
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_28e8ea48-df69-4419-a52f-e9311d0409bf"
      unitRef="U_USD">18000</rxst:InterestPaidOnFinancingLeases>
    <rxst:InterestPaidOnTermLoan
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_cdc6eab7-3810-411f-8b4f-564cfe74bf36"
      unitRef="U_USD">3464000</rxst:InterestPaidOnTermLoan>
    <rxst:InterestPaidOnTermLoan
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_4a51af69-1bfa-4198-bf88-972d6a9d2083"
      unitRef="U_USD">4239000</rxst:InterestPaidOnTermLoan>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_948becd7-63e6-44ae-acb4-578e74d2a8f5"
      unitRef="U_USD">46000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_d3b73b44-7890-4109-99f7-b427eb291ff0"
      unitRef="U_USD">1090000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_b1e0c690-e0e2-4b97-8440-7b4c9e1cb3fd"
      unitRef="U_USD">102000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f3c979c1-834d-42ce-bfe8-8feeea960e99"
      unitRef="U_USD">311000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <rxst:OperatingLeaseObligationsIncurred
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_435172b9-9d15-4dde-933b-8956748e3eee"
      unitRef="U_USD">46000</rxst:OperatingLeaseObligationsIncurred>
    <rxst:OperatingLeaseObligationsIncurred
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_3d75f472-4bb4-492e-aa32-030103a52c65"
      unitRef="U_USD">1090000</rxst:OperatingLeaseObligationsIncurred>
    <rxst:FinanceLeaseObligationsIncurred
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_4a97520f-2af5-4363-b484-0e3de0a03eef"
      unitRef="U_USD">102000</rxst:FinanceLeaseObligationsIncurred>
    <rxst:FinanceLeaseObligationsIncurred
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_5b503262-0ff9-4a77-a3f1-ec420bc5d506"
      unitRef="U_USD">311000</rxst:FinanceLeaseObligationsIncurred>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3a1e3905-3546-4244-b0f2-2fba10ad7939"
      unitRef="U_USD">282000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_9654c72f-5cf4-4ff8-930c-929c68c2edb9"
      unitRef="U_USD">299000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <rxst:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_8a92924d-5032-4c6b-b728-144584144bd4"
      unitRef="U_USD">145000</rxst:DeferredOfferingCostsIncludedInAccruedExpenses>
    <rxst:DeferredOfferingCostsIncludedInAccruedExpenses
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_27d7baac-2f1e-40f5-854d-1875e4d96c63"
      unitRef="U_USD">133000</rxst:DeferredOfferingCostsIncludedInAccruedExpenses>
    <rxst:ReclassificationOfDeferredCost
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_fb51021e-b649-48c8-9ddc-e16228ab0260"
      unitRef="U_USD">1390000</rxst:ReclassificationOfDeferredCost>
    <rxst:ReclassificationOfDeferredCost
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_b7535e52-f5a3-4a23-a84e-06b9e2df5956"
      unitRef="U_USD">90000</rxst:ReclassificationOfDeferredCost>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_da78ea31-6f4c-4ae4-99ed-0d61029c9bd6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 1 &#x2013; Organization and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RxSight&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Inc. (the &#x201c;Company&#x201d;) is a Delaware corporation headquartered in Aliso Viejo, California with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; wholly owned subsidiary located in Amsterdam, Netherlands (&#x201c;RxSight, B.V.&#x201d;).  The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany (&#x201c;RxSight GmbH&#x201d;).  The Company is engaged in the research and development, manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s products, which include the light adjustable lens (&#x201c;LAL&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201d;) and a specially designed machine for delivering light to the eye, the Light Delivery Device (&#x201c;LDD&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x99;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201d;), are approved by the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) primarily for sale in the U.S. and have regulatory approval in the U.S., Europe, Canada and Mexico. The Company began marketing its products in 2019. The LAL is a premium intraocular lens (&#x201c;IOL&#x201d;) which is partially reimbursable under Medicare. The Company competes with other IOLs in the premium market.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include the accounts of RxSight, Inc. and its wholly-owned subsidiaries, RxSight, B.V., and RxSight GmbH. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company&#x2019;s chief operating decision-maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.  The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Shelf Registration Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 8, 2022, the Company filed a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shelf registration statement on Form S-3 (&#x201c;shelf registration statement&#x201d;) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital.  At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million dollars of common stock through an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;) offering.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATM Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, through the ATM offering, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,617,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, have been issued and sold, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,142,089&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, were sold during the twelve months ended December 31, 2023.  As of December 31, 2023, the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million authorized under the ATM offering was sold.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 7, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock in a public offering (&#x201c;Public Offering&#x201d;), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;days from the date of the underwriting agreement to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock on the same terms and conditions.  The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023.  The Company received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Public Offering, after deducting underwriters' discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022 the Company has cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the years ended December 31, 2023 and 2022, the Company incurred losses from operations of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.  Based on the Company&#x2019;s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company&#x2019;s products and achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements.  The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and meet its future capital funding needs, as needed, through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <rxst:NumberOfWhollyOwnedSubsidiaries
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_8d49e288-44e7-472b-a83c-40d245e6bfd3"
      unitRef="U_Subsidiary">1</rxst:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_9ce2c82f-fba1-4bac-bd9e-3f515cdcc50d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include the accounts of RxSight, Inc. and its wholly-owned subsidiaries, RxSight, B.V., and RxSight GmbH. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company&#x2019;s chief operating decision-maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.  The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_801c0b37-9d38-4360-92e6-b015a53babdc"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <rxst:LiquidityAndFinancialPositionPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_ca4f1a31-79e9-4796-aa3e-1c4fcf65d79e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Shelf Registration Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 8, 2022, the Company filed a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shelf registration statement on Form S-3 (&#x201c;shelf registration statement&#x201d;) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital.  At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million dollars of common stock through an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;) offering.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATM Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, through the ATM offering, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,617,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, have been issued and sold, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,142,089&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, were sold during the twelve months ended December 31, 2023.  As of December 31, 2023, the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million authorized under the ATM offering was sold.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 7, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock in a public offering (&#x201c;Public Offering&#x201d;), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;days from the date of the underwriting agreement to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock on the same terms and conditions.  The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023.  The Company received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Public Offering, after deducting underwriters' discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022 the Company has cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;127.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the years ended December 31, 2023 and 2022, the Company incurred losses from operations of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.  Based on the Company&#x2019;s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company&#x2019;s products and achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying consolidated financial statements.  The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and meet its future capital funding needs, as needed, through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;</rxst:LiquidityAndFinancialPositionPolicyTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_935e5c68-4a2f-4fe7-830e-c64554a43bf9"
      decimals="-5"
      id="F_2c977391-e038-4dac-8db3-e58019eae4f5"
      unitRef="U_USD">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_115b5518-d11e-4805-8e6b-f554aae35196"
      decimals="-5"
      id="F_de5549af-18e9-4663-9423-48e8d0156a7a"
      unitRef="U_USD">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_8cd00306-7aef-4100-8205-c4511dea8fb8"
      decimals="-5"
      id="F_0064dd20-9a96-4253-840b-88e6934a3a8a"
      unitRef="U_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2"
      decimals="INF"
      id="F_d3c53975-d893-4799-a0de-d0d57a11a06a"
      unitRef="U_shares">2617964</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2"
      decimals="-5"
      id="F_0e7e071e-0857-4af0-8423-1a8450193f37"
      unitRef="U_USD">47500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_5e4f8477-6783-483b-8846-75d4dd7609bf"
      decimals="INF"
      id="F_ed50d3c4-cf8c-4e67-90d3-ad1218a88dec"
      unitRef="U_shares">2142089</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_5e4f8477-6783-483b-8846-75d4dd7609bf"
      decimals="-5"
      id="F_b943798e-0e5e-4fc3-aed1-ab8169fcc610"
      unitRef="U_USD">41600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_49a84f59-2893-49df-9918-73f7863dfea2"
      decimals="-6"
      id="F_c6f875b5-f8e1-455f-8dc9-3a8ac537d7c7"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb"
      id="F_50eb3c51-2cdd-4eca-8b8f-72306e8ddf35">2023-02-07</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb"
      decimals="INF"
      id="F_90d500bd-8621-46e0-852b-517263715487"
      unitRef="U_shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369"
      decimals="INF"
      id="F_02ccf930-04ff-4b0a-837f-a82fc9b8ae85"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <rxst:AdditionalNumberOfCommonSharesIssued
      contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb"
      decimals="INF"
      id="F_fdf5d58e-a117-4ad7-8a11-9dbd1e36ddb5"
      unitRef="U_shares">600000</rxst:AdditionalNumberOfCommonSharesIssued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_2b57291d-8c21-44bb-84bc-64c21d397bcb"
      decimals="-5"
      id="F_fb8eac6e-4894-42ff-8cab-21078eac4389"
      unitRef="U_USD">53600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted
      contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369"
      decimals="-5"
      id="F_8db41f8c-fe38-4715-b04b-0cbeb1326acc"
      unitRef="U_USD">3500000</rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted>
    <rxst:CommonStockOfferingCosts
      contextRef="C_f255c0ae-0062-4072-976a-b8a141cbb369"
      decimals="-5"
      id="F_e9ce8018-ec1c-4d8c-8ff4-f063f6aba3f0"
      unitRef="U_USD">500000</rxst:CommonStockOfferingCosts>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_fd26a721-4077-4117-832d-e0d9b63b4743"
      unitRef="U_USD">127200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-5"
      id="F_e1302e4d-49c7-4fa5-aaea-9d2c6a89b0a4"
      unitRef="U_USD">105800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <rxst:OperatingIncomeLoss1
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-5"
      id="F_8dbe7ccd-ae66-44f4-acfa-a8db68921c32"
      unitRef="U_USD">50100000</rxst:OperatingIncomeLoss1>
    <rxst:OperatingIncomeLoss1
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-5"
      id="F_a95171ba-c762-4474-9e01-dc818d1e2341"
      unitRef="U_USD">63300000</rxst:OperatingIncomeLoss1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_09e20fc8-794f-4ece-be67-8f4ab1cbf45a">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Summary of Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict.  Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company&#x2019;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the date of this filing.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents. Cash equivalents are recorded at face value or cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company&#x2019;s short-term investments, which are government securities, are classified as available-for-sale and are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company&#x2019;s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders&#x2019; Equity on the consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;whether the investment has been in a continuous loss position for over 12 months; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the duration to maturity of investments; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the credit rating, financial condition and near-term prospects of the issuer and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the type of investments made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had an unrealized gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of unrealized losses related to short-term investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023  and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record an allowance for credit losses for these investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.   For additional information see Note 3 &#x2013; Short-Term Investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of cash held as collateral for a letter of credit as security for future facility lease payments and corporate credit cards at the Company&#x2019;s bank. Restricted cash decreased $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as required for these operating activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash in the consolidated statements of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company&#x2019;s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company&#x2019;s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company&#x2019;s business and may impact business in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are presented net of allowances for credit losses. Accounts receivable are typically due between 30 and 90 days after invoicing.  The Company does not have a high concentration of business with any individual customer as of December 31, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company did not have any customer who individually accounted for greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. The allowance for credit losses is calculated quarterly and is developed using an aging of receivables where receivables are segregated into various categories based upon due date, and a historical loss percentage is applied to each category that is adjusted for current receivable composition, counterparty and specific risk and prevailing economic condition and supportable forecasted economic conditions. If a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the allowance for credit losses. The Company closely monitors the credit quality of its customers and has yet to experience a write-off of a receivable or uncollected receivable. After evaluation of the collectability of accounts receivable, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any significant allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company does not generally require collateral or other security on receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.  Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable and operating lease liabilities. Cash, cash equivalents, accounts receivable and accounts payable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company&#x2019;s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and amended term loan at December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of that date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment and leasehold improvements are recorded at cost, net of accumulated depreciation and amortization. Property and equipment are depreciated over the estimated useful lives of the related assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, using a straight-line method. Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or their estimated economic lives. Repairs and maintenance costs are charged directly to operations as incurred, while renewals and betterments are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All long-lived assets are reviewed for impairment whenever circumstances such as events or changes in the business indicate that an asset or asset group&#x2019;s carrying value may not be recoverable based on undiscounted future operating cash flows to be derived from their use. Factors that are considered important that could trigger an impairment review include a current period operating or cash flow loss or a history of operating or cash flow losses and a projection or forecast that demonstrates continuing losses or insufficient income associated with the use of a long-lived asset or asset group. Other factors include a significant change in the manner of the use of the asset or a significant negative industry or economic trend. This evaluation is performed based on estimated undiscounted future cash flows from operating activities compared with the carrying value of the related assets. If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized, measured by the difference between the carrying value and the estimated fair value of the assets. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (&#x201c;Commencement Date&#x201d;) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.332%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.684%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.504%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,860,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,926,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units issued under the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;685,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock issuable in offering period under the 2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. Canada and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company&#x2019;s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer.  Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer&#x2019;s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer&#x2019;s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation.  Revenue for training is also recorded at a point in time, generally 60 days after installation.  Revenue for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales are recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the years ended December 31, 2023 and 2022, credits related to returns and rebates on list prices were not significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company&#x2019;s contracts. Revenue for service agreements is recognized ratably over the term of each contract.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from contracts with customers consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LDD (including training)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LAL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service warranty, service contracts, and accessories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. the Company did not have any customers who individually accounted for greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of revenue.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:40pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Sales &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of sales consists of materials, labor and manufacturing overhead incurred to produce the Company&#x2019;s products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as royalty and license fee expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and development expenses are expensed as incurred. Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities for new products and technology. The expenses include personnel-related costs, including compensation and benefits and stock-based compensation, consultants hired to perform research projects, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs related to FDA premarket approval submission preparation, various laboratory and research supplies, write-off of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;development &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of manufacturing processes in excess of capitalizable value, fees paid to contract research organizations and direct FDA related costs. The Company also accrued the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense for equity-based awards on the date of grant to employees, board of directors and consultants based on the estimated grant date fair value of the award Equity-based payments include stock options, restricted stock units and employee stock plan purchases. The fair value of the option awards are estimated using the Black-Scholes option-pricing model and recognized in expense in the consolidated statements of operations and comprehensive loss over the requisite service period, which is generally four years. The Company amortizes the stock-based compensation for equity awards with service conditions on a straight-line basis over the vesting period of the awards. Compensation cost for stock options with performance conditions is recognized based upon the probability of that performance condition being met. Forfeitures of unvested stock option awards are recognized as reductions of expense as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company&#x2019;s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), and its shares being traded on the Nasdaq Global Market, the fair value of the Company&#x2019;s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company&#x2019;s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company&#x2019;s common stock. For all grants subsequent to the Company's shares being traded on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#x2019;s expected term; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to the lack of historical exercise history, the expected term for options granted is calculated using the &#x201c;simplified method&#x201d; and represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility is derived from the historical volatilities of a select group of comparable peer companies, for a look-back period commensurate with the expected term of the stock options, as the Company has limited trading history of common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in tax rates is recognized in the Consolidated Statements of Operations and Comprehensive Loss in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history and reliability of forecasting. The Company recognized a valuation allowance on deferred tax assets as of December 31, 2023 and 2022 after evaluating that it is more likely than not that deferred tax assets will not be realized as of those dates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates the accounting for uncertainty in income tax recognized in the consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax positions where it is &#x201c;not more likely than not&#x201d; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t accrued any liabilities for any such uncertain tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to file federal and state income tax returns in the United States, United Kingdom, Germany and Netherlands. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect on such jurisdictions, which could impact the amount of tax paid. An amount is accrued for the estimate of additional tax liabilities, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The accrual for uncertain tax positions is updated when more definitive information becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes to GAAP are established by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) in the form of accounting standards updates (&#x201c;ASU&#x201d;). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; that are of significance or potential significance to the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_f7d7fb8b-666c-4413-a4b4-8c1ee5aa9808">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict.  Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company&#x2019;s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the date of this filing.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_14f0cdf2-8eb6-48b5-9cba-ab59565c3efd">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents. Cash equivalents are recorded at face value or cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <rxst:ShortTermInvestmentsPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_b1ba8560-8bc3-4c15-9b19-940191396930">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company&#x2019;s short-term investments, which are government securities, are classified as available-for-sale and are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company&#x2019;s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders&#x2019; Equity on the consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;whether the investment has been in a continuous loss position for over 12 months; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the duration to maturity of investments; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the credit rating, financial condition and near-term prospects of the issuer and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.693432091613477%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the type of investments made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had an unrealized gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of unrealized losses related to short-term investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023  and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record an allowance for credit losses for these investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.   For additional information see Note 3 &#x2013; Short-Term Investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rxst:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_bc153b3c-1588-40d7-b395-64519f9ee759"
      unitRef="U_USD">10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="0"
      id="F_93ec9c3b-e2c9-4c44-934f-7f16a7879737"
      unitRef="U_USD">75000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-6"
      id="F_15429682-f746-4ca3-8f5e-d6a0002a690e"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-6"
      id="F_d563d21a-75aa-403f-987f-42688b800c25"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_f292c4b5-8d36-4ea3-a3fe-ab9648546a00">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of cash held as collateral for a letter of credit as security for future facility lease payments and corporate credit cards at the Company&#x2019;s bank. Restricted cash decreased $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as required for these operating activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash in the consolidated statements of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <rxst:IncreasedDecreasedInRestrictedCash
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_dac12bdb-4a7f-49ae-84d5-4ea12e5fecbd"
      unitRef="U_USD">50000</rxst:IncreasedDecreasedInRestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="0"
      id="F_71df588c-0d3d-4000-9a55-ec61af9093a1"
      unitRef="U_USD">711000</us-gaap:RestrictedCash>
    <rxst:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a4c4999d-a313-4e71-b0e4-79b4281f84ab">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the amount reported in the Consolidated Statement of Cash Flows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash in the consolidated statements of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</rxst:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_60228ba1-bd78-4312-8acd-9b83408e137d"
      unitRef="U_USD">9692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_8b318fba-79f5-46fe-aa80-1dc5887a50ad"
      unitRef="U_USD">11834000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_0c4718f4-6f11-418c-aa4c-341d6f1023ec"
      unitRef="U_USD">711000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_4cf0e20b-e065-475c-bd2d-d7aaad4cb992"
      unitRef="U_USD">761000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_7f6b41b2-05ad-4696-bc81-bacbb2a68c5e"
      unitRef="U_USD">10403000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_596c37ac-e32b-41ee-84c9-17d64af971d3"
      unitRef="U_USD">12595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_e7eef8e1-f291-4c28-a28a-a45783d4d9e4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company&#x2019;s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company&#x2019;s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company&#x2019;s business and may impact business in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8d557dcf-e0bb-41c3-b3b9-087b4abf6af9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are presented net of allowances for credit losses. Accounts receivable are typically due between 30 and 90 days after invoicing.  The Company does not have a high concentration of business with any individual customer as of December 31, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company did not have any customer who individually accounted for greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. The allowance for credit losses is calculated quarterly and is developed using an aging of receivables where receivables are segregated into various categories based upon due date, and a historical loss percentage is applied to each category that is adjusted for current receivable composition, counterparty and specific risk and prevailing economic condition and supportable forecasted economic conditions. If a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the allowance for credit losses. The Company closely monitors the credit quality of its customers and has yet to experience a write-off of a receivable or uncollected receivable. After evaluation of the collectability of accounts receivable, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any significant allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company does not generally require collateral or other security on receivables.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <rxst:AccountsReceivablePercentage
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="2"
      id="F_4af9d609-8fc2-48a4-9d05-da6de940e302"
      unitRef="U_pure">0.10</rxst:AccountsReceivablePercentage>
    <rxst:AccountsReceivablePercentage
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="2"
      id="F_c3bb6f66-f84b-42b4-95ea-61a5dc691e7e"
      unitRef="U_pure">0.10</rxst:AccountsReceivablePercentage>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_8a5ba23c-63e3-480e-9428-022c900c0821"
      unitRef="U_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_06f8eb57-35ff-4570-b847-b73c7d2ab798"
      unitRef="U_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_df56aab8-9cd9-49cf-ac0d-cf45586a0af3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.  Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable and operating lease liabilities. Cash, cash equivalents, accounts receivable and accounts payable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company&#x2019;s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and amended term loan at December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of that date.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_ac94c43f-0779-4a83-b792-c9d1655a3af6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_493d4d3d-84cc-452f-bd4b-02a81c40b169">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment and leasehold improvements are recorded at cost, net of accumulated depreciation and amortization. Property and equipment are depreciated over the estimated useful lives of the related assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6a36b754-6b59-4670-b3c8-cb504ad4fa0f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, using a straight-line method. Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or their estimated economic lives. Repairs and maintenance costs are charged directly to operations as incurred, while renewals and betterments are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All long-lived assets are reviewed for impairment whenever circumstances such as events or changes in the business indicate that an asset or asset group&#x2019;s carrying value may not be recoverable based on undiscounted future operating cash flows to be derived from their use. Factors that are considered important that could trigger an impairment review include a current period operating or cash flow loss or a history of operating or cash flow losses and a projection or forecast that demonstrates continuing losses or insufficient income associated with the use of a long-lived asset or asset group. Other factors include a significant change in the manner of the use of the asset or a significant negative industry or economic trend. This evaluation is performed based on estimated undiscounted future cash flows from operating activities compared with the carrying value of the related assets. If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized, measured by the difference between the carrying value and the estimated fair value of the assets. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d19decf9-3310-45a2-abd2-b456a757f5d2"
      id="F_e0d91e2c-b3a0-43eb-ab11-b91dbe431329">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_2ddd976f-1ddb-4a07-8700-22e5b34ab29d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (&#x201c;Commencement Date&#x201d;) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_e9cb291b-50df-4ef9-91c6-6c4584de4066">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.332%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.684%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.504%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,860,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,926,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units issued under the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;685,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock issuable in offering period under the 2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_e22d2d64-65c7-4c2a-bb24-69de25cce447">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.332%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.684%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.504%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,860,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,926,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units issued under the 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;685,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock issuable in offering period under the 2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b1e80520-b096-4bb3-86ce-8009a5315cb9"
      decimals="INF"
      id="F_75f3b7da-d457-4f95-95d5-4fa480faeb8f"
      unitRef="U_shares">6860328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_436ef63d-fc6d-4417-9b9b-5376ba16f03f"
      decimals="INF"
      id="F_2f3284c4-e271-491d-8e85-fea8523b39df"
      unitRef="U_shares">1926226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ea2ea0b1-ec63-404d-b9a1-340f4eae6e3e"
      decimals="INF"
      id="F_e4393910-4051-4779-92dd-47661c05c396"
      unitRef="U_shares">685029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_84f4cc9e-e25e-43fa-81e5-13a42f6b8d68"
      decimals="INF"
      id="F_1264d3da-30de-436a-8ed2-a672a79fd08f"
      unitRef="U_shares">543538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e81e1959-5dc9-462d-a83b-fe7fb4c2dc14"
      decimals="INF"
      id="F_06dae184-0cd7-4597-961f-7ff90ee08357"
      unitRef="U_shares">98189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5bafa0c3-726b-4976-a24a-5029c3f3ff37"
      decimals="INF"
      id="F_cd8e8156-8515-4c40-a154-a09da9d250e6"
      unitRef="U_shares">48594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_24c83ba6-24cc-49bc-af69-c7e1d795a816">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. Canada and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company&#x2019;s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer.  Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer&#x2019;s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer&#x2019;s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation.  Revenue for training is also recorded at a point in time, generally 60 days after installation.  Revenue for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales are recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the years ended December 31, 2023 and 2022, credits related to returns and rebates on list prices were not significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company&#x2019;s contracts. Revenue for service agreements is recognized ratably over the term of each contract.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from contracts with customers consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LDD (including training)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LAL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service warranty, service contracts, and accessories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. the Company did not have any customers who individually accounted for greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of revenue.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:40pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_14bede62-17db-47d5-a459-e5dc89778b55">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from contracts with customers consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LDD (including training)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;LAL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service warranty, service contracts, and accessories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_22015c87-a9d7-40c9-bba3-3d510e3d5d06"
      decimals="-3"
      id="F_3e096a88-f08b-4c84-a512-6bf3111e1a10"
      unitRef="U_USD">32091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ffa1d143-149d-4487-a305-e878c9ce191c"
      decimals="-3"
      id="F_c5d79634-e7dc-402e-a545-e7a0b04eda0f"
      unitRef="U_USD">22515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_41c727ce-a38b-4fac-af15-b2f7c97ca3f0"
      decimals="-3"
      id="F_2635d735-0f66-4d5c-a84b-6807295636ef"
      unitRef="U_USD">54092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3f2eeece-26e5-4b45-bad6-a36623117435"
      decimals="-3"
      id="F_20c48965-1fc2-45a3-84b6-6b7adac295e1"
      unitRef="U_USD">24965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4a7af93b-ffbb-4eba-bf5d-00c6faec0f6e"
      decimals="-3"
      id="F_213e0b92-5302-4579-b27c-c80e1a5dd0b5"
      unitRef="U_USD">2894000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c024e436-4a63-48c9-b8e3-a71a5ce33e50"
      decimals="-3"
      id="F_4ef98758-53c7-4b8f-bcbd-f09b200f2ee4"
      unitRef="U_USD">1525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_7361696b-474c-4181-b8fe-71dce6b7e4d6"
      unitRef="U_USD">89077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f33e872d-8c52-46b4-b539-0fbae4aee89a"
      unitRef="U_USD">49005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_4100cff0-e3c8-4a4e-a04b-cac826120706"
      decimals="2"
      id="F_e580e24a-2ba3-4b20-8305-a75f81080664"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2eee38f7-b0f6-4df6-b5d8-aa6c3374c148"
      decimals="2"
      id="F_1077e9d2-012b-4c13-aa0b-3a165d98b843"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_ee378c0c-984c-4797-9e55-4b8b284d189c">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, contract liabilities from sales activity recorded as liabilities on the Company's consolidated balance sheets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.039%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.369999999999997%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:18.127%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:40pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;"&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <rxst:DeferredRevenue1
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_a8272a89-2c52-40e7-b2c1-7b624d7055f8"
      unitRef="U_USD">1187000</rxst:DeferredRevenue1>
    <rxst:DeferredRevenue1
      contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075"
      decimals="-3"
      id="F_871ced67-af00-48b3-b3b4-d2d35f91cc47"
      unitRef="U_USD">540000</rxst:DeferredRevenue1>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_17745e99-809b-4661-97ac-28d5e241f7b4"
      unitRef="U_USD">3422000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_477a6fb3-1122-4a87-91c7-ea9402a5d2bb"
      unitRef="U_USD">2052000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_8a92b204-5cb3-4a71-96a8-ef378dc5abca"
      unitRef="U_USD">2721000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f955e3a1-f06f-4b66-9c16-9fc26ade687e"
      unitRef="U_USD">1405000</us-gaap:DeferredRevenueRevenueRecognized1>
    <rxst:DeferredRevenue1
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_2ed04ae2-df44-4979-bd6f-a8b96eaade2e"
      unitRef="U_USD">1888000</rxst:DeferredRevenue1>
    <rxst:DeferredRevenue1
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_0cf3d9d5-440d-4969-80e6-169687deda8a"
      unitRef="U_USD">1187000</rxst:DeferredRevenue1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_cf36b9dc-70e6-490c-8f16-122760deed3c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Sales &lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of sales consists of materials, labor and manufacturing overhead incurred to produce the Company&#x2019;s products as well as the cost of shipping and handling. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of sales also includes depreciation expense for production equipment and certain direct costs such as royalty and license fee expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_bf3c7f63-1d92-4d9e-89c7-b3667c2eb604">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and development expenses are expensed as incurred. Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities for new products and technology. The expenses include personnel-related costs, including compensation and benefits and stock-based compensation, consultants hired to perform research projects, costs incurred at clinical trial sites, regulatory and manufacturing engineering costs related to FDA premarket approval submission preparation, various laboratory and research supplies, write-off of pre-approved inventory utilized for clinical trial and research purposes, costs incurred in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;development &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of manufacturing processes in excess of capitalizable value, fees paid to contract research organizations and direct FDA related costs. The Company also accrued the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_664e43af-598d-4dff-8211-945c451f8613">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense for equity-based awards on the date of grant to employees, board of directors and consultants based on the estimated grant date fair value of the award Equity-based payments include stock options, restricted stock units and employee stock plan purchases. The fair value of the option awards are estimated using the Black-Scholes option-pricing model and recognized in expense in the consolidated statements of operations and comprehensive loss over the requisite service period, which is generally four years. The Company amortizes the stock-based compensation for equity awards with service conditions on a straight-line basis over the vesting period of the awards. Compensation cost for stock options with performance conditions is recognized based upon the probability of that performance condition being met. Forfeitures of unvested stock option awards are recognized as reductions of expense as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company&#x2019;s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), and its shares being traded on the Nasdaq Global Market, the fair value of the Company&#x2019;s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company&#x2019;s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company&#x2019;s common stock. For all grants subsequent to the Company's shares being traded on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#x2019;s expected term; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to the lack of historical exercise history, the expected term for options granted is calculated using the &#x201c;simplified method&#x201d; and represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility is derived from the historical volatilities of a select group of comparable peer companies, for a look-back period commensurate with the expected term of the stock options, as the Company has limited trading history of common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a3f70995-aee1-4df2-b674-6048ecb08be6">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit. The effect on deferred tax assets and liabilities of a change&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in tax rates is recognized in the Consolidated Statements of Operations and Comprehensive Loss in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history and reliability of forecasting. The Company recognized a valuation allowance on deferred tax assets as of December 31, 2023 and 2022 after evaluating that it is more likely than not that deferred tax assets will not be realized as of those dates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates the accounting for uncertainty in income tax recognized in the consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax positions where it is &#x201c;not more likely than not&#x201d; that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t accrued any liabilities for any such uncertain tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to file federal and state income tax returns in the United States, United Kingdom, Germany and Netherlands. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect on such jurisdictions, which could impact the amount of tax paid. An amount is accrued for the estimate of additional tax liabilities, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The accrual for uncertain tax positions is updated when more definitive information becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <rxst:LiabilityOnUncertainTaxPosition
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_031b37a0-e654-4dbb-be70-42c90e329e32"
      unitRef="U_USD">0</rxst:LiabilityOnUncertainTaxPosition>
    <rxst:LiabilityOnUncertainTaxPosition
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_2ddf4dc4-391e-4edc-b2c6-99423b2c294a"
      unitRef="U_USD">0</rxst:LiabilityOnUncertainTaxPosition>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_836add38-f207-4958-9ce8-c1ccdebea645">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All components of comprehensive loss, including net loss, are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_cfcb2cef-709c-42c0-9d26-80e5c98d4b1a">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes to GAAP are established by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) in the form of accounting standards updates (&#x201c;ASU&#x201d;). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; that are of significance or potential significance to the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_fd9148cb-d7f7-4247-9ec7-1e3f7fae91f5">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3 &#x2013; Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.259999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.471%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.066%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.089%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.828999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All available-for-sale securities held as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; had a maturity of less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ad232f5c-7ce0-4d92-95b3-b3019e7d245b;"&gt;&lt;span style="-sec-ix-hidden:F_1f005e07-66a8-4957-933b-b4aede44a4d8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company&#x2019;s ability and intent to use any and all of those marketable securities to satisfy the Company&#x2019;s liquidity requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Factors considered in determining whether a loss resulted from a credit loss or other factors include the Company&#x2019;s intent and ability to hold the investment until the recovery of its amortized cost basis, the extent to which the fair value is less than the amortized cost basis, the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer&#x2019;s industry, and any significant deterioration in economic conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest expense in the consolidated statements of operations through an allowance for credit losses. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Unrealized losses on available-for-sale debt securities as of December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Further, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record an allowance for credit losses with these investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_0d6f208a-4327-4634-a12b-f61e8d240d2c">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.259999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.619999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.471%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.066%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.089%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.181%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.828999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091"
      decimals="-3"
      id="F_0aed0d33-6ba6-45ab-a300-a1d46c43a437"
      unitRef="U_USD">117480000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091"
      decimals="-3"
      id="F_0014623f-e875-4ef2-868a-052aa1eb7d6b"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_687f53f5-912d-4d1e-ae9f-b2d98e1f0091"
      decimals="-3"
      id="F_77d373aa-185a-4f7e-9a6f-16ed2b49fd60"
      unitRef="U_USD">117490000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454"
      decimals="-3"
      id="F_a39e2bb1-d844-42c8-a1cd-93451222c522"
      unitRef="U_USD">94043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454"
      decimals="-3"
      id="F_bb0a9c0c-6fbe-4c1d-b356-f8b806880981"
      unitRef="U_USD">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6247c8ba-be57-4b31-8bf8-f4b4204a3454"
      decimals="-3"
      id="F_a69f738d-7cba-4f9a-a292-cd4d7b782cb5"
      unitRef="U_USD">93968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_cf432402-4d10-4728-8495-194dfe6ec712"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_f5160b0a-889e-4892-9e10-b3fdf34be24b"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_b08db59b-0816-43da-8702-8f309bde012f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2013; Inventories&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.94%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: reserve for excess and obsolete inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023 and 2022, finished goods included &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of inventory held on consignment at customer sites, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_30904506-60e0-41c1-a2f3-738725936f1f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.200000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.94%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: reserve for excess and obsolete inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_e39171ba-d37e-48d6-9187-382ffc6cc0d5"
      unitRef="U_USD">8092000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_4bde2be0-9f84-4a94-88c6-b892fb2fb812"
      unitRef="U_USD">6408000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_63ff8beb-9447-4544-af2d-5060156ed508"
      unitRef="U_USD">5680000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_a1152a7f-2b49-4843-9254-0f4b113e25b2"
      unitRef="U_USD">6494000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_9dbcd99b-da02-468c-a426-f9481ccb2881"
      unitRef="U_USD">4145000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_43a0b191-50f2-4f58-b728-8a7512dc548c"
      unitRef="U_USD">2567000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryGross
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_5cca4090-fe20-4580-99a8-bfa5548bf273"
      unitRef="U_USD">17917000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_2c739c76-f96e-419a-a20a-f3f2b383f75b"
      unitRef="U_USD">15469000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_1f0e3a1d-e031-4d05-8867-3de44ecd7476"
      unitRef="U_USD">496000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_420aaf17-d3f8-4653-9fc6-158d14f808b9"
      unitRef="U_USD">634000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_a7f8ef70-c943-4ffd-9fed-3fe6c846263d"
      unitRef="U_USD">17421000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_d9eb2362-2e12-49f5-a131-6a8e1e129351"
      unitRef="U_USD">14835000</us-gaap:InventoryNet>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_dc21228d-1f13-4fb3-93a0-677e9a530f10"
      unitRef="U_USD">4400000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-5"
      id="F_064e22f7-0ae4-40a6-8163-a43d0174165c"
      unitRef="U_USD">2800000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_d6156133-343a-4050-b5e5-064d2e95c615">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5 &#x2013; Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer hardware and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Production molds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and Equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in depreciation and amortization expense for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_f1219e2e-724b-4e1f-83c3-e3267d333391">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer hardware and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Production molds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and Equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_668f69a7-acb0-43b4-a348-1ac42e4921ca"
      decimals="-3"
      id="F_828b8127-5bce-40c0-b5eb-a7ab459a44b0"
      unitRef="U_USD">14638000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_04d3ef87-f8dc-4a39-8e22-74626d458f80"
      decimals="-3"
      id="F_70511ca9-6ec0-41dd-b484-2ed4a6cead4b"
      unitRef="U_USD">12799000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0c0d5359-a0dc-4cfd-ae75-3d2013478591"
      decimals="-3"
      id="F_30dc1b71-dbe2-4fe3-9003-a86a60dc8a88"
      unitRef="U_USD">11553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7e03f7a2-cd01-43e0-96bd-e479c8471a97"
      decimals="-3"
      id="F_f355fdf5-c1a1-4211-93f0-ecbe60aa0c07"
      unitRef="U_USD">11206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8d126cea-f298-4eca-b4ae-c0648a9c58e4"
      decimals="-3"
      id="F_98249842-250d-4431-867c-ac045ad1631f"
      unitRef="U_USD">2335000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f7039d17-9ee2-4e22-b624-e5756e318526"
      decimals="-3"
      id="F_8140d17c-b264-4200-a5db-e9672f0efd45"
      unitRef="U_USD">1331000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_47ec21cb-9507-465f-9a93-95dbd904a764"
      decimals="-3"
      id="F_40ed13e0-3f32-4503-ba80-edb54c2e8d16"
      unitRef="U_USD">1824000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c4dc177f-a41b-4a6c-9a51-c41f851cea5f"
      decimals="-3"
      id="F_4e8d32fd-d0fe-4b92-b2c4-1777a5b71486"
      unitRef="U_USD">1693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_28c73d3b-1f4e-47eb-8983-ab2974f6fec1"
      decimals="-3"
      id="F_96357c09-2019-4374-b07d-28d08ecdfdc1"
      unitRef="U_USD">2005000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fd90b2d8-aec9-4102-be22-34321f15f5b4"
      decimals="-3"
      id="F_702105c2-e5e2-49f6-a7c4-027c348775f1"
      unitRef="U_USD">1873000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0b42dce2-cf09-4fb9-9b81-1ed4c14f7dca"
      decimals="-3"
      id="F_cc7ddab0-e5b9-49b4-a1e1-46f9e09879c7"
      unitRef="U_USD">1028000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9e2c5118-f472-4fd8-bd76-d3936f7e7ba0"
      decimals="-3"
      id="F_1039099c-6bbd-46c4-bb82-fa361793f04b"
      unitRef="U_USD">928000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_366621b7-b9f6-4be8-a093-a9b4299ad983"
      decimals="-3"
      id="F_4bd847c9-839b-4950-88ca-5f9d85346959"
      unitRef="U_USD">156000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a53c973f-68a7-4092-8c03-15c10d086cf9"
      decimals="-3"
      id="F_065ea6d6-a9e7-492a-b58b-d89124eb4b73"
      unitRef="U_USD">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ef110426-2dc1-436d-9852-799bfc3afe9e"
      unitRef="U_USD">33539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_7362d410-ba2b-42a4-9bd7-7f51c83d551a"
      unitRef="U_USD">30036000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_8113e69e-7d1f-4b16-aac0-3e33df36c1cb"
      unitRef="U_USD">22698000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_1067a064-66f0-4e89-8927-c0f806d523a0"
      unitRef="U_USD">19898000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_5a8dc2ef-bded-4e83-bef2-17a6b3e4c062"
      unitRef="U_USD">10841000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_d8beda4d-f5cf-46f1-9ac2-e08049ae72ee"
      unitRef="U_USD">10138000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-5"
      id="F_06b294c1-347e-4a90-a137-7972bf2dab4e"
      unitRef="U_USD">4100000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-5"
      id="F_fb2b6e51-bcc3-4981-ad4a-f21908fde4b1"
      unitRef="U_USD">3900000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_5e3d642b-8dec-407d-8fcb-8e5c3af523ac">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6 &#x2013; Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below (in thousands) present information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value. The Company did not have any assets or liabilities measured at fair value on a recurring basis within Level 3 fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. U.S. Treasury are measured at fair value using Level 2 inputs. The Company reviews trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level I&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level II&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level I&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level II&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8c610718-0f48-45a4-9736-4545e6e0d06c">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level I&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level II&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level I&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level II&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87f27813-04b4-43a9-89cf-60f99646eed6"
      decimals="-3"
      id="F_d440456d-e3a6-457b-adf7-900b80874b16"
      unitRef="U_USD">4475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8d466df4-3d33-403f-8a77-220f9e7e5b8e"
      decimals="-3"
      id="F_50ada839-bcbd-4117-8788-4c2744664d2b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e59788db-8615-4e43-8e9d-3d404e52eb66"
      decimals="-3"
      id="F_477c6a9b-af54-48a1-a781-9795e806808d"
      unitRef="U_USD">4475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_829b96d2-f2b7-4707-8dc5-c513602f5c40"
      decimals="-3"
      id="F_18ab1630-42dc-45d5-b06c-a507002493b8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6bd8958d-ac74-435f-a9b1-65f5c5df5463"
      decimals="-3"
      id="F_e8a48e6b-cb27-4208-86fc-a9fa48e2f157"
      unitRef="U_USD">117490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fed1b82c-fcdc-47fb-8e4c-b26548a6ea85"
      decimals="-3"
      id="F_29a9b9b0-6fa6-4305-8bf0-bb4632903d7c"
      unitRef="U_USD">117490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8c73432c-1e8b-41d2-a8a2-ad9cf9e153b2"
      decimals="-3"
      id="F_e6818a93-56be-4325-9c7d-d7826d4a9d17"
      unitRef="U_USD">4475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0769e4e2-f071-4d16-811c-15ab6db50acd"
      decimals="-3"
      id="F_48cd46e7-0b0b-49d5-b624-d69b3abe0a52"
      unitRef="U_USD">117490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_e8b88708-416f-49a0-8452-66af86d2f87c"
      unitRef="U_USD">121965000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7e12529e-af41-4c48-9b3a-2cd9a1e05936"
      decimals="-3"
      id="F_ddd0f34a-3258-4547-ba6d-cc5a0ca614d0"
      unitRef="U_USD">8909000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa88a57b-a838-484b-b8a6-d0306d09b381"
      decimals="-3"
      id="F_fd8d9d4a-f83d-4b30-9ca4-e7af6bac66d5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b78bc7b3-79c3-4faf-8705-31df15a4698c"
      decimals="-3"
      id="F_94b3e415-55c1-4716-b6d7-a511012ad481"
      unitRef="U_USD">8909000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_28619841-2fee-441e-b364-8cc0d0d59ea3"
      decimals="-3"
      id="F_6ce5bd1e-78c4-4c47-989e-6e687941af3e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_88cb89e8-ba4b-4206-a251-8f43f4a4a237"
      decimals="-3"
      id="F_4bc2b05b-c351-4ab0-8e96-2462e59da09e"
      unitRef="U_USD">93968000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bfff9d89-3c68-4d8a-aaf1-ae180ad5659f"
      decimals="-3"
      id="F_800608ab-2a33-4dc9-967c-c4285738f3b3"
      unitRef="U_USD">93968000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13836f48-52b4-4300-9d56-4f50c234e19e"
      decimals="-3"
      id="F_75092cc1-c534-4667-8266-e3592571bfa5"
      unitRef="U_USD">8909000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f203818c-89e0-4e29-82a7-a9e012aac75d"
      decimals="-3"
      id="F_bdc2e7c9-96b4-495a-9224-a850b3da8c46"
      unitRef="U_USD">93968000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_324de39a-a702-4e19-85bb-fc8a4e510422"
      unitRef="U_USD">102877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_c4cf6ee8-d077-4d33-97b5-90ad51469a0d">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7 &#x2013; Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:27.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8bbf4836-2d85-4062-a1dc-bbe50cf397b3">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:27.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_3c241574-76ef-48b7-90ee-c6a1d7476d98"
      unitRef="U_USD">10637000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ee532dda-0f40-4972-9b9c-06154c9e760b"
      unitRef="U_USD">8537000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_b6503e48-4a0d-446e-bfc9-d3e3f0c06c23"
      unitRef="U_USD">2045000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_f99efe07-7752-48d7-8990-b031d08ff1e0"
      unitRef="U_USD">1348000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <rxst:AccruedInterestCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_98e1259b-2ec9-40d1-9485-51c2196b9889"
      unitRef="U_USD">0</rxst:AccruedInterestCurrent>
    <rxst:AccruedInterestCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_cf7fe860-3fd0-43cf-901f-6e1db0204819"
      unitRef="U_USD">455000</rxst:AccruedInterestCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_0c2634e2-6750-4c1a-b004-32b9937727b3"
      unitRef="U_USD">2557000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ea56b239-1cd7-4e23-ad79-1faef212d0b3"
      unitRef="U_USD">2332000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_9957bdfe-fa64-4d77-8f01-ec06a320cfe1"
      unitRef="U_USD">15239000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_44e92595-877f-4dc0-a90a-a1d5916daa20"
      unitRef="U_USD">12672000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_17c4538d-eeb4-4f57-90c1-6b9b3b148d52">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8 &#x2013; Term Loan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Refinancing and Payoff of Oxford Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 29, 2020, the Company and Oxford Finance LLC (&#x201c;Oxford&#x201d;), as collateral agent, and certain lenders (&#x201c;Lenders&#x201d;) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the &#x201c;May 2022 LSA&#x201d;), pursuant to which the Lenders provided to the Company certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the &#x201c;May 2022 Term Loan&#x201d;).  The May 2022 LSA increased the loan and security agreement to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was fully drawn upon as of May 3, 2022 from the original term loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 30, 2023, the Company entered into a new Loan and Security Agreement (the &#x201c;June 2023 LSA&#x201d;) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate Term A Loans (the &#x201c;Term A Loans&#x201d;). On that same date, the Company prepaid the May 2022 Term Loan in full which included approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in final payment and other fees using a combination of cash, primarily comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in Term A Loans and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash reserves.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 4, 2023, the Company repaid its outstanding June 2023 LSA of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million early which included outstanding accrued interest of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in final payment and other fees using $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash, net, raised under the ATM Facility and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash reserves.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_ec88e75c-ff75-4185-a750-95225b1dcd49"
      decimals="-5"
      id="F_7b9894db-4565-40ad-8d3f-723b2bf1ffeb"
      unitRef="U_USD">60000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromLoanOriginations1
      contextRef="C_8e853287-f8f2-492f-b2ee-7e9d752ea4ca"
      decimals="-5"
      id="F_09ab27f1-2997-4120-884b-93e963bd4921"
      unitRef="U_USD">40000000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_062bed15-9f98-4171-bfad-0df8a119278e"
      decimals="-5"
      id="F_24171641-2832-4576-9e63-fb3c875f8366"
      unitRef="U_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsForFees
      contextRef="C_ca4cbdee-0ada-4ebf-982e-0a37a5748260"
      decimals="-5"
      id="F_27558ce4-72e5-4dae-9f51-0ac2edaac283"
      unitRef="U_USD">1200000</us-gaap:PaymentsForFees>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4"
      decimals="-5"
      id="F_3b87c239-c7a9-4b91-aa9f-0faf64126493"
      unitRef="U_USD">19400000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLoanOriginations1
      contextRef="C_e94fd07c-c43c-4224-bee7-cdbe967f24b4"
      decimals="-5"
      id="F_75757591-b651-48a3-9173-6aecab89a36e"
      unitRef="U_USD">20000000</us-gaap:ProceedsFromLoanOriginations1>
    <rxst:DebtFromCashReserves
      contextRef="C_70360018-fdc1-4362-ac4e-ba7f96b09f5a"
      decimals="-5"
      id="F_883bc6e5-5329-4319-9d5f-103b7237e04d"
      unitRef="U_USD">1700000</rxst:DebtFromCashReserves>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518"
      decimals="-5"
      id="F_98281379-7d2a-4e8c-b9e4-6bc3105d5233"
      unitRef="U_USD">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestPaidNet
      contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518"
      decimals="-5"
      id="F_684301ca-44e0-432a-b808-8bbb51621e13"
      unitRef="U_USD">200000</us-gaap:InterestPaidNet>
    <us-gaap:PaymentsForFees
      contextRef="C_5b74aaf6-1816-4ba8-b25b-06f474253518"
      decimals="-5"
      id="F_f3b373de-d595-4a8a-8ec8-9f27ab342f8b"
      unitRef="U_USD">1000000</us-gaap:PaymentsForFees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4a21676c-9a43-4d66-b8cc-6cd51899920b"
      decimals="-5"
      id="F_e33ed535-3d40-498c-b838-04713f2be000"
      unitRef="U_USD">11900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rxst:DebtFromCashReserves
      contextRef="C_cfeaa0f9-8a0e-4a4c-af2e-cbfcae368f77"
      decimals="-5"
      id="F_b8641eea-b949-4e1f-ab3a-294d44f6ec8f"
      unitRef="U_USD">9300000</rxst:DebtFromCashReserves>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_598fc128-dea7-4a8d-ab3c-31171b677eb2">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 9 &#x2013; Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has three equity incentive compensation plans: the 2006 Stock Plan (the &#x201c;2006 Plan&#x201d;), the 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;) and the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2006 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2006 Plan was originally adopted by the Board and approved by the Company&#x2019;s stockholders in 2006. The 2006 Plan was terminated in 2015 in connection with the adoption of the 2015 Plan and as a result no new awards may be issued under the 2006 Plan. However, the 2006 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2006 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2015 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2015 Plan was originally adopted by the Board and approved by the Company&#x2019;s stockholders in 2015. The 2015 Plan was most recently amended in March 2021. In July 2021, upon completion of the IPO, the 2015 Plan terminated immediately prior to effectiveness of the 2021 Plan with respect to the grant of future awards. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 28, 2021, the 2021 Plan was adopted and approved by the Board and stockholders prior to the IPO and became effective on the business day immediately prior to the effective date of the Company&#x2019;s IPO registration statement.  The 2021 Plan provides for the grant of incentive stock options to employees and any subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (&#x201c;RSUs&#x201d;), and performance awards to employees, directors, and consultants and subsidiary corporations&#x2019; employees and consultants.  The number of shares of the Company&#x2019;s common stock originally available for issuance under the 2021 Plan was equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,420,135&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock plus any shares subject to awards granted under the 2015 Plan and the 2006 Plan that, after the effectiveness of the 2021 Plan, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by the Company for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest, with the maximum number of shares to be added to the 2021 Plan from the 2015 Plan and 2006 Plan equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569,530&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Evergreen provision&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of common shares reserved for issuance under the 2021 Plan will be increased automatically on the first day of each fiscal year beginning with the 2022 fiscal year and ending on the ten year anniversary of the date the Board approved the 2021 Plan, by a number equal to the least of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,260,406&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such lesser number of shares of our common stock as the administrator may determine. The 2021 Plan is administered by the Board.  On January 1, 2023 and 2022, the number of shares available under the 2021 Plan increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,130,735&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,094,670&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively pursuant to this feature.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 ESPP&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 28, 2021, the Board and stockholders adopted and approved the 2021 ESPP. The number of shares of the Company&#x2019;s common stock originally available for issuance under the 2021 ESPP was equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;664,976&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and the initial purchase period began on November 1, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2021 ESPP provides eligible employees of the Company and its subsidiaries with the opportunity to purchase shares of the Company&#x2019;s Common Stock at a purchase price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the common stock&#x2019;s fair market value on the first trading day or last trading day of each purchase period, whichever is lower. The 2021 ESPP provides for two six-month purchase periods every twelve months: May 1 through October 31 and November 1 through April 30. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the number of shares of the Company&#x2019;s common stock available for future issuance under the 2021 ESPP was equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;577,847&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Evergreen provision&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of common shares reserved for issuance under the 2021 ESPP plan will be increased automatically on the first day of each fiscal year beginning with our 2022 fiscal year, by a number equal to the least of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,081&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such other amount as the administrator may determine. The 2021 ESPP is administered by the Board. The Board determined that no additional shares would be reserved for issuance on January 1, 2023 pursuant to this feature. On January 1, 2022, the number of shares available under the 2021 ESPP increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;273,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock pursuant to this feature.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The purpose of the 2021 Plan and 2021 ESPP is to provide a means by which eligible recipients of stock awards may be given an opportunity to benefit from increases in the value of the common stock in order to retain or procure the services of the employees, members of the Board and consultants and provide them with an incentive to promote the Company&#x2019;s success and accomplish corporate goals.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as follows, subject to the optionee&#x2019;s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the stock option activities related to the Plans, as of and for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.549%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.342%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.922%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Avg&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,339,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,465,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,777,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,237,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of restricted stock unit activities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.5pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.472%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.163%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;262,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the intrinsic value of options vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and of all options outstanding was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. During the year ended  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the total cash received from the exercise of stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The total fair value less strike price of these options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the accompanying consolidated statements of operations and comprehensive income (loss) as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,539,445&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,447,687&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unvested options, respectively. Total unrecognized expense related to unvested stock options was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. Amounts are expected to be recognized over a weighted average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized expense related to unvested restricted stock units was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. Amounts are expected to be recognized over a weighted average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.81%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_c9b31877-61d1-447b-9f36-a10b15a4cba2"
      decimals="INF"
      id="F_2966b61b-e69f-46e6-8eb6-fde766070e7d"
      unitRef="U_shares">2420135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a4f444db-5996-4c90-8623-059c3f481ab2"
      decimals="INF"
      id="F_1bb9616f-d2db-4002-8b83-9d417f7ffc0f"
      unitRef="U_shares">4569530</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c9b31877-61d1-447b-9f36-a10b15a4cba2"
      decimals="INF"
      id="F_a99a7dce-293b-4433-91f6-0baf5f995048"
      unitRef="U_shares">7260406</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_d24bcbd2-389a-48da-b2a7-d4fe20dbb56e"
      decimals="2"
      id="F_1c44aad2-bbf9-43fe-a57e-89881d9770a1"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e15cdba7-7d58-4afa-a398-ee69435f47e1"
      decimals="0"
      id="F_26a3bd39-6615-4016-9b2e-efd6f2d0e283"
      unitRef="U_shares">1130735</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6fa4f2fd-ca66-4db8-b0ed-9ab91076fb17"
      decimals="INF"
      id="F_fbf3f3e4-78ba-4d29-961f-45ae7d8c2144"
      unitRef="U_shares">1094670</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe"
      decimals="INF"
      id="F_f72df2d6-0125-458e-892f-a41a22ea0ca2"
      unitRef="U_shares">664976</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_37cd287f-b1fe-417b-bb04-4b5f0d4c6f3f"
      decimals="2"
      id="F_7234591f-6f5e-4375-be1b-f838b7ad5a6d"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7f7038cd-03eb-4dd6-8464-7a639831af3e"
      decimals="INF"
      id="F_1c2f7123-f2ed-4128-a3c5-169b312f8cf8"
      unitRef="U_shares">577847</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f8b06f90-388f-4d24-b7c6-60290bdf1bfe"
      decimals="INF"
      id="F_b5dea144-c888-411c-86ab-d33320dd54d4"
      unitRef="U_shares">1452081</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_88b18fd6-1484-4233-9ccd-4639da1f1dde"
      decimals="2"
      id="F_0a807deb-6355-47a2-8006-9d78ef843419"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9b5f35bb-1962-4ed8-958d-db0a4a14c1cf"
      decimals="INF"
      id="F_9a275e84-70d2-48d5-ad75-f725d145b024"
      unitRef="U_shares">273667</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a"
      id="F_56ce79fa-d40d-4ab6-a352-1fc525d8708c">Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee&#x2019;s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_004ccfc5-4b88-4d96-ad5d-36b9f69c4d1a"
      id="F_d60f3931-87de-4322-9fc5-e65f25c67ade">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_2028879b-0ef5-419a-a68f-ddd39915e098">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the stock option activities related to the Plans, as of and for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.549%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.342%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.922%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Avg&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,339,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,465,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,777,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,237,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e"
      decimals="0"
      id="F_a9e7cc80-e7bb-4ba0-9cb6-94aa54125634"
      unitRef="U_shares">6339558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1d8556ea-ac49-44a5-91dd-da0264eccc3e"
      decimals="2"
      id="F_f2b28ffc-9c56-499b-9890-cf0a6e5ac4ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_5bc13ab9-a18c-40ae-9c04-bd63e0ed3ba8"
      id="F_3fc6ca6d-4c9d-47d3-a45f-542080e24763">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="0"
      id="F_d0d24e7f-b993-47f6-9e1f-000f7e4a2cc6"
      unitRef="U_shares">1465466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_0ff65197-4b31-47f0-b20e-92822261170d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_7f1facf0-2872-49c1-8e91-dd481db926ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="0"
      id="F_9fd14b50-d2e9-4b80-a6f2-ef083548a82b"
      unitRef="U_shares">841896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_7a42dc8d-cf27-405e-b2e8-c1aba8ff8ea7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_be887812-cc21-42db-b1a7-38e8e9882fd7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.74</rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="0"
      id="F_7a41cc1d-8c7f-4bea-8cc3-86a6cd117d8b"
      unitRef="U_shares">120711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_c684d5d8-fe45-4559-bb5b-41fa3a7e239e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_c69623dc-bb1e-4b25-9e06-e377aae12b1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="0"
      id="F_8c313241-74f6-498f-8a25-60dba862eb60"
      unitRef="U_shares">65013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      decimals="2"
      id="F_ea29434e-f743-45c7-8486-aa32ce3f66d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c"
      decimals="0"
      id="F_ebd5a7af-6036-4a29-8b95-f8545c643c29"
      unitRef="U_shares">6777404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c"
      decimals="2"
      id="F_e6830d5d-50df-4db6-84fb-a2e215095b4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      id="F_e5e87dff-f3fe-4e77-be41-05d448597d3e">P6Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c"
      decimals="0"
      id="F_17610f3b-0df8-4b95-ae6b-cd3e8928f872"
      unitRef="U_shares">4237959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1fa1999f-f48c-4136-b866-3f3c6b69fa0c"
      decimals="2"
      id="F_63300eea-a396-4198-a39f-9eeee0fe1132"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c7d47bd7-28e9-46c4-a183-a6e5c12597bf"
      id="F_bd0bcced-66cd-4a27-9526-eca97cb0005e">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_4254f09e-96d9-404c-890d-1d706f4d7af0">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of restricted stock unit activities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.472%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.163%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;262,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291"
      decimals="0"
      id="F_ce21a6fc-da01-4555-ac84-7c23a28ef6a0"
      unitRef="U_shares">492862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291"
      decimals="2"
      id="F_0bfca334-af15-4223-8633-1556aff1f53a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.08</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="0"
      id="F_a71d9f24-6d50-45df-9d48-7378f6e0d177"
      unitRef="U_shares">430926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="2"
      id="F_8533593d-ad08-43e8-afac-a4fb0309851b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="0"
      id="F_7ec1024a-f163-4a2e-a292-2a296b8d19cf"
      unitRef="U_shares">262078</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="2"
      id="F_28edc59e-f0a4-43a9-b74b-315b19a02cec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="0"
      id="F_84911e00-d800-44f7-847f-f75e9469046e"
      unitRef="U_shares">11353</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_5c9a00f6-c5c7-4f43-ab4c-34fa66e59cd7"
      decimals="2"
      id="F_e3381288-adda-4d5a-90d1-4ad178bc5656"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81"
      decimals="0"
      id="F_24b6a36b-1ae8-4cd9-ad03-905a215d19b7"
      unitRef="U_shares">650357</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81"
      decimals="2"
      id="F_b22b4d0e-751c-4a5a-a03b-fdaf0078261e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.8</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb"
      decimals="-5"
      id="F_b0782d30-b530-4379-a327-0859ae717678"
      unitRef="U_USD">121300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054"
      decimals="-5"
      id="F_700c814c-6298-4ed3-a3da-f1b83af6ad3a"
      unitRef="U_USD">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb"
      decimals="-5"
      id="F_540220ba-d1f6-464f-bfbc-981e77c88e78"
      unitRef="U_USD">185000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054"
      decimals="-5"
      id="F_70255ed5-3aa4-46b3-b3da-a098be37eedb"
      unitRef="U_USD">16400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce"
      decimals="-5"
      id="F_9a856812-dd4b-49c6-8e1a-7f460ce6a1af"
      unitRef="U_USD">8400000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e"
      decimals="-5"
      id="F_77b3b0fd-3797-4e0c-ae43-074b0a25f7e8"
      unitRef="U_USD">800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce"
      decimals="-5"
      id="F_0776930f-5c3c-4f07-99e3-bf88a4791345"
      unitRef="U_USD">13700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e"
      decimals="-5"
      id="F_e94f4c0e-8a81-483e-b88c-20a7d7c0b7d7"
      unitRef="U_USD">1800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_05767cbc-3591-4ef7-97a0-582cb5593225">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the accompanying consolidated statements of operations and comprehensive income (loss) as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0c2cf702-64b7-49e4-996a-cc8a823efe97"
      decimals="-3"
      id="F_31cf9281-ccd8-4184-81e8-5d2cb8497ab6"
      unitRef="U_USD">3963000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d1a568f-d394-4720-a1b6-9a88ef02d12b"
      decimals="-3"
      id="F_a62c572f-2523-419c-9e93-d7c0f0673278"
      unitRef="U_USD">3064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9fc400ca-bc44-4785-8a4c-ad2af354ffac"
      decimals="-3"
      id="F_ed42c5e5-3194-4f54-b74b-e612bce98be8"
      unitRef="U_USD">10609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cb92c51b-50ce-4557-91aa-51fc17ad1a81"
      decimals="-3"
      id="F_00d73044-6fa5-4d13-9f2c-d3bd866259ea"
      unitRef="U_USD">7399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2256ad1c-8fe9-4d3b-ad3f-3872402cb7c7"
      decimals="-3"
      id="F_7ac1d6c2-49a0-47ee-8d9b-a0430720138b"
      unitRef="U_USD">1174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1c4862f1-51c5-4005-ad1c-acfd1c889569"
      decimals="-3"
      id="F_fd4e6426-5e82-433d-830c-a3977cc1c455"
      unitRef="U_USD">934000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce"
      decimals="-3"
      id="F_4631a03a-8266-46d1-bc74-b92bbb6e268a"
      unitRef="U_USD">15746000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e"
      decimals="-3"
      id="F_661357fc-74c8-4a4c-997f-5abf081f3dc0"
      unitRef="U_USD">11397000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb"
      decimals="INF"
      id="F_648c8515-7e30-4b5e-b3f8-d268ffa59754"
      unitRef="U_shares">2539445</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054"
      decimals="INF"
      id="F_cadc36da-1127-4a02-abf2-b5da9e7c7091"
      unitRef="U_shares">2447687</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_d3ca2bbb-766c-4627-a3a6-fdaa652bcfbb"
      decimals="-5"
      id="F_639b188a-e005-4265-aa09-f956b143b8d7"
      unitRef="U_USD">22700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_ee2d4d90-23fb-46e2-9141-296d7b75f054"
      decimals="-5"
      id="F_2eab1a06-e60f-4775-bb6d-2db0b7850559"
      unitRef="U_USD">19100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_4afc0d75-e45f-41c5-a746-3f9e2d736cce"
      id="F_63281e4a-6b1d-466c-ad4e-c362bda521db">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_271a9f64-d7fb-4c83-8f60-0616504ca74e"
      id="F_b9eea829-99e2-4ca1-83c9-55f6c2d75322">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_73589d31-b91d-4d39-a440-7eb5a774c207"
      unitRef="U_USD">8300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-5"
      id="F_39b1fdba-7896-4c48-8665-303be7a74083"
      unitRef="U_USD">6100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_34ca7f16-9126-43a4-886f-fec2f9b38b8b"
      id="F_8579c4bb-a935-4fd7-ac69-c24b86ed2916">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_4f171370-a4c2-4d7d-836c-e03fb02cef6f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.81%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.581%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.467%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451"
      decimals="3"
      id="F_91fff7aa-e20a-4081-ba9c-4a04f3fba15e"
      unitRef="U_pure">0.649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8"
      decimals="3"
      id="F_4aebcf64-80c8-40d1-a647-7b573f893241"
      unitRef="U_pure">0.686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_87279b86-c118-467d-9889-19267918aefd"
      unitRef="U_pure">0.649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f"
      decimals="3"
      id="F_faa55623-0d15-487c-9d96-408b5e48061c"
      unitRef="U_pure">0.624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77"
      decimals="3"
      id="F_ced1821b-57fc-433a-91c9-54a15faa509b"
      unitRef="U_pure">0.649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_40168d1d-d786-4408-8b07-552e0fb66520"
      unitRef="U_pure">0.631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451"
      decimals="3"
      id="F_951552dc-be05-47b8-a21c-5c1dffaea3f7"
      unitRef="U_pure">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8"
      decimals="3"
      id="F_751a44a2-4447-4cc9-8649-4b04e875ab90"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_73ba641f-1e18-4620-a2f4-43e5ec50f256"
      unitRef="U_pure">0.041</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f"
      decimals="3"
      id="F_99f2bf8a-2382-4df2-a97a-fb39022ed6c0"
      unitRef="U_pure">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77"
      decimals="3"
      id="F_d35fc53b-c743-4077-a3ba-b64a52006f3e"
      unitRef="U_pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_e1c70487-faf0-421b-83ec-4d97e8def5d6"
      unitRef="U_pure">0.027</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451"
      id="F_2da0a8f3-92c0-4f6d-9e1e-deace2b41ef2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8"
      id="F_95e16254-3460-4b38-a0ba-16d5bb278bd3">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_dd3feb9d-e277-4510-871e-54f55992ae21">P6Y</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f"
      id="F_c43811e8-8b8d-4422-9e65-c6969c664331">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77"
      id="F_9732db76-927b-4ae2-bde8-5a0242581169">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      id="F_21ed4eb8-9da7-4046-8a6f-bcd0aad154c7">P6Y1M6D</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_2a01a493-61fd-4946-924f-8f4803f42ba2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_a8b7755f-5290-41db-ba93-4a23ed21b940"
      unitRef="U_pure">0</rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_d6cc8f89-f281-4d42-ae3d-4a437773da31"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_d136439d-1474-4a21-b248-8a5a3854fb5a"
      unitRef="U_pure">0</rxst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue
      contextRef="C_bda624d3-25b5-47d8-97a1-87d5fd21b451"
      decimals="2"
      id="F_e046b0c9-1a04-439d-a413-428e49239b0e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.91</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue
      contextRef="C_3910fa9f-eae3-48ac-b145-d6273c7505d8"
      decimals="2"
      id="F_833ba533-9e5c-4de5-b6c2-5ec1e4c001b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">39.71</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="2"
      id="F_e89708b5-ab30-4e98-9773-b8c401f36af5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.6</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue
      contextRef="C_e9c42bc0-7001-4b45-85fc-b0d229d50c7f"
      decimals="2"
      id="F_e7d3fdea-1311-4b21-95ea-10d8d21f5e16"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.74</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue
      contextRef="C_f267633b-a252-4c4b-a433-0ca95b359c77"
      decimals="2"
      id="F_d03ca2d5-f2d4-4ea7-896e-d94393d62932"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.52</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue>
    <rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="2"
      id="F_33f19f7c-1eb0-40d1-a05a-1640bae81b70"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.73</rxst:SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_eb89adff-0758-4d07-8f29-9ea685a11b73">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 10 &#x2013; Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Shelf Registration Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 8, 2022, the Company filed a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shelf registration statement which became effective on August 12, 2022. The shelf registration statement is effective for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and permits the Company to sell, from time to time, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate value of our common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.  Included in the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million dollars of our common stock through an ATM offering.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATM Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;475,875&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common shares for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions and other offering expenses.  As of December 31, 2023, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,617,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for total gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million), have been issued and sold pursuant to the ATM offering, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,142,089&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, were sold during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, which was the remaining authorized value of the common stock under the ATM offering.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,777,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,339,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future issuance under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;358,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;865,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units issued under the 2021 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future issuance under 2021 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;577,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;664,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future sale under the ATM offering &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,454,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,816,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The ATM offering was completed in July 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as reported on the Nasdaq Global Market on December 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm
      contextRef="C_18f22b78-7783-4b48-a916-de31acc7d1e6"
      decimals="-5"
      id="F_a6ae82c1-12b7-489b-b714-bb4472274473"
      unitRef="U_USD">200000000</rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm>
    <us-gaap:RegistrationPaymentArrangementTerm
      contextRef="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a"
      id="F_611e695f-732b-45be-981b-bcd49b74bc8d">three years</us-gaap:RegistrationPaymentArrangementTerm>
    <rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm
      contextRef="C_0abec27c-e9d5-42ec-8f2f-cd858ce7ee0c"
      decimals="-5"
      id="F_09f08f3b-8e2e-47e5-9083-a6b721062a51"
      unitRef="U_USD">200000000</rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm>
    <us-gaap:RegistrationPaymentArrangementGainsAndLosses
      contextRef="C_f48b9f07-b321-4e9b-8c0a-b14ce509ce1a"
      decimals="-5"
      id="F_c573d6f5-05ae-4ab1-8d73-9e03c010d694"
      unitRef="U_USD">200000000</us-gaap:RegistrationPaymentArrangementGainsAndLosses>
    <rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm
      contextRef="C_b7350b8e-419b-4564-9523-4be12bc48b7b"
      decimals="-5"
      id="F_afc30172-e63e-47ef-aabb-ff01689476d3"
      unitRef="U_USD">50000000</rxst:SecuritiesIssuableValueUnderSelfRegistrationStatementForm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="INF"
      id="F_2f5c0a82-ebc1-48e4-8e08-a70a07991a98"
      unitRef="U_shares">475875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-5"
      id="F_ef58ab0d-a646-4ba1-8484-3cf7dcb78705"
      unitRef="U_USD">6000000</rxst:CommonStockSaleUnderwritingDiscountsAndCommissionDeducted>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"
      decimals="INF"
      id="F_9b6b5fd5-c5f5-49d6-8b7e-ec79bb49eaf0"
      unitRef="U_shares">2617964</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"
      decimals="-5"
      id="F_b5174926-43d7-4ad5-96e9-54830a265535"
      unitRef="U_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"
      decimals="-5"
      id="F_713cb167-b858-47bd-a5cd-de137c056939"
      unitRef="U_USD">47500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"
      decimals="INF"
      id="F_732814d4-4f0b-49f8-aecf-325ee11fa573"
      unitRef="U_shares">2142089</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_08a244e1-1cd0-4f12-b52c-c33b4404b433"
      decimals="-5"
      id="F_0c5d41c6-b368-4ad9-b188-c79f1edd2c49"
      unitRef="U_USD">41500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <rxst:SharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_ed178054-dd8a-47f3-9bff-ce909cf02e82">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,777,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,339,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future issuance under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;358,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;865,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units issued under the 2021 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future issuance under 2021 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;577,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;664,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future sale under the ATM offering &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,454,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,816,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The ATM offering was completed in July 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as reported on the Nasdaq Global Market on December 30, 2022.&lt;/span&gt;&lt;/p&gt;</rxst:SharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b4eedea1-0f5b-4dfb-bc30-d9f477763ebe"
      decimals="0"
      id="F_790daa40-ef18-46ba-bb3f-2188633a2212"
      unitRef="U_shares">6777404</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5ee404e1-09d9-4e49-8567-7e3e99def558"
      decimals="0"
      id="F_5aa26584-b3b0-4883-a416-286c92d8b4a9"
      unitRef="U_shares">6339558</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bbfab71f-6665-4527-940a-db6f796b7bbd"
      decimals="0"
      id="F_4919383e-85f5-4509-8396-4d22b2c250fd"
      unitRef="U_shares">358610</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_080706bb-030b-4069-b6d7-d7d31567a27c"
      decimals="0"
      id="F_e463d07e-b6b4-46bd-9660-45574d08b204"
      unitRef="U_shares">865122</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a87c77b2-af20-4ffb-b5f9-e41ee36aee81"
      decimals="0"
      id="F_70469496-0629-4f6c-8e00-1ab8f8658734"
      unitRef="U_shares">650357</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b77127b8-810a-4edb-a388-e4c235f9b291"
      decimals="0"
      id="F_274c29cb-2092-4b43-aa68-31e322f0ecdb"
      unitRef="U_shares">492862</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_023ec558-5797-47a9-a985-808a5dc77077"
      decimals="0"
      id="F_718633b6-b768-4a29-9026-a1773f8faeb2"
      unitRef="U_shares">577847</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_49f1aec2-a4e1-4190-a936-3eb5ce2b4155"
      decimals="0"
      id="F_2c13c788-d12a-4aea-b690-b0c73d1b9125"
      unitRef="U_shares">664976</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6c3e38f4-8300-4d9a-93f9-acfee4e73ff2"
      decimals="0"
      id="F_34d697a0-dc87-4fab-baef-c88c9f27381b"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_245fe6f8-26ec-4721-8201-1bc9132d6013"
      decimals="0"
      id="F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c"
      unitRef="U_shares">3454064</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="0"
      id="F_19cb7ab3-b6ab-4466-8cd3-4e812c2e4d1a"
      unitRef="U_shares">8364218</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="0"
      id="F_0b80bba3-8795-4b7c-ad12-84eedc31148e"
      unitRef="U_shares">11816582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rxst:ClosingStockPrice
      contextRef="C_25a0e726-e847-4009-b9ba-5e81ccb68e86"
      decimals="2"
      id="F_d13fe3ae-ad65-4729-9fb7-b05a797f7c34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.67</rxst:ClosingStockPrice>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_9a0c85f2-fd03-459a-8256-fed6d14ba37b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 11 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2013; Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of loss before income taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. loss before taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign income before taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components that comprised the Company&#x2019;s net deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D expenditures capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes with the expected income tax computed by applying the federal statutory income tax rate to loss before provision for income taxes was calculated as follows (amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.120000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision at the federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other non-deductible permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired tax attributes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;tax effects of items that give rise to significant portions of deferred tax assets are primarily net operating loss carryforwards. The Company evaluates the recoverability of deferred tax assets and assesses all available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all the evidence, including a history of operating losses and the Company&#x2019;s ability to generate future taxable income to realize these assets, a full valuation allowance has been recorded to offset the net deferred tax asset as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;realization &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of such asset is uncertain. The Company&#x2019;s valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;148.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which will not expire and will be able to offset &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of taxable income in future years. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in federal NOLs, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will not expire and will be able to offset &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of taxable income in future years. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;148.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in state NOLs, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will not expire and will be able to offset &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of taxable income in future years. The remaining federal NOL carryforwards will expire between 2024 and 2037, and the remaining state NOL carryforwards will expire between 2025 and 2043. In addition, the Company also had federal credit carry forwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and state credit carry forwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, which may be available to offset future tax liabilities. The federal credits will expire between 2037 and 2043, and the state credits do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Inflation Reduction Act 2022 which incorporates a Corporate Alternative Minimum Tax (&#x201c;CAMT&#x201d;) was signed on August 16, 2022.   The changes will affect tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability.  The CAMT act is not expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of the net operating loss carryforwards may be subject to substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#x201c;ownership change,&#x201d; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and R&amp;amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company has not completed an IRC Sections 382 and 383 analysis regarding the limitation of net operating loss and R&amp;amp;D credit carryforwards as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The Company has not completed a formal R&amp;amp;D study but has estimated the federal and California credit for purposes of the tax footnote as of December 31, 2023.  However, the Company has not reflected a benefit in the consolidated financial statements due to the recorded valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.5pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions for prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;None of the unrecognized tax benefits, if recognized, would impact the annual effective rate, due to the valuation allowance. The Company&#x2019;s unrecognized tax benefits are recorded as a reduction in deferred tax assets. The Company does not expect any significant increases or decreases to the Company&#x2019;s unrecognized tax benefits within the next 12 months. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.  The Company has not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to U.S. federal and various states' income taxes. The federal returns for tax years 2020 through 2023 remain open to examination and the state returns remain subject to examination for tax years 2019 through 2023. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. All other state jurisdictions remain open to examination.  There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cumulative earnings in our foreign subsidiaries as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; that would be subject to U.S. income tax or foreign withholding tax. The Company plans to indefinitely reinvest any future earnings of its foreign subsidiaries.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_4d3506ee-5b58-4621-bcf9-299eba51bc6d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of loss before income taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. loss before taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign income before taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_863f427a-30de-45d1-a9c0-b3ad0c0a1011"
      unitRef="U_USD">-48590000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_878b89de-43dc-414b-bee1-ccd1f9f28477"
      unitRef="U_USD">-66750000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_659f58e6-3c5e-4314-895c-15dbf36bdf54"
      unitRef="U_USD">2000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_2eca05a8-3d0c-496a-93db-8c5d9fb77817"
      unitRef="U_USD">3000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_1a6f005c-2317-40ed-9b64-066a2ed700ac"
      unitRef="U_USD">-48588000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_61b9ba37-9e06-4de3-b6bf-93a338f7b221"
      unitRef="U_USD">-66747000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_76ea7fbd-b6df-497e-882f-aba7e60efefc">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_b9005f8c-7739-4df2-b4d8-eb778efe9755"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_fc78428a-5324-4f5a-b88c-72ae69850ff7"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_56b455ae-ac76-4dc9-ac21-fad10bda0b85"
      unitRef="U_USD">21000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_45d8752e-23c4-4f65-ae0a-fd6c21c106c4"
      unitRef="U_USD">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_34976fe2-0195-4021-831d-7b694f559b7a"
      unitRef="U_USD">-1000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_709e41b2-9528-4921-9894-40a6d63a27c5"
      unitRef="U_USD">1000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_6fd558c7-25a9-4e0f-8a0c-67df717c4565"
      unitRef="U_USD">20000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_e9f131d9-88ad-467c-b100-927c4fa91c7d"
      unitRef="U_USD">9000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_3a2312ec-07d0-443d-8723-04b5561d85f9"
      unitRef="U_USD">-9527000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f338eb05-8b5f-4a6a-be4b-89ca6c31a824"
      unitRef="U_USD">-11366000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_418928ff-4dd1-438a-9655-677c818d4126"
      unitRef="U_USD">-3266000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_190990d0-5221-47ea-9de2-feab77fa7f1c"
      unitRef="U_USD">-3542000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_6927f463-04cb-4e40-a04d-16e814d24416"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_c38a11c4-b317-43bb-b7ab-92189750bd80"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_ff7c02a0-1ca0-4e7d-b060-14dc680dddd6"
      unitRef="U_USD">-12793000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_fa984898-ba1e-4caf-9f13-8c502408db17"
      unitRef="U_USD">-14908000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_96d76fb5-5056-4a30-99d2-24ea1f0c6fec"
      unitRef="U_USD">12793000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_6576f0b6-32fc-4330-8bf9-0fb58badf198"
      unitRef="U_USD">14908000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_00719e86-fad2-4d13-b62d-388f8e5046c7"
      unitRef="U_USD">20000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_da38fe89-5cc2-438e-852d-caf8272950c6"
      unitRef="U_USD">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_45af50bc-dfba-4142-afad-a7c873be0fcd">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components that comprised the Company&#x2019;s net deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D expenditures capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_0300e7ad-39d9-4e2e-bd96-6f74c3489294"
      unitRef="U_USD">73600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_0c679bad-aa76-4f34-a61e-b7fc2f996f1e"
      unitRef="U_USD">70179000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <rxst:DeferredTaxAssetAmortization
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_04648cad-e299-4786-b96c-e27a8c761015"
      unitRef="U_USD">81000</rxst:DeferredTaxAssetAmortization>
    <rxst:DeferredTaxAssetAmortization
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_00fb097d-8fed-4d91-a760-3dd2cca101aa"
      unitRef="U_USD">99000</rxst:DeferredTaxAssetAmortization>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_92cc554e-43c4-4945-b391-4031f8642c95"
      unitRef="U_USD">10923000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_2aa96169-49ad-40c8-8569-94aa962abcd1"
      unitRef="U_USD">4879000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_817d62c9-93f4-4cf4-9733-7da98d7811fc"
      unitRef="U_USD">3292000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ee73bcec-a0b0-4001-a385-2cd61c3200ed"
      unitRef="U_USD">2960000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_325cd315-f454-4e5b-84bf-5204b9280f7e"
      unitRef="U_USD">11271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ec257443-9b64-4506-adaf-756339080966"
      unitRef="U_USD">9202000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <rxst:DeferredTaxAssetRightOfUseOfLiability
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_75875517-ec4b-49f3-87b6-0a0c3791ac98"
      unitRef="U_USD">752000</rxst:DeferredTaxAssetRightOfUseOfLiability>
    <rxst:DeferredTaxAssetRightOfUseOfLiability
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_72caa325-8e30-498e-a91f-856b18fe7aea"
      unitRef="U_USD">1204000</rxst:DeferredTaxAssetRightOfUseOfLiability>
    <rxst:DeferredTaxAssetDepreciation
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_d4bd9657-55cd-498b-99d4-e2ee7334cbec"
      unitRef="U_USD">1035000</rxst:DeferredTaxAssetDepreciation>
    <rxst:DeferredTaxAssetDepreciation
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_86a6ceda-c8ed-4d1b-be31-f2f61fd4aeb6"
      unitRef="U_USD">779000</rxst:DeferredTaxAssetDepreciation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_384f70af-a26f-42bb-a695-0065e54c9d19"
      unitRef="U_USD">2934000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_081dc949-bc03-410d-b1f2-9e997b856181"
      unitRef="U_USD">2332000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_04b6eb07-074b-451f-b4c5-301ab34234a3"
      unitRef="U_USD">103888000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_332ef87f-8cf3-43b3-845b-40bfaed44024"
      unitRef="U_USD">91634000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_b3badbc2-10db-4781-b07c-14c190e6e29c"
      unitRef="U_USD">103242000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_a27aa86f-c855-4163-95b0-59cd2cf3ba6d"
      unitRef="U_USD">90471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ccd4a461-c568-4b32-83b9-a1a6b925d189"
      unitRef="U_USD">646000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_92b294ea-0d1d-4905-97e0-dda491920ee2"
      unitRef="U_USD">1163000</us-gaap:DeferredTaxAssetsNet>
    <rxst:DeferredTaxAssetRightOfUseOfAsset
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_9b4dbbea-34da-407a-a49f-482f5df65a12"
      unitRef="U_USD">646000</rxst:DeferredTaxAssetRightOfUseOfAsset>
    <rxst:DeferredTaxAssetRightOfUseOfAsset
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_cb814320-6570-4ae9-963b-7b633c9b84de"
      unitRef="U_USD">1163000</rxst:DeferredTaxAssetRightOfUseOfAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_f4840fb2-ca0d-4ec7-9c2a-8c6c31bb28aa"
      unitRef="U_USD">646000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_99f8298e-a196-4f80-930b-6c634a5dd034"
      unitRef="U_USD">1163000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_4e5fe148-6441-4695-aa23-c06df779df63"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_61d5b1cb-f704-4fb3-9cae-a76ce5cbb19b"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_1603d2da-dd58-44b5-9699-3486eb7732b0">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes with the expected income tax computed by applying the federal statutory income tax rate to loss before provision for income taxes was calculated as follows (amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.120000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision at the federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other non-deductible permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired tax attributes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_dd7fec7e-c8da-48cf-afa1-49dda6d02a90"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_72757851-faa0-46eb-803d-739d5475a86d"
      unitRef="U_USD">10203000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_34ed2eae-07ca-4ec6-be7f-bdbf33684b86"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_5bf146f2-0be0-42fc-8db9-4f52eaff07f3"
      unitRef="U_USD">14017000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_8131b3c3-097c-44c0-8fa9-af07c1e79939"
      unitRef="U_pure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_e75a5e29-2fe9-4f54-a420-59a2d38dc0dd"
      unitRef="U_USD">1992000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_1020c382-7898-4e32-bdc7-f6ea01692dcb"
      unitRef="U_pure">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_3326a427-38dc-4fd6-a612-748d5079e626"
      unitRef="U_USD">2358000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_09a15856-9cc7-4687-a0ce-d8cf60f14d3e"
      unitRef="U_pure">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_967b1edc-e8de-4156-84d0-6daef9811ad9"
      unitRef="U_USD">-1805000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_9c8940ab-b8d9-4f0c-8ec7-e1e1f94da44c"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_516c6d05-4163-45ca-aaf2-65bae71dac1e"
      unitRef="U_USD">-1269000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_9e9a17bb-027d-4faa-b327-c7ebe8a5a3e8"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_f3545991-0861-4cef-8580-5a8a14e47b0f"
      unitRef="U_USD">150000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_0d1496d3-c616-4c76-bcc7-66bea0126346"
      unitRef="U_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_c1bf9f3b-d0ab-4fef-a4a8-dd43c27c7e1c"
      unitRef="U_USD">1625000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_dd88d1bc-b7d1-4ac6-8676-d9517730b55e"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_7fbe5d53-da9c-4b64-a19d-74f5b421e8c5"
      unitRef="U_USD">246000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_11042ef4-ecfa-47f9-99b0-bb4233d3d08b"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_599990ab-7307-4ac2-9556-c20ac266ab55"
      unitRef="U_USD">105000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_2bf96c24-ce51-41e4-965d-dcaf3e3b6508"
      unitRef="U_pure">-0.022</rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration>
    <rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_c665f077-361f-4435-92ce-8d1a4791d55c"
      unitRef="U_USD">1070000</rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration>
    <rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_cf8922e4-bd46-4022-aeda-8d8ae65ba07c"
      unitRef="U_pure">-0.015</rxst:EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration>
    <rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_d5298276-5dc5-4b86-94ea-402740669246"
      unitRef="U_USD">988000</rxst:IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_627798c3-58a8-44b3-9c90-98270128bbfb"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <rxst:IncomeTaxReconciliationTaxCreditOther
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_61cb183e-60e8-4b96-9199-71d4f2a07ca2"
      unitRef="U_USD">-239000</rxst:IncomeTaxReconciliationTaxCreditOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_428d17e1-d946-4b1a-8ad2-4eb209c48d13"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <rxst:IncomeTaxReconciliationTaxCreditOther
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_cad47e15-52a9-4998-b958-182577e1fc16"
      unitRef="U_USD">27000</rxst:IncomeTaxReconciliationTaxCreditOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_9657d3cd-f11e-4a75-896b-8fba332fda07"
      unitRef="U_pure">-0.263</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_40b11ed9-4044-476b-8c56-c6eacc3d55f8"
      unitRef="U_USD">12793000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_b003eb9b-4fe0-4eac-99d4-312992945ced"
      unitRef="U_pure">-0.223</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_f8e7c61c-b556-4129-b97e-e8b163dea385"
      unitRef="U_USD">14908000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <rxst:EffectiveIncomeTaxReconciliationTaxCredits
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="3"
      id="F_c0e48fa2-4af8-454a-ae89-af6f34d35eff"
      unitRef="U_pure">0</rxst:EffectiveIncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_092089ea-cefb-41f5-8c6c-aed26e0f9786"
      unitRef="U_USD">20000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <rxst:EffectiveIncomeTaxReconciliationTaxCredits
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="3"
      id="F_339db504-1233-4344-8cad-fb1491ab5643"
      unitRef="U_pure">0</rxst:EffectiveIncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_d01c3532-7b09-40ca-a333-30790c24486a"
      unitRef="U_USD">9000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-5"
      id="F_6f497fe9-558a-4f14-9eca-f2316f571cef"
      unitRef="U_USD">12800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-5"
      id="F_cbd0fe7a-70b4-4e88-af5d-607844cb4652"
      unitRef="U_USD">14900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_176b94e9-0ef1-4a7f-9238-5de69e264e60"
      unitRef="U_USD">311200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_c26bb62b-896b-4e4c-867e-8eed3c51e6e2"
      unitRef="U_USD">148600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <rxst:TaxableIncomeOffsetPercentage
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="2"
      id="F_4fa1b085-5cd6-40a2-a39e-b0c7a7127a0e"
      unitRef="U_pure">0.80</rxst:TaxableIncomeOffsetPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_2551e877-77c4-4fbc-b58b-a6ec512d0877"
      unitRef="U_USD">311200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <rxst:FederalOperatingLossCarryForwardsNotExpire
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_86aa3561-e3d2-499f-809c-df845627a65b"
      unitRef="U_USD">204800000</rxst:FederalOperatingLossCarryForwardsNotExpire>
    <rxst:TaxableIncomeOffsetPercentage
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="2"
      id="F_dbe6aa76-62a4-426c-9953-dac8428d92b5"
      unitRef="U_pure">0.80</rxst:TaxableIncomeOffsetPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_687a85ab-a13e-417e-9f45-c6e820ce8d46"
      unitRef="U_USD">148600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <rxst:StateOperatingLossCarryForwardsNotExpire
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_a9c21800-ab02-44bf-81bd-4cccd0872326"
      unitRef="U_USD">25300000</rxst:StateOperatingLossCarryForwardsNotExpire>
    <rxst:TaxableIncomeOffsetPercentage
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="2"
      id="F_3d9ec196-f5ea-484f-b9d3-9001040d8d83"
      unitRef="U_pure">0.80</rxst:TaxableIncomeOffsetPercentage>
    <rxst:FederalOperatingLossCarryForwards
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_b81367a8-3ed5-4c52-bba0-c49c33e8c47f"
      unitRef="U_USD">9900000</rxst:FederalOperatingLossCarryForwards>
    <rxst:StateOperatingLossCarryForwards
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-5"
      id="F_17f15938-b2c9-42bc-929c-20d5e134ba41"
      unitRef="U_USD">9300000</rxst:StateOperatingLossCarryForwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_7339555d-a5fa-4b3f-9de3-f50ef0487466">Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and R&amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_c7f699c5-1f08-4a9e-9129-492fb0972584">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.971%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.661%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.483%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.543000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions for prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_b84c2273-c54f-429b-8b67-a2ebb8b4ca9c"
      unitRef="U_USD">3494000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_295809f3-db7b-4e78-a9ef-56ea3cb4a075"
      decimals="-3"
      id="F_98b06947-798e-4e91-8285-a3e2db25b1c4"
      unitRef="U_USD">3013000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_1ee935af-e60e-45fe-bcec-4c9372e61171"
      unitRef="U_USD">683000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_c3b2a546-cfeb-4439-b49d-46988960a09a"
      unitRef="U_USD">481000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_d8d9fb7a-222b-4458-8d5e-92dad76057b8"
      unitRef="U_USD">67000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_3b0a5e88-17aa-4168-b4a8-21788d219bce"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_e6e7039b-8c5f-40db-8474-6fd0dc3cfcb4"
      unitRef="U_USD">4244000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_6bf1335c-460f-4754-97ce-90f069a40c00"
      unitRef="U_USD">3494000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ForeignEarningsRepatriated
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_f0e26e0a-5905-4235-8be9-b2f75501dc52"
      unitRef="U_USD">0</us-gaap:ForeignEarningsRepatriated>
    <us-gaap:ForeignEarningsRepatriated
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_772ac3b8-fc6e-4179-8075-1bb568374a81"
      unitRef="U_USD">0</us-gaap:ForeignEarningsRepatriated>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_83d5d0e7-6484-4705-8e6e-d5e952eb3912">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 12 &#x2013; Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has operating and finance leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not combine lease and non-lease components in the recognition of lease expense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s leases have remaining non-cancelable lease terms of up to 3 years, some of which include options to extend the leases for up to 15 years. The exercise of lease renewal options is at the Company&#x2019;s sole discretion. The Company recognizes rent expense for minimum lease payments on a straight-line basis over the expected lease term, including rent holidays, rent escalation clause and/or cancelable option periods where failure to exercise such options would result in an economic penalty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; leases for office, manufacturing and warehouse facilities in Aliso Viejo, California. The four leases are for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in the aggregate and expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For one of the facilities operating leases, the lessor provided $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;900,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in tenant allowances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 4, 2022, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;thirty-four-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sublease agreement for a portion of the 5 Columbia Building, in Aliso Viejo, CA. The sublease commencement date was June 13, 2022 and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The base rent receivable is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,410&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month.  On January 4, 2023, the Company amended the base rent of sublease agreement to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,319&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per month beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the lease balances within the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:16.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:30.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:24.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_98a9eb22-5875-4665-9fe4-7da6a3667f55;"&gt;&lt;span style="-sec-ix-hidden:F_4215fd74-502e-4548-a8dd-7b80b1cd43f0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82;"&gt;&lt;span style="-sec-ix-hidden:F_c8f26f61-f9dd-4949-8795-ad61341c192b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426;"&gt;&lt;span style="-sec-ix-hidden:F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b14603c8-a5d6-41d8-b49d-2b04b4c22671;"&gt;&lt;span style="-sec-ix-hidden:F_cfa28257-8c04-4096-a2b8-5d3340f0d040;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1c8ef374-722f-4dc2-918b-df585e24ce25;"&gt;&lt;span style="-sec-ix-hidden:F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As the implicit rates in the Company&#x2019;s leases were not readily available, the incremental borrowing rate was determined based upon information available at the lease commencement date in determining the present value of future lease payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities of the Company&#x2019;s operating and finance lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:39.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.119999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company&#x2019;s operating and finance leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.949%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:31.806%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.222999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Term and Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.42&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <rxst:NumberOfLeases
      contextRef="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd"
      decimals="INF"
      id="F_b345c2d4-44d2-49d6-af6f-512c15600bd2"
      unitRef="U_Item">4</rxst:NumberOfLeases>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_cad86f70-a9d8-4a3e-9fae-5796e364c7dd"
      decimals="INF"
      id="F_846f3fc7-0cf6-4b73-9c12-e0acf4dce166"
      unitRef="U_sqft">121000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0ec5af07-2372-4042-a3f4-8511845cf529"
      id="F_3a68a6cb-8637-434e-8e4c-98c27229dd34">2025-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_35054392-155d-4fc2-92bb-5c95eec04e48"
      id="F_14c7f72b-89c1-4cd2-867e-79adb2f1db98">2026-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_0ec5af07-2372-4042-a3f4-8511845cf529"
      decimals="0"
      id="F_fb4c37ee-cb7b-49c8-8ceb-5b2242e388f0"
      unitRef="U_USD">900000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_38073016-ce8b-4023-8081-103f403ab2bd"
      id="F_f8001d05-2055-44de-ba74-62c0296abc4d">P34M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_06262739-6be2-40d0-a27d-2ee73ccd9a32"
      id="F_46c04677-a8f2-41a4-adaa-9c6f0cc8cbe8">2025-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_06262739-6be2-40d0-a27d-2ee73ccd9a32"
      decimals="0"
      id="F_af39106c-bb38-43ff-b791-56ce913d73c4"
      unitRef="U_USD">11410</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="C_2848131a-3718-4555-b34d-a2e75cc52c9e"
      decimals="0"
      id="F_6dc22757-606f-484d-8607-fd0e129ac4d8"
      unitRef="U_USD">5319</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperationsCommencedDate1
      contextRef="C_2848131a-3718-4555-b34d-a2e75cc52c9e"
      id="F_293caa62-80a9-4523-af35-4bc521799f04">2023-03-01</us-gaap:OperationsCommencedDate1>
    <rxst:SummaryOfLeaseBalancesTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_f06aefa3-4e4e-489c-9185-f1daccf23632">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the lease balances within the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:16.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:30.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:24.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_98a9eb22-5875-4665-9fe4-7da6a3667f55;"&gt;&lt;span style="-sec-ix-hidden:F_4215fd74-502e-4548-a8dd-7b80b1cd43f0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e6e8ee5f-670a-4901-bd34-c31fbcf0fb82;"&gt;&lt;span style="-sec-ix-hidden:F_c8f26f61-f9dd-4949-8795-ad61341c192b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_0b2ce2c7-8eca-48e0-a396-dd1025ae8426;"&gt;&lt;span style="-sec-ix-hidden:F_5d8f70e6-b11b-4ba9-b613-93fbece0fa7b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b14603c8-a5d6-41d8-b49d-2b04b4c22671;"&gt;&lt;span style="-sec-ix-hidden:F_cfa28257-8c04-4096-a2b8-5d3340f0d040;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1c8ef374-722f-4dc2-918b-df585e24ce25;"&gt;&lt;span style="-sec-ix-hidden:F_2ae3e65a-c6d9-4b1a-af00-412a6ef88175;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rxst:SummaryOfLeaseBalancesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_38b06810-8b57-4faa-939a-5c96c7d6492d"
      unitRef="U_USD">2444000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_01a08618-fe8d-44d1-8714-28c4f1fbbbac"
      unitRef="U_USD">3943000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_6a57c4d8-3bed-44bc-b33c-e575dc365579"
      unitRef="U_USD">156000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_3a61b4aa-793a-41d6-9138-6c7e84e57947"
      unitRef="U_USD">206000</us-gaap:FinanceLeaseRightOfUseAsset>
    <rxst:TotalLeaseAssets
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_2edacc39-8e5c-4cd2-99c5-0b705d1d60cc"
      unitRef="U_USD">2600000</rxst:TotalLeaseAssets>
    <rxst:TotalLeaseAssets
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_12e0e052-c88c-4cdc-8ab1-d75a4309071f"
      unitRef="U_USD">4149000</rxst:TotalLeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_48c4de07-0004-45bc-b25d-332b76637a52"
      unitRef="U_USD">1764000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_514cb479-ed54-4f08-87ec-33cd6d125a6b"
      unitRef="U_USD">1818000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_7a98a796-ee8a-48d8-a766-43c27e720c7d"
      unitRef="U_USD">37000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_f5ae7213-1f71-45c7-b471-3ace3a2d2d12"
      unitRef="U_USD">152000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_4df2a724-a38e-41df-b59a-824972a3358b"
      unitRef="U_USD">1093000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_ca0637d7-2885-48a6-9a22-431a0e864453"
      unitRef="U_USD">2813000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_c3986596-82ab-4a10-925c-3d02a9b0405a"
      unitRef="U_USD">118000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_1f86685a-62ef-44ea-a3b5-c9568a2ba004"
      unitRef="U_USD">43000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <rxst:TotalLeaseLiabilities
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_4072fa1b-89f9-4df7-9141-6d7d933c75a1"
      unitRef="U_USD">3012000</rxst:TotalLeaseLiabilities>
    <rxst:TotalLeaseLiabilities
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="-3"
      id="F_02d6ffb1-301c-45b9-83cf-a8da9316f277"
      unitRef="U_USD">4826000</rxst:TotalLeaseLiabilities>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_2316454b-8316-4a60-8b53-6c91b4dfda55">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3836ee42-99e1-4b4c-b3f6-d7a829aa62e2"
      decimals="-3"
      id="F_6995bce3-12f3-4ae0-afda-62dc2c835a2d"
      unitRef="U_USD">14000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2f291850-e62c-4bcf-9ff7-f62a97675a66"
      decimals="-3"
      id="F_96eb1da7-7dc0-4715-946e-e7e951b28539"
      unitRef="U_USD">14000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_613e254a-d190-4764-a1ac-1d0b1edcfaae"
      decimals="-3"
      id="F_55539ce4-a953-42e3-8e81-b5bbc3eb7b9b"
      unitRef="U_USD">103000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0"
      decimals="-3"
      id="F_979d1a91-46c9-4b07-87fc-00847a7722c5"
      unitRef="U_USD">324000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48"
      decimals="-3"
      id="F_090f86f6-b4dd-4441-b78b-5643c7b16319"
      unitRef="U_USD">1766000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2"
      decimals="-3"
      id="F_c5e820ae-b11a-47ee-85f6-a06ed3589faf"
      unitRef="U_USD">1688000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_613e254a-d190-4764-a1ac-1d0b1edcfaae"
      decimals="-3"
      id="F_a408fbc8-8baa-4d2a-a544-6f4ba90e6531"
      unitRef="U_USD">119000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_60bbc885-f18b-4782-9559-f71fa5ff2ee0"
      decimals="-3"
      id="F_fee05fdd-3c68-41fe-89cd-691d75a5f54a"
      unitRef="U_USD">110000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_ee9ec2d4-a2e1-4710-945a-bedf1635cd48"
      decimals="-3"
      id="F_2826552e-38c0-4837-a27a-80118ee07ff5"
      unitRef="U_USD">33000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_5e43d5a3-c011-4c58-92a9-5e8eec7f6af2"
      decimals="-3"
      id="F_ca5acff2-76e3-4ed9-83c5-85819f6daf67"
      unitRef="U_USD">28000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_74742e89-d434-4978-9087-35aa9912af13"
      unitRef="U_USD">12000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_98a68587-09ad-4b47-b796-fee84e41592c"
      unitRef="U_USD">18000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_8350fd3b-a6e6-4901-b458-7ef583af4b7a">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities of the Company&#x2019;s operating and finance lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:39.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.119999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_8e7132da-d09d-4be9-92c4-793db1dcc806"
      unitRef="U_USD">1970000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_cbdebf16-5e9e-4ecd-819e-6db26107e39d"
      unitRef="U_USD">56000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_25e59c00-eb62-43d0-993c-7ddc29692ad9"
      unitRef="U_USD">1054000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_f9133f64-96be-4f5e-9f25-a2beb30020cf"
      unitRef="U_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_1edc3474-4c64-4bb9-bf32-4186dc59bcfa"
      unitRef="U_USD">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ea23637a-6715-4091-8a72-72c12b8850c7"
      unitRef="U_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_e7c0f342-98cd-42d4-b46e-603d98bb4236"
      unitRef="U_USD">11000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_46c17b2d-4d01-460b-bdeb-13a5d0934a38"
      unitRef="U_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_1806871e-1777-4d45-ab7e-38ddf8ec4094"
      unitRef="U_USD">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ac3610c4-796f-4b8a-bdae-6ac9b7bd8029"
      unitRef="U_USD">34000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_849d0d28-b87d-4b05-94a7-0cd9126c3985"
      unitRef="U_USD">3135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_7e8c161b-b369-49ea-86fb-2bb2d9f5e4ac"
      unitRef="U_USD">210000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_f1a3ff79-7900-451c-939b-311ba7e541b9"
      unitRef="U_USD">278000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_ed6393a2-4c5f-4e67-9b26-3eae0cd36c08"
      unitRef="U_USD">55000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_dd1e15e3-4719-431c-bb9a-e03f75f3019e"
      unitRef="U_USD">2857000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="-3"
      id="F_d321c96d-8945-4d21-b43e-1a5c6928b633"
      unitRef="U_USD">155000</us-gaap:FinanceLeaseLiability>
    <rxst:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_7a1cb4d3-332c-4158-9b5c-1367252ff208">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company&#x2019;s operating and finance leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.949%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:31.806%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.222999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Term and Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.42&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rxst:SummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_6972ee16-d74b-4384-94d5-99325e8718b1">P1Y8M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_e40a6b39-4ba5-45ee-a0ee-faafd1b26862">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      id="F_4e40927d-e449-4f02-a1e5-4782aa7a1cbb">P4Y4M13D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      id="F_f3ebdb84-8ebd-4b8c-8e47-566178d680bd">P1Y3M14D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="3"
      id="F_27e9a162-e66e-4ce5-80e0-d0a85920442e"
      unitRef="U_pure">0.104</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="3"
      id="F_2db1da16-1e4e-4b73-b9f7-eadbca0c8ff0"
      unitRef="U_pure">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4cc92432-cf1e-4695-bc70-b0ff049a2abb"
      decimals="3"
      id="F_043b973f-6eef-4456-9222-46426a0b20bd"
      unitRef="U_pure">0.14</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_81ab6b37-2ec1-4387-88a2-59b62a95b01c"
      decimals="3"
      id="F_1d00190d-77dd-4a24-9edd-db1895dc2b01"
      unitRef="U_pure">0.095</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_a5daa239-383d-4cb2-9395-3404f932263e">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 13 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Letter of credit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a standby letter of credit, expiring September 30, 2024, issued by a financial institution as required security for one operating lease. The aggregate amount of the letter of credit was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time-to-time, the Company may be involved in certain legal proceedings or regulatory matters arising in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any legal proceeding or regulatory matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome. At December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the outcome, legal proceedings, regulatory matters, and other disputes and claims can have an adverse impact on the Company because of legal costs, diversion of management time and resources, and other factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_6b82dab6-564a-4b17-993f-52bc89ea5908"
      decimals="-5"
      id="F_1078a566-fce0-4663-8580-c4b144c845c2"
      unitRef="U_USD">200000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_300d62ab-2d34-4a7f-a559-6b38f6978705"
      decimals="-5"
      id="F_f891c13e-8187-4ad5-80c0-afb197de92f0"
      unitRef="U_USD">300000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LegalFees
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="-3"
      id="F_d9c98113-4422-4dce-9b52-77308ef09a31"
      unitRef="U_USD">0</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="-3"
      id="F_825b1c90-50a9-4d54-a426-38003d28bc31"
      unitRef="U_USD">0</us-gaap:LegalFees>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      id="F_07411dc8-166d-4957-9ff0-72ce0879e87f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 14 &#x2013; Employee benefit plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;401(k) retirement savings plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains a defined contribution 401(k) retirement savings plan for the benefit of its employees, including its named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax or after-tax (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.  The Company makes matching contributions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of eligible compensation, as contributed by eligible participating employees. Employer matching contributions vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per year over four years. The Company contributed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;900,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;688,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, net of forfeitures, to the 401(k) plan for the year ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_b0f7e8c1-2867-41c6-ad24-d19e307fd9a6"
      decimals="2"
      id="F_07d0e293-d74b-4770-92d8-c70b0c2b0335"
      unitRef="U_pure">0.02</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="2"
      id="F_3d9533bf-e071-4122-b782-612812a1dc71"
      unitRef="U_pure">0.25</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_01f8a67f-a74e-480a-abb3-13c58f494e3f"
      decimals="0"
      id="F_188ad66e-41b3-4215-842d-7e283b81ab17"
      unitRef="U_USD">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_e79daabe-87c3-470f-bac2-ba4a90c89f7e"
      decimals="0"
      id="F_3c5a6d6f-9d98-4396-88d7-4290779e537e"
      unitRef="U_USD">688000</us-gaap:DefinedContributionPlanCostRecognized>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_34d697a0-dc87-4fab-baef-c88c9f27381b"
          xlink:label="F_34d697a0-dc87-4fab-baef-c88c9f27381b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c"
          xlink:label="F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c"
          xlink:type="locator"/>
        <link:footnote id="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed" xlink:label="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The ATM offering was completed in July 2023.</xhtml:span></xhtml:p><xhtml:p style="margin-left:2.667%;text-indent:-2.098%;padding-left:2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2) </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The December 31, 2022 shares available for issuance were calculated based on the closing stock price of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.67</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as reported on the Nasdaq Global Market on December 30, 2022.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_34d697a0-dc87-4fab-baef-c88c9f27381b"
          xlink:to="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7bde8d40-67e8-496a-b6a5-ade6c3c6771c"
          xlink:to="FNT_f65be8ee-b968-4e27-addc-0c7d101afbed"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
